



(86) Date de dépôt PCT/PCT Filing Date: 2011/06/23	(51) Cl.Int./Int.Cl. <i>G01N 33/68</i> (2006.01), <i>G01N 33/48</i> (2006.01), <i>G01N 33/53</i> (2006.01), <i>G01N 33/543</i> (2006.01)
(87) Date publication PCT/PCT Publication Date: 2011/12/29	
(85) Entrée phase nationale/National Entry: 2012/12/20	(71) Demandeur/Applicant: ASTUTE MEDICAL, INC., US
(86) N° demande PCT/PCT Application No.: US 2011/001125	(72) Inventeurs/Inventors: ANDERBERG, JOSEPH, US; GRAY, JEFF, US; MCPHERSON, PAUL, US; NAKAMURA, KEVIN, US; KAMPF, JAMES PATRICK, US
(87) N° publication PCT/PCT Publication No.: 2011/162819	(74) Agent: PERLEY-ROBERTSON, HILL & MCDOUGALL LLP
(30) Priorités/Priorities: 2010/06/23 (US61/357,956); 2010/06/23 (US61/357,966); 2010/06/23 (US61/357,965); 2010/07/14 (US61/364,305); 2010/07/14 (US61/364,296)	

(54) Titre : METHODES ET COMPOSITIONS POUR DIAGNOSTIQUER ET PRONOSTIQUER UNE LESION RENALE ET
UNE INSUFFISANCE RENALE
(54) Title: METHODS AND COMPOSITIONS FOR DIAGNOSIS AND PROGNOSIS OF RENAL INJURY AND RENAL
FAILURE

(57) **Abrégé/Abstract:**

The present invention relates to methods and compositions for monitoring, diagnosis, prognosis, and determination of treatment regimens in subjects suffering from or suspected of having a renal injury. In particular, the invention relates to using a one or more assays configured to detect a kidney injury marker selected from the group consisting of Tumor necrosis factor receptor superfamily member 8, Alpha-Fetoprotein, Thyroxine-binding globulin, Prostate-specific antigen (free form), Apolipoprotein A, Apolipoprotein E, Thyrotropin subunit beta, Platelet-derived growth factor B/B dimer, C-C motif chemokine 7, C-C motif chemokine 26, Complement C4-B, Corticotropin, Interferon alpha-2, Interleukin-4 receptor alpha chain, Insulin-like growth factor-binding protein 4, Insulin-like growth factor-binding protein 5, Interleukin 21, Interleukin 23 alpha subunit, Interleukin-28A, Interleukin-33, Lutropin subunit beta, Matrix Metalloproteinase- 1, Neural cell adhesion molecule 1, Pigment epithelium-derived factor, Vascular endothelial growth factor receptor 2, Vascular endothelial growth factor receptor 3, and IgG4 as diagnostic and prognostic biomarkers in renal injuries.



(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization
International Bureau(43) International Publication Date
29 December 2011 (29.12.2011)(10) International Publication Number
WO 2011/162819 A1(51) International Patent Classification:
G01N 33/48 (2006.01) *G01N 33/53* (2006.01)(21) International Application Number:
PCT/US2011/001125(22) International Filing Date:
23 June 2011 (23.06.2011)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:

61/357,956	23 June 2010 (23.06.2010)	US
61/357,965	23 June 2010 (23.06.2010)	US
61/357,966	23 June 2010 (23.06.2010)	US
61/364,296	14 July 2010 (14.07.2010)	US
61/364,305	14 July 2010 (14.07.2010)	US

(71) Applicant (*for all designated States except US*): **AS-TUTE MEDICAL, INC.** [US/US]; Bldg 2, 645, 3550 General Atomics Court, San Diego, CA 92121 (US).

(72) Inventors; and

(75) Inventors/Applicants (*for US only*): **ANDERBERG, Joseph** [US/US]; 470 Delage Court, Encinitas, CA 92024 (US). **GRAY, Jeff** [US/US]; 417 Bay Meadows Way, Solana Beach, CA 92075 (US). **McPHERSON, Paul** [US/US]; 1449 Elva Court, Encinitas, CA 92024 (US). **NAKAMURA, Kevin** [US/US]; 2409 Newcastle Ave, Cardiff By The Sea, CA 92007 (US). **KAMPF, James, Patrick** [US/US]; 5882 Gablewood Way, San Diego, CA 92130 (US).(74) Agents: **WHITTAKER, Michael, A.** et al.; Acuity Law Group, P.C., 12707 High Bluff Drive, Suite 200, San Diego, CA 92130 (US).(81) Designated States (*unless otherwise indicated, for every kind of national protection available*): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PE, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.(84) Designated States (*unless otherwise indicated, for every kind of regional protection available*): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

Published:

- with international search report (Art. 21(3))
- before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments (Rule 48.2(h))

(54) Title: METHODS AND COMPOSITIONS FOR DIAGNOSIS AND PROGNOSIS OF RENAL INJURY AND RENAL FAILURE

(57) Abstract: The present invention relates to methods and compositions for monitoring, diagnosis, prognosis, and determination of treatment regimens in subjects suffering from or suspected of having a renal injury. In particular, the invention relates to using a one or more assays configured to detect a kidney injury marker selected from the group consisting of Tumor necrosis factor receptor superfamily member 8, Alpha-Fetoprotein, Thyroxine-binding globulin, Prostate-specific antigen (free form), Apolipoprotein A, Apolipoprotein E, Thyrotropin subunit beta, Platelet-derived growth factor B/B dimer, C-C motif chemokine 7, C-C motif chemokine 26, Complement C4-B, Corticotropin, Interferon alpha-2, Interleukin-4 receptor alpha chain, Insulin-like growth factor-binding protein 4, Insulin-like growth factor-binding protein 5, Interleukin 21, Interleukin 23 alpha subunit, Interleukin-28A, Interleukin-33, Lutropin subunit beta, Matrix Metalloproteinase- 1, Neural cell adhesion molecule 1, Pigment epithelium-derived factor, Vascular endothelial growth factor receptor 2, Vascular endothelial growth factor receptor 3, and IgG4 as diagnostic and prognostic biomarkers in renal injuries.



WO 2011/162819 A1

DEMANDE OU BREVET VOLUMINEUX

LA PRÉSENTE PARTIE DE CETTE DEMANDE OU CE BREVET COMPREND PLUS D'UN TOME.

CECI EST LE TOME 1 DE 2
CONTENANT LES PAGES 1 À 337

NOTE : Pour les tomes additionels, veuillez contacter le Bureau canadien des brevets

JUMBO APPLICATIONS/PATENTS

THIS SECTION OF THE APPLICATION/PATENT CONTAINS MORE THAN ONE VOLUME

THIS IS VOLUME 1 OF 2
CONTAINING PAGES 1 TO 337

NOTE: For additional volumes, please contact the Canadian Patent Office

NOM DU FICHER / FILE NAME :

NOTE POUR LE TOME / VOLUME NOTE:

**METHODS AND COMPOSITIONS FOR DIAGNOSIS AND PROGNOSIS OF
RENAL INJURY AND RENAL FAILURE**

[0001] The present application claims priority to U.S. Provisional Patent Application No. 61/357,965 filed June 23, 2010; U.S. Provisional Patent Application No. 61/357,956 filed June 23, 2010; U.S. Provisional Patent Application No. 61/357,966 filed June 23, 2010; U.S. Provisional Patent Application No. 61/364,305 filed July 14, 2010; and U.S. Provisional Patent Application No. 61/364,296 filed July 14, 2010, each of which is hereby incorporated in its entirety including all tables, figures, and claims.

BACKGROUND OF THE INVENTION

[0002] The following discussion of the background of the invention is merely provided to aid the reader in understanding the invention and is not admitted to describe or constitute prior art to the present invention.

[0003] The kidney is responsible for water and solute excretion from the body. Its functions include maintenance of acid-base balance, regulation of electrolyte concentrations, control of blood volume, and regulation of blood pressure. As such, loss of kidney function through injury and/or disease results in substantial morbidity and mortality. A detailed discussion of renal injuries is provided in Harrison's Principles of Internal Medicine, 17th Ed., McGraw Hill, New York, pages 1741-1830, which are hereby incorporated by reference in their entirety. Renal disease and/or injury may be acute or chronic. Acute and chronic kidney disease are described as follows (from Current Medical Diagnosis & Treatment 2008, 47th Ed, McGraw Hill, New York, pages 785-815, which are hereby incorporated by reference in their entirety): "Acute renal failure is worsening of renal function over hours to days, resulting in the retention of nitrogenous wastes (such as urea nitrogen) and creatinine in the blood. Retention of these substances is called azotemia. Chronic renal failure (chronic kidney disease) results from an abnormal loss of renal function over months to years".

[0004] Acute renal failure (ARF, also known as acute kidney injury, or AKI) is an abrupt (typically detected within about 48 hours to 1 week) reduction in glomerular filtration. This loss of filtration capacity results in retention of nitrogenous (urea and creatinine) and non-nitrogenous waste products that are normally excreted by the kidney, a reduction in urine output, or both. It is reported that ARF complicates about 5% of

hospital admissions, 4-15% of cardiopulmonary bypass surgeries, and up to 30% of intensive care admissions. ARF may be categorized as prerenal, intrinsic renal, or postrenal in causation. Intrinsic renal disease can be further divided into glomerular, tubular, interstitial, and vascular abnormalities. Major causes of ARF are described in the following table, which is adapted from the Merck Manual, 17th ed., Chapter 222, and which is hereby incorporated by reference in their entirety:

Type	Risk Factors
Prerenal	
ECF volume depletion	Excessive diuresis, hemorrhage, GI losses, loss of intravascular fluid into the extravascular space (due to ascites, peritonitis, pancreatitis, or burns), loss of skin and mucus membranes, renal salt- and water-wasting states
Low cardiac output	Cardiomyopathy, MI, cardiac tamponade, pulmonary embolism, pulmonary hypertension, positive-pressure mechanical ventilation
Low systemic vascular resistance	Septic shock, liver failure, antihypertensive drugs
Increased renal vascular resistance	NSAIDs, cyclosporines, tacrolimus, hypercalcemia, anaphylaxis, anesthetics, renal artery obstruction, renal vein thrombosis, sepsis, hepatorenal syndrome
Decreased efferent arteriolar tone (leading to decreased GFR from reduced glomerular transcapillary pressure, especially in patients with bilateral renal artery stenosis)	ACE inhibitors or angiotensin II receptor blockers
Intrinsic Renal	
Acute tubular injury	Ischemia (prolonged or severe prerenal state): surgery, hemorrhage, arterial or venous obstruction; Toxins: NSAIDs, cyclosporines, tacrolimus, aminoglycosides, foscarnet, ethylene glycol, hemoglobin, myoglobin, ifosfamide, heavy metals, methotrexate, radiopaque contrast agents, streptozotocin
Acute glomerulonephritis	ANCA-associated: Crescentic glomerulonephritis, polyarteritis nodosa, Wegener's granulomatosis; Anti-GBM glomerulonephritis: Goodpasture's syndrome; Immune-complex: Lupus glomerulonephritis, postinfectious glomerulonephritis, cryoglobulinemic glomerulonephritis
Acute tubulointerstitial nephritis	Drug reaction (eg, β -lactams, NSAIDs, sulfonamides, ciprofloxacin, thiazide diuretics, furosemide, phenytoin, allopurinol, pyelonephritis, papillary necrosis)
Acute vascular	Vasculitis, malignant hypertension, thrombotic

Type	Risk Factors
nephropathy	microangiopathies, scleroderma, atheroembolism
Infiltrative diseases	Lymphoma, sarcoidosis, leukemia
Postrenal	
Tubular precipitation	Uric acid (tumor lysis), sulfonamides, triamterene, acyclovir, indinavir, methotrexate, ethylene glycol ingestion, myeloma protein, myoglobin
Ureteral obstruction	Intrinsic: Calculi, clots, sloughed renal tissue, fungus ball, edema, malignancy, congenital defects; Extrinsic: Malignancy, retroperitoneal fibrosis, ureteral trauma during surgery or high impact injury
Bladder obstruction	Mechanical: Benign prostatic hyperplasia, prostate cancer, bladder cancer, urethral strictures, phimosis, paraphimosis, urethral valves, obstructed indwelling urinary catheter; Neurogenic: Anticholinergic drugs, upper or lower motor neuron lesion

[0005] In the case of ischemic ARF, the course of the disease may be divided into four phases. During an initiation phase, which lasts hours to days, reduced perfusion of the kidney is evolving into injury. Glomerular ultrafiltration reduces, the flow of filtrate is reduced due to debris within the tubules, and back leakage of filtrate through injured epithelium occurs. Renal injury can be mediated during this phase by reperfusion of the kidney. Initiation is followed by an extension phase which is characterized by continued ischemic injury and inflammation and may involve endothelial damage and vascular congestion. During the maintenance phase, lasting from 1 to 2 weeks, renal cell injury occurs, and glomerular filtration and urine output reaches a minimum. A recovery phase can follow in which the renal epithelium is repaired and GFR gradually recovers. Despite this, the survival rate of subjects with ARF may be as low as about 60%.

[0006] Acute kidney injury caused by radiocontrast agents (also called contrast media) and other nephrotoxins such as cyclosporine, antibiotics including aminoglycosides and anticancer drugs such as cisplatin manifests over a period of days to about a week. Contrast induced nephropathy (CIN, which is AKI caused by radiocontrast agents) is thought to be caused by intrarenal vasoconstriction (leading to ischemic injury) and from the generation of reactive oxygen species that are directly toxic to renal tubular epithelial cells. CIN classically presents as an acute (onset within 24-48h) but reversible (peak 3-5 days, resolution within 1 week) rise in blood urea nitrogen and serum creatinine.

[0007] A commonly reported criteria for defining and detecting AKI is an abrupt (typically within about 2-7 days or within a period of hospitalization) elevation of serum creatinine. Although the use of serum creatinine elevation to define and detect AKI is well established, the magnitude of the serum creatinine elevation and the time over which it is measured to define AKI varies considerably among publications. Traditionally, relatively large increases in serum creatinine such as 100%, 200%, an increase of at least 100% to a value over 2 mg/dL and other definitions were used to define AKI. However, the recent trend has been towards using smaller serum creatinine rises to define AKI. The relationship between serum creatinine rise, AKI and the associated health risks are reviewed in Praught and Shlipak, *Curr Opin Nephrol Hypertens* 14:265-270, 2005 and Chertow et al, *J Am Soc Nephrol* 16: 3365-3370, 2005, which, with the references listed therein, are hereby incorporated by reference in their entirety. As described in these publications, acute worsening renal function (AKI) and increased risk of death and other detrimental outcomes are now known to be associated with very small increases in serum creatinine. These increases may be determined as a relative (percent) value or a nominal value. Relative increases in serum creatinine as small as 20% from the pre-injury value have been reported to indicate acutely worsening renal function (AKI) and increased health risk, but the more commonly reported value to define AKI and increased health risk is a relative increase of at least 25%. Nominal increases as small as 0.3 mg/dL, 0.2 mg/dL or even 0.1 mg/dL have been reported to indicate worsening renal function and increased risk of death. Various time periods for the serum creatinine to rise to these threshold values have been used to define AKI, for example, ranging from 2 days, 3 days, 7 days, or a variable period defined as the time the patient is in the hospital or intensive care unit. These studies indicate there is not a particular threshold serum creatinine rise (or time period for the rise) for worsening renal function or AKI, but rather a continuous increase in risk with increasing magnitude of serum creatinine rise.

[0008] One study (Lassnigg et al, *J Am Soc Nephrol* 15:1597-1605, 2004, hereby incorporated by reference in its entirety) investigated both increases and decreases in serum creatinine. Patients with a mild fall in serum creatinine of -0.1 to -0.3 mg/dL following heart surgery had the lowest mortality rate. Patients with a larger fall in serum creatinine (more than or equal to -0.4 mg/dL) or any increase in serum creatinine had a larger mortality rate. These findings caused the authors to conclude that even very subtle changes in renal function (as detected by small creatinine changes within 48 hours of

surgery) seriously effect patient's outcomes. In an effort to reach consensus on a unified classification system for using serum creatinine to define AKI in clinical trials and in clinical practice, Bellomo *et al.*, *Crit Care*. 8(4):R204-12, 2004, which is hereby incorporated by reference in its entirety, proposes the following classifications for stratifying AKI patients:

“Risk”: serum creatinine increased 1.5 fold from baseline OR urine production of <0.5 ml/kg body weight/hr for 6 hours;

“Injury”: serum creatinine increased 2.0 fold from baseline OR urine production <0.5 ml/kg/hr for 12 h;

“Failure”: serum creatinine increased 3.0 fold from baseline OR creatinine >355 $\mu\text{mol/l}$ (with a rise of >44) or urine output below 0.3 ml/kg/hr for 24 h or anuria for at least 12 hours;

And included two clinical outcomes:

“Loss”: persistent need for renal replacement therapy for more than four weeks.

“ESRD”: end stage renal disease—the need for dialysis for more than 3 months.

[0009] These criteria are called the RIFLE criteria, which provide a useful clinical tool to classify renal status. As discussed in Kellum, *Crit. Care Med.* 36: S141-45, 2008 and Ricci *et al.*, *Kidney Int.* 73, 538-546, 2008, each hereby incorporated by reference in its entirety, the RIFLE criteria provide a uniform definition of AKI which has been validated in numerous studies.

More recently, Mehta *et al.*, *Crit. Care* 11:R31 (doi:10.1186.cc5713), 2007, hereby incorporated by reference in its entirety, proposes the following similar classifications for stratifying AKI patients, which have been modified from RIFLE:

“Stage I”: increase in serum creatinine of more than or equal to 0.3 mg/dL ($\geq 26.4 \mu\text{mol/L}$) or increase to more than or equal to 150% (1.5-fold) from baseline OR urine output less than 0.5 mL/kg per hour for more than 6 hours;

“Stage II”: increase in serum creatinine to more than 200% (> 2-fold) from baseline OR urine output less than 0.5 mL/kg per hour for more than 12 hours;

“Stage III”: increase in serum creatinine to more than 300% (> 3-fold) from baseline OR serum creatinine $\geq 354 \mu\text{mol/L}$ accompanied by an acute increase of at least $44 \mu\text{mol/L}$ OR urine output less than 0.3 mL/kg per hour for 24 hours or anuria for 12 hours.

[0010] The CIN Consensus Working Panel (McCollough et al, Rev Cardiovasc Med. 2006;7(4):177-197, hereby incorporated by reference in its entirety) uses a serum creatinine rise of 25% to define Contrast induced nephropathy (which is a type of AKI). Although various groups propose slightly different criteria for using serum creatinine to detect AKI, the consensus is that small changes in serum creatinine, such as 0.3 mg/dL or 25%, are sufficient to detect AKI (worsening renal function) and that the magnitude of the serum creatinine change is an indicator of the severity of the AKI and mortality risk.

[0011] Although serial measurement of serum creatinine over a period of days is an accepted method of detecting and diagnosing AKI and is considered one of the most important tools to evaluate AKI patients, serum creatinine is generally regarded to have several limitations in the diagnosis, assessment and monitoring of AKI patients. The time period for serum creatinine to rise to values (e.g., a 0.3 mg/dL or 25% rise) considered diagnostic for AKI can be 48 hours or longer depending on the definition used. Since cellular injury in AKI can occur over a period of hours, serum creatinine elevations detected at 48 hours or longer can be a late indicator of injury, and relying on serum creatinine can thus delay diagnosis of AKI. Furthermore, serum creatinine is not a good indicator of the exact kidney status and treatment needs during the most acute phases of AKI when kidney function is changing rapidly. Some patients with AKI will recover fully, some will need dialysis (either short term or long term) and some will have other detrimental outcomes including death, major adverse cardiac events and chronic kidney disease. Because serum creatinine is a marker of filtration rate, it does not differentiate between the causes of AKI (pre-renal, intrinsic renal, post-renal obstruction, atheroembolic, etc) or the category or location of injury in intrinsic renal disease (for example, tubular, glomerular or interstitial in origin). Urine output is similarly limited. Knowing these things can be of vital importance in managing and treating patients with AKI.

[0012] These limitations underscore the need for better methods to detect and assess AKI, particularly in the early and subclinical stages, but also in later stages when

recovery and repair of the kidney can occur. Furthermore, there is a need to better identify patients who are at risk of having an AKI.

BRIEF SUMMARY OF THE INVENTION

[0013] It is an object of the invention to provide methods and compositions for evaluating renal function in a subject. As described herein, measurement of one or more biomarkers selected from the group consisting of Tumor necrosis factor receptor superfamily member 8, Alpha-Fetoprotein, Thyroxine-binding globulin, Prostate-specific antigen (free form), Apolipoprotein A, Apolipoprotein E, Thyrotropin subunit beta, Platelet-derived growth factor B/B dimer, C-C motif chemokine 7, C-C motif chemokine 26, Complement C4-B, Corticotropin, Interferon alpha-2, Interleukin-4 receptor alpha chain, Insulin-like growth factor-binding protein 4, Insulin-like growth factor-binding protein 5, Interleukin 21, Interleukin 23 alpha subunit, Interleukin-28A, Interleukin-33, Lutropin subunit beta, Matrix Metalloproteinase-1, Neural cell adhesion molecule 1, Pigment epithelium-derived factor, Vascular endothelial growth factor receptor 2, Vascular endothelial growth factor receptor 3, and IgG4 (each referred to herein as a “kidney injury marker”) can be used for diagnosis, prognosis, risk stratification, staging, monitoring, categorizing and determination of further diagnosis and treatment regimens in subjects suffering or at risk of suffering from an injury to renal function, reduced renal function, and/or acute renal failure (also called acute kidney injury).

[0014] The kidney injury markers of the present invention may be used, individually or in panels comprising a plurality of kidney injury markers, for risk stratification (that is, to identify subjects at risk for a future injury to renal function, for future progression to reduced renal function, for future progression to ARF, for future improvement in renal function, *etc.*); for diagnosis of existing disease (that is, to identify subjects who have suffered an injury to renal function, who have progressed to reduced renal function, who have progressed to ARF, *etc.*); for monitoring for deterioration or improvement of renal function; and for predicting a future medical outcome, such as improved or worsening renal function, a decreased or increased mortality risk, a decreased or increased risk that a subject will require renal replacement therapy (*i.e.*, hemodialysis, peritoneal dialysis, hemofiltration, and/or renal transplantation, a decreased or increased risk that a subject will recover from an injury to renal function, a decreased or increased risk that a subject will recover from ARF, a decreased or increased risk that a subject will progress to end

stage renal disease, a decreased or increased risk that a subject will progress to chronic renal failure, a decreased or increased risk that a subject will suffer rejection of a transplanted kidney, *etc.*

[0015] In a first aspect, the present invention relates to methods for evaluating renal status in a subject. These methods comprise performing an assay method that is configured to detect one or more biomarkers selected from the group consisting of Tumor necrosis factor receptor superfamily member 8, Alpha-Fetoprotein, Thyroxine-binding globulin, Prostate-specific antigen (free form), Apolipoprotein A, Apolipoprotein E, Thyrotropin subunit beta, Platelet-derived growth factor B/B dimer, C-C motif chemokine 7, C-C motif chemokine 26, Complement C4-B, Corticotropin, Interferon alpha-2, Interleukin-4 receptor alpha chain, Insulin-like growth factor-binding protein 4, Insulin-like growth factor-binding protein 5, Interleukin 21, Interleukin 23 alpha subunit, Interleukin-28A, Interleukin-33, Lutropin subunit beta, Matrix Metalloproteinase-1, Neural cell adhesion molecule 1, Pigment epithelium-derived factor, Vascular endothelial growth factor receptor 2, Vascular endothelial growth factor receptor 3, and IgG4 complex is/are then correlated to the renal status of the subject. This correlation to renal status may include correlating the assay result(s) to one or more of risk stratification, diagnosis, prognosis, staging, classifying and monitoring of the subject as described herein. Thus, the present invention utilizes one or more kidney injury markers of the present invention for the evaluation of renal injury.

[0016] In certain embodiments, the methods for evaluating renal status described herein are methods for risk stratification of the subject; that is, assigning a likelihood of one or more future changes in renal status to the subject. In these embodiments, the assay result(s) is/are correlated to one or more such future changes. The following are preferred risk stratification embodiments.

[0017] In preferred risk stratification embodiments, these methods comprise determining a subject's risk for a future injury to renal function, and the assay result(s) is/are correlated to a likelihood of such a future injury to renal function. For example, the measured concentration(s) may each be compared to a threshold value. For a "positive going" kidney injury marker, an increased likelihood of suffering a future injury to renal function is assigned to the subject when the measured concentration is above the threshold, relative to a likelihood assigned when the measured concentration is below the threshold. For a "negative going" kidney injury marker, an increased likelihood of

suffering a future injury to renal function is assigned to the subject when the measured concentration is below the threshold, relative to a likelihood assigned when the measured concentration is above the threshold.

[0018] In other preferred risk stratification embodiments, these methods comprise determining a subject's risk for future reduced renal function, and the assay result(s) is/are correlated to a likelihood of such reduced renal function. For example, the measured concentrations may each be compared to a threshold value. For a "positive going" kidney injury marker, an increased likelihood of suffering a future reduced renal function is assigned to the subject when the measured concentration is above the threshold, relative to a likelihood assigned when the measured concentration is below the threshold. For a "negative going" kidney injury marker, an increased likelihood of future reduced renal function is assigned to the subject when the measured concentration is below the threshold, relative to a likelihood assigned when the measured concentration is above the threshold.

[0019] In still other preferred risk stratification embodiments, these methods comprise determining a subject's likelihood for a future improvement in renal function, and the assay result(s) is/are correlated to a likelihood of such a future improvement in renal function. For example, the measured concentration(s) may each be compared to a threshold value. For a "positive going" kidney injury marker, an increased likelihood of a future improvement in renal function is assigned to the subject when the measured concentration is below the threshold, relative to a likelihood assigned when the measured concentration is above the threshold. For a "negative going" kidney injury marker, an increased likelihood of a future improvement in renal function is assigned to the subject when the measured concentration is above the threshold, relative to a likelihood assigned when the measured concentration is below the threshold.

[0020] In yet other preferred risk stratification embodiments, these methods comprise determining a subject's risk for progression to ARF, and the result(s) is/are correlated to a likelihood of such progression to ARF. For example, the measured concentration(s) may each be compared to a threshold value. For a "positive going" kidney injury marker, an increased likelihood of progression to ARF is assigned to the subject when the measured concentration is above the threshold, relative to a likelihood assigned when the measured concentration is below the threshold. For a "negative going" kidney injury marker, an increased likelihood of progression to ARF is assigned to the subject when the measured

concentration is below the threshold, relative to a likelihood assigned when the measured concentration is above the threshold.

[0021] And in other preferred risk stratification embodiments, these methods comprise determining a subject's outcome risk, and the assay result(s) is/are correlated to a likelihood of the occurrence of a clinical outcome related to a renal injury suffered by the subject. For example, the measured concentration(s) may each be compared to a threshold value. For a "positive going" kidney injury marker, an increased likelihood of one or more of: acute kidney injury, progression to a worsening stage of AKI, mortality, a requirement for renal replacement therapy, a requirement for withdrawal of renal toxins, end stage renal disease, heart failure, stroke, myocardial infarction, progression to chronic kidney disease, etc., is assigned to the subject when the measured concentration is above the threshold, relative to a likelihood assigned when the measured concentration is below the threshold. For a "negative going" kidney injury marker, an increased likelihood of one or more of: acute kidney injury, progression to a worsening stage of AKI, mortality, a requirement for renal replacement therapy, a requirement for withdrawal of renal toxins, end stage renal disease, heart failure, stroke, myocardial infarction, progression to chronic kidney disease, etc., is assigned to the subject when the measured concentration is below the threshold, relative to a likelihood assigned when the measured concentration is above the threshold.

[0022] In such risk stratification embodiments, preferably the likelihood or risk assigned is that an event of interest is more or less likely to occur within 180 days of the time at which the body fluid sample is obtained from the subject. In particularly preferred embodiments, the likelihood or risk assigned relates to an event of interest occurring within a shorter time period such as 18 months, 120 days, 90 days, 60 days, 45 days, 30 days, 21 days, 14 days, 7 days, 5 days, 96 hours, 72 hours, 48 hours, 36 hours, 24 hours, 12 hours, or less. A risk at 0 hours of the time at which the body fluid sample is obtained from the subject is equivalent to diagnosis of a current condition.

[0023] In preferred risk stratification embodiments, the subject is selected for risk stratification based on the pre-existence in the subject of one or more known risk factors for prerenal, intrinsic renal, or postrenal ARF. For example, a subject undergoing or having undergone major vascular surgery, coronary artery bypass, or other cardiac surgery; a subject having pre-existing congestive heart failure, preeclampsia, eclampsia, diabetes mellitus, hypertension, coronary artery disease, proteinuria, renal insufficiency,

glomerular filtration below the normal range, cirrhosis, serum creatinine above the normal range, or sepsis; or a subject exposed to NSAIDs, cyclosporines, tacrolimus, aminoglycosides, foscarnet, ethylene glycol, hemoglobin, myoglobin, ifosfamide, heavy metals, methotrexate, radiopaque contrast agents, or streptozotocin are all preferred subjects for monitoring risks according to the methods described herein. This list is not meant to be limiting. By “pre-existence” in this context is meant that the risk factor exists at the time the body fluid sample is obtained from the subject. In particularly preferred embodiments, a subject is chosen for risk stratification based on an existing diagnosis of injury to renal function, reduced renal function, or ARF.

[0024] In other embodiments, the methods for evaluating renal status described herein are methods for diagnosing a renal injury in the subject; that is, assessing whether or not a subject has suffered from an injury to renal function, reduced renal function, or ARF. In these embodiments, the assay result(s), for example measured concentration(s) of one or more biomarkers selected from the group consisting of Tumor necrosis factor receptor superfamily member 8, Alpha-Fetoprotein, Thyroxine-binding globulin, Prostate-specific antigen (free form), Apolipoprotein A, Apolipoprotein E, Thyrotropin subunit beta, Platelet-derived growth factor B/B dimer, C-C motif chemokine 7, C-C motif chemokine 26, Complement C4-B, Corticotropin, Interferon alpha-2, Interleukin-4 receptor alpha chain, Insulin-like growth factor-binding protein 4, Insulin-like growth factor-binding protein 5, Interleukin 21, Interleukin 23 alpha subunit, Interleukin-28A, Interleukin-33, Lutropin subunit beta, Matrix Metalloproteinase-1, Neural cell adhesion molecule 1, Pigment epithelium-derived factor, Vascular endothelial growth factor receptor 2, Vascular endothelial growth factor receptor 3, and IgG4 is/are correlated to the occurrence or nonoccurrence of a change in renal status. The following are preferred diagnostic embodiments.

[0025] In preferred diagnostic embodiments, these methods comprise diagnosing the occurrence or nonoccurrence of an injury to renal function, and the assay result(s) is/are correlated to the occurrence or nonoccurrence of such an injury. For example, each of the measured concentration(s) may be compared to a threshold value. For a positive going marker, an increased likelihood of the occurrence of an injury to renal function is assigned to the subject when the measured concentration is above the threshold (relative to the likelihood assigned when the measured concentration is below the threshold); alternatively, when the measured concentration is below the threshold, an increased

likelihood of the nonoccurrence of an injury to renal function may be assigned to the subject (relative to the likelihood assigned when the measured concentration is above the threshold). For a negative going marker, an increased likelihood of the occurrence of an injury to renal function is assigned to the subject when the measured concentration is below the threshold (relative to the likelihood assigned when the measured concentration is above the threshold); alternatively, when the measured concentration is above the threshold, an increased likelihood of the nonoccurrence of an injury to renal function may be assigned to the subject (relative to the likelihood assigned when the measured concentration is below the threshold).

[0026] In other preferred diagnostic embodiments, these methods comprise diagnosing the occurrence or nonoccurrence of reduced renal function, and the assay result(s) is/are correlated to the occurrence or nonoccurrence of an injury causing reduced renal function. For example, each of the measured concentration(s) may be compared to a threshold value. For a positive going marker, an increased likelihood of the occurrence of an injury causing reduced renal function is assigned to the subject when the measured concentration is above the threshold (relative to the likelihood assigned when the measured concentration is below the threshold); alternatively, when the measured concentration is below the threshold, an increased likelihood of the nonoccurrence of an injury causing reduced renal function may be assigned to the subject (relative to the likelihood assigned when the measured concentration is above the threshold). For a negative going marker, an increased likelihood of the occurrence of an injury causing reduced renal function is assigned to the subject when the measured concentration is below the threshold (relative to the likelihood assigned when the measured concentration is above the threshold); alternatively, when the measured concentration is above the threshold, an increased likelihood of the nonoccurrence of an injury causing reduced renal function may be assigned to the subject (relative to the likelihood assigned when the measured concentration is below the threshold).

[0027] In yet other preferred diagnostic embodiments, these methods comprise diagnosing the occurrence or nonoccurrence of ARF, and the assay result(s) is/are correlated to the occurrence or nonoccurrence of an injury causing ARF. For example, each of the measured concentration(s) may be compared to a threshold value. For a positive going marker, an increased likelihood of the occurrence of ARF is assigned to the subject when the measured concentration is above the threshold (relative to the

likelihood assigned when the measured concentration is below the threshold); alternatively, when the measured concentration is below the threshold, an increased likelihood of the nonoccurrence of ARF may be assigned to the subject (relative to the likelihood assigned when the measured concentration is above the threshold). For a negative going marker, an increased likelihood of the occurrence of ARF is assigned to the subject when the measured concentration is below the threshold (relative to the likelihood assigned when the measured concentration is above the threshold); alternatively, when the measured concentration is above the threshold, an increased likelihood of the nonoccurrence of ARF may be assigned to the subject (relative to the likelihood assigned when the measured concentration is below the threshold).

[0028] In still other preferred diagnostic embodiments, these methods comprise diagnosing a subject as being in need of renal replacement therapy, and the assay result(s) is/are correlated to a need for renal replacement therapy. For example, each of the measured concentration(s) may be compared to a threshold value. For a positive going marker, an increased likelihood of the occurrence of an injury creating a need for renal replacement therapy is assigned to the subject when the measured concentration is above the threshold (relative to the likelihood assigned when the measured concentration is below the threshold); alternatively, when the measured concentration is below the threshold, an increased likelihood of the nonoccurrence of an injury creating a need for renal replacement therapy may be assigned to the subject (relative to the likelihood assigned when the measured concentration is above the threshold). For a negative going marker, an increased likelihood of the occurrence of an injury creating a need for renal replacement therapy is assigned to the subject when the measured concentration is below the threshold (relative to the likelihood assigned when the measured concentration is above the threshold); alternatively, when the measured concentration is above the threshold, an increased likelihood of the nonoccurrence of an injury creating a need for renal replacement therapy may be assigned to the subject (relative to the likelihood assigned when the measured concentration is below the threshold).

[0029] In still other preferred diagnostic embodiments, these methods comprise diagnosing a subject as being in need of renal transplantation, and the assay result(s) is/are correlated to a need for renal transplantation. For example, each of the measured concentration(s) may be compared to a threshold value. For a positive going marker, an increased likelihood of the occurrence of an injury creating a need for renal

transplantation is assigned to the subject when the measured concentration is above the threshold (relative to the likelihood assigned when the measured concentration is below the threshold); alternatively, when the measured concentration is below the threshold, an increased likelihood of the nonoccurrence of an injury creating a need for renal transplantation may be assigned to the subject (relative to the likelihood assigned when the measured concentration is above the threshold). For a negative going marker, an increased likelihood of the occurrence of an injury creating a need for renal transplantation is assigned to the subject when the measured concentration is below the threshold (relative to the likelihood assigned when the measured concentration is above the threshold); alternatively, when the measured concentration is above the threshold, an increased likelihood of the nonoccurrence of an injury creating a need for renal transplantation may be assigned to the subject (relative to the likelihood assigned when the measured concentration is below the threshold).

[0030] In still other embodiments, the methods for evaluating renal status described herein are methods for monitoring a renal injury in the subject; that is, assessing whether or not renal function is improving or worsening in a subject who has suffered from an injury to renal function, reduced renal function, or ARF. In these embodiments, the assay result(s), for example measured concentration(s) of one or more biomarkers selected from the group consisting of Tumor necrosis factor receptor superfamily member 8, Alpha-Fetoprotein, Thyroxine-binding globulin, Prostate-specific antigen (free form), Apolipoprotein A, Apolipoprotein E, Thyrotropin subunit beta, Platelet-derived growth factor B/B dimer, C-C motif chemokine 7, C-C motif chemokine 26, Complement C4-B, Corticotropin, Interferon alpha-2, Interleukin-4 receptor alpha chain, Insulin-like growth factor-binding protein 4, Insulin-like growth factor-binding protein 5, Interleukin 21, Interleukin 23 alpha subunit, Interleukin-28A, Interleukin-33, Lutropin subunit beta, Matrix Metalloproteinase-1, Neural cell adhesion molecule 1, Pigment epithelium-derived factor, Vascular endothelial growth factor receptor 2, Vascular endothelial growth factor receptor 3, and IgG4 is/are correlated to the occurrence or nonoccurrence of a change in renal status. The following are preferred monitoring embodiments.

[0031] In preferred monitoring embodiments, these methods comprise monitoring renal status in a subject suffering from an injury to renal function, and the assay result(s) is/are correlated to the occurrence or nonoccurrence of a change in renal status in the subject. For example, the measured concentration(s) may be compared to a threshold

value. For a positive going marker, when the measured concentration is above the threshold, a worsening of renal function may be assigned to the subject; alternatively, when the measured concentration is below the threshold, an improvement of renal function may be assigned to the subject. For a negative going marker, when the measured concentration is below the threshold, a worsening of renal function may be assigned to the subject; alternatively, when the measured concentration is above the threshold, an improvement of renal function may be assigned to the subject.

[0032] In other preferred monitoring embodiments, these methods comprise monitoring renal status in a subject suffering from reduced renal function, and the assay result(s) is/are correlated to the occurrence or nonoccurrence of a change in renal status in the subject. For example, the measured concentration(s) may be compared to a threshold value. For a positive going marker, when the measured concentration is above the threshold, a worsening of renal function may be assigned to the subject; alternatively, when the measured concentration is below the threshold, an improvement of renal function may be assigned to the subject. For a negative going marker, when the measured concentration is below the threshold, a worsening of renal function may be assigned to the subject; alternatively, when the measured concentration is above the threshold, an improvement of renal function may be assigned to the subject.

[0033] In yet other preferred monitoring embodiments, these methods comprise monitoring renal status in a subject suffering from acute renal failure, and the assay result(s) is/are correlated to the occurrence or nonoccurrence of a change in renal status in the subject. For example, the measured concentration(s) may be compared to a threshold value. For a positive going marker, when the measured concentration is above the threshold, a worsening of renal function may be assigned to the subject; alternatively, when the measured concentration is below the threshold, an improvement of renal function may be assigned to the subject. For a negative going marker, when the measured concentration is below the threshold, a worsening of renal function may be assigned to the subject; alternatively, when the measured concentration is above the threshold, an improvement of renal function may be assigned to the subject.

[0034] In other additional preferred monitoring embodiments, these methods comprise monitoring renal status in a subject at risk of an injury to renal function due to the pre-existence of one or more known risk factors for prerenal, intrinsic renal, or postrenal ARF, and the assay result(s) is/are correlated to the occurrence or

nonoccurrence of a change in renal status in the subject. For example, the measured concentration(s) may be compared to a threshold value. For a positive going marker, when the measured concentration is above the threshold, a worsening of renal function may be assigned to the subject; alternatively, when the measured concentration is below the threshold, an improvement of renal function may be assigned to the subject. For a negative going marker, when the measured concentration is below the threshold, a worsening of renal function may be assigned to the subject; alternatively, when the measured concentration is above the threshold, an improvement of renal function may be assigned to the subject.

[0035] In still other embodiments, the methods for evaluating renal status described herein are methods for classifying a renal injury in the subject; that is, determining whether a renal injury in a subject is prerenal, intrinsic renal, or postrenal; and/or further subdividing these classes into subclasses such as acute tubular injury, acute glomerulonephritis acute tubulointerstitial nephritis, acute vascular nephropathy, or infiltrative disease; and/or assigning a likelihood that a subject will progress to a particular RIFLE stage. In these embodiments, the assay result(s), for example measured concentration(s) of one or more biomarkers selected from the group consisting of Tumor necrosis factor receptor superfamily member 8, Alpha-Fetoprotein, Thyroxine-binding globulin, Prostate-specific antigen (free form), Apolipoprotein A, Apolipoprotein E, Thyrotropin subunit beta, Platelet-derived growth factor B/B dimer, C-C motif chemokine 7, C-C motif chemokine 26, Complement C4-B, Corticotropin, Interferon alpha-2, Interleukin-4 receptor alpha chain, Insulin-like growth factor-binding protein 4, Insulin-like growth factor-binding protein 5, Interleukin 21, Interleukin 23 alpha subunit, Interleukin-28A, Interleukin-33, Lutropin subunit beta, Matrix Metalloproteinase-1, Neural cell adhesion molecule 1, Pigment epithelium-derived factor, Vascular endothelial growth factor receptor 2, Vascular endothelial growth factor receptor 3, and IgG4 is/are correlated to a particular class and/or subclass. The following are preferred classification embodiments.

[0036] In preferred classification embodiments, these methods comprise determining whether a renal injury in a subject is prerenal, intrinsic renal, or postrenal; and/or further subdividing these classes into subclasses such as acute tubular injury, acute glomerulonephritis acute tubulointerstitial nephritis, acute vascular nephropathy, or infiltrative disease; and/or assigning a likelihood that a subject will progress to a

particular RIFLE stage, and the assay result(s) is/are correlated to the injury classification for the subject. For example, the measured concentration may be compared to a threshold value, and when the measured concentration is above the threshold, a particular classification is assigned; alternatively, when the measured concentration is below the threshold, a different classification may be assigned to the subject.

[0037] A variety of methods may be used by the skilled artisan to arrive at a desired threshold value for use in these methods. For example, the threshold value may be determined from a population of normal subjects by selecting a concentration representing the 75th, 85th, 90th, 95th, or 99th percentile of a kidney injury marker measured in such normal subjects. Alternatively, the threshold value may be determined from a “diseased” population of subjects, e.g., those suffering from an injury or having a predisposition for an injury (e.g., progression to ARF or some other clinical outcome such as death, dialysis, renal transplantation, etc.), by selecting a concentration representing the 75th, 85th, 90th, 95th, or 99th percentile of a kidney injury marker measured in such subjects. In another alternative, the threshold value may be determined from a prior measurement of a kidney injury marker in the same subject; that is, a temporal change in the level of a kidney injury marker in the subject may be used to assign risk to the subject.

[0038] The foregoing discussion is not meant to imply, however, that the kidney injury markers of the present invention must be compared to corresponding individual thresholds. Methods for combining assay results can comprise the use of multivariate logistical regression, loglinear modeling, neural network analysis, n-of-m analysis, decision tree analysis, calculating ratios of markers, etc. This list is not meant to be limiting. In these methods, a composite result which is determined by combining individual markers may be treated as if it is itself a marker; that is, a threshold may be determined for the composite result as described herein for individual markers, and the composite result for an individual patient compared to this threshold.

[0039] The ability of a particular test to distinguish two populations can be established using ROC analysis. For example, ROC curves established from a “first” subpopulation which is predisposed to one or more future changes in renal status, and a “second” subpopulation which is not so predisposed can be used to calculate a ROC curve, and the area under the curve provides a measure of the quality of the test. Preferably, the tests described herein provide a ROC curve area greater than 0.5,

preferably at least 0.6, more preferably 0.7, still more preferably at least 0.8, even more preferably at least 0.9, and most preferably at least 0.95.

[0040] In certain aspects, the measured concentration of one or more kidney injury markers, or a composite of such markers, may be treated as continuous variables. For example, any particular concentration can be converted into a corresponding probability of a future reduction in renal function for the subject, the occurrence of an injury, a classification, etc. In yet another alternative, a threshold that can provide an acceptable level of specificity and sensitivity in separating a population of subjects into “bins” such as a “first” subpopulation (e.g., which is predisposed to one or more future changes in renal status, the occurrence of an injury, a classification, etc.) and a “second” subpopulation which is not so predisposed. A threshold value is selected to separate this first and second population by one or more of the following measures of test accuracy:

an odds ratio greater than 1, preferably at least about 2 or more or about 0.5 or less, more preferably at least about 3 or more or about 0.33 or less, still more preferably at least about 4 or more or about 0.25 or less, even more preferably at least about 5 or more or about 0.2 or less, and most preferably at least about 10 or more or about 0.1 or less;

a specificity of greater than 0.5, preferably at least about 0.6, more preferably at least about 0.7, still more preferably at least about 0.8, even more preferably at least about 0.9 and most preferably at least about 0.95, with a corresponding sensitivity greater than 0.2, preferably greater than about 0.3, more preferably greater than about 0.4, still more preferably at least about 0.5, even more preferably about 0.6, yet more preferably greater than about 0.7, still more preferably greater than about 0.8, more preferably greater than about 0.9, and most preferably greater than about 0.95;

a sensitivity of greater than 0.5, preferably at least about 0.6, more preferably at least about 0.7, still more preferably at least about 0.8, even more preferably at least about 0.9 and most preferably at least about 0.95, with a corresponding specificity greater than 0.2, preferably greater than about 0.3, more preferably greater than about 0.4, still more preferably at least about 0.5, even more preferably about 0.6, yet more preferably greater than about 0.7, still more preferably greater than about 0.8, more preferably greater than about 0.9, and most preferably greater than about 0.95;

at least about 75% sensitivity, combined with at least about 75% specificity;

a positive likelihood ratio (calculated as sensitivity/(1-specificity)) of greater than 1, at least about 2, more preferably at least about 3, still more preferably at least about 5, and most preferably at least about 10; or

a negative likelihood ratio (calculated as (1-sensitivity)/specificity) of less than 1, less than or equal to about 0.5, more preferably less than or equal to about 0.3, and most preferably less than or equal to about 0.1.

The term “about” in the context of any of the above measurements refers to +/- 5% of a given measurement.

[0041] Multiple thresholds may also be used to assess renal status in a subject. For example, a “first” subpopulation which is predisposed to one or more future changes in renal status, the occurrence of an injury, a classification, etc., and a “second” subpopulation which is not so predisposed can be combined into a single group. This group is then subdivided into three or more equal parts (known as tertiles, quartiles, quintiles, etc., depending on the number of subdivisions). An odds ratio is assigned to subjects based on which subdivision they fall into. If one considers a tertile, the lowest or highest tertile can be used as a reference for comparison of the other subdivisions. This reference subdivision is assigned an odds ratio of 1. The second tertile is assigned an odds ratio that is relative to that first tertile. That is, someone in the second tertile might be 3 times more likely to suffer one or more future changes in renal status in comparison to someone in the first tertile. The third tertile is also assigned an odds ratio that is relative to that first tertile.

[0042] In certain embodiments, the assay method is an immunoassay. Antibodies for use in such assays will specifically bind a full length kidney injury marker of interest, and may also bind one or more polypeptides that are “related” thereto, as that term is defined hereinafter. Numerous immunoassay formats are known to those of skill in the art. Preferred body fluid samples are selected from the group consisting of urine, blood, serum, saliva, tears, and plasma.

[0043] The foregoing method steps should not be interpreted to mean that the kidney injury marker assay result(s) is/are used in isolation in the methods described herein. Rather, additional variables or other clinical indicia may be included in the methods described herein. For example, a risk stratification, diagnostic, classification, monitoring, etc. method may combine the assay result(s) with one or more variables measured for the

subject selected from the group consisting of demographic information (e.g., weight, sex, age, race), medical history (e.g., family history, type of surgery, pre-existing disease such as aneurism, congestive heart failure, preeclampsia, eclampsia, diabetes mellitus, hypertension, coronary artery disease, proteinuria, renal insufficiency, or sepsis, type of toxin exposure such as NSAIDs, cyclosporines, tacrolimus, aminoglycosides, foscarnet, ethylene glycol, hemoglobin, myoglobin, ifosfamide, heavy metals, methotrexate, radiopaque contrast agents, or streptozotocin), clinical variables (e.g., blood pressure, temperature, respiration rate), risk scores (APACHE score, PREDICT score, TIMI Risk Score for UA/NSTEMI, Framingham Risk Score, risk scores of Thakar et al. (J. Am. Soc. Nephrol. 16: 162-68, 2005), Mehran et al. (J. Am. Coll. Cardiol. 44: 1393-99, 2004), Wijeyesundera et al. (JAMA 297: 1801-9, 2007), Goldstein and Chawla (Clin. J. Am. Soc. Nephrol. 5: 943-49, 2010), or Chawla et al. (Kidney Intl. 68: 2274-80, 2005)), a glomerular filtration rate, an estimated glomerular filtration rate, a urine production rate, a serum or plasma creatinine concentration, a urine creatinine concentration, a fractional excretion of sodium, a urine sodium concentration, a urine creatinine to serum or plasma creatinine ratio, a urine specific gravity, a urine osmolality, a urine urea nitrogen to plasma urea nitrogen ratio, a plasma BUN to creatinine ratio, a renal failure index calculated as $\text{urine sodium} / (\text{urine creatinine} / \text{plasma creatinine})$, a serum or plasma neutrophil gelatinase (NGAL) concentration, a urine NGAL concentration, a serum or plasma cystatin C concentration, a serum or plasma cardiac troponin concentration, a serum or plasma BNP concentration, a serum or plasma NTproBNP concentration, and a serum or plasma proBNP concentration. Other measures of renal function which may be combined with one or more kidney injury marker assay result(s) are described hereinafter and in Harrison's Principles of Internal Medicine, 17th Ed., McGraw Hill, New York, pages 1741-1830, and Current Medical Diagnosis & Treatment 2008, 47th Ed, McGraw Hill, New York, pages 785-815, each of which are hereby incorporated by reference in their entirety.

[0044] When more than one marker is measured, the individual markers may be measured in samples obtained at the same time, or may be determined from samples obtained at different (e.g., an earlier or later) times. The individual markers may also be measured on the same or different body fluid samples. For example, one kidney injury marker may be measured in a serum or plasma sample and another kidney injury marker may be measured in a urine sample. In addition, assignment of a likelihood may combine

an individual kidney injury marker assay result with temporal changes in one or more additional variables.

[0045] In various related aspects, the present invention also relates to devices and kits for performing the methods described herein. Suitable kits comprise reagents sufficient for performing an assay for at least one of the described kidney injury markers, together with instructions for performing the described threshold comparisons.

[0046] In certain embodiments, reagents for performing such assays are provided in an assay device, and such assay devices may be included in such a kit. Preferred reagents can comprise one or more solid phase antibodies, the solid phase antibody comprising antibody that detects the intended biomarker target(s) bound to a solid support. In the case of sandwich immunoassays, such reagents can also include one or more detectably labeled antibodies, the detectably labeled antibody comprising antibody that detects the intended biomarker target(s) bound to a detectable label. Additional optional elements that may be provided as part of an assay device are described hereinafter.

[0047] Detectable labels may include molecules that are themselves detectable (e.g., fluorescent moieties, electrochemical labels, ecl (electrochemical luminescence) labels, metal chelates, colloidal metal particles, etc.) as well as molecules that may be indirectly detected by production of a detectable reaction product (e.g., enzymes such as horseradish peroxidase, alkaline phosphatase, etc.) or through the use of a specific binding molecule which itself may be detectable (e.g., a labeled antibody that binds to the second antibody, biotin, digoxigenin, maltose, oligohistidine, 2,4-dinitrobenzene, phenylarsenate, ssDNA, dsDNA, etc.).

[0048] Generation of a signal from the signal development element can be performed using various optical, acoustical, and electrochemical methods well known in the art. Examples of detection modes include fluorescence, radiochemical detection, reflectance, absorbance, amperometry, conductance, impedance, interferometry, ellipsometry, etc. In certain of these methods, the solid phase antibody is coupled to a transducer (e.g., a diffraction grating, electrochemical sensor, etc) for generation of a signal, while in others, a signal is generated by a transducer that is spatially separate from the solid phase antibody (e.g., a fluorometer that employs an excitation light source and an optical detector). This list is not meant to be limiting. Antibody-based biosensors may

also be employed to determine the presence or amount of analytes that optionally eliminate the need for a labeled molecule.

DETAILED DESCRIPTION OF THE INVENTION

[0049] The present invention relates to methods and compositions for diagnosis, differential diagnosis, risk stratification, monitoring, classifying and determination of treatment regimens in subjects suffering or at risk of suffering from injury to renal function, reduced renal function and/or acute renal failure through measurement of one or more kidney injury markers. In various embodiments, a measured concentration of one or more biomarkers selected from the group consisting of Tumor necrosis factor receptor superfamily member 8, Alpha-Fetoprotein, Thyroxine-binding globulin, Prostate-specific antigen (free form), Apolipoprotein A, Apolipoprotein E, Thyrotropin subunit beta, Platelet-derived growth factor B/B dimer, C-C motif chemokine 7, C-C motif chemokine 26, Complement C4-B, Corticotropin, Interferon alpha-2, Interleukin-4 receptor alpha chain, Insulin-like growth factor-binding protein 4, Insulin-like growth factor-binding protein 5, Interleukin 21, Interleukin 23 alpha subunit, Interleukin-28A, Interleukin-33, Lutropin subunit beta, Matrix Metalloproteinase-1, Neural cell adhesion molecule 1, Pigment epithelium-derived factor, Vascular endothelial growth factor receptor 2, Vascular endothelial growth factor receptor 3, and IgG4 or one or more markers related thereto, are correlated to the renal status of the subject.

[0050] For purposes of this document, the following definitions apply:

[0051] As used herein, an “injury to renal function” is an abrupt (within 14 days, preferably within 7 days, more preferably within 72 hours, and still more preferably within 48 hours) measurable reduction in a measure of renal function. Such an injury may be identified, for example, by a decrease in glomerular filtration rate or estimated GFR, a reduction in urine output, an increase in serum creatinine, an increase in serum cystatin C, a requirement for renal replacement therapy, *etc.* “Improvement in Renal Function” is an abrupt (within 14 days, preferably within 7 days, more preferably within 72 hours, and still more preferably within 48 hours) measurable increase in a measure of renal function. Preferred methods for measuring and/or estimating GFR are described hereinafter.

[0052] As used herein, “reduced renal function” is an abrupt (within 14 days, preferably within 7 days, more preferably within 72 hours, and still more preferably within 48 hours) reduction in kidney function identified by an absolute increase in serum

creatinine of greater than or equal to 0.1 mg/dL ($\geq 8.8 \mu\text{mol/L}$), a percentage increase in serum creatinine of greater than or equal to 20% (1.2-fold from baseline), or a reduction in urine output (documented oliguria of less than 0.5 ml/kg per hour).

[0053] As used herein, “acute renal failure” or “ARF” is an abrupt (within 14 days, preferably within 7 days, more preferably within 72 hours, and still more preferably within 48 hours) reduction in kidney function identified by an absolute increase in serum creatinine of greater than or equal to 0.3 mg/dl ($\geq 26.4 \mu\text{mol/l}$), a percentage increase in serum creatinine of greater than or equal to 50% (1.5-fold from baseline), or a reduction in urine output (documented oliguria of less than 0.5 ml/kg per hour for at least 6 hours). This term is synonymous with “acute kidney injury” or “AKI.”

[0054] As used herein, the term “C-C motif chemokine 7” refers to one or more polypeptides present in a biological sample that are derived from the C-C motif chemokine 7 precursor (Swiss-Prot P80098 (SEQ ID NO: 1)).

```

      10      20      30      40      50      60
MKASAALLCL LLTAAAFSPQ GLAQPVGIN STCCYRFIN KKIPKQRLES YRRTTSSHCP

      70      80      90
REAVIFKTKL DKEICADPTQ KVVQDFMKHL DKKTQTPKL

```

[0055] The following domains have been identified in C-C motif chemokine 7:

Residues	Length	Domain ID
1-23	23	Signal peptide
24-99	76	C-C motif chemokine 7

[0056] As used herein, the term “C-C motif chemokine 26” refers to one or more polypeptides present in a biological sample that are derived from the C-C motif chemokine 26 precursor (Swiss-Prot Q9Y258 (SEQ ID NO: 2)).

```

      10      20      30      40      50      60
MMGLSLASAV LLASLLSLHL GTATRGSDIS KTCCFQYSHK PLPWTWVRSY EFTSNSCSQR

      70      80      90
AVIFTTKRGK KVCTHPRKKW VQKYISLLKT PKQL

```

[0057] The following domains have been identified in C-C motif chemokine 26:

Residues	Length	Domain ID

1-23 23 Signal peptide

24-94 71 C-C motif chemokine 26

[0058] As used herein, the term “Complement C4-B” refers to one or more polypeptides present in a biological sample that are derived from Complement C4-B precursor (Swiss-Prot P0C0L5 (SEQ ID NO: 3)).

10	20	30	40	50	60
MRLWGLIWA	SSFFTLSLQK	PRLLLFSPSV	VHLGVPLSVG	VQLQDVPRGQ	VVKGSVFLRN
70	80	90	100	110	120
PSRNNVPCSP	KVDFTLSSER	DFALLSLQVP	LKDAKSCGLH	QLLRGPEVQL	VAHSPWLKDS
130	140	150	160	170	180
LSRTTNIQGI	NLLFSSRRGH	LFLQTDQPIY	NPGQVRVRYRV	FALDQKMRPS	TDTITVMVEN
190	200	210	220	230	240
SHGLRVRKKE	VYMPSSIFQD	DFVIPDISEP	GTWKISARFS	DGLESNSSTQ	FEVKKYVLPN
250	260	270	280	290	300
FEVKITPGKP	YILTVPGHLD	EMQLDIQARY	IYGKPVQGVA	YVRFGLLDED	GKKTFFRGLE
310	320	330	340	350	360
SQTKLVNGQS	HISLSKAEFQ	DALEKLNMG	TDLQGLRLYV	AAAIIESPGG	EMEEAELTSW
370	380	390	400	410	420
YFVSSPFSLD	LSKTKRHLVP	GAPFLLQALV	REMSGSPASG	IPVKVSATVS	SPGSVPEVQD
430	440	450	460	470	480
IQQNTDGSGQ	VSIPIIIPQT	ISELQLSVSA	GSPHPAIARL	TVAAPPSGGP	GFLSIERPDS
490	500	510	520	530	540
RPPRVGDTLN	LNLRAVGSGA	TFSHYYMIL	SRGQIVFMNR	EPKRTLTSVS	VFVDHHLAPS
550	560	570	580	590	600
FYFVAFYYHG	DHPVANSLRV	DVQAGACEGK	LELSVDGAKQ	YRNGESVKLH	LETDSLALVA
610	620	630	640	650	660
LGALDTALYA	AGSKSHKPLN	MGKVFEAMNS	YDLGCGPGGG	DSALQVFQAA	GLAFSDGDQW
670	680	690	700	710	720
TLSRKRLSCP	KEKTTRKKRN	VNFQKAIN EK	LGQYASPTAK	RCCQDGVTRL	PMMRSCEQRA
730	740	750	760	770	780
ARVQQPD CRE	PFLSCCQFAE	SLRKKS RDKG	QAGLQRALEI	LQEEDLIDED	DIPVRSFFPE
790	800	810	820	830	840
NWLWRVETVD	RFQILTLWLP	DSLTTWEIHG	LSLSKTKGLC	VATPVQLRVF	REFHLHLRLP
850	860	870	880	890	900
MSVRRFEQLE	LRPVLYNYLD	KNLTVSVHVS	PVEGLCLAGG	GGLAQQVLVP	AGSARPVAFS
910	920	930	940	950	960


```

VVPTAAAVS LKVVARGSFE FPVGDAVSKV LQIEKEGAIH REELVYELNP LDHRGRTLEI
      970      980      990      1000      1010      1020
PGNSDPNMIP DGDFNSYVRV TASDPLDTLG SEGALSPGGV ASLLRLPRGC GEQTMIYLAP
      1030      1040      1050      1060      1070      1080
TLAASRYLDK TEQWSTLPPE TKDHAVDLIQ KGYMRIQQFR KADGSYAAWL SRDSSTWLTA
      1090      1100      1110      1120      1130      1140
FVLKVLSLAQ EQVGGSPEKL QETSNWLLSQ QQADGSFQDL SPVIHRSMQG GLVGNDETVA
      1150      1160      1170      1180      1190      1200
LTAFVTIALH HGLAVFQDEG AEPLKQRVEA SISKANSFLG EKASAGLLGA HAAAITAYAL
      1210      1220      1230      1240      1250      1260
SLTKAPVDLL GVAHNNLMAM AQETGDNLYW GSVTGSQSNA VSPTPAPRNP SDPMPQAPAL
      1270      1280      1290      1300      1310      1320
WIETTAYALL HLLLHEGKAE MADQASAWLT RQGSFQGGFR STQDTVIALD ALSAYWIASH
      1330      1340      1350      1360      1370      1380
TTEERGLNVT LSSTGRNGFK SHALQLNNRQ IRGLEEELQF SLGSKINVKV GGNSKGTCLKV
      1390      1400      1410      1420      1430      1440
LRTYNVLDK NTTCQDLQIE VTVKGHVEYT MEANEDYEDY EYDELPKDD PDAPLQPVTP
      1450      1460      1470      1480      1490      1500
LQLFEGRRNR RRREAPKVVE EQESRVHYTV CIWRNGKVGL SGMAIADVTL LSGFHALRAD
      1510      1520      1530      1540      1550      1560
LEKLTSLSDR YVSHFETEGP HVLLYFDSVP TSRECVGFEA VQEVVPVGLVQ PASATLYDYY
      1570      1580      1590      1600      1610      1620
NPERRCSVFY GAPSKSRLLA TLCSAEVCQC AEGKCPRQRR ALERGLQDED GYRMKFACY
      1630      1640      1650      1660      1670      1680
PRVEYGFQVK VLREDSRAAF RLFETKITQV LHFTKDVKAA ANQMRNFLVR ASCRLRLEPG
      1690      1700      1710      1720      1730      1740
KEYLIMGLDG ATYDLEGHPQ YLLDSNSWIE EMPSERLCRS TRQRAACAQL NDFLQEYGTQ

```

GCQV

[0059] The following domains have been identified in Complement C4-B:

Residues	Length	Domain ID
1-19	19	Signal peptide
20-675	656	Complement C4-B beta chain
676-679	4	Propeptide

680-1446	767	Complement C4-B alpha chain
680-756	77	Complement C4-a anaphylatoxin
757-1446	690	Complement C4b-B
957-1336	380	Complement C4d-B
1447-1453	7	propeptide
1454-1744	291	Complement C4-B gamma chain

[0060] As used herein, the term "Corticotropin" refers to one or more polypeptides present in a biological sample that are derived from pro-opiomelanocortin precursor (Swiss-Prot P01189 (SEQ ID NO: 4)) containing one or more epitopes of corticotropin.

```

      10      20      30      40      50      60
MPRSCCSRSG ALLLALLLQA SMEVRGWCLE SSQCQDLTTE SNLLECIRAC KPDLSAETPM

      70      80      90     100     110     120
FPGNGDEQPL TENPRKYVMG HFRWDRFGRR NSSSSGSSGA GQKREDVSAG EDCGPLPEGG

     130     140     150     160     170     180
PEPRSDGAKP GPREGKRSYS MEHFRWGKPV GKKRRPVKVY PNGAEDESAE AFPLEFKREL

     190     200     210     220     230     240
TGQRLREGDG PDGPADDGAG AQADLEHSLV VAAEKKDEGP YRMEHFRWGS PPKDKRYGGF

     250     260
MTSEKSQTPL VTLFKNAIIK NAYKKGE

```

[0061] The following domains have been identified in pro-opiomelanocortin:

Residues	Length	Domain ID
1-26	26	Signal peptide
27-102	76	NPP
77-87	11	Melanotropin gamma
105-134	30	peptide
138-176	39	Corticotropin
138-150	13	Melanotropin alpha
156-176	21	Corticotropin-like intermediary peptide
179-267	89	Lipotropin beta

179-234	56	Lipotropin gamma
217-234	18	Melanotropin beta
237-267	31	beta endorphin
237-241	5	met enkephalin

[0062] As used herein, the term “Interferon alpha-2” refers to one or more polypeptides present in a biological sample that are derived from the Interferon alpha-2 precursor (Swiss-Prot P01563 (SEQ ID NO: 5)).

```

      10      20      30      40      50      60
MALTFALLVA LLVLSCSSC SVGCDLPQTH SLGSRRTLML LAQMRKISLF SCLKDRHDFG

      70      80      90     100     110     120
FPQEEFGNQF QKAETIPVLH EMIQQIFNLF STKDSSAAWD ETLLDKFYTE LYQQLNDLEA

     130     140     150     160     170     180
CVIQGVGVTE TPLMKEDSIL AVRKYFQRIT LYLKEKKYSP CAWEVVRAEI MRSFSLSTNL

QESLRSKE

```

[0063] The following domains have been identified in Interferon alpha-2:

Residues	Length	Domain ID
1-23	23	Signal peptide
24-188	209	Interferon alpha-2

[0064] As used herein, the term “Interleukin-4 receptor subunit alpha” refers to one or more polypeptides present in a biological sample that are derived from the Interleukin-4 receptor subunit alpha precursor (Swiss-Prot P24394 (SEQ ID NO: 6)):

```

      10      20      30      40      50      60
MGWLCSGLLF PVSCLVLLQV ASSGNMKVLQ EPTCVSDYMS ISTCEWKMNNG PTNCSTELRL

      70      80      90     100     110     120
LYQLVFLLE AHTCIPENNG GAGCVCHLLM DDVVSADNYT LDLWAGQQLL WKGSKPKSEH

     130     140     150     160     170     180
VKPRAPGNLT VHTNVSDTLL LTWSNPYPYPD NYLYNHLYTA VNIWSENDPA DFRIYNVTYL

     190     200     210     220     230     240
EPSLRIAAST LKSGISYRAR VRAWAQCYN T WSEWSPSTK WHNSYREPFE QHLLLGVSVS

     250     260     270     280     290     300
CIVILAVCLL CYVSITIKKK EWWDDQIPNPA RSRLVAIIIQ DAQGSQWEKR SRGQEPKACP

```



```

      310      320      330      340      350      360
HWKNCLTKLL PCFLEHNMKR DEDPHKAAKE MPFQSGSKSA WCPVEISKTV LWPESISVVR

      370      380      390      400      410      420
CVELFEAPVE CEEEEEEVEEE KGSFCASPES SRDDFQEGRE GIVARLTESL FLDLLGEENG

      430      440      450      460      470      480
GFCQQDMGES CLLPPSGSTS AHMPWDEFPS AGPKEAPPWG KEQPLHLEPS PPASPTQSPD

      490      500      510      520      530      540
NLTCTETPLV IAGNPAYRSF SNSLSQSPCP RELGPDPLLA RHLEEVEPEM PCVPQLSEPT

      550      560      570      580      590      600
TVPQPEPETW EQILRRNVLQ HGAAAAPVSA PTSGYQEFVH AVEQGGTQAS AVVGLGPPGE

      610      620      630      640      650      660
AGYKAFSSLL ASSAVSPEKC GFGASSGEEG YKPFQDLIPG CPGDPAPVPV PLFTFGLDRE

      670      680      690      700      710      720
PPRSPQSSHL PSSSPEHLGL EPGEKVEDMP KPPLPQEQAT DPLVDSLGS G IVYSALTCHL

      730      740      750      760      770      780
CGHLKQCHGQ EDGGQTPVMA SPCCGCCCGD RSSPPTTPLR APDPSPGGVP LEASLCPASL

      790      800      810      820
APSGISEKSK SSSSFHPAPG NAQSSSQTPK IVNFVSVGPT YMRVS

```

[0065] Interleukin-4 receptor subunit alpha is a single-pass type I membrane protein having a large extracellular domain, some or all of which is present in soluble forms of Interleukin-4 receptor subunit alpha generated either through alternative splicing event which deletes all or a portion of the transmembrane domain, or by proteolysis of the membrane-bound form. In the case of an immunoassay, one or more antibodies that bind to epitopes within this extracellular domain may be used to detect these soluble form(s). The following domains have been identified in Interleukin-4 receptor subunit alpha:

Residues	Length	Domain ID
1-25	25	Signal peptide
26-825	800	Interleukin-4 receptor subunit alpha
26-232	319	Extracellular domain
233-256	20	Transmembrane domain
257-825	213	Cytoplasmic domain
228-825		Missing in soluble isoform 2

225-227

YRE → NIC in soluble isoform 2

[0066] As used herein, the term “Insulin-like growth factor-binding protein 4” refers to one or more polypeptides present in a biological sample that are derived from the Insulin-like growth factor-binding protein 4 precursor (Swiss-Prot P22692 (SEQ ID NO: 7)).

```

      10      20      30      40      50      60
MLPLCLVAAL LLAAGPGPSL GDEAIHCPPC SEEKLARCRP PVGCEELVRE PGCGCCATCA

      70      80      90     100     110     120
LGLGMPCGVY TPRCGSGLRC YPPRGVEKPL HTLMHGQGVC MELAEIEAIQ ESLQPSDKDE

     130     140     150     160     170     180
GDHPNNSFSP CSAHRRCLQ KHFAKIRDRS TSGGKMKVNG APREDARPVP QGSCQSELHR

     190     200     210     220     230     240
ALERLAASQS RTHEDLYIIP IPNCDRNGNF HPKQCHPALD GQRGKCWCVD RKTGVKLPGG

     250
LEPKGELDCH QLADSFRE

```

[0067] The following domains have been identified in Insulin-like growth factor-binding protein 4:

Residues	Length	Domain ID
1-21	21	Signal peptide
22-258	237	Insulin-like growth factor-binding protein 4

[0068] As used herein, the term “Insulin-like growth factor-binding protein 5” refers to one or more polypeptides present in a biological sample that are derived from the Insulin-like growth factor-binding protein 5 precursor (Swiss-Prot P24593 (SEQ ID NO: 8)).

```

      10      20      30      40      50      60
MVLLTAVLLL LAAYAGPAQS LGSFVHCEPC DEKALSMCPP SPLGCELVKE PGCGCCMTCA

      70      80      90     100     110     120
LAEGQSCGVY TERCAQGLRC LPRQDEEKPL HALLHGRGVC LNEKSYREQV KIERDSREHE

     130     140     150     160     170     180
EPTTSEMAEE TYSPKIFRPK HTRISELKAE AVKKDRRKKL TQSKFVGGAE NTAHPRIISA

     190     200     210     220     230     240
PEMRQESEQG PCRRHMEASL QELKASPRMV PRAVYLPNCD RKGFYKRKQC KPSRGRKRG I

     250     260     270

```


CWCVDKYGMK LPGMEYVDGD FQCHTFDSSN VE

[0069] The following domains have been identified in Insulin-like growth factor-binding protein 5:

Residues	Length	Domain ID
1-20	20	Signal peptide
21-272	252	Insulin-like growth factor-binding protein 5

[0070] As used herein, the term "Interleukin-21" refers to one or more polypeptides present in a biological sample that are derived from the Interleukin-21 precursor (Swiss-Prot Q9HBE4 (SEQ ID NO: 8)).

```

      10      20      30      40      50      60
MERIVICLMV IFLGTLVHKS SSQGQDRHMI RMRQLIDIVD QKKNYVNDLV PEFLPAPEDV

      70      80      90     100     110     120
ETNCEWSAFS CFQKAQLKSA NTGNNERIIN VSIKKLKRKP PSTNAGRQK HRLTCPSCDS

     130     140     150
YEKKPPKEFL ERFKSLQKM IHQHLSSRTH GSEDS

```

[0071] The following domains have been identified in Interleukin-21:

Residues	Length	Domain ID
1-22	22	Signal peptide
23-155	133	Interleukin-21

[0072] As used herein, the term "Interleukin-23 subunit alpha" refers to one or more polypeptides present in a biological sample that are derived from the Interleukin-23 subunit alpha precursor (Swiss-Prot Q9NPF7 (SEQ ID NO: 9)).

```

      10      20      30      40      50      60
MLGSRAVMLL LLLPWTAAQGR AVPGGSSPAW TQCQQLSQKL CTLAWSAHPL VGHMDLREEG

      70      80      90     100     110     120
DEETTNDVPH IQCGDGCDPQ GLRDNSQFCL QRIHQGLIFY EKLLGSDIFT GEPSLLPDSP

     130     140     150     160     170     180
VGQLHASLLG LSQLLQPEGH HWETQQIPSL SPSQPWQRL LRFKILRSLQ AFVAVAAARVF

AHGAATLSP

```


[0073] The following domains have been identified in Interleukin-23 subunit alpha:

Residues	Length	Domain ID
1-19	19	Signal peptide
20-189	170	Interleukin-23 subunit alpha

[0074] As used herein, the term "Interleukin-28A" refers to one or more polypeptides present in a biological sample that are derived from the Interleukin-28A precursor (Swiss-Prot Q8IZJ0 (SEQ ID NO: 10)).

10	20	30	40	50	60
MKLDMTGDCT	PVLVLMAAVL	TVTGAVPVAR	LHGALPDARG	CHIAQFKSLS	PQELQAFKRA
70	80	90	100	110	120
KDALEESLLL	KDCRCHSRLF	PRTWDLRQLQ	VRERPMALEA	ELALTLKVLE	ATADTDPALV
130	140	150	160	170	180
DVLDQPLHTL	HHILSQFRAC	IQPQPTAGPR	TRGRLHHWLY	RLQEAPKKES	PGCLEASVTF
190	200				
NLFRLLTRDL	NCVASGDLCV				

[0075] The following domains have been identified in Interleukin-28A:

Residues	Length	Domain ID
1-25	25	Signal peptide
26-200	175	Interleukin-28A

[0076] As used herein, the term "Interleukin-33" refers to one or more polypeptides present in a biological sample that are derived from the Interleukin-33 precursor (Swiss-Prot O95760 (SEQ ID NO: 11)).

10	20	30	40	50	60
MKPKMKYSTN	KISTAKWKNT	ASKALCFKLG	KSQQKAKEVC	PMYFMKLRSG	LMIKKEACYF
70	80	90	100	110	120
RRETTKRPSL	KTGRKHKRHL	VLAACQQQST	VECFAFGISG	VQKYTRALHD	SSITGISPIT
130	140	150	160	170	180
EYLASLSTYN	DQSITFALED	ESYEIYVEDL	KKDEKKDKVL	LSYYESQHPS	NESGDGVDGK
190	200	210	220	230	240
MLMVTLSPTK	DFWLHANNKE	HSVELHKCEK	PLPDQAFFVL	HNMHNSNCVSF	ECKTDPGVFI
250	260	270			
GVKDNHLALI	KVDSSENLCT	ENILFKLSET			

[0077] The following domains have been identified in Interleukin-33:

Residues	Length	Domain ID
1-270	270	Interleukin-33

[0078] As used herein, the term “Lutropin subunit beta” refers to one or more polypeptides present in a biological sample that are derived from the Lutropin subunit beta precursor (Swiss-Prot P01229 (SEQ ID NO: 12)).

10	20	30	40	50	60
MEMLQGLLLL	LLLSMGGAWA	SREPLRPWCH	PINAILAVEK	EGCPVCITVN	TTICAGYCPT
70	80	90	100	110	120
MMRVLQAVLP	PLPQVVCTYR	DVRFESIRLP	GCPRGVDPVV	SFPVALSCRC	GPCRRSTSDC
130	140				
GGPKDHPLTC	DHPQLSGLLF	L			

[0079] The following domains have been identified in Lutropin subunit beta:

Residues	Length	Domain ID
1-20	20	Signal peptide
21-141	121	Lutropin subunit beta

[0080] As used herein, the term “Interstitial collagenase” (also known as MMP-1 and matrix metalloproteinase 1) refers to one or more polypeptides present in a biological sample that are derived from the Interstitial collagenase precursor (Swiss-Prot P03956 (SEQ ID NO: 13)).

10	20	30	40	50	60
MHSFPPLLLL	LFWGVVSHSF	PATLETQEQD	VDLVQKYLEK	YYNLKNDGRQ	VEKRRNSGPV
70	80	90	100	110	120
VEKLRQMDEF	FGLKVTGKPD	AETLKVMKQP	RCGVDPVAQF	VLTEGNPRWE	QTHLTYRIEN
130	140	150	160	170	180
YTPDLPRADV	DHAIEKAFQL	WSNVTPLTFT	KVSEGQADIM	ISFVRGDHRD	NSPFDGPGGN
190	200	210	220	230	240
LAHAFQPGPG	IGGDAHFDDE	ERWTNNFREY	NLHRVAAHEL	GHSGLGLSHST	DIGALMYPST
250	260	270	280	290	300
TFSGDVQLAQ	DDIDGIQAIY	GRSQNPVQPI	GPQTPKACDS	KLTFDAITTI	RGEVMFFKDR
310	320	330	340	350	360


```

FYMRTNPFYP EVELNFISVF WPQLPNGLEA AYEFAADRDEV RFFKGNKYWA VQGQNVLHGY
      370      380      390      400      410      420
PKDIYSSFGF PRTVKHIDAA LSEENTGKTY FVANKYWRY DEYKRSMDFG YPKMIAHDFP
      430      440      450      460
GIGHKVDAVF MKDGFFYFFH GTRQYKFDPK TKRILTLQKA NSWFNCRKN

```

[0081] The following domains have been identified in Interstitial collagenase:

Residues	Length	Domain ID
1-19	19	Signal peptide
20-99	80	Activation peptide
100-469	370	Interstitial collagenase
100-269	170	22 kDa Interstitial collagenase
270-469	200	27 kDa Interstitial collagenase

[0082] As used herein, the term “Neural cell adhesion molecule 1” refers to one or more polypeptides present in a biological sample that are derived from the Neural cell adhesion molecule 1 precursor (Swiss-Prot P13591 (SEQ ID NO: 14):

```

      10      20      30      40      50      60
MLQTKDLIWT LFFLGTA VSL QVDIVPSQGE ISVGESKFFL CQVAGDAKDK DISWFSPNGE
      70      80      90     100     110     120
KLTPNQQRIS VWNDDSSST LTIYNANIDD AGIYKCVVTG EDGSESEATV NVKIFQKLMF
     130     140     150     160     170     180
KNAPTPQEFR EGEDAVIVCD VVSSLPPTII WKHKGRDVIL KKDVRFIVLS NNYLQIRGIK
     190     200     210     220     230     240
KTDEGTYRCE GRILARGEIN FKDIQVIVNV PPTIQARQNI VNATANLGQS VTLVCDAEGF
     250     260     270     280     290     300
PEPTMSWTKD GEQIEQEEDD EKYIFSDDSS QLTIKKVDKN DEAEYICIAE NKAGEQDATI
     310     320     330     340     350     360
HLKVFAKPKI TYVENQTAME LEEQVTLTCE ASGDPIPSIT WRTSTRNISS EEKASWTRPE
     370     380     390     400     410     420
KQETLDGHMV VRSHARVSSL TLKSIQYTDA GEYICTASNT IGQDSQSMYL EVQYAPKLQG
     430     440     450     460     470     480
PVAVYTWEGN QVNITCEVFA YPSATISWFR DGQLLPSSNY SNIKIYNTPS ASYLEVTPDS
     490     500     510     520     530     540
ENDFGNYNCT AVNRIGQESL EFILVQADTP SSPSIDQVEP YSSTAQVQFD EPEATGGVPI

```



```

      550      560      570      580      590      600
LKYKAEWRAV GEEVWHISKWY DAKEASMEGI VTIVGLKPET TYAVRLAALN GKGLGEISAA

      610      620      630      640      650      660
SEFKTQPVQG EPSAPKLEGQ MGEDGNSIKV NLIKQDDGGS PIRHYLVRYR ALSSEWKPEI

      670      680      690      700      710      720
RLPSGSDHVM LKSLDWNAEY EVYVVAENQQ GKSKAAHFVF RTSAQPTAIP ANGSP TSGLS

      730      740      750      760      770      780
TGAIVGILIV IFVLLL VVVD ITCYFLNKC G LFMCI AVNLC GKAGPGAKGK DMEEGKA AFS

      790      800      810      820      830      840
KDESKEPIVE VRTEEERTPN HDGGKHTEPN ETTPLTEPEK GPVEAKPECQ ETETKPAPAE

      850
VKTVPN DATQ TKENESKA

```

[0083] Neural cell adhesion molecule 1 is a single-pass type I membrane protein having a large extracellular domain, some or all of which is present in soluble forms of Neural cell adhesion molecule 1 generated either through alternative splicing event which deletes all or a portion of the transmembrane domain, or by proteolysis of the membrane-bound form. In the case of an immunoassay, one or more antibodies that bind to epitopes within this extracellular domain may be used to detect these soluble form(s). The following domains have been identified in Neural cell adhesion molecule 1:

Residues	Length	Domain ID
1-19	19	Signal peptide
20-858	839	Neural cell adhesion molecule 1
20-718	699	Extracellular domain
719-739	21	Transmembrane domain
740-858	119	Cytoplasmic domain
354-363		Missing in isoform 2
354-363		Missing in isoform 3
609		Q → HSPPPPASASSSTPVPLSPPD TTWPLP ALATTEPAK (SEQ ID NO: 15) in isoform 3

712-736 NGSPTSGLSTGAIVGILIVIFVLLL (SEQ ID NO: 16) →
 TLGGNSASYTFVSLLFSAVTLLLLC (SEQ ID NO: 17)
 in isoform 3

737-858 Missing in isoform 3

354-363 Missing in isoform 4

712-736 NGSPTSGLSTGAIVGILIVIFVLLL (SEQ ID NO: 18) →
 TLGGNSASYTFVSLLFSAVTLLLLC ((SEQ ID NO: 19)
 in isoform 4

737-858 Missing in isoform 4

609-665 QGEPSAPKLE...WKPEIRLPSG (SEQ ID NO: 20)→
 HSPPPASASSSTPVPLSPDPTTWPLPALATTEPAKNI
 AQ NHCCNMFQAGLHNALMK (SEQ ID NO: 21) in
 isoform 5

364 T → V in isoform 6

365-858 Missing in isoform 6

[0084] As used herein, the term “Pigment epithelium-derived factor” refers to one or more polypeptides present in a biological sample that are derived from the Pigment epithelium-derived factor precursor (Swiss-Prot P36955 (SEQ ID NO: 22)).

10	20	30	40	50	60
MQALVLLLCI	GALLGHSSCQ	NPASPPEEGS	PDPDSTGALV	EEEDPFFKVP	VNKLAAAVSN
70	80	90	100	110	120
FGYDLRVRS	SMSPTTNVLL	SPLSVATALS	ALSLGAEQRT	ESIIHRALYY	DLISSPDIHG
130	140	150	160	170	180
TYKELLDTVT	APQKNLKSAS	RIVFEKKLRI	KSSFVAPLEK	SYGTRPRVLT	GNPRLDLQEI
190	200	210	220	230	240
NNWVQAQMKG	KLARSTKEIP	DEISILLGVL	AHFKGQWVTK	FDSRKTSLED	FYLDEERTVR
250	260	270	280	290	300
VPMMSDPKAV	LRYGLDSDLS	CKIAQLPLTG	SMSIIFFLPL	KVTQNLTLIE	ESLTSEFIHD
310	320	330	340	350	360
IDRELKTVQA	VLTVPKLKLS	YEGEVTKSLQ	EMKLQSLFDS	PDFSKITGKP	IKLTQVEHRA
370	380	390	400	410	
GFEWNEDGAG	TTPSPGLQPA	HLTFPLDYHL	NQPFIFVLRD	TDTGALLFIG	KILDPRGP

[0085] The following domains have been identified in Pigment epithelium-derived factor:

Residues	Length	Domain ID
1-19	19	Signal peptide
20-418	399	Pigment epithelium-derived factor

[0086] As used herein, the term “Platelet-derived growth factor subunit A” refers to one or more polypeptides present in a biological sample that are derived from the Platelet-derived growth factor subunit A precursor (Swiss-Prot P04085 (SEQ ID NO: 23)).

```

      10      20      30      40      50      60
MRTLACLLLL GCGYLAHVLA EEAEIPREVI ERLARSQIHS IRDLQRLLEI DSVGSEDSLD

      70      80      90     100     110     120
TSLRAHGVHA TKHVPEKRPL PIRRKRSIEE AVPAVCKTRT VIYEIPRSQV DPTSANFLIW

     130     140     150     160     170     180
PPCVEVKRCT GCCNTSSVKC QPSRVHRSV KVAKVEYVRK KPKLKEVQVR LEEHLECACA

     190     200     210
TTSLNPDYRE EDTGRPRESG KKRKRKRLKP T

```

[0087] The following domains have been identified in Platelet-derived growth factor subunit A:

Residues	Length	Domain ID
1-20	20	Signal peptide
21-86	66	Propeptide
87-211	125	Platelet-derived growth factor subunit A

[0088] As used herein, the term “Vascular endothelial growth factor receptor 2” refers to one or more polypeptides present in a biological sample that are derived from the Vascular endothelial growth factor receptor 2 precursor (Swiss-Prot P35968 (SEQ ID NO: 24)):

```

      10      20      30      40      50      60
MQSKVLLAVA LWLCVETRAA SVGLPSVSLD LPRLSIQKDI LTIKANTTLQ ITCRGQRDL D

      70      80      90     100     110     120
WLWPNNQSGS EQRVEVTECS DGLFCKTLTI PKVIGNDTGA YKCFYRETDL ASVIYVYVQD

     130     140     150     160     170     180

```


YRSPFIASVS DQHGCVVYITE NKNKTVVIPC LGSISNLNVS LCARYPEKRF VPDGNRISWD
 190 200 210 220 230 240
 SKKGFTIPSY MISYAGMVFC EAKINDESYQ SIMYIVVVVG YRIYDVVLSP SHGIELSVGE
 250 260 270 280 290 300
 KLVLNCTART ELNVGIDFNW EYPSSKHQHK KLVNRDLKTQ SGSEMKKFLS TLTIDGVTRS
 310 320 330 340 350 360
 DQGLYTCAAS SGLMTKKNST FVRVHEKPFV AFGSGMESLV EATVGERVRI PAKYLGYP
 370 380 390 400 410 420
 EIKWYKNGIP LESNHTIKAG HVLTIMEVSE RDTGNYTVIL TNPISKEKQS HVVSLVVYVP
 430 440 450 460 470 480
 PQIGEKSLIS PVDSYQYGTI QTLTCTVYAI PPPHHIHWYW QLEEECANEP SQAVSVTNPY
 490 500 510 520 530 540
 PCEEWRSEVED FQGGNKIEVN KNQFALIEGK NKTVSTLVIQ AANVSALYKC EAVNKVGRGE
 550 560 570 580 590 600
 RVISFHVTRG PEITLQPDQM PTEQESVSLW CTADRSTFEN LTWYKLGPQP LPIHVGELPT
 610 620 630 640 650 660
 PVCKNLDTLW KLNATMFSNS TNDILIMELK NASLQDQGDY VCLAQDRKTK KRHCVVRLT
 670 680 690 700 710 720
 VLERVAPTIT GNLENQTISI GESIEVSCTA SGNPPPQIMW FKDNETLVED SGIVLKDGNR
 730 740 750 760 770 780
 NLTIRRVKE DEGLYTCQAC SVLGCAKVEA FFIIEGAQEK TNLEIIILVG TAVIAMFFWL
 790 800 810 820 830 840
 LLVIIILRTVK RANGGELKTG YLSIVMDPDE LPLDEHCERL PYDASKWEFP RDRLKLGKPL
 850 860 870 880 890 900
 GRGAFGQVIE ADAFGIDKTA TCRTVAVKML KEGATHSEHR ALMSELKILI HIGHHLNVVN
 910 920 930 940 950 960
 LLGACKPGG PLMVIVEFCK FGNLSTYLRK KRNEFVPYKT KGARFRQGKD YVGAIPVDLK
 970 980 990 1000 1010 1020
 RRLDSITSSQ SSASSGFVEE KSLSDVEEEE APEDLYKDFL TLEHLICYSF QVAKGMEFLA
 1030 1040 1050 1060 1070 1080
 SRKCIHRDLA ARNILLSEKN VVKICDFGLA RDIYKDPDYV RKGDLRLPLK WMAPETIFDR
 1090 1100 1110 1120 1130 1140
 VYTIQSDVWS FGVLLWEIFS LGASPYPGVK IDEEFCRRLK EGTRMRAPDY TTPEMYQTML
 1150 1160 1170 1180 1190 1200
 DCWHGEPQR PTFSELVEHL GNLLQANAQQ DGKDYIVLPI SETLSMEEDS GLSLPTSPVS
 1210 1220 1230 1240 1250 1260
 CMEEEEVCDP KFHYDNTAGI SQYLQNSKRK SRPVSVKTFE DIPLEEPEVK VIPDDNQDTS


```

      1270      1280      1290      1300      1310      1320
GMVLASEELK TLEDRTKLSP SFGGMVPSKS RESVASEGSN QTSGYQSGYH SDDTDTTVYS

      1330      1340      1350
SEEAELLKLI EIGVQTGSTA QILQPDSGTT LSSPPV

```

[0089] Vascular endothelial growth factor receptor 2 is a single-pass type I membrane protein having a large extracellular domain, some or all of which is present in soluble forms of Vascular endothelial growth factor receptor 2 generated either through alternative splicing event which deletes all or a portion of the transmembrane domain, or by proteolysis of the membrane-bound form. In the case of an immunoassay, one or more antibodies that bind to epitopes within this extracellular domain may be used to detect these soluble form(s). The following domains have been identified in Vascular endothelial growth factor receptor 2:

Residues	Length	Domain ID
1-19	19	Signal peptide
20-1356	1337	Vascular endothelial growth factor receptor 2
20-764	745	Extracellular domain
765-789	25	Transmembrane domain
790-1356	567	Cytoplasmic domain

[0090] As used herein, the term “Vascular endothelial growth factor receptor 3” refers to one or more polypeptides present in a biological sample that are derived from the Vascular endothelial growth factor receptor 3 precursor (Swiss-Prot P35916 (SEQ ID NO: 25)):

```

      10      20      30      40      50      60
MQRGAALCLR LWLCLGLLDG LVSGYSMTTP TLNITEESHV IDTGDSL SIS CRGQHPLEWA

      70      80      90      100     110     120
WPGAQEAPAT GDKDSEDITGV VRDCEGTDAR PYCKVLLLHE VHANDTGSYV CYYKYIKARI

      130     140     150     160     170     180
EGTTAASSYV FVRDFEQPFI NKPD TLLVNR KDAMWVPCLV SIPGLNVT LR SQSSVLWPDG

      190     200     210     220     230     240
QEVVWDDRRG MLVSTPLLHD ALYLQCETT W GDQDFLSNPF LVHITGNELY DIQLLPRKSL

      250     260     270     280     290     300
ELLVGEKLV L NCTVWAEFNS GVTFDWDYPG KQAERGKWVP ERRSQQTHTE LSSILTIHNV

      310     320     330     340     350     360

```



```

SQHDLGSYVC KANNGIQRF R ESTEVIVHEN PFISVEWLKG PILEATAGDE LVKLPVKLAA
      370      380      390      400      410      420
YPPPEFQWYK DGKALSGRHS PHALVLKEVT EASTGTYTLA LWNSAAGLRR NISLELVVNV
      430      440      450      460      470      480
PPQIHEKEAS SPSIYSRHSR QALTCTAYGV PLPLSIQWHW RPWTPCKMFA QRS LRRRQQQ
      490      500      510      520      530      540
DLMPQCRDWR AVTTQDAVNP IESLDTWTEF VEGKNKTVSK LVIQNANVSA MYKCVVSNKV
      550      560      570      580      590      600
GQDERLIYFY VTTIPDGFTI ESKPSEELLE GQPVLLSCQA DSYKYEHLRW YRLNLSTLHD
      610      620      630      640      650      660
AHGNPLLLDC KNVHLFATPL AASLEEVAPG ARHATLSLSI PRVAPEHEGH YVCEVQDRRS
      670      680      690      700      710      720
HDKHCHKKYL SVQALEAPRL TQNLTDLLVN VSDSLEMQL VAGAHAPSIV WYKDERLLEE
      730      740      750      760      770      780
KSGVDLADSN QKLSIQRVRE EDAGRYLCSV CNAKGCVNSS ASVAVEGSED KGSMEIVILV
      790      800      810      820      830      840
GTGVIAVFFW VLLLLLIFCNM RRP AHADIKT GYLSIIMDPG EVPLEEQCEY LSYDASQWEF
      850      860      870      880      890      900
PRERLHLGRV LGYGAFGKVV EASAFGIHKG SSCDTVAVKM LKEGATASEH RALMSELKIL
      910      920      930      940      950      960
IHIGNHLNVV NLLGACTKPQ GPLMVIVEFC KYGNLSNFLR AKRDAFSPCA EKSPEQRGRF
      970      980      990      1000      1010      1020
RAMVELARLD RRRPGSSDRV LFARFSKTEG GARRASPDQE AEDLWLSPLT MEDLVCYSFQ
      1030      1040      1050      1060      1070      1080
VARGMEFLAS RKC IHRDLAA RNILLSESDV VKICDFGLAR DIYKDPDYVR KGSARLPLKW
      1090      1100      1110      1120      1130      1140
MAPESIFDKV YTTQSDVWSF GVLLWEIFSL GASPYPGVQI NEEFCQRLRD GTRMRAPELA
      1150      1160      1170      1180      1190      1200
TPAIRRIMLN CWSGDPKARP AFSELVEILG DLLQGRGLQE EEEVCMAPRS SQSSEEGSFS
      1210      1220      1230      1240      1250      1260
QVSTMALHIA QADAEDSPPS LQRHSLAARY YNWVSFPGCL ARG AETRGS RMKTFEEFPM
      1270      1280      1290
TPTTYKGSVD NQTDSGMVLA SEEFEQIESR HRQESGFR

```

[0091] Vascular endothelial growth factor receptor 3 is a single-pass type I membrane protein having a large extracellular domain, some or all of which is present in soluble forms of Vascular endothelial growth factor receptor 3 generated either through

alternative splicing event which deletes all or a portion of the transmembrane domain, or by proteolysis of the membrane-bound form. In the case of an immunoassay, one or more antibodies that bind to epitopes within this extracellular domain may be used to detect these soluble form(s). The following domains have been identified in Vascular endothelial growth factor receptor 3:

Residues	Length	Domain ID
1-24	24	Signal peptide
25-1298	1274	Vascular endothelial growth factor receptor 3
25-775	751	Extracellular domain
776-797	25	Transmembrane domain
798-1298	501	Cytoplasmic domain

[0092] As used herein, the term "Tumor necrosis factor receptor superfamily member 8" refers to one or more polypeptides present in a biological sample that are derived from the Tumor necrosis factor receptor superfamily member 8 precursor (Swiss-Prot P28908 (SEQ ID NO: 26)):

10	20	30	40	50	60
MRVLLAALGL	LFLGALRAFP	QDRPFEDTCH	GNPSHYDKA	VRRCCYRCPM	GLFPTQQCPQ
70	80	90	100	110	120
RPTDCRKQCE	PDYYLDEADR	CTACVTCSR	DLVEKTPCAW	NSSRVCECRP	GMFCSTSAVN
130	140	150	160	170	180
SCARCFHHSV	CPAGMIVKFP	GTAQKNTVCE	PASPGVSPAC	ASPENCKEPS	SGTIPQAKPT
190	200	210	220	230	240
PVSPATSSAS	TMPVRGGTRL	AQEAASKLTR	APDSPSSVGR	PSSDPGLSPT	QPCPEGSGDC
250	260	270	280	290	300
RKQCEPDYYL	DEAGRCTACV	SCSRDDLVEK	TPCAWNSSRT	CECRPGMICA	TSATNSCARC
310	320	330	340	350	360
VPYPICAAET	VTKPQDMAEK	DTTFEAPPLG	TQPDCNPTPE	NGEAPASTSP	TQSLLVDSQA
370	380	390	400	410	420
SKTLPIPTSA	PVALSSTGKP	VLDAGPVLFW	VILVLVVVVG	SSAFLLCHRR	ACRKRIQKL
430	440	450	460	470	480
HLCYPVQTSQ	PKLELVDSRP	RRSSTQLRSG	ASVTEPVAEE	RGLMSQPLME	TCHSVGAAYL
490	500	510	520	530	540
ESLPLQDASP	AGGPSSPRDL	PEPRVSTEHT	NNKIEKIYIM	KADTVIVGTV	KAELPEGRGL

550 560 570 580 590
 AGPAEPELEE ELEADHTPHY PEQETEPPLG SCSDVMLSVE EEGKEDPLPT AASGK

[0093] Tumor necrosis factor receptor superfamily member 8 is a single-pass type I membrane protein having a large extracellular domain, some or all of which is present in soluble forms of Tumor necrosis factor receptor superfamily member 8 generated either through alternative splicing event which deletes all or a portion of the transmembrane domain, or by proteolysis of the membrane-bound form. In the case of an immunoassay, one or more antibodies that bind to epitopes within this extracellular domain may be used to detect these soluble form(s). The following domains have been identified in Tumor necrosis factor receptor superfamily member 8 :

Residues	Length	Domain ID
1-18	18	Signal peptide
19-595	577	Tumor necrosis factor receptor superfamily member 8
19-379	361	Extracellular domain
380-407	28	Transmembrane domain
1-463	463	Missing in short isoform

[0094] As used herein, the term "Alpha-fetoprotein" refers to one or more polypeptides present in a biological sample that are derived from the Alpha-fetoprotein precursor (Swiss-Prot P02771 (SEQ ID NO: 27)):

10	20	30	40	50	60
MKWVESIFLI	FLLNFTESTR	LHRNEYGIAS	ILDSYQCTAE	ISLADLATIF	FAQFVQEATY
70	80	90	100	110	120
KEVSKMVKDA	LTAIEKPTGD	EQSSGCLENQ	LPAFLEELCH	EKEILEKYGH	SDCCSQSEEG
130	140	150	160	170	180
RHNCFLAHKK	PTPASIPLFQ	VPEPVTSCFA	YEEDRETFMN	KFIYEIARRH	PFLYAPTILL
190	200	210	220	230	240
WAARYDKIIP	SCCKAENAVE	CFQTKAATVT	KELRESSLLN	QHACAVMKNF	GTRTFQAITV
250	260	270	280	290	300
TKLSQKFTKV	NFTEIQKLVL	DVAHVHEHCC	RGDVLDCLQD	GEKIMSYICS	QQDTLSNKIT
310	320	330	340	350	360


```

ECCKLTTLER GQCIHAEND EKPEGLSPNL NRFLGDRDFN QFSSGEKNIF LASFVHEYSR
      370      380      390      400      410      420
RHPQLAVSVI LRVAKGYQEL LEKCFQTENP LECQDKGEEE LQKYIQESQA LAKRSCGLFQ
      430      440      450      460      470      480
KLGEYYLQNA FLVAYTKKAP QLTSSSELMAI TRKMAATAAT CCQLSEDKLL ACGEGAADII
      490      500      510      520      530      540
IGHLCIRHEM TPVNPVGVC CTSSYANRRP CFSSLVVDET YVPPAFSDDK FIFHKDLCQA
      550      560      570      580      590      600
QGVALQTMKQ EFLINLVKQK PQITEEQLEA VIADFSGLLE KCCQGQEQEV CFAEEGQKLI

```

SKTRAALGV

[0095] The following domains have been identified in Alpha-fetoprotein:

Residues	Length	Domain ID
1-18	18	Signal peptide
19-609	591	Alpha-fetoprotein

[0096] As used herein, the term “Thyroxine-binding globulin” refers to one or more polypeptides present in a biological sample that are derived from the Thyroxine-binding globulin precursor (Swiss-Prot P05543 (SEQ ID NO: 28)).

```

      10      20      30      40      50      60
MSPFLYLVL VLG L HATIHC ASPEGKVTAC HSSQPNATLY KMSSINADFA FNLYRRFTVE
      70      80      90     100     110     120
TPDKNIFFSP VSISAALVML SFGACCSTQT EIVETLG FNL TDT PMVEIQH GFQHLICSLN
      130     140     150     160     170     180
FPKKELELQI GNALFIGKHL KPLAKFLNDV KTL YETEVFS TDFS NISAAK QEINSHVEMQ
      190     200     210     220     230     240
TKGKVVG LIQ DLKPNTIMVL VNYIHFKAQW ANPFDPSKTE DSSSFLIDKT TTVQVPM MHQ
      250     260     270     280     290     300
MEQYYHLVDM ELNCTVLQMD YSKNALALFV LPKEGQMESV EAAMSSKTLK KWNRL LQKGW
      310     320     330     340     350     360
VDLFVPKFSI SATYDLGATL LKMGIQHAYS ENADFSGLTE DNGLKLSNAA HKAVLHIG EK
      370     380     390     400     410
GTEAAAVPEV ELSDQPENTF LHPIIQIDRS FMLLILERST RSILFLGKV V NPTEA

```


[0097] The following domains have been identified in Thyroxine-binding globulin:

Residues	Length	Domain ID
1-20	20	Signal peptide
21-415	395	Thyroxine-binding globulin

[0098] As used herein, the term “Prostate-specific antigen” refers to one or more polypeptides present in a biological sample that are derived from the Prostate-specific antigen precursor (Swiss-Prot P07288 (SEQ ID NO: 29)).

```

      10      20      30      40      50      60
MWVPVFLTL SVTWIGAAPL ILSRIVGGWE CEKHSQPWQV LVASRGRAVC GGVLVHPQWV

      70      80      90     100     110     120
LTAAHCI RNK SVILLGRHSL FHPEDTGQVF QVSHSFPHPL YDMSLLKNRF LRP GDDSSHD

     130     140     150     160     170     180
LMLRLSEPA ELTDAVKVMD LPTQEPALGT TCYASGWGSI EPEEFLTPKK LQCVDLHVIS

     190     200     210     220     230     240
NDVCAQVHPQ KVTKFMLCAG RWTGGKSTCS GDSGGPLVCN GVLQGITSWG SEPCALPERP

     250     260
SLYTKVVHYR KWIKDTIVAN P

```

[0099] The following domains have been identified in Prostate-specific antigen:

Residues	Length	Domain ID
1-17	17	Signal peptide
18-24	7	Activation peptide
25-261	237	Prostate-specific antigen

[0100] As used herein, the terms “Apolipoprotein(a)” and “Apolipoprotein A” refer to one or more polypeptides present in a biological sample that are derived from the Apolipoprotein(a) precursor (Swiss-Prot P08519 (SEQ ID NO: 30)).

```

      10      20      30      40      50      60
MEHKEVLLLL LLFLKSAAPE QSHVVQDCYH GDGQSYRGTY STVTGRTCQ AWSSMTPHQH

      70      80      90     100     110     120
NRTTENYPNA GLIMNYCRNP DAVAAPYCYT RDPGVRWEYC NLTQCSDAEG TAVAPPTVTP

     130     140     150     160     170     180
VPSLEAPSEQ APTEQRPGVQ ECYHGNGQSY RGTYSTTVTG RTCQAWSSMT PHSHSRTPEY

```


190	200	210	220	230	240
YPNAGLIMNY	CRNPDAVAAP	YCYTRDPGVR	WEYCNLTQCS	DAEGTAVAPP	TVTPVPSLEA
250	260	270	280	290	300
PSEQAPTEQR	PGVQECYHGN	GQSYRGTYST	TVTGRTCQAW	SSMTPHSHSR	TPEYYPNAGL
310	320	330	340	350	360
IMNYCRNPDA	VAAPYCYTRD	PGVRWEYCNL	TQCSDAEGTA	VAPPTVTPVP	SLEAPSEQAP
370	380	390	400	410	420
TEQRPGVQEC	YHGNGQSYRG	TYSTTVTGRT	CQAWSSMTPH	SHSRTPEYYP	NAGLIMNYCR
430	440	450	460	470	480
NPDAAAPYC	YTRDPGVRWE	YCNLTQCSDA	EGTAVAPPTV	TPVPSLEAPS	EQAPTEQRPG
490	500	510	520	530	540
VQECYHGNGQ	SYRGTYSTTV	TGRTCQAWSS	MTPHSHSRTP	EYYPNAGLIM	NYCRNPDAVA
550	560	570	580	590	600
APYCYTRDPG	VRWEYCNLTQ	CSDAEGTAVA	PPTVTPVPSL	EAPSEQAPTE	QRPGVQECYH
610	620	630	640	650	660
GNGQSYRGTY	STTVTGRTCQ	AWSSMTPHSH	SRTPEYYPNA	GLIMNYCRNP	DAVAAPYCYT
670	680	690	700	710	720
RDPGVRWEYC	NLTQCSDAEG	TAVAPPTVTP	VPSLEAPSEQ	APTEQRPGVQ	ECYHGNGQSY
730	740	750	760	770	780
RGTYSTTVTG	RTCQAWSSMT	PHSHSRTPEY	YPNAGLIMNY	CRNPDAVAAP	YCYTRDPGVR
790	800	810	820	830	840
WEYCNLTQCS	DAEGTAVAPP	TVTPVPSLEA	PSEQAPTEQR	PGVQECYHGN	GQSYRGTYST
850	860	870	880	890	900
TVTGRTCQAW	SSMTPHSHSR	TPEYYPNAGL	IMNYCRNPDA	VAAPYCYTRD	PGVRWEYCNL
910	920	930	940	950	960
TQCSDAEGTA	VAPPTVTPVP	SLEAPSEQAP	TEQRPGVQEC	YHGNGQSYRG	TYSTTVTGRT
970	980	990	1000	1010	1020
CQAWSSMTPH	SHSRTPEYYP	NAGLIMNYCR	NPDAAAPYC	YTRDPGVRWE	YCNLTQCSDA
1030	1040	1050	1060	1070	1080
EGTAVAPPTV	TPVPSLEAPS	EQAPTEQRPG	VQECYHGNGQ	SYRGTYSTTV	TGRTCQAWSS
1090	1100	1110	1120	1130	1140
MTPHSHSRTP	EYYPNAGLIM	NYCRNPDAVA	APYCYTRDPG	VRWEYCNLTQ	CSDAEGTAVA
1150	1160	1170	1180	1190	1200
PPTVTPVPSL	EAPSEQAPTE	QRPGVQECYH	GNGQSYRGTY	STTVTGRTCQ	AWSSMTPHSH
1210	1220	1230	1240	1250	1260
SRTPEYYPNA	GLIMNYCRNP	DAVAAPYCYT	RDPGVRWEYC	NLTQCSDAEG	TAVAPPTVTP
1270	1280	1290	1300	1310	1320

VPSLEAPSEQ	APTEQRPGVQ	ECYHGNGQSY	RGTYSTTVTG	RTCQAWSSMT	PHSHSRTPEY
1330	1340	1350	1360	1370	1380
YPNAGLIMNY	CRNPDAVAAP	YCYTRDPGVR	WEYCNLTQCS	DAEGTAVAPP	TVTPVPSLEA
1390	1400	1410	1420	1430	1440
PSEQAPTEQR	PGVQECYHGN	GQSYRGTYST	TVTGRITCQAW	SSMTPHSHSR	TPEYYPNAGL
1450	1460	1470	1480	1490	1500
IMNYCRNPDA	VAPYCYTRD	PGVRWEYCNL	TQCSDAEGTA	VAPPTVTPVP	SLEAPSEQAP
1510	1520	1530	1540	1550	1560
TEQRPGVQEC	YHGNGQSYRG	TYSTTVTGRT	CQAWSSMTPH	SHSRTPEYYP	NAGLIMNYCR
1570	1580	1590	1600	1610	1620
NPDAVAAPYC	YTRDPGVRWE	YCNLTQCSDA	EGTAVAPPTV	TPVPSLEAPS	EQAPTEQRPG
1630	1640	1650	1660	1670	1680
VQECYHGNGQ	SYRGTYSTTV	TGRTICQAWSS	MTPHSHSRTP	EYYPNAGLIM	NYCRNPDAVA
1690	1700	1710	1720	1730	1740
APYCYTRDPG	VRWEYCNLTQ	CSDAEGTAVA	PPTVTPVPSL	EAPSEQAPTE	QRPGVQECYH
1750	1760	1770	1780	1790	1800
GNGQSYRGTY	STTVTGRTICQ	AWSSMTPHSH	SRTPEYYPNA	GLIMNYCRNP	DAVAAPYCYT
1810	1820	1830	1840	1850	1860
RDPGVRWEYC	NLTQCSDAEG	TAVAPPTVTP	VPSLEAPSEQ	APTEQRPGVQ	ECYHGNGQSY
1870	1880	1890	1900	1910	1920
RGTYSTTVTG	RTCQAWSSMT	PHSHSRTPEY	YPNAGLIMNY	CRNPDAVAAP	YCYTRDPGVR
1930	1940	1950	1960	1970	1980
WEYCNLTQCS	DAEGTAVAPP	TVTPVPSLEA	PSEQAPTEQR	PGVQECYHGN	GQSYRGTYST
1990	2000	2010	2020	2030	2040
TVTGRITCQAW	SSMTPHSHSR	TPEYYPNAGL	IMNYCRNPDA	VAPYCYTRD	PGVRWEYCNL
2050	2060	2070	2080	2090	2100
TQCSDAEGTA	VAPPTVTPVP	SLEAPSEQAP	TEQRPGVQEC	YHGNGQSYRG	TYSTTVTGRT
2110	2120	2130	2140	2150	2160
CQAWSSMTPH	SHSRTPEYYP	NAGLIMNYCR	NPDAVAAPYC	YTRDPGVRWE	YCNLTQCSDA
2170	2180	2190	2200	2210	2220
EGTAVAPPTV	TPVPSLEAPS	EQAPTEQRPG	VQECYHGNGQ	SYRGTYSTTV	TGRTICQAWSS
2230	2240	2250	2260	2270	2280
MTPHSHSRTP	EYYPNAGLIM	NYCRNPDAVA	APYCYTRDPG	VRWEYCNLTQ	CSDAEGTAVA
2290	2300	2310	2320	2330	2340
PPTVTPVPSL	EAPSEQAPTE	QRPGVQECYH	GNGQSYRGTY	STTVTGRTICQ	AWSSMTPHSH
2350	2360	2370	2380	2390	2400
SRTPEYYPNA	GLIMNYCRNP	DAVAAPYCYT	RDPGVRWEYC	NLTQCSDAEG	TAVAPPTVTP

2410	2420	2430	2440	2450	2460
VPSLEAPSEQ	APTEQRPGVQ	ECYHGNGQSY	RGTYSTTVTG	RTCQAWSSMT	PHSHSRTPEY
2470	2480	2490	2500	2510	2520
YPNAGLIMNY	CRNPDAVAAP	YCYTRDPGVR	WEYCNLTQCS	DAEGTAVAPP	TVTPVPSLEA
2530	2540	2550	2560	2570	2580
PSEQAPTEQR	PGVQECYHGN	GQSYRGTYST	TVTGRITCQAW	SSMTPHSHSR	TPEYYPNAGL
2590	2600	2610	2620	2630	2640
IMNYCRNPDA	VAAPYCYTRD	PGVRWEYCNL	TQCSDAEGTA	VAPPTVTPVP	SLEAPSEQAP
2650	2660	2670	2680	2690	2700
TEQRPGVQEC	YHGNGQSYRG	TYSTTVTGRT	CQAWSSMTPH	SHSRTPEYYP	NAGLIMNYCR
2710	2720	2730	2740	2750	2760
NPDAAAPYC	YTRDPGVRWE	YCNLTQCSDA	EGTAVAPPTV	TPVPSLEAPS	EQAPTEQRPG
2770	2780	2790	2800	2810	2820
VQECYHGNGQ	SYRGTYSTTV	TGRITCQAWSS	MTPHSHSRTP	EYYPNAGLIM	NYCRNPDAVA
2830	2840	2850	2860	2870	2880
APYCYTRDPG	VRWEYCNLTQ	CSDAEGTAVA	PPTVTPVPSL	EAPSEQAPTE	QRPGVQECYH
2890	2900	2910	2920	2930	2940
GNGQSYRGTY	STTVTGRTICQ	AWSSMTPHSH	SRTPEYYPNA	GLIMNYCRNP	DAVAAPYCYT
2950	2960	2970	2980	2990	3000
RDPGVRWEYC	NLTQCSDAEG	TAVAPPTVTP	VPSLEAPSEQ	APTEQRPGVQ	ECYHGNGQSY
3010	3020	3030	3040	3050	3060
RGTYSTTVTG	RTCQAWSSMT	PHSHSRTPEY	YPNAGLIMNY	CRNPDAVAAP	YCYTRDPGVR
3070	3080	3090	3100	3110	3120
WEYCNLTQCS	DAEGTAVAPP	TVTPVPSLEA	PSEQAPTEQR	PGVQECYHGN	GQSYRGTYST
3130	3140	3150	3160	3170	3180
TVTGRITCQAW	SSMTPHSHSR	TPEYYPNAGL	IMNYCRNPDA	VAAPYCYTRD	PGVRWEYCNL
3190	3200	3210	3220	3230	3240
TQCSDAEGTA	VAPPTVTPVP	SLEAPSEQAP	TEQRPGVQEC	YHGNGQSYRG	TYSTTVTGRT
3250	3260	3270	3280	3290	3300
CQAWSSMTPH	SHSRTPEYYP	NAGLIMNYCR	NPDAAAPYC	YTRDPGVRWE	YCNLTQCSDA
3310	3320	3330	3340	3350	3360
EGTAVAPPTV	TPVPSLEAPS	EQAPTEQRPG	VQECYHGNGQ	SYRGTYSTTV	TGRITCQAWSS
3370	3380	3390	3400	3410	3420
MTPHSHSRTP	EYYPNAGLIM	NYCRNPDPVA	APYCYTRDPS	VRWEYCNLTQ	CSDAEGTAVA
3430	3440	3450	3460	3470	3480
PPTITPIPSL	EAPSEQAPTE	QRPGVQECYH	GNGQSYQGTY	FITVTGRTICQ	AWSSMTPHSH
3490	3500	3510	3520	3530	3540
SRTPAYYPNA	GLIKNYCRNP	DPVAAPWCYT	TDPSVRWEYC	NLTRCSDAEW	TAFVPPNVIL

3550	3560	3570	3580	3590	3600
APSLEAFFEQ	ALTEETPGVQ	DCYYHYGQSY	RGTYSTTVTG	RTCQAWSSMT	PHQHSRTPEN
3610	3620	3630	3640	3650	3660
YPNAGLTRNY	CRNPDAEIRP	WCYTMDPSVR	WEYCNLTQCL	VTESSVLATL	TVVPDPSTEA
3670	3680	3690	3700	3710	3720
SSEEAPTEQS	PGVQDCYHGD	GQSYRGSFST	TVTGRTCQSW	SSMTPHWHQR	TTEYYPNGGL
3730	3740	3750	3760	3770	3780
TRNYCRNPDA	EISPWICYTMD	PNVRWEYCNL	TQCPVTESSV	LATSTAVSEQ	APTEQSPTVQ
3790	3800	3810	3820	3830	3840
DCYHGDGQSY	RGSFSTTVTG	RTCQSWSSMT	PHWHQRTTEY	YPNGGLTRNY	CRNPDAEIRP
3850	3860	3870	3880	3890	3900
WCYTMDPSVR	WEYCNLTQCP	VMESTLLTTP	TVVPVPSTEL	PSEEAPTENS	TGVQDCYRGD
3910	3920	3930	3940	3950	3960
GQSYRGTLST	TITGRTCQSW	SSMTPHWHRR	IPLYYPNAGL	TRNYCRNPDA	EIRPWCYTMD
3970	3980	3990	4000	4010	4020
PSVRWEYCNL	TRCPVTESSV	LTTPTVAPVP	STEAPSEQAP	PEKSPVVQDC	YHGDGRSYRG
4030	4040	4050	4060	4070	4080
ISSTTVTGRT	CQSWSSMIPH	WHQRTPENYP	NAGLTENYCR	NPDSGKQPWC	YTTDPCVRWE
4090	4100	4110	4120	4130	4140
YCNLTQCSET	ESGVLETPTV	VPVPSMEAHS	EAAPTeqTPV	VRQCYHGNGQ	SYRGTFSTTV
4150	4160	4170	4180	4190	4200
TGRTCQSWSS	MTPHRHQRTP	ENYPNDGLTM	NYCRNPADAT	GPWCFTMDPS	IRWEYCNLTR
4210	4220	4230	4240	4250	4260
CSDTEGTVVA	PPTVIQVPSL	GPPSEQDCMF	GNGKGYRGKK	ATTVTGTGPCQ	EWAAQEPHRH
4270	4280	4290	4300	4310	4320
STFIPGTNKW	AGLEKNYCRN	PDGDINGPWC	YTMNPRKLFD	YCDIPLCASS	SFDCGKPQVE
4330	4340	4350	4360	4370	4380
PKKCPGSIVG	GCVAHPSWP	WQVSLRTRFG	KHFCGGTLIS	PEWVLTAHC	LKKSSRPSSY
4390	4400	4410	4420	4430	4440
KVILGAHQEV	NLESHVQEIE	VSRLFLEPTQ	ADIALKLRS	PAVITDKVMP	ACLPSPDYMV
4450	4460	4470	4480	4490	4500
TARTECYITG	WGETQGTFGT	GLLKEAQLLV	IENEVCNHYK	YICAEHLARG	TDSCQGDSSG
4510	4520	4530	4540		
PLVCFEKDKY	ILQGVTSWGL	GCARPNKPGV	YARVSRFVTW	IEGMMRNN	

[0101] The following domains have been identified in Apolipoprotein(a):

Residues	Length	Domain ID
1-19	19	Signal peptide
20-4548	4529	Apolipoprotein(a)

[0102] As used herein, the term “Apolipoprotein E” refers to one or more polypeptides present in a biological sample that are derived from the Apolipoprotein E precursor (Swiss-Prot P02649 (SEQ ID NO: 31)).

```

      10      20      30      40      50      60
MKVLWAALLV TFLAGCQAKV EQAVETEPEP ELRQQTEWQS GQRWELALGR FWDYLRWVQT
      70      80      90     100     110     120
LSEQVQEELL SSQVTQELRA LMDETMKELK AYKSELEEQL TPVAEETRAR LSKELQAAQA
     130     140     150     160     170     180
RLGADMEDVC GRLVQYRGEV QAMLGQSTEE LRVRLASHLR KLRKRLLRDA DDLQKRLAVY
     190     200     210     220     230     240
QAGAREGAER GLSAIRERLG PLVEQGRVRA ATVGSLAGQP LQERAQAWGE RLRARMEEMG
     250     260     270     280     290     300
SRTRDRLDEV KEQVAEVRAR LEEQAQQIRL QAEAFQARLK SWFEPLVEDM QRQWAGLVEK
     310
VQAAVGTSAH PVPSDNH

```

[0103] The following domains have been identified in Apolipoprotein E:

Residues	Length	Domain ID
1-18	18	Signal peptide
19-317	299	Apolipoprotein E

[0104] As used herein, the term “Thyrotropin subunit beta” refers to one or more polypeptides present in a biological sample that are derived from the Thyrotropin subunit betaprecursor (Swiss-Prot P01222 (SEQ ID NO: 32)).

```

      10      20      30      40      50      60
MTALFLMSML FGLACGQAMS FCIPT EYTMH IERRECA YCL TINTTICAGY CMTRDINGKL
      70      80      90     100     110     120
FLPKYALSQD VCTYRDFIYR TVEIPGCPLH VAPYFSYPVA LSCKCGKCNT DYSDCIHEAI
     130
KTNYCTKPQK SYLVGFVS

```


[0105] The following domains have been identified in Thyrotropin subunit beta:

Residues	Length	Domain ID
1-20	20	Signal peptide
21-132	112	Thyrotropin subunit beta
133-138	6	Propeptide

[0106] As used herein, the term “Platelet-derived Growth Factor B/B dimer” refers to one or more polypeptides present in a biological sample that are derived from the Platelet-derived Growth Factor V precursor and that form a homodimer (Swiss-Prot P01127 (SEQ ID NO: 33)).

```

      10      20      30      40      50      60
MNRCWALFLS LCCYLRLVSA EGDPIPEELY EMLSDHSIRS FDDLQRL LHG DPGEEDGAEL

      70      80      90     100     110     120
DLNMTRSHSG GELESLARGR RSLGSLTIAE PAMIAECKTR TEVFEISRRL IDRTNANFLV

     130     140     150     160     170     180
WPPCVEVQRC SGCCNNRNVQ CRPTQVQLRP VQVRKIEIVR KKPIFKKATV TLEDHLACKC

     190     200     210     220     230     240
ETVAAARPVT RSPGGSQEQR AKTPQTRVTI RTVRVRRPPK GKHRKFKHTH DKTALKETLG

```

A

[0107] The following domains have been identified in Platelet-derived Growth Factor B:

Residues	Length	Domain ID
1-20	20	Signal peptide
21-81	61	Propeptide
82-190	109	Platelet-derived Growth Factor B
191-241	51	Propeptide

[0108] As used herein, the term “IgG4” refers to subclass 4 of the glycoprotein immunoglobulin G (IgG), a major effector molecule of the humoral immune response in man. Antibodies of the IgG class express their predominant activity during a secondary antibody response. The basic immunoglobulin G molecule has a four-chain structure,

comprising two identical heavy (H) chains and two identical light (L) chains, linked together by inter-chain disulfide bonds. Each heavy chain is encoded by 4 distinct types of gene segments, designated V_H (variable), D (diversity), J_H (joining) and C_H (constant). The variable region of the heavy chain is encoded by the V_H , D and J_H segments. The light chains are encoded by the 3 gene segments, V_L , J_L and C_L . The variable region of the light chains is encoded by the V_L and J_L segments.

[0109] The length and flexibility of the hinge region varies among the IgG subclasses. The hinge region of IgG1 encompasses amino acids 216-231 and since it is freely flexible, the Fab fragments can rotate about their axes of symmetry and move within a sphere centered at the first of two inter-heavy chain disulfide bridges (23). IgG2 has a shorter hinge than IgG1, with 12 amino acid residues and four disulfide bridges. The hinge region of IgG2 lacks a glycine residue, it is relatively short and contains a rigid poly-proline double helix, stabilised by extra inter-heavy chain disulfide bridges. These properties restrict the flexibility of the IgG2 molecule (24). IgG3 differs from the other subclasses by its unique extended hinge region (about four times as long as the IgG1 hinge), containing 62 amino acids (including 21 prolines and 11 cysteines), forming an inflexible poly-proline double helix (25,26). In IgG3 the Fab fragments are relatively far away from the Fc fragment, giving the molecule a greater flexibility. The elongated hinge in IgG3 is also responsible for its higher molecular weight compared to the other subclasses. The hinge region of IgG4 is shorter than that of IgG1 and its flexibility is intermediate between that of IgG1 and IgG2.

[0110] The four IgG subclasses also differ with respect to the number of inter-heavy chain disulfide bonds in the hinge region (26). The structural differences between the IgG subclasses are also reflected in their susceptibility to proteolytic enzymes. IgG3 is very susceptible to cleavage by these enzymes, whereas IgG2 is relatively resistant. IgG1 and IgG4 exhibit an intermediary sensitivity, depending upon the enzyme used. Since these proteolytic enzymes all cleave IgG molecules near or within the hinge region, it is likely that the high sensitivity of IgG3 to enzyme digestion is related to its accessible hinge. Another structural difference between the human IgG subclasses is the linkage of the heavy and light chain by a disulfide bond. This bond links the carboxy-terminal of the light chain with the cysteine residue at position 220 (in IgG) or at position 131 (in IgG2, IgG3 and IgG4) of the $CH1$ sequence of the heavy chain.

[0111] As a consequence of the structural differences, the four IgG subclasses may be distinguished from one another, for example using antibodies that are specific for differences between the isoforms. In the present application, a level of IgG1 is determined using an assay which distinguishes this subclass, relative to the other subclasses.

[0112] As used herein, the term “relating a signal to the presence or amount” of an analyte reflects the following understanding. Assay signals are typically related to the presence or amount of an analyte through the use of a standard curve calculated using known concentrations of the analyte of interest. As the term is used herein, an assay is “configured to detect” an analyte if an assay can generate a detectable signal indicative of the presence or amount of a physiologically relevant concentration of the analyte. Because an antibody epitope is on the order of 8 amino acids, an immunoassay configured to detect a marker of interest will also detect polypeptides related to the marker sequence, so long as those polypeptides contain the epitope(s) necessary to bind to the antibody or antibodies used in the assay. The term “related marker” as used herein with regard to a biomarker such as one of the kidney injury markers described herein refers to one or more fragments, variants, etc., of a particular marker or its biosynthetic parent that may be detected as a surrogate for the marker itself or as independent biomarkers. The term also refers to one or more polypeptides present in a biological sample that are derived from the biomarker precursor complexed to additional species, such as binding proteins, receptors, heparin, lipids, sugars, etc.

[0113] In this regard, the skilled artisan will understand that the signals obtained from an immunoassay are a direct result of complexes formed between one or more antibodies and the target biomolecule (*i.e.*, the analyte) and polypeptides containing the necessary epitope(s) to which the antibodies bind. While such assays may detect the full length biomarker and the assay result be expressed as a concentration of a biomarker of interest, the signal from the assay is actually a result of all such “immunoreactive” polypeptides present in the sample. Expression of biomarkers may also be determined by means other than immunoassays, including protein measurements (such as dot blots, western blots, chromatographic methods, mass spectrometry, *etc.*) and nucleic acid measurements (mRNA quantitation). This list is not meant to be limiting.

[0114] The term “positive going” marker as that term is used herein refer to a marker that is determined to be elevated in subjects suffering from a disease or condition, relative to subjects not suffering from that disease or condition. The term “negative going” marker

as that term is used herein refer to a marker that is determined to be reduced in subjects suffering from a disease or condition, relative to subjects not suffering from that disease or condition.

[0115] The term “subject” as used herein refers to a human or non-human organism. Thus, the methods and compositions described herein are applicable to both human and veterinary disease. Further, while a subject is preferably a living organism, the invention described herein may be used in post-mortem analysis as well. Preferred subjects are humans, and most preferably “patients,” which as used herein refers to living humans that are receiving medical care for a disease or condition. This includes persons with no defined illness who are being investigated for signs of pathology.

[0116] Preferably, an analyte is measured in a sample. Such a sample may be obtained from a subject, or may be obtained from biological materials intended to be provided to the subject. For example, a sample may be obtained from a kidney being evaluated for possible transplantation into a subject, and an analyte measurement used to evaluate the kidney for preexisting damage. Preferred samples are body fluid samples.

[0117] The term “body fluid sample” as used herein refers to a sample of bodily fluid obtained for the purpose of diagnosis, prognosis, classification or evaluation of a subject of interest, such as a patient or transplant donor. In certain embodiments, such a sample may be obtained for the purpose of determining the outcome of an ongoing condition or the effect of a treatment regimen on a condition. Preferred body fluid samples include blood, serum, plasma, cerebrospinal fluid, urine, saliva, sputum, and pleural effusions. In addition, one of skill in the art would realize that certain body fluid samples would be more readily analyzed following a fractionation or purification procedure, for example, separation of whole blood into serum or plasma components.

[0118] The term “diagnosis” as used herein refers to methods by which the skilled artisan can estimate and/or determine the probability (“a likelihood”) of whether or not a patient is suffering from a given disease or condition. In the case of the present invention, “diagnosis” includes using the results of an assay, most preferably an immunoassay, for a kidney injury marker of the present invention, optionally together with other clinical characteristics, to arrive at a diagnosis (that is, the occurrence or nonoccurrence) of an acute renal injury or ARF for the subject from which a sample was obtained and assayed. That such a diagnosis is “determined” is not meant to imply that the diagnosis is 100%

accurate. Many biomarkers are indicative of multiple conditions. The skilled clinician does not use biomarker results in an informational vacuum, but rather test results are used together with other clinical indicia to arrive at a diagnosis. Thus, a measured biomarker level on one side of a predetermined diagnostic threshold indicates a greater likelihood of the occurrence of disease in the subject relative to a measured level on the other side of the predetermined diagnostic threshold.

[0119] Similarly, a prognostic risk signals a probability (“a likelihood”) that a given course or outcome will occur. A level or a change in level of a prognostic indicator, which in turn is associated with an increased probability of morbidity (e.g., worsening renal function, future ARF, or death) is referred to as being “indicative of an increased likelihood” of an adverse outcome in a patient.

[0120] Marker Assays

[0121] In general, immunoassays involve contacting a sample containing or suspected of containing a biomarker of interest with at least one antibody that specifically binds to the biomarker. A signal is then generated indicative of the presence or amount of complexes formed by the binding of polypeptides in the sample to the antibody. The signal is then related to the presence or amount of the biomarker in the sample. Numerous methods and devices are well known to the skilled artisan for the detection and analysis of biomarkers. *See, e.g.*, U.S. Patents 6,143,576; 6,113,855; 6,019,944; 5,985,579; 5,947,124; 5,939,272; 5,922,615; 5,885,527; 5,851,776; 5,824,799; 5,679,526; 5,525,524; and 5,480,792, and *The Immunoassay Handbook*, David Wild, ed. Stockton Press, New York, 1994, each of which is hereby incorporated by reference in its entirety, including all tables, figures and claims.

[0122] The assay devices and methods known in the art can utilize labeled molecules in various sandwich, competitive, or non-competitive assay formats, to generate a signal that is related to the presence or amount of the biomarker of interest. Suitable assay formats also include chromatographic, mass spectrographic, and protein “blotting” methods. Additionally, certain methods and devices, such as biosensors and optical immunoassays, may be employed to determine the presence or amount of analytes without the need for a labeled molecule. *See, e.g.*, U.S. Patents 5,631,171; and 5,955,377, each of which is hereby incorporated by reference in its entirety, including all tables, figures and claims. One skilled in the art also recognizes that robotic instrumentation

including but not limited to Beckman ACCESS®, Abbott AXSYM®, Roche ELECSYS®, Dade Behring STRATUS® systems are among the immunoassay analyzers that are capable of performing immunoassays. But any suitable immunoassay may be utilized, for example, enzyme-linked immunoassays (ELISA), radioimmunoassays (RIAs), competitive binding assays, and the like.

[0123] Antibodies or other polypeptides may be immobilized onto a variety of solid supports for use in assays. Solid phases that may be used to immobilize specific binding members include those developed and/or used as solid phases in solid phase binding assays. Examples of suitable solid phases include membrane filters, cellulose-based papers, beads (including polymeric, latex and paramagnetic particles), glass, silicon wafers, microparticles, nanoparticles, TentaGels, AgroGels, PEGA gels, SPOCC gels, and multiple-well plates. An assay strip could be prepared by coating the antibody or a plurality of antibodies in an array on solid support. This strip could then be dipped into the test sample and then processed quickly through washes and detection steps to generate a measurable signal, such as a colored spot. Antibodies or other polypeptides may be bound to specific zones of assay devices either by conjugating directly to an assay device surface, or by indirect binding. In an example of the later case, antibodies or other polypeptides may be immobilized on particles or other solid supports, and that solid support immobilized to the device surface.

[0124] Biological assays require methods for detection, and one of the most common methods for quantitation of results is to conjugate a detectable label to a protein or nucleic acid that has affinity for one of the components in the biological system being studied. Detectable labels may include molecules that are themselves detectable (*e.g.*, fluorescent moieties, electrochemical labels, metal chelates, *etc.*) as well as molecules that may be indirectly detected by production of a detectable reaction product (*e.g.*, enzymes such as horseradish peroxidase, alkaline phosphatase, *etc.*) or by a specific binding molecule which itself may be detectable (*e.g.*, biotin, digoxigenin, maltose, oligohistidine, 2,4-dinitrobenzene, phenylarsenate, ssDNA, dsDNA, *etc.*).

[0125] Preparation of solid phases and detectable label conjugates often comprise the use of chemical cross-linkers. Cross-linking reagents contain at least two reactive groups, and are divided generally into homofunctional cross-linkers (containing identical reactive groups) and heterofunctional cross-linkers (containing non-identical reactive groups). Homobifunctional cross-linkers that couple through amines, sulfhydryls or react non-

specifically are available from many commercial sources. Maleimides, alkyl and aryl halides, alpha-haloacyls and pyridyl disulfides are thiol reactive groups. Maleimides, alkyl and aryl halides, and alpha-haloacyls react with sulfhydryls to form thiol ether bonds, while pyridyl disulfides react with sulfhydryls to produce mixed disulfides. The pyridyl disulfide product is cleavable. Imidoesters are also very useful for protein-protein cross-links. A variety of heterobifunctional cross-linkers, each combining different attributes for successful conjugation, are commercially available.

[0126] In certain aspects, the present invention provides kits for the analysis of the described kidney injury markers. The kit comprises reagents for the analysis of at least one test sample which comprise at least one antibody that a kidney injury marker. The kit can also include devices and instructions for performing one or more of the diagnostic and/or prognostic correlations described herein. Preferred kits will comprise an antibody pair for performing a sandwich assay, or a labeled species for performing a competitive assay, for the analyte. Preferably, an antibody pair comprises a first antibody conjugated to a solid phase and a second antibody conjugated to a detectable label, wherein each of the first and second antibodies that bind a kidney injury marker. Most preferably each of the antibodies are monoclonal antibodies. The instructions for use of the kit and performing the correlations can be in the form of labeling, which refers to any written or recorded material that is attached to, or otherwise accompanies a kit at any time during its manufacture, transport, sale or use. For example, the term labeling encompasses advertising leaflets and brochures, packaging materials, instructions, audio or video cassettes, computer discs, as well as writing imprinted directly on kits.

[0127] Antibodies

[0128] The term "antibody" as used herein refers to a peptide or polypeptide derived from, modeled after or substantially encoded by an immunoglobulin gene or immunoglobulin genes, or fragments thereof, capable of specifically binding an antigen or epitope. *See, e.g.* Fundamental Immunology, 3rd Edition, W.E. Paul, ed., Raven Press, N.Y. (1993); Wilson (1994; J. Immunol. Methods 175:267-273; Yarmush (1992) J. Biochem. Biophys. Methods 25:85-97. The term antibody includes antigen-binding portions, i.e., "antigen binding sites," (e.g., fragments, subsequences, complementarity determining regions (CDRs)) that retain capacity to bind antigen, including (i) a Fab fragment, a monovalent fragment consisting of the VL, VH, CL and CH1 domains; (ii) a F(ab')₂ fragment, a bivalent fragment comprising two Fab fragments linked by a disulfide

bridge at the hinge region; (iii) a Fd fragment consisting of the VH and CH1 domains; (iv) a Fv fragment consisting of the VL and VH domains of a single arm of an antibody, (v) a dAb fragment (Ward et al., (1989) Nature 341:544-546), which consists of a VH domain; and (vi) an isolated complementarity determining region (CDR). Single chain antibodies are also included by reference in the term "antibody."

[0129] Antibodies used in the immunoassays described herein preferably specifically bind to a kidney injury marker of the present invention. The term "specifically binds" is not intended to indicate that an antibody binds exclusively to its intended target since, as noted above, an antibody binds to any polypeptide displaying the epitope(s) to which the antibody binds. Rather, an antibody "specifically binds" if its affinity for its intended target is about 5-fold greater when compared to its affinity for a non-target molecule which does not display the appropriate epitope(s). Preferably the affinity of the antibody will be at least about 5 fold, preferably 10 fold, more preferably 25-fold, even more preferably 50-fold, and most preferably 100-fold or more, greater for a target molecule than its affinity for a non-target molecule. In preferred embodiments, Preferred antibodies bind with affinities of at least about 10^7 M^{-1} , and preferably between about 10^8 M^{-1} to about 10^9 M^{-1} , about 10^9 M^{-1} to about 10^{10} M^{-1} , or about 10^{10} M^{-1} to about 10^{12} M^{-1} .

[0130] Affinity is calculated as $K_d = k_{\text{off}}/k_{\text{on}}$ (k_{off} is the dissociation rate constant, K_{on} is the association rate constant and K_d is the equilibrium constant). Affinity can be determined at equilibrium by measuring the fraction bound (r) of labeled ligand at various concentrations (c). The data are graphed using the Scatchard equation: $r/c = K(n-r)$: where r = moles of bound ligand/mole of receptor at equilibrium; c = free ligand concentration at equilibrium; K = equilibrium association constant; and n = number of ligand binding sites per receptor molecule. By graphical analysis, r/c is plotted on the Y-axis versus r on the X-axis, thus producing a Scatchard plot. Antibody affinity measurement by Scatchard analysis is well known in the art. See, e.g., van Erp et al., *J. Immunoassay* 12: 425-43, 1991; Nelson and Griswold, *Comput. Methods Programs Biomed.* 27: 65-8, 1988.

[0131] The term "epitope" refers to an antigenic determinant capable of specific binding to an antibody. Epitopes usually consist of chemically active surface groupings of molecules such as amino acids or sugar side chains and usually have specific three dimensional structural characteristics, as well as specific charge characteristics. Conformational and nonconformational epitopes are distinguished in that the binding to the former but not the latter is lost in the presence of denaturing solvents.

[0132] Numerous publications discuss the use of phage display technology to produce and screen libraries of polypeptides for binding to a selected analyte. *See, e.g.*, Cwirla *et al.*, *Proc. Natl. Acad. Sci. USA* 87, 6378-82, 1990; Devlin *et al.*, *Science* 249, 404-6, 1990; Scott and Smith, *Science* 249, 386-88, 1990; and Ladner *et al.*, U.S. Pat. No. 5,571,698. A basic concept of phage display methods is the establishment of a physical association between DNA encoding a polypeptide to be screened and the polypeptide. This physical association is provided by the phage particle, which displays a polypeptide as part of a capsid enclosing the phage genome which encodes the polypeptide. The establishment of a physical association between polypeptides and their genetic material allows simultaneous mass screening of very large numbers of phage bearing different polypeptides. Phage displaying a polypeptide with affinity to a target bind to the target and these phage are enriched by affinity screening to the target. The identity of polypeptides displayed from these phage can be determined from their respective genomes. Using these methods a polypeptide identified as having a binding affinity for a desired target can then be synthesized in bulk by conventional means. *See, e.g.*, U.S. Patent No. 6,057,098, which is hereby incorporated in its entirety, including all tables, figures, and claims.

[0133] The antibodies that are generated by these methods may then be selected by first screening for affinity and specificity with the purified polypeptide of interest and, if required, comparing the results to the affinity and specificity of the antibodies with polypeptides that are desired to be excluded from binding. The screening procedure can involve immobilization of the purified polypeptides in separate wells of microtiter plates. The solution containing a potential antibody or groups of antibodies is then placed into the respective microtiter wells and incubated for about 30 min to 2 h. The microtiter wells are then washed and a labeled secondary antibody (for example, an anti-mouse antibody conjugated to alkaline phosphatase if the raised antibodies are mouse antibodies) is added to the wells and incubated for about 30 min and then washed. Substrate is added to the wells and a color reaction will appear where antibody to the immobilized polypeptide(s) are present.

[0134] The antibodies so identified may then be further analyzed for affinity and specificity in the assay design selected. In the development of immunoassays for a target protein, the purified target protein acts as a standard with which to judge the sensitivity and specificity of the immunoassay using the antibodies that have been selected. Because

the binding affinity of various antibodies may differ; certain antibody pairs (e.g., in sandwich assays) may interfere with one another sterically, etc., assay performance of an antibody may be a more important measure than absolute affinity and specificity of an antibody.

[0135] While the present application describes antibody-based binding assays in detail, alternatives to antibodies as binding species in assays are well known in the art. These include receptors for a particular target, aptamers, etc. Aptamers are oligonucleic acid or peptide molecules that bind to a specific target molecule. Aptamers are usually created by selecting them from a large random sequence pool, but natural aptamers also exist. High-affinity aptamers containing modified nucleotides conferring improved characteristics on the ligand, such as improved in vivo stability or improved delivery characteristics. Examples of such modifications include chemical substitutions at the ribose and/or phosphate and/or base positions, and may include amino acid side chain functionalities.

[0136] Assay Correlations

[0137] The term “correlating” as used herein in reference to the use of biomarkers refers to comparing the presence or amount of the biomarker(s) in a patient to its presence or amount in persons known to suffer from, or known to be at risk of, a given condition; or in persons known to be free of a given condition. Often, this takes the form of comparing an assay result in the form of a biomarker concentration to a predetermined threshold selected to be indicative of the occurrence or nonoccurrence of a disease or the likelihood of some future outcome.

[0138] Selecting a diagnostic threshold involves, among other things, consideration of the probability of disease, distribution of true and false diagnoses at different test thresholds, and estimates of the consequences of treatment (or a failure to treat) based on the diagnosis. For example, when considering administering a specific therapy which is highly efficacious and has a low level of risk, few tests are needed because clinicians can accept substantial diagnostic uncertainty. On the other hand, in situations where treatment options are less effective and more risky, clinicians often need a higher degree of diagnostic certainty. Thus, cost/benefit analysis is involved in selecting a diagnostic threshold.

[0139] Suitable thresholds may be determined in a variety of ways. For example, one recommended diagnostic threshold for the diagnosis of acute myocardial infarction using cardiac troponin is the 97.5th percentile of the concentration seen in a normal population. Another method may be to look at serial samples from the same patient, where a prior “baseline” result is used to monitor for temporal changes in a biomarker level.

[0140] Population studies may also be used to select a decision threshold. Receiver Operating Characteristic (“ROC”) arose from the field of signal detection theory developed during World War II for the analysis of radar images, and ROC analysis is often used to select a threshold able to best distinguish a “diseased” subpopulation from a “nondiseased” subpopulation. A false positive in this case occurs when the person tests positive, but actually does not have the disease. A false negative, on the other hand, occurs when the person tests negative, suggesting they are healthy, when they actually do have the disease. To draw a ROC curve, the true positive rate (TPR) and false positive rate (FPR) are determined as the decision threshold is varied continuously. Since TPR is equivalent with sensitivity and FPR is equal to 1 - specificity, the ROC graph is sometimes called the sensitivity vs (1 - specificity) plot. A perfect test will have an area under the ROC curve of 1.0; a random test will have an area of 0.5. A threshold is selected to provide an acceptable level of specificity and sensitivity.

[0141] In this context, “diseased” is meant to refer to a population having one characteristic (the presence of a disease or condition or the occurrence of some outcome) and “nondiseased” is meant to refer to a population lacking the characteristic. While a single decision threshold is the simplest application of such a method, multiple decision thresholds may be used. For example, below a first threshold, the absence of disease may be assigned with relatively high confidence, and above a second threshold the presence of disease may also be assigned with relatively high confidence. Between the two thresholds may be considered indeterminate. This is meant to be exemplary in nature only.

[0142] In addition to threshold comparisons, other methods for correlating assay results to a patient classification (occurrence or nonoccurrence of disease, likelihood of an outcome, etc.) include decision trees, rule sets, Bayesian methods, and neural network methods. These methods can produce probability values representing the degree to which a subject belongs to one classification out of a plurality of classifications.

[0143] Measures of test accuracy may be obtained as described in Fischer *et al.*, *Intensive Care Med.* 29: 1043-51, 2003, and used to determine the effectiveness of a given biomarker. These measures include sensitivity and specificity, predictive values, likelihood ratios, diagnostic odds ratios, and ROC curve areas. The area under the curve ("AUC") of a ROC plot is equal to the probability that a classifier will rank a randomly chosen positive instance higher than a randomly chosen negative one. The area under the ROC curve may be thought of as equivalent to the Mann-Whitney U test, which tests for the median difference between scores obtained in the two groups considered if the groups are of continuous data, or to the Wilcoxon test of ranks.

[0144] As discussed above, suitable tests may exhibit one or more of the following results on these various measures: a specificity of greater than 0.5, preferably at least 0.6, more preferably at least 0.7, still more preferably at least 0.8, even more preferably at least 0.9 and most preferably at least 0.95, with a corresponding sensitivity greater than 0.2, preferably greater than 0.3, more preferably greater than 0.4, still more preferably at least 0.5, even more preferably 0.6, yet more preferably greater than 0.7, still more preferably greater than 0.8, more preferably greater than 0.9, and most preferably greater than 0.95; a sensitivity of greater than 0.5, preferably at least 0.6, more preferably at least 0.7, still more preferably at least 0.8, even more preferably at least 0.9 and most preferably at least 0.95, with a corresponding specificity greater than 0.2, preferably greater than 0.3, more preferably greater than 0.4, still more preferably at least 0.5, even more preferably 0.6, yet more preferably greater than 0.7, still more preferably greater than 0.8, more preferably greater than 0.9, and most preferably greater than 0.95; at least 75% sensitivity, combined with at least 75% specificity; a ROC curve area of greater than 0.5, preferably at least 0.6, more preferably 0.7, still more preferably at least 0.8, even more preferably at least 0.9, and most preferably at least 0.95; an odds ratio different from 1, preferably at least about 2 or more or about 0.5 or less, more preferably at least about 3 or more or about 0.33 or less, still more preferably at least about 4 or more or about 0.25 or less, even more preferably at least about 5 or more or about 0.2 or less, and most preferably at least about 10 or more or about 0.1 or less; a positive likelihood ratio (calculated as sensitivity/(1-specificity)) of greater than 1, at least 2, more preferably at least 3, still more preferably at least 5, and most preferably at least 10; and or a negative likelihood ratio (calculated as (1-sensitivity)/specificity) of less than 1, less than or equal

to 0.5, more preferably less than or equal to 0.3, and most preferably less than or equal to 0.1

[0145] Additional clinical indicia may be combined with the kidney injury marker assay result(s) of the present invention. These include other biomarkers related to renal status. Examples include the following, which recite the common biomarker name, followed by the Swiss-Prot entry number for that biomarker or its parent: Actin (P68133); Adenosine deaminase binding protein (DPP4, P27487); Alpha-1-acid glycoprotein 1 (P02763); Alpha-1-microglobulin (P02760); Albumin (P02768); Angiotensinogenase (Renin, P00797); Annexin A2 (P07355); Beta-glucuronidase (P08236); B-2-microglobulin (P61679); Beta-galactosidase (P16278); BMP-7 (P18075); Brain natriuretic peptide (proBNP, BNP-32, NTproBNP; P16860); Calcium-binding protein Beta (S100-beta, P04271); Carbonic anhydrase (Q16790); Casein Kinase 2 (P68400); Ceruloplasmin (P00450); Clusterin (P10909); Complement C3 (P01024); Cysteine-rich protein (CYR61, O00622); Cytochrome C (P99999); Epidermal growth factor (EGF, P01133); Endothelin-1 (P05305); Exosomal Fetuin-A (P02765); Fatty acid-binding protein, heart (FABP3, P05413); Fatty acid-binding protein, liver (P07148); Ferritin (light chain, P02793; heavy chain P02794); Fructose-1,6-biphosphatase (P09467); GRO-alpha (CXCL1, (P09341); Growth Hormone (P01241); Hepatocyte growth factor (P14210); Insulin-like growth factor I (P01343); Immunoglobulin G; Immunoglobulin Light Chains (Kappa and Lambda); Interferon gamma (P01308); Lysozyme (P61626); Interleukin-1alpha (P01583); Interleukin-2 (P60568); Interleukin-4 (P60568); Interleukin-9 (P15248); Interleukin-12p40 (P29460); Interleukin-13 (P35225); Interleukin-16 (Q14005); L1 cell adhesion molecule (P32004); Lactate dehydrogenase (P00338); Leucine Aminopeptidase (P28838); Meprin A-alpha subunit (Q16819); Meprin A-beta subunit (Q16820); Midkine (P21741); MIP2-alpha (CXCL2, P19875); MMP-2 (P08253); MMP-9 (P14780); Netrin-1 (O95631); Neutral endopeptidase (P08473); Osteopontin (P10451); Renal papillary antigen 1 (RPA1); Renal papillary antigen 2 (RPA2); Retinol binding protein (P09455); Ribonuclease; S100 calcium-binding protein A6 (P06703); Serum Amyloid P Component (P02743); Sodium/Hydrogen exchanger isoform (NHE3, P48764); Spermidine/spermine N1-acetyltransferase (P21673); TGF-Beta1 (P01137); Transferrin (P02787); Trefoil factor 3 (TFF3, Q07654); Toll-Like protein 4 (O00206); Total protein; Tubulointerstitial nephritis antigen (Q9UJW2); Uromodulin (Tamm-Horsfall protein, P07911).

[0146] For purposes of risk stratification, Adiponectin (Q15848); Alkaline phosphatase (P05186); Aminopeptidase N (P15144); CalbindinD28k (P05937); Cystatin C (P01034); 8 subunit of F1FO ATPase (P03928); Gamma-glutamyltransferase (P19440); GSTa (alpha-glutathione-S-transferase, P08263); GSTpi (Glutathione-S-transferase P; GST class-pi; P09211); IGFBP-1 (P08833); IGFBP-2 (P18065); IGFBP-6 (P24592); Integral membrane protein 1 (Itm1, P46977); Interleukin-6 (P05231); Interleukin-8 (P10145); Interleukin-18 (Q14116); IP-10 (10 kDa interferon-gamma-induced protein, P02778); IRPR (IFRD1, O00458); Isovaleryl-CoA dehydrogenase (IVD, P26440); I-TAC/CXCL11 (O14625); Keratin 19 (P08727); Kim-1 (Hepatitis A virus cellular receptor 1, O43656); L-arginine:glycine amidinotransferase (P50440); Leptin (P41159); Lipocalin2 (NGAL, P80188); MCP-1 (P13500); MIG (Gamma-interferon-induced monokine Q07325); MIP-1a (P10147); MIP-3a (P78556); MIP-1beta (P13236); MIP-1d (Q16663); NAG (N-acetyl-beta-D-glucosaminidase, P54802); Organic ion transporter (OCT2, O15244); Osteoprotegerin (O14788); P8 protein (O60356); Plasminogen activator inhibitor 1 (PAI-1, P05121); ProANP(1-98) (P01160); Protein phosphatase 1-beta (PPI-beta, P62140); Rab GDI-beta (P50395); Renal kallikrein (Q86U61); RT1.B-1 (alpha) chain of the integral membrane protein (Q5Y7A8); Soluble tumor necrosis factor receptor superfamily member 1A (sTNFR-I, P19438); Soluble tumor necrosis factor receptor superfamily member 1B (sTNFR-II, P20333); Tissue inhibitor of metalloproteinases 3 (TIMP-3, P35625); uPAR (Q03405) may be combined with the kidney injury marker assay result(s) of the present invention.

[0147] Other clinical indicia which may be combined with the kidney injury marker assay result(s) of the present invention includes demographic information (e.g., weight, sex, age, race), medical history (e.g., family history, type of surgery, pre-existing disease such as aneurism, congestive heart failure, preeclampsia, eclampsia, diabetes mellitus, hypertension, coronary artery disease, proteinuria, renal insufficiency, or sepsis, type of toxin exposure such as NSAIDs, cyclosporines, tacrolimus, aminoglycosides, foscarnet, ethylene glycol, hemoglobin, myoglobin, ifosfamide, heavy metals, methotrexate, radiopaque contrast agents, or streptozotocin), clinical variables (e.g., blood pressure, temperature, respiration rate), risk scores (APACHE score, PREDICT score, TIMI Risk Score for UA/NSTEMI, Framingham Risk Score), a urine total protein measurement, a glomerular filtration rate, an estimated glomerular filtration rate, a urine production rate, a serum or plasma creatinine concentration, a renal papillary antigen 1 (RPA1)

measurement; a renal papillary antigen 2 (RPA2) measurement; a urine creatinine concentration, a fractional excretion of sodium, a urine sodium concentration, a urine creatinine to serum or plasma creatinine ratio, a urine specific gravity, a urine osmolality, a urine urea nitrogen to plasma urea nitrogen ratio, a plasma BUN to creatinine ratio, and/or a renal failure index calculated as urine sodium / (urine creatinine / plasma creatinine). Other measures of renal function which may be combined with the kidney injury marker assay result(s) are described hereinafter and in Harrison's Principles of Internal Medicine, 17th Ed., McGraw Hill, New York, pages 1741-1830, and Current Medical Diagnosis & Treatment 2008, 47th Ed, McGraw Hill, New York, pages 785-815, each of which are hereby incorporated by reference in their entirety.

[0148] Combining assay results/clinical indicia in this manner can comprise the use of multivariate logistical regression, loglinear modeling, neural network analysis, n-of-m analysis, decision tree analysis, etc. This list is not meant to be limiting.

[0149] Diagnosis of Acute Renal Failure

[0150] As noted above, the terms "acute renal (or kidney) injury" and "acute renal (or kidney) failure" as used herein are defined in part in terms of changes in serum creatinine from a baseline value. Most definitions of ARF have common elements, including the use of serum creatinine and, often, urine output. Patients may present with renal dysfunction without an available baseline measure of renal function for use in this comparison. In such an event, one may estimate a baseline serum creatinine value by assuming the patient initially had a normal GFR. Glomerular filtration rate (GFR) is the volume of fluid filtered from the renal (kidney) glomerular capillaries into the Bowman's capsule per unit time. Glomerular filtration rate (GFR) can be calculated by measuring any chemical that has a steady level in the blood, and is freely filtered but neither reabsorbed nor secreted by the kidneys. GFR is typically expressed in units of ml/min:

$$GFR = \frac{\text{Urine Concentration} \times \text{Urine Flow}}{\text{Plasma Concentration}}$$

[0151] By normalizing the GFR to the body surface area, a GFR of approximately 75-100 ml/min per 1.73 m² can be assumed. The rate therefore measured is the quantity of the substance in the urine that originated from a calculable volume of blood.

[0152] There are several different techniques used to calculate or estimate the glomerular filtration rate (GFR or eGFR). In clinical practice, however, creatinine clearance is used to measure GFR. Creatinine is produced naturally by the body (creatinine is a metabolite of creatine, which is found in muscle). It is freely filtered by the glomerulus, but also actively secreted by the renal tubules in very small amounts such that creatinine clearance overestimates actual GFR by 10-20%. This margin of error is acceptable considering the ease with which creatinine clearance is measured.

[0153] Creatinine clearance (CCr) can be calculated if values for creatinine's urine concentration (U_{Cr}), urine flow rate (V), and creatinine's plasma concentration (P_{Cr}) are known. Since the product of urine concentration and urine flow rate yields creatinine's excretion rate, creatinine clearance is also said to be its excretion rate ($U_{Cr} \times V$) divided by its plasma concentration. This is commonly represented mathematically as:

$$C_{Cr} = \frac{U_{Cr} \times V}{P_{Cr}}$$

Commonly a 24 hour urine collection is undertaken, from empty-bladder one morning to the contents of the bladder the following morning, with a comparative blood test then taken:

$$C_{Cr} = \frac{U_{Cr} \times 24\text{-hour volume}}{P_{Cr} \times 24 \times 60\text{mins}}$$

To allow comparison of results between people of different sizes, the CCr is often corrected for the body surface area (BSA) and expressed compared to the average sized man as ml/min/1.73 m². While most adults have a BSA that approaches 1.7 (1.6-1.9), extremely obese or slim patients should have their CCr corrected for their actual BSA:

$$C_{Cr\text{-corrected}} = \frac{C_{Cr} \times 1.73}{BSA}$$

[0154] The accuracy of a creatinine clearance measurement (even when collection is complete) is limited because as glomerular filtration rate (GFR) falls creatinine secretion is increased, and thus the rise in serum creatinine is less. Thus, creatinine excretion is much greater than the filtered load, resulting in a potentially large overestimation of the GFR (as much as a twofold difference). However, for clinical purposes it is important to determine whether renal function is stable or getting worse or better. This is often

determined by monitoring serum creatinine alone. Like creatinine clearance, the serum creatinine will not be an accurate reflection of GFR in the non-steady-state condition of ARF. Nonetheless, the degree to which serum creatinine changes from baseline will reflect the change in GFR. Serum creatinine is readily and easily measured and it is specific for renal function.

[0155] For purposes of determining urine output on a mL/kg/hr basis, hourly urine collection and measurement is adequate. In the case where, for example, only a cumulative 24-h output was available and no patient weights are provided, minor modifications of the RIFLE urine output criteria have been described. For example, Bagshaw *et al.*, *Nephrol. Dial. Transplant.* 23: 1203–1210, 2008, assumes an average patient weight of 70 kg, and patients are assigned a RIFLE classification based on the following: <35 mL/h (Risk), <21 mL/h (Injury) or <4 mL/h (Failure).

[0156] Selecting a Treatment Regimen

[0157] Once a diagnosis is obtained, the clinician can readily select a treatment regimen that is compatible with the diagnosis, such as initiating renal replacement therapy, withdrawing delivery of compounds that are known to be damaging to the kidney, kidney transplantation, delaying or avoiding procedures that are known to be damaging to the kidney, modifying diuretic administration, initiating goal directed therapy, etc. The skilled artisan is aware of appropriate treatments for numerous diseases discussed in relation to the methods of diagnosis described herein. See, e.g., Merck Manual of Diagnosis and Therapy, 17th Ed. Merck Research Laboratories, Whitehouse Station, NJ, 1999. In addition, since the methods and compositions described herein provide prognostic information, the markers of the present invention may be used to monitor a course of treatment. For example, improved or worsened prognostic state may indicate that a particular treatment is or is not efficacious.

[0158] One skilled in the art readily appreciates that the present invention is well adapted to carry out the objects and obtain the ends and advantages mentioned, as well as those inherent therein. The examples provided herein are representative of preferred embodiments, are exemplary, and are not intended as limitations on the scope of the invention.

[0159] Example 1: Contrast-induced nephropathy sample collection

[0160] The objective of this sample collection study is to collect samples of plasma and urine and clinical data from patients before and after receiving intravascular contrast media. Approximately 250 adults undergoing radiographic/angiographic procedures involving intravascular administration of iodinated contrast media are enrolled. To be enrolled in the study, each patient must meet all of the following inclusion criteria and none of the following exclusion criteria:

Inclusion Criteria

males and females 18 years of age or older;

undergoing a radiographic / angiographic procedure (such as a CT scan or coronary intervention) involving the intravascular administration of contrast media;

expected to be hospitalized for at least 48 hours after contrast administration.

able and willing to provide written informed consent for study participation and to comply with all study procedures.

Exclusion Criteria

renal transplant recipients;

acutely worsening renal function prior to the contrast procedure;

already receiving dialysis (either acute or chronic) or in imminent need of dialysis at enrollment;

expected to undergo a major surgical procedure (such as involving cardiopulmonary bypass) or an additional imaging procedure with contrast media with significant risk for further renal insult within the 48 hrs following contrast administration;

participation in an interventional clinical study with an experimental therapy within the previous 30 days;

known infection with human immunodeficiency virus (HIV) or a hepatitis virus.

[0161] Immediately prior to the first contrast administration (and after any pre-procedure hydration), an EDTA anti-coagulated blood sample (10 mL) and a urine sample (10 mL) are collected from each patient. Blood and urine samples are then collected at 4 (± 0.5), 8 (± 1), 24 (± 2), 48 (± 2), and 72 (± 2) hrs following the last administration of contrast media during the index contrast procedure. Blood is collected via direct venipuncture or via other available venous access, such as an existing femoral

sheath, central venous line, peripheral intravenous line or hep-lock. These study blood samples are processed to plasma at the clinical site, frozen and shipped to Astute Medical, Inc., San Diego, CA. The study urine samples are frozen and shipped to Astute Medical, Inc.

[0162] Serum creatinine is assessed at the site immediately prior to the first contrast administration (after any pre-procedure hydration) and at 4 (± 0.5), 8 (± 1), 24 (± 2) and 48 (± 2), and 72 (± 2) hours following the last administration of contrast (ideally at the same time as the study samples are obtained). In addition, each patient's status is evaluated through day 30 with regard to additional serum and urine creatinine measurements, a need for dialysis, hospitalization status, and adverse clinical outcomes (including mortality).

[0163] Prior to contrast administration, each patient is assigned a risk based on the following assessment: systolic blood pressure < 80 mm Hg = 5 points; intra-arterial balloon pump = 5 points; congestive heart failure (Class III-IV or history of pulmonary edema) = 5 points; age > 75 yrs = 4 points; hematocrit level $< 39\%$ for men, $< 35\%$ for women = 3 points; diabetes = 3 points; contrast media volume = 1 point for each 100 mL; serum creatinine level > 1.5 g/dL = 4 points OR estimated GFR $40-60$ mL/min/ 1.73 m² = 2 points, $20-40$ mL/min/ 1.73 m² = 4 points, < 20 mL/min/ 1.73 m² = 6 points. The risks assigned are as follows: risk for CIN and dialysis: 5 or less total points = risk of CIN - 7.5%, risk of dialysis - 0.04%; 6-10 total points = risk of CIN - 14%, risk of dialysis - 0.12%; 11-16 total points = risk of CIN - 26.1%, risk of dialysis - 1.09%; > 16 total points = risk of CIN - 57.3%, risk of dialysis - 12.8%.

[0164] Example 2: Cardiac surgery sample collection

[0165] The objective of this sample collection study is to collect samples of plasma and urine and clinical data from patients before and after undergoing cardiovascular surgery, a procedure known to be potentially damaging to kidney function. Approximately 900 adults undergoing such surgery are enrolled. To be enrolled in the study, each patient must meet all of the following inclusion criteria and none of the following exclusion criteria:

Inclusion Criteria

males and females 18 years of age or older;

undergoing cardiovascular surgery;

Toronto/Ottawa Predictive Risk Index for Renal Replacement risk score of at least 2 (Wijeysundera *et al.*, *JAMA* 297: 1801-9, 2007); and

able and willing to provide written informed consent for study participation and to comply with all study procedures.

Exclusion Criteria

known pregnancy;

previous renal transplantation;

acutely worsening renal function prior to enrollment (e.g., any category of RIFLE criteria);

already receiving dialysis (either acute or chronic) or in imminent need of dialysis at enrollment;

currently enrolled in another clinical study or expected to be enrolled in another clinical study within 7 days of cardiac surgery that involves drug infusion or a therapeutic intervention for AKI;

known infection with human immunodeficiency virus (HIV) or a hepatitis virus.

[0166] Within 3 hours prior to the first incision (and after any pre-procedure hydration), an EDTA anti-coagulated blood sample (10 mL), whole blood (3 mL), and a urine sample (35 mL) are collected from each patient. Blood and urine samples are then collected at 3 (± 0.5), 6 (± 0.5), 12 (± 1), 24 (± 2) and 48 (± 2) hrs following the procedure and then daily on days 3 through 7 if the subject remains in the hospital. Blood is collected via direct venipuncture or via other available venous access, such as an existing femoral sheath, central venous line, peripheral intravenous line or hep-lock. These study blood samples are frozen and shipped to Astute Medical, Inc., San Diego, CA. The study urine samples are frozen and shipped to Astute Medical, Inc.

[0167] Example 3: Acutely ill subject sample collection

[0168] The objective of this study is to collect samples from acutely ill patients. Approximately 1900 adults expected to be in the ICU for at least 48 hours will be enrolled. To be enrolled in the study, each patient must meet all of the following inclusion criteria and none of the following exclusion criteria:

Inclusion Criteria

males and females 18 years of age or older;

Study population 1: approximately 300 patients that have at least one of:

shock (SBP < 90 mmHg and/or need for vasopressor support to maintain MAP > 60 mmHg and/or documented drop in SBP of at least 40 mmHg); and

sepsis;

Study population 2: approximately 300 patients that have at least one of:

IV antibiotics ordered in computerized physician order entry (CPOE) within 24 hours of enrollment;

contrast media exposure within 24 hours of enrollment;

increased Intra-Abdominal Pressure with acute decompensated heart failure; and

severe trauma as the primary reason for ICU admission and likely to be hospitalized in the ICU for 48 hours after enrollment;

Study population 3: approximately 300 patients expected to be hospitalized through acute care setting (ICU or ED) with a known risk factor for acute renal injury (*e.g.* sepsis, hypotension/shock (Shock = systolic BP < 90 mmHg and/or the need for vasopressor support to maintain a MAP > 60 mmHg and/or a documented drop in SBP > 40 mmHg), major trauma, hemorrhage, or major surgery); and/or expected to be hospitalized to the ICU for at least 24 hours after enrollment;

Study population 4: approximately 1000 patients that are 21 years of age or older, within 24 hours of being admitted into the ICU, expected to have an indwelling urinary catheter for at least 48 hours after enrollment, and have at least one of the following acute conditions within 24 hours prior to enrollment:

(i) respiratory SOFA score of ≥ 2 ($\text{PaO}_2/\text{FiO}_2 < 300$), (ii) cardiovascular SOFA score of ≥ 1 (MAP < 70 mm Hg and/or any vasopressor required).

Exclusion Criteria

known pregnancy;

institutionalized individuals;

previous renal transplantation;

known acutely worsening renal function prior to enrollment (e.g., any category of RIFLE criteria);

received dialysis (either acute or chronic) within 5 days prior to enrollment or in imminent need of dialysis at the time of enrollment;

known infection with human immunodeficiency virus (HIV) or a hepatitis virus;

meets any of the following:

- (i) active bleeding with an anticipated need for > 4 units PRBC in a day;
- (ii) hemoglobin < 7 g/dL;
- (iii) any other condition that in the physician's opinion would contraindicate drawing serial blood samples for clinical study purposes;

meets only the SBP < 90 mmHg inclusion criterion set forth above, and does not have shock in the attending physician's or principal investigator's opinion;

[0169] After obtaining informed consent, an EDTA anti-coagulated blood sample (10 mL) and a urine sample (25-50 mL) are collected from each patient. Blood and urine samples are then collected at 4 ($\pm$ 0.5) and 8 ($\pm$ 1) hours after contrast administration (if applicable); at 12 ($\pm$ 1), 24 ($\pm$ 2), 36 ($\pm$ 2), 48 ($\pm$ 2), 60 ($\pm$ 2), 72 ($\pm$ 2), and 84 ($\pm$ 2) hours after enrollment, and thereafter daily up to day 7 to day 14 while the subject is hospitalized. Blood is collected via direct venipuncture or via other available venous access, such as an existing femoral sheath, central venous line, peripheral intravenous line or hep-lock. These study blood samples are processed to plasma at the clinical site, frozen and shipped to Astute Medical, Inc., San Diego, CA. The study urine samples are frozen and shipped to Astute Medical, Inc.

[0170] Example 4. Immunoassay format

[0171] Analytes are measured using standard sandwich enzyme immunoassay techniques. A first antibody which binds the analyte is immobilized in wells of a 96 well polystyrene microplate. Analyte standards and test samples are pipetted into the appropriate wells and any analyte present is bound by the immobilized antibody. After washing away any unbound substances, a horseradish peroxidase-conjugated second antibody which binds the analyte is added to the wells, thereby forming sandwich complexes with the analyte (if present) and the first antibody. Following a wash to remove any unbound antibody-enzyme reagent, a substrate solution comprising

tetramethylbenzidine and hydrogen peroxide is added to the wells. Color develops in proportion to the amount of analyte present in the sample. The color development is stopped and the intensity of the color is measured at 540 nm or 570 nm. An analyte concentration is assigned to the test sample by comparison to a standard curve determined from the analyte standards. In the case of kidney injury markers that are membrane proteins, assays are directed to soluble forms thereof as described above.

[0172] Commercially-available reagents were sourced from the following vendors:

<u>Analyte</u>	<u>Assay Source</u>	<u>Catalog number</u>
Platelet-derived growth factor (AB/BB)	Millipore	Cat. #HNDG3-36K
Platelet-derived growth factor subunit A (AA-dimer)	Millipore	Cat. #HNDG3-36K
Immunoglobulin G, subclass 4	Millipore	Cat. # HGAM-301
Interleukin-4 receptor alpha chain	Millipore	Cat. # HSCR-32K
Alpha-Fetoprotein	EMD Chemicals	Cat. # BPHCP001-6
Apolipoprotein E	EMD Chemicals	Cat. # BPHCVD01-7
Apolipoprotein(a)	EMD Chemicals	Cat. # BPHCVD05-8
C-C motif chemokine 26	Millipore	Cat. # MPXHCYP2-62K
C-C motif chemokine 7	Millipore	Cat. # MPXHCYTO-60K
Complement C4-B	Millipore	Cat. #HNDG2-36K

Corticotropin	Millipore	Cat. #HPT-66K
Insulin-like growth factor-binding protein 4	Millipore	Cat. # HIGFBP-53K
Insulin-like growth factor-binding protein 5	Millipore	Cat. # HIGFBP-53K
Interferon alpha-2	Millipore	Cat. # MPXHCYTO-60K
Interleukin 23, alpha subunit	Millipore	Cat. # MPXHCYP2-62K
Interleukin-21	Millipore	Cat. # MPXHCYP2-62K
Interleukin-28A (interferon, lambda 2)	Millipore	Cat. # MPXHCYP2-62K
Interleukin-33 (IL-33)	Millipore	Cat. # MPXHCYP2-62K
Lutropin subunit beta	Millipore	Cat # HBDP-33K
Matrix Metalloproteinase-1	R&D Systems	Cat. # LMP000
Neural cell adhesion molecule 1	Millipore	Cat. #HNDG3-36K
Pigment epithelium-derived factor	Millipore	Cat. #HNDG2-36K
Platelet-derived growth factor	Bio-Rad	Cat. #171-A4011M

(BB-dimer)		
Prostate-specific antigen, free	Millipore	Cat # HCCBP1MAG-58K
Thyrotropin subunit beta	Millipore	Cat # HPT-66K
Thyroxine-binding globulin	Rules-Based Medicine	No catalog number
Tumor necrosis factor receptor superfamily member 8	Millipore	Cat. # HSCR-32K
Vascular endothelial growth factor receptor 2	Millipore	Cat. # HSCR-32K
Vascular endothelial growth factor receptor 3	Millipore	Cat. # HSCR-32K

[0173] Units for the concentrations reported in the following data tables are as follows: Tumor necrosis factor receptor superfamily member 8 - pg/mL, Alpha-Fetoprotein - ng/mL, Thyroxine-binding globulin - µg/mL, Prostate-specific antigen (free form) - ng/mL, Apolipoprotein A - ng/mL, Apolipoprotein E - ng/mL, Thyrotropin subunit beta - µg/mL, Platelet-derived growth factor B/B dimer - pg/mL, C-C motif chemokine 7 - pg/mL, C-C motif chemokine 26 - pg/mL, Complement C4-B - ng/mL, Corticotropin - ng/mL, Interferon alpha-2 - pg/mL, Interleukin-4 receptor alpha chain - pg/mL, Insulin-like growth factor-binding protein 4 - ng/mL, Insulin-like growth factor-binding protein 5 - ng/mL, Interleukin 21 - pg/mL, Interleukin 23 alpha subunit - pg/mL, Interleukin-28A - pg/mL, Interleukin-33 - pg/mL, Lutropin subunit beta - mIU/mL, Matrix Metalloproteinase-1 - pg/mL, Neural cell adhesion molecule 1 - pg/mL, Pigment epithelium-derived factor - ng/mL, Vascular Vascular endothelial growth factor receptor 2 - pg/mL, Vascular endothelial growth factor receptor 3 - pg/mL, IgG4 - ng/mL.

[0174] Example 5. Apparently Healthy Donor and Chronic Disease Patient Samples

[0175] Human urine samples from donors with no known chronic or acute disease ("Apparently Healthy Donors") were purchased from two vendors (Golden West Biologicals, Inc., 27625 Commerce Center Dr., Temecula, CA 92590 and Virginia Medical Research, Inc., 915 First Colonial Rd., Virginia Beach, VA 23454). The urine samples were shipped and stored frozen at less than -20° C. The vendors supplied demographic information for the individual donors including gender, race (Black /White), smoking status and age.

[0176] Human urine samples from donors with various chronic diseases ("Chronic Disease Patients") including congestive heart failure, coronary artery disease, chronic kidney disease, chronic obstructive pulmonary disease, diabetes mellitus and hypertension were purchased from Virginia Medical Research, Inc., 915 First Colonial Rd., Virginia Beach, VA 23454. The urine samples were shipped and stored frozen at less than -20 degrees centigrade. The vendor provided a case report form for each individual donor with age, gender, race (Black/White), smoking status and alcohol use, height, weight, chronic disease(s) diagnosis, current medications and previous surgeries.

Example 6. Use of Kidney Injury Markers for evaluating renal status in patients

[0177] Patients from the intensive care unit (ICU) were enrolled in the following study. Each patient was classified by kidney status as non-injury (0), risk of injury (R), injury (I), and failure (F) according to the maximum stage reached within 7 days of enrollment as determined by the RIFLE criteria. EDTA anti-coagulated blood samples (10 mL) and a urine samples (25-30 mL) were collected from each patient at enrollment, 4 ($\pm$ 0.5) and 8 ($\pm$ 1) hours after contrast administration (if applicable); at 12 ($\pm$ 1), 24 ($\pm$ 2), and 48 ($\pm$ 2) hours after enrollment, and thereafter daily up to day 7 to day 14 while the subject is hospitalized. Markers were each measured by standard immunoassay methods using commercially available assay reagents in the urine samples and the plasma component of the blood samples collected.

[0178] Two cohorts were defined to represent a "diseased" and a "normal" population. While these terms are used for convenience, "diseased" and "normal" simply represent two cohorts for comparison (say RIFLE 0 vs RIFLE R, I and F; RIFLE 0 vs RIFLE R; RIFLE 0 and R vs RIFLE I and F; etc.). The time "prior max stage" represents

the time at which a sample is collected, relative to the time a particular patient reaches the lowest disease stage as defined for that cohort, binned into three groups which are +/- 12 hours. For example, "24 hr prior" which uses 0 vs R, I, F as the two cohorts would mean 24 hr (+/- 12 hours) prior to reaching stage R (or I if no sample at R, or F if no sample at R or I).

[0179] A receiver operating characteristic (ROC) curve was generated for each biomarker measured and the area under each ROC curve (AUC) is determined. Patients in Cohort 2 were also separated according to the reason for adjudication to cohort 2 as being based on serum creatinine measurements (sCr), being based on urine output (UO), or being based on either serum creatinine measurements or urine output. Using the same example discussed above (0 vs R, I, F), for those patients adjudicated to stage R, I, or F on the basis of serum creatinine measurements alone, the stage 0 cohort may include patients adjudicated to stage R, I, or F on the basis of urine output; for those patients adjudicated to stage R, I, or F on the basis of urine output alone, the stage 0 cohort may include patients adjudicated to stage R, I, or F on the basis of serum creatinine measurements; and for those patients adjudicated to stage R, I, or F on the basis of serum creatinine measurements or urine output, the stage 0 cohort contains only patients in stage 0 for both serum creatinine measurements and urine output. Also, in the data for patients adjudicated on the basis of serum creatinine measurements or urine output, the adjudication method which yielded the most severe RIFLE stage is used.

[0180] The ability to distinguish cohort 1 from Cohort 2 was determined using ROC analysis. SE is the standard error of the AUC, n is the number of sample or individual patients ("pts," as indicated). Standard errors are calculated as described in Hanley, J. A., and McNeil, B.J., The meaning and use of the area under a receiver operating characteristic (ROC) curve. Radiology (1982) 143: 29-36; p values are calculated with a two-tailed Z-test. An AUC < 0.5 is indicative of a negative going marker for the comparison, and an AUC > 0.5 is indicative of a positive going marker for the comparison.

[0181] Various threshold (or "cutoff") concentrations were selected, and the associated sensitivity and specificity for distinguishing cohort 1 from cohort 2 are determined. OR is the odds ratio calculated for the particular cutoff concentration, and 95% CI is the confidence interval for the odds ratio.

[0182] Fig. 1: Comparison of marker levels in urine samples collected from Cohort 1 (patients that did not progress beyond RIFLE stage 0) and in urine samples collected from subjects at 0, 24 hours, and 48 hours prior to reaching stage R, I or F in Cohort 2.

Complement C4-B

sCr or UO	0hr prior to AKI stage		24hr prior to AKI stage		48hr prior to AKI stage	
	Cohort 1	Cohort 2	Cohort 1	Cohort 2	Cohort 1	Cohort 2
Median	14.6	18.7	14.6	18.9	14.6	22.3
Average	52.6	70.9	52.6	51.2	52.6	47.9
Stdev	134	196	134	98.2	134	92.5
p(t-test)		0.23		0.91		0.81
Min	0.00607	0.383	0.00607	0.211	0.00607	0.448
Max	1950	2000	1950	625	1950	562
n (Samp)	463	119	463	128	463	47
n (Patient)	223	119	223	128	223	47

sCr only	0hr prior to AKI stage		24hr prior to AKI stage		48hr prior to AKI stage	
	Cohort 1	Cohort 2	Cohort 1	Cohort 2	Cohort 1	Cohort 2
Median	17.3	14.0	17.3	22.3	17.3	21.1
Average	59.1	23.1	59.1	43.1	59.1	48.7
Stdev	139	29.6	139	84.8	139	65.3
p(t-test)		0.10		0.44		0.70
Min	0.00607	0.754	0.00607	0.211	0.00607	0.448
Max	2000	130	2000	556	2000	252
n (Samp)	1015	40	1015	46	1015	26
n (Patient)	374	40	374	46	374	26

UO only	0hr prior to AKI stage		24hr prior to AKI stage		48hr prior to AKI stage	
	Cohort 1	Cohort 2	Cohort 1	Cohort 2	Cohort 1	Cohort 2
Median	17.7	27.6	17.7	19.8	17.7	23.2
Average	53.8	80.7	53.8	53.9	53.8	44.1
Stdev	128	206	128	95.8	128	89.5
p(t-test)		0.090		0.99		0.62
Min	0.00329	0.383	0.00329	0.259	0.00329	0.544
Max	1950	2000	1950	625	1950	562
n (Samp)	436	107	436	117	436	44
n (Patient)	173	107	173	117	173	44

	0hr prior to AKI stage			24hr prior to AKI stage			48hr prior to AKI stage		
	sCr or UO	sCr only	UO only	sCr or UO	sCr only	UO only	sCr or UO	sCr only	UO only
AUC	0.56	0.44	0.56	0.52	0.51	0.50	0.55	0.52	0.51
SE	0.030	0.048	0.032	0.029	0.044	0.030	0.045	0.058	0.046
p	0.041	0.23	0.042	0.51	0.77	0.89	0.25	0.69	0.81
nCohort 1	463	1015	436	463	1015	436	463	1015	436
nCohort 2	119	40	107	128	46	117	47	26	44
Cutoff 1	8.26	4.22	10.2	4.60	5.88	5.01	10.5	6.04	6.59
Sens 1	71%	70%	70%	70%	72%	70%	70%	73%	70%
Spec 1	40%	26%	39%	30%	31%	26%	45%	31%	30%

	0hr prior to AKI stage			24hr prior to AKI stage			48hr prior to AKI stage		
	sCr or UO	sCr only	UO only	sCr or UO	sCr only	UO only	sCr or UO	sCr only	UO only
Cutoff 2	3.27	2.69	4.12	1.77	4.60	2.22	4.27	2.22	3.99
Sens 2	81%	80%	80%	80%	80%	80%	81%	81%	82%
Spec 2	23%	19%	21%	15%	28%	13%	28%	17%	21%
Cutoff 3	1.35	1.88	1.30	0.895	1.66	1.09	3.00	0.995	2.76
Sens 3	91%	90%	91%	91%	91%	91%	91%	92%	91%
Spec 3	12%	15%	9%	8%	14%	7%	22%	9%	15%
Cutoff 4	36.1	41.3	40.6	36.1	41.3	40.6	36.1	41.3	40.6
Sens 4	42%	18%	44%	34%	33%	35%	26%	31%	27%
Spec 4	70%	70%	70%	70%	70%	70%	70%	70%	70%
Cutoff 5	60.0	68.7	60.5	60.0	68.7	60.5	60.0	68.7	60.5
Sens 5	28%	8%	34%	23%	13%	26%	21%	23%	18%
Spec 5	80%	80%	80%	80%	80%	80%	80%	80%	80%
Cutoff 6	133	144	133	133	144	133	133	144	133
Sens 6	12%	0%	16%	9%	4%	10%	6%	12%	5%
Spec 6	90%	90%	90%	90%	90%	90%	90%	90%	90%
OR Quart 2	0.99	4.1	0.90	0.77	1.3	0.58	1.6	0.83	0.71
p Value	0.98	0.029	0.73	0.36	0.51	0.074	0.34	0.76	0.47
95% CI of	0.54	1.2	0.48	0.43	0.56	0.32	0.60	0.25	0.27
OR Quart2	1.8	15	1.7	1.4	3.3	1.1	4.3	2.8	1.8
OR Quart 3	1.1	4.9	0.85	1.0	1.8	0.68	2.8	1.2	1.4
p Value	0.65	0.014	0.61	0.91	0.16	0.19	0.025	0.78	0.41
95% CI of	0.64	1.4	0.45	0.59	0.79	0.38	1.1	0.39	0.62
OR Quart3	2.1	17	1.6	1.8	4.2	1.2	7.0	3.5	3.2
OR Quart 4	1.6	3.8	1.6	1.2	1.00	1.1	1.6	1.3	0.90
p Value	0.097	0.042	0.090	0.51	0.99	0.81	0.34	0.59	0.82
95% CI of	0.92	1.0	0.92	0.70	0.39	0.62	0.60	0.46	0.37
OR Quart4	2.8	14	2.9	2.1	2.6	1.8	4.3	3.9	2.2

C-C motif chemokine 26

sCr or UO	0hr prior to AKI stage		24hr prior to AKI stage		48hr prior to AKI stage	
	Cohort 1	Cohort 2	Cohort 1	Cohort 2	Cohort 1	Cohort 2
Median	0.0320	0.0240	0.0320	0.0311	0.0320	0.0254
Average	0.0543	0.155	0.0543	0.391	0.0543	0.0836
Stdev	0.424	1.33	0.424	3.72	0.424	0.251
p(t-test)		0.17		0.057		0.64
Min	0.00872	0.00872	0.00872	0.00872	0.00872	0.00872
Max	9.14	14.6	9.14	42.3	9.14	1.25
n (Samp)	463	120	463	130	463	46
n (Patient)	223	120	223	130	223	46

sCr only	0hr prior to AKI stage		24hr prior to AKI stage		48hr prior to AKI stage	
	Cohort 1	Cohort 2	Cohort 1	Cohort 2	Cohort 1	Cohort 2
Median	0.0368	0.0240	0.0368	0.0311	0.0368	0.0240
Average	0.243	0.0346	0.243	0.0675	0.243	0.0794
Stdev	2.46	0.0171	2.46	0.239	2.46	0.244
p(t-test)		0.59		0.63		0.74
Min	0.00872	0.00872	0.00872	0.00872	0.00872	0.00872

sCr only	0hr prior to AKI stage		24hr prior to AKI stage		48hr prior to AKI stage	
	Cohort 1	Cohort 2	Cohort 1	Cohort 2	Cohort 1	Cohort 2
Max	42.3	0.0633	42.3	1.65	42.3	1.25
n (Samp)	1019	40	1019	46	1019	25
n (Patient)	375	40	375	46	375	25

UO only	0hr prior to AKI stage		24hr prior to AKI stage		48hr prior to AKI stage	
	Cohort 1	Cohort 2	Cohort 1	Cohort 2	Cohort 1	Cohort 2
Median	0.0383	0.0276	0.0383	0.0247	0.0383	0.0240
Average	0.0390	0.387	0.0390	0.473	0.0390	0.0572
Stdev	0.0608	2.15	0.0608	3.94	0.0608	0.184
p(t-test)		7.5E-4		0.022		0.15
Min	0.00872	0.00872	0.00872	0.00872	0.00872	0.00872
Max	1.25	14.6	1.25	42.3	1.25	1.25
n (Samp)	435	108	435	119	435	44
n (Patient)	173	108	173	119	173	44

	0hr prior to AKI stage			24hr prior to AKI stage			48hr prior to AKI stage		
	sCr or UO	sCr only	UO only	sCr or UO	sCr only	UO only	sCr or UO	sCr only	UO only
AUC	0.49	0.50	0.47	0.47	0.46	0.43	0.47	0.45	0.40
SE	0.030	0.047	0.031	0.029	0.044	0.030	0.045	0.060	0.047
p	0.78	0.98	0.36	0.29	0.32	0.025	0.46	0.45	0.028
nCohort 1	463	1019	435	463	1019	435	463	1019	435
nCohort 2	120	40	108	130	46	119	46	25	44
Cutoff 1	0.0195	0.0226	0.0195	0.0204	0.0232	0.0204	0.0218	0.0218	0.0204
Sens 1	78%	72%	79%	72%	72%	71%	72%	72%	70%
Spec 1	19%	26%	16%	23%	31%	21%	29%	26%	21%
Cutoff 2	0.0192	0.0195	0.0192	0.0192	0.0195	0.0143	0.0195	0.0204	0.0173
Sens 2	80%	85%	81%	82%	80%	86%	80%	84%	82%
Spec 2	13%	16%	11%	13%	16%	7%	19%	21%	11%
Cutoff 3	0.0143	0.0143	0.00872	0.00872	0.00872	0.00872	0.00872	0.00872	0.00872
Sens 3	90%	90%	95%	95%	96%	93%	98%	92%	95%
Spec 3	9%	8%	4%	6%	4%	4%	6%	4%	4%
Cutoff 4	0.0443	0.0443	0.0486	0.0443	0.0443	0.0486	0.0443	0.0443	0.0486
Sens 4	35%	35%	26%	20%	20%	16%	17%	24%	9%
Spec 4	74%	73%	75%	74%	73%	75%	74%	73%	75%
Cutoff 5	0.0504	0.0504	0.0504	0.0504	0.0504	0.0504	0.0504	0.0504	0.0504
Sens 5	22%	28%	22%	14%	9%	15%	13%	16%	9%
Spec 5	84%	83%	81%	84%	83%	81%	84%	83%	81%
Cutoff 6	0.0526	0.0526	0.0526	0.0526	0.0526	0.0526	0.0526	0.0526	0.0526
Sens 6	8%	8%	10%	8%	7%	8%	11%	12%	5%
Spec 6	92%	90%	91%	92%	90%	91%	92%	90%	91%
OR Quart 2	0.54	0.45	0.83	1.6	2.1	1.8	1.7	0.60	3.8
p Value	0.042	0.11	0.54	0.11	0.12	0.049	0.25	0.48	0.021
95% CI of	0.30	0.17	0.45	0.90	0.82	1.0	0.68	0.14	1.2
OR Quart2	0.98	1.2	1.5	2.8	5.2	3.4	4.3	2.5	12
OR Quart 3	0.60	0.76	0.74	1.2	2.1	1.4	1.9	2.3	3.2
p Value	0.084	0.52	0.35	0.53	0.12	0.34	0.18	0.14	0.048
95% CI of	0.34	0.33	0.40	0.67	0.82	0.72	0.75	0.77	1.0

	0hr prior to AKI stage			24hr prior to AKI stage			48hr prior to AKI stage		
	sCr or UO	sCr only	UO only	sCr or UO	sCr only	UO only	sCr or UO	sCr only	UO only
OR Quart3	1.1	1.8	1.4	2.2	5.2	2.5	4.6	6.6	10
OR Quart 4	1.1	0.84	1.3	1.6	1.6	2.1	1.4	1.2	3.9
p Value	0.76	0.68	0.37	0.11	0.34	0.018	0.47	0.76	0.020
95% CI of	0.64	0.37	0.74	0.90	0.61	1.1	0.55	0.36	1.2
OR Quart4	1.8	1.9	2.3	2.8	4.2	3.7	3.7	4.0	12

C-C motif chemokine 7

sCr or UO	0hr prior to AKI stage		24hr prior to AKI stage		48hr prior to AKI stage	
	Cohort 1	Cohort 2	Cohort 1	Cohort 2	Cohort 1	Cohort 2
Median	0.515	0.812	0.515	0.584	0.515	0.584
Average	1.72	3.44	1.72	3.13	1.72	1.59
Stdev	7.00	16.1	7.00	15.0	7.00	3.45
p(t-test)		0.082		0.13		0.90
Min	0.146	0.146	0.146	0.146	0.146	0.146
Max	125	161	125	163	125	13.6
n (Samp)	462	120	462	130	462	47
n (Patient)	223	120	223	130	223	47

sCr only	0hr prior to AKI stage		24hr prior to AKI stage		48hr prior to AKI stage	
	Cohort 1	Cohort 2	Cohort 1	Cohort 2	Cohort 1	Cohort 2
Median	0.584	0.604	0.584	0.737	0.584	0.625
Average	2.20	2.18	2.20	3.16	2.20	2.44
Stdev	13.0	6.16	13.0	8.29	13.0	4.49
p(t-test)		0.99		0.62		0.93
Min	0.146	0.146	0.146	0.146	0.146	0.146
Max	291	29.9	291	43.8	291	13.6
n (Samp)	1019	40	1019	46	1019	26
n (Patient)	375	40	375	46	375	26

UO only	0hr prior to AKI stage		24hr prior to AKI stage		48hr prior to AKI stage	
	Cohort 1	Cohort 2	Cohort 1	Cohort 2	Cohort 1	Cohort 2
Median	0.584	0.812	0.584	0.584	0.584	0.484
Average	1.83	5.88	1.83	4.24	1.83	1.66
Stdev	7.17	23.3	7.17	18.7	7.17	5.26
p(t-test)		0.0021		0.030		0.88
Min	0.146	0.146	0.146	0.146	0.146	0.146
Max	125	166	125	163	125	33.0
n (Samp)	436	108	436	119	436	44
n (Patient)	173	108	173	119	173	44

	0hr prior to AKI stage			24hr prior to AKI stage			48hr prior to AKI stage		
	sCr or UO	sCr only	UO only	sCr or UO	sCr only	UO only	sCr or UO	sCr only	UO only
AUC	0.60	0.50	0.60	0.56	0.59	0.51	0.51	0.53	0.46
SE	0.030	0.047	0.031	0.029	0.045	0.030	0.044	0.058	0.047
p	5.6E-4	0.99	9.7E-4	0.054	0.046	0.65	0.81	0.65	0.37
nCohort 1	462	1019	436	462	1019	436	462	1019	436

	0hr prior to AKI stage			24hr prior to AKI stage			48hr prior to AKI stage		
	sCr or UO	sCr only	UO only	sCr or UO	sCr only	UO only	sCr or UO	sCr only	UO only
nCohort 2	120	40	108	130	46	119	47	26	44
Cutoff 1	0.551	0.320	0.584	0.336	0.512	0.320	0.336	0.320	0.336
Sens 1	70%	78%	71%	72%	74%	76%	77%	73%	73%
Spec 1	52%	30%	50%	39%	44%	31%	39%	30%	36%
Cutoff 2	0.320	0.319	0.483	0.319	0.336	0.319	0.282	0.319	0.319
Sens 2	81%	82%	81%	82%	80%	82%	85%	81%	82%
Spec 2	35%	26%	44%	29%	34%	27%	18%	26%	23%
Cutoff 3	0.282	0.254	0.282	0.301	0.254	0.301	0.254	0.301	0.264
Sens 3	92%	92%	93%	91%	93%	91%	91%	92%	91%
Spec 3	18%	8%	18%	18%	8%	18%	9%	17%	14%
Cutoff 4	0.816	1.04	1.04	0.816	1.04	1.04	0.816	1.04	1.04
Sens 4	38%	20%	31%	35%	39%	23%	26%	27%	14%
Spec 4	71%	72%	72%	71%	72%	72%	71%	72%	72%
Cutoff 5	1.12	1.12	1.12	1.12	1.12	1.12	1.12	1.12	1.12
Sens 5	27%	20%	31%	22%	33%	20%	17%	23%	14%
Spec 5	83%	81%	80%	83%	81%	80%	83%	81%	80%
Cutoff 6	1.59	1.59	1.59	1.59	1.59	1.59	1.59	1.59	1.59
Sens 6	7%	8%	11%	8%	11%	9%	9%	15%	7%
Spec 6	94%	94%	94%	94%	94%	94%	94%	94%	94%
OR Quart 2	1.7	1.7	2.6	1.8	1.0	2.2	1.1	1.0	1.9
p Value	0.14	0.27	0.0087	0.057	1.0	0.010	0.82	1.0	0.21
95% CI of	0.85	0.68	1.3	0.98	0.37	1.2	0.45	0.29	0.69
OR Quart2	3.3	4.1	5.2	3.2	2.7	3.9	2.7	3.5	5.4
OR Quart 3	3.7	1.5	2.9	2.0	1.8	1.7	1.8	1.8	3.4
p Value	3.6E-5	0.37	0.0026	0.016	0.20	0.075	0.16	0.29	0.014
95% CI of	2.0	0.61	1.5	1.1	0.74	0.95	0.79	0.60	1.3
OR Quart3	7.0	3.8	5.8	3.7	4.3	3.2	4.1	5.5	8.8
OR Quart 4	2.4	0.88	3.2	1.7	2.1	1.3	0.88	1.4	1.5
p Value	0.0096	0.80	0.0011	0.077	0.10	0.44	0.80	0.57	0.43
95% CI of	1.2	0.31	1.6	0.94	0.86	0.68	0.35	0.44	0.53
OR Quart4	4.5	2.4	6.3	3.1	4.9	2.4	2.3	4.5	4.5

Thyrotropin

sCr or UO	0hr prior to AKI stage		24hr prior to AKI stage		48hr prior to AKI stage	
	Cohort 1	Cohort 2	Cohort 1	Cohort 2	Cohort 1	Cohort 2
Median	0.1000	0.118	0.1000	0.106	0.1000	0.124
Average	0.296	0.126	0.296	0.195	0.296	0.214
Stdev	1.96	0.0588	1.96	0.250	1.96	0.408
p(t-test)		0.55		0.71		0.83
Min	0.0321	0.0383	0.0321	0.0574	0.0321	0.0189
Max	21.8	0.303	21.8	1.58	21.8	2.18
n (Samp)	122	47	122	51	122	26
n (Patient)	99	47	99	51	99	26

sCr only	0hr prior to AKI stage		24hr prior to AKI stage		48hr prior to AKI stage	
	Cohort 1	Cohort 2	Cohort 1	Cohort 2	Cohort 1	Cohort 2
Median	0.106	0.132	0.106	0.123	0.106	0.123

sCr only	0hr prior to AKI stage		24hr prior to AKI stage		48hr prior to AKI stage	
	Cohort 1	Cohort 2	Cohort 1	Cohort 2	Cohort 1	Cohort 2
Average	0.232	0.129	0.232	0.152	0.232	0.130
Stdev	1.35	0.0472	1.35	0.0958	1.35	0.0635
p(t-test)		0.78		0.80		0.79
Min	0.0321	0.0383	0.0321	0.0698	0.0321	0.0189
Max	21.8	0.198	21.8	0.430	21.8	0.248
n (Samp)	262	14	262	19	262	13
n (Patient)	160	14	160	19	160	13

UO only	0hr prior to AKI stage		24hr prior to AKI stage		48hr prior to AKI stage	
	Cohort 1	Cohort 2	Cohort 1	Cohort 2	Cohort 1	Cohort 2
Median	0.109	0.118	0.109	0.105	0.109	0.130
Average	0.322	0.126	0.322	0.202	0.322	0.234
Stdev	2.05	0.0582	2.05	0.257	2.05	0.431
p(t-test)		0.53		0.69		0.84
Min	0.0230	0.0403	0.0230	0.0574	0.0230	0.0383
Max	21.8	0.303	21.8	1.58	21.8	2.18
n (Samp)	111	44	111	47	111	23
n (Patient)	86	44	86	47	86	23

	0hr prior to AKI stage			24hr prior to AKI stage			48hr prior to AKI stage		
	sCr or UO	sCr only	UO only	sCr or UO	sCr only	UO only	sCr or UO	sCr only	UO only
AUC	0.56	0.56	0.52	0.60	0.59	0.57	0.58	0.55	0.59
SE	0.050	0.082	0.052	0.048	0.071	0.051	0.064	0.084	0.068
p	0.22	0.43	0.71	0.036	0.22	0.15	0.19	0.56	0.17
nCohort 1	122	262	111	122	262	111	122	262	111
nCohort 2	47	14	44	51	19	47	26	13	23
Cutoff 1	0.0862	0.114	0.0862	0.0930	0.105	0.0930	0.0862	0.104	0.0950
Sens 1	70%	71%	70%	71%	74%	72%	73%	77%	74%
Spec 1	41%	55%	36%	45%	50%	41%	41%	49%	42%
Cutoff 2	0.0698	0.0808	0.0780	0.0854	0.0918	0.0854	0.0666	0.0877	0.0666
Sens 2	81%	86%	82%	80%	84%	81%	81%	85%	83%
Spec 2	28%	31%	32%	40%	41%	35%	25%	37%	19%
Cutoff 3	0.0617	0.0715	0.0627	0.0717	0.0717	0.0717	0.0509	0.0360	0.0608
Sens 3	91%	93%	91%	92%	95%	91%	92%	92%	91%
Spec 3	21%	23%	18%	29%	23%	24%	11%	2%	17%
Cutoff 4	0.146	0.154	0.151	0.146	0.154	0.151	0.146	0.154	0.151
Sens 4	32%	43%	27%	33%	32%	34%	38%	31%	48%
Spec 4	71%	71%	70%	71%	71%	70%	71%	71%	70%
Cutoff 5	0.161	0.186	0.170	0.161	0.186	0.170	0.161	0.186	0.170
Sens 5	21%	7%	18%	27%	21%	30%	31%	23%	35%
Spec 5	80%	80%	80%	80%	80%	80%	80%	80%	80%
Cutoff 6	0.212	0.248	0.215	0.212	0.248	0.215	0.212	0.248	0.215
Sens 6	6%	0%	7%	22%	11%	23%	15%	0%	17%
Spec 6	90%	90%	90%	90%	90%	90%	90%	90%	90%
OR Quart 2	1.2	1.0	1.7	2.8	2.6	5.0	0.46	1.5	0.97
p Value	0.79	1.0	0.33	0.052	0.26	0.0032	0.29	0.66	0.96
95% CI of	0.40	0.14	0.59	0.99	0.49	1.7	0.10	0.24	0.25

	0hr prior to AKI stage			24hr prior to AKI stage			48hr prior to AKI stage		
	sCr or UO	sCr only	UO only	sCr or UO	sCr only	UO only	sCr or UO	sCr only	UO only
OR Quart2	3.4	7.3	4.7	7.7	14	14	2.0	9.3	3.7
OR Quart 3	2.9	2.6	2.1	2.5	4.4	1.4	1.4	2.6	0.56
p Value	0.035	0.26	0.15	0.084	0.068	0.56	0.55	0.27	0.46
95% CI of	1.1	0.49	0.76	0.89	0.90	0.44	0.44	0.48	0.12
OR Quart3	7.7	14	5.8	7.0	21	4.6	4.6	14	2.6
OR Quart 4	1.8	2.6	1.3	2.7	2.0	3.0	1.7	1.5	2.3
p Value	0.24	0.26	0.63	0.061	0.42	0.050	0.39	0.66	0.17
95% CI of	0.67	0.49	0.45	0.96	0.36	1.00	0.52	0.24	0.70
OR Quart4	5.0	14	3.7	7.4	11	8.8	5.3	9.3	7.8

Vascular endothelial growth factor receptor 3

sCr or UO	0hr prior to AKI stage		24hr prior to AKI stage		48hr prior to AKI stage	
	Cohort 1	Cohort 2	Cohort 1	Cohort 2	Cohort 1	Cohort 2
Median	277	318	277	351	277	366
Average	300	374	300	365	300	374
Stdev	237	217	237	181	237	229
p(t-test)		0.011		0.018		0.096
Min	1.37	1.37	1.37	1.37	1.37	1.37
Max	2070	1280	2070	901	2070	942
n (Samp)	217	90	217	94	217	32
n (Patient)	128	90	128	94	128	32

sCr only	0hr prior to AKI stage		24hr prior to AKI stage		48hr prior to AKI stage	
	Cohort 1	Cohort 2	Cohort 1	Cohort 2	Cohort 1	Cohort 2
Median	318	359	318	375	318	307
Average	339	387	339	398	339	372
Stdev	246	241	246	213	246	295
p(t-test)		0.32		0.19		0.59
Min	1.37	2.36	1.37	3.28	1.37	1.37
Max	2750	901	2750	913	2750	942
n (Samp)	513	28	513	32	513	18
n (Patient)	240	28	240	32	240	18

UO only	0hr prior to AKI stage		24hr prior to AKI stage		48hr prior to AKI stage	
	Cohort 1	Cohort 2	Cohort 1	Cohort 2	Cohort 1	Cohort 2
Median	282	346	282	351	282	354
Average	310	378	310	356	310	375
Stdev	240	213	240	167	240	200
p(t-test)		0.026		0.11		0.15
Min	1.37	1.37	1.37	1.37	1.37	2.01
Max	2070	1280	2070	901	2070	854
n (Samp)	227	80	227	84	227	31
n (Patient)	122	80	122	84	122	31

	0hr prior to AKI stage			24hr prior to AKI stage			48hr prior to AKI stage		
	sCr or UO	sCr only	UO only	sCr or UO	sCr only	UO only	sCr or UO	sCr only	UO only

	0hr prior to AKI stage			24hr prior to AKI stage			48hr prior to AKI stage		
	sCr or UO	sCr only	UO only	sCr or UO	sCr only	UO only	sCr or UO	sCr only	UO only
AUC	0.61	0.55	0.62	0.62	0.59	0.61	0.62	0.51	0.62
SE	0.036	0.057	0.038	0.036	0.054	0.037	0.056	0.070	0.057
p	0.0022	0.34	0.0022	7.9E-4	0.100	0.0038	0.039	0.91	0.034
nCohort 1	217	513	227	217	513	227	217	513	227
nCohort 2	90	28	80	94	32	84	32	18	31
Cutoff 1	249	230	249	251	251	277	249	166	282
Sens 1	71%	71%	74%	71%	72%	71%	72%	72%	71%
Spec 1	44%	32%	42%	46%	38%	48%	44%	20%	52%
Cutoff 2	208	179	208	208	208	219	166	130	247
Sens 2	80%	82%	81%	81%	81%	81%	81%	83%	81%
Spec 2	37%	24%	36%	37%	28%	38%	29%	14%	41%
Cutoff 3	136	127	136	161	160	163	39.3	0	130
Sens 3	90%	93%	90%	90%	91%	90%	91%	100%	90%
Spec 3	22%	13%	19%	26%	16%	23%	10%	0%	18%
Cutoff 4	386	414	386	386	414	386	386	414	386
Sens 4	42%	32%	46%	43%	41%	42%	41%	39%	39%
Spec 4	71%	70%	71%	71%	70%	71%	71%	70%	71%
Cutoff 5	440	468	440	440	468	440	440	468	440
Sens 5	33%	32%	38%	30%	34%	26%	38%	33%	35%
Spec 5	80%	80%	80%	80%	80%	80%	80%	80%	80%
Cutoff 6	496	572	509	496	572	509	496	572	509
Sens 6	26%	21%	24%	24%	25%	17%	25%	28%	23%
Spec 6	90%	90%	90%	90%	90%	90%	90%	90%	90%
OR Quart 2	2.3	1.6	1.7	2.3	1.2	2.0	1.2	0.27	0.98
p Value	0.030	0.40	0.18	0.030	0.78	0.088	0.75	0.11	0.98
95% CI of	1.1	0.52	0.78	1.1	0.38	0.90	0.35	0.056	0.27
OR Quart2	5.0	5.1	3.7	5.0	3.6	4.4	4.2	1.3	3.6
OR Quart 3	1.9	1.2	1.4	2.8	1.2	2.6	1.9	0.27	1.9
p Value	0.094	0.76	0.44	0.0084	0.78	0.018	0.26	0.11	0.26
95% CI of	0.89	0.36	0.61	1.3	0.38	1.2	0.61	0.056	0.61
OR Quart3	4.2	4.1	3.1	5.9	3.6	5.6	6.1	1.3	6.1
OR Quart 4	3.1	1.8	3.1	2.8	2.1	2.7	2.7	0.99	2.7
p Value	0.0033	0.28	0.0033	0.0084	0.16	0.012	0.081	0.99	0.082
95% CI of	1.5	0.60	1.5	1.3	0.76	1.2	0.88	0.34	0.88
OR Quart4	6.6	5.6	6.6	5.9	5.7	5.9	8.1	2.9	8.1

Interferon alpha-2

sCr or UO	0hr prior to AKI stage		24hr prior to AKI stage		48hr prior to AKI stage	
	Cohort 1	Cohort 2	Cohort 1	Cohort 2	Cohort 1	Cohort 2
Median	0.0967	0.0974	0.0967	0.0974	0.0967	5.72
Average	7.58	12.0	7.58	9.69	7.58	15.2
Stdev	17.4	24.3	17.4	19.9	17.4	18.2
p(t-test)		0.023		0.24		0.0045
Min	0.0238	0.0348	0.0238	0.0238	0.0238	0.0369
Max	126	125	126	108	126	67.1
n (Samp)	462	120	462	130	462	47
n (Patient)	223	120	223	130	223	47

sCr only	0hr prior to AKI stage		24hr prior to AKI stage		48hr prior to AKI stage	
	Cohort 1	Cohort 2	Cohort 1	Cohort 2	Cohort 1	Cohort 2
Median	0.0967	0.0974	0.0967	0.0967	0.0967	0.113
Average	7.94	7.91	7.94	9.73	7.94	14.4
Stdev	18.2	16.7	18.2	19.4	18.2	19.7
p(t-test)		0.99		0.52		0.075
Min	0.0238	0.0348	0.0238	0.0348	0.0238	0.0369
Max	126	60.4	126	77.3	126	67.1
n (Samp)	1019	40	1019	46	1019	26
n (Patient)	375	40	375	46	375	26

UO only	0hr prior to AKI stage		24hr prior to AKI stage		48hr prior to AKI stage	
	Cohort 1	Cohort 2	Cohort 1	Cohort 2	Cohort 1	Cohort 2
Median	0.0974	0.0974	0.0974	0.0974	0.0974	2.50
Average	7.12	13.5	7.12	8.00	7.12	10.7
Stdev	16.4	26.2	16.4	18.0	16.4	14.9
p(t-test)		0.0015		0.61		0.16
Min	0.0238	0.0348	0.0238	0.0238	0.0238	0.0348
Max	126	125	126	108	126	57.3
n (Samp)	436	108	436	119	436	44
n (Patient)	173	108	173	119	173	44

	0hr prior to AKI stage			24hr prior to AKI stage			48hr prior to AKI stage		
	sCr or UO	sCr only	UO only	sCr or UO	sCr only	UO only	sCr or UO	sCr only	UO only
AUC	0.55	0.50	0.56	0.52	0.53	0.51	0.65	0.61	0.59
SE	0.030	0.047	0.032	0.029	0.044	0.030	0.045	0.059	0.047
p	0.093	0.92	0.066	0.41	0.45	0.68	6.6E-4	0.061	0.044
nCohort 1	462	1019	436	462	1019	436	462	1019	436
nCohort 2	120	40	108	130	46	119	47	26	44
Cutoff 1	0.0724	0.0656	0.0724	0.0709	0.0709	0.0709	0.0815	0.0724	0.0724
Sens 1	73%	75%	74%	70%	72%	71%	70%	77%	70%
Spec 1	39%	29%	36%	36%	37%	33%	47%	41%	36%
Cutoff 2	0.0656	0.0398	0.0709	0.0435	0.0606	0.0435	0.0709	0.0672	0.0656
Sens 2	83%	80%	81%	81%	80%	81%	81%	81%	82%
Spec 2	29%	14%	33%	19%	26%	17%	36%	33%	26%
Cutoff 3	0.0369	0.0348	0.0398	0.0369	0.0369	0.0348	0.0398	0.0398	0.0369
Sens 3	90%	92%	91%	90%	93%	92%	91%	92%	95%
Spec 3	8%	7%	12%	8%	11%	6%	14%	14%	9%
Cutoff 4	0.311	0.311	0.311	0.311	0.311	0.311	0.311	0.311	0.311
Sens 4	26%	22%	30%	29%	30%	28%	60%	46%	50%
Spec 4	71%	73%	72%	71%	73%	72%	71%	73%	72%
Cutoff 5	10.9	12.7	9.75	10.9	12.7	9.75	10.9	12.7	9.75
Sens 5	24%	20%	28%	25%	24%	23%	47%	42%	36%
Spec 5	80%	80%	80%	80%	80%	80%	80%	80%	80%
Cutoff 6	28.7	30.2	27.4	28.7	30.2	27.4	28.7	30.2	27.4
Sens 6	20%	15%	21%	15%	15%	11%	21%	19%	14%
Spec 6	90%	90%	90%	90%	90%	90%	90%	90%	90%
OR Quart 2	2.0	0.89	2.9	0.96	1.8	0.95	1.3	1.0	1.0
p Value	0.020	0.81	0.0015	0.89	0.16	0.86	0.61	1.0	1.0

	0hr prior to AKI stage			24hr prior to AKI stage			48hr prior to AKI stage		
	sCr or UO	sCr only	UO only	sCr or UO	sCr only	UO only	sCr or UO	sCr only	UO only
95% CI of	1.1	0.36	1.5	0.55	0.79	0.52	0.47	0.29	0.36
OR Quart2	3.7	2.2	5.6	1.7	4.2	1.7	3.6	3.5	2.8
OR Quart 3	1.8	1.2	1.9	1.1	1.0	1.2	1.3	0.80	1.0
p Value	0.050	0.67	0.065	0.78	1.0	0.58	0.61	0.74	1.0
95% CI of	1.00	0.51	0.96	0.62	0.39	0.66	0.47	0.21	0.36
OR Quart3	3.4	2.8	3.8	1.9	2.6	2.1	3.6	3.0	2.8
OR Quart 4	1.7	0.89	2.4	1.2	1.3	1.2	3.6	2.5	2.8
p Value	0.097	0.81	0.011	0.49	0.51	0.58	0.0052	0.096	0.019
95% CI of	0.91	0.36	1.2	0.70	0.56	0.66	1.5	0.85	1.2
OR Quart4	3.1	2.2	4.7	2.1	3.2	2.1	8.7	7.1	6.6

Insulin-like growth factor-binding protein 4

sCr or UO	0hr prior to AKI stage		24hr prior to AKI stage		48hr prior to AKI stage	
	Cohort 1	Cohort 2	Cohort 1	Cohort 2	Cohort 1	Cohort 2
Median	0.733	0.670	0.733	0.896	0.733	0.957
Average	1.33	1.05	1.33	2.36	1.33	4.27
Stdev	4.52	1.46	4.52	5.77	4.52	17.0
p(t-test)		0.63		0.17		0.072
Min	0.0319	0.0319	0.0319	0.0319	0.0319	0.0558
Max	53.9	7.51	53.9	42.8	53.9	85.6
n (Samp)	155	61	155	60	155	25
n (Patient)	109	61	109	60	109	25

sCr only	0hr prior to AKI stage		24hr prior to AKI stage		48hr prior to AKI stage	
	Cohort 1	Cohort 2	Cohort 1	Cohort 2	Cohort 1	Cohort 2
Median	0.733	0.733	0.733	0.398	0.733	0.660
Average	1.92	1.67	1.92	1.63	1.92	0.908
Stdev	6.94	2.39	6.94	2.27	6.94	1.12
p(t-test)		0.88		0.84		0.59
Min	0.0319	0.0319	0.0319	0.0558	0.0319	0.0319
Max	85.6	9.68	85.6	7.59	85.6	3.90
n (Samp)	338	20	338	23	338	14
n (Patient)	184	20	184	23	184	14

UO only	0hr prior to AKI stage		24hr prior to AKI stage		48hr prior to AKI stage	
	Cohort 1	Cohort 2	Cohort 1	Cohort 2	Cohort 1	Cohort 2
Median	0.733	0.733	0.733	0.923	0.733	0.957
Average	1.20	1.20	1.20	2.56	1.20	4.79
Stdev	4.49	1.52	4.49	6.01	4.49	17.6
p(t-test)		1.00		0.079		0.034
Min	0.0319	0.0319	0.0319	0.0319	0.0319	0.0319
Max	53.9	7.51	53.9	42.8	53.9	85.6
n (Samp)	155	54	155	56	155	23
n (Patient)	99	54	99	56	99	23

	0hr prior to AKI stage		24hr prior to AKI stage		48hr prior to AKI stage	

	sCr or UO	sCr only	UO only	sCr or UO	sCr only	UO only	sCr or UO	sCr only	UO only
AUC	0.47	0.51	0.55	0.55	0.51	0.61	0.55	0.48	0.63
SE	0.044	0.067	0.046	0.044	0.063	0.045	0.064	0.080	0.066
p	0.44	0.86	0.29	0.23	0.85	0.019	0.39	0.84	0.052
nCohort 1	155	338	155	155	338	155	155	338	155
nCohort 2	61	20	54	60	23	56	25	14	23
Cutoff 1	0.184	0.141	0.141	0.141	0.0585	0.341	0.382	0.141	0.382
Sens 1	72%	70%	76%	72%	78%	71%	72%	71%	74%
Spec 1	25%	28%	30%	25%	16%	39%	32%	28%	39%
Cutoff 2	0.0558	0.0558	0.0558	0.0558	0.0558	0.0558	0.0439	0.0439	0.0439
Sens 2	90%	80%	91%	82%	83%	82%	100%	93%	96%
Spec 2	14%	16%	15%	14%	16%	15%	10%	10%	13%
Cutoff 3	0.0558	0	0.0558	0.0439	0.0439	0	0.0439	0.0439	0.0439
Sens 3	90%	100%	91%	92%	100%	100%	100%	93%	96%
Spec 3	14%	0%	15%	10%	10%	0%	10%	10%	13%
Cutoff 4	0.923	0.957	0.923	0.923	0.957	0.923	0.923	0.957	0.923
Sens 4	25%	40%	31%	43%	35%	43%	52%	21%	57%
Spec 4	72%	76%	74%	72%	76%	74%	72%	76%	74%
Cutoff 5	1.05	1.37	0.957	1.05	1.37	0.957	1.05	1.37	0.957
Sens 5	21%	35%	30%	37%	30%	36%	20%	14%	30%
Spec 5	80%	80%	81%	80%	80%	81%	80%	80%	81%
Cutoff 6	2.07	3.12	1.88	2.07	3.12	1.88	2.07	3.12	1.88
Sens 6	20%	20%	28%	27%	17%	29%	12%	7%	22%
Spec 6	91%	90%	90%	91%	90%	90%	91%	90%	90%
OR Quart 2	0.91	0.81	1.4	0.59	0.48	0.59	0.81	1.3	0.56
p Value	0.82	0.74	0.50	0.24	0.24	0.30	0.75	0.70	0.44
95% CI of	0.38	0.24	0.56	0.24	0.14	0.22	0.23	0.29	0.12
OR Quart2	2.2	2.8	3.3	1.4	1.6	1.6	2.9	6.2	2.5
OR Quart 3	1.4	0.16	0.79	0.59	0.35	1.4	1.4	1.0	1.7
p Value	0.40	0.090	0.63	0.24	0.13	0.41	0.56	1.0	0.37
95% CI of	0.62	0.019	0.31	0.24	0.091	0.60	0.44	0.20	0.52
OR Quart3	3.3	1.3	2.0	1.4	1.4	3.4	4.4	5.1	5.8
OR Quart 4	1.2	1.3	1.6	1.6	0.99	2.0	1.0	1.3	1.4
p Value	0.67	0.59	0.30	0.26	0.98	0.11	1.0	0.70	0.56
95% CI of	0.52	0.45	0.66	0.71	0.35	0.86	0.30	0.29	0.42
OR Quart4	2.8	4.1	3.7	3.5	2.8	4.7	3.4	6.2	4.9

Insulin-like growth factor-binding protein 5

sCr or UO	0hr prior to AKI stage		24hr prior to AKI stage		48hr prior to AKI stage	
	Cohort 1	Cohort 2	Cohort 1	Cohort 2	Cohort 1	Cohort 2
Median	0.0407	0.0682	0.0407	0.0682	0.0407	0.397
Average	0.473	0.722	0.473	0.778	0.473	0.991
Stdev	1.04	1.54	1.04	1.57	1.04	1.96
p(t-test)		0.17		0.099		0.048
Min	0.0116	0.0116	0.0116	0.0116	0.0116	0.0393
Max	5.79	8.53	5.79	8.07	5.79	9.43
n (Samp)	155	61	155	60	155	25
n (Patient)	109	61	109	60	109	25

sCr only	0hr prior to AKI stage		24hr prior to AKI stage		48hr prior to AKI stage	
	Cohort 1	Cohort 2	Cohort 1	Cohort 2	Cohort 1	Cohort 2
Median	0.0682	0.0682	0.0682	0.0682	0.0682	0.403
Average	0.598	1.28	0.598	0.648	0.598	1.32
Stdev	1.31	2.31	1.31	1.19	1.31	1.56
p(t-test)		0.034		0.86		0.047
Min	0.0116	0.0116	0.0116	0.0210	0.0116	0.0116
Max	9.43	10.0	9.43	4.35	9.43	4.63
n (Samp)	338	20	338	23	338	14
n (Patient)	184	20	184	23	184	14

UO only	0hr prior to AKI stage		24hr prior to AKI stage		48hr prior to AKI stage	
	Cohort 1	Cohort 2	Cohort 1	Cohort 2	Cohort 1	Cohort 2
Median	0.0407	0.0682	0.0407	0.0400	0.0407	0.397
Average	0.402	0.853	0.402	0.737	0.402	0.930
Stdev	0.925	1.66	0.925	1.54	0.925	2.00
p(t-test)		0.014		0.056		0.035
Min	0.0116	0.0116	0.0116	0.0116	0.0116	0.0116
Max	5.79	8.53	5.79	8.07	5.79	9.43
n (Samp)	156	54	156	56	156	23
n (Patient)	100	54	100	56	100	23

	0hr prior to AKI stage			24hr prior to AKI stage			48hr prior to AKI stage		
	sCr or UO	sCr only	UO only	sCr or UO	sCr only	UO only	sCr or UO	sCr only	UO only
AUC	0.55	0.55	0.60	0.54	0.56	0.51	0.74	0.71	0.67
SE	0.044	0.068	0.046	0.044	0.064	0.045	0.060	0.079	0.065
p	0.22	0.45	0.027	0.37	0.35	0.74	7.0E-5	0.0068	0.010
nCohort 1	155	338	156	155	338	156	155	338	156
nCohort 2	61	20	54	60	23	56	25	14	23
Cutoff 1	0.0358	0.0400	0.0400	0.0255	0.0358	0.0116	0.0682	0.0838	0.0400
Sens 1	70%	70%	72%	78%	83%	88%	80%	79%	74%
Spec 1	38%	37%	40%	26%	33%	13%	64%	60%	40%
Cutoff 2	0.0255	0.0116	0.0262	0.0116	0.0358	0.0116	0.0682	0.0544	0.0358
Sens 2	87%	80%	91%	92%	83%	88%	80%	86%	87%
Spec 2	26%	10%	26%	9%	33%	13%	64%	46%	38%
Cutoff 3	0.0116	0	0.0262	0.0116	0.0255	0	0.0358	0.0358	0.0116
Sens 3	92%	100%	91%	92%	91%	100%	100%	93%	96%
Spec 3	9%	0%	26%	9%	21%	0%	38%	33%	13%
Cutoff 4	0.0994	0.397	0.0994	0.0994	0.397	0.0994	0.0994	0.397	0.0994
Sens 4	31%	45%	37%	37%	22%	38%	68%	50%	61%
Spec 4	72%	79%	75%	72%	79%	75%	72%	79%	75%
Cutoff 5	0.397	0.465	0.397	0.397	0.465	0.397	0.397	0.465	0.397
Sens 5	26%	45%	30%	23%	22%	23%	32%	43%	26%
Spec 5	82%	80%	85%	82%	80%	85%	82%	80%	85%
Cutoff 6	1.75	1.99	1.58	1.75	1.99	1.58	1.75	1.99	1.58
Sens 6	13%	15%	19%	17%	13%	14%	16%	36%	17%
Spec 6	91%	90%	90%	91%	90%	90%	91%	90%	90%
OR Quart 2	2.2	0.99	2.0	1.2	2.8	0.62	>4.4	1.0	1.3
p Value	0.082	0.99	0.17	0.70	0.13	0.28	<0.19	1.0	0.72

	0hr prior to AKI stage			24hr prior to AKI stage			48hr prior to AKI stage		
	sCr or UO	sCr only	UO only	sCr or UO	sCr only	UO only	sCr or UO	sCr only	UO only
95% CI of	0.90	0.28	0.75	0.50	0.73	0.26	>0.47	0.062	0.28
OR Quart2	5.4	3.5	5.2	2.8	11	1.5	na	16	6.3
OR Quart 3	2.0	0.19	2.4	1.4	2.1	0.27	>15	5.2	0.98
p Value	0.12	0.13	0.067	0.42	0.31	0.013	<0.012	0.13	0.98
95% CI of	0.83	0.022	0.94	0.60	0.50	0.097	>1.8	0.60	0.19
OR Quart3	4.9	1.7	6.4	3.3	8.6	0.75	na	46	5.1
OR Quart 4	1.9	1.9	2.4	1.2	2.0	1.4	>13	7.5	5.6
p Value	0.18	0.28	0.075	0.70	0.32	0.42	<0.017	0.062	0.012
95% CI of	0.75	0.60	0.92	0.50	0.50	0.63	>1.6	0.91	1.5
OR Quart4	4.6	5.8	6.2	2.8	8.5	3.1	na	62	21

Immunoglobulin G4

sCr or UO	0hr prior to AKI stage		24hr prior to AKI stage		48hr prior to AKI stage	
	Cohort 1	Cohort 2	Cohort 1	Cohort 2	Cohort 1	Cohort 2
Median	163	269	163	282	163	167
Average	430	558	430	525	430	487
Stdev	667	726	667	697	667	702
p(t-test)		0.069		0.16		0.58
Min	0.619	1.73	0.619	2.63	0.619	4.92
Max	2400	2400	2400	2400	2400	2400
n (Samp)	461	119	461	126	461	47
n (Patient)	222	119	222	126	222	47

sCr only	0hr prior to AKI stage		24hr prior to AKI stage		48hr prior to AKI stage	
	Cohort 1	Cohort 2	Cohort 1	Cohort 2	Cohort 1	Cohort 2
Median	210	293	210	358	210	291
Average	479	521	479	589	479	542
Stdev	689	736	689	742	689	675
p(t-test)		0.71		0.29		0.65
Min	0.00642	28.3	0.00642	5.21	0.00642	8.44
Max	2400	2400	2400	2400	2400	2400
n (Samp)	1011	40	1011	46	1011	26
n (Patient)	373	40	373	46	373	26

UO only	0hr prior to AKI stage		24hr prior to AKI stage		48hr prior to AKI stage	
	Cohort 1	Cohort 2	Cohort 1	Cohort 2	Cohort 1	Cohort 2
Median	203	309	203	307	203	172
Average	482	603	482	552	482	497
Stdev	702	741	702	708	702	707
p(t-test)		0.12		0.35		0.89
Min	0.619	1.73	0.619	2.63	0.619	4.92
Max	2400	2400	2400	2400	2400	2400
n (Samp)	433	107	433	115	433	44
n (Patient)	171	107	171	115	171	44

	0hr prior to AKI stage		24hr prior to AKI stage		48hr prior to AKI stage	

	sCr or UO	sCr only	UO only	sCr or UO	sCr only	UO only	sCr or UO	sCr only	UO only
AUC	0.60	0.56	0.58	0.58	0.56	0.56	0.53	0.55	0.50
SE	0.030	0.048	0.032	0.029	0.045	0.031	0.045	0.059	0.046
p	0.0012	0.25	0.0089	0.0055	0.20	0.040	0.49	0.37	0.94
nCohort 1	461	1011	433	461	1011	433	461	1011	433
nCohort 2	119	40	107	126	46	115	47	26	44
Cutoff 1	146	146	181	113	107	129	80.8	120	78.5
Sens 1	71%	70%	70%	71%	72%	70%	70%	73%	70%
Spec 1	47%	40%	49%	42%	33%	38%	34%	36%	30%
Cutoff 2	75.7	108	93.8	80.8	55.4	98.1	55.4	53.9	55.4
Sens 2	81%	80%	80%	80%	80%	80%	81%	81%	82%
Spec 2	34%	33%	32%	34%	23%	32%	29%	23%	25%
Cutoff 3	28.9	48.3	27.6	21.5	27.6	21.3	20.5	11.3	26.1
Sens 3	91%	90%	91%	90%	91%	90%	91%	92%	91%
Spec 3	15%	21%	12%	12%	14%	9%	11%	7%	11%
Cutoff 4	356	402	402	356	402	402	356	402	402
Sens 4	34%	22%	38%	41%	46%	37%	30%	42%	30%
Spec 4	70%	70%	70%	70%	70%	70%	70%	70%	70%
Cutoff 5	523	597	587	523	597	587	523	597	587
Sens 5	26%	18%	26%	27%	28%	26%	26%	27%	23%
Spec 5	80%	80%	80%	80%	80%	80%	80%	80%	80%
Cutoff 6	1470	1640	1910	1470	1640	1910	1470	1640	1910
Sens 6	13%	12%	11%	12%	13%	10%	13%	8%	9%
Spec 6	90%	90%	90%	90%	90%	90%	90%	90%	90%
OR Quart 2	1.2	0.62	1.5	1.4	0.72	1.6	1.5	0.66	1.6
p Value	0.61	0.40	0.24	0.35	0.49	0.15	0.37	0.53	0.28
95% CI of	0.61	0.20	0.77	0.72	0.28	0.84	0.62	0.18	0.68
OR Quart2	2.4	1.9	2.9	2.6	1.8	3.0	3.6	2.4	3.9
OR Quart 3	3.3	2.3	2.4	2.4	0.91	2.1	1.4	1.0	1.1
p Value	1.2E-4	0.051	0.0064	0.0033	0.82	0.023	0.50	1.0	0.81
95% CI of	1.8	1.00	1.3	1.3	0.38	1.1	0.56	0.32	0.44
OR Quart3	6.0	5.5	4.6	4.4	2.2	3.8	3.4	3.1	2.9
OR Quart 4	2.2	1.1	2.1	2.3	1.6	2.1	1.5	1.7	1.2
p Value	0.016	0.81	0.028	0.0070	0.25	0.023	0.37	0.32	0.65
95% CI of	1.2	0.43	1.1	1.3	0.72	1.1	0.62	0.60	0.49
OR Quart4	4.0	3.0	4.0	4.1	3.4	3.8	3.6	4.7	3.1

Interleukin-21

sCr or UO	0hr prior to AKI stage		24hr prior to AKI stage		48hr prior to AKI stage	
	Cohort 1	Cohort 2	Cohort 1	Cohort 2	Cohort 1	Cohort 2
Median	9.57	4.21	9.57	4.50	9.57	5.09
Average	11.9	7.35	11.9	8.30	11.9	8.54
Stdev	11.4	8.68	11.4	10.1	11.4	10.4
p(t-test)		4.2E-5		9.9E-4		0.049
Min	0.00404	0.00411	0.00404	0.0122	0.00404	0.0210
Max	87.9	56.2	87.9	59.4	87.9	49.5
n (Samp)	463	120	463	130	463	47
n (Patient)	223	120	223	130	223	47

sCr only	0hr prior to AKI stage		24hr prior to AKI stage		48hr prior to AKI stage	
	Cohort 1	Cohort 2	Cohort 1	Cohort 2	Cohort 1	Cohort 2
Median	7.83	7.12	7.83	5.28	7.83	3.77
Average	10.7	10.9	10.7	8.66	10.7	5.91
Stdev	11.1	12.0	11.1	8.54	11.1	6.18
p(t-test)		0.89		0.23		0.030
Min	0.00404	0.0177	0.00404	0.0122	0.00404	0.0210
Max	87.9	56.2	87.9	41.5	87.9	20.6
n (Samp)	1019	40	1019	46	1019	26
n (Patient)	375	40	375	46	375	26

UO only	0hr prior to AKI stage		24hr prior to AKI stage		48hr prior to AKI stage	
	Cohort 1	Cohort 2	Cohort 1	Cohort 2	Cohort 1	Cohort 2
Median	9.33	3.57	9.33	4.53	9.33	5.20
Average	11.6	6.81	11.6	8.06	11.6	8.62
Stdev	11.1	7.25	11.1	9.91	11.1	10.6
p(t-test)		2.0E-5		0.0016		0.085
Min	0.00404	0.00404	0.00404	0.0122	0.00404	0.0177
Max	87.9	30.5	87.9	59.4	87.9	49.5
n (Samp)	435	108	435	119	435	44
n (Patient)	173	108	173	119	173	44

	0hr prior to AKI stage			24hr prior to AKI stage			48hr prior to AKI stage		
	sCr or UO	sCr only	UO only	sCr or UO	sCr only	UO only	sCr or UO	sCr only	UO only
AUC	0.36	0.50	0.36	0.38	0.47	0.39	0.38	0.37	0.39
SE	0.030	0.047	0.031	0.029	0.044	0.030	0.045	0.059	0.047
p	2.4E-6	0.95	5.5E-6	6.4E-5	0.47	1.4E-4	0.010	0.027	0.024
nCohort 1	463	1019	435	463	1019	435	463	1019	435
nCohort 2	120	40	108	130	46	119	47	26	44
Cutoff 1	1.82	3.10	1.62	1.99	3.10	1.76	1.29	0.728	1.57
Sens 1	71%	70%	70%	70%	72%	71%	70%	73%	70%
Spec 1	17%	32%	17%	18%	32%	17%	13%	14%	17%
Cutoff 2	1.05	2.19	1.03	1.37	2.16	1.13	0.689	0.418	0.362
Sens 2	80%	80%	81%	80%	80%	81%	81%	81%	82%
Spec 2	11%	24%	13%	13%	24%	13%	9%	12%	9%
Cutoff 3	0.0528	0.313	0.0528	0.296	0.968	0.227	0.136	0.0350	0.136
Sens 3	90%	90%	91%	90%	91%	91%	91%	92%	91%
Spec 3	4%	11%	6%	7%	15%	9%	6%	5%	8%
Cutoff 4	15.8	13.5	14.9	15.8	13.5	14.9	15.8	13.5	14.9
Sens 4	12%	28%	13%	14%	26%	14%	17%	15%	18%
Spec 4	70%	70%	70%	70%	70%	70%	70%	70%	70%
Cutoff 5	19.2	17.9	19.2	19.2	17.9	19.2	19.2	17.9	19.2
Sens 5	11%	22%	9%	10%	17%	9%	13%	4%	14%
Spec 5	80%	80%	80%	80%	80%	80%	80%	80%	80%
Cutoff 6	26.2	25.1	25.4	26.2	25.1	25.4	26.2	25.1	25.4
Sens 6	3%	12%	2%	5%	4%	5%	6%	0%	7%
Spec 6	90%	90%	90%	90%	90%	90%	90%	90%	90%
OR Quart 2	1.8	0.79	2.1	1.6	0.72	2.0	1.5	3.1	0.87
p Value	0.12	0.63	0.050	0.14	0.49	0.044	0.44	0.17	0.79

	0hr prior to AKI stage			24hr prior to AKI stage			48hr prior to AKI stage		
	sCr or UO	sCr only	UO only	sCr or UO	sCr only	UO only	sCr or UO	sCr only	UO only
95% CI of	0.87	0.31	1.0	0.85	0.29	1.0	0.54	0.61	0.30
OR Quart2	3.6	2.0	4.4	3.1	1.8	4.0	4.0	15	2.5
OR Quart 3	3.2	1.3	2.9	2.7	1.6	2.6	1.8	3.1	1.6
p Value	6.1E-4	0.52	0.0034	0.0015	0.24	0.0052	0.24	0.17	0.35
95% CI of	1.6	0.57	1.4	1.5	0.73	1.3	0.68	0.61	0.61
OR Quart3	6.2	3.1	6.0	5.0	3.5	5.0	4.7	15	4.0
OR Quart 4	4.4	0.90	4.8	3.2	0.91	3.9	2.9	6.3	2.3
p Value	9.1E-6	0.82	8.8E-6	1.8E-4	0.83	3.9E-5	0.024	0.017	0.060
95% CI of	2.3	0.36	2.4	1.7	0.38	2.0	1.1	1.4	0.97
OR Quart4	8.4	2.3	9.7	5.8	2.2	7.4	7.1	28	5.6

Interleukin-23

sCr or UO	0hr prior to AKI stage		24hr prior to AKI stage		48hr prior to AKI stage	
	Cohort 1	Cohort 2	Cohort 1	Cohort 2	Cohort 1	Cohort 2
Median	392	156	392	186	392	127
Average	625	311	625	330	625	376
Stdev	802	435	802	412	802	537
p(t-test)		4.1E-5		5.8E-5		0.038
Min	0.491	0.564	0.491	0.491	0.491	0.552
Max	8520	2340	8520	1760	8520	2000
n (Samp)	463	120	463	130	463	47
n (Patient)	223	120	223	130	223	47

sCr only	0hr prior to AKI stage		24hr prior to AKI stage		48hr prior to AKI stage	
	Cohort 1	Cohort 2	Cohort 1	Cohort 2	Cohort 1	Cohort 2
Median	272	185	272	167	272	145
Average	518	343	518	307	518	333
Stdev	706	468	706	375	706	454
p(t-test)		0.12		0.044		0.18
Min	0.491	0.785	0.491	0.552	0.491	0.491
Max	8520	2000	8520	1370	8520	1820
n (Samp)	1019	40	1019	46	1019	26
n (Patient)	375	40	375	46	375	26

UO only	0hr prior to AKI stage		24hr prior to AKI stage		48hr prior to AKI stage	
	Cohort 1	Cohort 2	Cohort 1	Cohort 2	Cohort 1	Cohort 2
Median	385	138	385	150	385	135
Average	634	287	634	314	634	358
Stdev	804	401	804	419	804	500
p(t-test)		1.6E-5		3.3E-5		0.026
Min	0.491	0.564	0.491	0.491	0.491	0.552
Max	8520	2340	8520	1760	8520	2000
n (Samp)	435	108	435	119	435	44
n (Patient)	173	108	173	119	173	44

	0hr prior to AKI stage		24hr prior to AKI stage		48hr prior to AKI stage	

	sCr or UO	sCr only	UO only	sCr or UO	sCr only	UO only	sCr or UO	sCr only	UO only
AUC	0.38	0.47	0.35	0.39	0.43	0.36	0.39	0.43	0.37
SE	0.030	0.047	0.031	0.029	0.045	0.030	0.045	0.059	0.047
p	9.5E-5	0.50	2.2E-6	1.3E-4	0.14	6.6E-6	0.013	0.21	0.0044
nCohort 1	463	1019	435	463	1019	435	463	1019	435
nCohort 2	120	40	108	130	46	119	47	26	44
Cutoff 1	38.3	66.6	1.31	3.48	1.41	3.02	1.41	1.41	1.11
Sens 1	70%	70%	72%	70%	74%	71%	72%	73%	70%
Spec 1	25%	32%	19%	21%	25%	20%	20%	25%	17%
Cutoff 2	1.09	21.4	1.05	1.05	1.08	1.01	0.754	1.01	0.723
Sens 2	81%	80%	81%	81%	83%	81%	85%	81%	82%
Spec 2	17%	28%	14%	15%	20%	12%	9%	18%	7%
Cutoff 3	0.844	1.09	0.723	0.723	0.754	0.720	0.720	0.682	0.643
Sens 3	91%	90%	92%	90%	93%	92%	91%	92%	91%
Spec 3	11%	21%	7%	9%	11%	7%	8%	6%	3%
Cutoff 4	735	608	756	735	608	756	735	608	756
Sens 4	11%	20%	9%	14%	17%	13%	19%	23%	16%
Spec 4	70%	70%	70%	70%	70%	70%	70%	70%	70%
Cutoff 5	1120	894	1020	1120	894	1020	1120	894	1020
Sens 5	6%	10%	6%	5%	11%	9%	11%	8%	9%
Spec 5	80%	80%	80%	80%	80%	80%	80%	80%	80%
Cutoff 6	1580	1400	1630	1580	1400	1630	1580	1400	1630
Sens 6	2%	5%	1%	2%	0%	3%	6%	4%	5%
Spec 6	90%	90%	90%	90%	90%	90%	90%	90%	90%
OR Quart 2	2.2	2.0	2.3	1.8	1.8	1.5	1.4	0.66	2.3
p Value	0.036	0.20	0.040	0.079	0.25	0.28	0.47	0.53	0.10
95% CI of	1.1	0.69	1.0	0.94	0.68	0.73	0.55	0.19	0.85
OR Quart2	4.6	6.0	5.1	3.4	4.5	3.0	3.7	2.4	6.3
OR Quart 3	5.6	4.0	5.1	2.8	2.2	3.7	1.3	1.5	1.0
p Value	6.9E-7	0.0065	1.9E-5	9.9E-4	0.087	7.0E-5	0.63	0.43	1.0
95% CI of	2.8	1.5	2.4	1.5	0.89	1.9	0.48	0.53	0.31
OR Quart3	11	11	11	5.1	5.5	7.1	3.3	4.3	3.2
OR Quart 4	3.6	1.2	4.9	2.9	1.8	3.4	2.5	1.2	3.6
p Value	4.0E-4	0.76	2.7E-5	6.5E-4	0.25	2.4E-4	0.042	0.77	0.0085
95% CI of	1.8	0.36	2.3	1.6	0.68	1.8	1.0	0.39	1.4
OR Quart4	7.2	4.0	10	5.3	4.5	6.5	5.9	3.5	9.4

Interleukin-28A

sCr or UO	0hr prior to AKI stage		24hr prior to AKI stage		48hr prior to AKI stage	
	Cohort 1	Cohort 2	Cohort 1	Cohort 2	Cohort 1	Cohort 2
Median	20.8	11.8	20.8	10.4	20.8	12.4
Average	36.5	24.4	36.5	24.9	36.5	26.3
Stdev	43.7	31.6	43.7	34.6	43.7	39.8
p(t-test)		0.0048		0.0055		0.12
Min	0.0254	0.0254	0.0254	0.0254	0.0254	0.0254
Max	228	168	228	172	228	186
n (Samp)	463	120	463	130	463	47
n (Patient)	223	120	223	130	223	47

sCr only	0hr prior to AKI stage		24hr prior to AKI stage		48hr prior to AKI stage	
	Cohort 1	Cohort 2	Cohort 1	Cohort 2	Cohort 1	Cohort 2
Median	16.1	10.1	16.1	10.4	16.1	7.94
Average	33.0	26.8	33.0	21.8	33.0	20.9
Stdev	41.3	37.0	41.3	30.9	41.3	29.6
p(t-test)		0.35		0.071		0.14
Min	0.0254	0.0777	0.0254	0.0254	0.0254	0.0495
Max	235	168	235	131	235	89.5
n (Samp)	1019	40	1019	46	1019	26
n (Patient)	375	40	375	46	375	26

UO only	0hr prior to AKI stage		24hr prior to AKI stage		48hr prior to AKI stage	
	Cohort 1	Cohort 2	Cohort 1	Cohort 2	Cohort 1	Cohort 2
Median	23.1	11.8	23.1	12.0	23.1	12.3
Average	37.9	24.0	37.9	25.3	37.9	25.9
Stdev	44.6	29.8	44.6	34.5	44.6	40.1
p(t-test)		0.0022		0.0046		0.089
Min	0.0254	0.0254	0.0254	0.0254	0.0254	0.0254
Max	228	127	228	172	228	186
n (Samp)	435	108	435	119	435	44
n (Patient)	173	108	173	119	173	44

	0hr prior to AKI stage			24hr prior to AKI stage			48hr prior to AKI stage		
	sCr or UO	sCr only	UO only	sCr or UO	sCr only	UO only	sCr or UO	sCr only	UO only
AUC	0.45	0.49	0.43	0.44	0.45	0.43	0.43	0.42	0.42
SE	0.030	0.047	0.032	0.029	0.045	0.030	0.045	0.059	0.047
p	0.074	0.87	0.025	0.036	0.28	0.018	0.10	0.18	0.087
nCohort 1	463	1019	435	463	1019	435	463	1019	435
nCohort 2	120	40	108	130	46	119	47	26	44
Cutoff 1	0.246	0.246	0.243	0.198	0.216	0.198	0.189	0.176	0.198
Sens 1	72%	70%	73%	72%	72%	71%	70%	73%	70%
Spec 1	29%	32%	25%	25%	30%	23%	24%	23%	23%
Cutoff 2	0.182	0.194	0.176	0.176	0.184	0.155	0.134	0.0996	0.142
Sens 2	81%	80%	82%	80%	80%	81%	81%	81%	82%
Spec 2	22%	26%	19%	21%	24%	19%	18%	17%	17%
Cutoff 3	0.0996	0.149	0.0775	0.0854	0.0854	0.0854	0.0775	0.0775	0.0784
Sens 3	91%	95%	91%	93%	93%	91%	91%	92%	93%
Spec 3	16%	20%	7%	12%	12%	11%	7%	6%	10%
Cutoff 4	51.6	45.8	53.1	51.6	45.8	53.1	51.6	45.8	53.1
Sens 4	18%	20%	16%	17%	17%	16%	17%	15%	16%
Spec 4	70%	70%	70%	70%	70%	70%	70%	70%	70%
Cutoff 5	68.1	62.2	68.3	68.1	62.2	68.3	68.1	62.2	68.3
Sens 5	11%	15%	10%	11%	9%	11%	15%	15%	14%
Spec 5	80%	80%	80%	80%	80%	80%	80%	80%	80%
Cutoff 6	98.2	90.1	96.2	98.2	90.1	96.2	98.2	90.1	96.2
Sens 6	3%	8%	4%	5%	7%	5%	4%	0%	7%
Spec 6	90%	90%	90%	90%	90%	90%	90%	90%	90%
OR Quart 2	1.6	1.6	1.9	1.7	2.7	2.1	1.6	1.5	1.2
p Value	0.12	0.34	0.070	0.092	0.063	0.026	0.32	0.52	0.79

	0hr prior to AKI stage			24hr prior to AKI stage			48hr prior to AKI stage		
	sCr or UO	sCr only	UO only	sCr or UO	sCr only	UO only	sCr or UO	sCr only	UO only
95% CI of	0.88	0.61	0.95	0.92	0.95	1.1	0.61	0.42	0.40
OR Quart2	3.0	4.2	3.6	3.1	7.7	4.0	4.4	5.4	3.3
OR Quart 3	2.6	2.1	2.8	2.6	3.6	2.5	2.0	1.5	2.1
p Value	0.0013	0.13	0.0017	0.0014	0.014	0.0044	0.17	0.52	0.12
95% CI of	1.5	0.82	1.5	1.4	1.3	1.3	0.75	0.42	0.83
OR Quart3	4.7	5.2	5.3	4.6	9.8	4.7	5.1	5.4	5.5
OR Quart 4	1.4	1.2	2.0	1.7	2.3	2.4	2.5	2.6	2.3
p Value	0.26	0.79	0.048	0.069	0.14	0.0060	0.053	0.11	0.077
95% CI of	0.77	0.41	1.0	0.96	0.77	1.3	0.99	0.80	0.91
OR Quart4	2.7	3.2	3.8	3.2	6.6	4.6	6.3	8.3	5.9

Interleukin-33

sCr or UO	0hr prior to AKI stage		24hr prior to AKI stage		48hr prior to AKI stage	
	Cohort 1	Cohort 2	Cohort 1	Cohort 2	Cohort 1	Cohort 2
Median	51.7	28.7	51.7	30.6	51.7	28.5
Average	66.3	36.4	66.3	41.3	66.3	35.3
Stdev	72.8	34.8	72.8	37.4	72.8	38.8
p(t-test)		1.4E-5		1.7E-4		0.0041
Min	0.0232	0.0372	0.0232	0.0232	0.0232	0.0232
Max	958	148	958	162	958	155
n (Samp)	463	120	463	130	463	47
n (Patient)	223	120	223	130	223	47

sCr only	0hr prior to AKI stage		24hr prior to AKI stage		48hr prior to AKI stage	
	Cohort 1	Cohort 2	Cohort 1	Cohort 2	Cohort 1	Cohort 2
Median	42.7	32.7	42.7	31.8	42.7	18.8
Average	58.1	38.1	58.1	38.9	58.1	33.3
Stdev	62.9	30.5	62.9	34.0	62.9	33.5
p(t-test)		0.046		0.040		0.046
Min	0.0232	0.0743	0.0232	0.0232	0.0232	0.0591
Max	958	138	958	133	958	122
n (Samp)	1019	40	1019	46	1019	26
n (Patient)	375	40	375	46	375	26

UO only	0hr prior to AKI stage		24hr prior to AKI stage		48hr prior to AKI stage	
	Cohort 1	Cohort 2	Cohort 1	Cohort 2	Cohort 1	Cohort 2
Median	50.4	23.2	50.4	28.8	50.4	33.1
Average	67.0	35.9	67.0	39.9	67.0	35.2
Stdev	74.1	38.6	74.1	38.5	74.1	37.5
p(t-test)		2.9E-5		1.3E-4		0.0051
Min	0.0232	0.0372	0.0232	0.0232	0.0232	0.0232
Max	958	203	958	162	958	155
n (Samp)	435	108	435	119	435	44
n (Patient)	173	108	173	119	173	44

	0hr prior to AKI stage		24hr prior to AKI stage		48hr prior to AKI stage	

	sCr or UO	sCr only	UO only	sCr or UO	sCr only	UO only	sCr or UO	sCr only	UO only
AUC	0.36	0.43	0.35	0.39	0.42	0.38	0.35	0.38	0.35
SE	0.030	0.048	0.031	0.029	0.045	0.030	0.045	0.059	0.047
p	4.7E-6	0.13	8.1E-7	2.2E-4	0.087	4.4E-5	7.1E-4	0.044	9.5E-4
nCohort 1	463	1019	435	463	1019	435	463	1019	435
nCohort 2	120	40	108	130	46	119	47	26	44
Cutoff 1	12.9	16.3	9.92	16.8	17.0	15.3	4.46	6.25	6.20
Sens 1	70%	70%	71%	70%	74%	71%	70%	73%	70%
Spec 1	21%	27%	18%	24%	28%	21%	14%	18%	15%
Cutoff 2	7.93	12.1	2.92	10.7	6.57	6.58	0.172	2.84	0.172
Sens 2	80%	80%	81%	80%	80%	81%	81%	81%	82%
Spec 2	17%	23%	14%	20%	18%	16%	13%	14%	12%
Cutoff 3	0.0837	7.09	0.0731	0.0768	0.0768	0.0749	0.0591	0.0631	0.0686
Sens 3	90%	90%	91%	90%	91%	92%	91%	96%	91%
Spec 3	11%	19%	6%	9%	10%	8%	5%	6%	5%
Cutoff 4	84.4	74.8	85.3	84.4	74.8	85.3	84.4	74.8	85.3
Sens 4	10%	15%	11%	14%	20%	12%	11%	12%	9%
Spec 4	70%	70%	70%	70%	70%	70%	70%	70%	70%
Cutoff 5	109	96.1	109	109	96.1	109	109	96.1	109
Sens 5	4%	2%	5%	8%	7%	9%	6%	8%	7%
Spec 5	80%	80%	80%	80%	80%	80%	80%	80%	80%
Cutoff 6	145	130	148	145	130	148	145	130	148
Sens 6	1%	2%	1%	1%	2%	1%	2%	0%	2%
Spec 6	90%	90%	90%	90%	90%	90%	90%	90%	90%
OR Quart 2	2.5	4.1	2.3	1.7	1.1	2.0	1.7	2.4	1.5
p Value	0.012	0.029	0.031	0.11	0.80	0.057	0.39	0.21	0.52
95% CI of	1.2	1.2	1.1	0.89	0.43	0.98	0.53	0.61	0.42
OR Quart2	5.2	15	5.0	3.2	3.0	4.0	5.2	9.3	5.6
OR Quart 3	3.9	4.9	3.2	3.2	2.2	3.6	2.8	2.4	4.1
p Value	1.2E-4	0.014	0.0019	1.8E-4	0.070	1.5E-4	0.059	0.21	0.014
95% CI of	2.0	1.4	1.5	1.7	0.94	1.9	0.96	0.61	1.3
OR Quart3	7.9	17	6.7	5.8	5.2	7.0	8.0	9.3	13
OR Quart 4	4.7	3.8	5.5	2.6	1.5	3.6	4.9	3.1	5.5
p Value	1.1E-5	0.042	2.9E-6	0.0022	0.36	1.3E-4	0.0021	0.094	0.0026
95% CI of	2.4	1.0	2.7	1.4	0.61	1.9	1.8	0.83	1.8
OR Quart4	9.4	14	11	4.8	3.8	7.1	13	12	17

Vascular endothelial growth factor receptor 2

sCr or UO	0hr prior to AKI stage		24hr prior to AKI stage		48hr prior to AKI stage	
	Cohort 1	Cohort 2	Cohort 1	Cohort 2	Cohort 1	Cohort 2
Median	393	825	393	599	393	370
Average	584	1020	584	794	584	576
Stdev	622	838	622	701	622	601
p(t-test)		1.3E-6		0.0092		0.95
Min	0.218	0.218	0.218	0.386	0.218	1.13
Max	4170	3930	4170	4210	4170	2260
n (Samp)	212	87	212	93	212	31
n (Patient)	124	87	124	93	124	31

sCr only	0hr prior to AKI stage		24hr prior to AKI stage		48hr prior to AKI stage	
	Cohort 1	Cohort 2	Cohort 1	Cohort 2	Cohort 1	Cohort 2
Median	647	617	647	587	647	448
Average	807	876	807	747	807	884
Stdev	796	985	796	809	796	970
p(t-test)		0.66		0.68		0.69
Min	0.218	0.218	0.218	0.386	0.218	1.13
Max	5940	3930	5940	4210	5940	2720
n (Samp)	504	28	504	32	504	18
n (Patient)	236	28	236	32	236	18

UO only	0hr prior to AKI stage		24hr prior to AKI stage		48hr prior to AKI stage	
	Cohort 1	Cohort 2	Cohort 1	Cohort 2	Cohort 1	Cohort 2
Median	407	916	407	665	407	455
Average	612	1160	612	897	612	639
Stdev	669	1080	669	987	669	684
p(t-test)		3.3E-7		0.0042		0.84
Min	0.218	0.218	0.218	0.616	0.218	0.218
Max	4210	7140	4210	7060	4210	2820
n (Samp)	224	77	224	83	224	30
n (Patient)	120	77	120	83	120	30

	0hr prior to AKI stage			24hr prior to AKI stage			48hr prior to AKI stage		
	sCr or UO	sCr only	UO only	sCr or UO	sCr only	UO only	sCr or UO	sCr only	UO only
AUC	0.67	0.49	0.70	0.61	0.48	0.62	0.50	0.48	0.51
SE	0.036	0.056	0.037	0.036	0.053	0.037	0.056	0.070	0.057
p	2.3E-6	0.89	6.1E-8	0.0018	0.65	0.0018	0.99	0.78	0.83
nCohort 1	212	504	224	212	504	224	212	504	224
nCohort 2	87	28	77	93	32	83	31	18	30
Cutoff 1	524	291	606	346	288	346	140	92.0	196
Sens 1	70%	71%	70%	71%	72%	72%	71%	72%	73%
Spec 1	58%	30%	62%	46%	30%	46%	27%	15%	31%
Cutoff 2	252	54.3	495	262	182	234	11.6	22.6	7.42
Sens 2	80%	82%	81%	81%	81%	81%	81%	83%	80%
Spec 2	39%	14%	57%	39%	22%	35%	14%	11%	12%
Cutoff 3	27.3	1.40	140	113	64.5	119	1.40	1.48	1.40
Sens 3	91%	93%	91%	90%	91%	90%	94%	94%	93%
Spec 3	16%	8%	25%	25%	14%	23%	12%	8%	10%
Cutoff 4	708	1010	710	708	1010	710	708	1010	710
Sens 4	61%	29%	66%	43%	28%	47%	35%	39%	37%
Spec 4	70%	70%	70%	70%	70%	70%	70%	70%	70%
Cutoff 5	975	1360	1070	975	1360	1070	975	1360	1070
Sens 5	43%	18%	42%	34%	12%	30%	19%	28%	17%
Spec 5	80%	80%	80%	80%	80%	80%	80%	80%	80%
Cutoff 6	1410	1740	1450	1410	1740	1450	1410	1740	1450
Sens 6	29%	14%	32%	15%	6%	16%	10%	22%	10%
Spec 6	90%	90%	90%	90%	90%	90%	90%	90%	90%
OR Quart 2	0.68	1.4	0.89	1.8	1.6	1.6	0.63	0	0.58
p Value	0.37	0.58	0.81	0.13	0.40	0.25	0.41	na	0.37

	0hr prior to AKI stage			24hr prior to AKI stage			48hr prior to AKI stage		
	sCr or UO	sCr only	UO only	sCr or UO	sCr only	UO only	sCr or UO	sCr only	UO only
95% CI of	0.29	0.46	0.34	0.84	0.52	0.72	0.21	na	0.18
OR Quart2	1.6	4.0	2.3	3.9	5.1	3.5	1.9	na	1.9
OR Quart 3	2.1	1.0	3.4	2.2	2.5	1.9	0.75	0.56	1.3
p Value	0.051	1.0	0.0030	0.043	0.089	0.094	0.59	0.36	0.61
95% CI of	1.00	0.31	1.5	1.0	0.87	0.89	0.26	0.16	0.48
OR Quart3	4.4	3.2	7.8	4.6	7.4	4.2	2.2	2.0	3.5
OR Quart 4	3.4	1.4	4.7	3.1	1.4	2.9	1.0	1.0	0.84
p Value	8.5E-4	0.58	1.6E-4	0.0023	0.56	0.0052	0.97	0.99	0.76
95% CI of	1.7	0.46	2.1	1.5	0.44	1.4	0.37	0.34	0.29
OR Quart4	7.1	4.0	11	6.6	4.6	6.2	2.8	3.0	2.5

Prostate-specific antigen

sCr or UO	0hr prior to AKI stage		24hr prior to AKI stage		48hr prior to AKI stage	
	Cohort 1	Cohort 2	Cohort 1	Cohort 2	Cohort 1	Cohort 2
Median	0.0131	0.0123	0.0131	0.126	nd	nd
Average	4.19	4.25	4.19	7.92	nd	nd
Stdev	7.89	8.36	7.89	9.60	nd	nd
p(t-test)		0.98		0.10	nd	nd
Min	0.00354	0.00392	0.00354	0.00462	nd	nd
Max	20.0	20.0	20.0	20.0	nd	nd
n (Samp)	52	19	52	19	nd	nd
n (Patient)	41	19	41	19	nd	nd

UO only	0hr prior to AKI stage		24hr prior to AKI stage		48hr prior to AKI stage	
	Cohort 1	Cohort 2	Cohort 1	Cohort 2	Cohort 1	Cohort 2
Median	0.0140	0.0349	0.0140	0.0849	nd	nd
Average	3.70	4.05	3.70	6.79	nd	nd
Stdev	7.37	8.26	7.37	9.06	nd	nd
p(t-test)		0.88		0.15	nd	nd
Min	0.00354	0.00392	0.00354	0.00462	nd	nd
Max	20.0	20.0	20.0	20.0	nd	nd
n (Samp)	44	15	44	20	nd	nd
n (Patient)	34	15	34	20	nd	nd

	0hr prior to AKI stage			24hr prior to AKI stage			48hr prior to AKI stage		
	sCr or UO	sCr only	UO only	sCr or UO	sCr only	UO only	sCr or UO	sCr only	UO only
AUC	0.55	nd	0.53	0.65	nd	0.63	nd	nd	nd
SE	0.079	nd	0.088	0.077	nd	0.078	nd	nd	nd
p	0.54	nd	0.71	0.046	nd	0.11	nd	nd	nd
nCohort 1	52	nd	44	52	nd	44	nd	nd	nd
nCohort 2	19	nd	15	19	nd	20	nd	nd	nd
Cutoff 1	0.0105	nd	0.00959	0.0127	nd	0.0135	nd	nd	nd
Sens 1	74%	nd	73%	74%	nd	70%	nd	nd	nd
Spec 1	44%	nd	36%	50%	nd	50%	nd	nd	nd
Cutoff 2	0.00897	nd	0.00870	0.00938	nd	0.0127	nd	nd	nd
Sens 2	84%	nd	87%	84%	nd	80%	nd	nd	nd
Spec 2	33%	nd	25%	37%	nd	45%	nd	nd	nd

	0hr prior to AKI stage			24hr prior to AKI stage			48hr prior to AKI stage		
	sCr or UO	sCr only	UO only	sCr or UO	sCr only	UO only	sCr or UO	sCr only	UO only
Cutoff 3	0.00606	nd	0.00776	0.00776	nd	0.00781	nd	nd	nd
Sens 3	95%	nd	93%	95%	nd	90%	nd	nd	nd
Spec 3	8%	nd	18%	21%	nd	18%	nd	nd	nd
Cutoff 4	0.105	nd	0.127	0.105	nd	0.127	nd	nd	nd
Sens 4	26%	nd	27%	53%	nd	45%	nd	nd	nd
Spec 4	71%	nd	70%	71%	nd	70%	nd	nd	nd
Cutoff 5	11.9	nd	4.24	11.9	nd	4.24	nd	nd	nd
Sens 5	21%	nd	20%	37%	nd	40%	nd	nd	nd
Spec 5	81%	nd	82%	81%	nd	82%	nd	nd	nd
Cutoff 6	20.0	nd	20.0	20.0	nd	20.0	nd	nd	nd
Sens 6	0%	nd	0%	0%	nd	0%	nd	nd	nd
Spec 6	100%	nd	100%	100%	nd	100%	nd	nd	nd
OR Quart 2	3.0	nd	3.0	2.9	nd	2.0	nd	nd	nd
p Value	0.17	nd	0.24	0.25	nd	0.42	nd	nd	nd
95% CI of	0.62	nd	0.48	0.48	nd	0.38	nd	nd	nd
OR Quart2	14	nd	19	17	nd	10	nd	nd	nd
OR Quart 3	1.8	nd	3.0	2.9	nd	1.4	nd	nd	nd
p Value	0.48	nd	0.24	0.25	nd	0.67	nd	nd	nd
95% CI of	0.36	nd	0.48	0.48	nd	0.27	nd	nd	nd
OR Quart3	9.1	nd	19	17	nd	7.8	nd	nd	nd
OR Quart 4	1.3	nd	1.5	4.8	nd	4.3	nd	nd	nd
p Value	0.74	nd	0.69	0.081	nd	0.071	nd	nd	nd
95% CI of	0.25	nd	0.21	0.83	nd	0.88	nd	nd	nd
OR Quart4	7.1	nd	11	28	nd	21	nd	nd	nd

Lutropin subunit beta

sCr or UO	0hr prior to AKI stage		24hr prior to AKI stage		48hr prior to AKI stage	
	Cohort 1	Cohort 2	Cohort 1	Cohort 2	Cohort 1	Cohort 2
Median	19.2	16.5	19.2	25.6	nd	nd
Average	60.1	41.4	60.1	69.5	nd	nd
Stdev	101	64.5	101	92.5	nd	nd
p(t-test)		0.20		0.58	nd	nd
Min	0.0297	0.130	0.0297	0.0746	nd	nd
Max	400	277	400	325	nd	nd
n (Samp)	127	59	127	46	nd	nd
n (Patient)	68	59	68	46	nd	nd

sCr only	0hr prior to AKI stage		24hr prior to AKI stage		48hr prior to AKI stage	
	Cohort 1	Cohort 2	Cohort 1	Cohort 2	Cohort 1	Cohort 2
Median	21.0	5.20	21.0	23.1	21.0	9.45
Average	60.1	36.1	60.1	77.8	60.1	12.5
Stdev	92.4	55.8	92.4	91.5	92.4	13.5
p(t-test)		0.29		0.45		0.21
Min	0.0297	0.211	0.0297	0.146	0.0297	0.505
Max	400	179	400	256	400	36.9
n (Samp)	267	17	267	16	267	6

sCr only	0hr prior to AKI stage		24hr prior to AKI stage		48hr prior to AKI stage	
	Cohort 1	Cohort 2	Cohort 1	Cohort 2	Cohort 1	Cohort 2
n (Patient)	128	17	128	16	128	6

UO only	0hr prior to AKI stage		24hr prior to AKI stage		48hr prior to AKI stage	
	Cohort 1	Cohort 2	Cohort 1	Cohort 2	Cohort 1	Cohort 2
Median	19.4	21.0	19.4	23.6	19.4	16.2
Average	63.9	48.5	63.9	68.9	63.9	86.8
Stdev	99.3	74.9	99.3	100	99.3	119
p(t-test)		0.31		0.76		0.51
Min	0.0297	0.130	0.0297	0.0746	0.0297	0.463
Max	400	325	400	393	400	332
n (Samp)	148	51	148	47	148	9
n (Patient)	72	51	72	47	72	9

	0hr prior to AKI stage			24hr prior to AKI stage			48hr prior to AKI stage		
	sCr or UO	sCr only	UO only	sCr or UO	sCr only	UO only	sCr or UO	sCr only	UO only
AUC	0.48	0.39	0.51	0.57	0.54	0.55	nd	0.33	0.57
SE	0.046	0.075	0.047	0.050	0.076	0.049	nd	0.12	0.10
p	0.74	0.16	0.89	0.19	0.63	0.28	nd	0.17	0.51
nCohort 1	127	267	148	127	267	148	nd	267	148
nCohort 2	59	17	51	46	16	47	nd	6	9
Cutoff 1	4.35	3.23	7.60	10.6	5.10	10.6	nd	3.00	11.6
Sens 1	71%	71%	71%	72%	75%	70%	nd	83%	78%
Spec 1	28%	19%	35%	41%	24%	39%	nd	18%	40%
Cutoff 2	2.03	1.98	4.33	6.10	4.35	6.19	nd	3.00	6.57
Sens 2	81%	82%	80%	80%	81%	81%	nd	83%	89%
Spec 2	16%	15%	26%	37%	22%	34%	nd	18%	34%
Cutoff 3	0.393	0.339	0.986	0.933	0.408	3.86	nd	0.448	0.422
Sens 3	92%	94%	90%	91%	94%	91%	nd	100%	100%
Spec 3	9%	8%	11%	13%	9%	26%	nd	10%	9%
Cutoff 4	38.7	46.3	43.9	38.7	46.3	43.9	nd	46.3	43.9
Sens 4	29%	24%	29%	37%	38%	32%	nd	0%	33%
Spec 4	70%	70%	70%	70%	70%	70%	nd	70%	70%
Cutoff 5	80.9	89.1	134	80.9	89.1	134	nd	89.1	134
Sens 5	14%	18%	10%	28%	38%	19%	nd	0%	33%
Spec 5	80%	80%	80%	80%	80%	80%	nd	80%	80%
Cutoff 6	232	225	217	232	225	217	nd	225	217
Sens 6	5%	0%	8%	11%	6%	13%	nd	0%	22%
Spec 6	91%	90%	91%	91%	90%	91%	nd	90%	91%
OR Quart 2	0.84	0.49	1.7	3.0	0.57	1.8	nd	>1.0	4.3
p Value	0.70	0.41	0.27	0.046	0.46	0.24	nd	<0.98	0.20
95% CI of	0.35	0.086	0.67	1.0	0.13	0.67	nd	>0.063	0.46
OR Quart2	2.0	2.7	4.2	8.7	2.5	4.9	nd	na	41
OR Quart 3	1.2	0.74	1.7	2.4	0.38	2.0	nd	>2.1	1.0
p Value	0.66	0.70	0.27	0.12	0.25	0.17	nd	<0.55	1.0
95% CI of	0.51	0.16	0.67	0.80	0.071	0.75	nd	>0.19	0.060
OR Quart3	2.8	3.4	4.2	7.1	2.0	5.3	nd	na	17
OR Quart 4	0.93	2.1	1.1	2.9	1.2	1.6	nd	>3.2	3.1

	0hr prior to AKI stage			24hr prior to AKI stage			48hr prior to AKI stage		
	sCr or UO	sCr only	UO only	sCr or UO	sCr only	UO only	sCr or UO	sCr only	UO only
p Value	0.88	0.24	0.85	0.053	0.77	0.34	nd	<0.32	0.34
95% CI of	0.39	0.61	0.42	0.99	0.35	0.60	nd	>0.32	0.31
OR Quart4	2.2	7.4	2.9	8.4	4.1	4.4	nd	na	31

Neural cell adhesion molecule 1

sCr or UO	0hr prior to AKI stage		24hr prior to AKI stage		48hr prior to AKI stage	
	Cohort 1	Cohort 2	Cohort 1	Cohort 2	Cohort 1	Cohort 2
Median	2250	3580	2250	2690	2250	2950
Average	2910	3890	2910	4150	2910	3090
Stdev	2240	4020	2240	6560	2240	1780
p(t-test)		3.9E-4		6.5E-4		0.59
Min	6.83	221	6.83	216	6.83	293
Max	22000	40700	22000	55700	22000	6560
n (Samp)	463	119	463	128	463	47
n (Patient)	223	119	223	128	223	47

sCr only	0hr prior to AKI stage		24hr prior to AKI stage		48hr prior to AKI stage	
	Cohort 1	Cohort 2	Cohort 1	Cohort 2	Cohort 1	Cohort 2
Median	2830	2300	2830	2420	2830	1930
Average	3460	2540	3460	3220	3460	2360
Stdev	3360	1640	3360	2380	3360	1600
p(t-test)		0.085		0.63		0.097
Min	6.83	221	6.83	216	6.83	387
Max	55700	6210	55700	10800	55700	6110
n (Samp)	1014	40	1014	46	1014	26
n (Patient)	373	40	373	46	373	26

UO only	0hr prior to AKI stage		24hr prior to AKI stage		48hr prior to AKI stage	
	Cohort 1	Cohort 2	Cohort 1	Cohort 2	Cohort 1	Cohort 2
Median	2400	3900	2400	2850	2400	2920
Average	2980	4670	2980	4590	2980	3220
Stdev	2070	4820	2070	7080	2070	1960
p(t-test)		4.3E-8		4.0E-5		0.45
Min	173	506	173	224	173	293
Max	11700	40700	11700	55700	11700	9700
n (Samp)	436	107	436	117	436	44
n (Patient)	173	107	173	117	173	44

	0hr prior to AKI stage			24hr prior to AKI stage			48hr prior to AKI stage		
	sCr or UO	sCr only	UO only	sCr or UO	sCr only	UO only	sCr or UO	sCr only	UO only
AUC	0.62	0.40	0.66	0.56	0.48	0.58	0.56	0.37	0.56
SE	0.030	0.048	0.031	0.029	0.044	0.031	0.045	0.059	0.047
p	1.2E-4	0.043	2.3E-7	0.026	0.61	0.0086	0.20	0.025	0.21
nCohort 1	463	1014	436	463	1014	436	463	1014	436
nCohort 2	119	40	107	128	46	117	47	26	44
Cutoff 1	2270	1150	2690	1950	1680	2080	2150	1190	2250

	0hr prior to AKI stage			24hr prior to AKI stage			48hr prior to AKI stage		
	sCr or UO	sCr only	UO only	sCr or UO	sCr only	UO only	sCr or UO	sCr only	UO only
Sens 1	71%	70%	70%	70%	72%	70%	70%	73%	70%
Spec 1	51%	14%	56%	42%	25%	43%	48%	14%	46%
Cutoff 2	1550	994	2000	1250	1110	1560	1500	1110	1650
Sens 2	81%	80%	80%	80%	80%	80%	81%	81%	82%
Spec 2	30%	11%	41%	20%	13%	30%	29%	13%	32%
Cutoff 3	919	830	1450	898	883	1030	485	491	881
Sens 3	91%	90%	91%	91%	91%	91%	91%	92%	91%
Spec 3	11%	7%	27%	11%	8%	14%	3%	2%	10%
Cutoff 4	3530	4050	3620	3530	4050	3620	3530	4050	3620
Sens 4	51%	18%	56%	37%	33%	38%	38%	15%	36%
Spec 4	70%	70%	70%	70%	70%	70%	70%	70%	70%
Cutoff 5	4180	4930	4360	4180	4930	4360	4180	4930	4360
Sens 5	32%	8%	34%	30%	22%	32%	28%	8%	25%
Spec 5	80%	80%	80%	80%	80%	80%	80%	80%	80%
Cutoff 6	5630	6450	6000	5630	6450	6000	5630	6450	6000
Sens 6	17%	0%	23%	20%	9%	20%	9%	0%	9%
Spec 6	90%	90%	90%	90%	90%	90%	90%	90%	90%
OR Quart 2	1.2	1.5	1.3	0.99	0.74	1.4	1.1	1.0	1.3
p Value	0.63	0.43	0.47	0.98	0.51	0.27	0.83	1.0	0.61
95% CI of	0.61	0.53	0.63	0.55	0.31	0.76	0.44	0.25	0.47
OR Quart2	2.3	4.3	2.8	1.8	1.8	2.6	2.8	4.0	3.6
OR Quart 3	2.0	1.7	2.8	1.1	1.0	1.4	1.6	2.0	2.5
p Value	0.034	0.31	0.0032	0.79	1.0	0.27	0.28	0.25	0.055
95% CI of	1.1	0.61	1.4	0.61	0.44	0.76	0.68	0.60	0.98
OR Quart3	3.6	4.7	5.5	1.9	2.3	2.6	3.9	6.8	6.3
OR Quart 4	3.0	2.6	3.9	1.9	1.1	2.3	1.6	2.6	1.8
p Value	3.7E-4	0.052	6.4E-5	0.017	0.84	0.0072	0.29	0.12	0.24
95% CI of	1.6	0.99	2.0	1.1	0.49	1.2	0.67	0.79	0.68
OR Quart4	5.4	6.8	7.5	3.3	2.4	4.1	3.9	8.3	4.7

Platelet-derived growth factor subunit B (dimer)

sCr or UO	0hr prior to AKI stage		24hr prior to AKI stage		48hr prior to AKI stage	
	Cohort 1	Cohort 2	Cohort 1	Cohort 2	Cohort 1	Cohort 2
Median	0.961	1.70	0.961	1.70	0.961	1.75
Average	3.43	3.67	3.43	14.0	3.43	4.02
Stdev	15.8	10.6	15.8	102	15.8	7.14
p(t-test)		0.90		0.060		0.81
Min	0.00246	0.00313	0.00246	0.00408	0.00246	0.00683
Max	270	86.2	270	935	270	34.8
n (Samp)	365	70	365	84	365	41
n (Patient)	191	70	191	84	191	41

sCr only	0hr prior to AKI stage		24hr prior to AKI stage		48hr prior to AKI stage	
	Cohort 1	Cohort 2	Cohort 1	Cohort 2	Cohort 1	Cohort 2
Median	1.06	2.21	1.06	2.31	1.06	2.18
Average	4.26	6.20	4.26	3.16	4.26	4.35
Stdev	35.9	16.9	35.9	3.24	35.9	7.82

sCr only	0hr prior to AKI stage		24hr prior to AKI stage		48hr prior to AKI stage	
	Cohort 1	Cohort 2	Cohort 1	Cohort 2	Cohort 1	Cohort 2
p(t-test)		0.79		0.86		0.99
Min	0.00246	0.0144	0.00246	0.0140	0.00246	0.00408
Max	935	86.2	935	16.9	935	34.8
n (Samp)	754	25	754	32	754	21
n (Patient)	295	25	295	32	295	21

UO only	0hr prior to AKI stage		24hr prior to AKI stage		48hr prior to AKI stage	
	Cohort 1	Cohort 2	Cohort 1	Cohort 2	Cohort 1	Cohort 2
Median	1.14	1.82	1.14	1.77	1.14	1.63
Average	3.66	3.62	3.66	15.7	3.66	3.35
Stdev	16.6	7.97	16.6	106	16.6	5.16
p(t-test)		0.99		0.054		0.91
Min	0.00246	0.00313	0.00246	0.00408	0.00246	0.00683
Max	270	59.1	270	935	270	22.1
n (Samp)	317	65	317	77	317	36
n (Patient)	136	65	136	77	136	36

	0hr prior to AKI stage			24hr prior to AKI stage			48hr prior to AKI stage		
	sCr or UO	sCr only	UO only	sCr or UO	sCr only	UO only	sCr or UO	sCr only	UO only
AUC	0.60	0.66	0.60	0.60	0.67	0.58	0.59	0.64	0.56
SE	0.038	0.060	0.040	0.036	0.053	0.037	0.049	0.066	0.052
p	0.0078	0.0097	0.010	0.0046	0.0015	0.027	0.057	0.030	0.25
nCohort 1	365	754	317	365	754	317	365	754	317
nCohort 2	70	25	65	84	32	77	41	21	36
Cutoff 1	0.718	1.09	1.14	0.901	1.39	0.965	0.392	1.24	0.353
Sens 1	70%	72%	71%	70%	72%	70%	71%	71%	72%
Spec 1	40%	51%	50%	48%	57%	46%	30%	54%	27%
Cutoff 2	0.483	0.737	0.536	0.273	0.465	0.162	0.286	0.869	0.232
Sens 2	80%	80%	80%	81%	81%	81%	80%	81%	81%
Spec 2	32%	39%	32%	25%	31%	21%	26%	44%	22%
Cutoff 3	0.0238	0.477	0.0238	0.0238	0.278	0.0238	0.0244	0.0244	0.0140
Sens 3	94%	92%	95%	93%	91%	91%	90%	90%	92%
Spec 3	17%	31%	15%	17%	25%	15%	20%	19%	11%
Cutoff 4	1.79	1.99	1.99	1.79	1.99	1.99	1.79	1.99	1.99
Sens 4	47%	64%	49%	48%	62%	45%	46%	62%	42%
Spec 4	70%	70%	70%	70%	70%	70%	70%	70%	70%
Cutoff 5	2.54	3.02	3.08	2.54	3.02	3.08	2.54	3.02	3.08
Sens 5	34%	32%	31%	31%	44%	25%	39%	38%	31%
Spec 5	80%	80%	80%	80%	80%	80%	80%	80%	80%
Cutoff 6	4.63	4.73	5.05	4.63	4.73	5.05	4.63	4.73	5.05
Sens 6	13%	20%	14%	15%	19%	13%	15%	10%	17%
Spec 6	90%	90%	90%	90%	90%	90%	90%	90%	90%
OR Quart 2	0.99	2.5	1.6	0.57	0.74	0.66	0.99	0.99	0.47
p Value	0.98	0.27	0.30	0.17	0.70	0.30	0.98	0.99	0.19
95% CI of	0.42	0.48	0.67	0.26	0.16	0.30	0.36	0.20	0.15
OR Quart2	2.3	13	3.7	1.3	3.4	1.5	2.7	5.0	1.4
OR Quart 3	1.9	3.0	1.9	1.6	2.9	1.4	1.0	1.7	0.78

	0hr prior to AKI stage			24hr prior to AKI stage			48hr prior to AKI stage		
	sCr or UO	sCr only	UO only	sCr or UO	sCr only	UO only	sCr or UO	sCr only	UO only
p Value	0.098	0.18	0.15	0.18	0.077	0.37	1.0	0.48	0.62
95% CI of	0.89	0.61	0.80	0.81	0.89	0.68	0.36	0.39	0.29
OR Quart3	4.1	15	4.3	3.1	9.1	2.8	2.8	7.1	2.1
OR Quart 4	2.4	6.3	2.7	1.8	3.7	1.7	2.3	3.4	1.3
p Value	0.023	0.017	0.017	0.079	0.024	0.13	0.063	0.064	0.52
95% CI of	1.1	1.4	1.2	0.93	1.2	0.85	0.95	0.93	0.55
OR Quart4	5.0	29	6.0	3.5	11	3.4	5.7	13	3.2

Thyroxine-binding globulin

sCr or UO	0hr prior to AKI stage		24hr prior to AKI stage		48hr prior to AKI stage	
	Cohort 1	Cohort 2	Cohort 1	Cohort 2	Cohort 1	Cohort 2
Median	0.0694	0.0901	0.0694	0.106	0.0694	0.148
Average	0.182	0.240	0.182	0.238	0.182	0.169
Stdev	0.262	0.381	0.262	0.515	0.262	0.173
p(t-test)		0.20		0.24		0.80
Min	0.000191	8.30E-5	0.000191	0.000156	0.000191	0.00190
Max	1.59	1.86	1.59	3.60	1.59	0.775
n (Samp)	255	48	255	56	255	27
n (Patient)	103	48	103	56	103	27

sCr only	0hr prior to AKI stage		24hr prior to AKI stage		48hr prior to AKI stage	
	Cohort 1	Cohort 2	Cohort 1	Cohort 2	Cohort 1	Cohort 2
Median	0.0777	0.0623	0.0777	0.0721	0.0777	0.0390
Average	0.189	0.0799	0.189	0.162	0.189	0.0671
Stdev	0.308	0.0770	0.308	0.219	0.308	0.0674
p(t-test)		0.16		0.70		0.15
Min	0.000191	8.30E-5	0.000191	0.000156	0.000191	0.00190
Max	3.60	0.250	3.60	0.792	3.60	0.218
n (Samp)	447	16	447	20	447	13
n (Patient)	170	16	170	20	170	13

UO only	0hr prior to AKI stage		24hr prior to AKI stage		48hr prior to AKI stage	
	Cohort 1	Cohort 2	Cohort 1	Cohort 2	Cohort 1	Cohort 2
Median	0.0675	0.0555	0.0675	0.114	0.0675	0.149
Average	0.172	0.241	0.172	0.249	0.172	0.178
Stdev	0.259	0.391	0.259	0.537	0.259	0.177
p(t-test)		0.14		0.14		0.91
Min	0.000191	0.00106	0.000191	0.00324	0.000191	0.00366
Max	1.59	1.86	1.59	3.60	1.59	0.775
n (Samp)	218	46	218	51	218	25
n (Patient)	87	46	87	51	87	25

	0hr prior to AKI stage			24hr prior to AKI stage			48hr prior to AKI stage		
	sCr or UO	sCr only	UO only	sCr or UO	sCr only	UO only	sCr or UO	sCr only	UO only
AUC	0.52	0.41	0.51	0.52	0.47	0.53	0.57	0.37	0.60
SE	0.046	0.076	0.047	0.043	0.067	0.045	0.060	0.084	0.063

	0hr prior to AKI stage			24hr prior to AKI stage			48hr prior to AKI stage		
	sCr or UO	sCr only	UO only	sCr or UO	sCr only	UO only	sCr or UO	sCr only	UO only
p	0.66	0.24	0.83	0.69	0.68	0.47	0.28	0.12	0.098
nCohort 1	255	447	218	255	447	218	255	447	218
nCohort 2	48	16	46	56	20	51	27	13	25
Cutoff 1	0.0279	0.0196	0.0169	0.0293	0.0357	0.0287	0.0617	0.0196	0.0694
Sens 1	71%	75%	72%	71%	70%	71%	70%	77%	72%
Spec 1	30%	23%	22%	31%	33%	32%	47%	23%	52%
Cutoff 2	0.0150	0.0157	0.0138	0.0194	0.0187	0.0164	0.0471	0.00877	0.0547
Sens 2	81%	81%	80%	80%	80%	80%	81%	85%	80%
Spec 2	20%	20%	20%	22%	22%	22%	41%	15%	46%
Cutoff 3	0.00405	0.00990	0.00446	0.00715	0.00325	0.0100	0.00715	0.00319	0.0138
Sens 3	92%	94%	91%	91%	90%	90%	93%	92%	92%
Spec 3	7%	16%	8%	14%	6%	16%	14%	6%	20%
Cutoff 4	0.193	0.198	0.174	0.193	0.198	0.174	0.193	0.198	0.174
Sens 4	35%	12%	39%	30%	25%	37%	33%	8%	44%
Spec 4	70%	70%	70%	70%	70%	70%	70%	70%	70%
Cutoff 5	0.274	0.290	0.248	0.274	0.290	0.248	0.274	0.290	0.248
Sens 5	23%	0%	28%	21%	15%	25%	11%	0%	16%
Spec 5	80%	80%	80%	80%	80%	80%	80%	80%	80%
Cutoff 6	0.448	0.466	0.418	0.448	0.466	0.418	0.448	0.466	0.418
Sens 6	19%	0%	20%	12%	10%	12%	7%	0%	8%
Spec 6	90%	90%	90%	90%	90%	90%	90%	90%	90%
OR Quart 2	0.64	5.2	0.54	0.74	1.5	0.59	2.1	>5.2	1.7
p Value	0.34	0.14	0.18	0.49	0.52	0.26	0.32	<0.13	0.48
95% CI of	0.26	0.60	0.22	0.31	0.42	0.23	0.49	>0.60	0.39
OR Quart2	1.6	45	1.3	1.7	5.6	1.5	8.6	na	7.4
OR Quart 3	0.89	5.2	0.40	1.3	1.3	1.0	4.6	>4.1	3.3
p Value	0.80	0.14	0.067	0.45	0.73	1.0	0.022	<0.21	0.086
95% CI of	0.38	0.60	0.15	0.62	0.33	0.43	1.2	>0.46	0.84
OR Quart3	2.1	45	1.1	3.0	4.8	2.3	17	na	13
OR Quart 4	1.1	5.2	1.0	0.90	1.3	0.98	2.1	>4.1	2.9
p Value	0.86	0.13	1.0	0.80	0.72	0.96	0.32	<0.21	0.13
95% CI of	0.47	0.60	0.44	0.39	0.33	0.43	0.49	>0.46	0.72
OR Quart4	2.5	45	2.3	2.1	4.9	2.3	8.6	na	11

Pigment epithelium-derived factor

sCr or UO	0hr prior to AKI stage		24hr prior to AKI stage		48hr prior to AKI stage	
	Cohort 1	Cohort 2	Cohort 1	Cohort 2	Cohort 1	Cohort 2
Median	3.04	4.18	3.04	2.78	3.04	3.54
Average	20.4	23.7	20.4	22.4	20.4	17.8
Stdev	49.4	52.1	49.4	51.0	49.4	34.6
p(t-test)		0.52		0.68		0.72
Min	0.000563	0.0167	0.000563	0.00102	0.000563	0.159
Max	400	302	400	400	400	171
n (Samp)	463	119	463	128	463	47
n (Patient)	223	119	223	128	223	47

sCr only	0hr prior to AKI stage	24hr prior to AKI stage	48hr prior to AKI stage

	Cohort 1	Cohort 2	Cohort 1	Cohort 2	Cohort 1	Cohort 2
Median	3.10	3.91	3.10	3.28	3.10	2.70
Average	18.7	25.3	18.7	27.7	18.7	25.4
Stdev	45.5	64.6	45.5	53.3	45.5	50.3
p(t-test)		0.38		0.19		0.46
Min	0.000401	0.115	0.000401	0.0102	0.000401	0.00102
Max	400	361	400	302	400	218
n (Samp)	1015	40	1015	46	1015	26
n (Patient)	374	40	374	46	374	26

UO only	0hr prior to AKI stage		24hr prior to AKI stage		48hr prior to AKI stage	
	Cohort 1	Cohort 2	Cohort 1	Cohort 2	Cohort 1	Cohort 2
Median	3.33	4.99	3.33	3.59	3.33	6.11
Average	24.7	27.8	24.7	29.2	24.7	22.5
Stdev	54.1	56.4	54.1	65.5	54.1	41.4
p(t-test)		0.60		0.44		0.80
Min	0.000563	0.0167	0.000563	0.00102	0.000563	0.189
Max	400	302	400	400	400	171
n (Samp)	436	107	436	117	436	44
n (Patient)	173	107	173	117	173	44

	0hr prior to AKI stage			24hr prior to AKI stage			48hr prior to AKI stage		
	sCr or UO	sCr only	UO only	sCr or UO	sCr only	UO only	sCr or UO	sCr only	UO only
AUC	0.55	0.52	0.56	0.51	0.54	0.52	0.54	0.50	0.55
SE	0.030	0.047	0.032	0.029	0.044	0.030	0.045	0.058	0.047
p	0.081	0.73	0.055	0.70	0.43	0.61	0.39	0.94	0.29
nCohort 1	463	1015	436	463	1015	436	463	1015	436
nCohort 2	119	40	107	128	46	117	47	26	44
Cutoff 1	1.88	1.94	2.14	1.13	0.884	1.45	1.56	0.913	2.03
Sens 1	71%	70%	70%	70%	72%	70%	70%	73%	70%
Spec 1	41%	40%	41%	31%	25%	33%	38%	26%	40%
Cutoff 2	0.861	0.565	1.30	0.602	0.596	0.751	0.863	0.514	0.874
Sens 2	81%	80%	80%	80%	80%	81%	81%	81%	82%
Spec 2	26%	17%	30%	21%	18%	20%	26%	15%	22%
Cutoff 3	0.329	0.169	0.596	0.283	0.132	0.320	0.361	0.185	0.681
Sens 3	91%	90%	91%	91%	91%	91%	91%	92%	91%
Spec 3	11%	5%	16%	10%	4%	8%	13%	6%	19%
Cutoff 4	9.21	8.99	11.3	9.21	8.99	11.3	9.21	8.99	11.3
Sens 4	36%	30%	40%	32%	41%	34%	30%	31%	36%
Spec 4	70%	70%	70%	70%	70%	70%	70%	70%	70%
Cutoff 5	19.2	18.7	27.1	19.2	18.7	27.1	19.2	18.7	27.1
Sens 5	27%	18%	23%	26%	37%	24%	23%	23%	18%
Spec 5	80%	80%	80%	80%	80%	80%	80%	80%	80%
Cutoff 6	52.9	45.1	83.6	52.9	45.1	83.6	52.9	45.1	83.6
Sens 6	11%	15%	8%	12%	20%	9%	9%	19%	9%
Spec 6	90%	90%	90%	90%	90%	90%	90%	90%	90%
OR Quart 2	1.3	0.79	1.6	0.99	0.76	1.2	1.5	1.2	0.89
p Value	0.37	0.63	0.16	0.98	0.52	0.55	0.36	0.77	0.81
95% CI of	0.72	0.31	0.84	0.57	0.33	0.67	0.61	0.39	0.35

	0hr prior to AKI stage			24hr prior to AKI stage			48hr prior to AKI stage		
	sCr or UO	sCr only	UO only	sCr or UO	sCr only	UO only	sCr or UO	sCr only	UO only
OR Quart2	2.4	2.0	3.0	1.7	1.8	2.1	3.9	3.5	2.3
OR Quart 3	1.4	1.1	1.4	0.67	0.30	0.95	1.8	1.0	1.2
p Value	0.29	0.83	0.27	0.18	0.036	0.88	0.19	0.99	0.65
95% CI of	0.76	0.46	0.76	0.37	0.096	0.52	0.74	0.32	0.51
OR Quart3	2.5	2.6	2.8	1.2	0.92	1.7	4.6	3.2	2.9
OR Quart 4	1.8	1.1	2.0	1.2	1.5	1.3	1.7	1.2	1.3
p Value	0.047	0.83	0.025	0.52	0.28	0.40	0.27	0.77	0.51
95% CI of	1.0	0.46	1.1	0.70	0.72	0.72	0.67	0.39	0.56
OR Quart4	3.2	2.6	3.8	2.0	3.1	2.3	4.2	3.5	3.2

Tumor necrosis factor receptor superfamily member 8

sCr or UO	0hr prior to AKI stage		24hr prior to AKI stage		48hr prior to AKI stage	
	Cohort 1	Cohort 2	Cohort 1	Cohort 2	Cohort 1	Cohort 2
Median	15.0	24.9	15.0	19.7	15.0	30.0
Average	25.2	35.9	25.2	27.2	25.2	32.8
Stdev	36.7	35.9	36.7	24.9	36.7	25.6
p(t-test)		0.020		0.63		0.26
Min	0.0493	0.0493	0.0493	0.121	0.0493	0.196
Max	277	176	277	111	277	110
n (Samp)	217	91	217	96	217	32
n (Patient)	128	91	128	96	128	32

sCr only	0hr prior to AKI stage		24hr prior to AKI stage		48hr prior to AKI stage	
	Cohort 1	Cohort 2	Cohort 1	Cohort 2	Cohort 1	Cohort 2
Median	19.5	19.8	19.5	30.5	19.5	33.4
Average	31.1	29.5	31.1	43.0	31.1	38.0
Stdev	48.0	28.0	48.0	60.6	48.0	31.6
p(t-test)		0.86		0.18		0.55
Min	0.0493	0.121	0.0493	0.121	0.0493	0.0561
Max	554	126	554	353	554	110
n (Samp)	517	28	517	33	517	18
n (Patient)	242	28	242	33	242	18

UO only	0hr prior to AKI stage		24hr prior to AKI stage		48hr prior to AKI stage	
	Cohort 1	Cohort 2	Cohort 1	Cohort 2	Cohort 1	Cohort 2
Median	13.2	26.6	13.2	19.0	13.2	18.8
Average	23.7	37.3	23.7	26.7	23.7	27.7
Stdev	36.2	36.1	36.2	25.8	36.2	24.0
p(t-test)		0.0040		0.47		0.55
Min	0.0493	0.0493	0.0493	0.196	0.0493	0.196
Max	277	176	277	126	277	111
n (Samp)	227	81	227	86	227	31
n (Patient)	122	81	122	86	122	31

	0hr prior to AKI stage			24hr prior to AKI stage			48hr prior to AKI stage		
	sCr or UO	sCr only	UO only	sCr or UO	sCr only	UO only	sCr or UO	sCr only	UO only

	0hr prior to AKI stage			24hr prior to AKI stage			48hr prior to AKI stage		
	sCr or UO	sCr only	UO only	sCr or UO	sCr only	UO only	sCr or UO	sCr only	UO only
AUC	0.63	0.54	0.66	0.57	0.62	0.58	0.65	0.61	0.62
SE	0.036	0.057	0.037	0.036	0.054	0.037	0.056	0.072	0.057
p	4.6E-4	0.46	1.4E-5	0.047	0.025	0.022	0.0079	0.14	0.037
nCohort 1	217	517	227	217	517	227	217	517	227
nCohort 2	91	28	81	96	33	86	32	18	31
Cutoff 1	12.5	12.5	12.5	9.84	19.8	8.69	18.3	18.3	12.4
Sens 1	71%	71%	70%	71%	73%	71%	72%	72%	71%
Spec 1	47%	39%	49%	36%	52%	39%	53%	46%	48%
Cutoff 2	8.52	5.14	7.30	5.14	12.3	5.14	12.1	5.76	7.30
Sens 2	80%	89%	80%	81%	82%	81%	81%	83%	81%
Spec 2	35%	21%	39%	27%	37%	30%	43%	23%	39%
Cutoff 3	4.86	0.811	4.86	2.45	5.09	2.45	6.53	0.196	5.14
Sens 3	90%	96%	90%	91%	94%	91%	91%	94%	90%
Spec 3	23%	11%	24%	20%	20%	22%	30%	8%	30%
Cutoff 4	27.0	32.9	25.8	27.0	32.9	25.8	27.0	32.9	25.8
Sens 4	45%	36%	53%	39%	39%	41%	53%	50%	45%
Spec 4	70%	71%	70%	70%	71%	70%	70%	71%	70%
Cutoff 5	35.9	42.2	34.0	35.9	42.2	34.0	35.9	42.2	34.0
Sens 5	38%	29%	43%	33%	30%	31%	41%	33%	29%
Spec 5	80%	80%	81%	80%	80%	81%	80%	80%	81%
Cutoff 6	53.5	62.7	50.8	53.5	62.7	50.8	53.5	62.7	50.8
Sens 6	20%	14%	21%	15%	12%	13%	12%	22%	10%
Spec 6	90%	90%	91%	90%	90%	91%	90%	90%	91%
OR Quart 2	1.3	1.2	2.3	1.5	1.2	2.2	3.8	0.49	3.3
p Value	0.56	0.78	0.061	0.29	0.74	0.044	0.10	0.41	0.087
95% CI of	0.58	0.38	0.96	0.73	0.33	1.0	0.76	0.088	0.84
OR Quart2	2.7	3.6	5.5	3.0	4.8	4.6	19	2.7	13
OR Quart 3	1.8	1.2	2.7	1.1	3.2	1.3	5.1	1.2	2.5
p Value	0.14	0.78	0.027	0.85	0.049	0.55	0.043	0.74	0.20
95% CI of	0.84	0.38	1.1	0.52	1.0	0.58	1.1	0.33	0.62
OR Quart3	3.7	3.6	6.3	2.2	10	2.8	25	4.8	10
OR Quart 4	3.4	1.3	6.0	2.1	3.2	2.8	8.6	1.8	4.6
p Value	7.7E-4	0.59	2.3E-5	0.032	0.051	0.0061	0.0059	0.37	0.023
95% CI of	1.7	0.45	2.6	1.1	1.00	1.3	1.9	0.51	1.2
OR Quart4	7.1	4.0	14	4.2	10	5.8	40	6.2	17

Alpha-fetoprotein

sCr or UO	0hr prior to AKI stage		24hr prior to AKI stage		48hr prior to AKI stage	
	Cohort 1	Cohort 2	Cohort 1	Cohort 2	Cohort 1	Cohort 2
Median	0.00520	0.00428	0.00520	0.00587	0.00520	0.00587
Average	0.0545	0.0877	0.0545	0.0927	0.0545	0.0161
Stdev	0.124	0.239	0.124	0.347	0.124	0.0327
p(t-test)		0.13		0.18		0.12
Min	0.000463	0.000463	0.000463	0.000463	0.000463	0.000523
Max	0.803	1.74	0.803	2.85	0.803	0.118
n (Samp)	194	86	194	76	194	26
n (Patient)	123	86	123	76	123	26

sCr only	0hr prior to AKI stage		24hr prior to AKI stage		48hr prior to AKI stage	
	Cohort 1	Cohort 2	Cohort 1	Cohort 2	Cohort 1	Cohort 2
Median	0.00520	0.00508	0.00520	0.00428	0.00520	0.00546
Average	0.0560	0.170	0.0560	0.0759	0.0560	0.0270
Stdev	0.186	0.369	0.186	0.199	0.186	0.0391
p(t-test)		0.0052		0.58		0.53
Min	0.000463	0.000463	0.000463	0.000463	0.000463	0.000523
Max	2.85	1.74	2.85	0.889	2.85	0.109
n (Samp)	428	26	428	28	428	16
n (Patient)	210	26	210	28	210	16

UO only	0hr prior to AKI stage		24hr prior to AKI stage		48hr prior to AKI stage	
	Cohort 1	Cohort 2	Cohort 1	Cohort 2	Cohort 1	Cohort 2
Median	0.00505	0.00428	0.00505	0.00624	0.00505	0.00587
Average	0.0557	0.0575	0.0557	0.0924	0.0557	0.107
Stdev	0.132	0.144	0.132	0.343	0.132	0.346
p(t-test)		0.92		0.19		0.14
Min	0.000463	0.000463	0.000463	0.000463	0.000463	0.000463
Max	0.803	0.840	0.803	2.85	0.803	1.74
n (Samp)	210	78	210	72	210	27
n (Patient)	119	78	119	72	119	27

	0hr prior to AKI stage			24hr prior to AKI stage			48hr prior to AKI stage		
	sCr or UO	sCr only	UO only	sCr or UO	sCr only	UO only	sCr or UO	sCr only	UO only
AUC	0.46	0.52	0.46	0.50	0.41	0.57	0.46	0.51	0.52
SE	0.038	0.059	0.039	0.039	0.058	0.040	0.061	0.074	0.060
p	0.25	0.79	0.28	0.99	0.11	0.074	0.47	0.86	0.77
nCohort 1	194	428	210	194	428	210	194	428	210
nCohort 2	86	26	78	76	28	72	26	16	27
Cutoff 1	0.00296	0.00296	0.00296	0.00367	0.00132	0.00428	0.00367	0.00367	0.00423
Sens 1	74%	73%	72%	71%	86%	71%	73%	75%	70%
Spec 1	19%	21%	21%	30%	13%	42%	30%	32%	32%
Cutoff 2	0.00132	0.00132	0.00132	0.000523	0.00132	0.00296	0.000523	0.00132	0.000523
Sens 2	81%	85%	81%	87%	86%	81%	96%	94%	93%
Spec 2	12%	13%	17%	12%	13%	21%	12%	13%	17%
Cutoff 3	0.000463	0	0.000463	0	0	0.000463	0.000523	0.00132	0.000523
Sens 3	91%	100%	92%	100%	100%	92%	96%	94%	93%
Spec 3	5%	0%	10%	0%	0%	10%	12%	13%	17%
Cutoff 4	0.0385	0.00660	0.0128	0.0385	0.00660	0.0128	0.0385	0.00660	0.0128
Sens 4	29%	35%	27%	30%	18%	43%	12%	31%	22%
Spec 4	71%	71%	70%	71%	71%	70%	71%	71%	70%
Cutoff 5	0.0728	0.0499	0.0641	0.0728	0.0499	0.0641	0.0728	0.0499	0.0641
Sens 5	20%	31%	18%	20%	18%	28%	12%	25%	22%
Spec 5	81%	80%	80%	81%	80%	80%	81%	80%	80%
Cutoff 6	0.176	0.162	0.176	0.176	0.162	0.176	0.176	0.162	0.176
Sens 6	14%	31%	10%	8%	14%	8%	0%	0%	7%
Spec 6	90%	91%	90%	90%	91%	90%	90%	91%	90%
OR Quart 2	0.56	0.84	0.57	1.1	1.0	0.98	4.8	1.0	0.22
p Value	0.13	0.76	0.17	0.88	1.0	0.97	0.020	1.0	0.066

	0hr prior to AKI stage			24hr prior to AKI stage			48hr prior to AKI stage		
	sCr or UO	sCr only	UO only	sCr or UO	sCr only	UO only	sCr or UO	sCr only	UO only
95% CI of	0.26	0.27	0.26	0.49	0.28	0.43	1.3	0.24	0.045
OR Quart2	1.2	2.6	1.3	2.3	3.6	2.2	18	4.1	1.1
OR Quart 3	1.0	0.70	1.2	1.3	1.6	1.8	1.4	1.0	1.5
p Value	1.0	0.55	0.59	0.44	0.40	0.12	0.70	1.0	0.45
95% CI of	0.49	0.22	0.60	0.63	0.52	0.85	0.29	0.24	0.54
OR Quart3	2.0	2.3	2.5	2.9	5.2	4.0	6.4	4.1	3.9
OR Quart 4	1.1	1.1	1.1	1.2	2.1	1.8	2.5	1.0	0.71
p Value	0.72	0.80	0.71	0.60	0.19	0.14	0.20	1.0	0.55
95% CI of	0.56	0.40	0.56	0.57	0.69	0.83	0.62	0.24	0.23
OR Quart4	2.3	3.3	2.3	2.6	6.3	3.9	10	4.1	2.2

Apolipoprotein E

sCr or UO	0hr prior to AKI stage		24hr prior to AKI stage		48hr prior to AKI stage	
	Cohort 1	Cohort 2	Cohort 1	Cohort 2	Cohort 1	Cohort 2
Median	3.26	2.40	3.26	2.03	3.26	2.72
Average	27.3	21.6	27.3	25.4	27.3	7.72
Stdev	162	164	162	183	162	12.5
p(t-test)		0.71		0.90		0.40
Min	0.000147	0.00122	0.000147	0.000147	0.000147	0.000147
Max	2160	1960	2160	2140	2160	63.1
n (Samp)	499	143	499	143	499	48
n (Patient)	235	143	235	143	235	48

sCr only	0hr prior to AKI stage		24hr prior to AKI stage		48hr prior to AKI stage	
	Cohort 1	Cohort 2	Cohort 1	Cohort 2	Cohort 1	Cohort 2
Median	2.68	1.25	2.68	1.18	2.68	2.72
Average	22.5	3.42	22.5	5.41	22.5	8.50
Stdev	142	6.10	142	9.08	142	16.4
p(t-test)		0.36		0.39		0.60
Min	0.000147	0.000147	0.000147	0.000147	0.000147	0.000147
Max	2160	33.8	2160	37.9	2160	82.5
n (Samp)	1100	46	1100	51	1100	28
n (Patient)	397	46	397	51	397	28

UO only	0hr prior to AKI stage		24hr prior to AKI stage		48hr prior to AKI stage	
	Cohort 1	Cohort 2	Cohort 1	Cohort 2	Cohort 1	Cohort 2
Median	2.97	3.06	2.97	2.03	2.97	2.24
Average	22.4	25.0	22.4	26.8	22.4	7.59
Stdev	131	173	131	190	131	13.1
p(t-test)		0.85		0.75		0.44
Min	0.000147	0.00122	0.000147	0.000147	0.000147	0.00122
Max	2140	1960	2140	2140	2140	63.1
n (Samp)	487	130	487	133	487	47
n (Patient)	190	130	190	133	190	47

	0hr prior to AKI stage		24hr prior to AKI stage		48hr prior to AKI stage	

	sCr or UO	sCr only	UO only	sCr or UO	sCr only	UO only	sCr or UO	sCr only	UO only
AUC	0.46	0.37	0.49	0.45	0.41	0.45	0.48	0.48	0.46
SE	0.028	0.045	0.029	0.028	0.043	0.029	0.044	0.056	0.045
p	0.20	0.0027	0.80	0.073	0.042	0.082	0.62	0.75	0.34
nCohort 1	499	1100	487	499	1100	487	499	1100	487
nCohort 2	143	46	130	143	51	133	48	28	47
Cutoff 1	0.858	0.393	0.882	0.737	0.628	0.737	0.942	1.06	0.711
Sens 1	71%	72%	70%	71%	71%	71%	71%	71%	70%
Spec 1	26%	17%	27%	24%	23%	23%	30%	32%	22%
Cutoff 2	0.467	0.103	0.554	0.411	0.404	0.393	0.211	0.103	0.211
Sens 2	80%	80%	80%	80%	80%	80%	81%	82%	81%
Spec 2	19%	8%	19%	18%	17%	15%	12%	8%	11%
Cutoff 3	0.0862	0.0258	0.130	0.0999	0.0258	0.103	0.0520	0.00238	0.0263
Sens 3	91%	91%	90%	90%	90%	90%	92%	93%	91%
Spec 3	8%	6%	10%	9%	6%	10%	8%	4%	8%
Cutoff 4	7.57	7.31	6.96	7.57	7.31	6.96	7.57	7.31	6.96
Sens 4	27%	13%	33%	22%	20%	23%	31%	29%	30%
Spec 4	70%	70%	70%	70%	70%	70%	70%	70%	70%
Cutoff 5	13.3	12.7	11.4	13.3	12.7	11.4	13.3	12.7	11.4
Sens 5	17%	4%	22%	17%	16%	18%	17%	14%	19%
Spec 5	81%	80%	80%	81%	80%	80%	81%	80%	80%
Cutoff 6	30.2	27.2	28.8	30.2	27.2	28.8	30.2	27.2	28.8
Sens 6	8%	2%	10%	6%	6%	6%	6%	7%	9%
Spec 6	90%	90%	90%	90%	90%	90%	90%	90%	90%
OR Quart 2	1.2	2.6	0.74	1.2	1.4	1.1	0.59	1.3	0.83
p Value	0.56	0.12	0.28	0.55	0.49	0.66	0.26	0.59	0.67
95% CI of	0.68	0.79	0.43	0.68	0.55	0.64	0.24	0.46	0.34
OR Quart2	2.0	8.3	1.3	2.1	3.5	2.0	1.5	3.9	2.0
OR Quart 3	1.3	3.6	0.68	1.6	1.8	1.4	1.1	1.2	0.73
p Value	0.34	0.025	0.17	0.079	0.20	0.26	0.84	0.78	0.50
95% CI of	0.76	1.2	0.39	0.95	0.74	0.79	0.49	0.39	0.30
OR Quart3	2.2	11	1.2	2.8	4.3	2.4	2.4	3.5	1.8
OR Quart 4	1.4	4.8	1.0	1.7	2.3	1.7	1.0	1.2	1.4
p Value	0.27	0.0053	0.97	0.056	0.050	0.056	0.98	0.78	0.41
95% CI of	0.79	1.6	0.60	0.99	1.0	0.99	0.45	0.39	0.63
OR Quart4	2.3	14	1.7	2.9	5.5	2.9	2.3	3.5	3.1

Apolipoprotein(a)

sCr or UO	0hr prior to AKI stage		24hr prior to AKI stage		48hr prior to AKI stage	
	Cohort 1	Cohort 2	Cohort 1	Cohort 2	Cohort 1	Cohort 2
Median	1.92	2.90	1.92	2.91	1.92	2.09
Average	26.2	147	26.2	48.0	26.2	32.2
Stdev	128	1540	128	402	128	151
p(t-test)		0.092		0.31		0.77
Min	0.00770	0.00479	0.00770	0.00241	0.00770	0.00838
Max	1510	17500	1510	4580	1510	1000
n (Samp)	471	129	471	133	471	45
n (Patient)	230	129	230	133	230	45

sCr only	0hr prior to AKI stage		24hr prior to AKI stage		48hr prior to AKI stage	
	Cohort 1	Cohort 2	Cohort 1	Cohort 2	Cohort 1	Cohort 2
Median	2.04	1.80	2.04	2.90	2.04	3.02
Average	45.0	4.31	45.0	9.65	45.0	11.7
Stdev	578	9.90	578	30.9	578	31.2
p(t-test)		0.64		0.67		0.77
Min	0.00241	0.00770	0.00241	0.00241	0.00241	0.00838
Max	17500	60.7	17500	215	17500	161
n (Samp)	1040	43	1040	49	1040	26
n (Patient)	391	43	391	49	391	26

UO only	0hr prior to AKI stage		24hr prior to AKI stage		48hr prior to AKI stage	
	Cohort 1	Cohort 2	Cohort 1	Cohort 2	Cohort 1	Cohort 2
Median	2.11	3.31	2.11	2.86	2.11	2.04
Average	20.0	172	20.0	50.6	20.0	30.5
Stdev	111	1630	111	420	111	153
p(t-test)		0.049		0.16		0.57
Min	0.00770	0.00479	0.00770	0.00241	0.00770	0.00790
Max	1510	17500	1510	4580	1510	1000
n (Samp)	457	115	457	122	457	43
n (Patient)	185	115	185	122	185	43

	0hr prior to AKI stage			24hr prior to AKI stage			48hr prior to AKI stage		
	sCr or UO	sCr only	UO only	sCr or UO	sCr only	UO only	sCr or UO	sCr only	UO only
AUC	0.58	0.46	0.61	0.58	0.53	0.58	0.53	0.59	0.51
SE	0.029	0.046	0.031	0.029	0.043	0.030	0.046	0.059	0.046
p	0.0097	0.40	4.2E-4	0.0068	0.48	0.0099	0.50	0.13	0.84
nCohort 1	471	1040	457	471	1040	457	471	1040	457
nCohort 2	129	43	115	133	49	122	45	26	43
Cutoff 1	1.51	0.917	1.95	1.67	0.863	1.65	1.16	1.67	1.19
Sens 1	71%	72%	70%	71%	71%	72%	71%	73%	72%
Spec 1	42%	29%	49%	46%	27%	44%	34%	45%	33%
Cutoff 2	0.977	0.556	1.23	1.16	0.108	1.24	0.766	1.65	0.766
Sens 2	81%	81%	80%	80%	82%	80%	80%	81%	81%
Spec 2	31%	22%	33%	34%	12%	33%	27%	45%	26%
Cutoff 3	0.108	0.108	0.496	0.108	0.0112	0.430	0.479	0.369	0.479
Sens 3	92%	91%	90%	90%	92%	90%	93%	92%	93%
Spec 3	14%	12%	22%	14%	4%	17%	19%	15%	18%
Cutoff 4	3.77	3.78	3.85	3.77	3.78	3.85	3.77	3.78	3.85
Sens 4	39%	23%	43%	37%	37%	36%	31%	42%	23%
Spec 4	70%	70%	70%	70%	70%	70%	70%	70%	70%
Cutoff 5	5.63	5.65	5.30	5.63	5.65	5.30	5.63	5.65	5.30
Sens 5	22%	12%	30%	28%	33%	26%	20%	23%	19%
Spec 5	80%	80%	80%	80%	80%	80%	80%	80%	80%
Cutoff 6	16.0	18.3	12.9	16.0	18.3	12.9	16.0	18.3	12.9
Sens 6	12%	7%	17%	11%	8%	11%	13%	15%	14%
Spec 6	90%	90%	90%	90%	90%	90%	90%	90%	90%
OR Quart 2	1.4	1.9	1.8	1.1	0.28	1.6	1.2	1.2	2.0
p Value	0.28	0.18	0.098	0.76	0.024	0.17	0.64	0.74	0.13

	0hr prior to AKI stage			24hr prior to AKI stage			48hr prior to AKI stage		
	sCr or UO	sCr only	UO only	sCr or UO	sCr only	UO only	sCr or UO	sCr only	UO only
95% CI of	0.76	0.75	0.90	0.60	0.089	0.83	0.50	0.33	0.81
OR Quart2	2.6	4.8	3.5	2.0	0.85	2.9	3.1	4.7	4.9
OR Quart 3	2.2	1.9	2.4	2.1	1.0	2.0	1.5	1.8	1.4
p Value	0.0072	0.18	0.0088	0.0093	1.0	0.020	0.38	0.37	0.48
95% CI of	1.2	0.75	1.2	1.2	0.47	1.1	0.62	0.51	0.55
OR Quart3	4.0	4.8	4.6	3.7	2.1	3.7	3.6	6.1	3.6
OR Quart 4	2.2	1.5	3.1	1.9	1.2	2.1	1.4	2.5	1.1
p Value	0.0072	0.46	5.2E-4	0.026	0.59	0.014	0.50	0.12	0.80
95% CI of	1.2	0.54	1.6	1.1	0.59	1.2	0.56	0.79	0.42
OR Quart4	4.0	3.9	5.8	3.4	2.5	3.9	3.4	8.2	3.0

[0183] Fig. 2: Comparison of marker levels in urine samples collected from Cohort 1 (patients that did not progress beyond RIFLE stage 0 or R) and in urine samples collected from subjects at 0, 24 hours, and 48 hours prior to reaching stage I or F in Cohort 2.

Complement C4-B

sCr or UO	0hr prior to AKI stage		24hr prior to AKI stage		48hr prior to AKI stage	
	Cohort 1	Cohort 2	Cohort 1	Cohort 2	Cohort 1	Cohort 2
Median	16.8	30.7	16.8	30.3	16.8	11.2
Average	54.2	59.9	54.2	69.1	54.2	35.1
Stdev	132	84.9	132	155	132	61.6
p(t-test)		0.74		0.37		0.37
Min	0.00329	0.161	0.00329	0.211	0.00329	0.00263
Max	2000	417	2000	1150	2000	341
n (Samp)	927	62	927	70	927	39
n (Patient)	360	62	360	70	360	39

sCr only	0hr prior to AKI stage		24hr prior to AKI stage		48hr prior to AKI stage	
	Cohort 1	Cohort 2	Cohort 1	Cohort 2	Cohort 1	Cohort 2
Median	17.8	6.31	17.8	5.52	17.8	17.8
Average	59.9	13.8	59.9	29.0	59.9	40.1
Stdev	146	17.1	146	47.7	146	51.7
p(t-test)		0.22		0.37		0.58
Min	0.00329	0.161	0.00329	0.211	0.00329	0.448
Max	2000	47.7	2000	173	2000	146
n (Samp)	1230	15	1230	18	1230	17
n (Patient)	440	15	440	18	440	17

UO only	0hr prior to AKI stage		24hr prior to AKI stage		48hr prior to AKI stage	
	Cohort 1	Cohort 2	Cohort 1	Cohort 2	Cohort 1	Cohort 2
Median	17.8	30.6	17.8	33.3	17.8	15.3
Average	55.4	63.6	55.4	72.3	55.4	39.5
Stdev	134	87.3	134	162	134	63.7
p(t-test)		0.65		0.34		0.49
Min	0.00329	0.754	0.00329	0.383	0.00329	0.00263
Max	2000	417	2000	1150	2000	341

UO only	0hr prior to AKI stage		24hr prior to AKI stage		48hr prior to AKI stage	
	Cohort 1	Cohort 2	Cohort 1	Cohort 2	Cohort 1	Cohort 2
n (Samp)	815	57	815	63	815	34
n (Patient)	282	57	282	63	282	34

	0hr prior to AKI stage			24hr prior to AKI stage			48hr prior to AKI stage		
	sCr or UO	sCr only	UO only	sCr or UO	sCr only	UO only	sCr or UO	sCr only	UO only
AUC	0.57	0.33	0.59	0.55	0.41	0.56	0.45	0.47	0.48
SE	0.039	0.077	0.041	0.037	0.071	0.039	0.048	0.072	0.051
p	0.071	0.027	0.031	0.13	0.20	0.10	0.29	0.71	0.69
nCohort 1	927	1230	815	927	1230	815	927	1230	815
nCohort 2	62	15	57	70	18	63	39	17	34
Cutoff 1	10.5	2.00	13.2	6.41	4.28	7.34	3.33	6.89	4.30
Sens 1	71%	73%	70%	70%	72%	71%	72%	71%	71%
Spec 1	41%	15%	43%	32%	25%	33%	22%	31%	25%
Cutoff 2	4.21	0.968	8.26	4.21	3.21	3.60	1.74	1.49	2.00
Sens 2	81%	80%	81%	80%	83%	81%	82%	82%	82%
Spec 2	26%	8%	35%	26%	20%	21%	13%	11%	14%
Cutoff 3	0.990	0.587	2.46	1.70	1.66	1.74	0.752	0.544	1.66
Sens 3	90%	93%	91%	90%	94%	90%	92%	94%	91%
Spec 3	8%	4%	16%	13%	12%	13%	6%	4%	12%
Cutoff 4	38.7	42.6	41.5	38.7	42.6	41.5	38.7	42.6	41.5
Sens 4	44%	13%	40%	40%	22%	43%	26%	35%	32%
Spec 4	70%	70%	70%	70%	70%	70%	70%	70%	70%
Cutoff 5	61.6	68.8	65.8	61.6	68.8	65.8	61.6	68.8	65.8
Sens 5	29%	0%	30%	29%	17%	24%	21%	18%	21%
Spec 5	80%	80%	80%	80%	80%	80%	80%	80%	80%
Cutoff 6	130	141	130	130	141	130	130	141	130
Sens 6	11%	0%	12%	14%	6%	14%	8%	6%	6%
Spec 6	90%	90%	90%	90%	90%	90%	90%	90%	90%
OR Quart 2	1.1	>4.1	1.4	1.0	1.0	0.91	0.59	1.3	0.77
p Value	0.84	<0.21	0.50	1.0	1.0	0.83	0.32	0.74	0.62
95% CI of	0.49	>0.45	0.56	0.47	0.20	0.41	0.21	0.33	0.28
OR Quart2	2.4	na	3.3	2.1	5.0	2.1	1.7	4.7	2.1
OR Quart 3	1.4	>5.1	1.7	1.3	2.4	1.2	1.1	0.75	1.0
p Value	0.44	<0.14	0.21	0.47	0.22	0.70	0.82	0.70	0.99
95% CI of	0.63	>0.59	0.73	0.64	0.61	0.54	0.46	0.17	0.39
OR Quart3	2.9	na	4.0	2.7	9.2	2.5	2.7	3.4	2.6
OR Quart 4	1.8	>6.1	2.5	1.8	1.7	1.9	1.2	1.3	1.0
p Value	0.11	<0.094	0.027	0.098	0.48	0.088	0.66	0.73	0.99
95% CI of	0.87	>0.73	1.1	0.90	0.40	0.91	0.52	0.33	0.39
OR Quart4	3.8	na	5.5	3.5	7.1	3.8	2.9	4.7	2.6

C-C motif chemokine 7

sCr or UO	0hr prior to AKI stage		24hr prior to AKI stage		48hr prior to AKI stage	
	Cohort 1	Cohort 2	Cohort 1	Cohort 2	Cohort 1	Cohort 2
Median	0.584	0.662	0.584	0.643	0.584	0.584
Average	1.89	5.43	1.89	2.29	1.89	3.19
Stdev	9.38	13.3	9.38	6.39	9.38	7.98

sCr or UO	0hr prior to AKI stage		24hr prior to AKI stage		48hr prior to AKI stage	
	Cohort 1	Cohort 2	Cohort 1	Cohort 2	Cohort 1	Cohort 2
p(t-test)		0.0054		0.73		0.39
Min	0.146	0.146	0.146	0.146	0.146	0.264
Max	163	61.7	163	45.7	163	33.9
n (Samp)	930	62	930	70	930	39
n (Patient)	361	62	361	70	361	39

sCr only	0hr prior to AKI stage		24hr prior to AKI stage		48hr prior to AKI stage	
	Cohort 1	Cohort 2	Cohort 1	Cohort 2	Cohort 1	Cohort 2
Median	0.584	0.812	0.584	0.637	0.584	0.816
Average	2.24	8.59	2.24	5.64	2.24	3.49
Stdev	12.2	18.9	12.2	14.5	12.2	8.42
p(t-test)		0.046		0.24		0.67
Min	0.146	0.264	0.146	0.282	0.146	0.264
Max	291	69.7	291	61.7	291	33.9
n (Samp)	1234	15	1234	18	1234	17
n (Patient)	441	15	441	18	441	17

UO only	0hr prior to AKI stage		24hr prior to AKI stage		48hr prior to AKI stage	
	Cohort 1	Cohort 2	Cohort 1	Cohort 2	Cohort 1	Cohort 2
Median	0.625	0.662	0.625	0.662	0.625	0.584
Average	2.01	8.67	2.01	4.29	2.01	2.87
Stdev	9.92	25.3	9.92	15.7	9.92	7.34
p(t-test)		2.7E-5		0.095		0.62
Min	0.146	0.146	0.146	0.146	0.146	0.264
Max	163	166	163	114	163	33.0
n (Samp)	819	57	819	63	819	34
n (Patient)	283	57	283	63	283	34

	0hr prior to AKI stage			24hr prior to AKI stage			48hr prior to AKI stage		
	sCr or UO	sCr only	UO only	sCr or UO	sCr only	UO only	sCr or UO	sCr only	UO only
AUC	0.63	0.65	0.61	0.56	0.59	0.54	0.56	0.64	0.52
SE	0.039	0.078	0.041	0.037	0.071	0.038	0.048	0.073	0.051
p	0.0012	0.059	0.0085	0.12	0.18	0.31	0.22	0.063	0.74
nCohort 1	930	1234	819	930	1234	819	930	1234	819
nCohort 2	62	15	57	70	18	63	39	17	34
Cutoff 1	0.551	0.512	0.515	0.320	0.336	0.320	0.385	0.584	0.385
Sens 1	77%	73%	77%	73%	78%	73%	72%	82%	71%
Spec 1	50%	44%	46%	32%	34%	29%	41%	52%	37%
Cutoff 2	0.336	0.424	0.336	0.319	0.320	0.319	0.336	0.584	0.336
Sens 2	81%	80%	81%	86%	83%	87%	85%	82%	85%
Spec 2	36%	39%	34%	28%	30%	26%	36%	52%	34%
Cutoff 3	0.319	0.320	0.319	0.301	0.301	0.301	0.319	0.301	0.320
Sens 3	92%	93%	93%	96%	94%	95%	92%	94%	91%
Spec 3	23%	30%	21%	17%	17%	17%	23%	17%	29%
Cutoff 4	1.04	1.04	1.04	1.04	1.04	1.04	1.04	1.04	1.04
Sens 4	37%	47%	35%	27%	39%	25%	21%	29%	18%
Spec 4	74%	72%	72%	74%	72%	72%	74%	72%	72%

	0hr prior to AKI stage			24hr prior to AKI stage			48hr prior to AKI stage		
	sCr or UO	sCr only	UO only	sCr or UO	sCr only	UO only	sCr or UO	sCr only	UO only
Cutoff 5	1.12	1.12	1.15	1.12	1.12	1.15	1.12	1.12	1.15
Sens 5	37%	47%	32%	26%	39%	22%	21%	24%	18%
Spec 5	82%	81%	84%	82%	81%	84%	82%	81%	84%
Cutoff 6	1.59	1.59	1.59	1.59	1.59	1.59	1.59	1.59	1.59
Sens 6	16%	20%	19%	10%	22%	11%	13%	12%	12%
Spec 6	94%	94%	94%	94%	94%	94%	94%	94%	94%
OR Quart 2	2.6	4.0	3.0	2.2	1.7	2.8	5.6	0	6.1
p Value	0.052	0.21	0.024	0.046	0.48	0.017	0.0065	na	0.0044
95% CI of	0.99	0.45	1.2	1.0	0.40	1.2	1.6	na	1.8
OR Quart2	6.8	36	7.7	4.8	7.1	6.4	20	na	21
OR Quart 3	3.2	3.0	2.4	2.2	1.0	2.5	4.2	5.1	2.7
p Value	0.017	0.34	0.075	0.046	1.0	0.034	0.029	0.036	0.14
95% CI of	1.2	0.31	0.91	1.0	0.20	1.1	1.2	1.1	0.71
OR Quart3	8.1	29	6.4	4.8	5.0	5.9	15	24	10
OR Quart 4	4.1	7.1	3.6	1.9	2.4	1.9	2.7	2.5	2.0
p Value	0.0025	0.067	0.0075	0.12	0.22	0.14	0.14	0.27	0.32
95% CI of	1.6	0.87	1.4	0.84	0.61	0.80	0.71	0.48	0.50
OR Quart4	10	58	9.1	4.1	9.2	4.6	10	13	8.2

Vascular endothelial growth factor receptor 3

sCr or UO	0hr prior to AKI stage		24hr prior to AKI stage		48hr prior to AKI stage	
	Cohort 1	Cohort 2	Cohort 1	Cohort 2	Cohort 1	Cohort 2
Median	304	364	304	318	304	316
Average	314	398	314	379	314	354
Stdev	214	273	214	378	214	221
p(t-test)		0.013		0.056		0.34
Min	1.37	81.1	1.37	1.37	1.37	3.04
Max	2070	1700	2070	2750	2070	913
n (Samp)	470	47	470	53	470	28
n (Patient)	239	47	239	53	239	28

sCr only	0hr prior to AKI stage		24hr prior to AKI stage		48hr prior to AKI stage	
	Cohort 1	Cohort 2	Cohort 1	Cohort 2	Cohort 1	Cohort 2
Median	318	354	318	351	318	512
Average	340	395	340	335	340	495
Stdev	248	284	248	113	248	264
p(t-test)		0.51		0.95		0.040
Min	1.37	76.2	1.37	145	1.37	161
Max	2750	901	2750	512	2750	913
n (Samp)	630	9	630	10	630	11
n (Patient)	293	9	293	10	293	11

UO only	0hr prior to AKI stage		24hr prior to AKI stage		48hr prior to AKI stage	
	Cohort 1	Cohort 2	Cohort 1	Cohort 2	Cohort 1	Cohort 2
Median	308	364	308	315	308	318
Average	322	394	322	384	322	367
Stdev	217	274	217	402	217	225

UO only	0hr prior to AKI stage		24hr prior to AKI stage		48hr prior to AKI stage	
	Cohort 1	Cohort 2	Cohort 1	Cohort 2	Cohort 1	Cohort 2
p(t-test)		0.042		0.091		0.31
Min	1.37	81.1	1.37	1.37	1.37	3.04
Max	2070	1700	2070	2750	2070	901
n (Samp)	438	43	438	47	438	25
n (Patient)	209	43	209	47	209	25

	0hr prior to AKI stage			24hr prior to AKI stage			48hr prior to AKI stage		
	sCr or UO	sCr only	UO only	sCr or UO	sCr only	UO only	sCr or UO	sCr only	UO only
AUC	0.59	0.54	0.58	0.55	0.54	0.54	0.54	0.68	0.55
SE	0.045	0.099	0.047	0.043	0.094	0.045	0.057	0.090	0.061
p	0.039	0.66	0.083	0.22	0.69	0.38	0.45	0.043	0.41
nCohort 1	470	630	438	470	630	438	470	630	438
nCohort 2	47	9	43	53	10	47	28	11	25
Cutoff 1	249	247	242	249	305	249	249	264	277
Sens 1	70%	78%	72%	72%	70%	70%	71%	73%	72%
Spec 1	39%	35%	36%	39%	47%	37%	39%	40%	44%
Cutoff 2	178	76.8	178	174	230	171	166	249	242
Sens 2	83%	89%	81%	81%	80%	81%	82%	82%	80%
Spec 2	25%	11%	23%	24%	33%	22%	24%	37%	36%
Cutoff 3	163	74.3	163	74.3	208	61.2	120	166	120
Sens 3	91%	100%	91%	91%	90%	94%	93%	91%	92%
Spec 3	22%	9%	20%	11%	29%	9%	15%	20%	13%
Cutoff 4	397	414	397	397	414	397	397	414	397
Sens 4	38%	22%	42%	38%	30%	38%	29%	64%	28%
Spec 4	71%	71%	70%	71%	71%	70%	71%	71%	70%
Cutoff 5	445	469	445	445	469	445	445	469	445
Sens 5	28%	22%	30%	26%	10%	32%	25%	55%	24%
Spec 5	81%	80%	81%	81%	80%	81%	81%	80%	81%
Cutoff 6	534	574	537	534	574	537	534	574	537
Sens 6	19%	22%	19%	11%	0%	13%	14%	36%	16%
Spec 6	90%	90%	91%	90%	90%	91%	90%	90%	91%
OR Quart 2	1.3	0.49	0.68	1.1	3.0	0.91	1.2	1.0	1.2
p Value	0.63	0.57	0.45	0.84	0.34	0.83	0.79	1.0	0.77
95% CI of	0.48	0.044	0.25	0.46	0.31	0.38	0.38	0.14	0.36
OR Quart2	3.3	5.5	1.9	2.6	30	2.1	3.6	7.2	4.0
OR Quart 3	2.0	2.0	1.2	1.3	5.1	0.64	1.4	0	1.6
p Value	0.13	0.42	0.65	0.54	0.14	0.35	0.58	na	0.40
95% CI of	0.81	0.36	0.51	0.56	0.59	0.25	0.46	na	0.52
OR Quart3	4.9	11	2.9	3.0	44	1.6	4.0	na	5.1
OR Quart 4	1.8	0.99	1.4	1.5	1.0	1.4	1.2	3.6	1.2
p Value	0.19	0.99	0.40	0.32	1.0	0.44	0.79	0.11	0.77
95% CI of	0.74	0.14	0.61	0.67	0.062	0.62	0.38	0.73	0.36
OR Quart4	4.5	7.1	3.4	3.4	16	3.0	3.6	18	4.0

Interferon alpha-2

sCr or UO	0hr prior to AKI stage		24hr prior to AKI stage		48hr prior to AKI stage	
	Cohort 1	Cohort 2	Cohort 1	Cohort 2	Cohort 1	Cohort 2

sCr or UO	0hr prior to AKI stage		24hr prior to AKI stage		48hr prior to AKI stage	
	Cohort 1	Cohort 2	Cohort 1	Cohort 2	Cohort 1	Cohort 2
Median	0.0967	0.104	0.0967	0.0974	0.0967	0.122
Average	7.76	13.4	7.76	8.07	7.76	11.1
Stdev	17.7	23.4	17.7	17.5	17.7	16.9
p(t-test)		0.018		0.89		0.24
Min	0.0238	0.0348	0.0238	0.0348	0.0238	0.0348
Max	126	99.7	126	77.3	126	74.5
n (Samp)	930	62	930	70	930	39
n (Patient)	361	62	361	70	361	39

sCr only	0hr prior to AKI stage		24hr prior to AKI stage		48hr prior to AKI stage	
	Cohort 1	Cohort 2	Cohort 1	Cohort 2	Cohort 1	Cohort 2
Median	0.0967	0.0724	0.0967	0.0864	0.0967	0.0967
Average	7.73	4.18	7.73	9.65	7.73	7.16
Stdev	18.1	13.1	18.1	22.9	18.1	12.2
p(t-test)		0.45		0.66		0.90
Min	0.0238	0.0238	0.0238	0.0348	0.0238	0.0369
Max	126	50.5	126	77.3	126	39.0
n (Samp)	1234	15	1234	18	1234	17
n (Patient)	441	15	441	18	441	17

UO only	0hr prior to AKI stage		24hr prior to AKI stage		48hr prior to AKI stage	
	Cohort 1	Cohort 2	Cohort 1	Cohort 2	Cohort 1	Cohort 2
Median	0.0967	0.104	0.0967	0.0974	0.0967	1.02
Average	7.47	15.1	7.47	6.62	7.47	12.4
Stdev	17.2	24.8	17.2	14.3	17.2	18.2
p(t-test)		0.0019		0.70		0.10
Min	0.0238	0.0348	0.0238	0.0348	0.0238	0.0348
Max	126	99.7	126	66.2	126	74.5
n (Samp)	819	57	819	63	819	34
n (Patient)	283	57	283	63	283	34

	0hr prior to AKI stage			24hr prior to AKI stage			48hr prior to AKI stage		
	sCr or UO	sCr only	UO only	sCr or UO	sCr only	UO only	sCr or UO	sCr only	UO only
AUC	0.57	0.40	0.59	0.55	0.48	0.55	0.60	0.57	0.61
SE	0.039	0.078	0.041	0.037	0.069	0.039	0.049	0.073	0.052
p	0.062	0.19	0.036	0.19	0.83	0.16	0.041	0.31	0.039
nCohort 1	930	1234	819	930	1234	819	930	1234	819
nCohort 2	62	15	57	70	18	63	39	17	34
Cutoff 1	0.0724	0.0606	0.0724	0.0754	0.0435	0.0754	0.0754	0.0754	0.0815
Sens 1	71%	73%	72%	70%	78%	75%	72%	76%	71%
Spec 1	40%	26%	38%	44%	19%	42%	44%	45%	47%
Cutoff 2	0.0656	0.0369	0.0656	0.0709	0.0398	0.0709	0.0435	0.0724	0.0435
Sens 2	84%	80%	82%	81%	83%	83%	82%	82%	82%
Spec 2	29%	11%	27%	36%	15%	34%	19%	41%	17%
Cutoff 3	0.0398	0.0238	0.0398	0.0398	0.0369	0.0398	0.0369	0.0398	0.0369
Sens 3	92%	93%	91%	93%	94%	94%	92%	94%	91%
Spec 3	14%	3%	12%	14%	11%	12%	10%	15%	10%

	0hr prior to AKI stage			24hr prior to AKI stage			48hr prior to AKI stage		
	sCr or UO	sCr only	UO only	sCr or UO	sCr only	UO only	sCr or UO	sCr only	UO only
Cutoff 4	0.311	0.311	0.311	0.311	0.311	0.311	0.311	0.311	0.311
Sens 4	34%	13%	39%	24%	17%	25%	49%	35%	50%
Spec 4	73%	74%	73%	73%	74%	73%	73%	74%	73%
Cutoff 5	10.9	10.8	9.93	10.9	10.8	9.93	10.9	10.8	9.93
Sens 5	32%	13%	37%	20%	17%	21%	38%	29%	44%
Spec 5	80%	80%	80%	80%	80%	80%	80%	80%	80%
Cutoff 6	30.2	29.7	30.0	30.2	29.7	30.0	30.2	29.7	30.0
Sens 6	19%	7%	21%	11%	17%	8%	13%	6%	15%
Spec 6	90%	90%	90%	90%	90%	90%	90%	90%	90%
OR Quart 2	2.0	1.0	1.5	1.4	2.0	1.6	0.62	3.0	0.56
p Value	0.090	1.00	0.31	0.44	0.32	0.29	0.40	0.18	0.37
95% CI of	0.90	0.14	0.67	0.63	0.50	0.67	0.20	0.61	0.16
OR Quart2	4.3	7.2	3.5	2.9	8.1	3.7	1.9	15	2.0
OR Quart 3	1.2	3.6	1.1	2.2	1.0	2.9	1.3	2.0	1.1
p Value	0.66	0.11	0.82	0.030	1.0	0.0089	0.63	0.42	0.79
95% CI of	0.51	0.74	0.46	1.1	0.20	1.3	0.49	0.36	0.41
OR Quart3	2.9	17	2.7	4.5	5.0	6.3	3.3	11	3.2
OR Quart 4	2.2	2.0	2.2	1.4	2.0	1.8	2.1	2.5	2.2
p Value	0.046	0.42	0.045	0.34	0.32	0.16	0.10	0.27	0.089
95% CI of	1.0	0.37	1.0	0.68	0.50	0.79	0.87	0.48	0.89
OR Quart4	4.8	11	4.8	3.1	8.1	4.2	4.9	13	5.6

Insulin-like growth factor-binding protein 4

sCr or UO	0hr prior to AKI stage		24hr prior to AKI stage		48hr prior to AKI stage	
	Cohort 1	Cohort 2	Cohort 1	Cohort 2	Cohort 1	Cohort 2
Median	0.733	0.441	0.733	0.923	0.733	0.660
Average	1.83	1.47	1.83	2.61	1.83	0.852
Stdev	6.92	2.61	6.92	4.90	6.92	0.999
p(t-test)		0.77		0.49		0.53
Min	0.0319	0.0319	0.0319	0.0319	0.0319	0.0319
Max	85.6	13.8	85.6	28.0	85.6	3.77
n (Samp)	322	31	322	40	322	20
n (Patient)	185	31	185	40	185	20

sCr only	0hr prior to AKI stage		24hr prior to AKI stage		48hr prior to AKI stage	
	Cohort 1	Cohort 2	Cohort 1	Cohort 2	Cohort 1	Cohort 2
Median	nd	nd	0.733	0.733	0.733	1.80
Average	nd	nd	1.77	2.04	1.77	2.08
Stdev	nd	nd	6.31	3.45	6.31	2.18
p(t-test)	nd	nd		0.91		0.89
Min	nd	nd	0.0319	0.0319	0.0319	0.0612
Max	nd	nd	85.6	9.68	85.6	6.53
n (Samp)	nd	nd	416	7	416	8
n (Patient)	nd	nd	221	7	221	8

UO only	0hr prior to AKI stage		24hr prior to AKI stage		48hr prior to AKI stage	
	Cohort 1	Cohort 2	Cohort 1	Cohort 2	Cohort 1	Cohort 2

UO only	0hr prior to AKI stage		24hr prior to AKI stage		48hr prior to AKI stage	
	Cohort 1	Cohort 2	Cohort 1	Cohort 2	Cohort 1	Cohort 2
Median	0.733	0.419	0.733	0.923	0.733	0.733
Average	1.91	1.67	1.91	2.55	1.91	0.946
Stdev	7.28	3.20	7.28	4.93	7.28	1.21
p(t-test)		0.86		0.60		0.57
Min	0.0319	0.0319	0.0319	0.0319	0.0319	0.0319
Max	85.6	13.8	85.6	28.0	85.6	4.20
n (Samp)	290	30	290	37	290	19
n (Patient)	158	30	158	37	158	19

	0hr prior to AKI stage			24hr prior to AKI stage			48hr prior to AKI stage		
	sCr or UO	sCr only	UO only	sCr or UO	sCr only	UO only	sCr or UO	sCr only	UO only
AUC	0.52	nd	0.52	0.58	0.54	0.59	0.48	0.66	0.48
SE	0.055	nd	0.056	0.050	0.11	0.052	0.067	0.11	0.069
p	0.69	nd	0.78	0.10	0.75	0.081	0.72	0.13	0.74
nCohort 1	322	nd	290	322	416	290	322	416	290
nCohort 2	31	nd	30	40	7	37	20	8	19
Cutoff 1	0.184	nd	0.141	0.390	0.390	0.390	0.0439	0.390	0.0439
Sens 1	71%	nd	70%	72%	71%	73%	85%	75%	84%
Spec 1	29%	nd	30%	37%	38%	38%	11%	38%	12%
Cutoff 2	0.0585	nd	0.0585	0.184	0.184	0.0585	0.0439	0.141	0.0439
Sens 2	81%	nd	80%	80%	86%	86%	85%	88%	84%
Spec 2	15%	nd	15%	29%	30%	15%	11%	30%	12%
Cutoff 3	0	nd	0	0.0439	0	0.0439	0	0.0585	0
Sens 3	100%	nd	100%	92%	100%	92%	100%	100%	100%
Spec 3	0%	nd	0%	11%	0%	12%	0%	18%	0%
Cutoff 4	0.957	nd	0.957	0.957	0.957	0.957	0.957	0.957	0.957
Sens 4	32%	nd	30%	35%	29%	35%	25%	50%	26%
Spec 4	76%	nd	76%	76%	75%	76%	76%	75%	76%
Cutoff 5	1.37	nd	1.27	1.37	1.46	1.27	1.37	1.46	1.27
Sens 5	26%	nd	23%	35%	29%	35%	20%	50%	21%
Spec 5	80%	nd	80%	80%	80%	80%	80%	80%	80%
Cutoff 6	3.09	nd	3.12	3.09	3.30	3.12	3.09	3.30	3.12
Sens 6	10%	nd	10%	22%	14%	22%	5%	12%	11%
Spec 6	90%	nd	90%	90%	90%	90%	90%	90%	90%
OR Quart 2	1.0	nd	1.8	1.6	3.0	0.85	1.0	2.0	0.80
p Value	1.0	nd	0.30	0.34	0.34	0.77	0.98	0.57	0.75
95% CI of	0.36	nd	0.61	0.60	0.31	0.29	0.28	0.18	0.21
OR Quart2	2.8	nd	5.1	4.4	30	2.5	3.6	23	3.1
OR Quart 3	0.60	nd	0.82	1.2	0.99	1.1	0.59	1.0	0.59
p Value	0.39	nd	0.76	0.79	0.99	0.82	0.47	1.0	0.48
95% CI of	0.19	nd	0.24	0.40	0.061	0.41	0.14	0.062	0.14
OR Quart3	1.9	nd	2.8	3.3	16	3.1	2.5	16	2.6
OR Quart 4	1.3	nd	1.6	2.2	2.0	1.7	1.5	4.1	1.5
p Value	0.64	nd	0.42	0.12	0.57	0.26	0.54	0.21	0.53
95% CI of	0.47	nd	0.53	0.83	0.18	0.67	0.44	0.45	0.44
OR Quart4	3.4	nd	4.6	5.6	22	4.4	4.8	37	4.8

Insulin-like growth factor-binding protein 5

sCr or UO	0hr prior to AKI stage		24hr prior to AKI stage		48hr prior to AKI stage	
	Cohort 1	Cohort 2	Cohort 1	Cohort 2	Cohort 1	Cohort 2
Median	0.0682	0.397	0.0682	0.0682	0.0682	0.248
Average	0.587	1.22	0.587	0.858	0.587	0.859
Stdev	1.27	2.20	1.27	1.63	1.27	1.19
p(t-test)		0.014		0.22		0.35
Min	0.0116	0.0116	0.0116	0.0116	0.0116	0.0116
Max	9.43	10.0	9.43	8.53	9.43	3.48
n (Samp)	323	31	323	40	323	20
n (Patient)	186	31	186	40	186	20

sCr only	0hr prior to AKI stage		24hr prior to AKI stage		48hr prior to AKI stage	
	Cohort 1	Cohort 2	Cohort 1	Cohort 2	Cohort 1	Cohort 2
Median	nd	nd	0.0682	0.0407	0.0682	0.811
Average	nd	nd	0.624	0.664	0.624	1.23
Stdev	nd	nd	1.30	1.15	1.30	1.34
p(t-test)	nd	nd		0.94		0.19
Min	nd	nd	0.0116	0.0116	0.0116	0.0393
Max	nd	nd	9.43	2.99	9.43	3.48
n (Samp)	nd	nd	417	7	417	8
n (Patient)	nd	nd	222	7	222	8

UO only	0hr prior to AKI stage		24hr prior to AKI stage		48hr prior to AKI stage	
	Cohort 1	Cohort 2	Cohort 1	Cohort 2	Cohort 1	Cohort 2
Median	0.0682	0.397	0.0682	0.0682	0.0682	0.0938
Average	0.598	0.937	0.598	0.815	0.598	1.22
Stdev	1.39	1.50	1.39	1.64	1.39	2.37
p(t-test)		0.21		0.38		0.073
Min	0.0116	0.0116	0.0116	0.0116	0.0116	0.0116
Max	10.3	5.59	10.3	8.53	10.3	10.0
n (Samp)	291	30	291	37	291	19
n (Patient)	159	30	159	37	159	19

	0hr prior to AKI stage			24hr prior to AKI stage			48hr prior to AKI stage		
	sCr or UO	sCr only	UO only	sCr or UO	sCr only	UO only	sCr or UO	sCr only	UO only
AUC	0.64	nd	0.64	0.52	0.48	0.51	0.61	0.73	0.59
SE	0.056	nd	0.057	0.049	0.11	0.051	0.069	0.10	0.071
p	0.0099	nd	0.012	0.66	0.84	0.83	0.12	0.026	0.22
nCohort 1	323	nd	291	323	417	291	323	417	291
nCohort 2	31	nd	30	40	7	37	20	8	19
Cutoff 1	0.0544	nd	0.0544	0.0262	0.0262	0.0262	0.0400	0.0838	0.0358
Sens 1	81%	nd	80%	75%	71%	73%	75%	75%	79%
Spec 1	48%	nd	48%	23%	23%	22%	38%	59%	35%
Cutoff 2	0.0544	nd	0.0544	0.0116	0.0116	0.0116	0.0358	0.0544	0.0262
Sens 2	81%	nd	80%	90%	86%	89%	85%	88%	84%
Spec 2	48%	nd	48%	11%	12%	12%	36%	46%	22%
Cutoff 3	0	nd	0	0.0116	0	0	0.0116	0.0358	0
Sens 3	100%	nd	100%	90%	100%	100%	90%	100%	100%
Spec 3	0%	nd	0%	11%	0%	0%	11%	34%	0%

	0hr prior to AKI stage			24hr prior to AKI stage			48hr prior to AKI stage		
	sCr or UO	sCr only	UO only	sCr or UO	sCr only	UO only	sCr or UO	sCr only	UO only
Cutoff 4	0.397	nd	0.232	0.397	0.397	0.232	0.397	0.397	0.232
Sens 4	39%	nd	57%	32%	29%	35%	30%	50%	47%
Spec 4	79%	nd	70%	79%	77%	70%	79%	77%	70%
Cutoff 5	0.518	nd	0.397	0.518	0.689	0.397	0.518	0.689	0.397
Sens 5	35%	nd	40%	32%	29%	30%	30%	50%	32%
Spec 5	80%	nd	81%	80%	80%	81%	80%	80%	81%
Cutoff 6	1.99	nd	1.99	1.99	2.04	1.99	1.99	2.04	1.99
Sens 6	16%	nd	13%	12%	14%	11%	25%	25%	26%
Spec 6	91%	nd	90%	91%	90%	90%	91%	90%	90%
OR Quart 2	0.78	nd	0.19	0.69	0.50	0.78	1.3	>1.0	1.7
p Value	0.72	nd	0.13	0.45	0.57	0.62	0.71	<0.99	0.48
95% CI of	0.20	nd	0.022	0.26	0.044	0.29	0.29	>0.062	0.39
OR Quart2	3.0	nd	1.7	1.8	5.5	2.1	6.1	na	7.3
OR Quart 3	2.1	nd	2.6	0.69	1.0	0.78	1.3	>3.1	1.0
p Value	0.19	nd	0.081	0.45	1.0	0.62	0.71	<0.33	1.0
95% CI of	0.70	nd	0.89	0.26	0.14	0.29	0.29	>0.32	0.20
OR Quart3	6.5	nd	7.9	1.8	7.2	2.1	6.1	na	5.1
OR Quart 4	2.6	nd	2.6	1.2	1.0	1.1	3.2	>4.1	2.8
p Value	0.087	nd	0.086	0.68	1.0	0.82	0.090	<0.21	0.14
95% CI of	0.87	nd	0.87	0.51	0.14	0.45	0.83	>0.45	0.72
OR Quart4	7.7	nd	7.8	2.8	7.2	2.8	12	na	11

Immunoglobulin G4

sCr or UO	0hr prior to AKI stage		24hr prior to AKI stage		48hr prior to AKI stage	
	Cohort 1	Cohort 2	Cohort 1	Cohort 2	Cohort 1	Cohort 2
Median	209	304	209	353	209	170
Average	471	576	471	661	471	294
Stdev	682	766	682	753	682	441
p(t-test)		0.24		0.025		0.11
Min	0.00862	5.90	0.00862	2.63	0.00862	0.203
Max	2400	2400	2400	2400	2400	2400
n (Samp)	922	62	922	70	922	39
n (Patient)	358	62	358	70	358	39

sCr only	0hr prior to AKI stage		24hr prior to AKI stage		48hr prior to AKI stage	
	Cohort 1	Cohort 2	Cohort 1	Cohort 2	Cohort 1	Cohort 2
Median	219	288	219	330	219	354
Average	499	473	499	635	499	492
Stdev	704	698	704	799	704	600
p(t-test)		0.89		0.42		0.97
Min	0.00642	27.3	0.00642	11.5	0.00642	8.44
Max	2400	2400	2400	2400	2400	2400
n (Samp)	1225	15	1225	18	1225	17
n (Patient)	438	15	438	18	438	17

UO only	0hr prior to AKI stage		24hr prior to AKI stage		48hr prior to AKI stage	
	Cohort 1	Cohort 2	Cohort 1	Cohort 2	Cohort 1	Cohort 2

UO only	0hr prior to AKI stage		24hr prior to AKI stage		48hr prior to AKI stage	
	Cohort 1	Cohort 2	Cohort 1	Cohort 2	Cohort 1	Cohort 2
Median	227	336	227	384	227	201
Average	487	639	487	743	487	364
Stdev	688	802	688	797	688	519
p(t-test)		0.11		0.0050		0.30
Min	0.00962	5.90	0.00962	2.63	0.00962	0.203
Max	2400	2400	2400	2400	2400	2400
n (Samp)	810	57	810	63	810	34
n (Patient)	280	57	280	63	280	34

	0hr prior to AKI stage			24hr prior to AKI stage			48hr prior to AKI stage		
	sCr or UO	sCr only	UO only	sCr or UO	sCr only	UO only	sCr or UO	sCr only	UO only
AUC	0.56	0.51	0.58	0.60	0.54	0.62	0.45	0.54	0.47
SE	0.039	0.076	0.041	0.037	0.070	0.039	0.048	0.072	0.051
p	0.11	0.88	0.055	0.0084	0.52	0.0019	0.28	0.55	0.60
nCohort 1	922	1225	810	922	1225	810	922	1225	810
nCohort 2	62	15	57	70	18	63	39	17	34
Cutoff 1	174	143	189	146	103	182	75.7	118	78.5
Sens 1	71%	73%	70%	70%	72%	71%	72%	71%	71%
Spec 1	46%	38%	46%	41%	31%	46%	28%	34%	27%
Cutoff 2	45.1	108	57.6	103	34.8	112	53.9	53.9	67.5
Sens 2	81%	80%	81%	80%	83%	81%	82%	82%	82%
Spec 2	20%	32%	23%	32%	15%	33%	22%	21%	25%
Cutoff 3	28.9	36.0	28.0	27.6	21.7	81.1	10.6	11.0	26.3
Sens 3	90%	93%	91%	90%	94%	90%	92%	94%	91%
Spec 3	13%	15%	12%	13%	10%	27%	6%	6%	11%
Cutoff 4	389	416	409	389	416	409	389	416	409
Sens 4	37%	20%	42%	46%	39%	48%	23%	41%	26%
Spec 4	70%	70%	70%	70%	70%	70%	70%	70%	70%
Cutoff 5	581	622	609	581	622	609	581	622	609
Sens 5	21%	13%	25%	33%	28%	38%	8%	29%	12%
Spec 5	80%	80%	80%	80%	80%	80%	80%	80%	80%
Cutoff 6	1540	2060	1570	1540	2060	1570	1540	2060	1570
Sens 6	15%	7%	16%	16%	11%	17%	3%	6%	6%
Spec 6	90%	90%	90%	90%	90%	90%	90%	90%	90%
OR Quart 2	0.70	1.0	0.65	2.0	0.75	2.8	1.9	0.75	2.0
p Value	0.40	1.0	0.36	0.11	0.70	0.035	0.22	0.70	0.20
95% CI of	0.31	0.20	0.26	0.85	0.17	1.1	0.68	0.17	0.69
OR Quart2	1.6	5.0	1.6	4.5	3.4	7.3	5.2	3.4	6.1
OR Quart 3	1.5	2.4	1.6	2.0	1.00	2.4	2.2	1.3	2.5
p Value	0.29	0.22	0.20	0.11	1.00	0.075	0.11	0.74	0.093
95% CI of	0.72	0.61	0.77	0.85	0.25	0.91	0.84	0.33	0.86
OR Quart3	3.0	9.2	3.4	4.5	4.0	6.4	6.0	4.7	7.2
OR Quart 4	1.3	0.66	1.5	3.2	1.8	5.0	1.5	1.2	1.4
p Value	0.47	0.66	0.26	0.0030	0.37	5.2E-4	0.43	0.74	0.56
95% CI of	0.64	0.11	0.72	1.5	0.51	2.0	0.53	0.33	0.44
OR Quart4	2.7	4.0	3.3	7.1	6.1	12	4.4	4.7	4.5

Interleukin-21

sCr or UO	0hr prior to AKI stage		24hr prior to AKI stage		48hr prior to AKI stage	
	Cohort 1	Cohort 2	Cohort 1	Cohort 2	Cohort 1	Cohort 2
Median	8.31	3.89	8.31	5.21	8.31	4.89
Average	11.3	7.73	11.3	7.98	11.3	7.18
Stdev	11.5	9.96	11.5	8.29	11.5	6.85
p(t-test)		0.018		0.019		0.028
Min	0.00404	0.00761	0.00404	0.00404	0.00404	0.0177
Max	87.9	56.2	87.9	33.5	87.9	27.6
n (Samp)	928	62	928	70	928	39
n (Patient)	361	62	361	70	361	39

sCr only	0hr prior to AKI stage		24hr prior to AKI stage		48hr prior to AKI stage	
	Cohort 1	Cohort 2	Cohort 1	Cohort 2	Cohort 1	Cohort 2
Median	7.64	8.82	7.64	7.31	7.64	5.50
Average	10.7	15.1	10.7	9.85	10.7	10.5
Stdev	11.4	15.6	11.4	8.89	11.4	9.11
p(t-test)		0.14		0.76		0.96
Min	0.00404	0.418	0.00404	0.0537	0.00404	1.29
Max	105	56.2	105	29.9	105	27.6
n (Samp)	1232	15	1232	18	1232	17
n (Patient)	441	15	441	18	441	17

UO only	0hr prior to AKI stage		24hr prior to AKI stage		48hr prior to AKI stage	
	Cohort 1	Cohort 2	Cohort 1	Cohort 2	Cohort 1	Cohort 2
Median	8.23	3.57	8.23	4.60	8.23	3.75
Average	11.0	6.36	11.0	7.33	11.0	6.34
Stdev	11.1	6.83	11.1	7.99	11.1	6.02
p(t-test)		0.0020		0.011		0.016
Min	0.00404	0.00761	0.00404	0.00404	0.00404	0.0177
Max	87.9	26.7	87.9	33.5	87.9	19.3
n (Samp)	817	57	817	63	817	34
n (Patient)	283	57	283	63	283	34

	0hr prior to AKI stage			24hr prior to AKI stage			48hr prior to AKI stage		
	sCr or UO	sCr only	UO only	sCr or UO	sCr only	UO only	sCr or UO	sCr only	UO only
AUC	0.40	0.58	0.38	0.42	0.50	0.41	0.41	0.53	0.39
SE	0.039	0.078	0.041	0.037	0.069	0.039	0.049	0.072	0.052
p	0.0075	0.29	0.0030	0.031	0.95	0.015	0.058	0.68	0.031
nCohort 1	928	1232	817	928	1232	817	928	1232	817
nCohort 2	62	15	57	70	18	63	39	17	34
Cutoff 1	1.78	3.73	1.78	2.09	3.24	1.37	2.16	3.10	2.55
Sens 1	71%	73%	70%	70%	72%	71%	72%	71%	71%
Spec 1	20%	34%	21%	23%	32%	18%	24%	31%	27%
Cutoff 2	1.26	3.01	1.04	1.13	2.34	1.04	0.728	2.18	0.386
Sens 2	81%	80%	81%	80%	83%	81%	82%	82%	82%
Spec 2	16%	31%	16%	16%	26%	16%	13%	25%	12%
Cutoff 3	0.161	1.29	0.161	0.527	0.0537	0.527	0.0528	1.58	0.0528
Sens 3	92%	93%	91%	90%	94%	90%	92%	94%	91%
Spec 3	9%	18%	10%	12%	7%	13%	6%	21%	7%

	0hr prior to AKI stage			24hr prior to AKI stage			48hr prior to AKI stage		
	sCr or UO	sCr only	UO only	sCr or UO	sCr only	UO only	sCr or UO	sCr only	UO only
Cutoff 4	14.4	13.5	14.2	14.4	13.5	14.2	14.4	13.5	14.2
Sens 4	18%	47%	14%	21%	33%	19%	15%	35%	15%
Spec 4	70%	70%	70%	70%	70%	70%	70%	70%	70%
Cutoff 5	18.6	17.9	18.6	18.6	17.9	18.6	18.6	17.9	18.6
Sens 5	16%	47%	11%	13%	17%	11%	8%	24%	6%
Spec 5	80%	80%	80%	80%	80%	80%	80%	80%	80%
Cutoff 6	25.8	24.7	25.4	25.8	24.7	25.4	25.8	24.7	25.4
Sens 6	5%	20%	2%	4%	11%	5%	3%	12%	0%
Spec 6	90%	90%	90%	90%	90%	90%	90%	90%	90%
OR Quart 2	0.90	2.5	2.1	1.8	2.0	1.9	4.2	0.80	3.1
p Value	0.82	0.27	0.15	0.15	0.33	0.18	0.029	0.74	0.094
95% CI of	0.36	0.48	0.76	0.80	0.50	0.75	1.2	0.21	0.82
OR Quart2	2.3	13	5.6	4.2	8.1	4.9	15	3.0	12
OR Quart 3	2.4	0.50	3.6	2.7	1.7	3.2	4.2	0.60	4.2
p Value	0.023	0.57	0.0075	0.013	0.48	0.0091	0.029	0.48	0.029
95% CI of	1.1	0.045	1.4	1.2	0.40	1.3	1.2	0.14	1.2
OR Quart3	5.2	5.5	9.1	6.0	7.1	7.7	15	2.5	15
OR Quart 4	2.1	3.5	3.4	2.6	1.3	3.4	4.2	1.00	3.5
p Value	0.063	0.12	0.011	0.019	0.71	0.0062	0.028	1.00	0.062
95% CI of	0.96	0.73	1.3	1.2	0.30	1.4	1.2	0.29	0.94
OR Quart4	4.6	17	8.7	5.8	6.0	8.1	15	3.5	13

Interleukin-23

sCr or UO	0hr prior to AKI stage		24hr prior to AKI stage		48hr prior to AKI stage	
	Cohort 1	Cohort 2	Cohort 1	Cohort 2	Cohort 1	Cohort 2
Median	304	141	304	222	304	79.6
Average	548	252	548	379	548	292
Stdev	730	346	730	415	730	518
p(t-test)		0.0016		0.056		0.030
Min	0.491	0.491	0.491	0.564	0.491	0.491
Max	8520	1350	8520	1540	8520	2340
n (Samp)	928	62	928	70	928	39
n (Patient)	361	62	361	70	361	39

sCr only	0hr prior to AKI stage		24hr prior to AKI stage		48hr prior to AKI stage	
	Cohort 1	Cohort 2	Cohort 1	Cohort 2	Cohort 1	Cohort 2
Median	246	105	246	293	246	190
Average	499	379	499	399	499	407
Stdev	691	583	691	423	691	494
p(t-test)		0.50		0.54		0.58
Min	0.491	0.491	0.491	0.564	0.491	0.651
Max	8520	2120	8520	1370	8520	1820
n (Samp)	1232	15	1232	18	1232	17
n (Patient)	441	15	441	18	441	17

UO only	0hr prior to AKI stage		24hr prior to AKI stage		48hr prior to AKI stage	
	Cohort 1	Cohort 2	Cohort 1	Cohort 2	Cohort 1	Cohort 2

UO only	0hr prior to AKI stage		24hr prior to AKI stage		48hr prior to AKI stage	
	Cohort 1	Cohort 2	Cohort 1	Cohort 2	Cohort 1	Cohort 2
Median	311	141	311	173	311	75.4
Average	552	248	552	335	552	232
Stdev	733	341	733	398	733	466
p(t-test)		0.0020		0.020		0.012
Min	0.491	0.491	0.491	0.564	0.491	0.491
Max	8520	1350	8520	1540	8520	2340
n (Samp)	817	57	817	63	817	34
n (Patient)	283	57	283	63	283	34

	0hr prior to AKI stage			24hr prior to AKI stage			48hr prior to AKI stage		
	sCr or UO	sCr only	UO only	sCr or UO	sCr only	UO only	sCr or UO	sCr only	UO only
AUC	0.37	0.43	0.36	0.47	0.49	0.44	0.36	0.50	0.32
SE	0.039	0.077	0.041	0.036	0.069	0.039	0.049	0.071	0.052
p	8.8E-4	0.35	6.3E-4	0.36	0.87	0.097	0.0040	0.97	6.3E-4
nCohort 1	928	1232	817	928	1232	817	928	1232	817
nCohort 2	62	15	57	70	18	63	39	17	34
Cutoff 1	1.06	1.05	1.06	48.7	1.21	16.8	1.06	79.3	1.06
Sens 1	71%	73%	70%	70%	72%	71%	72%	71%	71%
Spec 1	18%	19%	18%	29%	24%	25%	18%	35%	18%
Cutoff 2	0.754	0.754	0.754	1.21	1.08	1.08	0.754	1.41	0.754
Sens 2	87%	87%	84%	80%	83%	81%	82%	82%	82%
Spec 2	10%	11%	10%	21%	20%	18%	10%	26%	10%
Cutoff 3	0.682	0.682	0.643	0.844	0.682	0.844	0.552	0.844	0.552
Sens 3	92%	93%	91%	91%	94%	90%	92%	94%	91%
Spec 3	6%	6%	4%	13%	6%	13%	1%	14%	1%
Cutoff 4	640	583	647	640	583	647	640	583	647
Sens 4	13%	27%	11%	26%	39%	19%	13%	29%	6%
Spec 4	70%	70%	70%	70%	70%	70%	70%	70%	70%
Cutoff 5	923	857	935	923	857	935	923	857	935
Sens 5	10%	13%	9%	11%	11%	10%	10%	18%	6%
Spec 5	80%	80%	80%	80%	80%	80%	80%	80%	80%
Cutoff 6	1520	1380	1460	1520	1380	1460	1520	1380	1460
Sens 6	0%	7%	0%	3%	0%	3%	5%	6%	3%
Spec 6	90%	90%	90%	90%	90%	90%	90%	90%	90%
OR Quart 2	1.2	0.66	1.4	1.9	0.80	2.2	2.0	0.60	3.1
p Value	0.79	0.66	0.58	0.098	0.74	0.070	0.25	0.48	0.17
95% CI of	0.41	0.11	0.46	0.89	0.21	0.94	0.60	0.14	0.61
OR Quart2	3.2	4.0	4.0	4.0	3.0	5.3	6.8	2.5	15
OR Quart 3	3.7	1.7	3.8	2.1	0.60	2.8	2.8	1.2	5.7
p Value	0.0030	0.48	0.0051	0.052	0.48	0.016	0.078	0.76	0.024
95% CI of	1.6	0.40	1.5	0.99	0.14	1.2	0.89	0.36	1.3
OR Quart3	8.7	7.1	9.5	4.4	2.5	6.5	9.0	4.0	26
OR Quart 4	3.5	1.7	4.0	1.6	1.2	2.2	4.2	0.60	8.0
p Value	0.0042	0.48	0.0033	0.24	0.76	0.070	0.011	0.48	0.0061
95% CI of	1.5	0.40	1.6	0.73	0.36	0.94	1.4	0.14	1.8
OR Quart4	8.4	7.1	10	3.5	4.0	5.3	13	2.5	36

Interleukin-28A

sCr or UO	0hr prior to AKI stage		24hr prior to AKI stage		48hr prior to AKI stage	
	Cohort 1	Cohort 2	Cohort 1	Cohort 2	Cohort 1	Cohort 2
Median	16.3	11.6	16.3	22.4	16.3	6.62
Average	34.6	24.2	34.6	32.9	34.6	18.5
Stdev	45.7	33.4	45.7	37.2	45.7	24.7
p(t-test)		0.080		0.76		0.029
Min	0.0254	0.0517	0.0254	0.0495	0.0254	0.0517
Max	587	164	587	156	587	82.9
n (Samp)	928	62	928	70	928	39
n (Patient)	361	62	361	70	361	39

sCr only	0hr prior to AKI stage		24hr prior to AKI stage		48hr prior to AKI stage	
	Cohort 1	Cohort 2	Cohort 1	Cohort 2	Cohort 1	Cohort 2
Median	14.7	20.2	14.7	26.1	14.7	22.5
Average	32.5	29.6	32.5	36.7	32.5	27.9
Stdev	43.6	31.8	43.6	38.1	43.6	28.4
p(t-test)		0.80		0.68		0.67
Min	0.0254	0.0777	0.0254	0.0517	0.0254	0.155
Max	587	105	587	131	587	82.9
n (Samp)	1232	15	1232	18	1232	17
n (Patient)	441	15	441	18	441	17

UO only	0hr prior to AKI stage		24hr prior to AKI stage		48hr prior to AKI stage	
	Cohort 1	Cohort 2	Cohort 1	Cohort 2	Cohort 1	Cohort 2
Median	18.7	8.37	18.7	14.6	18.7	3.36
Average	35.5	22.9	35.5	28.2	35.5	14.5
Stdev	46.4	33.0	46.4	34.9	46.4	19.7
p(t-test)		0.044		0.22		0.0088
Min	0.0254	0.0517	0.0254	0.0495	0.0254	0.0517
Max	587	164	587	156	587	70.2
n (Samp)	817	57	817	63	817	34
n (Patient)	283	57	283	63	283	34

	0hr prior to AKI stage			24hr prior to AKI stage			48hr prior to AKI stage		
	sCr or UO	sCr only	UO only	sCr or UO	sCr only	UO only	sCr or UO	sCr only	UO only
AUC	0.45	0.53	0.43	0.52	0.57	0.48	0.41	0.54	0.38
SE	0.039	0.076	0.041	0.036	0.071	0.038	0.049	0.072	0.052
p	0.20	0.70	0.097	0.59	0.34	0.54	0.081	0.62	0.018
nCohort 1	928	1232	817	928	1232	817	928	1232	817
nCohort 2	62	15	57	70	18	63	39	17	34
Cutoff 1	0.194	4.33	0.194	8.60	16.3	0.243	0.194	4.11	0.194
Sens 1	74%	73%	74%	70%	72%	71%	72%	71%	71%
Spec 1	24%	39%	24%	41%	52%	28%	24%	38%	24%
Cutoff 2	0.176	3.53	0.176	0.194	7.98	0.184	0.142	0.184	0.0896
Sens 2	84%	80%	84%	80%	83%	81%	82%	82%	88%
Spec 2	22%	38%	21%	24%	41%	22%	18%	25%	14%
Cutoff 3	0.0896	0.0896	0.0896	0.142	0.0854	0.0854	0.0854	0.176	0.0854
Sens 3	90%	93%	91%	90%	94%	90%	97%	94%	97%
Spec 3	14%	15%	14%	18%	12%	12%	12%	23%	12%

	0hr prior to AKI stage			24hr prior to AKI stage			48hr prior to AKI stage		
	sCr or UO	sCr only	UO only	sCr or UO	sCr only	UO only	sCr or UO	sCr only	UO only
Cutoff 4	47.5	44.0	50.6	47.5	44.0	50.6	47.5	44.0	50.6
Sens 4	16%	33%	14%	24%	22%	19%	15%	29%	9%
Spec 4	70%	70%	70%	70%	70%	70%	70%	70%	70%
Cutoff 5	65.2	61.1	66.6	65.2	61.1	66.6	65.2	61.1	66.6
Sens 5	10%	20%	11%	19%	22%	14%	8%	12%	3%
Spec 5	80%	80%	80%	80%	80%	80%	80%	80%	80%
Cutoff 6	90.8	88.8	91.5	90.8	88.8	91.5	90.8	88.8	91.5
Sens 6	5%	7%	4%	9%	11%	6%	0%	0%	0%
Spec 6	90%	90%	90%	90%	90%	90%	90%	90%	90%
OR Quart 2	1.8	2.0	2.4	1.1	0.66	1.9	1.8	1.3	5.2
p Value	0.17	0.42	0.059	0.72	0.65	0.098	0.28	0.70	0.035
95% CI of	0.79	0.36	0.97	0.56	0.11	0.89	0.60	0.30	1.1
OR Quart2	3.9	11	6.0	2.3	4.0	4.1	5.5	6.0	24
OR Quart 3	1.6	2.5	2.4	1.6	3.1	1.5	2.9	2.0	4.1
p Value	0.23	0.27	0.061	0.18	0.096	0.32	0.044	0.32	0.076
95% CI of	0.73	0.48	0.96	0.81	0.82	0.68	1.0	0.50	0.86
OR Quart3	3.7	13	5.9	3.1	11	3.3	8.2	8.1	20
OR Quart 4	2.0	2.0	2.7	1.00	1.3	1.5	2.3	1.3	7.5
p Value	0.088	0.42	0.028	0.99	0.71	0.32	0.13	0.71	0.0084
95% CI of	0.90	0.36	1.1	0.48	0.30	0.68	0.78	0.30	1.7
OR Quart4	4.4	11	6.7	2.1	6.0	3.3	6.6	6.0	33

Interleukin-33

sCr or UO	0hr prior to AKI stage		24hr prior to AKI stage		48hr prior to AKI stage	
	Cohort 1	Cohort 2	Cohort 1	Cohort 2	Cohort 1	Cohort 2
Median	43.8	20.7	43.8	37.6	43.8	25.0
Average	60.0	31.0	60.0	44.0	60.0	34.4
Stdev	64.2	30.3	64.2	41.1	64.2	39.8
p(t-test)		4.5E-4		0.041		0.014
Min	0.0232	0.0360	0.0232	0.0232	0.0232	0.0554
Max	958	112	958	235	958	148
n (Samp)	928	62	928	70	928	39
n (Patient)	361	62	361	70	361	39

sCr only	0hr prior to AKI stage		24hr prior to AKI stage		48hr prior to AKI stage	
	Cohort 1	Cohort 2	Cohort 1	Cohort 2	Cohort 1	Cohort 2
Median	41.0	33.6	41.0	43.0	41.0	26.5
Average	56.3	42.0	56.3	44.8	56.3	50.6
Stdev	61.2	34.0	61.2	34.6	61.2	47.5
p(t-test)		0.37		0.43		0.70
Min	0.0232	3.22	0.0232	0.0591	0.0232	0.111
Max	958	109	958	117	958	146
n (Samp)	1232	15	1232	18	1232	17
n (Patient)	441	15	441	18	441	17

UO only	0hr prior to AKI stage		24hr prior to AKI stage		48hr prior to AKI stage	
	Cohort 1	Cohort 2	Cohort 1	Cohort 2	Cohort 1	Cohort 2

UO only	0hr prior to AKI stage		24hr prior to AKI stage		48hr prior to AKI stage	
	Cohort 1	Cohort 2	Cohort 1	Cohort 2	Cohort 1	Cohort 2
Median	43.9	17.8	43.9	32.9	43.9	19.2
Average	60.2	29.1	60.2	41.1	60.2	32.0
Stdev	65.3	29.7	65.3	41.1	65.3	38.0
p(t-test)		3.8E-4		0.023		0.013
Min	0.0232	0.0360	0.0232	0.0232	0.0232	0.0554
Max	958	112	958	235	958	148
n (Samp)	817	57	817	63	817	34
n (Patient)	283	57	283	63	283	34

	0hr prior to AKI stage			24hr prior to AKI stage			48hr prior to AKI stage		
	sCr or UO	sCr only	UO only	sCr or UO	sCr only	UO only	sCr or UO	sCr only	UO only
AUC	0.36	0.46	0.34	0.44	0.48	0.41	0.36	0.49	0.34
SE	0.039	0.076	0.040	0.037	0.069	0.039	0.049	0.071	0.052
p	2.1E-4	0.64	5.1E-5	0.091	0.77	0.028	0.0046	0.89	0.0028
nCohort 1	928	1232	817	928	1232	817	928	1232	817
nCohort 2	62	15	57	70	18	63	39	17	34
Cutoff 1	10.4	14.5	7.17	16.2	23.2	14.5	7.06	17.0	7.06
Sens 1	71%	73%	70%	70%	72%	71%	72%	71%	71%
Spec 1	21%	26%	18%	26%	34%	24%	18%	29%	18%
Cutoff 2	4.04	14.2	2.67	12.4	13.6	8.99	2.98	10.4	0.0768
Sens 2	81%	80%	81%	80%	83%	81%	82%	82%	82%
Spec 2	15%	26%	14%	23%	25%	19%	15%	22%	9%
Cutoff 3	0.0837	10.4	0.0558	0.106	0.0749	0.106	0.0686	5.13	0.0686
Sens 3	90%	93%	91%	91%	94%	90%	95%	94%	94%
Spec 3	11%	22%	4%	11%	9%	11%	6%	17%	6%
Cutoff 4	78.3	73.3	77.4	78.3	73.3	77.4	78.3	73.3	77.4
Sens 4	8%	20%	7%	16%	22%	13%	13%	24%	12%
Spec 4	70%	70%	70%	70%	70%	70%	70%	70%	70%
Cutoff 5	99.1	93.9	98.2	99.1	93.9	98.2	99.1	93.9	98.2
Sens 5	5%	13%	4%	9%	11%	6%	10%	24%	9%
Spec 5	80%	80%	80%	80%	80%	80%	80%	80%	80%
Cutoff 6	135	127	135	135	127	135	135	127	135
Sens 6	0%	0%	0%	1%	0%	2%	5%	6%	6%
Spec 6	90%	90%	90%	90%	90%	90%	90%	90%	90%
OR Quart 2	3.9	2.0	4.9	3.2	2.0	2.8	1.8	1.0	2.0
p Value	0.016	0.42	0.013	0.0092	0.32	0.035	0.37	1.00	0.32
95% CI of	1.3	0.37	1.4	1.3	0.50	1.1	0.51	0.25	0.50
OR Quart2	12	11	17	7.7	8.2	7.3	6.1	4.0	8.2
OR Quart 3	4.8	3.0	5.7	3.2	2.0	3.6	2.8	1.3	2.7
p Value	0.0053	0.18	0.0064	0.0094	0.32	0.0075	0.078	0.73	0.14
95% CI of	1.6	0.61	1.6	1.3	0.50	1.4	0.89	0.33	0.71
OR Quart3	14	15	20	7.6	8.1	9.1	9.0	4.7	10
OR Quart 4	6.9	1.5	8.9	3.2	1.0	3.8	4.5	1.0	6.1
p Value	4.2E-4	0.65	4.2E-4	0.0092	1.00	0.0051	0.0075	1.00	0.0043
95% CI of	2.4	0.25	2.6	1.3	0.20	1.5	1.5	0.25	1.8
OR Quart4	20	9.1	30	7.7	5.0	9.5	14	4.0	21

Interleukin-4 receptor alpha chain

sCr or UO	0hr prior to AKI stage		24hr prior to AKI stage		48hr prior to AKI stage	
	Cohort 1	Cohort 2	Cohort 1	Cohort 2	Cohort 1	Cohort 2
Median	46.5	47.2	46.5	69.4	46.5	48.6
Average	56.0	57.0	56.0	76.7	56.0	50.1
Stdev	49.4	56.5	49.4	60.5	49.4	32.8
p(t-test)		0.89		0.0057		0.54
Min	0.839	2.31	0.839	2.31	0.839	4.67
Max	297	293	297	239	297	122
n (Samp)	460	46	460	51	460	28
n (Patient)	234	46	234	51	234	28

sCr only	0hr prior to AKI stage		24hr prior to AKI stage		48hr prior to AKI stage	
	Cohort 1	Cohort 2	Cohort 1	Cohort 2	Cohort 1	Cohort 2
Median	47.8	24.4	47.8	76.6	47.8	85.3
Average	58.1	40.6	58.1	68.4	58.1	82.2
Stdev	53.5	34.4	53.5	58.4	53.5	46.3
p(t-test)		0.33		0.53		0.14
Min	0.839	10.3	0.839	4.67	0.839	10.3
Max	299	97.7	299	200	299	154
n (Samp)	617	9	617	11	617	11
n (Patient)	287	9	287	11	287	11

UO only	0hr prior to AKI stage		24hr prior to AKI stage		48hr prior to AKI stage	
	Cohort 1	Cohort 2	Cohort 1	Cohort 2	Cohort 1	Cohort 2
Median	46.2	49.3	46.2	68.0	46.2	49.3
Average	56.2	60.7	56.2	75.6	56.2	50.8
Stdev	50.8	57.8	50.8	60.5	50.8	32.2
p(t-test)		0.59		0.017		0.60
Min	0.839	2.31	0.839	2.31	0.839	4.67
Max	297	293	297	239	297	122
n (Samp)	431	42	431	45	431	25
n (Patient)	206	42	206	45	206	25

	0hr prior to AKI stage			24hr prior to AKI stage			48hr prior to AKI stage		
	sCr or UO	sCr only	UO only	sCr or UO	sCr only	UO only	sCr or UO	sCr only	UO only
AUC	0.50	0.45	0.51	0.61	0.56	0.60	0.50	0.67	0.51
SE	0.045	0.100	0.047	0.044	0.090	0.047	0.056	0.090	0.060
p	0.97	0.60	0.75	0.012	0.53	0.025	0.94	0.057	0.81
nCohort 1	460	617	431	460	617	431	460	617	431
nCohort 2	46	9	42	51	11	45	28	11	25
Cutoff 1	11.8	11.8	19.1	35.1	24.0	35.1	38.0	67.2	38.0
Sens 1	80%	89%	71%	71%	73%	71%	71%	73%	72%
Spec 1	25%	24%	33%	42%	34%	42%	42%	64%	43%
Cutoff 2	11.8	11.8	11.3	11.8	11.8	11.8	11.8	41.5	19.1
Sens 2	80%	89%	81%	86%	82%	84%	86%	82%	80%
Spec 2	25%	24%	21%	25%	24%	25%	25%	46%	33%
Cutoff 3	7.93	9.16	6.56	11.3	6.56	9.16	9.16	11.8	10.3
Sens 3	91%	100%	93%	90%	91%	91%	93%	91%	92%
Spec 3	13%	12%	6%	20%	6%	13%	13%	24%	20%

	0hr prior to AKI stage			24hr prior to AKI stage			48hr prior to AKI stage		
	sCr or UO	sCr only	UO only	sCr or UO	sCr only	UO only	sCr or UO	sCr only	UO only
Cutoff 4	75.2	75.2	75.2	75.2	75.2	75.2	75.2	75.2	75.2
Sens 4	24%	22%	26%	45%	55%	40%	18%	64%	16%
Spec 4	71%	71%	71%	71%	71%	71%	71%	71%	71%
Cutoff 5	93.9	95.7	93.9	93.9	95.7	93.9	93.9	95.7	93.9
Sens 5	22%	11%	24%	31%	18%	33%	14%	45%	12%
Spec 5	80%	80%	80%	80%	80%	80%	80%	80%	80%
Cutoff 6	116	126	122	116	126	122	116	126	122
Sens 6	17%	0%	17%	20%	9%	18%	7%	18%	0%
Spec 6	90%	90%	90%	90%	90%	90%	90%	90%	90%
OR Quart 2	1.3	1.0	1.2	1.5	1.0	1.0	2.3	2.0	2.8
p Value	0.50	0.99	0.64	0.46	1.0	1.0	0.16	0.57	0.14
95% CI of	0.57	0.14	0.50	0.54	0.14	0.34	0.70	0.18	0.72
OR Quart2	3.2	7.2	3.1	3.9	7.2	2.9	7.8	22	11
OR Quart 3	1.4	2.0	1.4	2.3	1.5	2.3	2.9	3.0	3.6
p Value	0.39	0.42	0.49	0.084	0.65	0.080	0.073	0.34	0.059
95% CI of	0.62	0.37	0.55	0.89	0.25	0.91	0.90	0.31	0.95
OR Quart3	3.4	11	3.4	5.8	9.2	5.9	9.5	30	13
OR Quart 4	0.90	0.50	1.1	3.0	2.0	2.5	1.0	5.1	1.3
p Value	0.83	0.57	0.83	0.018	0.42	0.054	1.0	0.14	0.70
95% CI of	0.35	0.045	0.43	1.2	0.37	0.98	0.24	0.59	0.29
OR Quart4	2.3	5.6	2.8	7.4	11	6.3	4.1	44	6.2

Vascular endothelial growth factor receptor 2

sCr or UO	0hr prior to AKI stage		24hr prior to AKI stage		48hr prior to AKI stage	
	Cohort 1	Cohort 2	Cohort 1	Cohort 2	Cohort 1	Cohort 2
Median	545	857	545	746	545	455
Average	735	1230	735	997	735	642
Stdev	803	1210	803	952	803	706
p(t-test)		1.7E-4		0.030		0.56
Min	0.218	1.48	0.218	0.218	0.218	1.48
Max	7140	5940	7140	4750	7140	2820
n (Samp)	462	46	462	51	462	27
n (Patient)	235	46	235	51	235	27

sCr only	0hr prior to AKI stage		24hr prior to AKI stage		48hr prior to AKI stage	
	Cohort 1	Cohort 2	Cohort 1	Cohort 2	Cohort 1	Cohort 2
Median	651	806	651	658	651	609
Average	863	1060	863	954	863	522
Stdev	917	1180	917	975	917	406
p(t-test)		0.53		0.76		0.22
Min	0.218	1.48	0.218	1.48	0.218	1.48
Max	7140	3710	7140	2870	7140	1350
n (Samp)	618	9	618	10	618	11
n (Patient)	288	9	288	10	288	11

UO only	0hr prior to AKI stage		24hr prior to AKI stage		48hr prior to AKI stage	
	Cohort 1	Cohort 2	Cohort 1	Cohort 2	Cohort 1	Cohort 2

UO only	0hr prior to AKI stage		24hr prior to AKI stage		48hr prior to AKI stage	
	Cohort 1	Cohort 2	Cohort 1	Cohort 2	Cohort 1	Cohort 2
Median	539	932	539	825	539	495
Average	732	1240	732	1040	732	714
Stdev	805	1170	805	967	805	722
p(t-test)		2.4E-4		0.018		0.91
Min	0.218	10.8	0.218	0.218	0.218	1.48
Max	7140	5940	7140	4750	7140	2820
n (Samp)	433	42	433	45	433	24
n (Patient)	207	42	207	45	207	24

	0hr prior to AKI stage			24hr prior to AKI stage			48hr prior to AKI stage		
	sCr or UO	sCr only	UO only	sCr or UO	sCr only	UO only	sCr or UO	sCr only	UO only
AUC	0.64	0.54	0.66	0.60	0.53	0.61	0.46	0.41	0.50
SE	0.046	0.099	0.048	0.044	0.093	0.046	0.058	0.091	0.061
p	0.0017	0.72	8.4E-4	0.028	0.78	0.017	0.53	0.30	1.00
nCohort 1	462	618	433	462	618	433	462	618	433
nCohort 2	46	9	42	51	10	45	27	11	24
Cutoff 1	566	189	581	421	421	577	159	164	237
Sens 1	72%	78%	71%	71%	70%	71%	70%	73%	71%
Spec 1	51%	22%	53%	43%	38%	52%	23%	20%	29%
Cutoff 2	292	152	333	304	354	228	106	134	106
Sens 2	80%	89%	81%	80%	80%	80%	81%	82%	83%
Spec 2	34%	20%	37%	35%	35%	27%	20%	18%	18%
Cutoff 3	113	1.48	185	129	321	123	1.48	35.7	1.48
Sens 3	91%	100%	90%	90%	90%	91%	100%	91%	100%
Spec 3	20%	8%	24%	21%	32%	19%	10%	12%	9%
Cutoff 4	907	1070	903	907	1070	903	907	1070	903
Sens 4	48%	33%	50%	39%	20%	44%	26%	9%	29%
Spec 4	70%	70%	70%	70%	70%	70%	70%	70%	70%
Cutoff 5	1190	1410	1180	1190	1410	1180	1190	1410	1180
Sens 5	33%	33%	36%	29%	20%	33%	22%	0%	25%
Spec 5	80%	80%	80%	80%	80%	80%	80%	80%	80%
Cutoff 6	1660	1850	1650	1660	1850	1650	1660	1850	1650
Sens 6	26%	11%	24%	12%	20%	11%	7%	0%	8%
Spec 6	90%	90%	90%	90%	90%	90%	90%	90%	90%
OR Quart 2	0.87	0.33	1.4	1.3	4.1	0.60	0.83	2.0	0.83
p Value	0.79	0.34	0.57	0.63	0.21	0.39	0.77	0.57	0.77
95% CI of	0.30	0.034	0.44	0.48	0.45	0.19	0.25	0.18	0.25
OR Quart2	2.5	3.2	4.6	3.3	37	1.9	2.8	23	2.8
OR Quart 3	1.7	0.66	2.8	2.1	3.0	2.0	1.2	4.1	1.2
p Value	0.26	0.65	0.061	0.092	0.34	0.13	0.76	0.21	0.76
95% CI of	0.68	0.11	0.96	0.88	0.31	0.81	0.39	0.45	0.39
OR Quart3	4.2	4.0	8.0	5.2	30	4.9	3.6	37	3.7
OR Quart 4	2.5	0.99	3.8	2.3	2.0	2.3	1.6	4.1	1.0
p Value	0.043	0.99	0.012	0.067	0.57	0.066	0.42	0.21	0.99
95% CI of	1.0	0.20	1.3	0.95	0.18	0.95	0.54	0.45	0.32
OR Quart4	5.9	5.0	11	5.5	22	5.5	4.5	37	3.2

Neural cell adhesion molecule 1

sCr or UO	0hr prior to AKI stage		24hr prior to AKI stage		48hr prior to AKI stage	
	Cohort 1	Cohort 2	Cohort 1	Cohort 2	Cohort 1	Cohort 2
Median	2640	3420	2640	2770	2640	2260
Average	3270	3890	3270	4280	3270	2770
Stdev	2970	2700	2970	6730	2970	2190
p(t-test)		0.11		0.015		0.30
Min	6.83	85.5	6.83	375	6.83	138
Max	48400	15000	48400	55700	48400	9700
n (Samp)	926	62	926	70	926	39
n (Patient)	359	62	359	70	359	39

sCr only	0hr prior to AKI stage		24hr prior to AKI stage		48hr prior to AKI stage	
	Cohort 1	Cohort 2	Cohort 1	Cohort 2	Cohort 1	Cohort 2
Median	2800	2420	2800	2590	2800	2370
Average	3450	2380	3450	3790	3450	3200
Stdev	3250	1460	3250	2950	3250	2300
p(t-test)		0.20		0.66		0.75
Min	6.83	301	6.83	921	6.83	932
Max	55700	4670	55700	10800	55700	8410
n (Samp)	1229	15	1229	18	1229	17
n (Patient)	439	15	439	18	439	17

UO only	0hr prior to AKI stage		24hr prior to AKI stage		48hr prior to AKI stage	
	Cohort 1	Cohort 2	Cohort 1	Cohort 2	Cohort 1	Cohort 2
Median	2730	4020	2730	3060	2730	2460
Average	3320	4690	3320	4760	3320	2920
Stdev	2980	4040	2980	7510	2980	2190
p(t-test)		0.0011		0.0016		0.44
Min	0.234	85.5	0.234	375	0.234	138
Max	48400	26600	48400	55700	48400	9700
n (Samp)	814	57	814	63	814	34
n (Patient)	281	57	281	63	281	34

	0hr prior to AKI stage			24hr prior to AKI stage			48hr prior to AKI stage		
	sCr or UO	sCr only	UO only	sCr or UO	sCr only	UO only	sCr or UO	sCr only	UO only
AUC	0.58	0.39	0.63	0.54	0.53	0.55	0.43	0.47	0.45
SE	0.039	0.078	0.041	0.036	0.070	0.039	0.049	0.072	0.052
p	0.040	0.16	0.0016	0.30	0.70	0.24	0.16	0.71	0.34
nCohort 1	926	1229	814	926	1229	814	926	1229	814
nCohort 2	62	15	57	70	18	63	39	17	34
Cutoff 1	2290	1120	2720	2030	2080	2030	1250	1670	1650
Sens 1	71%	73%	70%	70%	72%	71%	72%	71%	71%
Spec 1	44%	14%	50%	37%	35%	34%	17%	26%	26%
Cutoff 2	1570	849	1960	1210	1700	1210	962	965	1180
Sens 2	81%	80%	81%	80%	83%	81%	82%	82%	82%
Spec 2	26%	8%	32%	17%	27%	16%	11%	10%	15%
Cutoff 3	863	615	1210	1040	1080	986	402	950	402
Sens 3	90%	93%	91%	90%	94%	90%	92%	94%	91%
Spec 3	9%	4%	16%	13%	13%	11%	2%	10%	2%

	0hr prior to AKI stage			24hr prior to AKI stage			48hr prior to AKI stage		
	sCr or UO	sCr only	UO only	sCr or UO	sCr only	UO only	sCr or UO	sCr only	UO only
Cutoff 4	3860	4020	3910	3860	4020	3910	3860	4020	3910
Sens 4	44%	7%	51%	37%	39%	40%	21%	35%	21%
Spec 4	70%	70%	70%	70%	70%	70%	70%	70%	70%
Cutoff 5	4660	4940	4740	4660	4940	4740	4660	4940	4740
Sens 5	34%	0%	42%	29%	28%	32%	18%	24%	18%
Spec 5	80%	80%	80%	80%	80%	80%	80%	80%	80%
Cutoff 6	6190	6480	6230	6190	6480	6230	6190	6480	6230
Sens 6	21%	0%	25%	17%	17%	17%	8%	6%	9%
Spec 6	90%	90%	90%	90%	90%	90%	90%	90%	90%
OR Quart 2	0.83	6.1	1.5	1.1	2.0	1.3	0.88	0.16	1.1
p Value	0.66	0.095	0.37	0.71	0.33	0.45	0.80	0.096	0.79
95% CI of	0.35	0.73	0.61	0.56	0.50	0.63	0.31	0.020	0.41
OR Quart2	1.9	51	3.8	2.3	8.1	2.8	2.5	1.4	3.2
OR Quart 3	1.4	2.0	1.5	1.1	1.3	0.92	1.5	0.83	1.4
p Value	0.34	0.57	0.37	0.85	0.71	0.84	0.36	0.76	0.46
95% CI of	0.68	0.18	0.61	0.52	0.30	0.41	0.62	0.25	0.54
OR Quart3	3.1	22	3.8	2.2	6.0	2.1	3.8	2.8	3.9
OR Quart 4	2.0	6.1	3.4	1.5	1.7	1.7	1.5	0.83	1.3
p Value	0.058	0.095	0.0036	0.23	0.48	0.16	0.36	0.77	0.61
95% CI of	0.98	0.73	1.5	0.77	0.40	0.82	0.62	0.25	0.47
OR Quart4	4.1	51	7.7	3.0	7.1	3.4	3.8	2.8	3.6

Platelet-derived growth factor subunit B (dimer)

sCr or UO	0hr prior to AKI stage		24hr prior to AKI stage		48hr prior to AKI stage	
	Cohort 1	Cohort 2	Cohort 1	Cohort 2	Cohort 1	Cohort 2
Median	1.16	2.27	1.16	1.69	1.16	2.14
Average	3.31	3.21	3.31	22.5	3.31	2.17
Stdev	12.7	4.27	12.7	137	12.7	1.82
p(t-test)		0.96		5.2E-4		0.64
Min	0.00246	0.00313	0.00246	0.00408	0.00246	0.00313
Max	270	24.9	270	935	270	8.46
n (Samp)	691	36	691	46	691	28
n (Patient)	280	36	280	46	280	28

sCr only	0hr prior to AKI stage		24hr prior to AKI stage		48hr prior to AKI stage	
	Cohort 1	Cohort 2	Cohort 1	Cohort 2	Cohort 1	Cohort 2
Median	1.17	2.02	1.17	2.53	1.17	2.18
Average	4.08	2.61	4.08	5.64	4.08	2.38
Stdev	33.0	1.80	33.0	8.01	33.0	2.33
p(t-test)		0.90		0.87		0.85
Min	0.00246	0.709	0.00246	0.00741	0.00246	0.166
Max	935	5.92	935	26.6	935	8.93
n (Samp)	899	8	899	12	899	13
n (Patient)	335	8	335	12	335	13

UO only	0hr prior to AKI stage		24hr prior to AKI stage		48hr prior to AKI stage	
	Cohort 1	Cohort 2	Cohort 1	Cohort 2	Cohort 1	Cohort 2

UO only	0hr prior to AKI stage		24hr prior to AKI stage		48hr prior to AKI stage	
	Cohort 1	Cohort 2	Cohort 1	Cohort 2	Cohort 1	Cohort 2
Median	1.24	2.75	1.24	1.69	1.24	2.10
Average	3.34	4.89	3.34	25.0	3.34	2.26
Stdev	13.1	10.4	13.1	142	13.1	1.83
p(t-test)		0.49		4.8E-4		0.68
Min	0.00246	0.00313	0.00246	0.00408	0.00246	0.00313
Max	270	59.1	270	935	270	8.46
n (Samp)	581	35	581	43	581	25
n (Patient)	208	35	208	43	208	25

	0hr prior to AKI stage			24hr prior to AKI stage			48hr prior to AKI stage		
	sCr or UO	sCr only	UO only	sCr or UO	sCr only	UO only	sCr or UO	sCr only	UO only
AUC	0.64	0.67	0.63	0.57	0.68	0.55	0.59	0.60	0.60
SE	0.051	0.11	0.052	0.045	0.086	0.047	0.058	0.084	0.061
p	0.0079	0.10	0.011	0.12	0.036	0.30	0.12	0.24	0.11
nCohort 1	691	899	581	691	899	581	691	899	581
nCohort 2	36	8	35	46	12	43	28	13	25
Cutoff 1	1.39	1.39	1.66	0.943	1.26	0.536	0.884	0.505	1.04
Sens 1	72%	75%	71%	72%	75%	72%	71%	77%	72%
Spec 1	56%	55%	58%	45%	53%	30%	43%	31%	45%
Cutoff 2	0.621	1.14	0.506	0.447	1.18	0.0558	0.393	0.365	0.742
Sens 2	81%	88%	80%	80%	83%	81%	82%	85%	80%
Spec 2	34%	49%	30%	29%	50%	18%	28%	27%	36%
Cutoff 3	0.0183	0.708	0.0183	0.0140	1.09	0.0140	0.361	0.361	0.392
Sens 3	92%	100%	91%	98%	92%	98%	93%	92%	92%
Spec 3	13%	36%	13%	10%	48%	10%	27%	27%	27%
Cutoff 4	2.13	2.17	2.22	2.13	2.17	2.22	2.13	2.17	2.22
Sens 4	53%	38%	57%	39%	58%	35%	50%	54%	44%
Spec 4	70%	70%	70%	70%	70%	70%	70%	70%	70%
Cutoff 5	3.13	3.13	3.15	3.13	3.13	3.15	3.13	3.13	3.15
Sens 5	36%	38%	40%	28%	42%	28%	21%	23%	24%
Spec 5	80%	80%	80%	80%	80%	80%	80%	80%	80%
Cutoff 6	5.18	5.05	5.21	5.18	5.05	5.21	5.18	5.05	5.21
Sens 6	14%	12%	17%	9%	25%	12%	4%	8%	4%
Spec 6	90%	90%	90%	90%	90%	90%	90%	90%	90%
OR Quart 2	0.99	>2.0	0.66	0.88	1.00	0.79	4.7	4.1	3.1
p Value	0.99	<0.57	0.52	0.80	1.00	0.63	0.051	0.21	0.17
95% CI of	0.28	>0.18	0.18	0.33	0.062	0.30	0.99	0.45	0.61
OR Quart2	3.5	na	2.4	2.3	16	2.1	22	37	15
OR Quart 3	1.8	>3.0	1.9	1.6	4.0	1.1	3.1	2.0	4.7
p Value	0.29	<0.34	0.22	0.29	0.21	0.82	0.18	0.57	0.050
95% CI of	0.60	>0.31	0.68	0.68	0.45	0.46	0.61	0.18	1.0
OR Quart3	5.6	na	5.3	3.8	36	2.7	15	22	22
OR Quart 4	3.6	>3.0	2.5	1.7	6.1	1.4	5.8	6.1	4.1
p Value	0.013	<0.34	0.072	0.21	0.095	0.40	0.024	0.094	0.076
95% CI of	1.3	>0.31	0.92	0.73	0.73	0.62	1.3	0.73	0.86
OR Quart4	10	na	6.6	4.0	51	3.3	26	51	20

Corticotropin

sCr or UO	0hr prior to AKI stage		24hr prior to AKI stage		48hr prior to AKI stage	
	Cohort 1	Cohort 2	Cohort 1	Cohort 2	Cohort 1	Cohort 2
Median	0.00163	0.00162	0.00163	0.00208	0.00163	0.00175
Average	0.00229	0.00185	0.00229	0.00430	0.00229	0.00180
Stdev	0.00404	0.00124	0.00404	0.00727	0.00404	0.000819
p(t-test)		0.61		0.018		0.63
Min	3.92E-6	0.000273	3.92E-6	0.000388	3.92E-6	0.000570
Max	0.0489	0.00666	0.0489	0.0377	0.0489	0.00318
n (Samp)	249	22	249	32	249	16
n (Patient)	162	22	162	32	162	16

sCr only	0hr prior to AKI stage		24hr prior to AKI stage		48hr prior to AKI stage	
	Cohort 1	Cohort 2	Cohort 1	Cohort 2	Cohort 1	Cohort 2
Median	nd	nd	0.00163	0.00293	0.00163	0.00274
Average	nd	nd	0.00223	0.00603	0.00223	0.00742
Stdev	nd	nd	0.00365	0.00820	0.00365	0.0134
p(t-test)	nd	nd		0.015		9.1E-4
Min	nd	nd	3.92E-6	0.00134	3.92E-6	0.00109
Max	nd	nd	0.0489	0.0224	0.0489	0.0377
n (Samp)	nd	nd	315	6	315	7
n (Patient)	nd	nd	189	6	189	7

UO only	0hr prior to AKI stage		24hr prior to AKI stage		48hr prior to AKI stage	
	Cohort 1	Cohort 2	Cohort 1	Cohort 2	Cohort 1	Cohort 2
Median	0.00163	0.00162	0.00163	0.00204	0.00163	0.00160
Average	0.00239	0.00186	0.00239	0.00374	0.00239	0.00300
Stdev	0.00430	0.00126	0.00430	0.00680	0.00430	0.00542
p(t-test)		0.57		0.14		0.60
Min	0.000355	0.000273	0.000355	0.000388	0.000355	0.000570
Max	0.0489	0.00666	0.0489	0.0377	0.0489	0.0224
n (Samp)	217	22	217	29	217	15
n (Patient)	135	22	135	29	135	15

	0hr prior to AKI stage			24hr prior to AKI stage			48hr prior to AKI stage		
	sCr or UO	sCr only	UO only	sCr or UO	sCr only	UO only	sCr or UO	sCr only	UO only
AUC	0.48	nd	0.47	0.62	0.66	0.60	0.50	0.73	0.47
SE	0.065	nd	0.066	0.056	0.12	0.059	0.075	0.11	0.078
p	0.79	nd	0.66	0.025	0.18	0.085	0.97	0.038	0.69
nCohort 1	249	nd	217	249	315	217	249	315	217
nCohort 2	22	nd	22	32	6	29	16	7	15
Cutoff 1	0.00134	nd	0.00134	0.00149	0.00134	0.00149	0.00111	0.00212	0.00111
Sens 1	77%	nd	73%	72%	83%	72%	75%	71%	73%
Spec 1	33%	nd	32%	42%	32%	41%	22%	69%	23%
Cutoff 2	0.00106	nd	0.00106	0.00124	0.00134	0.00111	0.00109	0.00201	0.00109
Sens 2	86%	nd	86%	81%	83%	83%	81%	86%	80%
Spec 2	20%	nd	21%	32%	32%	23%	21%	65%	22%
Cutoff 3	0.000794	nd	0.000794	0.00109	0.00124	0.000888	0.000523	0.00106	0.000523
Sens 3	91%	nd	91%	91%	100%	93%	100%	100%	100%
Spec 3	10%	nd	9%	21%	31%	15%	7%	19%	6%

	0hr prior to AKI stage			24hr prior to AKI stage			48hr prior to AKI stage		
	sCr or UO	sCr only	UO only	sCr or UO	sCr only	UO only	sCr or UO	sCr only	UO only
Cutoff 4	0.00222	nd	0.00227	0.00222	0.00222	0.00227	0.00222	0.00222	0.00227
Sens 4	23%	nd	27%	47%	50%	41%	31%	57%	20%
Spec 4	70%	nd	70%	70%	70%	70%	70%	70%	70%
Cutoff 5	0.00282	nd	0.00282	0.00282	0.00274	0.00282	0.00282	0.00274	0.00282
Sens 5	9%	nd	9%	34%	50%	28%	12%	43%	13%
Spec 5	80%	nd	81%	80%	80%	81%	80%	80%	81%
Cutoff 6	0.00362	nd	0.00380	0.00362	0.00352	0.00380	0.00362	0.00352	0.00380
Sens 6	5%	nd	5%	28%	50%	14%	0%	14%	7%
Spec 6	91%	nd	91%	91%	90%	91%	91%	90%	91%
OR Quart 2	2.5	nd	4.5	1.0	>3.1	0.39	1.0	0	1.0
p Value	0.20	nd	0.066	1.0	<0.33	0.19	0.98	na	1.0
95% CI of	0.62	nd	0.91	0.31	>0.32	0.097	0.24	na	0.19
OR Quart2	10	nd	22	3.3	na	1.6	4.2	na	5.2
OR Quart 3	2.5	nd	3.2	1.4	>0	1.3	0.75	2.0	1.4
p Value	0.20	nd	0.16	0.57	<na	0.59	0.71	0.57	0.70
95% CI of	0.62	nd	0.62	0.45	>na	0.46	0.16	0.18	0.29
OR Quart3	10	nd	17	4.2	na	3.8	3.5	23	6.4
OR Quart 4	1.7	nd	3.3	2.2	>3.1	1.5	1.3	4.1	1.7
p Value	0.46	nd	0.16	0.15	<0.33	0.46	0.71	0.21	0.47
95% CI of	0.40	nd	0.63	0.77	>0.31	0.53	0.33	0.45	0.39
OR Quart4	7.6	nd	17	6.1	na	4.2	5.0	38	7.6

Thyroxine-binding globulin

sCr or UO	0hr prior to AKI stage		24hr prior to AKI stage		48hr prior to AKI stage	
	Cohort 1	Cohort 2	Cohort 1	Cohort 2	Cohort 1	Cohort 2
Median	0.0709	0.0370	0.0709	0.0576	0.0709	0.136
Average	0.176	0.107	0.176	0.246	0.176	0.165
Stdev	0.265	0.203	0.265	0.631	0.265	0.173
p(t-test)		0.20		0.21		0.86
Min	8.30E-5	0.000476	8.30E-5	0.00330	8.30E-5	0.00324
Max	1.86	0.885	1.86	3.60	1.86	0.602
n (Samp)	421	25	421	32	421	17
n (Patient)	165	25	165	32	165	17

sCr only	0hr prior to AKI stage		24hr prior to AKI stage		48hr prior to AKI stage	
	Cohort 1	Cohort 2	Cohort 1	Cohort 2	Cohort 1	Cohort 2
Median	nd	nd	0.0749	0.0237	0.0749	0.0201
Average	nd	nd	0.178	0.130	0.178	0.0811
Stdev	nd	nd	0.294	0.177	0.294	0.107
p(t-test)	nd	nd		0.67		0.38
Min	nd	nd	8.30E-5	0.00330	8.30E-5	0.00324
Max	nd	nd	3.60	0.466	3.60	0.250
n (Samp)	nd	nd	511	7	511	7
n (Patient)	nd	nd	198	7	198	7

UO only	0hr prior to AKI stage		24hr prior to AKI stage		48hr prior to AKI stage	
	Cohort 1	Cohort 2	Cohort 1	Cohort 2	Cohort 1	Cohort 2

UO only	0hr prior to AKI stage		24hr prior to AKI stage		48hr prior to AKI stage	
	Cohort 1	Cohort 2	Cohort 1	Cohort 2	Cohort 1	Cohort 2
Median	0.0686	0.0423	0.0686	0.0428	0.0686	0.142
Average	0.178	0.119	0.178	0.251	0.178	0.173
Stdev	0.272	0.204	0.272	0.661	0.272	0.168
p(t-test)		0.28		0.24		0.94
Min	0.000191	0.000476	0.000191	0.00343	0.000191	0.00768
Max	1.86	0.885	1.86	3.60	1.86	0.602
n (Samp)	357	25	357	29	357	17
n (Patient)	135	25	135	29	135	17

	0hr prior to AKI stage			24hr prior to AKI stage			48hr prior to AKI stage		
	sCr or UO	sCr only	UO only	sCr or UO	sCr only	UO only	sCr or UO	sCr only	UO only
AUC	0.38	nd	0.41	0.49	0.42	0.49	0.56	0.38	0.60
SE	0.061	nd	0.062	0.053	0.11	0.056	0.073	0.11	0.074
p	0.058	nd	0.15	0.88	0.47	0.85	0.41	0.28	0.19
nCohort 1	421	nd	357	421	511	357	421	511	357
nCohort 2	25	nd	25	32	7	29	17	7	17
Cutoff 1	0.0145	nd	0.0131	0.0184	0.00990	0.0184	0.0617	0.0187	0.109
Sens 1	72%	nd	72%	72%	71%	72%	71%	71%	71%
Spec 1	20%	nd	18%	23%	16%	23%	47%	23%	59%
Cutoff 2	0.0112	nd	0.00915	0.00971	0.00423	0.0158	0.0353	0.0145	0.0497
Sens 2	80%	nd	80%	81%	86%	83%	82%	86%	82%
Spec 2	17%	nd	16%	16%	8%	21%	33%	20%	43%
Cutoff 3	0.00446	nd	0.00423	0.00556	0.00325	0.00556	0.00767	0.00319	0.0196
Sens 3	92%	nd	92%	91%	100%	93%	94%	100%	94%
Spec 3	9%	nd	8%	11%	6%	11%	14%	6%	24%
Cutoff 4	0.179	nd	0.179	0.179	0.179	0.179	0.179	0.179	0.179
Sens 4	16%	nd	20%	34%	29%	34%	24%	29%	24%
Spec 4	70%	nd	70%	70%	70%	70%	70%	70%	70%
Cutoff 5	0.251	nd	0.249	0.251	0.259	0.249	0.251	0.259	0.249
Sens 5	8%	nd	8%	28%	29%	28%	18%	0%	18%
Spec 5	80%	nd	80%	80%	80%	80%	80%	80%	80%
Cutoff 6	0.434	nd	0.466	0.434	0.422	0.466	0.434	0.422	0.466
Sens 6	8%	nd	8%	9%	14%	7%	12%	0%	12%
Spec 6	90%	nd	90%	90%	90%	90%	90%	90%	90%
OR Quart 2	3.1	nd	2.5	0.43	0.50	0.38	0.99	0	1.5
p Value	0.17	nd	0.20	0.13	0.57	0.11	0.99	na	0.66
95% CI of	0.62	nd	0.62	0.15	0.045	0.11	0.20	na	0.24
OR Quart2	16	nd	9.8	1.3	5.6	1.3	5.0	na	9.2
OR Quart 3	3.1	nd	1.7	0.43	0.50	0.47	2.8	0.50	4.9
p Value	0.17	nd	0.47	0.13	0.57	0.19	0.14	0.57	0.047
95% CI of	0.61	nd	0.40	0.15	0.044	0.16	0.72	0.044	1.0
OR Quart3	16	nd	7.3	1.3	5.5	1.4	11	5.5	23
OR Quart 4	6.0	nd	3.6	1.0	1.5	1.0	0.99	2.0	1.5
p Value	0.021	nd	0.055	0.98	0.65	0.98	0.99	0.41	0.66
95% CI of	1.3	nd	0.97	0.42	0.25	0.40	0.20	0.37	0.24
OR Quart4	28	nd	14	2.4	9.3	2.6	5.0	11	9.2

Tumor necrosis factor receptor superfamily member 8

sCr or UO	0hr prior to AKI stage		24hr prior to AKI stage		48hr prior to AKI stage	
	Cohort 1	Cohort 2	Cohort 1	Cohort 2	Cohort 1	Cohort 2
Median	18.5	33.8	18.5	26.4	18.5	18.6
Average	24.9	46.9	24.9	36.4	24.9	27.1
Stdev	30.5	60.4	30.5	36.8	30.5	27.6
p(t-test)		3.0E-5		0.010		0.70
Min	0.0493	0.121	0.0493	0.0561	0.0493	0.0688
Max	277	350	277	158	277	111
n (Samp)	473	47	473	54	473	28
n (Patient)	240	47	240	54	240	28

sCr only	0hr prior to AKI stage		24hr prior to AKI stage		48hr prior to AKI stage	
	Cohort 1	Cohort 2	Cohort 1	Cohort 2	Cohort 1	Cohort 2
Median	19.8	12.5	19.8	32.3	19.8	38.9
Average	31.0	23.4	31.0	59.4	31.0	32.8
Stdev	46.2	25.8	46.2	98.6	46.2	21.4
p(t-test)		0.62		0.050		0.90
Min	0.0493	0.196	0.0493	12.1	0.0493	0.0688
Max	554	63.3	554	353	554	59.7
n (Samp)	634	9	634	11	634	11
n (Patient)	295	9	295	11	295	11

UO only	0hr prior to AKI stage		24hr prior to AKI stage		48hr prior to AKI stage	
	Cohort 1	Cohort 2	Cohort 1	Cohort 2	Cohort 1	Cohort 2
Median	16.9	35.1	16.9	26.4	16.9	18.8
Average	24.3	49.2	24.3	37.3	24.3	27.5
Stdev	31.1	62.2	31.1	38.9	31.1	28.0
p(t-test)		9.9E-6		0.0075		0.62
Min	0.0493	0.121	0.0493	0.0561	0.0493	0.196
Max	277	350	277	158	277	111
n (Samp)	441	43	441	48	441	25
n (Patient)	210	43	210	48	210	25

	0hr prior to AKI stage			24hr prior to AKI stage			48hr prior to AKI stage		
	sCr or UO	sCr only	UO only	sCr or UO	sCr only	UO only	sCr or UO	sCr only	UO only
AUC	0.64	0.45	0.67	0.60	0.65	0.60	0.53	0.61	0.55
SE	0.045	0.100	0.047	0.043	0.091	0.045	0.057	0.091	0.061
p	0.0018	0.59	2.9E-4	0.021	0.098	0.028	0.59	0.24	0.37
nCohort 1	473	634	441	473	634	441	473	634	441
nCohort 2	47	9	43	54	11	48	28	11	25
Cutoff 1	15.4	5.09	15.4	12.3	23.1	9.75	8.69	18.3	10.4
Sens 1	70%	78%	72%	70%	73%	71%	71%	73%	72%
Spec 1	48%	19%	49%	40%	56%	35%	31%	46%	36%
Cutoff 2	6.53	1.18	12.1	5.14	18.5	5.09	5.76	9.75	6.53
Sens 2	81%	89%	81%	83%	82%	81%	82%	82%	84%
Spec 2	27%	12%	41%	23%	47%	23%	25%	30%	29%
Cutoff 3	1.18	0.121	5.14	1.80	13.6	1.18	0.196	5.76	0.196
Sens 3	94%	100%	91%	91%	91%	94%	93%	91%	96%
Spec 3	14%	6%	25%	16%	43%	15%	9%	23%	11%

	0hr prior to AKI stage			24hr prior to AKI stage			48hr prior to AKI stage		
	sCr or UO	sCr only	UO only	sCr or UO	sCr only	UO only	sCr or UO	sCr only	UO only
Cutoff 4	29.5	32.9	27.0	29.5	32.9	27.0	29.5	32.9	27.0
Sens 4	55%	33%	60%	48%	27%	48%	39%	55%	40%
Spec 4	70%	71%	70%	70%	71%	70%	70%	71%	70%
Cutoff 5	38.9	42.2	37.4	38.9	42.2	37.4	38.9	42.2	37.4
Sens 5	43%	33%	49%	35%	27%	42%	25%	45%	24%
Spec 5	81%	80%	80%	81%	80%	80%	81%	80%	80%
Cutoff 6	53.5	63.6	53.5	53.5	63.6	53.5	53.5	63.6	53.5
Sens 6	26%	0%	26%	20%	9%	21%	7%	0%	8%
Spec 6	90%	90%	90%	90%	90%	90%	90%	90%	90%
OR Quart 2	1.8	0	2.3	0.89	>3.1	0.89	1.4	1.0	1.8
p Value	0.24	na	0.13	0.81	<0.34	0.81	0.56	1.0	0.37
95% CI of	0.68	na	0.78	0.37	>0.31	0.35	0.44	0.14	0.51
OR Quart2	4.7	na	6.9	2.2	na	2.3	4.6	7.2	6.3
OR Quart 3	0.70	0.66	1.0	1.1	>5.2	0.79	1.6	0.50	1.3
p Value	0.56	0.65	1.0	0.84	<0.14	0.62	0.40	0.57	0.73
95% CI of	0.22	0.11	0.28	0.46	>0.60	0.30	0.52	0.045	0.33
OR Quart3	2.3	4.0	3.5	2.6	na	2.1	5.2	5.5	4.8
OR Quart 4	3.8	1.4	5.2	2.1	>3.0	2.3	1.6	3.1	2.3
p Value	0.0032	0.70	0.0014	0.066	<0.34	0.041	0.41	0.18	0.17
95% CI of	1.6	0.30	1.9	0.95	>0.31	1.0	0.52	0.61	0.70
OR Quart4	9.2	6.1	14	4.5	na	5.1	5.1	15	7.8

Alpha-fetoprotein

sCr or UO	0hr prior to AKI stage		24hr prior to AKI stage		48hr prior to AKI stage	
	Cohort 1	Cohort 2	Cohort 1	Cohort 2	Cohort 1	Cohort 2
Median	0.00508	0.00505	0.00508	0.00587	0.00508	0.00428
Average	0.0492	0.0230	0.0492	0.109	0.0492	0.0706
Stdev	0.117	0.0651	0.117	0.406	0.117	0.242
p(t-test)		0.17		0.021		0.40
Min	0.000463	0.000463	0.000463	0.000463	0.000463	0.000463
Max	0.889	0.280	0.889	2.85	0.889	1.25
n (Samp)	407	39	407	50	407	27
n (Patient)	214	39	214	50	214	27

sCr only	0hr prior to AKI stage		24hr prior to AKI stage		48hr prior to AKI stage	
	Cohort 1	Cohort 2	Cohort 1	Cohort 2	Cohort 1	Cohort 2
Median	nd	nd	0.00505	0.00624	0.00505	0.00286
Average	nd	nd	0.0563	0.0846	0.0563	0.0277
Stdev	nd	nd	0.178	0.126	0.178	0.0583
p(t-test)	nd	nd		0.62		0.60
Min	nd	nd	0.000463	0.000463	0.000463	0.000463
Max	nd	nd	2.85	0.317	2.85	0.185
n (Samp)	nd	nd	535	10	535	11
n (Patient)	nd	nd	256	10	256	11

UO only	0hr prior to AKI stage		24hr prior to AKI stage		48hr prior to AKI stage	
	Cohort 1	Cohort 2	Cohort 1	Cohort 2	Cohort 1	Cohort 2

UO only	0hr prior to AKI stage		24hr prior to AKI stage		48hr prior to AKI stage	
	Cohort 1	Cohort 2	Cohort 1	Cohort 2	Cohort 1	Cohort 2
Median	0.00505	0.00505	0.00505	0.00587	0.00505	0.00428
Average	0.0537	0.0230	0.0537	0.111	0.0537	0.0739
Stdev	0.148	0.0651	0.148	0.418	0.148	0.251
p(t-test)		0.20		0.058		0.53
Min	0.000463	0.000463	0.000463	0.000463	0.000463	0.000463
Max	1.74	0.280	1.74	2.85	1.74	1.25
n (Samp)	380	39	380	47	380	25
n (Patient)	189	39	189	47	189	25

	0hr prior to AKI stage			24hr prior to AKI stage			48hr prior to AKI stage		
	sCr or UO	sCr only	UO only	sCr or UO	sCr only	UO only	sCr or UO	sCr only	UO only
AUC	0.42	nd	0.42	0.52	0.57	0.53	0.43	0.38	0.44
SE	0.050	nd	0.050	0.044	0.095	0.045	0.059	0.091	0.061
p	0.100	nd	0.13	0.57	0.43	0.53	0.22	0.19	0.31
nCohort 1	407	nd	380	407	535	380	407	535	380
nCohort 2	39	nd	39	50	10	47	27	11	25
Cutoff 1	0.00132	nd	0.00132	0.00296	0.00483	0.00296	0.00132	0.00132	0.00132
Sens 1	87%	nd	87%	78%	70%	77%	81%	91%	80%
Spec 1	14%	nd	15%	19%	44%	20%	14%	15%	15%
Cutoff 2	0.00132	nd	0.00132	0.00132	0.00296	0.00132	0.00132	0.00132	0.00132
Sens 2	87%	nd	87%	84%	80%	83%	81%	91%	80%
Spec 2	14%	nd	15%	14%	22%	15%	14%	15%	15%
Cutoff 3	0	nd	0	0.000463	0.000463	0.000463	0.000463	0.00132	0.000463
Sens 3	100%	nd	100%	92%	90%	91%	93%	91%	92%
Spec 3	0%	nd	0%	8%	9%	9%	8%	15%	9%
Cutoff 4	0.0128	nd	0.00660	0.0128	0.00660	0.00660	0.0128	0.00660	0.00660
Sens 4	10%	nd	10%	40%	40%	40%	22%	18%	24%
Spec 4	70%	nd	71%	70%	72%	71%	70%	72%	71%
Cutoff 5	0.0613	nd	0.0613	0.0613	0.0499	0.0613	0.0613	0.0499	0.0613
Sens 5	8%	nd	8%	24%	30%	23%	19%	18%	16%
Spec 5	80%	nd	80%	80%	80%	80%	80%	80%	80%
Cutoff 6	0.141	nd	0.131	0.141	0.154	0.131	0.141	0.154	0.131
Sens 6	8%	nd	8%	16%	30%	15%	11%	9%	12%
Spec 6	90%	nd	90%	90%	90%	90%	90%	90%	90%
OR Quart 2	5.2	nd	5.2	1.2	1.0	0.99	1.4	0.50	1.4
p Value	0.011	nd	0.011	0.67	1.0	0.98	0.54	0.57	0.54
95% CI of	1.5	nd	1.5	0.52	0.14	0.41	0.44	0.045	0.44
OR Quart2	19	nd	19	2.8	7.2	2.4	4.7	5.6	4.7
OR Quart 3	3.6	nd	3.6	1.2	1.0	0.99	0.59	1.0	0.80
p Value	0.059	nd	0.058	0.67	1.0	0.98	0.48	1.0	0.74
95% CI of	0.95	nd	0.96	0.52	0.14	0.41	0.14	0.14	0.21
OR Quart3	13	nd	13	2.8	7.2	2.4	2.5	7.2	3.1
OR Quart 4	4.4	nd	4.4	1.2	2.0	1.3	2.6	3.1	1.9
p Value	0.025	nd	0.024	0.68	0.42	0.54	0.083	0.17	0.27
95% CI of	1.2	nd	1.2	0.51	0.36	0.56	0.88	0.62	0.61
OR Quart4	16	nd	16	2.8	11	3.0	7.7	16	5.9

Apolipoprotein E

sCr or UO	0hr prior to AKI stage		24hr prior to AKI stage		48hr prior to AKI stage	
	Cohort 1	Cohort 2	Cohort 1	Cohort 2	Cohort 1	Cohort 2
Median	2.68	1.90	2.68	1.73	2.68	1.37
Average	21.4	9.42	21.4	34.9	21.4	4.56
Stdev	132	20.1	132	239	132	12.4
p(t-test)		0.45		0.41		0.39
Min	0.000147	0.00122	0.000147	0.000147	0.000147	0.000147
Max	2160	135	2160	2140	2160	83.4
n (Samp)	1008	70	1008	80	1008	46
n (Patient)	386	70	386	80	386	46

sCr only	0hr prior to AKI stage		24hr prior to AKI stage		48hr prior to AKI stage	
	Cohort 1	Cohort 2	Cohort 1	Cohort 2	Cohort 1	Cohort 2
Median	2.56	0.695	2.56	1.07	2.56	1.79
Average	20.2	1.91	20.2	3.33	20.2	3.52
Stdev	129	3.03	129	6.71	129	4.87
p(t-test)		0.57		0.55		0.56
Min	0.000147	0.00154	0.000147	0.000147	0.000147	0.000147
Max	2160	10.5	2160	28.7	2160	19.7
n (Samp)	1344	16	1344	21	1344	20
n (Patient)	472	16	472	21	472	20

UO only	0hr prior to AKI stage		24hr prior to AKI stage		48hr prior to AKI stage	
	Cohort 1	Cohort 2	Cohort 1	Cohort 2	Cohort 1	Cohort 2
Median	2.57	3.56	2.57	1.85	2.57	1.41
Average	19.5	11.2	19.5	38.5	19.5	4.94
Stdev	120	22.0	120	250	120	13.3
p(t-test)		0.58		0.24		0.44
Min	0.000147	0.00122	0.000147	0.000147	0.000147	0.00328
Max	2140	135	2140	2140	2140	83.4
n (Samp)	900	65	900	73	900	40
n (Patient)	310	65	310	73	310	40

	0hr prior to AKI stage			24hr prior to AKI stage			48hr prior to AKI stage		
	sCr or UO	sCr only	UO only	sCr or UO	sCr only	UO only	sCr or UO	sCr only	UO only
AUC	0.47	0.29	0.50	0.45	0.34	0.47	0.37	0.40	0.39
SE	0.036	0.074	0.037	0.034	0.066	0.036	0.045	0.067	0.048
p	0.36	0.0050	0.94	0.13	0.016	0.37	0.0052	0.15	0.027
nCohort 1	1008	1344	900	1008	1344	900	1008	1344	900
nCohort 2	70	16	65	80	21	73	46	20	40
Cutoff 1	0.809	0.201	0.825	0.551	0.423	0.422	0.505	0.757	0.515
Sens 1	70%	75%	71%	70%	71%	71%	72%	70%	70%
Spec 1	26%	12%	26%	20%	18%	16%	19%	26%	19%
Cutoff 2	0.393	0.130	0.393	0.153	0.260	0.153	0.172	0.178	0.177
Sens 2	80%	81%	80%	80%	81%	81%	83%	80%	80%
Spec 2	16%	10%	16%	10%	13%	10%	11%	12%	10%
Cutoff 3	0.103	0.00323	0.103	0.00463	0.00129	0.0258	0.0258	0.0258	0.0994
Sens 3	90%	94%	91%	90%	90%	90%	93%	95%	90%
Spec 3	9%	5%	9%	6%	2%	7%	6%	6%	9%

	0hr prior to AKI stage			24hr prior to AKI stage			48hr prior to AKI stage		
	sCr or UO	sCr only	UO only	sCr or UO	sCr only	UO only	sCr or UO	sCr only	UO only
Cutoff 4	7.24	6.96	6.93	7.24	6.96	6.93	7.24	6.96	6.93
Sens 4	33%	12%	37%	26%	14%	29%	15%	20%	15%
Spec 4	70%	70%	70%	70%	70%	70%	70%	70%	70%
Cutoff 5	12.6	12.4	11.5	12.6	12.4	11.5	12.6	12.4	11.5
Sens 5	17%	0%	28%	22%	10%	26%	7%	5%	10%
Spec 5	80%	80%	80%	80%	80%	80%	80%	80%	80%
Cutoff 6	28.1	26.8	27.0	28.1	26.8	27.0	28.1	26.8	27.0
Sens 6	6%	0%	11%	9%	5%	10%	2%	0%	2%
Spec 6	90%	90%	90%	90%	90%	90%	90%	90%	90%
OR Quart 2	0.63	3.0	0.87	0.94	2.0	0.79	1.5	2.5	1.5
p Value	0.22	0.34	0.71	0.86	0.42	0.50	0.43	0.27	0.43
95% CI of	0.31	0.31	0.43	0.48	0.37	0.40	0.53	0.49	0.53
OR Quart2	1.3	29	1.8	1.8	11	1.6	4.3	13	4.3
OR Quart 3	0.84	3.0	0.63	0.78	3.0	0.53	2.4	3.6	1.7
p Value	0.61	0.34	0.25	0.48	0.17	0.10	0.076	0.12	0.31
95% CI of	0.43	0.31	0.29	0.39	0.61	0.25	0.91	0.73	0.61
OR Quart3	1.6	29	1.4	1.6	15	1.1	6.4	17	4.7
OR Quart 4	1.0	9.2	1.3	1.5	4.6	1.3	3.0	3.0	2.6
p Value	0.99	0.036	0.41	0.17	0.052	0.35	0.024	0.18	0.052
95% CI of	0.53	1.2	0.68	0.83	0.99	0.73	1.2	0.61	0.99
OR Quart4	1.9	73	2.5	2.8	21	2.5	7.7	15	6.8

Apolipoprotein(a)

sCr or UO	0hr prior to AKI stage		24hr prior to AKI stage		48hr prior to AKI stage	
	Cohort 1	Cohort 2	Cohort 1	Cohort 2	Cohort 1	Cohort 2
Median	2.16	2.88	2.16	3.39	2.16	2.04
Average	46.7	10.1	46.7	23.9	46.7	5.40
Stdev	602	22.6	602	97.8	602	13.0
p(t-test)		0.62		0.74		0.66
Min	0.00241	0.00241	0.00241	0.00838	0.00241	0.00838
Max	17500	118	17500	802	17500	75.7
n (Samp)	953	65	953	75	953	41
n (Patient)	381	65	381	75	381	41

sCr only	0hr prior to AKI stage		24hr prior to AKI stage		48hr prior to AKI stage	
	Cohort 1	Cohort 2	Cohort 1	Cohort 2	Cohort 1	Cohort 2
Median	2.09	1.68	2.09	3.09	2.09	2.25
Average	39.7	3.70	39.7	5.16	39.7	11.5
Stdev	523	6.91	523	8.41	523	21.6
p(t-test)		0.80		0.77		0.81
Min	0.00241	0.0122	0.00241	0.00479	0.00241	0.00838
Max	17500	27.0	17500	37.7	17500	91.1
n (Samp)	1273	14	1273	20	1273	19
n (Patient)	466	14	466	20	466	19

UO only	0hr prior to AKI stage		24hr prior to AKI stage		48hr prior to AKI stage	
	Cohort 1	Cohort 2	Cohort 1	Cohort 2	Cohort 1	Cohort 2

UO only	0hr prior to AKI stage		24hr prior to AKI stage		48hr prior to AKI stage	
	Cohort 1	Cohort 2	Cohort 1	Cohort 2	Cohort 1	Cohort 2
Median	2.19	2.95	2.19	3.88	2.19	2.13
Average	46.2	20.7	46.2	26.4	46.2	6.18
Stdev	637	81.1	637	102	637	14.0
p(t-test)		0.76		0.80		0.71
Min	0.00241	0.00241	0.00241	0.00838	0.00241	0.0122
Max	17500	618	17500	802	17500	75.7
n (Samp)	845	61	845	68	845	35
n (Patient)	305	61	305	68	305	35

	0hr prior to AKI stage			24hr prior to AKI stage			48hr prior to AKI stage		
	sCr or UO	sCr only	UO only	sCr or UO	sCr only	UO only	sCr or UO	sCr only	UO only
AUC	0.56	0.45	0.59	0.60	0.54	0.64	0.49	0.53	0.54
SE	0.038	0.080	0.039	0.036	0.066	0.037	0.046	0.068	0.051
p	0.10	0.49	0.020	0.0058	0.58	2.2E-4	0.89	0.64	0.44
nCohort 1	953	1273	845	953	1273	845	953	1273	845
nCohort 2	65	14	61	75	20	68	41	19	35
Cutoff 1	1.40	0.892	1.82	1.65	1.65	1.82	1.18	0.971	1.38
Sens 1	71%	71%	70%	71%	70%	71%	71%	74%	71%
Spec 1	39%	28%	46%	44%	44%	46%	33%	30%	38%
Cutoff 2	0.917	0.108	0.977	1.20	0.751	1.26	0.826	0.0122	0.977
Sens 2	80%	86%	80%	80%	80%	81%	80%	84%	80%
Spec 2	28%	11%	31%	34%	25%	35%	26%	6%	31%
Cutoff 3	0.108	0.0847	0.108	0.0847	0.0140	0.509	0.182	0.00790	0.699
Sens 3	91%	93%	92%	91%	90%	91%	90%	100%	91%
Spec 3	13%	11%	12%	12%	7%	22%	14%	1%	25%
Cutoff 4	3.89	3.89	3.74	3.89	3.89	3.74	3.89	3.89	3.74
Sens 4	37%	14%	43%	44%	40%	53%	24%	42%	31%
Spec 4	70%	70%	70%	70%	70%	70%	70%	70%	70%
Cutoff 5	5.71	5.71	5.25	5.71	5.71	5.25	5.71	5.71	5.25
Sens 5	25%	7%	28%	31%	15%	40%	12%	37%	20%
Spec 5	80%	80%	80%	80%	80%	80%	80%	80%	80%
Cutoff 6	17.0	18.8	13.7	17.0	18.8	13.7	17.0	18.8	13.7
Sens 6	15%	7%	18%	15%	5%	19%	5%	16%	6%
Spec 6	90%	90%	90%	90%	90%	90%	90%	90%	90%
OR Quart 2	1.1	2.0	1.1	1.4	1.0	1.8	1.0	0.80	4.0
p Value	0.85	0.42	0.83	0.42	1.0	0.20	0.99	0.74	0.016
95% CI of	0.48	0.37	0.46	0.62	0.25	0.74	0.39	0.21	1.3
OR Quart2	2.4	11	2.6	3.1	4.0	4.4	2.6	3.0	12
OR Quart 3	1.7	2.0	2.0	2.1	1.5	2.1	1.8	0.40	1.5
p Value	0.15	0.42	0.089	0.052	0.53	0.100	0.16	0.27	0.53
95% CI of	0.82	0.37	0.90	0.99	0.42	0.87	0.79	0.076	0.42
OR Quart3	3.6	11	4.4	4.4	5.4	5.0	4.2	2.1	5.4
OR Quart 4	1.7	2.0	2.2	2.6	1.5	4.1	0.77	1.6	2.6
p Value	0.15	0.42	0.046	0.0090	0.53	5.2E-4	0.62	0.40	0.12
95% CI of	0.82	0.37	1.0	1.3	0.42	1.9	0.28	0.52	0.79
OR Quart4	3.6	11	4.8	5.4	5.4	9.3	2.1	5.0	8.3

[0184] Fig. 3: Comparison of marker levels in urine samples collected within 12 hours of reaching stage R from Cohort 1 (patients that reached, but did not progress beyond, RIFLE stage R) and from Cohort 2 (patients that reached RIFLE stage I or F).

C-C motif chemokine 7

	sCr or UO		sCr only		UO only	
	Cohort 1	Cohort 2	Cohort 1	Cohort 2	Cohort 1	Cohort 2
Median	0.737	0.625	0.515	0.428	0.816	0.625
Average	3.18	2.02	2.28	1.04	3.91	1.08
Stdev	15.8	5.30	6.57	1.96	17.8	1.64
p(t-test)		0.63		0.49		0.38
Min	0.146	0.146	0.146	0.146	0.146	0.264
Max	161	33.0	33.0	7.75	161	7.33
n (Samp)	124	45	49	14	97	31
n (Patient)	124	45	49	14	97	31

	At Enrollment		
	sCr or UO	sCr only	UO only
AUC	0.45	0.44	0.40
SE	0.051	0.089	0.060
p	0.37	0.48	0.086
nCohort 1	124	49	97
nCohort 2	45	14	31
Cutoff 1	0.341	0.319	0.515
Sens 1	71%	79%	71%
Spec 1	25%	20%	27%
Cutoff 2	0.320	0.146	0.336
Sens 2	80%	93%	81%
Spec 2	19%	6%	20%
Cutoff 3	0.264	0.146	0.319
Sens 3	91%	93%	90%
Spec 3	6%	6%	11%
Cutoff 4	1.04	0.812	1.15
Sens 4	22%	21%	13%
Spec 4	73%	73%	77%
Cutoff 5	1.15	1.04	1.29
Sens 5	20%	14%	10%
Spec 5	81%	84%	82%
Cutoff 6	1.59	1.59	6.92
Sens 6	11%	7%	3%
Spec 6	92%	92%	91%
OR Quart 2	0.78	1.4	2.3
p Value	0.64	0.67	0.21
95% CI of	0.27	0.27	0.62
OR Quart2	2.2	7.8	8.7
OR Quart 3	2.0	1.0	3.2
p Value	0.14	1.0	0.078
95% CI of	0.79	0.17	0.88
OR Quart3	5.2	5.9	12

	At Enrollment		
	sCr or UO	sCr only	UO only
OR Quart 4	1.2	1.6	2.7
p Value	0.75	0.60	0.13
95% CI of	0.44	0.29	0.75
OR Quart4	3.1	8.6	10

Interleukin-33

	sCr or UO		sCr only		UO only	
	Cohort 1	Cohort 2	Cohort 1	Cohort 2	Cohort 1	Cohort 2
Median	22.3	38.9	18.4	33.3	23.5	39.6
Average	34.5	48.9	32.2	42.7	36.8	54.2
Stdev	34.0	41.1	33.2	33.6	37.8	42.3
p(t-test)		0.023		0.30		0.032
Min	0.0232	0.0591	0.0232	0.0591	0.0232	0.0645
Max	138	148	138	136	203	148
n (Samp)	124	45	49	14	97	31
n (Patient)	124	45	49	14	97	31

	At Enrollment		
	sCr or UO	sCr only	UO only
AUC	0.61	0.62	0.64
SE	0.051	0.089	0.060
p	0.028	0.16	0.020
nCohort 1	124	49	97
nCohort 2	45	14	31
Cutoff 1	23.5	22.7	26.3
Sens 1	71%	71%	71%
Spec 1	52%	55%	54%
Cutoff 2	14.6	18.6	19.4
Sens 2	80%	86%	81%
Spec 2	40%	53%	46%
Cutoff 3	0.0879	12.9	13.7
Sens 3	91%	93%	90%
Spec 3	14%	39%	37%
Cutoff 4	48.0	46.3	53.0
Sens 4	33%	36%	39%
Spec 4	70%	71%	70%
Cutoff 5	65.3	59.3	70.3
Sens 5	29%	14%	29%
Spec 5	81%	82%	80%
Cutoff 6	82.3	80.5	88.8
Sens 6	18%	7%	19%
Spec 6	90%	92%	91%
OR Quart 2	1.4	3.2	3.2
p Value	0.58	0.34	0.11
95% CI of	0.46	0.30	0.77
OR Quart2	4.1	35	14
OR Quart 3	3.1	8.4	3.8

	At Enrollment		
	sCr or UO	sCr only	UO only
p Value	0.031	0.066	0.066
95% CI of	1.1	0.87	0.92
OR Quart3	8.6	81	16
OR Quart 4	2.2	4.7	5.1
p Value	0.15	0.19	0.023
95% CI of	0.77	0.46	1.3
OR Quart4	6.1	48	20

Interleukin-4 receptor alpha chain

	sCr or UO		sCr only		UO only	
	Cohort 1	Cohort 2	Cohort 1	Cohort 2	Cohort 1	Cohort 2
Median	46.2	69.6	47.1	80.3	46.2	69.6
Average	56.0	74.5	53.5	62.1	60.2	80.6
Stdev	50.9	55.4	37.9	40.8	56.9	62.8
p(t-test)		0.081		0.54		0.15
Min	2.31	7.12	2.31	4.67	2.31	10.3
Max	256	239	122	119	256	239
n (Samp)	90	34	34	10	71	22
n (Patient)	90	34	34	10	71	22

	At Enrollment		
	sCr or UO	sCr only	UO only
AUC	0.63	0.57	0.63
SE	0.058	0.11	0.071
p	0.027	0.50	0.066
nCohort 1	90	34	71
nCohort 2	34	10	22
Cutoff 1	40.7	49.3	25.4
Sens 1	71%	70%	73%
Spec 1	39%	56%	37%
Cutoff 2	12.4	11.7	20.5
Sens 2	82%	80%	82%
Spec 2	33%	26%	35%
Cutoff 3	11.8	4.67	11.8
Sens 3	91%	90%	91%
Spec 3	28%	6%	25%
Cutoff 4	69.4	79.9	68.1
Sens 4	50%	50%	55%
Spec 4	70%	71%	70%
Cutoff 5	93.9	94.4	105
Sens 5	35%	10%	27%
Spec 5	80%	82%	80%
Cutoff 6	115	104	137
Sens 6	15%	10%	14%
Spec 6	90%	91%	90%
OR Quart 2	2.3	0.45	3.7
p Value	0.21	0.54	0.14

	At Enrollment		
	sCr or UO	sCr only	UO only
95% CI of	0.63	0.035	0.66
OR Quart2	8.8	5.8	21
OR Quart 3	3.2	2.6	3.7
p Value	0.077	0.35	0.14
95% CI of	0.88	0.36	0.66
OR Quart3	12	18	21
OR Quart 4	4.3	1.7	5.2
p Value	0.026	0.61	0.053
95% CI of	1.2	0.22	0.98
OR Quart4	15	13	28

Lutropin subunit beta

	sCr or UO		sCr only		UO only	
	Cohort 1	Cohort 2	Cohort 1	Cohort 2	Cohort 1	Cohort 2
Median	16.9	10.4	nd	nd	20.2	27.2
Average	45.9	40.9	nd	nd	41.3	64.1
Stdev	67.7	70.4	nd	nd	61.1	97.6
p(t-test)		0.75	nd	nd		0.27
Min	0.211	0.0858	nd	nd	0.311	0.0858
Max	268	277	nd	nd	268	325
n (Samp)	54	28	nd	nd	40	20
n (Patient)	54	28	nd	nd	40	20

	At Enrollment		
	sCr or UO	sCr only	UO only
AUC	0.45	nd	0.52
SE	0.068	nd	0.080
p	0.42	nd	0.77
nCohort 1	54	nd	40
nCohort 2	28	nd	20
Cutoff 1	4.22	nd	8.91
Sens 1	71%	nd	70%
Spec 1	24%	nd	40%
Cutoff 2	2.03	nd	4.22
Sens 2	82%	nd	80%
Spec 2	19%	nd	20%
Cutoff 3	0.388	nd	0.388
Sens 3	93%	nd	90%
Spec 3	7%	nd	8%
Cutoff 4	42.8	nd	43.5
Sens 4	25%	nd	35%
Spec 4	70%	nd	70%
Cutoff 5	68.4	nd	59.7
Sens 5	14%	nd	25%
Spec 5	81%	nd	80%
Cutoff 6	162	nd	76.4

	At Enrollment		
	sCr or UO	sCr only	UO only
Sens 6	7%	nd	20%
Spec 6	91%	nd	90%
OR Quart 2	1.3	nd	0.38
p Value	0.66	nd	0.24
95% CI of	0.36	nd	0.073
OR Quart2	5.0	nd	1.9
OR Quart 3	1.2	nd	1.0
p Value	0.74	nd	1.0
95% CI of	0.34	nd	0.23
OR Quart3	4.6	nd	4.3
OR Quart 4	1.7	nd	0.75
p Value	0.44	nd	0.71
95% CI of	0.45	nd	0.17
OR Quart4	6.1	nd	3.3

Platelet-derived growth factor subunit B (dimer)

	sCr or UO		sCr only		UO only	
	Cohort 1	Cohort 2	Cohort 1	Cohort 2	Cohort 1	Cohort 2
Median	1.82	2.07	2.78	1.24	1.71	1.76
Average	3.46	2.36	5.94	1.92	2.45	2.25
Stdev	9.80	2.42	15.1	2.62	2.77	2.39
p(t-test)		0.53		0.41		0.76
Min	0.00313	0.00369	0.0244	0.0144	0.00313	0.00369
Max	86.2	10.8	86.2	8.93	17.1	10.8
n (Samp)	77	33	31	10	61	24
n (Patient)	77	33	31	10	61	24

	At Enrollment		
	sCr or UO	sCr only	UO only
AUC	0.48	0.25	0.49
SE	0.061	0.097	0.070
p	0.73	0.0084	0.84
nCohort 1	77	31	61
nCohort 2	33	10	24
Cutoff 1	0.484	0.463	0.545
Sens 1	73%	70%	71%
Spec 1	18%	3%	21%
Cutoff 2	0.365	0.0244	0.365
Sens 2	82%	80%	83%
Spec 2	17%	3%	20%
Cutoff 3	0.0144	0	0.0244
Sens 3	91%	100%	92%
Spec 3	3%	0%	11%
Cutoff 4	3.07	3.71	3.00
Sens 4	27%	10%	29%
Spec 4	70%	71%	70%
Cutoff 5	3.71	4.20	3.42

	At Enrollment		
	sCr or UO	sCr only	UO only
Sens 5	21%	10%	25%
Spec 5	81%	81%	80%
Cutoff 6	6.35	8.43	5.18
Sens 6	6%	10%	4%
Spec 6	91%	90%	90%
OR Quart 2	0.89	1.1	1.1
p Value	0.84	0.94	0.92
95% CI of	0.28	0.060	0.28
OR Quart2	2.8	20	4.0
OR Quart 3	0.46	4.3	0.63
p Value	0.22	0.25	0.53
95% CI of	0.13	0.37	0.15
OR Quart3	1.6	50	2.6
OR Quart 4	1.5	10	1.6
p Value	0.51	0.060	0.45
95% CI of	0.48	0.91	0.45
OR Quart4	4.4	110	5.9

Corticotropin

	sCr or UO		sCr only		UO only	
	Cohort 1	Cohort 2	Cohort 1	Cohort 2	Cohort 1	Cohort 2
Median	0.00163	0.00194	nd	nd	0.00163	0.00171
Average	0.00250	0.00276	nd	nd	0.00260	0.00164
Stdev	0.00498	0.00438	nd	nd	0.00550	0.000678
p(t-test)		0.82	nd	nd		0.49
Min	3.92E-6	0.000355	nd	nd	0.000355	0.000355
Max	0.0373	0.0224	nd	nd	0.0373	0.00282
n (Samp)	53	23	nd	nd	43	16
n (Patient)	53	23	nd	nd	43	16

	At Enrollment		
	sCr or UO	sCr only	UO only
AUC	0.53	nd	0.47
SE	0.073	nd	0.086
p	0.66	nd	0.73
nCohort 1	53	nd	43
nCohort 2	23	nd	16
Cutoff 1	0.00119	nd	0.00134
Sens 1	74%	nd	75%
Spec 1	30%	nd	35%
Cutoff 2	0.00111	nd	0.00111
Sens 2	87%	nd	81%
Spec 2	23%	nd	21%
Cutoff 3	0.000909	nd	0.000355
Sens 3	91%	nd	94%
Spec 3	23%	nd	5%
Cutoff 4	0.00222	nd	0.00222

	At Enrollment		
	sCr or UO	sCr only	UO only
Sens 4	26%	nd	12%
Spec 4	72%	nd	72%
Cutoff 5	0.00291	nd	0.00256
Sens 5	13%	nd	12%
Spec 5	85%	nd	81%
Cutoff 6	0.00362	nd	0.00304
Sens 6	13%	nd	0%
Spec 6	91%	nd	91%
OR Quart 2	1.0	nd	4.3
p Value	1.0	nd	0.11
95% CI of	0.24	nd	0.71
OR Quart2	4.2	nd	27
OR Quart 3	1.6	nd	2.4
p Value	0.49	nd	0.37
95% CI of	0.41	nd	0.36
OR Quart3	6.5	nd	15
OR Quart 4	1.3	nd	2.6
p Value	0.72	nd	0.32
95% CI of	0.32	nd	0.39
OR Quart4	5.3	nd	17

Thyroxine-binding globulin

	sCr or UO		sCr only		UO only	
	Cohort 1	Cohort 2	Cohort 1	Cohort 2	Cohort 1	Cohort 2
Median	0.0750	0.136	nd	nd	0.0894	0.150
Average	0.225	0.184	nd	nd	0.263	0.191
Stdev	0.373	0.205	nd	nd	0.411	0.184
p(t-test)		0.62	nd	nd		0.50
Min	8.30E-5	0.00330	nd	nd	0.00106	0.00330
Max	1.86	0.748	nd	nd	1.86	0.564
n (Samp)	52	23	nd	nd	43	16
n (Patient)	52	23	nd	nd	43	16

	At Enrollment		
	sCr or UO	sCr only	UO only
AUC	0.52	nd	0.51
SE	0.073	nd	0.085
p	0.83	nd	0.93
nCohort 1	52	nd	43
nCohort 2	23	nd	16
Cutoff 1	0.0183	nd	0.0179
Sens 1	74%	nd	75%
Spec 1	27%	nd	28%
Cutoff 2	0.0138	nd	0.0119
Sens 2	83%	nd	81%
Spec 2	19%	nd	21%
Cutoff 3	0.00575	nd	0.00330

	At Enrollment		
	sCr or UO	sCr only	UO only
Sens 3	91%	nd	94%
Spec 3	12%	nd	5%
Cutoff 4	0.212	nd	0.296
Sens 4	35%	nd	31%
Spec 4	71%	nd	72%
Cutoff 5	0.369	nd	0.468
Sens 5	13%	nd	12%
Spec 5	83%	nd	81%
Cutoff 6	0.486	nd	0.792
Sens 6	9%	nd	0%
Spec 6	90%	nd	91%
OR Quart 2	0.93	nd	0.62
p Value	0.92	nd	0.59
95% CI of	0.22	nd	0.11
OR Quart2	4.0	nd	3.5
OR Quart 3	1.5	nd	1.7
p Value	0.56	nd	0.52
95% CI of	0.38	nd	0.35
OR Quart3	6.1	nd	7.9
OR Quart 4	1.2	nd	0.62
p Value	0.80	nd	0.59
95% CI of	0.29	nd	0.11
OR Quart4	4.9	nd	3.5

Alpha-fetoprotein

	sCr or UO		sCr only		UO only	
	Cohort 1	Cohort 2	Cohort 1	Cohort 2	Cohort 1	Cohort 2
Median	0.00505	0.00587	0.00428	0.0385	0.00486	0.00587
Average	0.0525	0.122	0.0656	0.297	0.0435	0.0801
Stdev	0.106	0.321	0.126	0.568	0.0900	0.196
p(t-test)		0.083		0.037		0.22
Min	0.000463	0.000463	0.000463	0.000523	0.000463	0.000463
Max	0.585	1.74	0.585	1.74	0.507	0.840
n (Samp)	79	40	31	9	62	31
n (Patient)	79	40	31	9	62	31

	At Enrollment		
	sCr or UO	sCr only	UO only
AUC	0.50	0.67	0.50
SE	0.056	0.11	0.064
p	0.99	0.12	0.96
nCohort 1	79	31	62
nCohort 2	40	9	31
Cutoff 1	0.00286	0.00483	0.00132
Sens 1	70%	78%	74%
Spec 1	18%	55%	15%
Cutoff 2	0.000463	0.000523	0.000463

	At Enrollment		
	sCr or UO	sCr only	UO only
Sens 2	85%	89%	90%
Spec 2	8%	19%	6%
Cutoff 3	0	0.000463	0.000463
Sens 3	100%	100%	90%
Spec 3	0%	19%	6%
Cutoff 4	0.0499	0.0671	0.00660
Sens 4	25%	44%	32%
Spec 4	72%	71%	71%
Cutoff 5	0.0728	0.107	0.0613
Sens 5	22%	44%	19%
Spec 5	81%	81%	81%
Cutoff 6	0.198	0.236	0.130
Sens 6	10%	22%	16%
Spec 6	91%	90%	90%
OR Quart 2	0.43	0	2.2
p Value	0.14	na	0.19
95% CI of	0.14	na	0.67
OR Quart2	1.3	na	7.4
OR Quart 3	0.82	1.7	0.36
p Value	0.71	0.61	0.19
95% CI of	0.29	0.22	0.081
OR Quart3	2.3	13	1.6
OR Quart 4	0.71	2.7	1.9
p Value	0.52	0.34	0.31
95% CI of	0.25	0.36	0.56
OR Quart4	2.0	20	6.2

Apolipoprotein E

	sCr or UO		sCr only		UO only	
	Cohort 1	Cohort 2	Cohort 1	Cohort 2	Cohort 1	Cohort 2
Median	3.11	1.74	1.37	1.13	4.13	1.77
Average	24.3	6.24	8.39	3.15	27.8	6.55
Stdev	169	12.6	34.1	6.55	190	13.7
p(t-test)		0.41		0.55		0.46
Min	0.00102	0.000147	0.000147	0.000147	0.00122	0.00129
Max	1960	83.4	254	26.8	1960	83.4
n (Samp)	137	59	56	16	107	43
n (Patient)	137	59	56	16	107	43

	At Enrollment		
	sCr or UO	sCr only	UO only
AUC	0.45	0.44	0.42
SE	0.045	0.083	0.053
p	0.24	0.46	0.15
nCohort 1	137	56	107
nCohort 2	59	16	43
Cutoff 1	0.957	0.177	1.00

	At Enrollment		
	sCr or UO	sCr only	UO only
Sens 1	71%	75%	72%
Spec 1	34%	23%	31%
Cutoff 2	0.551	0.0954	0.551
Sens 2	81%	81%	81%
Spec 2	20%	16%	17%
Cutoff 3	0.0862	0.00122	0.0954
Sens 3	92%	94%	91%
Spec 3	9%	5%	7%
Cutoff 4	7.35	3.25	9.11
Sens 4	19%	25%	19%
Spec 4	70%	71%	71%
Cutoff 5	14.2	4.55	17.3
Sens 5	12%	12%	12%
Spec 5	80%	80%	80%
Cutoff 6	25.4	14.2	30.5
Sens 6	7%	6%	2%
Spec 6	91%	91%	91%
OR Quart 2	1.9	1.4	1.2
p Value	0.17	0.67	0.74
95% CI of	0.76	0.27	0.41
OR Quart2	4.7	7.5	3.6
OR Quart 3	2.3	1.4	2.4
p Value	0.077	0.67	0.084
95% CI of	0.92	0.27	0.89
OR Quart3	5.6	7.5	6.8
OR Quart 4	1.7	1.9	1.6
p Value	0.25	0.43	0.39
95% CI of	0.68	0.38	0.55
OR Quart4	4.3	9.6	4.5

[0185] Fig. 4: Comparison of the maximum marker levels in urine samples collected from Cohort 1 (patients that did not progress beyond RIFLE stage 0) and the maximum values in urine samples collected from subjects between enrollment and 0, 24 hours, and 48 hours prior to reaching stage F in Cohort 2.

Complement C4-B

sCr or UO	0hr prior to AKI stage		24hr prior to AKI stage		48hr prior to AKI stage	
	Cohort 1	Cohort 2	Cohort 1	Cohort 2	Cohort 1	Cohort 2
Median	24.7	74.8	24.7	63.2	24.7	53.0
Average	80.6	110	80.6	103	80.6	92.3
Stdev	182	165	182	163	182	110
p(t-test)		0.41		0.52		0.80
Min	0.00607	0.499	0.00607	0.499	0.00607	3.05
Max	1950	827	1950	827	1950	425
n (Samp)	223	30	223	30	223	16
n (Patient)	223	30	223	30	223	16

sCr only	0hr prior to AKI stage	24hr prior to AKI stage	48hr prior to AKI stage

	Cohort 1	Cohort 2	Cohort 1	Cohort 2	Cohort 1	Cohort 2
Median	35.2	71.6	35.2	71.6	35.2	71.6
Average	106	101	106	101	106	115
Stdev	206	118	206	118	206	142
p(t-test)		0.94		0.94		0.90
Min	0.00607	0.499	0.00607	0.499	0.00607	17.0
Max	2000	425	2000	425	2000	425
n (Samp)	374	13	374	13	374	7
n (Patient)	374	13	374	13	374	7

UO only	0hr prior to AKI stage		24hr prior to AKI stage		48hr prior to AKI stage	
	Cohort 1	Cohort 2	Cohort 1	Cohort 2	Cohort 1	Cohort 2
Median	28.0	78.0	28.0	71.6	28.0	63.2
Average	88.7	111	88.7	103	88.7	84.8
Stdev	187	169	187	168	187	72.8
p(t-test)		0.59		0.73		0.94
Min	0.00329	0.904	0.00329	0.672	0.00329	3.05
Max	1950	827	1950	827	1950	236
n (Samp)	173	23	173	23	173	14
n (Patient)	173	23	173	23	173	14

	0hr prior to AKI stage			24hr prior to AKI stage			48hr prior to AKI stage		
	sCr or UO	sCr only	UO only	sCr or UO	sCr only	UO only	sCr or UO	sCr only	UO only
AUC	0.60	0.55	0.60	0.59	0.55	0.58	0.63	0.64	0.61
SE	0.058	0.084	0.066	0.058	0.084	0.066	0.077	0.11	0.083
p	0.080	0.54	0.12	0.14	0.54	0.20	0.085	0.22	0.18
nCohort 1	223	374	173	223	374	173	223	374	173
nCohort 2	30	13	23	30	13	23	16	7	14
Cutoff 1	16.9	17.0	16.9	16.9	17.0	16.9	17.8	47.7	30.8
Sens 1	70%	77%	74%	70%	77%	74%	75%	71%	71%
Spec 1	44%	34%	38%	44%	34%	38%	45%	56%	51%
Cutoff 2	8.71	5.52	8.98	5.52	5.52	8.71	17.0	32.9	16.9
Sens 2	80%	85%	83%	80%	85%	83%	81%	86%	86%
Spec 2	35%	19%	27%	26%	19%	27%	44%	48%	38%
Cutoff 3	2.76	0.923	4.28	2.22	0.923	2.76	4.27	17.0	4.27
Sens 3	90%	92%	91%	90%	92%	91%	94%	100%	93%
Spec 3	16%	4%	17%	13%	4%	10%	22%	34%	16%
Cutoff 4	57.6	87.6	63.7	57.6	87.6	63.7	57.6	87.6	63.7
Sens 4	53%	38%	57%	50%	38%	52%	44%	29%	50%
Spec 4	70%	70%	71%	70%	70%	71%	70%	70%	71%
Cutoff 5	106	150	128	106	150	128	106	150	128
Sens 5	37%	23%	35%	33%	23%	30%	31%	14%	36%
Spec 5	80%	80%	80%	80%	80%	80%	80%	80%	80%
Cutoff 6	213	260	229	213	260	229	213	260	229
Sens 6	10%	8%	9%	7%	8%	4%	12%	14%	7%
Spec 6	90%	90%	90%	90%	90%	90%	90%	90%	90%
OR Quart 2	1.4	0.65	1.7	1.0	0.65	1.0	1.5	>2.0	0.98
p Value	0.55	0.64	0.47	1.0	0.64	1.0	0.66	<0.56	0.98
95% CI of	0.43	0.11	0.39	0.30	0.11	0.24	0.24	>0.18	0.13

	0hr prior to AKI stage			24hr prior to AKI stage			48hr prior to AKI stage		
	sCr or UO	sCr only	UO only	sCr or UO	sCr only	UO only	sCr or UO	sCr only	UO only
OR Quart2	4.8	4.0	7.7	3.3	4.0	4.2	9.3	na	7.3
OR Quart 3	0.79	1.3	2.1	0.82	1.3	1.9	2.0	>3.1	2.0
p Value	0.73	0.71	0.30	0.75	0.71	0.34	0.42	<0.33	0.42
95% CI of	0.20	0.29	0.50	0.24	0.29	0.51	0.36	>0.32	0.36
OR Quart3	3.1	6.1	9.1	2.8	6.1	6.9	12	na	12
OR Quart 4	3.2	1.3	3.4	2.4	1.3	2.2	3.8	>2.0	3.2
p Value	0.034	0.71	0.077	0.095	0.71	0.23	0.11	<0.57	0.17
95% CI of	1.1	0.29	0.87	0.86	0.29	0.61	0.75	>0.18	0.61
OR Quart4	9.7	6.1	14	6.8	6.1	7.8	19	na	17

C-C motif chemokine 26

sCr or UO	0hr prior to AKI stage		24hr prior to AKI stage		48hr prior to AKI stage	
	Cohort 1	Cohort 2	Cohort 1	Cohort 2	Cohort 1	Cohort 2
Median	0.0402	0.0421	0.0402	0.0405	0.0402	0.0379
Average	0.0784	1.93	0.0784	1.93	0.0784	0.0347
Stdev	0.610	8.08	0.610	8.08	0.610	0.0128
p(t-test)		7.9E-4		8.0E-4		0.78
Min	0.00872	0.00872	0.00872	0.00872	0.00872	0.0195
Max	9.14	42.3	9.14	42.3	9.14	0.0526
n (Samp)	223	30	223	30	223	16
n (Patient)	223	30	223	30	223	16

sCr only	0hr prior to AKI stage		24hr prior to AKI stage		48hr prior to AKI stage	
	Cohort 1	Cohort 2	Cohort 1	Cohort 2	Cohort 1	Cohort 2
Median	0.0438	0.0402	0.0438	0.0402	0.0438	0.0443
Average	0.408	0.0374	0.408	0.0359	0.408	0.0393
Stdev	3.41	0.0150	3.41	0.0152	3.41	0.0124
p(t-test)		0.70		0.69		0.78
Min	0.00872	0.00872	0.00872	0.00872	0.00872	0.0195
Max	42.3	0.0633	42.3	0.0633	42.3	0.0526
n (Samp)	375	13	375	13	375	7
n (Patient)	375	13	375	13	375	7

UO only	0hr prior to AKI stage		24hr prior to AKI stage		48hr prior to AKI stage	
	Cohort 1	Cohort 2	Cohort 1	Cohort 2	Cohort 1	Cohort 2
Median	0.0443	0.0433	0.0443	0.0433	0.0443	0.0363
Average	0.0482	2.91	0.0482	2.83	0.0482	0.0340
Stdev	0.0942	9.28	0.0942	9.23	0.0942	0.0117
p(t-test)		5.6E-5		7.9E-5		0.57
Min	0.00872	0.0196	0.00872	0.0196	0.00872	0.0196
Max	1.25	42.3	1.25	42.3	1.25	0.0525
n (Samp)	173	23	173	23	173	14
n (Patient)	173	23	173	23	173	14

	0hr prior to AKI stage			24hr prior to AKI stage			48hr prior to AKI stage		
	sCr or UO	sCr only	UO only	sCr or UO	sCr only	UO only	sCr or UO	sCr only	UO only

	0hr prior to AKI stage			24hr prior to AKI stage			48hr prior to AKI stage		
	sCr or UO	sCr only	UO only	sCr or UO	sCr only	UO only	sCr or UO	sCr only	UO only
AUC	0.55	0.44	0.53	0.51	0.42	0.48	0.47	0.47	0.38
SE	0.057	0.084	0.065	0.057	0.084	0.065	0.076	0.11	0.083
p	0.37	0.48	0.62	0.85	0.37	0.81	0.66	0.79	0.15
nCohort 1	223	375	173	223	375	173	223	375	173
nCohort 2	30	13	23	30	13	23	16	7	14
Cutoff 1	0.0311	0.0240	0.0386	0.0235	0.0235	0.0232	0.0232	0.0433	0.0232
Sens 1	70%	77%	74%	73%	77%	78%	75%	71%	79%
Spec 1	47%	30%	41%	39%	27%	28%	39%	47%	28%
Cutoff 2	0.0232	0.0232	0.0232	0.0231	0.0232	0.0231	0.0196	0.0232	0.0196
Sens 2	83%	85%	87%	80%	85%	83%	81%	86%	86%
Spec 2	39%	27%	28%	32%	27%	23%	15%	27%	13%
Cutoff 3	0.0196	0.0188	0.0231	0.0195	0.0188	0.0196	0.0195	0.0188	0.0195
Sens 3	90%	92%	91%	93%	92%	91%	94%	100%	100%
Spec 3	15%	8%	23%	15%	8%	13%	15%	8%	13%
Cutoff 4	0.0504	0.0525	0.0525	0.0504	0.0525	0.0525	0.0504	0.0525	0.0525
Sens 4	23%	15%	22%	20%	15%	17%	12%	14%	0%
Spec 4	78%	76%	77%	78%	76%	77%	78%	76%	77%
Cutoff 5	0.0525	0.0526	0.0526	0.0525	0.0526	0.0526	0.0525	0.0526	0.0526
Sens 5	20%	8%	22%	17%	8%	17%	6%	0%	0%
Spec 5	85%	82%	86%	85%	82%	86%	85%	82%	86%
Cutoff 6	0.0628	0.0628	0.0628	0.0628	0.0628	0.0628	0.0628	0.0628	0.0628
Sens 6	17%	8%	22%	13%	8%	17%	0%	0%	0%
Spec 6	95%	90%	92%	95%	90%	92%	95%	90%	92%
OR Quart 2	2.5	1.5	4.4	1.4	1.5	0.78	3.2	3.1	3.1
p Value	0.15	0.65	0.030	0.57	0.65	0.73	0.16	0.33	0.33
95% CI of	0.72	0.25	1.2	0.45	0.25	0.20	0.62	0.32	0.31
OR Quart2	8.4	9.3	17	4.2	9.3	3.1	17	30	31
OR Quart 3	2.8	3.1	1.0	1.8	3.1	2.3	2.1	2.0	8.0
p Value	0.099	0.17	1.0	0.29	0.17	0.17	0.41	0.57	0.056
95% CI of	0.82	0.62	0.19	0.61	0.62	0.71	0.36	0.18	0.95
OR Quart3	9.4	16	5.2	5.3	16	7.2	12	23	68
OR Quart 4	1.8	1.0	2.1	0.98	1.0	0.78	2.1	1.0	3.2
p Value	0.36	1.0	0.30	0.98	1.0	0.73	0.40	0.99	0.32
95% CI of	0.50	0.14	0.50	0.30	0.14	0.20	0.37	0.062	0.32
OR Quart4	6.5	7.2	9.1	3.2	7.2	3.1	12	16	32

C-C motif chemokine 7

sCr or UO	0hr prior to AKI stage		24hr prior to AKI stage		48hr prior to AKI stage	
	Cohort 1	Cohort 2	Cohort 1	Cohort 2	Cohort 1	Cohort 2
Median	0.662	1.22	0.662	0.812	0.662	0.625
Average	2.62	17.1	2.62	9.44	2.62	11.0
Stdev	9.67	24.1	9.67	18.5	9.67	22.3
p(t-test)		4.3E-9		0.0017		0.0035
Min	0.146	0.188	0.146	0.188	0.146	0.319
Max	125	82.4	125	82.4	125	82.4
n (Samp)	223	30	223	30	223	16
n (Patient)	223	30	223	30	223	16

sCr only	0hr prior to AKI stage		24hr prior to AKI stage		48hr prior to AKI stage	
	Cohort 1	Cohort 2	Cohort 1	Cohort 2	Cohort 1	Cohort 2
Median	0.816	1.29	0.816	1.15	0.816	0.625
Average	3.99	34.0	3.99	12.4	3.99	7.89
Stdev	19.3	80.2	19.3	20.1	19.3	13.3
p(t-test)		8.9E-6		0.12		0.59
Min	0.146	0.188	0.146	0.188	0.146	0.319
Max	291	293	291	67.6	291	33.9
n (Samp)	375	13	375	13	375	7
n (Patient)	375	13	375	13	375	7

UO only	0hr prior to AKI stage		24hr prior to AKI stage		48hr prior to AKI stage	
	Cohort 1	Cohort 2	Cohort 1	Cohort 2	Cohort 1	Cohort 2
Median	0.816	1.15	0.816	0.812	0.816	0.625
Average	3.35	26.1	3.35	14.4	3.35	8.82
Stdev	10.9	40.2	10.9	29.5	10.9	22.9
p(t-test)		7.5E-9		5.7E-4		0.11
Min	0.146	0.341	0.146	0.319	0.146	0.341
Max	125	166	125	114	125	82.4
n (Samp)	173	23	173	23	173	14
n (Patient)	173	23	173	23	173	14

	0hr prior to AKI stage			24hr prior to AKI stage			48hr prior to AKI stage		
	sCr or UO	sCr only	UO only	sCr or UO	sCr only	UO only	sCr or UO	sCr only	UO only
AUC	0.72	0.64	0.67	0.62	0.60	0.54	0.59	0.50	0.46
SE	0.055	0.084	0.065	0.058	0.084	0.065	0.077	0.11	0.082
p	9.6E-5	0.088	0.0087	0.038	0.26	0.50	0.22	1.00	0.62
nCohort 1	223	375	173	223	375	173	223	375	173
nCohort 2	30	13	23	30	13	23	16	7	14
Cutoff 1	0.584	0.380	0.584	0.515	0.380	0.515	0.483	0.336	0.515
Sens 1	73%	77%	78%	70%	77%	74%	75%	86%	71%
Spec 1	46%	29%	31%	43%	29%	29%	43%	22%	29%
Cutoff 2	0.483	0.336	0.515	0.406	0.336	0.499	0.380	0.336	0.380
Sens 2	83%	85%	83%	80%	85%	83%	81%	86%	86%
Spec 2	43%	22%	29%	41%	22%	28%	41%	22%	25%
Cutoff 3	0.380	0.319	0.499	0.320	0.319	0.320	0.320	0.319	0.320
Sens 3	90%	92%	91%	90%	92%	96%	94%	100%	100%
Spec 3	41%	12%	28%	31%	12%	20%	31%	12%	20%
Cutoff 4	1.04	1.15	1.29	1.04	1.15	1.29	1.04	1.15	1.29
Sens 4	60%	54%	43%	40%	46%	26%	31%	29%	14%
Spec 4	74%	74%	77%	74%	74%	77%	74%	74%	77%
Cutoff 5	1.29	1.29	1.59	1.29	1.29	1.59	1.29	1.29	1.59
Sens 5	43%	46%	43%	27%	38%	26%	25%	29%	14%
Spec 5	84%	81%	87%	84%	81%	87%	84%	81%	87%
Cutoff 6	1.59	7.96	13.6	1.59	7.96	13.6	1.59	7.96	13.6
Sens 6	43%	46%	43%	27%	38%	26%	25%	29%	14%
Spec 6	90%	90%	97%	90%	90%	97%	90%	90%	97%
OR Quart 2	5.1	1.5	3.9	4.2	2.0	2.5	8.9	0.32	1.0
p Value	0.043	0.65	0.100	0.033	0.42	0.15	0.042	0.33	1.0

	0hr prior to AKI stage			24hr prior to AKI stage			48hr prior to AKI stage		
	sCr or UO	sCr only	UO only	sCr or UO	sCr only	UO only	sCr or UO	sCr only	UO only
95% CI of	1.1	0.25	0.77	1.1	0.37	0.72	1.1	0.033	0.13
OR Quart2	25	9.3	20	16	11	8.9	74	3.2	7.4
OR Quart 3	1.0	0.49	2.1	1.4	0.49	1.0	2.0	0.33	3.9
p Value	1.0	0.57	0.41	0.70	0.57	1.0	0.58	0.34	0.099
95% CI of	0.14	0.044	0.36	0.29	0.044	0.24	0.18	0.033	0.77
OR Quart3	7.3	5.5	12	6.3	5.5	4.2	23	3.2	20
OR Quart 4	11	3.7	6.0	4.6	3.1	1.6	5.3	0.65	1.6
p Value	0.0019	0.11	0.026	0.023	0.17	0.51	0.13	0.64	0.63
95% CI of	2.4	0.75	1.2	1.2	0.62	0.41	0.60	0.11	0.25
OR Quart4	50	18	29	17	16	5.9	47	4.0	9.9

Vascular endothelial growth factor receptor 3

sCr or UO	0hr prior to AKI stage		24hr prior to AKI stage		48hr prior to AKI stage	
	Cohort 1	Cohort 2	Cohort 1	Cohort 2	Cohort 1	Cohort 2
Median	343	467	343	414	343	414
Average	340	507	340	494	340	470
Stdev	278	193	278	207	278	270
p(t-test)		0.0076		0.017		0.11
Min	1.37	166	1.37	166	1.37	3.04
Max	2070	913	2070	913	2070	913
n (Samp)	128	22	128	21	128	13
n (Patient)	128	22	128	21	128	13

sCr only	0hr prior to AKI stage		24hr prior to AKI stage		48hr prior to AKI stage	
	Cohort 1	Cohort 2	Cohort 1	Cohort 2	Cohort 1	Cohort 2
Median	397	414	397	401	nd	nd
Average	405	524	405	494	nd	nd
Stdev	292	206	292	232	nd	nd
p(t-test)		0.26		0.40	nd	nd
Min	1.37	362	1.37	249	nd	nd
Max	2750	913	2750	913	nd	nd
n (Samp)	240	8	240	8	nd	nd
n (Patient)	240	8	240	8	nd	nd

UO only	0hr prior to AKI stage		24hr prior to AKI stage		48hr prior to AKI stage	
	Cohort 1	Cohort 2	Cohort 1	Cohort 2	Cohort 1	Cohort 2
Median	356	509	356	511	356	406
Average	362	511	362	508	362	437
Stdev	286	188	286	193	286	245
p(t-test)		0.039		0.049		0.38
Min	1.37	166	1.37	166	1.37	3.04
Max	2070	835	2070	835	2070	835
n (Samp)	122	17	122	16	122	12
n (Patient)	122	17	122	16	122	12

	0hr prior to AKI stage		24hr prior to AKI stage		48hr prior to AKI stage	

	sCr or UO	sCr only	UO only	sCr or UO	sCr only	UO only	sCr or UO	sCr only	UO only
AUC	0.74	0.66	0.73	0.71	0.60	0.72	0.65	nd	0.60
SE	0.064	0.11	0.073	0.067	0.11	0.075	0.086	nd	0.090
p	1.5E-4	0.15	0.0014	0.0017	0.37	0.0031	0.083	nd	0.24
nCohort 1	128	240	122	128	240	122	128	nd	122
nCohort 2	22	8	17	21	8	16	13	nd	12
Cutoff 1	397	397	407	364	358	397	354	nd	354
Sens 1	73%	75%	71%	71%	75%	75%	77%	nd	75%
Spec 1	65%	51%	63%	58%	43%	61%	53%	nd	50%
Cutoff 2	364	366	364	337	295	364	242	nd	236
Sens 2	82%	88%	82%	81%	88%	81%	85%	nd	83%
Spec 2	58%	47%	53%	49%	31%	53%	36%	nd	30%
Cutoff 3	337	358	236	247	247	236	145	nd	145
Sens 3	91%	100%	94%	90%	100%	94%	92%	nd	92%
Spec 3	49%	43%	30%	36%	25%	30%	24%	nd	20%
Cutoff 4	425	486	441	425	486	441	425	nd	441
Sens 4	50%	38%	59%	48%	38%	56%	38%	nd	33%
Spec 4	70%	72%	70%	70%	72%	70%	70%	nd	70%
Cutoff 5	475	534	475	475	534	475	475	nd	475
Sens 5	50%	38%	59%	48%	38%	56%	38%	nd	33%
Spec 5	81%	82%	80%	81%	82%	80%	81%	nd	80%
Cutoff 6	534	651	574	534	651	574	534	nd	574
Sens 6	36%	25%	29%	33%	25%	31%	38%	nd	33%
Spec 6	91%	90%	90%	91%	90%	90%	91%	nd	90%
OR Quart 2	3.1	>2.1	3.1	4.4	2.0	3.1	0.49	nd	0.97
p Value	0.34	<0.56	0.34	0.20	0.57	0.34	0.56	nd	0.98
95% CI of	0.31	>0.18	0.31	0.46	0.18	0.31	0.042	nd	0.13
OR Quart2	31	na	31	41	23	31	5.6	nd	7.3
OR Quart 3	8.4	>3.2	3.1	7.0	2.0	3.2	2.8	nd	2.1
p Value	0.052	<0.33	0.34	0.080	0.57	0.33	0.25	nd	0.40
95% CI of	0.98	>0.32	0.31	0.79	0.18	0.32	0.50	nd	0.36
OR Quart3	72	na	31	61	23	32	15	nd	13
OR Quart 4	15	>3.2	13	13	3.1	11	2.7	nd	2.1
p Value	0.012	<0.33	0.017	0.018	0.33	0.025	0.26	nd	0.42
95% CI of	1.8	>0.32	1.6	1.6	0.31	1.4	0.48	nd	0.35
OR Quart4	120	na	110	110	31	96	15	nd	12

Interferon alpha-2

sCr or UO	0hr prior to AKI stage		24hr prior to AKI stage		48hr prior to AKI stage	
	Cohort 1	Cohort 2	Cohort 1	Cohort 2	Cohort 1	Cohort 2
Median	0.122	3.93	0.122	2.03	0.122	9.04
Average	13.0	10.4	13.0	9.15	13.0	13.7
Stdev	22.3	12.8	22.3	12.4	22.3	13.6
p(t-test)		0.53		0.36		0.90
Min	0.0369	0.0450	0.0369	0.0398	0.0369	0.0450
Max	126	34.7	126	34.7	126	34.7
n (Samp)	223	30	223	30	223	16
n (Patient)	223	30	223	30	223	16

sCr only	0hr prior to AKI stage		24hr prior to AKI stage		48hr prior to AKI stage	
	Cohort 1	Cohort 2	Cohort 1	Cohort 2	Cohort 1	Cohort 2
Median	0.122	5.88	0.122	2.21	0.122	0.122
Average	14.5	10.5	14.5	8.16	14.5	9.54
Stdev	24.0	12.9	24.0	11.6	24.0	13.9
p(t-test)		0.55		0.34		0.59
Min	0.0238	0.0450	0.0238	0.0450	0.0238	0.0398
Max	126	34.7	126	34.7	126	34.7
n (Samp)	375	13	375	13	375	7
n (Patient)	375	13	375	13	375	7

UO only	0hr prior to AKI stage		24hr prior to AKI stage		48hr prior to AKI stage	
	Cohort 1	Cohort 2	Cohort 1	Cohort 2	Cohort 1	Cohort 2
Median	0.311	5.47	0.311	2.39	0.311	10.8
Average	14.4	11.0	14.4	10.7	14.4	15.1
Stdev	22.4	12.9	22.4	13.0	22.4	13.8
p(t-test)		0.48		0.45		0.91
Min	0.0348	0.0672	0.0348	0.0398	0.0348	0.104
Max	126	34.7	126	34.7	126	34.7
n (Samp)	173	23	173	23	173	14
n (Patient)	173	23	173	23	173	14

	0hr prior to AKI stage			24hr prior to AKI stage			48hr prior to AKI stage		
	sCr or UO	sCr only	UO only	sCr or UO	sCr only	UO only	sCr or UO	sCr only	UO only
AUC	0.58	0.57	0.53	0.54	0.52	0.51	0.65	0.46	0.64
SE	0.058	0.084	0.065	0.057	0.083	0.064	0.077	0.11	0.083
p	0.19	0.43	0.67	0.48	0.77	0.93	0.055	0.76	0.095
nCohort 1	223	375	173	223	375	173	223	375	173
nCohort 2	30	13	23	30	13	23	16	7	14
Cutoff 1	0.0974	0.0974	0.0974	0.0974	0.0967	0.0974	1.45	0.0802	2.24
Sens 1	77%	77%	78%	70%	77%	74%	75%	71%	71%
Spec 1	42%	39%	30%	42%	34%	30%	59%	33%	57%
Cutoff 2	0.0967	0.0967	0.0967	0.0802	0.0724	0.0802	0.112	0.0418	1.45
Sens 2	83%	85%	83%	80%	85%	83%	81%	86%	86%
Spec 2	34%	34%	25%	33%	24%	24%	48%	13%	54%
Cutoff 3	0.0606	0.0754	0.0606	0.0606	0.0656	0.0606	0.0974	0.0369	0.0974
Sens 3	97%	92%	100%	90%	92%	91%	94%	100%	100%
Spec 3	22%	27%	14%	22%	18%	14%	42%	5%	30%
Cutoff 4	16.0	17.0	20.3	16.0	17.0	20.3	16.0	17.0	20.3
Sens 4	30%	31%	30%	27%	23%	30%	38%	29%	43%
Spec 4	70%	70%	71%	70%	70%	71%	70%	70%	71%
Cutoff 5	25.6	30.0	29.7	25.6	30.0	29.7	25.6	30.0	29.7
Sens 5	20%	15%	13%	17%	8%	13%	31%	14%	21%
Spec 5	80%	80%	80%	80%	80%	80%	80%	80%	80%
Cutoff 6	40.0	47.3	41.7	40.0	47.3	41.7	40.0	47.3	41.7
Sens 6	0%	0%	0%	0%	0%	0%	0%	0%	0%
Spec 6	90%	90%	90%	90%	90%	90%	90%	90%	90%
OR Quart 2	1.4	3.1	1.0	1.4	1.0	0.78	3.1	3.1	>2.0
p Value	0.55	0.34	1.0	0.55	1.0	0.73	0.34	0.33	<0.56

	0hr prior to AKI stage			24hr prior to AKI stage			48hr prior to AKI stage		
	sCr or UO	sCr only	UO only	sCr or UO	sCr only	UO only	sCr or UO	sCr only	UO only
95% CI of	0.43	0.31	0.24	0.43	0.14	0.20	0.31	0.32	>0.18
OR Quart2	4.8	30	4.2	4.8	7.2	3.1	30	30	na
OR Quart 3	1.9	6.3	2.5	2.2	3.7	1.7	6.4	1.0	>8.0
p Value	0.26	0.090	0.15	0.18	0.11	0.38	0.089	1.0	<0.056
95% CI of	0.61	0.75	0.72	0.70	0.75	0.52	0.75	0.062	>0.95
OR Quart3	6.1	54	8.9	6.8	18	5.7	55	16	na
OR Quart 4	1.9	3.1	1.6	1.7	1.0	1.2	6.4	2.0	>5.5
p Value	0.28	0.34	0.51	0.40	1.0	0.75	0.089	0.56	<0.13
95% CI of	0.60	0.31	0.41	0.51	0.14	0.35	0.75	0.18	>0.61
OR Quart4	6.0	30	5.9	5.4	7.2	4.3	55	23	na

Insulin-like growth factor-binding protein 4

sCr or UO	0hr prior to AKI stage		24hr prior to AKI stage		48hr prior to AKI stage	
	Cohort 1	Cohort 2	Cohort 1	Cohort 2	Cohort 1	Cohort 2
Median	0.923	2.85	0.923	2.84	0.923	2.33
Average	1.70	4.02	1.70	3.86	1.70	2.23
Stdev	5.34	3.59	5.34	3.69	5.34	1.89
p(t-test)		0.13		0.16		0.78
Min	0.0439	0.0558	0.0439	0.0558	0.0439	0.0558
Max	53.9	11.4	53.9	11.4	53.9	5.52
n (Samp)	109	13	109	13	109	8
n (Patient)	109	13	109	13	109	8

sCr only	0hr prior to AKI stage		24hr prior to AKI stage		48hr prior to AKI stage	
	Cohort 1	Cohort 2	Cohort 1	Cohort 2	Cohort 1	Cohort 2
Median	0.923	2.85	0.923	0.923	nd	nd
Average	2.46	3.66	2.46	3.36	nd	nd
Stdev	8.16	3.70	8.16	3.86	nd	nd
p(t-test)		0.70		0.77	nd	nd
Min	0.0319	0.0558	0.0319	0.0558	nd	nd
Max	85.6	9.68	85.6	9.68	nd	nd
n (Samp)	184	7	184	7	nd	nd
n (Patient)	184	7	184	7	nd	nd

UO only	0hr prior to AKI stage		24hr prior to AKI stage		48hr prior to AKI stage	
	Cohort 1	Cohort 2	Cohort 1	Cohort 2	Cohort 1	Cohort 2
Median	0.923	4.65	0.923	4.65	0.923	2.43
Average	1.65	4.84	1.65	4.84	1.65	2.53
Stdev	5.56	3.27	5.56	3.27	5.56	1.97
p(t-test)		0.11		0.11		0.70
Min	0.0439	0.957	0.0439	0.957	0.0439	0.0558
Max	53.9	11.4	53.9	11.4	53.9	5.52
n (Samp)	99	8	99	8	99	6
n (Patient)	99	8	99	8	99	6

	0hr prior to AKI stage		24hr prior to AKI stage		48hr prior to AKI stage	

	sCr or UO	sCr only	UO only	sCr or UO	sCr only	UO only	sCr or UO	sCr only	UO only
AUC	0.75	0.62	0.92	0.71	0.55	0.92	0.67	nd	0.74
SE	0.081	0.12	0.068	0.084	0.11	0.068	0.11	nd	0.12
p	0.0016	0.30	8.9E-10	0.010	0.65	8.9E-10	0.11	nd	0.046
nCohort 1	109	184	99	109	184	99	109	nd	99
nCohort 2	13	7	8	13	7	8	8	nd	6
Cutoff 1	0.923	0.733	2.44	0.733	0.670	2.44	0.923	nd	0.923
Sens 1	77%	71%	75%	77%	71%	75%	75%	nd	83%
Spec 1	64%	41%	91%	43%	34%	91%	64%	nd	65%
Cutoff 2	0.733	0.0558	1.94	0.670	0.0558	1.94	0.0558	nd	0.923
Sens 2	85%	86%	88%	85%	86%	88%	88%	nd	83%
Spec 2	43%	6%	89%	36%	6%	89%	6%	nd	65%
Cutoff 3	0.0558	0.0439	0.923	0.0558	0.0439	0.923	0.0439	nd	0.0439
Sens 3	92%	100%	100%	92%	100%	100%	100%	nd	100%
Spec 3	6%	1%	65%	6%	1%	65%	1%	nd	1%
Cutoff 4	0.957	1.17	0.957	0.957	1.17	0.957	0.957	nd	0.957
Sens 4	69%	57%	88%	62%	43%	88%	62%	nd	67%
Spec 4	73%	71%	74%	73%	71%	74%	73%	nd	74%
Cutoff 5	1.46	2.33	1.46	1.46	2.33	1.46	1.46	nd	1.46
Sens 5	69%	57%	88%	62%	43%	88%	62%	nd	67%
Spec 5	81%	80%	82%	81%	80%	82%	81%	nd	82%
Cutoff 6	2.50	3.90	2.44	2.50	3.90	2.44	2.50	nd	2.44
Sens 6	62%	43%	75%	54%	43%	75%	50%	nd	50%
Spec 6	91%	90%	91%	91%	90%	91%	91%	nd	91%
OR Quart 2	0.47	0.48	>0	0.97	0.98	>0	0	nd	0
p Value	0.54	0.55	<na	0.97	0.98	<na	na	nd	na
95% CI of	0.040	0.042	>na	0.13	0.13	>na	na	nd	na
OR Quart2	5.4	5.5	na	7.3	7.2	na	na	nd	na
OR Quart 3	0.48	0	>1.0	0.48	0	>1.0	0.48	nd	1.0
p Value	0.56	na	<1.0	0.56	na	<1.0	0.56	nd	1.0
95% CI of	0.041	na	>0.059	0.041	na	>0.059	0.041	nd	0.059
OR Quart3	5.6	na	na	5.6	na	na	5.6	nd	17
OR Quart 4	5.7	2.0	>9.1	4.9	1.5	>9.1	2.7	nd	4.3
p Value	0.036	0.42	<0.047	0.059	0.67	<0.047	0.26	nd	0.20
95% CI of	1.1	0.36	>1.0	0.94	0.24	>1.0	0.48	nd	0.45
OR Quart4	29	12	na	25	9.4	na	15	nd	42

Insulin-like growth factor-binding protein 5

sCr or UO	0hr prior to AKI stage		24hr prior to AKI stage		48hr prior to AKI stage	
	Cohort 1	Cohort 2	Cohort 1	Cohort 2	Cohort 1	Cohort 2
Median	0.0682	1.58	0.0682	1.22	0.0682	2.34
Average	0.622	1.87	0.622	1.55	0.622	2.16
Stdev	1.19	1.87	1.19	1.80	1.19	2.03
p(t-test)		0.0012		0.014		0.0011
Min	0.0210	0.0210	0.0210	0.0210	0.0210	0.0393
Max	5.79	5.59	5.79	5.59	5.79	5.59
n (Samp)	109	13	109	13	109	8
n (Patient)	109	13	109	13	109	8

sCr only	0hr prior to AKI stage		24hr prior to AKI stage		48hr prior to AKI stage	
	Cohort 1	Cohort 2	Cohort 1	Cohort 2	Cohort 1	Cohort 2
Median	0.0994	1.22	0.0994	0.0938	nd	nd
Average	0.941	1.76	0.941	1.18	nd	nd
Stdev	1.65	1.83	1.65	1.60	nd	nd
p(t-test)		0.20		0.70	nd	nd
Min	0.0116	0.0210	0.0116	0.0210	nd	nd
Max	9.43	4.11	9.43	3.48	nd	nd
n (Samp)	184	7	184	7	nd	nd
n (Patient)	184	7	184	7	nd	nd

UO only	0hr prior to AKI stage		24hr prior to AKI stage		48hr prior to AKI stage	
	Cohort 1	Cohort 2	Cohort 1	Cohort 2	Cohort 1	Cohort 2
Median	0.0682	1.68	0.0682	1.68	0.0682	2.34
Average	0.567	1.92	0.567	1.92	0.567	2.29
Stdev	1.10	1.98	1.10	1.98	1.10	2.14
p(t-test)		0.0024		0.0024		7.0E-4
Min	0.0210	0.0210	0.0210	0.0210	0.0210	0.0393
Max	5.79	5.59	5.79	5.59	5.79	5.59
n (Samp)	100	8	100	8	100	6
n (Patient)	100	8	100	8	100	6

	0hr prior to AKI stage			24hr prior to AKI stage			48hr prior to AKI stage		
	sCr or UO	sCr only	UO only	sCr or UO	sCr only	UO only	sCr or UO	sCr only	UO only
AUC	0.67	0.61	0.65	0.61	0.50	0.65	0.74	nd	0.73
SE	0.086	0.12	0.11	0.087	0.11	0.11	0.10	nd	0.12
p	0.055	0.33	0.16	0.21	0.97	0.16	0.022	nd	0.054
nCohort 1	109	184	100	109	184	100	109	nd	100
nCohort 2	13	7	8	13	7	8	8	nd	6
Cutoff 1	0.0358	0.0682	0.0358	0.0358	0.0358	0.0358	0.0682	nd	0.0400
Sens 1	85%	71%	88%	77%	71%	88%	75%	nd	83%
Spec 1	29%	46%	26%	29%	22%	26%	54%	nd	28%
Cutoff 2	0.0358	0.0358	0.0358	0.0255	0.0255	0.0358	0.0400	nd	0.0400
Sens 2	85%	86%	88%	85%	86%	88%	88%	nd	83%
Spec 2	29%	22%	26%	19%	14%	26%	32%	nd	28%
Cutoff 3	0	0.0116	0	0	0.0116	0	0.0358	nd	0.0358
Sens 3	100%	100%	100%	100%	100%	100%	100%	nd	100%
Spec 3	0%	1%	0%	0%	1%	0%	29%	nd	26%
Cutoff 4	0.397	0.558	0.397	0.397	0.558	0.397	0.397	nd	0.397
Sens 4	62%	57%	62%	54%	43%	62%	62%	nd	67%
Spec 4	76%	70%	78%	76%	70%	78%	76%	nd	78%
Cutoff 5	0.593	1.58	0.465	0.593	1.58	0.465	0.593	nd	0.465
Sens 5	62%	43%	62%	54%	29%	62%	62%	nd	67%
Spec 5	81%	80%	80%	81%	80%	80%	81%	nd	80%
Cutoff 6	2.38	3.03	1.76	2.38	3.03	1.76	2.38	nd	1.76
Sens 6	38%	43%	50%	31%	29%	50%	50%	nd	67%
Spec 6	91%	90%	90%	91%	90%	90%	91%	nd	90%
OR Quart 2	0.97	0.48	2.1	0.62	0.31	2.1	>2.1	nd	>2.1
p Value	0.97	0.55	0.56	0.62	0.32	0.56	<0.54	nd	<0.56

	0hr prior to AKI stage			24hr prior to AKI stage			48hr prior to AKI stage		
	sCr or UO	sCr only	UO only	sCr or UO	sCr only	UO only	sCr or UO	sCr only	UO only
95% CI of	0.13	0.042	0.18	0.096	0.031	0.18	>0.18	nd	>0.18
OR Quart2	7.3	5.5	24	4.0	3.1	24	na	nd	na
OR Quart 3	0.48	0	0	0.31	0	0	>1.0	nd	>0
p Value	0.56	na	na	0.32	na	na	<0.98	nd	<na
95% CI of	0.041	na	na	0.030	na	na	>0.062	nd	>na
OR Quart3	5.6	na	na	3.2	na	na	na	nd	na
OR Quart 4	4.9	2.0	5.9	2.6	0.98	5.9	>5.8	nd	>4.5
p Value	0.059	0.42	0.12	0.20	0.98	0.12	<0.12	nd	<0.19
95% CI of	0.94	0.36	0.64	0.61	0.19	0.64	>0.63	nd	>0.47
OR Quart4	25	12	54	11	5.1	54	na	nd	na

Interleukin-21

sCr or UO	0hr prior to AKI stage		24hr prior to AKI stage		48hr prior to AKI stage	
	Cohort 1	Cohort 2	Cohort 1	Cohort 2	Cohort 1	Cohort 2
Median	13.0	9.95	13.0	7.46	13.0	9.22
Average	15.4	11.4	15.4	9.90	15.4	10.5
Stdev	13.1	9.82	13.1	9.70	13.1	12.0
p(t-test)		0.11		0.027		0.14
Min	0.0191	0.0219	0.0191	0.0219	0.0191	0.0177
Max	87.9	49.5	87.9	49.5	87.9	49.5
n (Samp)	223	30	223	30	223	16
n (Patient)	223	30	223	30	223	16

sCr only	0hr prior to AKI stage		24hr prior to AKI stage		48hr prior to AKI stage	
	Cohort 1	Cohort 2	Cohort 1	Cohort 2	Cohort 1	Cohort 2
Median	13.0	8.34	13.0	8.34	13.0	6.02
Average	15.9	12.5	15.9	12.2	15.9	13.7
Stdev	13.8	12.3	13.8	12.5	13.8	16.7
p(t-test)		0.37		0.33		0.68
Min	0.0122	2.66	0.0122	2.65	0.0122	2.35
Max	87.9	49.5	87.9	49.5	87.9	49.5
n (Samp)	375	13	375	13	375	7
n (Patient)	375	13	375	13	375	7

UO only	0hr prior to AKI stage		24hr prior to AKI stage		48hr prior to AKI stage	
	Cohort 1	Cohort 2	Cohort 1	Cohort 2	Cohort 1	Cohort 2
Median	12.6	8.82	12.6	6.02	12.6	8.02
Average	15.2	10.3	15.2	8.31	15.2	7.93
Stdev	12.9	6.93	12.9	6.17	12.9	6.07
p(t-test)		0.071		0.012		0.037
Min	0.0160	0.0219	0.0160	0.0219	0.0160	0.0177
Max	87.9	24.2	87.9	20.6	87.9	17.2
n (Samp)	173	23	173	23	173	14
n (Patient)	173	23	173	23	173	14

	0hr prior to AKI stage		24hr prior to AKI stage		48hr prior to AKI stage	

	sCr or UO	sCr only	UO only	sCr or UO	sCr only	UO only	sCr or UO	sCr only	UO only
AUC	0.41	0.42	0.39	0.36	0.41	0.33	0.36	0.42	0.32
SE	0.058	0.084	0.066	0.057	0.084	0.065	0.077	0.11	0.081
p	0.12	0.34	0.10	0.015	0.26	0.0091	0.059	0.46	0.025
nCohort 1	223	375	173	223	375	173	223	375	173
nCohort 2	30	13	23	30	13	23	16	7	14
Cutoff 1	5.82	5.90	5.32	3.89	5.44	3.50	2.73	5.44	2.95
Sens 1	70%	77%	74%	70%	77%	74%	75%	71%	71%
Spec 1	26%	27%	25%	20%	26%	16%	15%	26%	14%
Cutoff 2	3.89	5.44	3.50	2.73	4.24	2.35	2.61	2.61	0.0975
Sens 2	80%	85%	83%	80%	85%	83%	81%	86%	86%
Spec 2	20%	26%	16%	15%	21%	12%	14%	13%	3%
Cutoff 3	2.73	4.24	2.22	2.22	2.65	0.689	0.0191	2.34	0.0191
Sens 3	90%	92%	91%	90%	92%	91%	94%	100%	93%
Spec 3	15%	21%	12%	13%	13%	5%	0%	12%	1%
Cutoff 4	19.2	19.3	19.6	19.2	19.3	19.6	19.2	19.3	19.6
Sens 4	20%	15%	17%	13%	15%	9%	6%	14%	0%
Spec 4	70%	70%	71%	70%	70%	71%	70%	70%	71%
Cutoff 5	24.9	25.4	24.9	24.9	25.4	24.9	24.9	25.4	24.9
Sens 5	3%	8%	0%	3%	8%	0%	6%	14%	0%
Spec 5	80%	80%	80%	80%	80%	80%	80%	80%	80%
Cutoff 6	31.3	33.5	31.2	31.3	33.5	31.2	31.3	33.5	31.2
Sens 6	3%	8%	0%	3%	8%	0%	6%	14%	0%
Spec 6	91%	90%	90%	91%	90%	90%	91%	90%	90%
OR Quart 2	0.66	3.1	6.7	1.0	3.1	6.7	4.2	2.0	>3.2
p Value	0.53	0.34	0.084	0.98	0.34	0.084	0.20	0.56	<0.32
95% CI of	0.18	0.31	0.77	0.24	0.31	0.77	0.46	0.18	>0.32
OR Quart2	2.4	30	58	4.3	30	58	39	23	na
OR Quart 3	2.3	7.5	12	3.2	6.3	9.4	5.4	2.0	>6.9
p Value	0.12	0.062	0.019	0.060	0.090	0.039	0.13	0.57	<0.080
95% CI of	0.80	0.90	1.5	0.95	0.75	1.1	0.61	0.18	>0.79
OR Quart3	6.5	62	100	11	54	78	47	23	na
OR Quart 4	1.4	2.0	6.7	3.2	3.1	9.4	6.7	2.0	>5.7
p Value	0.55	0.57	0.084	0.060	0.34	0.039	0.083	0.56	<0.12
95% CI of	0.46	0.18	0.77	0.95	0.31	1.1	0.78	0.18	>0.64
OR Quart4	4.3	23	58	11	30	78	57	23	na

Interleukin-23

sCr or UO	0hr prior to AKI stage		24hr prior to AKI stage		48hr prior to AKI stage	
	Cohort 1	Cohort 2	Cohort 1	Cohort 2	Cohort 1	Cohort 2
Median	583	447	583	304	583	562
Average	800	615	800	483	800	666
Stdev	942	593	942	512	942	597
p(t-test)		0.30		0.072		0.58
Min	0.643	0.552	0.643	0.552	0.643	0.564
Max	8520	2120	8520	2000	8520	2000
n (Samp)	223	30	223	30	223	16
n (Patient)	223	30	223	30	223	16

sCr only	0hr prior to AKI stage		24hr prior to AKI stage		48hr prior to AKI stage	
	Cohort 1	Cohort 2	Cohort 1	Cohort 2	Cohort 1	Cohort 2
Median	588	389	588	229	588	279
Average	798	520	798	475	798	633
Stdev	890	559	890	579	890	747
p(t-test)		0.26		0.20		0.63
Min	0.552	0.552	0.552	0.552	0.552	1.09
Max	8520	2000	8520	2000	8520	2000
n (Samp)	375	13	375	13	375	7
n (Patient)	375	13	375	13	375	7

UO only	0hr prior to AKI stage		24hr prior to AKI stage		48hr prior to AKI stage	
	Cohort 1	Cohort 2	Cohort 1	Cohort 2	Cohort 1	Cohort 2
Median	652	420	652	329	652	562
Average	870	608	870	457	870	587
Stdev	990	598	990	474	990	521
p(t-test)		0.22		0.050		0.29
Min	0.564	0.552	0.564	0.552	0.564	0.552
Max	8520	2120	8520	1450	8520	1450
n (Samp)	173	23	173	23	173	14
n (Patient)	173	23	173	23	173	14

	0hr prior to AKI stage			24hr prior to AKI stage			48hr prior to AKI stage		
	sCr or UO	sCr only	UO only	sCr or UO	sCr only	UO only	sCr or UO	sCr only	UO only
AUC	0.45	0.41	0.41	0.39	0.38	0.34	0.48	0.45	0.41
SE	0.057	0.084	0.066	0.058	0.084	0.065	0.076	0.11	0.083
p	0.39	0.28	0.19	0.059	0.17	0.015	0.80	0.65	0.30
nCohort 1	223	375	173	223	375	173	223	375	173
nCohort 2	30	13	23	30	13	23	16	7	14
Cutoff 1	233	152	129	135	136	1.61	233	152	214
Sens 1	70%	77%	74%	70%	77%	74%	75%	71%	71%
Spec 1	32%	26%	17%	24%	24%	10%	32%	26%	28%
Cutoff 2	129	84.5	0.967	1.61	1.61	0.967	152	1.61	0.967
Sens 2	80%	85%	83%	80%	85%	83%	81%	86%	86%
Spec 2	24%	19%	5%	14%	14%	5%	26%	14%	5%
Cutoff 3	0.967	1.09	0.682	0.967	1.09	0.682	0.967	1.06	0.552
Sens 3	90%	92%	91%	90%	92%	91%	94%	100%	93%
Spec 3	9%	11%	2%	9%	11%	2%	9%	10%	0%
Cutoff 4	952	977	983	952	977	983	952	977	983
Sens 4	27%	15%	26%	17%	15%	17%	31%	29%	29%
Spec 4	70%	70%	71%	70%	70%	71%	70%	70%	71%
Cutoff 5	1390	1360	1390	1390	1360	1390	1390	1360	1390
Sens 5	10%	8%	9%	7%	8%	4%	12%	14%	7%
Spec 5	80%	80%	80%	80%	80%	80%	80%	80%	80%
Cutoff 6	1830	1900	1960	1830	1900	1960	1830	1900	1960
Sens 6	7%	8%	4%	3%	8%	0%	6%	14%	0%
Spec 6	90%	90%	90%	90%	90%	90%	90%	90%	90%
OR Quart 2	0.86	1.0	0.47	1.2	1.0	0.73	1.0	0.50	0.48
p Value	0.79	1.0	0.30	0.73	1.0	0.70	1.0	0.57	0.41

	0hr prior to AKI stage			24hr prior to AKI stage			48hr prior to AKI stage		
	sCr or UO	sCr only	UO only	sCr or UO	sCr only	UO only	sCr or UO	sCr only	UO only
95% CI of	0.27	0.14	0.11	0.36	0.14	0.16	0.24	0.045	0.083
OR Quart2	2.7	7.2	2.0	4.3	7.2	3.5	4.2	5.6	2.7
OR Quart 3	1.5	3.1	1.2	2.0	2.6	1.6	1.3	1.0	1.0
p Value	0.42	0.17	0.77	0.25	0.26	0.51	0.73	1.0	1.0
95% CI of	0.55	0.62	0.37	0.62	0.49	0.41	0.32	0.14	0.23
OR Quart3	4.3	16	3.9	6.2	14	5.9	5.0	7.2	4.3
OR Quart 4	1.0	1.5	1.2	2.2	2.0	2.9	0.75	1.0	1.0
p Value	0.98	0.65	0.77	0.17	0.42	0.093	0.71	0.99	0.97
95% CI of	0.34	0.25	0.37	0.72	0.37	0.84	0.16	0.14	0.24
OR Quart4	3.1	9.3	3.9	6.9	11	9.9	3.5	7.3	4.4

Interleukin-28A

sCr or UO	0hr prior to AKI stage		24hr prior to AKI stage		48hr prior to AKI stage	
	Cohort 1	Cohort 2	Cohort 1	Cohort 2	Cohort 1	Cohort 2
Median	34.2	30.9	34.2	26.9	34.2	25.5
Average	48.6	42.1	48.6	34.5	48.6	42.0
Stdev	50.2	41.0	50.2	38.4	50.2	46.6
p(t-test)		0.50		0.14		0.61
Min	0.0495	0.0996	0.0495	0.0854	0.0495	0.155
Max	228	186	228	186	228	186
n (Samp)	223	30	223	30	223	16
n (Patient)	223	30	223	30	223	16

sCr only	0hr prior to AKI stage		24hr prior to AKI stage		48hr prior to AKI stage	
	Cohort 1	Cohort 2	Cohort 1	Cohort 2	Cohort 1	Cohort 2
Median	38.8	28.9	38.8	27.7	38.8	26.1
Average	51.6	43.5	51.6	40.0	51.6	50.8
Stdev	50.3	50.2	50.3	50.9	50.3	67.4
p(t-test)		0.57		0.41		0.96
Min	0.0254	0.0996	0.0254	0.0996	0.0254	0.0860
Max	235	186	235	186	235	186
n (Samp)	375	13	375	13	375	7
n (Patient)	375	13	375	13	375	7

UO only	0hr prior to AKI stage		24hr prior to AKI stage		48hr prior to AKI stage	
	Cohort 1	Cohort 2	Cohort 1	Cohort 2	Cohort 1	Cohort 2
Median	40.0	29.2	40.0	24.2	40.0	24.5
Average	54.0	38.1	54.0	29.4	54.0	32.2
Stdev	52.2	33.0	52.2	27.4	52.2	28.1
p(t-test)		0.16		0.028		0.12
Min	0.0517	0.204	0.0517	0.0777	0.0517	0.155
Max	228	127	228	91.0	228	91.0
n (Samp)	173	23	173	23	173	14
n (Patient)	173	23	173	23	173	14

	0hr prior to AKI stage		24hr prior to AKI stage		48hr prior to AKI stage	

	sCr or UO	sCr only	UO only	sCr or UO	sCr only	UO only	sCr or UO	sCr only	UO only
AUC	0.49	0.45	0.44	0.43	0.43	0.37	0.48	0.46	0.41
SE	0.057	0.083	0.066	0.057	0.084	0.066	0.075	0.11	0.083
p	0.86	0.57	0.37	0.25	0.39	0.045	0.84	0.76	0.25
nCohort 1	223	375	173	223	375	173	223	375	173
nCohort 2	30	13	23	30	13	23	16	7	14
Cutoff 1	21.6	14.7	18.7	14.1	10.1	0.932	18.7	10.1	18.7
Sens 1	70%	77%	74%	70%	77%	74%	75%	71%	71%
Spec 1	40%	33%	32%	35%	30%	22%	38%	30%	32%
Cutoff 2	10.1	10.1	1.80	0.198	1.55	0.198	10.1	1.55	2.62
Sens 2	80%	85%	83%	83%	85%	83%	81%	86%	86%
Spec 2	33%	30%	22%	16%	23%	11%	33%	23%	23%
Cutoff 3	0.198	0.131	0.198	0.131	0.131	0.0854	0.198	0.0854	0.198
Sens 3	93%	92%	100%	90%	92%	91%	94%	100%	93%
Spec 3	16%	11%	11%	14%	11%	8%	16%	7%	11%
Cutoff 4	65.2	70.9	78.3	65.2	70.9	78.3	65.2	70.9	78.3
Sens 4	23%	15%	9%	17%	15%	4%	25%	29%	7%
Spec 4	70%	70%	71%	70%	70%	71%	70%	70%	71%
Cutoff 5	92.2	94.0	96.2	92.2	94.0	96.2	92.2	94.0	96.2
Sens 5	7%	8%	4%	3%	8%	0%	6%	14%	0%
Spec 5	80%	80%	80%	80%	80%	80%	80%	80%	80%
Cutoff 6	120	123	120	120	123	120	120	123	120
Sens 6	7%	8%	4%	3%	8%	0%	6%	14%	0%
Spec 6	90%	90%	90%	90%	90%	90%	90%	90%	90%
OR Quart 2	3.8	1.0	3.3	5.2	0.49	6.7	2.1	0	3.1
p Value	0.050	1.0	0.16	0.041	0.57	0.084	0.41	na	0.33
95% CI of	1.0	0.14	0.63	1.1	0.044	0.77	0.36	na	0.31
OR Quart2	15	7.2	17	25	5.5	58	12	na	31
OR Quart 3	4.3	3.7	6.0	6.6	3.7	11	4.5	1.5	8.0
p Value	0.031	0.11	0.026	0.017	0.11	0.027	0.066	0.65	0.056
95% CI of	1.1	0.75	1.2	1.4	0.75	1.3	0.91	0.25	0.95
OR Quart3	16	18	29	31	18	89	22	9.3	68
OR Quart 4	2.1	1.0	2.7	4.5	1.5	8.0	1.0	1.0	3.2
p Value	0.30	1.0	0.25	0.064	0.65	0.056	0.99	0.99	0.32
95% CI of	0.51	0.14	0.49	0.92	0.25	0.95	0.14	0.14	0.32
OR Quart4	9.0	7.2	14	22	9.3	68	7.5	7.3	32

Interleukin-33

sCr or UO	0hr prior to AKI stage		24hr prior to AKI stage		48hr prior to AKI stage	
	Cohort 1	Cohort 2	Cohort 1	Cohort 2	Cohort 1	Cohort 2
Median	69.0	48.4	69.0	43.9	69.0	54.0
Average	83.7	58.2	83.7	52.1	83.7	61.6
Stdev	88.6	45.1	88.6	44.4	88.6	44.2
p(t-test)		0.12		0.056		0.32
Min	0.0360	0.0523	0.0360	0.0232	0.0360	0.0523
Max	958	170	958	170	958	136
n (Samp)	223	30	223	30	223	16
n (Patient)	223	30	223	30	223	16

sCr only	0hr prior to AKI stage		24hr prior to AKI stage		48hr prior to AKI stage	
	Cohort 1	Cohort 2	Cohort 1	Cohort 2	Cohort 1	Cohort 2
Median	68.9	45.5	68.9	38.8	68.9	57.9
Average	82.6	57.8	82.6	55.5	82.6	58.4
Stdev	79.9	46.6	79.9	47.9	79.9	39.9
p(t-test)		0.27		0.22		0.42
Min	0.0232	1.78	0.0232	1.78	0.0232	14.4
Max	958	170	958	170	958	135
n (Samp)	375	13	375	13	375	7
n (Patient)	375	13	375	13	375	7

UO only	0hr prior to AKI stage		24hr prior to AKI stage		48hr prior to AKI stage	
	Cohort 1	Cohort 2	Cohort 1	Cohort 2	Cohort 1	Cohort 2
Median	71.8	50.0	71.8	43.5	71.8	48.0
Average	91.0	53.0	91.0	45.9	91.0	55.6
Stdev	95.6	42.0	95.6	39.6	95.6	43.3
p(t-test)		0.061		0.027		0.17
Min	0.0447	0.0436	0.0447	0.0232	0.0447	0.0523
Max	958	136	958	136	958	136
n (Samp)	173	23	173	23	173	14
n (Patient)	173	23	173	23	173	14

	0hr prior to AKI stage			24hr prior to AKI stage			48hr prior to AKI stage		
	sCr or UO	sCr only	UO only	sCr or UO	sCr only	UO only	sCr or UO	sCr only	UO only
AUC	0.41	0.40	0.36	0.37	0.38	0.31	0.44	0.41	0.37
SE	0.058	0.084	0.065	0.057	0.084	0.064	0.077	0.11	0.083
p	0.14	0.24	0.029	0.027	0.17	0.0032	0.41	0.45	0.11
nCohort 1	223	375	173	223	375	173	223	375	173
nCohort 2	30	13	23	30	13	23	16	7	14
Cutoff 1	33.2	33.2	14.4	24.0	23.7	14.4	43.4	38.4	43.4
Sens 1	70%	77%	74%	70%	77%	74%	75%	71%	71%
Spec 1	27%	26%	12%	20%	19%	12%	35%	31%	31%
Cutoff 2	14.9	23.7	12.3	14.9	22.0	2.92	38.4	23.7	0.0743
Sens 2	80%	85%	83%	80%	85%	83%	81%	86%	86%
Spec 2	15%	19%	12%	15%	18%	6%	32%	19%	3%
Cutoff 3	2.92	20.9	0.0743	0.172	12.9	0.0447	0.0558	12.9	0.0558
Sens 3	90%	92%	91%	90%	92%	91%	94%	100%	93%
Spec 3	9%	17%	3%	8%	13%	1%	4%	13%	1%
Cutoff 4	103	103	115	103	103	115	103	103	115
Sens 4	23%	15%	9%	17%	15%	9%	25%	14%	14%
Spec 4	70%	70%	71%	70%	70%	71%	70%	70%	71%
Cutoff 5	127	127	130	127	127	130	127	127	130
Sens 5	10%	15%	4%	10%	15%	4%	12%	14%	7%
Spec 5	80%	80%	80%	80%	80%	80%	80%	80%	80%
Cutoff 6	159	157	176	159	157	176	159	157	176
Sens 6	3%	8%	0%	3%	8%	0%	0%	0%	0%
Spec 6	90%	90%	90%	90%	90%	90%	90%	90%	90%
OR Quart 2	2.2	1.0	3.3	1.6	1.0	2.7	1.4	2.0	1.0
p Value	0.22	1.0	0.16	0.50	1.0	0.25	0.70	0.56	1.0

	0hr prior to AKI stage			24hr prior to AKI stage			48hr prior to AKI stage		
	sCr or UO	sCr only	UO only	sCr or UO	sCr only	UO only	sCr or UO	sCr only	UO only
95% CI of	0.62	0.14	0.63	0.42	0.14	0.49	0.29	0.18	0.13
OR Quart2	7.7	7.2	17	5.9	7.2	14	6.3	23	7.4
OR Quart 3	2.5	3.1	3.3	2.5	2.6	2.7	2.1	2.0	3.3
p Value	0.15	0.17	0.16	0.15	0.26	0.25	0.31	0.57	0.16
95% CI of	0.73	0.62	0.63	0.73	0.49	0.49	0.50	0.18	0.63
OR Quart3	8.6	16	17	8.6	14	14	8.9	23	17
OR Quart 4	2.5	1.5	5.3	3.2	2.0	6.8	1.0	2.0	2.1
p Value	0.15	0.65	0.040	0.060	0.42	0.016	0.98	0.56	0.39
95% CI of	0.73	0.25	1.1	0.95	0.37	1.4	0.20	0.18	0.37
OR Quart4	8.6	9.3	26	11	11	33	5.3	23	12

Vascular endothelial growth factor receptor 2

sCr or UO	0hr prior to AKI stage		24hr prior to AKI stage		48hr prior to AKI stage	
	Cohort 1	Cohort 2	Cohort 1	Cohort 2	Cohort 1	Cohort 2
Median	412	1060	412	830	412	752
Average	634	1330	634	1160	634	1150
Stdev	691	962	691	784	691	885
p(t-test)		7.5E-5		0.0019		0.018
Min	0.218	106	0.218	106	0.218	27.3
Max	4170	4230	4170	2820	4170	2820
n (Samp)	124	22	124	21	124	12
n (Patient)	124	22	124	21	124	12

sCr only	0hr prior to AKI stage		24hr prior to AKI stage		48hr prior to AKI stage	
	Cohort 1	Cohort 2	Cohort 1	Cohort 2	Cohort 1	Cohort 2
Median	692	1320	692	939	nd	nd
Average	955	1350	955	1200	nd	nd
Stdev	940	841	940	817	nd	nd
p(t-test)		0.24		0.47	nd	nd
Min	0.218	122	0.218	122	nd	nd
Max	5940	2630	5940	2630	nd	nd
n (Samp)	236	8	236	8	nd	nd
n (Patient)	236	8	236	8	nd	nd

UO only	0hr prior to AKI stage		24hr prior to AKI stage		48hr prior to AKI stage	
	Cohort 1	Cohort 2	Cohort 1	Cohort 2	Cohort 1	Cohort 2
Median	488	1050	488	939	488	757
Average	706	1350	706	1200	706	1120
Stdev	774	1010	774	811	774	878
p(t-test)		0.0025		0.017		0.097
Min	0.218	106	0.218	106	0.218	27.3
Max	4210	4230	4210	2820	4210	2820
n (Samp)	120	17	120	16	120	11
n (Patient)	120	17	120	16	120	11

	0hr prior to AKI stage		24hr prior to AKI stage		48hr prior to AKI stage	

	sCr or UO	sCr only	UO only	sCr or UO	sCr only	UO only	sCr or UO	sCr only	UO only
AUC	0.76	0.67	0.75	0.74	0.63	0.73	0.72	nd	0.69
SE	0.062	0.11	0.071	0.065	0.11	0.075	0.086	nd	0.092
p	2.8E-5	0.11	5.4E-4	3.0E-4	0.23	0.0025	0.012	nd	0.040
nCohort 1	124	236	120	124	236	120	124	nd	120
nCohort 2	22	8	17	21	8	16	12	nd	11
Cutoff 1	734	825	747	734	741	734	623	nd	626
Sens 1	73%	75%	71%	71%	75%	75%	75%	nd	73%
Spec 1	72%	59%	69%	72%	53%	69%	62%	nd	61%
Cutoff 2	623	606	626	623	606	626	606	nd	623
Sens 2	82%	88%	82%	81%	88%	81%	83%	nd	82%
Spec 2	62%	44%	61%	62%	44%	61%	61%	nd	60%
Cutoff 3	508	113	508	508	113	508	508	nd	508
Sens 3	91%	100%	94%	90%	100%	94%	92%	nd	91%
Spec 3	57%	15%	53%	57%	15%	53%	57%	nd	53%
Cutoff 4	708	1220	757	708	1220	757	708	nd	757
Sens 4	73%	50%	65%	71%	38%	62%	58%	nd	45%
Spec 4	70%	70%	70%	70%	70%	70%	70%	nd	70%
Cutoff 5	1130	1600	1220	1130	1600	1220	1130	nd	1220
Sens 5	45%	38%	41%	33%	38%	31%	33%	nd	27%
Spec 5	81%	81%	80%	81%	81%	80%	81%	nd	80%
Cutoff 6	1630	2040	1660	1630	2040	1660	1630	nd	1660
Sens 6	27%	25%	24%	24%	12%	19%	25%	nd	18%
Spec 6	90%	90%	90%	90%	90%	90%	90%	nd	90%
OR Quart 2	0	1.0	1.0	0	1.0	1.0	0	nd	0
p Value	na	1.0	1.0	na	1.0	1.0	na	nd	na
95% CI of	na	0.061	0.060	na	0.061	0.060	na	nd	na
OR Quart2	na	16	17	na	16	17	na	nd	na
OR Quart 3	6.5	2.0	10	5.7	3.1	12	7.1	nd	8.3
p Value	0.022	0.57	0.034	0.035	0.33	0.023	0.078	nd	0.054
95% CI of	1.3	0.18	1.2	1.1	0.31	1.4	0.80	nd	0.96
OR Quart3	32	23	86	28	31	100	62	nd	72
OR Quart 4	6.3	4.2	8.2	6.3	3.1	5.7	5.7	nd	3.1
p Value	0.024	0.20	0.055	0.024	0.33	0.12	0.12	nd	0.34
95% CI of	1.3	0.46	0.96	1.3	0.31	0.63	0.63	nd	0.31
OR Quart4	31	39	71	31	31	52	52	nd	31

Lutropin subunit beta

sCr or UO	0hr prior to AKI stage		24hr prior to AKI stage		48hr prior to AKI stage	
	Cohort 1	Cohort 2	Cohort 1	Cohort 2	Cohort 1	Cohort 2
Median	23.7	9.51	23.7	9.51	23.7	8.03
Average	76.3	57.0	76.3	57.0	76.3	79.4
Stdev	120	111	120	111	120	135
p(t-test)		0.58		0.58		0.94
Min	0.0297	0.341	0.0297	0.341	0.0297	0.505
Max	400	393	400	393	400	393
n (Samp)	68	14	68	14	68	9
n (Patient)	68	14	68	14	68	9

sCr only	0hr prior to AKI stage		24hr prior to AKI stage		48hr prior to AKI stage	
	Cohort 1	Cohort 2	Cohort 1	Cohort 2	Cohort 1	Cohort 2
Median	29.6	37.1	29.6	37.1	29.6	46.2
Average	78.0	86.3	78.0	86.3	78.0	118
Stdev	110	132	110	132	110	154
p(t-test)		0.83		0.83		0.40
Min	0.0297	0.341	0.0297	0.341	0.0297	4.62
Max	400	393	400	393	400	393
n (Samp)	128	9	128	9	128	6
n (Patient)	128	9	128	9	128	6

UO only	0hr prior to AKI stage		24hr prior to AKI stage		48hr prior to AKI stage	
	Cohort 1	Cohort 2	Cohort 1	Cohort 2	Cohort 1	Cohort 2
Median	26.4	4.44	26.4	4.44	nd	nd
Average	85.1	9.51	85.1	9.51	nd	nd
Stdev	120	12.7	120	12.7	nd	nd
p(t-test)		0.10		0.10	nd	nd
Min	0.0297	0.505	0.0297	0.505	nd	nd
Max	400	37.1	400	37.1	nd	nd
n (Samp)	72	7	72	7	nd	nd
n (Patient)	72	7	72	7	nd	nd

	0hr prior to AKI stage			24hr prior to AKI stage			48hr prior to AKI stage		
	sCr or UO	sCr only	UO only	sCr or UO	sCr only	UO only	sCr or UO	sCr only	UO only
AUC	0.42	0.52	0.25	0.42	0.52	0.25	0.46	0.59	nd
SE	0.087	0.10	0.11	0.087	0.10	0.11	0.10	0.12	nd
p	0.36	0.84	0.021	0.36	0.84	0.021	0.73	0.46	nd
nCohort 1	68	128	72	68	128	72	68	128	nd
nCohort 2	14	9	7	14	9	7	9	6	nd
Cutoff 1	4.35	7.97	3.37	4.35	7.97	3.37	4.35	7.97	nd
Sens 1	71%	78%	71%	71%	78%	71%	78%	83%	nd
Spec 1	21%	30%	19%	21%	30%	19%	21%	30%	nd
Cutoff 2	0.933	4.00	0.840	0.933	4.00	0.840	4.00	7.97	nd
Sens 2	86%	89%	86%	86%	89%	86%	89%	83%	nd
Spec 2	12%	19%	12%	12%	19%	12%	21%	30%	nd
Cutoff 3	0.341	0.311	0.422	0.341	0.311	0.422	0.234	4.00	nd
Sens 3	93%	100%	100%	93%	100%	100%	100%	100%	nd
Spec 3	6%	6%	8%	6%	6%	8%	6%	19%	nd
Cutoff 4	43.9	63.3	68.2	43.9	63.3	68.2	43.9	63.3	nd
Sens 4	29%	22%	0%	29%	22%	0%	33%	33%	nd
Spec 4	71%	70%	71%	71%	70%	71%	71%	70%	nd
Cutoff 5	134	139	151	134	139	151	134	139	nd
Sens 5	14%	22%	0%	14%	22%	0%	22%	33%	nd
Spec 5	81%	80%	81%	81%	80%	81%	81%	80%	nd
Cutoff 6	315	275	311	315	275	311	315	275	nd
Sens 6	7%	11%	0%	7%	11%	0%	11%	17%	nd
Spec 6	91%	91%	90%	91%	91%	90%	91%	91%	nd
OR Quart 2	0.67	1.0	>1.1	0.67	1.0	>1.1	1.1	0.97	nd

	0hr prior to AKI stage			24hr prior to AKI stage			48hr prior to AKI stage		
	sCr or UO	sCr only	UO only	sCr or UO	sCr only	UO only	sCr or UO	sCr only	UO only
p Value	0.68	1.0	<0.97	0.68	1.0	<0.97	0.96	0.98	nd
95% CI of	0.099	0.13	>0.061	0.099	0.13	>0.061	0.13	0.058	nd
OR Quart2	4.5	7.5	na	4.5	7.5	na	8.4	16	nd
OR Quart 3	1.0	1.5	>2.2	1.0	1.5	>2.2	0.50	2.1	nd
p Value	1.0	0.64	<0.53	1.0	0.64	<0.53	0.59	0.56	nd
95% CI of	0.18	0.24	>0.19	0.18	0.24	>0.19	0.042	0.18	nd
OR Quart3	5.6	9.9	na	5.6	9.9	na	6.0	24	nd
OR Quart 4	2.6	0.97	>5.3	2.6	0.97	>5.3	2.4	2.0	nd
p Value	0.23	0.98	<0.15	0.23	0.98	<0.15	0.35	0.58	nd
95% CI of	0.54	0.13	>0.54	0.54	0.13	>0.54	0.38	0.17	nd
OR Quart4	12	7.3	na	12	7.3	na	15	23	nd

Neural cell adhesion molecule 1

sCr or UO	0hr prior to AKI stage		24hr prior to AKI stage		48hr prior to AKI stage	
	Cohort 1	Cohort 2	Cohort 1	Cohort 2	Cohort 1	Cohort 2
Median	2810	4940	2810	4490	2810	3900
Average	3350	6880	3350	6380	3350	4540
Stdev	2580	9710	2580	9720	2580	2430
p(t-test)		1.4E-5		1.8E-4		0.076
Min	6.83	161	6.83	142	6.83	1650
Max	22000	55700	22000	55700	22000	9700
n (Samp)	223	30	223	30	223	16
n (Patient)	223	30	223	30	223	16

sCr only	0hr prior to AKI stage		24hr prior to AKI stage		48hr prior to AKI stage	
	Cohort 1	Cohort 2	Cohort 1	Cohort 2	Cohort 1	Cohort 2
Median	3740	4080	3740	4080	3740	5050
Average	4460	4520	4460	4470	4460	5230
Stdev	4470	2200	4470	2240	4470	1940
p(t-test)		0.96		0.99		0.65
Min	6.83	161	6.83	142	6.83	2880
Max	55700	7860	55700	7860	55700	7860
n (Samp)	373	13	373	13	373	7
n (Patient)	373	13	373	13	373	7

UO only	0hr prior to AKI stage		24hr prior to AKI stage		48hr prior to AKI stage	
	Cohort 1	Cohort 2	Cohort 1	Cohort 2	Cohort 1	Cohort 2
Median	3210	5230	3210	5050	3210	4490
Average	3630	8840	3630	8180	3630	4640
Stdev	2320	11500	2320	11600	2320	2470
p(t-test)		3.6E-7		8.1E-6		0.12
Min	485	1700	485	1120	485	1650
Max	11700	55700	11700	55700	11700	9700
n (Samp)	173	23	173	23	173	14
n (Patient)	173	23	173	23	173	14

	0hr prior to AKI stage			24hr prior to AKI stage			48hr prior to AKI stage		
	sCr or UO	sCr only	UO only	sCr or UO	sCr only	UO only	sCr or UO	sCr only	UO only
AUC	0.72	0.58	0.74	0.67	0.57	0.68	0.67	0.66	0.63
SE	0.055	0.084	0.062	0.057	0.084	0.065	0.076	0.11	0.083
p	5.5E-5	0.37	8.9E-5	0.0033	0.42	0.0065	0.030	0.16	0.12
nCohort 1	223	373	173	223	373	173	223	373	173
nCohort 2	30	13	23	30	13	23	16	7	14
Cutoff 1	3720	3410	3940	2810	2870	2690	2870	3970	2990
Sens 1	70%	77%	74%	70%	77%	74%	75%	71%	71%
Spec 1	65%	46%	65%	51%	37%	44%	53%	56%	49%
Cutoff 2	2870	2870	2990	2210	2810	2160	2690	3720	1720
Sens 2	80%	85%	83%	80%	85%	83%	81%	86%	86%
Spec 2	53%	37%	49%	41%	36%	36%	49%	50%	22%
Cutoff 3	2170	2200	2160	1720	2200	1720	1700	2870	1700
Sens 3	90%	92%	91%	90%	92%	91%	94%	100%	93%
Spec 3	41%	27%	36%	27%	27%	22%	26%	37%	21%
Cutoff 4	3930	5290	4360	3930	5290	4360	3930	5290	4360
Sens 4	63%	31%	65%	57%	31%	61%	50%	29%	50%
Spec 4	70%	70%	71%	70%	70%	71%	70%	70%	71%
Cutoff 5	4960	6450	5580	4960	6450	5580	4960	6450	5580
Sens 5	50%	23%	48%	47%	23%	43%	38%	29%	36%
Spec 5	80%	80%	80%	80%	80%	80%	80%	80%	80%
Cutoff 6	6160	7690	6670	6160	7690	6670	6160	7690	6670
Sens 6	33%	15%	35%	30%	15%	35%	25%	29%	21%
Spec 6	90%	90%	90%	90%	90%	90%	90%	90%	90%
OR Quart 2	1.4	4.1	1.5	2.5	4.1	1.0	3.1	>2.0	0.64
p Value	0.70	0.21	0.65	0.20	0.21	1.0	0.34	<0.56	0.63
95% CI of	0.29	0.45	0.24	0.62	0.45	0.24	0.31	>0.18	0.10
OR Quart2	6.3	37	9.6	10	37	4.2	30	na	4.0
OR Quart 3	2.5	5.2	3.9	1.7	5.2	1.3	5.3	>3.1	1.3
p Value	0.20	0.13	0.100	0.47	0.13	0.73	0.13	<0.33	0.72
95% CI of	0.62	0.60	0.77	0.39	0.60	0.32	0.60	>0.32	0.28
OR Quart3	10	46	20	7.5	46	5.1	47	na	6.3
OR Quart 4	6.7	3.0	6.8	6.1	3.0	2.9	7.7	>2.0	1.7
p Value	0.0040	0.34	0.016	0.0061	0.34	0.093	0.061	<0.56	0.48
95% CI of	1.8	0.31	1.4	1.7	0.31	0.84	0.91	>0.18	0.38
OR Quart4	24	30	33	22	30	9.9	64	na	7.6

Platelet-derived growth factor subunit B (dimer)

sCr or UO	0hr prior to AKI stage		24hr prior to AKI stage		48hr prior to AKI stage	
	Cohort 1	Cohort 2	Cohort 1	Cohort 2	Cohort 1	Cohort 2
Median	1.35	3.57	1.35	3.33	1.35	3.23
Average	5.15	52.4	5.15	52.1	5.15	4.20
Stdev	21.4	208	21.4	208	21.4	3.82
p(t-test)		0.0026		0.0028		0.88
Min	0.00246	0.283	0.00246	0.166	0.00246	0.283
Max	270	935	270	935	270	12.9
n (Samp)	191	20	191	20	191	11
n (Patient)	191	20	191	20	191	11

sCr only	0hr prior to AKI stage		24hr prior to AKI stage		48hr prior to AKI stage	
	Cohort 1	Cohort 2	Cohort 1	Cohort 2	Cohort 1	Cohort 2
Median	1.68	4.25	1.68	3.52	1.68	2.23
Average	8.22	7.08	8.22	5.72	8.22	4.46
Stdev	57.1	6.03	57.1	5.43	57.1	5.26
p(t-test)		0.95		0.89		0.87
Min	0.00246	0.283	0.00246	0.283	0.00246	0.166
Max	935	16.9	935	16.9	935	12.9
n (Samp)	295	10	295	10	295	6
n (Patient)	295	10	295	10	295	6

UO only	0hr prior to AKI stage		24hr prior to AKI stage		48hr prior to AKI stage	
	Cohort 1	Cohort 2	Cohort 1	Cohort 2	Cohort 1	Cohort 2
Median	1.81	4.34	1.81	3.71	1.81	3.71
Average	6.27	71.8	6.27	69.4	6.27	4.77
Stdev	24.9	239	24.9	240	24.9	3.98
p(t-test)		0.0021		0.0031		0.86
Min	0.00246	0.401	0.00246	0.166	0.00246	0.401
Max	270	935	270	935	270	12.9
n (Samp)	136	15	136	15	136	9
n (Patient)	136	15	136	15	136	9

	0hr prior to AKI stage			24hr prior to AKI stage			48hr prior to AKI stage		
	sCr or UO	sCr only	UO only	sCr or UO	sCr only	UO only	sCr or UO	sCr only	UO only
AUC	0.75	0.75	0.76	0.71	0.71	0.69	0.68	0.55	0.69
SE	0.065	0.091	0.075	0.068	0.093	0.079	0.091	0.12	0.10
p	1.3E-4	0.0059	6.1E-4	0.0024	0.023	0.014	0.050	0.69	0.060
nCohort 1	191	295	136	191	295	136	191	295	136
nCohort 2	20	10	15	20	10	15	11	6	9
Cutoff 1	2.84	3.05	3.16	2.40	2.50	2.37	2.40	0.279	2.37
Sens 1	70%	70%	73%	70%	70%	73%	73%	83%	78%
Spec 1	75%	71%	74%	71%	65%	65%	71%	15%	65%
Cutoff 2	2.13	2.50	2.84	1.39	2.13	1.39	0.903	0.279	0.903
Sens 2	80%	80%	80%	80%	80%	80%	82%	83%	89%
Spec 2	67%	65%	69%	51%	60%	44%	37%	15%	29%
Cutoff 3	0.903	2.13	0.903	0.392	2.01	0.392	0.392	0.132	0.392
Sens 3	90%	90%	93%	90%	90%	93%	91%	100%	100%
Spec 3	37%	60%	29%	20%	58%	16%	20%	13%	16%
Cutoff 4	2.30	3.00	2.99	2.30	3.00	2.99	2.30	3.00	2.99
Sens 4	75%	70%	73%	70%	60%	67%	73%	50%	67%
Spec 4	70%	70%	71%	70%	70%	71%	70%	70%	71%
Cutoff 5	3.30	3.77	3.85	3.30	3.77	3.85	3.30	3.77	3.85
Sens 5	55%	60%	53%	50%	50%	47%	45%	33%	44%
Spec 5	80%	80%	80%	80%	80%	80%	80%	80%	80%
Cutoff 6	5.81	7.01	6.04	5.81	7.01	6.04	5.81	7.01	6.04
Sens 6	25%	40%	33%	25%	30%	33%	18%	33%	22%
Spec 6	90%	90%	90%	90%	90%	90%	90%	90%	90%
OR Quart 2	0.48	0	0.97	0.64	0	0.97	0.48	0.49	1.0
p Value	0.55	na	0.98	0.63	na	0.98	0.55	0.57	1.0

	0hr prior to AKI stage			24hr prior to AKI stage			48hr prior to AKI stage		
	sCr or UO	sCr only	UO only	sCr or UO	sCr only	UO only	sCr or UO	sCr only	UO only
95% CI of	0.042	na	0.059	0.10	na	0.13	0.042	0.044	0.060
OR Quart2	5.5	na	16	4.0	na	7.3	5.5	5.6	17
OR Quart 3	2.6	3.1	5.5	1.3	4.2	1.5	1.0	0.49	2.1
p Value	0.27	0.33	0.13	0.72	0.21	0.67	1.0	0.57	0.56
95% CI of	0.48	0.31	0.61	0.28	0.45	0.24	0.14	0.044	0.18
OR Quart3	14	30	49	6.3	38	9.5	7.4	5.6	24
OR Quart 4	7.3	6.3	9.6	4.3	5.2	4.7	3.2	0.99	5.5
p Value	0.012	0.091	0.038	0.034	0.14	0.063	0.17	0.99	0.13
95% CI of	1.5	0.74	1.1	1.1	0.59	0.92	0.61	0.14	0.61
OR Quart4	35	54	81	16	46	24	17	7.2	49

Corticotropin

sCr or UO	0hr prior to AKI stage		24hr prior to AKI stage		48hr prior to AKI stage	
	Cohort 1	Cohort 2	Cohort 1	Cohort 2	Cohort 1	Cohort 2
Median	0.00187	0.00448	0.00187	0.00448	0.00187	0.00227
Average	0.00264	0.00863	0.00264	0.00863	0.00264	0.00340
Stdev	0.00485	0.0109	0.00485	0.0109	0.00485	0.00271
p(t-test)		9.1E-4		9.1E-4		0.68
Min	0.000316	0.00109	0.000316	0.00109	0.000316	0.00111
Max	0.0489	0.0377	0.0489	0.0377	0.0489	0.00909
n (Samp)	99	12	99	12	99	7
n (Patient)	99	12	99	12	99	7

sCr only	0hr prior to AKI stage		24hr prior to AKI stage		48hr prior to AKI stage	
	Cohort 1	Cohort 2	Cohort 1	Cohort 2	Cohort 1	Cohort 2
Median	0.00205	0.00713	0.00205	0.00713	nd	nd
Average	0.00292	0.0133	0.00292	0.0133	nd	nd
Stdev	0.00497	0.0141	0.00497	0.0141	nd	nd
p(t-test)		1.0E-5		1.0E-5	nd	nd
Min	0.000316	0.00109	0.000316	0.00109	nd	nd
Max	0.0489	0.0377	0.0489	0.0377	nd	nd
n (Samp)	160	6	160	6	nd	nd
n (Patient)	160	6	160	6	nd	nd

UO only	0hr prior to AKI stage		24hr prior to AKI stage		48hr prior to AKI stage	
	Cohort 1	Cohort 2	Cohort 1	Cohort 2	Cohort 1	Cohort 2
Median	0.00182	0.00425	0.00182	0.00425	0.00182	0.00219
Average	0.00266	0.00883	0.00266	0.00883	0.00266	0.00333
Stdev	0.00519	0.0121	0.00519	0.0121	0.00519	0.00296
p(t-test)		0.0066		0.0066		0.76
Min	0.000388	0.00136	0.000388	0.00136	0.000388	0.00111
Max	0.0489	0.0377	0.0489	0.0377	0.0489	0.00909
n (Samp)	86	8	86	8	86	6
n (Patient)	86	8	86	8	86	6

	0hr prior to AKI stage		24hr prior to AKI stage		48hr prior to AKI stage	

	sCr or UO	sCr only	UO only	sCr or UO	sCr only	UO only	sCr or UO	sCr only	UO only
AUC	0.78	0.82	0.79	0.78	0.82	0.79	0.65	nd	0.62
SE	0.081	0.11	0.097	0.081	0.11	0.097	0.12	nd	0.13
p	5.8E-4	0.0026	0.0027	5.8E-4	0.0026	0.0027	0.19	nd	0.33
nCohort 1	99	160	86	99	160	86	99	nd	86
nCohort 2	12	6	8	12	6	8	7	nd	6
Cutoff 1	0.00217	0.00415	0.00217	0.00217	0.00415	0.00217	0.00210	nd	0.00159
Sens 1	75%	83%	75%	75%	83%	75%	71%	nd	83%
Spec 1	61%	91%	62%	61%	91%	62%	60%	nd	44%
Cutoff 2	0.00210	0.00415	0.00206	0.00210	0.00415	0.00206	0.00159	nd	0.00159
Sens 2	83%	83%	88%	83%	83%	88%	86%	nd	83%
Spec 2	60%	91%	60%	60%	91%	60%	38%	nd	44%
Cutoff 3	0.00124	0.00106	0.00124	0.00124	0.00106	0.00124	0.00109	nd	0.00109
Sens 3	92%	100%	100%	92%	100%	100%	100%	nd	100%
Spec 3	30%	11%	31%	30%	11%	31%	15%	nd	19%
Cutoff 4	0.00275	0.00275	0.00274	0.00275	0.00275	0.00274	0.00275	nd	0.00274
Sens 4	67%	83%	62%	67%	83%	62%	43%	nd	33%
Spec 4	72%	71%	71%	72%	71%	71%	72%	nd	71%
Cutoff 5	0.00307	0.00306	0.00285	0.00307	0.00306	0.00285	0.00307	nd	0.00285
Sens 5	67%	83%	62%	67%	83%	62%	43%	nd	33%
Spec 5	81%	80%	80%	81%	80%	80%	81%	nd	80%
Cutoff 6	0.00380	0.00404	0.00412	0.00380	0.00404	0.00412	0.00380	nd	0.00412
Sens 6	58%	83%	50%	58%	83%	50%	29%	nd	17%
Spec 6	91%	90%	91%	91%	90%	91%	91%	nd	91%
OR Quart 2	0.96	0	>1.0	0.96	0	>1.0	0.96	nd	1.0
p Value	0.98	na	<1.0	0.98	na	<1.0	0.98	nd	1.0
95% CI of	0.057	na	>0.059	0.057	na	>0.059	0.057	nd	0.059
OR Quart2	16	na	na	16	na	na	16	nd	17
OR Quart 3	2.0	0	>2.2	2.0	0	>2.2	2.1	nd	2.1
p Value	0.58	na	<0.53	0.58	na	<0.53	0.56	nd	0.56
95% CI of	0.17	na	>0.18	0.17	na	>0.18	0.18	nd	0.18
OR Quart3	23	na	na	23	na	na	25	nd	25
OR Quart 4	10	5.4	>6.1	10	5.4	>6.1	3.1	nd	2.1
p Value	0.034	0.13	<0.11	0.034	0.13	<0.11	0.34	nd	0.56
95% CI of	1.2	0.60	>0.65	1.2	0.60	>0.65	0.30	nd	0.18
OR Quart4	90	48	na	90	48	na	32	nd	25

Thyroxine-binding globulin

sCr or UO	0hr prior to AKI stage		24hr prior to AKI stage		48hr prior to AKI stage	
	Cohort 1	Cohort 2	Cohort 1	Cohort 2	Cohort 1	Cohort 2
Median	0.155	0.225	0.155	0.197	0.155	0.159
Average	0.268	0.589	0.268	0.610	0.268	0.451
Stdev	0.327	0.955	0.327	0.988	0.327	0.621
p(t-test)		0.011		0.0091		0.16
Min	0.000191	0.00635	0.000191	0.00635	0.000191	0.0485
Max	1.59	3.60	1.59	3.60	1.59	1.88
n (Samp)	103	15	103	14	103	8
n (Patient)	103	15	103	14	103	8

sCr only	0hr prior to AKI stage		24hr prior to AKI stage		48hr prior to AKI stage	
	Cohort 1	Cohort 2	Cohort 1	Cohort 2	Cohort 1	Cohort 2
Median	0.182	0.225	0.182	0.225	nd	nd
Average	0.313	0.470	0.313	0.470	nd	nd
Stdev	0.425	0.648	0.425	0.648	nd	nd
p(t-test)		0.35		0.35	nd	nd
Min	0.000191	0.00635	0.000191	0.00635	nd	nd
Max	3.60	1.88	3.60	1.88	nd	nd
n (Samp)	170	7	170	7	nd	nd
n (Patient)	170	7	170	7	nd	nd

UO only	0hr prior to AKI stage		24hr prior to AKI stage		48hr prior to AKI stage	
	Cohort 1	Cohort 2	Cohort 1	Cohort 2	Cohort 1	Cohort 2
Median	0.155	0.234	0.155	0.225	0.155	0.128
Average	0.252	0.637	0.252	0.676	0.252	0.260
Stdev	0.323	1.07	0.323	1.13	0.323	0.269
p(t-test)		0.012		0.0088		0.95
Min	0.000191	0.0485	0.000191	0.0485	0.000191	0.0485
Max	1.59	3.60	1.59	3.60	1.59	0.607
n (Samp)	87	10	87	9	87	6
n (Patient)	87	10	87	9	87	6

	0hr prior to AKI stage			24hr prior to AKI stage			48hr prior to AKI stage		
	sCr or UO	sCr only	UO only	sCr or UO	sCr only	UO only	sCr or UO	sCr only	UO only
AUC	0.61	0.57	0.66	0.60	0.57	0.65	0.59	nd	0.54
SE	0.082	0.11	0.098	0.085	0.11	0.10	0.11	nd	0.12
p	0.19	0.57	0.10	0.25	0.57	0.16	0.43	nd	0.74
nCohort 1	103	170	87	103	170	87	103	nd	87
nCohort 2	15	7	10	14	7	9	8	nd	6
Cutoff 1	0.135	0.163	0.135	0.135	0.163	0.104	0.103	nd	0.0496
Sens 1	73%	71%	70%	71%	71%	78%	75%	nd	83%
Spec 1	46%	46%	48%	46%	46%	43%	41%	nd	30%
Cutoff 2	0.103	0.136	0.104	0.0496	0.136	0.0496	0.0496	nd	0.0496
Sens 2	80%	86%	80%	86%	86%	89%	88%	nd	83%
Spec 2	41%	42%	43%	29%	42%	30%	29%	nd	30%
Cutoff 3	0.0462	0.00446	0.0927	0.0462	0.00446	0.0462	0.0462	nd	0.0462
Sens 3	93%	100%	90%	93%	100%	100%	100%	nd	100%
Spec 3	27%	5%	40%	27%	5%	29%	27%	nd	29%
Cutoff 4	0.313	0.356	0.249	0.313	0.356	0.249	0.313	nd	0.249
Sens 4	33%	29%	40%	36%	29%	44%	38%	nd	33%
Spec 4	71%	70%	70%	71%	70%	70%	71%	nd	70%
Cutoff 5	0.407	0.448	0.368	0.407	0.448	0.368	0.407	nd	0.368
Sens 5	33%	29%	40%	36%	29%	44%	38%	nd	33%
Spec 5	81%	80%	80%	81%	80%	80%	81%	nd	80%
Cutoff 6	0.693	0.750	0.693	0.693	0.750	0.693	0.693	nd	0.693
Sens 6	13%	14%	10%	14%	14%	11%	12%	nd	0%
Spec 6	90%	90%	91%	90%	90%	91%	90%	nd	91%
OR Quart 2	7.0	2.0	>4.8	5.8	2.0	>4.8	>4.5	nd	>4.8
p Value	0.081	0.56	<0.18	0.12	0.56	<0.18	<0.19	nd	<0.17

	0hr prior to AKI stage			24hr prior to AKI stage			48hr prior to AKI stage		
	sCr or UO	sCr only	UO only	sCr or UO	sCr only	UO only	sCr or UO	sCr only	UO only
95% CI of	0.79	0.18	>0.50	0.64	0.18	>0.50	>0.47	nd	>0.50
OR Quart2	62	23	na	53	23	na	na	nd	na
OR Quart 3	3.2	2.0	>2.2	3.2	2.0	>1.0	>1.0	nd	>0
p Value	0.32	0.56	<0.54	0.32	0.56	<0.98	<1.0	nd	<na
95% CI of	0.32	0.18	>0.18	0.32	0.18	>0.062	>0.059	nd	>na
OR Quart3	33	23	na	33	23	na	na	nd	na
OR Quart 4	5.6	2.0	>4.6	5.6	2.0	>4.8	>3.2	nd	>2.1
p Value	0.13	0.58	<0.19	0.13	0.58	<0.18	<0.32	nd	<0.56
95% CI of	0.61	0.17	>0.47	0.61	0.17	>0.50	>0.32	nd	>0.18
OR Quart4	51	23	na	51	23	na	na	nd	na

Pigment epithelium-derived factor

sCr or UO	0hr prior to AKI stage		24hr prior to AKI stage		48hr prior to AKI stage	
	Cohort 1	Cohort 2	Cohort 1	Cohort 2	Cohort 1	Cohort 2
Median	3.77	40.6	3.77	34.8	3.77	14.1
Average	25.0	61.2	25.0	54.2	25.0	42.7
Stdev	52.8	66.7	52.8	60.6	52.8	58.4
p(t-test)		7.5E-4		0.0056		0.20
Min	0.00100	0.121	0.00100	0.0312	0.00100	0.683
Max	400	218	400	218	400	218
n (Samp)	223	30	223	30	223	16
n (Patient)	223	30	223	30	223	16

sCr only	0hr prior to AKI stage		24hr prior to AKI stage		48hr prior to AKI stage	
	Cohort 1	Cohort 2	Cohort 1	Cohort 2	Cohort 1	Cohort 2
Median	5.82	58.3	5.82	47.1	5.82	70.8
Average	28.4	66.5	28.4	62.7	28.4	79.6
Stdev	55.5	66.4	55.5	68.0	55.5	71.7
p(t-test)		0.016		0.030		0.017
Min	0.00100	0.121	0.00100	0.0312	0.00100	2.29
Max	400	218	400	218	400	218
n (Samp)	374	13	374	13	374	7
n (Patient)	374	13	374	13	374	7

UO only	0hr prior to AKI stage		24hr prior to AKI stage		48hr prior to AKI stage	
	Cohort 1	Cohort 2	Cohort 1	Cohort 2	Cohort 1	Cohort 2
Median	5.79	44.2	5.79	44.2	5.79	10.0
Average	30.8	73.7	30.8	66.7	30.8	42.8
Stdev	60.5	79.4	60.5	73.2	60.5	61.7
p(t-test)		0.0024		0.0099		0.48
Min	0.00106	2.09	0.00106	2.00	0.00106	0.683
Max	400	250	400	250	400	218
n (Samp)	173	23	173	23	173	14
n (Patient)	173	23	173	23	173	14

	0hr prior to AKI stage		24hr prior to AKI stage		48hr prior to AKI stage	

	sCr or UO	sCr only	UO only	sCr or UO	sCr only	UO only	sCr or UO	sCr only	UO only
AUC	0.74	0.73	0.74	0.71	0.70	0.71	0.67	0.79	0.62
SE	0.054	0.081	0.062	0.055	0.082	0.063	0.076	0.10	0.083
p	8.8E-6	0.0053	1.2E-4	1.1E-4	0.014	7.3E-4	0.028	0.0041	0.15
nCohort 1	223	374	173	223	374	173	223	374	173
nCohort 2	30	13	23	30	13	23	16	7	14
Cutoff 1	8.99	7.75	8.99	7.24	6.55	7.24	3.22	56.9	6.44
Sens 1	70%	77%	74%	70%	77%	74%	75%	71%	71%
Spec 1	62%	55%	59%	59%	52%	55%	47%	87%	53%
Cutoff 2	6.55	6.55	6.44	3.77	4.09	3.77	3.11	18.0	3.11
Sens 2	80%	85%	83%	80%	85%	83%	81%	86%	86%
Spec 2	57%	52%	53%	50%	45%	47%	46%	67%	40%
Cutoff 3	2.56	2.25	3.11	2.19	2.25	2.14	1.56	2.25	1.56
Sens 3	90%	92%	91%	90%	92%	91%	94%	100%	93%
Spec 3	42%	32%	40%	39%	32%	31%	33%	32%	24%
Cutoff 4	17.4	21.1	20.5	17.4	21.1	20.5	17.4	21.1	20.5
Sens 4	63%	69%	65%	60%	62%	61%	50%	71%	43%
Spec 4	70%	70%	71%	70%	70%	71%	70%	70%	71%
Cutoff 5	27.6	32.9	37.5	27.6	32.9	37.5	27.6	32.9	37.5
Sens 5	57%	62%	52%	53%	54%	52%	38%	71%	36%
Spec 5	80%	80%	80%	80%	80%	80%	80%	80%	80%
Cutoff 6	70.1	81.7	105	70.1	81.7	105	70.1	81.7	105
Sens 6	33%	23%	30%	33%	23%	30%	31%	29%	14%
Spec 6	90%	90%	90%	90%	90%	90%	90%	90%	90%
OR Quart 2	5.3	0.99	>5.6	7.8	2.0	>6.8	4.1	>1.0	0.98
p Value	0.13	0.99	<0.12	0.059	0.57	<0.081	0.21	<0.99	0.98
95% CI of	0.61	0.061	>0.63	0.92	0.18	>0.79	0.45	>0.062	0.13
OR Quart2	47	16	na	65	22	na	38	na	7.3
OR Quart 3	7.8	2.0	>5.6	6.5	2.0	>4.4	4.1	>1.0	2.6
p Value	0.059	0.57	<0.12	0.087	0.57	<0.20	0.21	<0.99	0.27
95% CI of	0.92	0.18	>0.63	0.76	0.18	>0.47	0.45	>0.062	0.48
OR Quart3	65	22	na	56	22	na	38	na	14
OR Quart 4	22	9.7	>18	21	8.5	>18	7.7	>5.2	2.6
p Value	0.0030	0.033	<0.0068	0.0039	0.045	<0.0068	0.061	<0.13	0.27
95% CI of	2.9	1.2	>2.2	2.6	1.0	>2.2	0.91	>0.60	0.48
OR Quart4	170	78	na	160	70	na	64	na	14

Tumor necrosis factor receptor superfamily member 8

sCr or UO	0hr prior to AKI stage		24hr prior to AKI stage		48hr prior to AKI stage	
	Cohort 1	Cohort 2	Cohort 1	Cohort 2	Cohort 1	Cohort 2
Median	21.7	39.4	21.7	38.9	21.7	38.9
Average	30.9	55.9	30.9	54.7	30.9	34.7
Stdev	38.1	68.3	38.1	69.1	38.1	22.0
p(t-test)		0.012		0.018		0.72
Min	0.0561	4.17	0.0561	4.17	0.0561	0.196
Max	277	353	277	353	277	68.6
n (Samp)	128	24	128	23	128	13
n (Patient)	128	24	128	23	128	13

sCr only	0hr prior to AKI stage		24hr prior to AKI stage		48hr prior to AKI stage	
	Cohort 1	Cohort 2	Cohort 1	Cohort 2	Cohort 1	Cohort 2
Median	27.0	43.9	27.0	43.9	nd	nd
Average	43.4	75.5	43.4	75.5	nd	nd
Stdev	61.9	105	61.9	105	nd	nd
p(t-test)		0.14		0.14	nd	nd
Min	0.0561	25.7	0.0561	25.7	nd	nd
Max	554	353	554	353	nd	nd
n (Samp)	242	9	242	9	nd	nd
n (Patient)	242	9	242	9	nd	nd

UO only	0hr prior to AKI stage		24hr prior to AKI stage		48hr prior to AKI stage	
	Cohort 1	Cohort 2	Cohort 1	Cohort 2	Cohort 1	Cohort 2
Median	19.9	39.4	19.9	38.9	19.9	33.1
Average	30.3	44.9	30.3	42.6	30.3	33.8
Stdev	39.0	29.0	39.0	26.7	39.0	22.8
p(t-test)		0.13		0.21		0.76
Min	0.0561	4.17	0.0561	4.17	0.0561	0.196
Max	277	117	277	102	277	68.6
n (Samp)	122	18	122	17	122	12
n (Patient)	122	18	122	17	122	12

	0hr prior to AKI stage			24hr prior to AKI stage			48hr prior to AKI stage		
	sCr or UO	sCr only	UO only	sCr or UO	sCr only	UO only	sCr or UO	sCr only	UO only
AUC	0.71	0.69	0.71	0.70	0.69	0.69	0.61	nd	0.61
SE	0.063	0.100	0.072	0.065	0.100	0.075	0.087	nd	0.090
p	8.7E-4	0.062	0.0028	0.0025	0.062	0.0096	0.20	nd	0.22
nCohort 1	128	242	122	128	242	122	128	nd	122
nCohort 2	24	9	18	23	9	17	13	nd	12
Cutoff 1	30.9	31.1	30.2	27.2	31.1	27.2	15.0	nd	15.0
Sens 1	71%	78%	72%	74%	78%	71%	77%	nd	75%
Spec 1	66%	57%	67%	61%	57%	64%	38%	nd	39%
Cutoff 2	26.3	26.3	24.9	24.9	26.3	24.5	12.7	nd	12.7
Sens 2	83%	89%	83%	83%	89%	82%	85%	nd	83%
Spec 2	58%	49%	57%	55%	49%	55%	34%	nd	35%
Cutoff 3	24.5	25.6	5.76	19.5	25.6	5.76	6.53	nd	6.53
Sens 3	92%	100%	94%	91%	100%	94%	92%	nd	92%
Spec 3	54%	45%	16%	46%	45%	16%	14%	nd	17%
Cutoff 4	34.0	42.3	32.9	34.0	42.3	32.9	34.0	nd	32.9
Sens 4	62%	56%	67%	57%	56%	59%	54%	nd	50%
Spec 4	70%	70%	71%	70%	70%	71%	70%	nd	71%
Cutoff 5	47.1	53.5	41.1	47.1	53.5	41.1	47.1	nd	41.1
Sens 5	29%	22%	39%	30%	22%	41%	31%	nd	42%
Spec 5	80%	80%	80%	80%	80%	80%	80%	nd	80%
Cutoff 6	58.1	90.9	56.7	58.1	90.9	56.7	58.1	nd	56.7
Sens 6	21%	11%	22%	22%	11%	24%	15%	nd	17%
Spec 6	91%	90%	90%	91%	90%	90%	91%	nd	90%
OR Quart 2	1.0	>2.0	0.49	1.5	>2.0	0.47	1.0	nd	0.97
p Value	1.0	<0.57	0.56	0.67	<0.57	0.55	1.0	nd	0.98

	0hr prior to AKI stage			24hr prior to AKI stage			48hr prior to AKI stage		
	sCr or UO	sCr only	UO only	sCr or UO	sCr only	UO only	sCr or UO	sCr only	UO only
95% CI of	0.13	>0.18	0.042	0.24	>0.18	0.041	0.13	nd	0.13
OR Quart2	7.5	na	5.6	9.5	na	5.4	7.5	nd	7.3
OR Quart 3	6.4	>4.2	3.4	4.7	>4.2	3.3	1.5	nd	1.0
p Value	0.022	<0.20	0.15	0.063	<0.20	0.16	0.64	nd	1.0
95% CI of	1.3	>0.46	0.64	0.92	>0.46	0.62	0.24	nd	0.13
OR Quart3	32	na	18	24	na	18	9.9	nd	7.6
OR Quart 4	6.4	>3.1	5.7	6.2	>3.1	4.7	3.3	nd	3.3
p Value	0.022	<0.33	0.035	0.025	<0.33	0.062	0.16	nd	0.16
95% CI of	1.3	>0.31	1.1	1.3	>0.31	0.93	0.62	nd	0.62
OR Quart4	32	na	29	31	na	24	18	nd	18

Alpha-fetoprotein

sCr or UO	0hr prior to AKI stage		24hr prior to AKI stage		48hr prior to AKI stage	
	Cohort 1	Cohort 2	Cohort 1	Cohort 2	Cohort 1	Cohort 2
Median	0.00587	0.142	0.00587	0.142	0.00587	0.0837
Average	0.0687	0.323	0.0687	0.323	0.0687	0.116
Stdev	0.133	0.650	0.133	0.650	0.133	0.157
p(t-test)		1.6E-4		1.6E-4		0.23
Min	0.000523	0.000523	0.000523	0.000523	0.000523	0.000463
Max	0.803	2.85	0.803	2.85	0.803	0.537
n (Samp)	123	18	123	18	123	13
n (Patient)	123	18	123	18	123	13

sCr only	0hr prior to AKI stage		24hr prior to AKI stage		48hr prior to AKI stage	
	Cohort 1	Cohort 2	Cohort 1	Cohort 2	Cohort 1	Cohort 2
Median	0.00660	0.189	0.00660	0.189	0.00660	0.107
Average	0.0908	0.188	0.0908	0.188	0.0908	0.158
Stdev	0.246	0.162	0.246	0.162	0.246	0.189
p(t-test)		0.20		0.20		0.45
Min	0.000523	0.000523	0.000523	0.000523	0.000523	0.000523
Max	2.85	0.537	2.85	0.537	2.85	0.537
n (Samp)	210	11	210	11	210	8
n (Patient)	210	11	210	11	210	8

UO only	0hr prior to AKI stage		24hr prior to AKI stage		48hr prior to AKI stage	
	Cohort 1	Cohort 2	Cohort 1	Cohort 2	Cohort 1	Cohort 2
Median	0.00587	0.123	0.00587	0.123	0.00587	0.0604
Average	0.0775	0.406	0.0775	0.406	0.0775	0.0703
Stdev	0.151	0.870	0.151	0.870	0.151	0.0706
p(t-test)		3.8E-4		3.8E-4		0.89
Min	0.000463	0.00286	0.000463	0.00286	0.000463	0.000463
Max	0.803	2.85	0.803	2.85	0.803	0.189
n (Samp)	119	10	119	10	119	8
n (Patient)	119	10	119	10	119	8

	0hr prior to AKI stage		24hr prior to AKI stage		48hr prior to AKI stage	

	sCr or UO	sCr only	UO only	sCr or UO	sCr only	UO only	sCr or UO	sCr only	UO only
AUC	0.73	0.71	0.70	0.73	0.71	0.70	0.55	0.58	0.52
SE	0.071	0.090	0.096	0.071	0.090	0.096	0.086	0.11	0.11
p	0.0011	0.021	0.040	0.0011	0.021	0.040	0.59	0.48	0.84
nCohort 1	123	210	119	123	210	119	123	210	119
nCohort 2	18	11	10	18	11	10	13	8	8
Cutoff 1	0.0728	0.0880	0.0728	0.0728	0.0880	0.0728	0.00296	0.00296	0.00296
Sens 1	72%	73%	70%	72%	73%	70%	77%	75%	75%
Spec 1	76%	78%	76%	76%	78%	76%	11%	10%	10%
Cutoff 2	0.0309	0.0309	0.0309	0.0309	0.0309	0.0309	0.000523	0.00132	0.000523
Sens 2	83%	82%	80%	83%	82%	80%	85%	88%	88%
Spec 2	59%	57%	61%	59%	57%	61%	2%	3%	5%
Cutoff 3	0.000523	0.00132	0.00296	0.000523	0.00132	0.00296	0.000463	0	0
Sens 3	94%	91%	90%	94%	91%	90%	92%	100%	100%
Spec 3	2%	3%	10%	2%	3%	10%	0%	0%	0%
Cutoff 4	0.0499	0.0728	0.0613	0.0499	0.0728	0.0613	0.0499	0.0728	0.0613
Sens 4	72%	73%	70%	72%	73%	70%	54%	62%	50%
Spec 4	71%	73%	71%	71%	73%	71%	71%	73%	71%
Cutoff 5	0.0842	0.112	0.0880	0.0842	0.112	0.0880	0.0842	0.112	0.0880
Sens 5	67%	64%	60%	67%	64%	60%	46%	50%	38%
Spec 5	80%	80%	81%	80%	80%	81%	80%	80%	81%
Cutoff 6	0.198	0.213	0.259	0.198	0.213	0.259	0.198	0.213	0.259
Sens 6	33%	36%	20%	33%	36%	20%	15%	25%	0%
Spec 6	91%	90%	91%	91%	90%	91%	91%	90%	91%
OR Quart 2	0	0	0	0	0	0	0	0	0
p Value	na	na	na	na	na	na	na	na	na
95% CI of	na	na	na	na	na	na	na	na	na
OR Quart2	na	na	na	na	na	na	na	na	na
OR Quart 3	1.0	0.49	0.48	1.0	0.49	0.48	0.18	0	0.30
p Value	1.0	0.57	0.56	1.0	0.57	0.56	0.12	na	0.31
95% CI of	0.19	0.043	0.042	0.19	0.043	0.042	0.019	na	0.030
OR Quart3	5.3	5.6	5.6	5.3	5.6	5.6	1.6	na	3.1
OR Quart 4	5.3	4.4	4.0	5.3	4.4	4.0	1.5	1.7	1.3
p Value	0.017	0.068	0.099	0.017	0.068	0.099	0.53	0.48	0.72
95% CI of	1.4	0.89	0.77	1.4	0.89	0.77	0.43	0.39	0.27
OR Quart4	21	22	21	21	22	21	5.3	7.5	6.5

Apolipoprotein E

sCr or UO	0hr prior to AKI stage		24hr prior to AKI stage		48hr prior to AKI stage	
	Cohort 1	Cohort 2	Cohort 1	Cohort 2	Cohort 1	Cohort 2
Median	5.23	5.48	5.23	4.43	5.23	4.43
Average	43.6	94.8	43.6	90.7	43.6	10.3
Stdev	222	370	222	371	222	18.1
p(t-test)		0.25		0.29		0.49
Min	0.000147	0.00247	0.000147	0.00247	0.000147	0.211
Max	2160	2140	2160	2140	2160	82.5
n (Samp)	235	35	235	35	235	21
n (Patient)	235	35	235	35	235	21

sCr only	0hr prior to AKI stage		24hr prior to AKI stage		48hr prior to AKI stage	
	Cohort 1	Cohort 2	Cohort 1	Cohort 2	Cohort 1	Cohort 2
Median	5.95	3.82	5.95	3.60	5.95	3.60
Average	46.5	39.7	46.5	39.0	46.5	4.20
Stdev	226	143	226	143	226	3.93
p(t-test)		0.90		0.89		0.54
Min	0.000147	0.500	0.000147	0.290	0.000147	0.556
Max	2160	594	2160	594	2160	12.3
n (Samp)	397	17	397	17	397	11
n (Patient)	397	17	397	17	397	11

UO only	0hr prior to AKI stage		24hr prior to AKI stage		48hr prior to AKI stage	
	Cohort 1	Cohort 2	Cohort 1	Cohort 2	Cohort 1	Cohort 2
Median	5.32	6.96	5.32	5.48	5.32	4.87
Average	38.7	110	38.7	104	38.7	12.2
Stdev	192	425	192	425	192	20.5
p(t-test)		0.15		0.19		0.58
Min	0.000147	0.00247	0.000147	0.00247	0.000147	0.211
Max	2140	2140	2140	2140	2140	82.5
n (Samp)	190	25	190	25	190	16
n (Patient)	190	25	190	25	190	16

	0hr prior to AKI stage			24hr prior to AKI stage			48hr prior to AKI stage		
	sCr or UO	sCr only	UO only	sCr or UO	sCr only	UO only	sCr or UO	sCr only	UO only
AUC	0.52	0.40	0.54	0.48	0.37	0.51	0.47	0.34	0.47
SE	0.053	0.074	0.063	0.053	0.074	0.062	0.067	0.091	0.076
p	0.78	0.16	0.54	0.75	0.088	0.87	0.63	0.077	0.72
nCohort 1	235	397	190	235	397	190	235	397	190
nCohort 2	35	17	25	35	17	25	21	11	16
Cutoff 1	1.82	1.06	3.39	1.82	1.06	3.25	3.25	0.890	3.25
Sens 1	71%	71%	72%	71%	71%	72%	71%	73%	75%
Spec 1	26%	17%	37%	26%	17%	34%	35%	14%	34%
Cutoff 2	0.882	0.692	1.06	0.626	0.609	0.626	1.76	0.626	2.00
Sens 2	80%	82%	80%	80%	82%	80%	81%	82%	81%
Spec 2	17%	12%	15%	14%	11%	9%	25%	11%	23%
Cutoff 3	0.460	0.554	0.380	0.380	0.380	0.380	0.882	0.609	0.500
Sens 3	91%	94%	92%	91%	94%	92%	90%	91%	94%
Spec 3	11%	10%	7%	10%	8%	7%	17%	11%	8%
Cutoff 4	11.3	14.7	11.3	11.3	14.7	11.3	11.3	14.7	11.3
Sens 4	34%	6%	40%	29%	6%	36%	19%	0%	25%
Spec 4	70%	70%	70%	70%	70%	70%	70%	70%	70%
Cutoff 5	19.4	24.7	22.9	19.4	24.7	22.9	19.4	24.7	22.9
Sens 5	23%	6%	32%	20%	6%	28%	14%	0%	19%
Spec 5	80%	80%	80%	80%	80%	80%	80%	80%	80%
Cutoff 6	59.6	64.4	57.8	59.6	64.4	57.8	59.6	64.4	57.8
Sens 6	14%	6%	20%	11%	6%	12%	5%	0%	6%
Spec 6	90%	90%	90%	90%	90%	90%	90%	90%	90%
OR Quart 2	0.86	6.4	0.53	0.76	5.3	0.67	2.5	>4.2	1.4
p Value	0.77	0.089	0.33	0.62	0.13	0.52	0.20	<0.21	0.68

	0hr prior to AKI stage			24hr prior to AKI stage			48hr prior to AKI stage		
	sCr or UO	sCr only	UO only	sCr or UO	sCr only	UO only	sCr or UO	sCr only	UO only
95% CI of	0.31	0.75	0.14	0.27	0.60	0.20	0.62	>0.46	0.30
OR Quart2	2.4	54	1.9	2.2	46	2.3	10	na	6.5
OR Quart 3	0.87	3.1	0.67	1.1	4.1	0.67	2.1	>2.0	1.7
p Value	0.80	0.34	0.52	0.80	0.21	0.52	0.31	<0.56	0.47
95% CI of	0.32	0.31	0.20	0.43	0.45	0.20	0.50	>0.18	0.39
OR Quart3	2.4	30	2.3	3.0	38	2.3	8.8	na	7.7
OR Quart 4	1.1	7.5	1.3	1.0	7.5	1.1	1.7	>5.3	1.4
p Value	0.83	0.062	0.62	0.97	0.062	0.81	0.47	<0.13	0.68
95% CI of	0.42	0.91	0.45	0.38	0.91	0.38	0.39	>0.60	0.30
OR Quart4	2.9	62	3.8	2.7	62	3.4	7.5	na	6.5

Apolipoprotein(a)

sCr or UO	0hr prior to AKI stage		24hr prior to AKI stage		48hr prior to AKI stage	
	Cohort 1	Cohort 2	Cohort 1	Cohort 2	Cohort 1	Cohort 2
Median	2.89	5.31	2.89	5.01	2.89	5.01
Average	45.1	70.6	45.1	67.4	45.1	18.3
Stdev	176	234	176	234	176	34.3
p(t-test)		0.45		0.51		0.49
Min	0.00770	0.123	0.00770	0.0122	0.00770	0.0122
Max	1510	1170	1510	1170	1510	118
n (Samp)	230	35	230	35	230	21
n (Patient)	230	35	230	35	230	21

sCr only	0hr prior to AKI stage		24hr prior to AKI stage		48hr prior to AKI stage	
	Cohort 1	Cohort 2	Cohort 1	Cohort 2	Cohort 1	Cohort 2
Median	3.62	7.43	3.62	5.47	3.62	7.43
Average	93.7	10.7	93.7	9.98	93.7	11.5
Stdev	910	12.9	910	13.1	910	15.4
p(t-test)		0.71		0.70		0.76
Min	0.00479	1.16	0.00479	0.0122	0.00479	1.16
Max	17500	54.1	17500	54.1	17500	54.1
n (Samp)	391	17	391	17	391	11
n (Patient)	391	17	391	17	391	11

UO only	0hr prior to AKI stage		24hr prior to AKI stage		48hr prior to AKI stage	
	Cohort 1	Cohort 2	Cohort 1	Cohort 2	Cohort 1	Cohort 2
Median	3.46	5.31	3.46	5.31	3.46	5.16
Average	39.4	119	39.4	91.2	39.4	20.4
Stdev	166	293	166	275	166	37.7
p(t-test)		0.045		0.18		0.65
Min	0.00790	0.123	0.00790	0.0122	0.00790	0.0122
Max	1510	1170	1510	1170	1510	118
n (Samp)	185	25	185	25	185	16
n (Patient)	185	25	185	25	185	16

	0hr prior to AKI stage		24hr prior to AKI stage		48hr prior to AKI stage	

	sCr or UO	sCr only	UO only	sCr or UO	sCr only	UO only	sCr or UO	sCr only	UO only
AUC	0.62	0.60	0.60	0.59	0.55	0.58	0.59	0.58	0.56
SE	0.054	0.074	0.063	0.054	0.073	0.063	0.068	0.091	0.077
p	0.024	0.20	0.11	0.10	0.49	0.21	0.20	0.39	0.46
nCohort 1	230	391	185	230	391	185	230	391	185
nCohort 2	35	17	25	35	17	25	21	11	16
Cutoff 1	2.20	4.09	1.80	1.80	3.14	1.80	1.95	3.14	1.24
Sens 1	71%	71%	72%	71%	71%	72%	71%	73%	75%
Spec 1	43%	55%	33%	39%	43%	33%	40%	43%	19%
Cutoff 2	1.25	1.61	1.24	1.25	1.25	1.24	1.25	1.61	1.16
Sens 2	83%	82%	80%	80%	82%	80%	81%	82%	81%
Spec 2	26%	28%	19%	26%	20%	19%	26%	28%	19%
Cutoff 3	1.07	1.16	0.751	0.123	0.893	0.123	1.07	1.25	0.123
Sens 3	91%	94%	92%	91%	94%	92%	90%	91%	94%
Spec 3	23%	19%	15%	12%	16%	8%	23%	20%	8%
Cutoff 4	5.04	7.01	5.73	5.04	7.01	5.73	5.04	7.01	5.73
Sens 4	51%	53%	48%	49%	47%	44%	48%	55%	38%
Spec 4	70%	70%	70%	70%	70%	70%	70%	70%	70%
Cutoff 5	9.17	16.0	9.17	9.17	16.0	9.17	9.17	16.0	9.17
Sens 5	37%	24%	40%	31%	24%	36%	29%	27%	31%
Spec 5	80%	80%	80%	80%	80%	80%	80%	80%	80%
Cutoff 6	61.4	61.4	52.0	61.4	61.4	52.0	61.4	61.4	52.0
Sens 6	11%	0%	20%	9%	0%	12%	10%	0%	12%
Spec 6	90%	90%	90%	90%	90%	90%	90%	90%	90%
OR Quart 2	1.0	0.66	0.63	0.69	0.49	0.63	0.72	0.99	0.18
p Value	1.0	0.65	0.49	0.55	0.42	0.49	0.68	0.99	0.13
95% CI of	0.31	0.11	0.17	0.21	0.088	0.17	0.16	0.14	0.021
OR Quart2	3.3	4.0	2.4	2.3	2.7	2.4	3.4	7.2	1.6
OR Quart 3	1.4	2.1	0.64	1.5	1.5	0.82	1.5	1.5	0.78
p Value	0.57	0.32	0.51	0.44	0.52	0.75	0.53	0.65	0.73
95% CI of	0.45	0.50	0.17	0.54	0.42	0.23	0.41	0.25	0.20
OR Quart3	4.2	8.5	2.4	4.2	5.6	2.9	5.7	9.3	3.1
OR Quart 4	2.9	2.1	2.0	2.0	1.3	1.8	2.1	2.0	1.2
p Value	0.041	0.32	0.21	0.16	0.73	0.30	0.24	0.42	0.78
95% CI of	1.0	0.50	0.68	0.75	0.33	0.60	0.60	0.36	0.34
OR Quart4	8.0	8.5	5.9	5.5	4.8	5.3	7.4	11	4.2

[0186] Fig. 5: Comparison of marker levels in EDTA samples collected from Cohort 1 (patients that did not progress beyond RIFLE stage 0) and in EDTA samples collected from subjects at 0, 24 hours, and 48 hours prior to reaching stage R, I or F in Cohort 2.

Complement C4-B

sCr or UO	0hr prior to AKI stage		24hr prior to AKI stage		48hr prior to AKI stage	
	Cohort 1	Cohort 2	Cohort 1	Cohort 2	Cohort 1	Cohort 2
Median	65500	78300	65500	83200	65500	65900
Average	72500	79400	72500	78500	72500	73500
Stdev	40600	45100	40600	38300	40600	36100
p(t-test)		0.32		0.37		0.91
Min	305	1250	305	10700	305	21500

sCr or UO	0hr prior to AKI stage		24hr prior to AKI stage		48hr prior to AKI stage	
	Cohort 1	Cohort 2	Cohort 1	Cohort 2	Cohort 1	Cohort 2
Max	203000	223000	203000	188000	203000	140000
n (Samp)	121	53	121	53	121	26
n (Patient)	87	53	87	53	87	26

sCr only	0hr prior to AKI stage		24hr prior to AKI stage		48hr prior to AKI stage	
	Cohort 1	Cohort 2	Cohort 1	Cohort 2	Cohort 1	Cohort 2
Median	70800	87600	70800	93700	70800	90200
Average	77800	83300	77800	91300	77800	84300
Stdev	42600	39300	42600	43900	42600	46200
p(t-test)		0.61		0.23		0.64
Min	305	7620	305	5510	305	10700
Max	223000	144000	223000	161000	223000	140000
n (Samp)	288	16	288	15	288	10
n (Patient)	161	16	161	15	161	10

UO only	0hr prior to AKI stage		24hr prior to AKI stage		48hr prior to AKI stage	
	Cohort 1	Cohort 2	Cohort 1	Cohort 2	Cohort 1	Cohort 2
Median	65500	64200	65500	77100	65500	62800
Average	71100	78000	71100	75500	71100	67500
Stdev	36500	48100	36500	38900	36500	32700
p(t-test)		0.33		0.46		0.67
Min	305	1250	305	10700	305	21500
Max	160000	223000	160000	188000	160000	136000
n (Samp)	125	43	125	54	125	23
n (Patient)	80	43	80	54	80	23

	0hr prior to AKI stage			24hr prior to AKI stage			48hr prior to AKI stage		
	sCr or UO	sCr only	UO only	sCr or UO	sCr only	UO only	sCr or UO	sCr only	UO only
AUC	0.55	0.56	0.53	0.56	0.62	0.53	0.51	0.56	0.47
SE	0.048	0.076	0.052	0.048	0.079	0.047	0.063	0.096	0.066
p	0.34	0.43	0.57	0.23	0.13	0.55	0.83	0.53	0.66
nCohort 1	121	288	125	121	288	125	121	288	125
nCohort 2	53	16	43	53	15	54	26	10	23
Cutoff 1	47600	68900	46200	51400	79100	49100	49100	66700	40700
Sens 1	72%	75%	72%	72%	73%	70%	73%	70%	74%
Spec 1	31%	49%	29%	36%	57%	32%	33%	49%	21%
Cutoff 2	39400	46200	36700	43600	77900	41700	39400	42000	38300
Sens 2	81%	81%	81%	81%	80%	81%	81%	80%	83%
Spec 2	21%	26%	18%	27%	55%	22%	21%	23%	19%
Cutoff 3	29600	20400	21400	25500	5890	25500	29100	25600	29100
Sens 3	91%	94%	91%	91%	93%	91%	92%	90%	91%
Spec 3	10%	4%	6%	7%	2%	6%	8%	7%	7%
Cutoff 4	86800	99700	87900	86800	99700	87900	86800	99700	87900
Sens 4	42%	38%	40%	43%	40%	35%	35%	40%	26%
Spec 4	70%	70%	70%	70%	70%	70%	70%	70%	70%
Cutoff 5	105000	113000	100000	105000	113000	100000	105000	113000	100000
Sens 5	23%	19%	33%	23%	33%	26%	27%	40%	22%

	0hr prior to AKI stage			24hr prior to AKI stage			48hr prior to AKI stage		
	sCr or UO	sCr only	UO only	sCr or UO	sCr only	UO only	sCr or UO	sCr only	UO only
Spec 5	80%	80%	80%	80%	80%	80%	80%	80%	80%
Cutoff 6	132000	133000	129000	132000	133000	129000	132000	133000	129000
Sens 6	13%	12%	14%	6%	13%	6%	8%	10%	4%
Spec 6	90%	90%	90%	90%	90%	90%	90%	90%	90%
OR Quart 2	0.97	0.66	1.0	1.2	0.49	1.1	1.2	0.32	0.81
p Value	0.95	0.65	1.0	0.67	0.56	0.87	0.80	0.33	0.74
95% CI of	0.38	0.11	0.38	0.47	0.043	0.43	0.35	0.033	0.22
OR Quart2	2.5	4.1	2.6	3.3	5.5	2.7	3.9	3.1	2.9
OR Quart 3	1.0	2.5	0.47	1.8	3.7	1.1	0.78	0.66	0.81
p Value	1.0	0.20	0.18	0.24	0.11	0.87	0.71	0.65	0.74
95% CI of	0.39	0.61	0.16	0.69	0.74	0.43	0.22	0.11	0.22
OR Quart3	2.6	9.9	1.4	4.6	18	2.7	2.8	4.1	2.9
OR Quart 4	1.6	1.4	1.6	1.9	2.6	1.5	1.4	1.3	1.2
p Value	0.29	0.70	0.35	0.18	0.27	0.40	0.59	0.71	0.76
95% CI of	0.66	0.29	0.62	0.74	0.48	0.60	0.43	0.29	0.36
OR Quart4	4.0	6.3	4.0	4.8	14	3.6	4.5	6.2	4.0

C-C motif chemokine 26

sCr or UO	0hr prior to AKI stage		24hr prior to AKI stage		48hr prior to AKI stage	
	Cohort 1	Cohort 2	Cohort 1	Cohort 2	Cohort 1	Cohort 2
Median	0.725	1.25	0.725	1.62	0.725	5.42
Average	12.8	5.27	12.8	8.50	12.8	11.0
Stdev	65.9	10.1	65.9	14.0	65.9	15.6
p(t-test)		0.45		0.68		0.91
Min	0.0121	0.0232	0.0121	0.0121	0.0121	0.0339
Max	468	55.4	468	51.1	468	53.5
n (Samp)	93	45	93	42	93	18
n (Patient)	64	45	64	42	64	18

sCr only	0hr prior to AKI stage		24hr prior to AKI stage		48hr prior to AKI stage	
	Cohort 1	Cohort 2	Cohort 1	Cohort 2	Cohort 1	Cohort 2
Median	0.785	3.74	0.785	3.16	0.785	4.75
Average	8.23	7.35	8.23	11.6	8.23	12.3
Stdev	43.2	9.45	43.2	16.6	43.2	18.3
p(t-test)		0.94		0.74		0.78
Min	0.0121	0.0121	0.0121	0.0232	0.0121	0.0121
Max	468	29.4	468	51.1	468	50.9
n (Samp)	224	14	224	18	224	9
n (Patient)	131	14	131	18	131	9

UO only	0hr prior to AKI stage		24hr prior to AKI stage		48hr prior to AKI stage	
	Cohort 1	Cohort 2	Cohort 1	Cohort 2	Cohort 1	Cohort 2
Median	0.0587	0.725	0.0587	1.48	0.0587	5.00
Average	12.3	3.90	12.3	6.69	12.3	8.29
Stdev	63.1	9.51	63.1	11.4	63.1	13.5
p(t-test)		0.42		0.57		0.81
Min	0.0121	0.0232	0.0121	0.0121	0.0121	0.0325

UO only	0hr prior to AKI stage		24hr prior to AKI stage		48hr prior to AKI stage	
	Cohort 1	Cohort 2	Cohort 1	Cohort 2	Cohort 1	Cohort 2
Max	468	55.4	468	46.1	468	53.5
n (Samp)	102	37	102	41	102	15
n (Patient)	63	37	63	41	63	15

	0hr prior to AKI stage			24hr prior to AKI stage			48hr prior to AKI stage		
	sCr or UO	sCr only	UO only	sCr or UO	sCr only	UO only	sCr or UO	sCr only	UO only
AUC	0.56	0.60	0.55	0.60	0.68	0.58	0.76	0.64	0.68
SE	0.053	0.082	0.056	0.054	0.072	0.054	0.070	0.10	0.080
p	0.23	0.25	0.41	0.068	0.015	0.14	2.3E-4	0.17	0.029
nCohort 1	93	224	102	93	224	102	93	224	102
nCohort 2	45	14	37	42	18	41	18	9	15
Cutoff 1	0.0339	0.0503	0.0339	0.0339	1.25	0.0339	4.62	0.0503	0.0587
Sens 1	82%	71%	81%	81%	72%	73%	72%	78%	73%
Spec 1	25%	41%	27%	25%	56%	27%	80%	41%	51%
Cutoff 2	0.0339	0.0232	0.0339	0.0339	0.652	0.0325	1.84	0.0339	0.0339
Sens 2	82%	93%	81%	81%	83%	85%	83%	89%	80%
Spec 2	25%	4%	27%	25%	47%	25%	67%	25%	27%
Cutoff 3	0.0232	0.0232	0.0232	0.0232	0.0339	0.0232	0.0325	0	0.0325
Sens 3	98%	93%	97%	93%	94%	93%	100%	100%	93%
Spec 3	5%	4%	5%	5%	25%	5%	22%	0%	25%
Cutoff 4	2.43	3.90	2.43	2.43	3.90	2.43	2.43	3.90	2.43
Sens 4	36%	50%	27%	43%	44%	44%	78%	56%	67%
Spec 4	71%	70%	72%	71%	70%	72%	71%	70%	72%
Cutoff 5	5.00	6.86	5.00	5.00	6.86	5.00	5.00	6.86	5.00
Sens 5	29%	43%	19%	31%	33%	32%	50%	33%	40%
Spec 5	83%	81%	82%	83%	81%	82%	83%	81%	82%
Cutoff 6	10.6	10.7	13.4	10.6	10.7	13.4	10.6	10.7	13.4
Sens 6	13%	21%	5%	24%	28%	15%	28%	33%	13%
Spec 6	91%	90%	90%	91%	90%	90%	91%	90%	90%
OR Quart 2	1.4	0.64	1.1	1.1	0.98	1.5	0.46	2.0	1.6
p Value	0.48	0.64	0.82	0.83	0.99	0.44	0.54	0.57	0.64
95% CI of	0.52	0.10	0.36	0.37	0.13	0.51	0.039	0.18	0.24
OR Quart2	4.1	4.0	3.6	3.4	7.2	4.6	5.4	23	10
OR Quart 3	1.0	0.65	2.3	1.5	3.2	1.3	2.7	2.0	0.48
p Value	1.0	0.65	0.13	0.46	0.16	0.61	0.26	0.57	0.56
95% CI of	0.34	0.11	0.78	0.51	0.62	0.43	0.48	0.18	0.041
OR Quart3	2.9	4.1	6.7	4.4	17	4.1	15	23	5.6
OR Quart 4	2.1	2.5	1.3	2.2	4.4	2.9	6.9	4.1	5.8
p Value	0.16	0.21	0.61	0.14	0.069	0.052	0.020	0.21	0.035
95% CI of	0.76	0.61	0.43	0.77	0.89	0.99	1.4	0.45	1.1
OR Quart4	5.7	10	4.1	6.2	22	8.3	36	38	30

C-C motif chemokine 7

sCr or UO	0hr prior to AKI stage		24hr prior to AKI stage		48hr prior to AKI stage	
	Cohort 1	Cohort 2	Cohort 1	Cohort 2	Cohort 1	Cohort 2
Median	0.620	0.512	0.620	0.804	0.620	0.512
Average	8.13	7.46	8.13	10.4	8.13	12.7

sCr or UO	0hr prior to AKI stage		24hr prior to AKI stage		48hr prior to AKI stage	
	Cohort 1	Cohort 2	Cohort 1	Cohort 2	Cohort 1	Cohort 2
Stdev	22.1	14.3	22.1	15.1	22.1	21.1
p(t-test)		0.85		0.55		0.42
Min	0.193	0.193	0.193	0.193	0.193	0.193
Max	128	79.4	128	60.8	128	75.6
n (Samp)	94	45	94	42	94	18
n (Patient)	65	45	65	42	65	18

sCr only	0hr prior to AKI stage		24hr prior to AKI stage		48hr prior to AKI stage	
	Cohort 1	Cohort 2	Cohort 1	Cohort 2	Cohort 1	Cohort 2
Median	0.620	0.712	0.620	0.620	0.620	0.512
Average	9.35	5.26	9.35	23.9	9.35	11.1
Stdev	24.0	8.50	24.0	54.7	24.0	25.1
p(t-test)		0.53		0.031		0.83
Min	0.193	0.193	0.193	0.193	0.193	0.193
Max	181	26.1	181	219	181	75.6
n (Samp)	225	14	225	18	225	9
n (Patient)	132	14	132	18	132	9

UO only	0hr prior to AKI stage		24hr prior to AKI stage		48hr prior to AKI stage	
	Cohort 1	Cohort 2	Cohort 1	Cohort 2	Cohort 1	Cohort 2
Median	0.620	0.512	0.620	0.804	0.620	0.512
Average	6.86	7.17	6.86	11.9	6.86	8.74
Stdev	20.9	15.2	20.9	17.6	20.9	15.0
p(t-test)		0.93		0.18		0.74
Min	0.193	0.193	0.193	0.193	0.193	0.193
Max	128	79.4	128	67.3	128	48.7
n (Samp)	103	37	103	41	103	15
n (Patient)	64	37	64	41	64	15

	0hr prior to AKI stage			24hr prior to AKI stage			48hr prior to AKI stage		
	sCr or UO	sCr only	UO only	sCr or UO	sCr only	UO only	sCr or UO	sCr only	UO only
AUC	0.49	0.50	0.50	0.58	0.52	0.64	0.57	0.49	0.57
SE	0.053	0.080	0.056	0.054	0.072	0.053	0.076	0.099	0.082
p	0.87	0.95	0.95	0.16	0.73	0.010	0.34	0.90	0.40
nCohort 1	94	225	103	94	225	103	94	225	103
nCohort 2	45	14	37	42	18	41	18	9	15
Cutoff 1	0.193	0.308	0.193	0.193	0.193	0.308	0.308	0.308	0.308
Sens 1	76%	71%	76%	88%	78%	80%	94%	78%	87%
Spec 1	18%	30%	20%	18%	19%	38%	34%	30%	38%
Cutoff 2	0	0.193	0	0.193	0	0.308	0.308	0.193	0.308
Sens 2	100%	86%	100%	88%	100%	80%	94%	89%	87%
Spec 2	0%	19%	0%	18%	0%	38%	34%	19%	38%
Cutoff 3	0	0	0	0	0	0.193	0.308	0	0.193
Sens 3	100%	100%	100%	100%	100%	93%	94%	100%	93%
Spec 3	0%	0%	0%	0%	0%	20%	34%	0%	20%
Cutoff 4	0.804	2.71	0.804	0.804	2.71	0.804	0.804	2.71	0.804
Sens 4	36%	29%	32%	45%	44%	46%	39%	22%	33%

	0hr prior to AKI stage			24hr prior to AKI stage			48hr prior to AKI stage		
	sCr or UO	sCr only	UO only	sCr or UO	sCr only	UO only	sCr or UO	sCr only	UO only
Spec 4	70%	70%	75%	70%	70%	75%	70%	70%	75%
Cutoff 5	8.42	9.52	5.10	8.42	9.52	5.10	8.42	9.52	5.10
Sens 5	31%	29%	27%	38%	39%	41%	33%	22%	33%
Spec 5	84%	80%	81%	84%	80%	81%	84%	80%	81%
Cutoff 6	19.2	28.8	14.4	19.2	28.8	14.4	19.2	28.8	14.4
Sens 6	13%	0%	16%	21%	17%	29%	28%	11%	20%
Spec 6	90%	90%	90%	90%	90%	90%	90%	90%	90%
OR Quart 2	0.38	0.72	0.45	0.86	1.5	1.2	15	1.0	8.5
p Value	0.072	0.68	0.17	0.79	0.53	0.78	0.013	0.99	0.053
95% CI of	0.13	0.15	0.15	0.30	0.41	0.39	1.8	0.14	0.98
OR Quart2	1.1	3.4	1.4	2.5	5.7	3.5	130	7.5	74
OR Quart 3	0.69	0.72	0.55	0.62	0.23	1.0	0	1.5	2.1
p Value	0.46	0.68	0.28	0.40	0.20	1.0	na	0.65	0.56
95% CI of	0.26	0.15	0.18	0.20	0.025	0.33	na	0.25	0.18
OR Quart3	1.8	3.4	1.6	1.9	2.2	3.0	na	9.5	24
OR Quart 4	0.93	0.98	1.3	2.1	1.8	2.8	9.0	1.0	5.6
p Value	0.88	0.98	0.61	0.14	0.36	0.049	0.047	0.99	0.13
95% CI of	0.35	0.23	0.48	0.79	0.50	1.0	1.0	0.14	0.61
OR Quart4	2.4	4.1	3.5	5.8	6.6	7.8	79	7.5	51

Thyrotropin

sCr or UO	0hr prior to AKI stage		24hr prior to AKI stage		48hr prior to AKI stage	
	Cohort 1	Cohort 2	Cohort 1	Cohort 2	Cohort 1	Cohort 2
Median	1.37	1.65	1.37	1.55	1.37	1.52
Average	2.10	3.14	2.10	2.51	2.10	2.57
Stdev	2.10	4.63	2.10	2.75	2.10	3.77
p(t-test)		0.092		0.35		0.42
Min	0.0304	0.0228	0.0304	0.174	0.0304	0.101
Max	9.94	20.0	9.94	12.1	9.94	14.7
n (Samp)	85	35	85	42	85	25
n (Patient)	75	35	75	42	75	25

sCr only	0hr prior to AKI stage		24hr prior to AKI stage		48hr prior to AKI stage	
	Cohort 1	Cohort 2	Cohort 1	Cohort 2	Cohort 1	Cohort 2
Median	1.55	2.14	1.55	1.82	1.55	1.36
Average	3.21	3.62	3.21	2.43	3.21	1.69
Stdev	5.66	5.87	5.66	2.33	5.66	1.27
p(t-test)		0.82		0.65		0.45
Min	0.0304	0.0228	0.0304	0.244	0.0304	0.101
Max	60.1	20.0	60.1	8.20	60.1	3.88
n (Samp)	201	10	201	11	201	8
n (Patient)	132	10	132	11	132	8

UO only	0hr prior to AKI stage		24hr prior to AKI stage		48hr prior to AKI stage	
	Cohort 1	Cohort 2	Cohort 1	Cohort 2	Cohort 1	Cohort 2
Median	1.37	1.65	1.37	1.40	1.37	1.16
Average	2.63	2.84	2.63	2.61	2.63	2.64

UO only	0hr prior to AKI stage		24hr prior to AKI stage		48hr prior to AKI stage	
	Cohort 1	Cohort 2	Cohort 1	Cohort 2	Cohort 1	Cohort 2
Stdev	3.37	3.87	3.37	2.99	3.37	4.07
p(t-test)		0.79		0.97		0.99
Min	0.0304	0.0956	0.0304	0.174	0.0304	0.106
Max	20.0	19.8	20.0	12.1	20.0	14.7
n (Samp)	77	29	77	43	77	21
n (Patient)	64	29	64	43	64	21

	0hr prior to AKI stage			24hr prior to AKI stage			48hr prior to AKI stage		
	sCr or UO	sCr only	UO only	sCr or UO	sCr only	UO only	sCr or UO	sCr only	UO only
AUC	0.53	0.52	0.52	0.53	0.52	0.51	0.49	0.47	0.47
SE	0.059	0.095	0.063	0.055	0.091	0.055	0.066	0.11	0.072
p	0.57	0.80	0.78	0.57	0.80	0.84	0.91	0.75	0.64
nCohort 1	85	201	77	85	201	77	85	201	77
nCohort 2	35	10	29	42	11	43	25	8	21
Cutoff 1	0.568	1.25	0.568	0.785	1.25	0.785	0.714	1.13	0.714
Sens 1	71%	70%	72%	71%	73%	72%	72%	75%	71%
Spec 1	26%	45%	26%	33%	45%	35%	29%	43%	30%
Cutoff 2	0.395	1.00	0.383	0.463	0.645	0.463	0.463	0.787	0.463
Sens 2	80%	80%	83%	81%	82%	81%	80%	88%	81%
Spec 2	20%	39%	18%	22%	28%	23%	22%	34%	23%
Cutoff 3	0.268	0.380	0.268	0.395	0.418	0.341	0.106	0.0956	0.216
Sens 3	91%	90%	93%	90%	91%	91%	92%	100%	90%
Spec 3	13%	16%	12%	20%	18%	16%	6%	3%	10%
Cutoff 4	2.84	3.09	3.18	2.84	3.09	3.18	2.84	3.09	3.18
Sens 4	34%	20%	24%	29%	27%	28%	24%	25%	19%
Spec 4	71%	70%	70%	71%	70%	70%	71%	70%	70%
Cutoff 5	3.68	4.30	3.82	3.68	4.30	3.82	3.68	4.30	3.82
Sens 5	26%	10%	24%	21%	18%	23%	20%	0%	19%
Spec 5	80%	80%	81%	80%	80%	81%	80%	80%	81%
Cutoff 6	4.63	7.46	6.31	4.63	7.46	6.31	4.63	7.46	6.31
Sens 6	14%	10%	10%	17%	9%	14%	8%	0%	10%
Spec 6	91%	90%	91%	91%	90%	91%	91%	90%	91%
OR Quart 2	0.71	0.98	0.78	1.3	1.5	1.2	1.3	3.2	1.8
p Value	0.56	0.98	0.69	0.65	0.65	0.79	0.70	0.32	0.44
95% CI of	0.22	0.13	0.22	0.44	0.25	0.40	0.37	0.32	0.43
OR Quart2	2.2	7.2	2.7	3.7	9.5	3.3	4.5	32	7.2
OR Quart 3	1.2	2.0	1.4	1.3	2.1	1.3	1.0	3.2	1.7
p Value	0.78	0.42	0.55	0.65	0.41	0.59	1.0	0.32	0.48
95% CI of	0.39	0.36	0.44	0.44	0.36	0.46	0.28	0.32	0.41
OR Quart3	3.5	12	4.7	3.7	12	3.8	3.6	32	6.8
OR Quart 4	1.0	0.98	0.95	1.3	1.0	1.0	1.0	1.0	1.4
p Value	1.0	0.98	0.93	0.65	1.0	1.0	0.94	0.99	0.66
95% CI of	0.33	0.13	0.28	0.44	0.14	0.34	0.29	0.062	0.32
OR Quart4	3.0	7.2	3.2	3.7	7.4	2.9	3.8	17	5.9

Vascular endothelial growth factor receptor 3

sCr or UO	0hr prior to AKI stage	24hr prior to AKI stage	48hr prior to AKI stage

	Cohort 1	Cohort 2	Cohort 1	Cohort 2	Cohort 1	Cohort 2
Median	5470	5330	5470	5760	5470	6250
Average	6870	8430	6870	7300	6870	6400
Stdev	5340	7900	5340	5490	5340	2520
p(t-test)		0.17		0.66		0.72
Min	219	1360	219	1000	219	2840
Max	29400	43200	29400	26900	29400	12100
n (Samp)	94	45	94	42	94	18
n (Patient)	65	45	65	42	65	18

sCr only	0hr prior to AKI stage		24hr prior to AKI stage		48hr prior to AKI stage	
	Cohort 1	Cohort 2	Cohort 1	Cohort 2	Cohort 1	Cohort 2
Median	6210	5870	6210	5070	6210	3710
Average	7000	8490	7000	7680	7000	4330
Stdev	5110	7420	5110	6800	5110	2310
p(t-test)		0.30		0.60		0.12
Min	219	4080	219	1280	219	1030
Max	43200	32800	43200	26900	43200	8610
n (Samp)	225	14	225	18	225	9
n (Patient)	132	14	132	18	132	9

UO only	0hr prior to AKI stage		24hr prior to AKI stage		48hr prior to AKI stage	
	Cohort 1	Cohort 2	Cohort 1	Cohort 2	Cohort 1	Cohort 2
Median	5640	5240	5640	5950	5640	6330
Average	7340	7870	7340	6590	7340	6900
Stdev	6250	7620	6250	4150	6250	2300
p(t-test)		0.68		0.48		0.78
Min	219	1360	219	924	219	2840
Max	32800	43200	32800	16600	32800	12100
n (Samp)	103	37	103	41	103	15
n (Patient)	64	37	64	41	64	15

	0hr prior to AKI stage			24hr prior to AKI stage			48hr prior to AKI stage		
	sCr or UO	sCr only	UO only	sCr or UO	sCr only	UO only	sCr or UO	sCr only	UO only
AUC	0.56	0.56	0.51	0.52	0.48	0.49	0.54	0.32	0.58
SE	0.053	0.082	0.056	0.054	0.072	0.054	0.076	0.10	0.082
p	0.24	0.47	0.83	0.74	0.80	0.85	0.57	0.074	0.32
nCohort 1	94	225	103	94	225	103	94	225	103
nCohort 2	45	14	37	42	18	41	18	9	15
Cutoff 1	4260	5140	4160	3490	4050	3400	4580	3020	5450
Sens 1	71%	71%	70%	71%	72%	71%	72%	78%	73%
Spec 1	35%	40%	29%	27%	31%	22%	38%	17%	49%
Cutoff 2	3620	4120	3440	2930	3440	2580	3700	3010	5360
Sens 2	80%	86%	81%	81%	83%	80%	83%	89%	80%
Spec 2	30%	31%	22%	18%	23%	12%	32%	17%	49%
Cutoff 3	2930	4080	2580	2070	1720	1720	2930	1010	4530
Sens 3	91%	93%	92%	90%	94%	90%	94%	100%	93%
Spec 3	18%	31%	12%	11%	7%	7%	18%	4%	31%
Cutoff 4	7770	8350	7770	7770	8350	7770	7770	8350	7770

	0hr prior to AKI stage			24hr prior to AKI stage			48hr prior to AKI stage		
	sCr or UO	sCr only	UO only	sCr or UO	sCr only	UO only	sCr or UO	sCr only	UO only
Sens 4	40%	29%	35%	38%	22%	37%	28%	11%	33%
Spec 4	70%	71%	71%	70%	71%	71%	70%	71%	71%
Cutoff 5	9000	9630	8980	9000	9630	8980	9000	9630	8980
Sens 5	27%	21%	24%	31%	22%	32%	11%	0%	13%
Spec 5	81%	80%	81%	81%	80%	81%	81%	80%	81%
Cutoff 6	13200	11800	13800	13200	11800	13800	13200	11800	13800
Sens 6	11%	7%	11%	10%	17%	5%	0%	0%	0%
Spec 6	90%	90%	90%	90%	90%	90%	90%	90%	90%
OR Quart 2	2.4	>7.8	1.3	1.1	0.74	0.51	1.8	>2.1	4.3
p Value	0.092	<0.059	0.60	0.79	0.70	0.20	0.45	<0.55	0.20
95% CI of	0.86	>0.93	0.47	0.41	0.16	0.18	0.39	>0.19	0.45
OR Quart2	6.9	na	3.8	3.2	3.4	1.4	8.4	na	41
OR Quart 3	0.81	>4.2	0.48	0.74	1.8	0.43	2.3	>3.2	8.9
p Value	0.72	<0.20	0.24	0.58	0.35	0.12	0.28	<0.33	0.048
95% CI of	0.26	>0.46	0.14	0.25	0.51	0.15	0.51	>0.32	1.0
OR Quart3	2.6	na	1.6	2.2	6.7	1.2	10	na	78
OR Quart 4	2.4	>3.1	1.5	1.5	1.0	1.0	1.4	>4.4	3.1
p Value	0.092	<0.33	0.44	0.44	0.98	1.0	0.69	<0.19	0.34
95% CI of	0.86	>0.31	0.54	0.54	0.24	0.38	0.28	>0.47	0.30
OR Quart4	6.9	na	4.2	4.1	4.3	2.6	6.9	na	32

Interferon alpha-2

sCr or UO	0hr prior to AKI stage		24hr prior to AKI stage		48hr prior to AKI stage	
	Cohort 1	Cohort 2	Cohort 1	Cohort 2	Cohort 1	Cohort 2
Median	9.44	17.2	9.44	13.4	9.44	23.0
Average	17.1	19.3	17.1	16.9	17.1	22.5
Stdev	29.3	19.4	29.3	16.2	29.3	10.6
p(t-test)		0.64		0.97		0.44
Min	0.0320	0.0627	0.0320	0.0320	0.0320	0.0627
Max	223	108	223	67.7	223	44.7
n (Samp)	94	45	94	42	94	18
n (Patient)	65	45	65	42	65	18

sCr only	0hr prior to AKI stage		24hr prior to AKI stage		48hr prior to AKI stage	
	Cohort 1	Cohort 2	Cohort 1	Cohort 2	Cohort 1	Cohort 2
Median	13.5	10.2	13.5	11.2	13.5	11.8
Average	18.1	17.0	18.1	23.4	18.1	15.4
Stdev	24.6	27.7	24.6	39.4	24.6	10.2
p(t-test)		0.87		0.40		0.74
Min	0.0320	0.0627	0.0320	0.0320	0.0320	5.14
Max	223	108	223	163	223	35.3
n (Samp)	225	14	225	18	225	9
n (Patient)	132	14	132	18	132	9

UO only	0hr prior to AKI stage		24hr prior to AKI stage		48hr prior to AKI stage	
	Cohort 1	Cohort 2	Cohort 1	Cohort 2	Cohort 1	Cohort 2
Median	7.03	17.2	7.03	13.5	7.03	24.2

UO only	0hr prior to AKI stage		24hr prior to AKI stage		48hr prior to AKI stage	
	Cohort 1	Cohort 2	Cohort 1	Cohort 2	Cohort 1	Cohort 2
Average	15.4	18.8	15.4	17.0	15.4	22.0
Stdev	29.5	14.7	29.5	14.9	29.5	12.8
p(t-test)		0.50		0.74		0.39
Min	0.0320	0.0627	0.0320	0.0320	0.0320	0.0627
Max	223	49.9	223	52.4	223	44.7
n (Samp)	103	37	103	41	103	15
n (Patient)	64	37	64	41	64	15

	0hr prior to AKI stage			24hr prior to AKI stage			48hr prior to AKI stage		
	sCr or UO	sCr only	UO only	sCr or UO	sCr only	UO only	sCr or UO	sCr only	UO only
AUC	0.58	0.46	0.64	0.54	0.46	0.61	0.71	0.54	0.73
SE	0.053	0.081	0.055	0.054	0.072	0.054	0.073	0.10	0.078
p	0.13	0.60	0.013	0.43	0.59	0.041	0.0036	0.71	0.0035
nCohort 1	94	225	103	94	225	103	94	225	103
nCohort 2	45	14	37	42	18	41	18	9	15
Cutoff 1	5.80	4.47	6.46	3.73	0.0324	7.03	19.0	7.76	19.0
Sens 1	71%	71%	70%	71%	89%	71%	72%	78%	73%
Spec 1	40%	33%	49%	33%	2%	50%	70%	40%	77%
Cutoff 2	3.73	0.0764	3.73	0.0627	0.0324	0.0997	13.5	5.98	13.5
Sens 2	80%	93%	81%	86%	89%	80%	83%	89%	80%
Spec 2	33%	17%	38%	16%	2%	27%	60%	37%	65%
Cutoff 3	0.0324	0.0764	0.0324	0.0324	0.0320	0.0627	5.80	4.65	0.0627
Sens 3	100%	93%	100%	95%	94%	93%	94%	100%	93%
Spec 3	2%	17%	2%	2%	1%	17%	40%	34%	17%
Cutoff 4	19.0	23.2	14.8	19.0	23.2	14.8	19.0	23.2	14.8
Sens 4	42%	14%	62%	38%	28%	49%	72%	22%	73%
Spec 4	70%	71%	71%	70%	71%	71%	70%	71%	71%
Cutoff 5	26.9	29.0	20.8	26.9	29.0	20.8	26.9	29.0	20.8
Sens 5	27%	14%	41%	26%	28%	37%	28%	11%	67%
Spec 5	81%	80%	82%	81%	80%	82%	81%	80%	82%
Cutoff 6	36.4	39.9	29.4	36.4	39.9	29.4	36.4	39.9	29.4
Sens 6	18%	7%	24%	10%	11%	20%	6%	0%	33%
Spec 6	90%	90%	90%	90%	90%	90%	90%	90%	90%
OR Quart 2	0.96	2.1	0.83	0.74	0.58	1.0	2.1	>5.4	0.47
p Value	0.94	0.41	0.76	0.58	0.47	1.0	0.56	<0.13	0.54
95% CI of	0.33	0.36	0.25	0.25	0.13	0.33	0.18	>0.61	0.040
OR Quart2	2.8	12	2.8	2.2	2.5	3.0	24	na	5.4
OR Quart 3	1.6	2.1	1.4	1.3	0.79	1.2	9.0	>3.2	1.0
p Value	0.34	0.41	0.57	0.60	0.73	0.78	0.047	<0.32	1.0
95% CI of	0.59	0.36	0.45	0.47	0.20	0.39	1.0	>0.32	0.13
OR Quart3	4.6	12	4.3	3.6	3.1	3.5	79	na	7.6
OR Quart 4	1.9	2.1	3.0	1.3	1.2	2.8	11	>1.0	6.8
p Value	0.24	0.40	0.043	0.60	0.73	0.049	0.031	<1.0	0.021
95% CI of	0.67	0.37	1.0	0.47	0.36	1.0	1.2	>0.061	1.3
OR Quart4	5.1	12	8.7	3.6	4.3	7.8	93	na	34

Insulin-like growth factor-binding protein 4

sCr or UO	0hr prior to AKI stage		24hr prior to AKI stage		48hr prior to AKI stage	
	Cohort 1	Cohort 2	Cohort 1	Cohort 2	Cohort 1	Cohort 2
Median	2.93	3.18	2.93	2.93	2.93	2.93
Average	14.5	13.6	14.5	10.9	14.5	6.68
Stdev	26.1	14.8	26.1	12.5	26.1	7.82
p(t-test)		0.82		0.35		0.14
Min	0.0862	0.572	0.0862	0.572	0.0862	0.572
Max	158	57.3	158	52.0	158	24.1
n (Samp)	119	52	119	53	119	26
n (Patient)	87	52	87	53	87	26

sCr only	0hr prior to AKI stage		24hr prior to AKI stage		48hr prior to AKI stage	
	Cohort 1	Cohort 2	Cohort 1	Cohort 2	Cohort 1	Cohort 2
Median	2.93	8.11	2.93	2.93	2.93	2.93
Average	12.8	13.3	12.8	13.1	12.8	10.2
Stdev	19.6	13.6	19.6	15.9	19.6	11.9
p(t-test)		0.92		0.95		0.68
Min	0.0862	0.572	0.0862	0.572	0.0862	0.572
Max	158	46.7	158	52.0	158	30.5
n (Samp)	283	16	283	14	283	10
n (Patient)	161	16	161	14	161	10

UO only	0hr prior to AKI stage		24hr prior to AKI stage		48hr prior to AKI stage	
	Cohort 1	Cohort 2	Cohort 1	Cohort 2	Cohort 1	Cohort 2
Median	3.29	3.18	3.29	2.93	3.29	2.93
Average	15.0	13.6	15.0	9.49	15.0	6.86
Stdev	25.6	14.9	25.6	10.6	25.6	7.85
p(t-test)		0.74		0.13		0.13
Min	0.0728	0.572	0.0728	0.572	0.0728	0.572
Max	158	57.3	158	33.5	158	21.7
n (Samp)	123	42	123	54	123	23
n (Patient)	80	42	80	54	80	23

	0hr prior to AKI stage			24hr prior to AKI stage			48hr prior to AKI stage		
	sCr or UO	sCr only	UO only	sCr or UO	sCr only	UO only	sCr or UO	sCr only	UO only
AUC	0.57	0.55	0.55	0.52	0.54	0.48	0.50	0.53	0.45
SE	0.048	0.076	0.052	0.048	0.081	0.047	0.063	0.095	0.067
p	0.16	0.52	0.30	0.68	0.66	0.69	0.95	0.76	0.42
nCohort 1	119	283	123	119	283	123	119	283	123
nCohort 2	52	16	42	53	14	54	26	10	23
Cutoff 1	0.971	0.971	0.971	0.971	0.971	0.971	0.971	2.43	0.572
Sens 1	79%	81%	81%	72%	86%	72%	77%	70%	87%
Spec 1	36%	29%	33%	36%	29%	33%	36%	41%	15%
Cutoff 2	0.572	0.971	0.971	0.572	0.971	0.572	0.572	0.971	0.572
Sens 2	88%	81%	81%	83%	86%	83%	92%	90%	87%
Spec 2	16%	29%	33%	16%	29%	15%	16%	29%	15%
Cutoff 3	0.0862	0.0862	0.572	0.0862	0.0862	0.0862	0.572	0.971	0.0862
Sens 3	100%	100%	90%	100%	100%	100%	92%	90%	100%
Spec 3	1%	0%	15%	1%	0%	2%	16%	29%	2%

	0hr prior to AKI stage			24hr prior to AKI stage			48hr prior to AKI stage		
	sCr or UO	sCr only	UO only	sCr or UO	sCr only	UO only	sCr or UO	sCr only	UO only
Cutoff 4	14.4	17.1	16.6	14.4	17.1	16.6	14.4	17.1	16.6
Sens 4	40%	38%	43%	28%	29%	22%	23%	30%	17%
Spec 4	71%	70%	72%	71%	70%	72%	71%	70%	72%
Cutoff 5	23.1	23.1	23.1	23.1	23.1	23.1	23.1	23.1	23.1
Sens 5	25%	31%	24%	21%	29%	17%	4%	30%	0%
Spec 5	81%	81%	80%	81%	81%	80%	81%	81%	80%
Cutoff 6	36.9	31.3	34.8	36.9	31.3	34.8	36.9	31.3	34.8
Sens 6	8%	6%	10%	2%	14%	0%	0%	0%	0%
Spec 6	92%	90%	90%	92%	90%	90%	92%	90%	90%
OR Quart 2	2.8	3.1	1.9	0.79	2.1	1.4	2.8	4.2	1.0
p Value	0.042	0.17	0.21	0.63	0.41	0.44	0.12	0.21	0.97
95% CI of	1.0	0.61	0.69	0.31	0.37	0.57	0.76	0.46	0.24
OR Quart2	7.4	16	5.3	2.0	12	3.7	9.9	38	4.5
OR Quart 3	1.6	0.99	1.3	1.5	2.1	1.8	2.8	2.0	2.7
p Value	0.34	0.99	0.59	0.37	0.41	0.22	0.12	0.57	0.14
95% CI of	0.59	0.14	0.47	0.62	0.37	0.71	0.76	0.18	0.74
OR Quart3	4.6	7.2	3.8	3.7	12	4.4	9.9	23	9.5
OR Quart 4	2.3	3.1	1.5	0.89	2.0	1.3	1.0	3.0	1.6
p Value	0.10	0.17	0.47	0.81	0.42	0.59	0.97	0.34	0.47
95% CI of	0.84	0.61	0.52	0.35	0.36	0.51	0.24	0.31	0.42
OR Quart4	6.1	16	4.1	2.3	11	3.3	4.5	30	6.4

Insulin-like growth factor-binding protein 5

sCr or UO	0hr prior to AKI stage		24hr prior to AKI stage		48hr prior to AKI stage	
	Cohort 1	Cohort 2	Cohort 1	Cohort 2	Cohort 1	Cohort 2
Median	21.0	5.45	21.0	9.99	21.0	24.0
Average	37.8	33.6	37.8	36.6	37.8	41.1
Stdev	49.2	53.3	49.2	55.6	49.2	48.4
p(t-test)		0.62		0.89		0.75
Min	0.204	0.204	0.204	0.204	0.204	0.204
Max	257	189	257	228	257	149
n (Samp)	119	52	119	53	119	26
n (Patient)	87	52	87	53	87	26

sCr only	0hr prior to AKI stage		24hr prior to AKI stage		48hr prior to AKI stage	
	Cohort 1	Cohort 2	Cohort 1	Cohort 2	Cohort 1	Cohort 2
Median	14.7	0.763	14.7	0.763	14.7	6.07
Average	34.2	29.8	34.2	44.9	34.2	45.5
Stdev	47.7	51.3	47.7	66.8	47.7	62.9
p(t-test)		0.72		0.42		0.47
Min	0.204	0.222	0.204	0.316	0.204	0.222
Max	257	151	257	177	257	149
n (Samp)	283	16	283	14	283	10
n (Patient)	161	16	161	14	161	10

UO only	0hr prior to AKI stage		24hr prior to AKI stage		48hr prior to AKI stage	
	Cohort 1	Cohort 2	Cohort 1	Cohort 2	Cohort 1	Cohort 2

UO only	0hr prior to AKI stage		24hr prior to AKI stage		48hr prior to AKI stage	
	Cohort 1	Cohort 2	Cohort 1	Cohort 2	Cohort 1	Cohort 2
Median	8.50	5.45	8.50	11.4	8.50	8.58
Average	30.2	34.4	30.2	34.0	30.2	33.3
Stdev	47.5	53.1	47.5	50.4	47.5	44.1
p(t-test)		0.64		0.63		0.78
Min	0.204	0.204	0.204	0.204	0.204	0.204
Max	257	189	257	228	257	149
n (Samp)	123	42	123	54	123	23
n (Patient)	80	42	80	54	80	23

	0hr prior to AKI stage			24hr prior to AKI stage			48hr prior to AKI stage		
	sCr or UO	sCr only	UO only	sCr or UO	sCr only	UO only	sCr or UO	sCr only	UO only
AUC	0.44	0.44	0.51	0.46	0.52	0.51	0.54	0.53	0.55
SE	0.048	0.076	0.052	0.048	0.080	0.047	0.063	0.094	0.067
p	0.25	0.47	0.89	0.40	0.80	0.79	0.57	0.77	0.43
nCohort 1	119	283	123	119	283	123	119	283	123
nCohort 2	52	16	42	53	14	54	26	10	23
Cutoff 1	0.357	0.316	0.357	0.316	0.357	0.316	0.696	0.357	0.488
Sens 1	73%	75%	71%	75%	71%	70%	73%	70%	74%
Spec 1	22%	22%	28%	18%	26%	24%	32%	26%	41%
Cutoff 2	0.222	0.222	0.222	0.222	0.316	0.222	0.357	0.316	0.222
Sens 2	87%	81%	86%	87%	93%	83%	81%	90%	91%
Spec 2	16%	16%	20%	16%	22%	20%	22%	22%	20%
Cutoff 3	0.204	0.204	0.204	0.204	0.316	0.204	0.222	0.316	0.222
Sens 3	94%	100%	93%	96%	93%	96%	96%	90%	91%
Spec 3	4%	5%	5%	4%	22%	5%	16%	22%	20%
Cutoff 4	47.6	41.5	36.4	47.6	41.5	36.4	47.6	41.5	36.4
Sens 4	19%	31%	29%	26%	36%	28%	35%	30%	30%
Spec 4	71%	70%	71%	71%	70%	71%	71%	70%	71%
Cutoff 5	64.4	61.4	49.7	64.4	61.4	49.7	64.4	61.4	49.7
Sens 5	15%	19%	21%	19%	29%	26%	27%	30%	30%
Spec 5	81%	80%	80%	81%	80%	80%	81%	80%	80%
Cutoff 6	97.6	97.6	80.9	97.6	97.6	80.9	97.6	97.6	80.9
Sens 6	13%	12%	17%	15%	21%	13%	19%	30%	13%
Spec 6	91%	90%	90%	91%	90%	90%	91%	90%	90%
OR Quart 2	1.3	0.66	1.0	0.89	1.0	0.57	1.5	1.0	1.2
p Value	0.62	0.65	1.0	0.81	1.0	0.24	0.53	1.0	0.78
95% CI of	0.48	0.11	0.38	0.34	0.24	0.22	0.43	0.20	0.33
OR Quart2	3.4	4.1	2.7	2.3	4.2	1.5	5.2	5.1	4.3
OR Quart 3	2.0	2.5	0.88	1.2	0.24	1.0	1.2	0.32	1.0
p Value	0.16	0.20	0.80	0.64	0.21	1.0	0.74	0.33	1.0
95% CI of	0.76	0.61	0.33	0.50	0.026	0.41	0.34	0.033	0.26
OR Quart3	5.0	9.9	2.4	3.1	2.2	2.4	4.5	3.2	3.8
OR Quart 4	1.6	1.4	0.85	1.5	1.2	0.87	1.7	0.99	1.4
p Value	0.30	0.69	0.75	0.36	0.75	0.76	0.39	0.99	0.56
95% CI of	0.63	0.30	0.32	0.62	0.32	0.36	0.50	0.19	0.41
OR Quart4	4.3	6.4	2.3	3.8	4.9	2.1	5.8	5.1	5.1

Immunoglobulin G4

sCr or UO	0hr prior to AKI stage		24hr prior to AKI stage		48hr prior to AKI stage	
	Cohort 1	Cohort 2	Cohort 1	Cohort 2	Cohort 1	Cohort 2
Median	416000	348000	416000	364000	416000	325000
Average	815000	435000	815000	451000	815000	395000
Stdev	1020000	366000	1020000	338000	1020000	384000
p(t-test)		0.033		0.035		0.20
Min	15300	2000	15300	14400	15300	18500
Max	5190000	1690000	5190000	1480000	5190000	1070000
n (Samp)	94	35	94	37	94	10
n (Patient)	67	35	67	37	67	10

sCr only	0hr prior to AKI stage		24hr prior to AKI stage		48hr prior to AKI stage	
	Cohort 1	Cohort 2	Cohort 1	Cohort 2	Cohort 1	Cohort 2
Median	364000	506000	364000	357000	nd	nd
Average	626000	585000	626000	454000	nd	nd
Stdev	765000	449000	765000	347000	nd	nd
p(t-test)		0.87		0.53	nd	nd
Min	2000	61100	2000	58300	nd	nd
Max	5190000	1690000	5190000	939000	nd	nd
n (Samp)	205	10	205	8	nd	nd
n (Patient)	126	10	126	8	nd	nd

UO only	0hr prior to AKI stage		24hr prior to AKI stage		48hr prior to AKI stage	
	Cohort 1	Cohort 2	Cohort 1	Cohort 2	Cohort 1	Cohort 2
Median	417000	328000	417000	409000	417000	385000
Average	719000	486000	719000	585000	719000	434000
Stdev	858000	677000	858000	651000	858000	371000
p(t-test)		0.19		0.40		0.26
Min	15300	2000	15300	14400	15300	18500
Max	5140000	3560000	5140000	3700000	5140000	1070000
n (Samp)	101	28	101	36	101	12
n (Patient)	65	28	65	36	65	12

	0hr prior to AKI stage			24hr prior to AKI stage			48hr prior to AKI stage		
	sCr or UO	sCr only	UO only	sCr or UO	sCr only	UO only	sCr or UO	sCr only	UO only
AUC	0.42	0.57	0.40	0.44	0.48	0.48	0.37	nd	0.41
SE	0.058	0.096	0.063	0.057	0.11	0.056	0.099	nd	0.091
p	0.15	0.49	0.11	0.32	0.82	0.77	0.18	nd	0.30
nCohort 1	94	205	101	94	205	101	94	nd	101
nCohort 2	35	10	28	37	8	36	10	nd	12
Cutoff 1	191000	402000	186000	277000	250000	299000	71200	nd	71200
Sens 1	71%	70%	71%	70%	75%	72%	70%	nd	75%
Spec 1	30%	53%	28%	40%	34%	40%	13%	nd	11%
Cutoff 2	83300	347000	56300	164000	90700	245000	37500	nd	37500
Sens 2	80%	80%	82%	81%	88%	81%	80%	nd	83%
Spec 2	16%	49%	7%	26%	18%	34%	5%	nd	4%
Cutoff 3	33600	191000	15300	38600	58100	38600	18500	nd	18500
Sens 3	91%	90%	93%	92%	100%	92%	90%	nd	92%
Spec 3	4%	29%	1%	5%	12%	4%	1%	nd	1%

	0hr prior to AKI stage			24hr prior to AKI stage			48hr prior to AKI stage		
	sCr or UO	sCr only	UO only	sCr or UO	sCr only	UO only	sCr or UO	sCr only	UO only
Cutoff 4	977000	705000	884000	977000	705000	884000	977000	nd	884000
Sens 4	3%	20%	14%	5%	25%	19%	10%	nd	8%
Spec 4	70%	70%	70%	70%	70%	70%	70%	nd	70%
Cutoff 5	1370000	977000	1080000	1370000	977000	1080000	1370000	nd	1080000
Sens 5	3%	10%	4%	3%	0%	8%	0%	nd	0%
Spec 5	81%	80%	80%	81%	80%	80%	81%	nd	80%
Cutoff 6	2130000	1380000	1590000	2130000	1380000	1590000	2130000	nd	1590000
Sens 6	0%	10%	4%	0%	0%	3%	0%	nd	0%
Spec 6	90%	90%	90%	90%	90%	90%	90%	nd	90%
OR Quart 2	6.8	2.0	2.0	4.7	1.0	1.9	3.3	nd	4.7
p Value	0.0063	0.58	0.30	0.016	0.98	0.25	0.32	nd	0.18
95% CI of	1.7	0.18	0.53	1.3	0.14	0.64	0.32	nd	0.49
OR Quart2	27	23	7.8	17	7.5	5.7	34	nd	45
OR Quart 3	5.2	6.5	2.8	4.1	1.0	1.9	2.1	nd	3.4
p Value	0.020	0.088	0.12	0.027	0.98	0.25	0.56	nd	0.31
95% CI of	1.3	0.75	0.77	1.2	0.14	0.64	0.18	nd	0.33
OR Quart3	21	56	10	15	7.5	5.7	25	nd	34
OR Quart 4	3.3	0.98	2.4	2.4	1.0	1.0	4.5	nd	4.7
p Value	0.099	0.99	0.19	0.19	0.98	0.95	0.19	nd	0.18
95% CI of	0.80	0.060	0.65	0.65	0.14	0.32	0.47	nd	0.49
OR Quart4	14	16	9.0	9.0	7.5	3.4	44	nd	45

Interleukin-21

sCr or UO	0hr prior to AKI stage		24hr prior to AKI stage		48hr prior to AKI stage	
	Cohort 1	Cohort 2	Cohort 1	Cohort 2	Cohort 1	Cohort 2
Median	0.694	0.220	0.694	0.631	0.694	1.76
Average	62.7	2.10	62.7	2.18	62.7	2.97
Stdev	560	4.20	560	3.76	560	4.00
p(t-test)		0.47		0.49		0.65
Min	0.0102	0.0102	0.0102	0.0102	0.0102	0.0102
Max	5430	18.3	5430	15.6	5430	14.3
n (Samp)	94	45	94	42	94	18
n (Patient)	65	45	65	42	65	18

sCr only	0hr prior to AKI stage		24hr prior to AKI stage		48hr prior to AKI stage	
	Cohort 1	Cohort 2	Cohort 1	Cohort 2	Cohort 1	Cohort 2
Median	0.430	1.62	0.430	1.56	0.430	1.36
Average	27.5	4.80	27.5	4.77	27.5	3.68
Stdev	362	6.58	362	7.34	362	5.30
p(t-test)		0.82		0.79		0.84
Min	0.0102	0.0102	0.0102	0.0257	0.0102	0.0102
Max	5430	18.3	5430	26.6	5430	14.3
n (Samp)	225	14	225	18	225	9
n (Patient)	132	14	132	18	132	9

UO only	0hr prior to AKI stage		24hr prior to AKI stage		48hr prior to AKI stage	
	Cohort 1	Cohort 2	Cohort 1	Cohort 2	Cohort 1	Cohort 2

UO only	0hr prior to AKI stage		24hr prior to AKI stage		48hr prior to AKI stage	
	Cohort 1	Cohort 2	Cohort 1	Cohort 2	Cohort 1	Cohort 2
Median	0.829	0.174	0.829	0.630	0.829	0.829
Average	57.9	1.06	57.9	1.90	57.9	2.24
Stdev	535	2.03	535	3.33	535	3.16
p(t-test)		0.52		0.50		0.69
Min	0.0102	0.0102	0.0102	0.0102	0.0102	0.0102
Max	5430	8.97	5430	16.0	5430	11.5
n (Samp)	103	37	103	41	103	15
n (Patient)	64	37	64	41	64	15

	0hr prior to AKI stage			24hr prior to AKI stage			48hr prior to AKI stage		
	sCr or UO	sCr only	UO only	sCr or UO	sCr only	UO only	sCr or UO	sCr only	UO only
AUC	0.45	0.58	0.37	0.52	0.68	0.47	0.62	0.63	0.54
SE	0.053	0.082	0.055	0.054	0.072	0.054	0.076	0.10	0.081
p	0.37	0.33	0.020	0.70	0.011	0.56	0.099	0.20	0.63
nCohort 1	94	225	103	94	225	103	94	225	103
nCohort 2	45	14	37	42	18	41	18	9	15
Cutoff 1	0.0154	0.0154	0.0154	0.0257	0.231	0.0257	0.605	0.783	0.430
Sens 1	76%	79%	70%	74%	72%	71%	78%	78%	73%
Spec 1	19%	22%	14%	33%	48%	32%	50%	59%	46%
Cutoff 2	0.0142	0.0142	0.0102	0.0182	0.174	0.0154	0.430	0.0182	0.174
Sens 2	82%	86%	89%	83%	89%	85%	83%	89%	80%
Spec 2	15%	14%	5%	24%	43%	14%	49%	29%	36%
Cutoff 3	0.0102	0.0102	0	0.0142	0.0257	0.0142	0.0142	0	0.0142
Sens 3	91%	93%	100%	93%	94%	93%	94%	100%	93%
Spec 3	10%	9%	0%	15%	39%	11%	15%	0%	11%
Cutoff 4	1.77	1.61	2.03	1.77	1.61	2.03	1.77	1.61	2.03
Sens 4	29%	50%	19%	31%	39%	24%	50%	44%	20%
Spec 4	70%	71%	72%	70%	71%	72%	70%	71%	72%
Cutoff 5	2.93	2.46	3.18	2.93	2.46	3.18	2.93	2.46	3.18
Sens 5	16%	43%	8%	24%	39%	17%	22%	22%	20%
Spec 5	81%	80%	81%	81%	80%	81%	81%	80%	81%
Cutoff 6	10.6	5.00	14.5	10.6	5.00	14.5	10.6	5.00	14.5
Sens 6	7%	29%	0%	7%	28%	2%	11%	22%	0%
Spec 6	90%	90%	90%	90%	90%	90%	90%	90%	90%
OR Quart 2	0.57	0.47	1.4	1.5	>6.5	1.0	2.2	0.98	3.4
p Value	0.29	0.40	0.55	0.43	<0.087	1.0	0.40	0.99	0.16
95% CI of	0.20	0.083	0.44	0.54	>0.76	0.34	0.36	0.060	0.62
OR Quart2	1.6	2.7	4.7	4.3	na	2.9	13	16	18
OR Quart 3	1.1	0.23	2.2	1.0	>5.4	1.5	4.3	4.2	2.2
p Value	0.80	0.20	0.17	1.0	<0.13	0.44	0.086	0.20	0.40
95% CI of	0.43	0.025	0.71	0.34	>0.61	0.54	0.81	0.46	0.36
OR Quart3	3.0	2.1	6.9	2.9	na	4.2	23	39	13
OR Quart 4	1.0	1.8	2.5	1.5	>7.8	1.3	2.8	3.1	1.5
p Value	0.93	0.36	0.11	0.43	<0.059	0.60	0.24	0.34	0.67
95% CI of	0.39	0.50	0.82	0.54	>0.93	0.47	0.50	0.31	0.23
OR Quart4	2.8	6.6	7.7	4.3	na	3.7	16	30	9.7

Interleukin-23

sCr or UO	0hr prior to AKI stage		24hr prior to AKI stage		48hr prior to AKI stage	
	Cohort 1	Cohort 2	Cohort 1	Cohort 2	Cohort 1	Cohort 2
Median	0.886	1.10	0.886	1.10	0.886	6.06
Average	1780	3580	1780	4170	1780	1560
Stdev	10800	15400	10800	15900	10800	4960
p(t-test)		0.43		0.31		0.93
Min	0.257	0.257	0.257	0.257	0.257	0.603
Max	100000	100000	100000	100000	100000	20500
n (Samp)	93	45	93	42	93	18
n (Patient)	64	45	64	42	64	18

sCr only	0hr prior to AKI stage		24hr prior to AKI stage		48hr prior to AKI stage	
	Cohort 1	Cohort 2	Cohort 1	Cohort 2	Cohort 1	Cohort 2
Median	1.10	0.886	1.10	1.10	1.10	0.603
Average	2750	3820	2750	8680	2750	2270
Stdev	14900	7430	14900	23800	14900	6820
p(t-test)		0.79		0.12		0.92
Min	0.257	0.257	0.257	0.257	0.257	0.257
Max	100000	20000	100000	100000	100000	20500
n (Samp)	224	14	224	18	224	9
n (Patient)	131	14	131	18	131	9

UO only	0hr prior to AKI stage		24hr prior to AKI stage		48hr prior to AKI stage	
	Cohort 1	Cohort 2	Cohort 1	Cohort 2	Cohort 1	Cohort 2
Median	0.995	1.10	0.995	1.10	0.995	44.5
Average	2480	2920	2480	3160	2480	511
Stdev	11000	16400	11000	15600	11000	1650
p(t-test)		0.86		0.77		0.49
Min	0.257	0.257	0.257	0.257	0.257	0.603
Max	100000	100000	100000	100000	100000	6480
n (Samp)	102	37	102	41	102	15
n (Patient)	63	37	63	41	63	15

	0hr prior to AKI stage			24hr prior to AKI stage			48hr prior to AKI stage		
	sCr or UO	sCr only	UO only	sCr or UO	sCr only	UO only	sCr or UO	sCr only	UO only
AUC	0.52	0.50	0.49	0.55	0.60	0.53	0.55	0.34	0.60
SE	0.053	0.080	0.056	0.054	0.073	0.054	0.076	0.10	0.082
p	0.74	0.98	0.79	0.32	0.17	0.56	0.51	0.11	0.24
nCohort 1	93	224	102	93	224	102	93	224	102
nCohort 2	45	14	37	42	18	41	18	9	15
Cutoff 1	0.603	0.603	0.603	0.603	0.770	0.603	0.257	0.257	0.653
Sens 1	78%	79%	76%	79%	78%	80%	100%	89%	80%
Spec 1	25%	22%	24%	25%	38%	24%	18%	13%	41%
Cutoff 2	0.257	0.257	0.257	0.257	0.257	0.603	0.257	0.257	0.653
Sens 2	84%	86%	84%	81%	83%	80%	100%	89%	80%
Spec 2	18%	13%	19%	18%	13%	24%	18%	13%	41%
Cutoff 3	0	0	0	0	0	0	0.257	0	0.257
Sens 3	100%	100%	100%	100%	100%	100%	100%	100%	100%
Spec 3	0%	0%	0%	0%	0%	0%	18%	0%	19%

	0hr prior to AKI stage			24hr prior to AKI stage			48hr prior to AKI stage		
	sCr or UO	sCr only	UO only	sCr or UO	sCr only	UO only	sCr or UO	sCr only	UO only
Cutoff 4	11.0	44.5	55.0	11.0	44.5	55.0	11.0	44.5	55.0
Sens 4	31%	29%	27%	43%	44%	34%	44%	11%	47%
Spec 4	71%	71%	71%	71%	71%	71%	71%	71%	71%
Cutoff 5	501	267	530	501	267	530	501	267	530
Sens 5	16%	29%	8%	29%	39%	24%	11%	11%	7%
Spec 5	81%	80%	80%	81%	80%	80%	81%	80%	80%
Cutoff 6	1500	1040	2000	1500	1040	2000	1500	1040	2000
Sens 6	11%	29%	5%	14%	33%	12%	11%	11%	7%
Spec 6	90%	90%	90%	90%	90%	90%	90%	90%	90%
OR Quart 2	1.1	1.7	2.9	1.1	0.72	1.7	0.34	1.0	1.6
p Value	0.86	0.48	0.065	0.85	0.68	0.33	0.22	0.99	0.64
95% CI of	0.39	0.39	0.94	0.38	0.16	0.59	0.060	0.062	0.24
OR Quart2	3.1	7.4	8.7	3.2	3.4	4.8	1.9	17	10
OR Quart 3	1.9	0.65	1.7	1.3	0.74	1.5	1.5	2.1	4.3
p Value	0.21	0.65	0.38	0.65	0.70	0.47	0.56	0.56	0.087
95% CI of	0.70	0.11	0.52	0.45	0.16	0.51	0.40	0.18	0.81
OR Quart3	5.2	4.1	5.3	3.6	3.4	4.3	5.3	23	23
OR Quart 4	0.83	1.3	1.7	1.5	2.1	1.3	0.73	5.5	1.5
p Value	0.73	0.71	0.35	0.48	0.24	0.63	0.67	0.13	0.67
95% CI of	0.29	0.29	0.54	0.51	0.60	0.44	0.17	0.62	0.23
OR Quart4	2.4	6.2	5.6	4.1	7.4	3.8	3.1	48	9.7

Interleukin-28A

sCr or UO	0hr prior to AKI stage		24hr prior to AKI stage		48hr prior to AKI stage	
	Cohort 1	Cohort 2	Cohort 1	Cohort 2	Cohort 1	Cohort 2
Median	0.168	0.265	0.168	0.265	0.168	12.7
Average	60.1	15.3	60.1	13.9	60.1	26.7
Stdev	387	47.2	387	41.9	387	54.8
p(t-test)		0.44		0.44		0.72
Min	0.0727	0.0727	0.0727	0.0727	0.0727	0.148
Max	3150	246	3150	243	3150	235
n (Samp)	93	45	93	42	93	18
n (Patient)	64	45	64	42	64	18

sCr only	0hr prior to AKI stage		24hr prior to AKI stage		48hr prior to AKI stage	
	Cohort 1	Cohort 2	Cohort 1	Cohort 2	Cohort 1	Cohort 2
Median	0.195	0.230	0.195	0.265	0.195	0.265
Average	28.7	36.9	28.7	136	28.7	31.0
Stdev	250	80.9	250	470	250	77.2
p(t-test)		0.90		0.11		0.98
Min	0.0727	0.0727	0.0727	0.148	0.0727	0.0727
Max	3150	246	3150	2000	3150	235
n (Samp)	224	14	224	18	224	9
n (Patient)	131	14	131	18	131	9

UO only	0hr prior to AKI stage		24hr prior to AKI stage		48hr prior to AKI stage	
	Cohort 1	Cohort 2	Cohort 1	Cohort 2	Cohort 1	Cohort 2

UO only	0hr prior to AKI stage		24hr prior to AKI stage		48hr prior to AKI stage	
	Cohort 1	Cohort 2	Cohort 1	Cohort 2	Cohort 1	Cohort 2
Median	0.168	0.265	0.168	0.265	0.168	0.265
Average	57.5	4.69	57.5	7.99	57.5	13.5
Stdev	370	10.1	370	16.8	370	18.3
p(t-test)		0.39		0.39		0.65
Min	0.0727	0.0727	0.0727	0.0727	0.0727	0.0727
Max	3150	49.8	3150	92.3	3150	62.9
n (Samp)	102	37	102	41	102	15
n (Patient)	63	37	63	41	63	15

	0hr prior to AKI stage			24hr prior to AKI stage			48hr prior to AKI stage		
	sCr or UO	sCr only	UO only	sCr or UO	sCr only	UO only	sCr or UO	sCr only	UO only
AUC	0.59	0.55	0.61	0.62	0.65	0.62	0.76	0.60	0.69
SE	0.053	0.082	0.056	0.054	0.073	0.053	0.069	0.10	0.080
p	0.072	0.53	0.051	0.026	0.036	0.028	2.1E-4	0.31	0.015
nCohort 1	93	224	102	93	224	102	93	224	102
nCohort 2	45	14	37	42	18	41	18	9	15
Cutoff 1	0.120	0.120	0.120	0.168	0.168	0.148	0.168	0.158	0.168
Sens 1	91%	79%	92%	71%	72%	73%	89%	78%	80%
Spec 1	19%	17%	24%	54%	48%	46%	54%	38%	56%
Cutoff 2	0.120	0	0.120	0.120	0.158	0.120	0.168	0.120	0.168
Sens 2	91%	100%	92%	88%	83%	83%	89%	89%	80%
Spec 2	19%	0%	24%	19%	38%	24%	54%	17%	56%
Cutoff 3	0.120	0	0.120	0	0.120	0	0.148	0	0.120
Sens 3	91%	100%	92%	100%	100%	100%	94%	100%	93%
Spec 3	19%	0%	24%	0%	17%	0%	41%	0%	24%
Cutoff 4	0.265	0.265	0.265	0.265	0.265	0.265	0.265	0.265	0.265
Sens 4	42%	36%	41%	36%	39%	39%	61%	44%	47%
Spec 4	80%	71%	82%	80%	71%	82%	80%	71%	82%
Cutoff 5	3.03	10.2	0.265	3.03	10.2	0.265	3.03	10.2	0.265
Sens 5	33%	36%	41%	33%	28%	39%	56%	33%	47%
Spec 5	81%	80%	82%	81%	80%	82%	81%	80%	82%
Cutoff 6	16.5	19.3	16.5	16.5	19.3	16.5	16.5	19.3	16.5
Sens 6	16%	29%	8%	12%	28%	10%	39%	22%	33%
Spec 6	90%	90%	90%	90%	90%	90%	90%	90%	90%
OR Quart 2	5.0	1.3	3.4	0.81	>6.5	0.47	>3.2	2.0	1.0
p Value	0.011	0.71	0.056	0.72	<0.087	0.22	<0.32	0.57	1.0
95% CI of	1.4	0.29	0.97	0.26	>0.76	0.14	>0.32	0.18	0.060
OR Quart2	17	6.2	12	2.6	na	1.6	na	23	17
OR Quart 3	3.6	0.65	1.9	1.7	>6.7	1.3	>5.9	3.1	7.3
p Value	0.048	0.65	0.36	0.33	<0.084	0.65	<0.12	0.33	0.075
95% CI of	1.0	0.11	0.49	0.59	>0.78	0.45	>0.64	0.31	0.82
OR Quart3	13	4.1	7.1	4.9	na	3.6	na	31	65
OR Quart 4	6.3	1.7	5.6	2.5	>6.5	2.3	>15	3.1	8.5
p Value	0.0035	0.48	0.0063	0.090	<0.087	0.10	<0.013	0.34	0.053
95% CI of	1.8	0.39	1.6	0.87	>0.76	0.85	>1.8	0.31	0.98
OR Quart4	22	7.4	19	7.0	na	6.3	na	30	74

Interleukin-33

sCr or UO	0hr prior to AKI stage		24hr prior to AKI stage		48hr prior to AKI stage	
	Cohort 1	Cohort 2	Cohort 1	Cohort 2	Cohort 1	Cohort 2
Median	0.0981	0.0981	0.0981	0.101	0.0981	0.101
Average	481	183	481	184	481	63.4
Stdev	4130	710	4130	626	4130	210
p(t-test)		0.63		0.64		0.67
Min	0.0445	0.0445	0.0445	0.0445	0.0445	0.0445
Max	40000	4440	40000	3770	40000	892
n (Samp)	94	45	94	42	94	18
n (Patient)	65	45	65	42	65	18

sCr only	0hr prior to AKI stage		24hr prior to AKI stage		48hr prior to AKI stage	
	Cohort 1	Cohort 2	Cohort 1	Cohort 2	Cohort 1	Cohort 2
Median	0.0981	0.0762	0.0981	0.0993	0.0981	0.101
Average	327	240	327	844	327	99.4
Stdev	2850	485	2850	2870	2850	297
p(t-test)		0.91		0.46		0.81
Min	0.0445	0.0445	0.0445	0.0445	0.0445	0.0455
Max	40000	1270	40000	12300	40000	892
n (Samp)	225	14	225	18	225	9
n (Patient)	132	14	132	18	132	9

UO only	0hr prior to AKI stage		24hr prior to AKI stage		48hr prior to AKI stage	
	Cohort 1	Cohort 2	Cohort 1	Cohort 2	Cohort 1	Cohort 2
Median	0.0981	0.0981	0.0981	0.101	0.0981	0.101
Average	503	132	503	131	503	16.7
Stdev	3950	730	3950	595	3950	38.5
p(t-test)		0.57		0.55		0.64
Min	0.0445	0.0445	0.0445	0.0445	0.0445	0.0445
Max	40000	4440	40000	3770	40000	149
n (Samp)	103	37	103	41	103	15
n (Patient)	64	37	64	41	64	15

	0hr prior to AKI stage			24hr prior to AKI stage			48hr prior to AKI stage		
	sCr or UO	sCr only	UO only	sCr or UO	sCr only	UO only	sCr or UO	sCr only	UO only
AUC	0.46	0.46	0.45	0.55	0.54	0.56	0.62	0.55	0.59
SE	0.053	0.081	0.056	0.054	0.072	0.054	0.076	0.10	0.082
p	0.49	0.63	0.39	0.38	0.59	0.27	0.13	0.61	0.28
nCohort 1	94	225	103	94	225	103	94	225	103
nCohort 2	45	14	37	42	18	41	18	9	15
Cutoff 1	0.0455	0.0494	0.0455	0.0494	0.0445	0.0494	0.0996	0.0846	0.0996
Sens 1	73%	71%	73%	76%	83%	83%	83%	78%	73%
Spec 1	24%	21%	23%	24%	10%	23%	55%	36%	60%
Cutoff 2	0.0445	0.0445	0.0445	0.0445	0.0445	0.0494	0.0996	0.0494	0.0543
Sens 2	89%	86%	89%	95%	83%	83%	83%	89%	80%
Spec 2	11%	10%	8%	11%	10%	23%	55%	21%	41%
Cutoff 3	0	0	0	0.0445	0	0.0445	0	0.0445	0
Sens 3	100%	100%	100%	95%	100%	98%	100%	100%	100%
Spec 3	0%	0%	0%	11%	0%	8%	0%	10%	0%

	0hr prior to AKI stage			24hr prior to AKI stage			48hr prior to AKI stage		
	sCr or UO	sCr only	UO only	sCr or UO	sCr only	UO only	sCr or UO	sCr only	UO only
Cutoff 4	2.20	3.29	3.29	2.20	3.29	3.29	2.20	3.29	3.29
Sens 4	24%	29%	19%	43%	44%	39%	39%	11%	40%
Spec 4	70%	70%	71%	70%	70%	71%	70%	70%	71%
Cutoff 5	27.4	14.4	33.8	27.4	14.4	33.8	27.4	14.4	33.8
Sens 5	13%	29%	8%	19%	28%	20%	17%	11%	13%
Spec 5	81%	80%	81%	81%	80%	81%	81%	80%	81%
Cutoff 6	79.4	76.8	99.5	79.4	76.8	99.5	79.4	76.8	99.5
Sens 6	11%	21%	5%	17%	28%	15%	11%	11%	7%
Spec 6	90%	90%	90%	90%	90%	90%	90%	90%	90%
OR Quart 2	1.0	0.24	1.4	0.54	0.47	1.8	1.0	2.0	0.47
p Value	1.0	0.20	0.57	0.27	0.30	0.28	1.0	0.58	0.54
95% CI of	0.36	0.026	0.45	0.18	0.11	0.61	0.13	0.18	0.040
OR Quart2	2.7	2.2	4.3	1.6	2.0	5.4	7.6	23	5.4
OR Quart 3	1.1	1.0	1.8	1.0	0.31	2.1	5.2	5.4	4.3
p Value	0.80	1.0	0.28	1.0	0.16	0.19	0.051	0.13	0.087
95% CI of	0.42	0.24	0.61	0.36	0.059	0.71	0.99	0.61	0.81
OR Quart3	3.1	4.2	5.5	2.8	1.6	6.1	27	48	23
OR Quart 4	1.0	1.3	1.6	1.3	1.2	1.8	3.5	0.98	2.7
p Value	0.93	0.71	0.41	0.61	0.79	0.28	0.14	0.99	0.26
95% CI of	0.38	0.33	0.53	0.48	0.37	0.61	0.65	0.060	0.48
OR Quart4	2.9	5.1	4.8	3.5	3.7	5.4	19	16	15

Vascular endothelial growth factor receptor 2

sCr or UO	0hr prior to AKI stage		24hr prior to AKI stage		48hr prior to AKI stage	
	Cohort 1	Cohort 2	Cohort 1	Cohort 2	Cohort 1	Cohort 2
Median	8090	7910	8090	7810	8090	6760
Average	11100	9090	11100	9460	11100	7180
Stdev	15800	5160	15800	4940	15800	2560
p(t-test)		0.41		0.52		0.30
Min	3720	3140	3720	4110	3720	3790
Max	153000	32000	153000	26100	153000	14300
n (Samp)	94	45	94	42	94	18
n (Patient)	65	45	65	42	65	18

sCr only	0hr prior to AKI stage		24hr prior to AKI stage		48hr prior to AKI stage	
	Cohort 1	Cohort 2	Cohort 1	Cohort 2	Cohort 1	Cohort 2
Median	7990	8380	7990	7560	7990	6380
Average	10200	10500	10200	21300	10200	7330
Stdev	14900	7740	14900	49000	14900	2720
p(t-test)		0.94		0.020		0.56
Min	3640	3020	3640	3140	3640	5310
Max	166000	32000	166000	216000	166000	14300
n (Samp)	225	14	225	18	225	9
n (Patient)	132	14	132	18	132	9

UO only	0hr prior to AKI stage		24hr prior to AKI stage		48hr prior to AKI stage	
	Cohort 1	Cohort 2	Cohort 1	Cohort 2	Cohort 1	Cohort 2

UO only	0hr prior to AKI stage		24hr prior to AKI stage		48hr prior to AKI stage	
	Cohort 1	Cohort 2	Cohort 1	Cohort 2	Cohort 1	Cohort 2
Median	8040	7390	8040	7820	8040	6900
Average	11500	8180	11500	8500	11500	6830
Stdev	15500	3310	15500	3670	15500	2010
p(t-test)		0.20		0.23		0.25
Min	3900	3140	3900	4110	3900	3790
Max	153000	19800	153000	26100	153000	11800
n (Samp)	103	37	103	41	103	15
n (Patient)	64	37	64	41	64	15

	0hr prior to AKI stage			24hr prior to AKI stage			48hr prior to AKI stage		
	sCr or UO	sCr only	UO only	sCr or UO	sCr only	UO only	sCr or UO	sCr only	UO only
AUC	0.45	0.51	0.43	0.47	0.51	0.45	0.31	0.34	0.30
SE	0.053	0.080	0.056	0.054	0.071	0.054	0.074	0.10	0.079
p	0.33	0.93	0.19	0.60	0.87	0.33	0.0082	0.11	0.013
nCohort 1	94	225	103	94	225	103	94	225	103
nCohort 2	45	14	37	42	18	41	18	9	15
Cutoff 1	6200	6200	6340	6710	6110	6690	5920	6010	5440
Sens 1	71%	71%	70%	71%	72%	71%	72%	78%	73%
Spec 1	19%	24%	23%	28%	22%	30%	13%	20%	11%
Cutoff 2	5620	5310	5570	6250	5560	6210	5050	5920	5140
Sens 2	80%	86%	81%	81%	83%	80%	83%	89%	80%
Spec 2	10%	12%	11%	19%	14%	21%	6%	19%	8%
Cutoff 3	5230	4920	5230	5070	4780	5620	3900	5300	4330
Sens 3	91%	93%	92%	90%	94%	90%	94%	100%	93%
Spec 3	7%	7%	9%	6%	6%	12%	2%	11%	2%
Cutoff 4	9710	9520	10000	9710	9520	10000	9710	9520	10000
Sens 4	29%	29%	19%	26%	33%	17%	11%	11%	7%
Spec 4	70%	70%	71%	70%	70%	71%	70%	70%	71%
Cutoff 5	11000	10600	11300	11000	10600	11300	11000	10600	11300
Sens 5	16%	21%	11%	21%	33%	12%	11%	11%	7%
Spec 5	81%	80%	81%	81%	80%	81%	81%	80%	81%
Cutoff 6	15300	14200	18800	15300	14200	18800	15300	14200	18800
Sens 6	9%	21%	3%	12%	28%	2%	0%	11%	0%
Spec 6	90%	90%	90%	90%	90%	90%	90%	90%	90%
OR Quart 2	1.1	0.72	1.6	0.74	0.63	1.8	0.48	0	1.0
p Value	0.79	0.68	0.41	0.58	0.49	0.28	0.56	na	0.98
95% CI of	0.41	0.15	0.53	0.25	0.17	0.61	0.041	na	0.062
OR Quart2	3.2	3.4	4.8	2.2	2.4	5.4	5.6	na	17
OR Quart 3	1.0	0.72	1.4	1.7	0.31	2.3	4.3	4.2	8.8
p Value	1.0	0.68	0.57	0.31	0.16	0.12	0.086	0.20	0.049
95% CI of	0.35	0.15	0.45	0.61	0.059	0.80	0.81	0.46	1.0
OR Quart3	2.8	3.4	4.3	4.6	1.6	6.8	23	39	77
OR Quart 4	1.8	0.98	1.8	1.0	0.98	1.6	5.2	4.3	7.6
p Value	0.27	0.98	0.28	1.0	0.98	0.41	0.051	0.20	0.070
95% CI of	0.64	0.23	0.61	0.35	0.30	0.53	0.99	0.47	0.85
OR Quart4	4.8	4.1	5.5	2.8	3.2	4.8	27	40	67

Lutropin subunit beta

sCr or UO	0hr prior to AKI stage		24hr prior to AKI stage		48hr prior to AKI stage	
	Cohort 1	Cohort 2	Cohort 1	Cohort 2	Cohort 1	Cohort 2
Median	4.52	3.87	4.52	4.46	4.52	1.63
Average	7.77	7.10	7.77	5.30	7.77	2.03
Stdev	10.8	10.6	10.8	4.52	10.8	2.17
p(t-test)		0.79		0.25		0.14
Min	0.00783	0.0399	0.00783	0.00467	0.00783	4.11E-5
Max	66.0	50.0	66.0	16.5	66.0	6.33
n (Samp)	68	25	68	27	68	8
n (Patient)	43	25	43	27	43	8

sCr only	0hr prior to AKI stage		24hr prior to AKI stage		48hr prior to AKI stage	
	Cohort 1	Cohort 2	Cohort 1	Cohort 2	Cohort 1	Cohort 2
Median	3.65	5.59	3.65	4.50	nd	nd
Average	7.37	6.27	7.37	5.90	nd	nd
Stdev	11.4	4.33	11.4	4.44	nd	nd
p(t-test)		0.80		0.74	nd	nd
Min	4.11E-5	1.36	4.11E-5	1.58	nd	nd
Max	66.0	15.3	66.0	14.5	nd	nd
n (Samp)	153	7	153	7	nd	nd
n (Patient)	89	7	89	7	nd	nd

UO only	0hr prior to AKI stage		24hr prior to AKI stage		48hr prior to AKI stage	
	Cohort 1	Cohort 2	Cohort 1	Cohort 2	Cohort 1	Cohort 2
Median	4.52	3.40	4.52	4.46	4.52	1.22
Average	7.66	7.21	7.66	5.08	7.66	1.87
Stdev	10.3	11.7	10.3	4.52	10.3	2.19
p(t-test)		0.87		0.21		0.12
Min	0.0621	0.0399	0.0621	0.00467	0.0621	4.11E-5
Max	66.0	50.0	66.0	16.5	66.0	6.33
n (Samp)	76	20	76	27	76	8
n (Patient)	43	20	43	27	43	8

	0hr prior to AKI stage			24hr prior to AKI stage			48hr prior to AKI stage		
	sCr or UO	sCr only	UO only	sCr or UO	sCr only	UO only	sCr or UO	sCr only	UO only
AUC	0.46	0.63	0.42	0.48	0.59	0.45	0.26	nd	0.23
SE	0.068	0.12	0.074	0.066	0.12	0.066	0.10	nd	0.10
p	0.58	0.26	0.30	0.78	0.42	0.46	0.024	nd	0.0062
nCohort 1	68	153	76	68	153	76	68	nd	76
nCohort 2	25	7	20	27	7	27	8	nd	8
Cutoff 1	1.85	5.10	1.85	2.38	3.52	1.54	0.471	nd	0.471
Sens 1	72%	71%	70%	70%	71%	70%	75%	nd	75%
Spec 1	34%	64%	29%	35%	50%	20%	9%	nd	7%
Cutoff 2	1.17	4.12	0.544	1.40	2.38	1.32	4.11E-5	nd	4.11E-5
Sens 2	80%	86%	80%	81%	86%	81%	88%	nd	88%
Spec 2	25%	55%	9%	25%	41%	20%	0%	nd	0%
Cutoff 3	0.218	1.17	0.134	0.218	1.54	0.158	0	nd	0
Sens 3	92%	100%	90%	93%	100%	93%	100%	nd	100%

	0hr prior to AKI stage			24hr prior to AKI stage			48hr prior to AKI stage		
	sCr or UO	sCr only	UO only	sCr or UO	sCr only	UO only	sCr or UO	sCr only	UO only
Spec 3	6%	29%	4%	6%	33%	4%	0%	nd	0%
Cutoff 4	6.94	6.28	6.94	6.94	6.28	6.94	6.94	nd	6.94
Sens 4	20%	29%	20%	26%	29%	22%	0%	nd	0%
Spec 4	71%	71%	71%	71%	71%	71%	71%	nd	71%
Cutoff 5	11.6	9.89	9.89	11.6	9.89	9.89	11.6	nd	9.89
Sens 5	20%	14%	20%	15%	14%	15%	0%	nd	0%
Spec 5	81%	80%	80%	81%	80%	80%	81%	nd	80%
Cutoff 6	22.6	18.0	20.6	22.6	18.0	20.6	22.6	nd	20.6
Sens 6	4%	0%	10%	0%	0%	0%	0%	nd	0%
Spec 6	91%	90%	91%	91%	90%	91%	91%	nd	91%
OR Quart 2	1.3	>1.0	1.0	1.2	>3.2	1.2	>1.1	nd	>1.0
p Value	0.67	<0.99	1.0	0.75	<0.32	0.75	<0.97	nd	<0.97
95% CI of	0.35	>0.062	0.22	0.34	>0.32	0.35	>0.061	nd	>0.061
OR Quart2	5.2	na	4.6	4.4	na	4.3	na	nd	na
OR Quart 3	2.0	>5.7	1.7	1.5	>2.1	0.79	>5.1	nd	>2.2
p Value	0.29	<0.12	0.48	0.53	<0.55	0.73	<0.17	nd	<0.53
95% CI of	0.55	>0.64	0.40	0.43	>0.18	0.21	>0.51	nd	>0.19
OR Quart3	7.5	na	6.9	5.3	na	3.0	na	nd	na
OR Quart 4	1.3	>1.0	1.7	1.1	>2.1	1.9	>3.6	nd	>6.6
p Value	0.67	<0.99	0.48	0.93	<0.55	0.31	<0.29	nd	<0.10
95% CI of	0.35	>0.062	0.40	0.29	>0.18	0.55	>0.34	nd	>0.70
OR Quart4	5.2	na	6.9	3.9	na	6.4	na	nd	na

Interstitial collagenase

sCr or UO	0hr prior to AKI stage		24hr prior to AKI stage		48hr prior to AKI stage	
	Cohort 1	Cohort 2	Cohort 1	Cohort 2	Cohort 1	Cohort 2
Median	54.1	65.2	54.1	46.2	54.1	92.4
Average	136	206	136	149	136	174
Stdev	174	477	174	202	174	294
p(t-test)		0.16		0.68		0.39
Min	0.0125	0.0125	0.0125	0.0125	0.0125	0.0125
Max	764	3260	764	760	764	1230
n (Samp)	121	53	121	52	121	26
n (Patient)	87	53	87	52	87	26

sCr only	0hr prior to AKI stage		24hr prior to AKI stage		48hr prior to AKI stage	
	Cohort 1	Cohort 2	Cohort 1	Cohort 2	Cohort 1	Cohort 2
Median	53.7	73.9	53.7	65.2	53.7	56.4
Average	146	98.2	146	145	146	121
Stdev	271	103	271	213	271	156
p(t-test)		0.49		0.99		0.77
Min	0.0125	0.0125	0.0125	0.0131	0.0125	0.0125
Max	3260	332	3260	760	3260	488
n (Samp)	287	16	287	15	287	10
n (Patient)	161	16	161	15	161	10

UO only	0hr prior to AKI stage		24hr prior to AKI stage		48hr prior to AKI stage	

	Cohort 1	Cohort 2	Cohort 1	Cohort 2	Cohort 1	Cohort 2
Median	47.3	82.2	47.3	54.7	47.3	110
Average	113	236	113	149	113	195
Stdev	157	524	157	189	157	309
p(t-test)		0.020		0.19		0.056
Min	0.0125	0.0131	0.0125	0.0125	0.0125	4.10
Max	711	3260	711	741	711	1230
n (Samp)	125	43	125	53	125	23
n (Patient)	80	43	80	53	80	23

	0hr prior to AKI stage			24hr prior to AKI stage			48hr prior to AKI stage		
	sCr or UO	sCr only	UO only	sCr or UO	sCr only	UO only	sCr or UO	sCr only	UO only
AUC	0.51	0.49	0.59	0.48	0.48	0.54	0.51	0.47	0.61
SE	0.048	0.075	0.052	0.048	0.077	0.048	0.063	0.095	0.067
p	0.84	0.86	0.080	0.62	0.78	0.39	0.87	0.73	0.12
nCohort 1	121	287	125	121	287	125	121	287	125
nCohort 2	53	16	43	52	15	53	26	10	23
Cutoff 1	18.5	2.35	31.6	18.2	2.08	20.2	24.3	12.0	38.7
Sens 1	72%	75%	72%	71%	73%	72%	73%	70%	74%
Spec 1	24%	15%	39%	23%	15%	33%	31%	23%	43%
Cutoff 2	5.04	2.08	17.3	1.65	1.45	8.43	10.4	0.0270	24.3
Sens 2	81%	81%	81%	81%	80%	81%	81%	80%	83%
Spec 2	13%	15%	30%	12%	14%	23%	18%	10%	37%
Cutoff 3	0.0281	0.0243	1.65	0.0131	0.0131	0.0270	4.08	0.0125	8.08
Sens 3	91%	94%	91%	92%	93%	91%	92%	90%	91%
Spec 3	10%	7%	18%	5%	6%	13%	12%	1%	22%
Cutoff 4	167	129	105	167	129	105	167	129	105
Sens 4	34%	31%	47%	29%	33%	34%	27%	40%	52%
Spec 4	70%	70%	70%	70%	70%	70%	70%	70%	70%
Cutoff 5	232	218	198	232	218	198	232	218	198
Sens 5	21%	12%	30%	25%	20%	26%	12%	20%	17%
Spec 5	80%	80%	80%	80%	80%	80%	80%	80%	80%
Cutoff 6	354	406	333	354	406	333	354	406	333
Sens 6	11%	0%	14%	19%	13%	21%	12%	10%	13%
Spec 6	90%	90%	90%	90%	90%	90%	90%	90%	90%
OR Quart 2	0.48	4.4	1.3	0.92	1.0	1.1	0.97	0.24	2.6
p Value	0.14	0.069	0.60	0.87	0.98	0.87	0.96	0.21	0.19
95% CI of	0.18	0.89	0.47	0.36	0.24	0.43	0.28	0.027	0.63
OR Quart2	1.3	21	3.8	2.3	4.2	2.7	3.3	2.2	11
OR Quart 3	1.1	0.49	1.5	0.92	0.49	1.0	1.9	0.24	2.6
p Value	0.82	0.57	0.44	0.87	0.41	1.0	0.29	0.21	0.19
95% CI of	0.46	0.044	0.54	0.36	0.086	0.39	0.59	0.027	0.63
OR Quart3	2.7	5.6	4.2	2.3	2.7	2.6	5.8	2.2	11
OR Quart 4	0.78	2.6	2.1	1.3	1.3	1.5	0.61	1.0	2.2
p Value	0.59	0.25	0.14	0.59	0.72	0.40	0.47	0.98	0.29
95% CI of	0.32	0.50	0.78	0.52	0.33	0.60	0.16	0.24	0.50
OR Quart4	1.9	14	5.8	3.1	5.0	3.6	2.4	4.2	9.5

Neural cell adhesion molecule 1

sCr or UO	0hr prior to AKI stage		24hr prior to AKI stage		48hr prior to AKI stage	
	Cohort 1	Cohort 2	Cohort 1	Cohort 2	Cohort 1	Cohort 2
Median	186000	192000	186000	182000	186000	174000
Average	194000	192000	194000	191000	194000	182000
Stdev	76100	67500	76100	71400	76100	61100
p(t-test)		0.86		0.86		0.46
Min	73000	63300	73000	93300	73000	49200
Max	520000	371000	520000	506000	520000	297000
n (Samp)	120	53	120	53	120	26
n (Patient)	86	53	86	53	86	26

sCr only	0hr prior to AKI stage		24hr prior to AKI stage		48hr prior to AKI stage	
	Cohort 1	Cohort 2	Cohort 1	Cohort 2	Cohort 1	Cohort 2
Median	181000	199000	181000	206000	181000	183000
Average	186000	200000	186000	219000	186000	189000
Stdev	67200	62800	67200	99400	67200	58600
p(t-test)		0.44		0.080		0.92
Min	49200	118000	49200	105000	49200	108000
Max	520000	316000	520000	506000	520000	280000
n (Samp)	287	16	287	15	287	10
n (Patient)	160	16	160	15	160	10

UO only	0hr prior to AKI stage		24hr prior to AKI stage		48hr prior to AKI stage	
	Cohort 1	Cohort 2	Cohort 1	Cohort 2	Cohort 1	Cohort 2
Median	180000	182000	180000	182000	180000	172000
Average	191000	187000	191000	184000	191000	178000
Stdev	77000	69700	77000	54300	77000	59400
p(t-test)		0.72		0.52		0.44
Min	73000	63300	73000	93300	73000	49200
Max	520000	371000	520000	337000	520000	297000
n (Samp)	124	43	124	54	124	23
n (Patient)	79	43	79	54	79	23

	0hr prior to AKI stage			24hr prior to AKI stage			48hr prior to AKI stage		
	sCr or UO	sCr only	UO only	sCr or UO	sCr only	UO only	sCr or UO	sCr only	UO only
AUC	0.51	0.57	0.49	0.49	0.59	0.50	0.48	0.52	0.48
SE	0.048	0.076	0.051	0.048	0.079	0.047	0.063	0.094	0.066
p	0.84	0.33	0.91	0.88	0.23	0.98	0.80	0.80	0.80
nCohort 1	120	287	124	120	287	124	120	287	124
nCohort 2	53	16	43	53	15	54	26	10	23
Cutoff 1	151000	160000	141000	161000	166000	161000	147000	169000	147000
Sens 1	72%	75%	72%	72%	73%	70%	73%	70%	74%
Spec 1	31%	36%	23%	36%	40%	37%	26%	40%	28%
Cutoff 2	133000	125000	119000	135000	164000	133000	125000	144000	125000
Sens 2	81%	81%	81%	81%	80%	81%	81%	80%	83%
Spec 2	18%	16%	11%	18%	38%	21%	12%	25%	15%
Cutoff 3	105000	118000	105000	111000	129000	111000	115000	115000	119000
Sens 3	91%	94%	91%	91%	93%	91%	92%	90%	91%
Spec 3	8%	13%	6%	8%	18%	7%	10%	13%	11%

	0hr prior to AKI stage			24hr prior to AKI stage			48hr prior to AKI stage		
	sCr or UO	sCr only	UO only	sCr or UO	sCr only	UO only	sCr or UO	sCr only	UO only
Cutoff 4	212000	207000	209000	212000	207000	209000	212000	207000	209000
Sens 4	30%	44%	33%	30%	47%	26%	35%	30%	35%
Spec 4	70%	70%	70%	70%	70%	70%	70%	70%	70%
Cutoff 5	227000	227000	228000	227000	227000	228000	227000	227000	228000
Sens 5	25%	38%	21%	26%	40%	24%	35%	30%	35%
Spec 5	80%	80%	81%	80%	80%	81%	80%	80%	81%
Cutoff 6	262000	263000	257000	262000	263000	257000	262000	263000	257000
Sens 6	13%	12%	14%	8%	13%	9%	12%	20%	9%
Spec 6	90%	90%	90%	90%	90%	90%	90%	90%	90%
OR Quart 2	0.80	0.48	1.0	0.66	1.3	1.0	0.18	1.5	0.21
p Value	0.64	0.40	1.0	0.39	0.71	0.94	0.039	0.65	0.058
95% CI of	0.32	0.085	0.38	0.26	0.29	0.42	0.037	0.25	0.041
OR Quart2	2.0	2.7	2.6	1.7	6.2	2.5	0.92	9.4	1.1
OR Quart 3	0.80	0.99	0.77	0.84	0.66	0.81	0.86	1.0	0.85
p Value	0.64	0.98	0.61	0.70	0.65	0.64	0.78	1.0	0.77
95% CI of	0.32	0.24	0.28	0.34	0.11	0.32	0.29	0.14	0.27
OR Quart3	2.0	4.1	2.1	2.1	4.1	2.0	2.5	7.3	2.6
OR Quart 4	1.1	1.5	1.2	0.93	2.1	1.0	0.75	1.5	0.72
p Value	0.88	0.53	0.75	0.88	0.32	0.94	0.61	0.66	0.59
95% CI of	0.44	0.41	0.45	0.38	0.50	0.42	0.25	0.24	0.22
OR Quart4	2.6	5.6	3.1	2.3	8.5	2.5	2.3	9.2	2.3

Platelet-derived growth factor subunit B (dimer)

sCr or UO	0hr prior to AKI stage		24hr prior to AKI stage		48hr prior to AKI stage	
	Cohort 1	Cohort 2	Cohort 1	Cohort 2	Cohort 1	Cohort 2
Median	358	321	358	367	358	468
Average	426	373	426	433	426	470
Stdev	264	206	264	405	264	204
p(t-test)		0.19		0.89		0.45
Min	39.4	33.7	39.4	0.189	39.4	91.4
Max	1540	854	1540	2690	1540	836
n (Samp)	119	52	119	49	119	24
n (Patient)	85	52	85	49	85	24

sCr only	0hr prior to AKI stage		24hr prior to AKI stage		48hr prior to AKI stage	
	Cohort 1	Cohort 2	Cohort 1	Cohort 2	Cohort 1	Cohort 2
Median	348	260	348	283	348	425
Average	399	346	399	503	399	454
Stdev	245	218	245	670	245	238
p(t-test)		0.40		0.17		0.49
Min	0.189	43.4	0.189	33.7	0.189	129
Max	1540	807	1540	2690	1540	836
n (Samp)	278	16	278	14	278	10
n (Patient)	157	16	157	14	157	10

UO only	0hr prior to AKI stage		24hr prior to AKI stage		48hr prior to AKI stage	
	Cohort 1	Cohort 2	Cohort 1	Cohort 2	Cohort 1	Cohort 2

UO only	0hr prior to AKI stage		24hr prior to AKI stage		48hr prior to AKI stage	
	Cohort 1	Cohort 2	Cohort 1	Cohort 2	Cohort 1	Cohort 2
Median	321	321	321	363	321	463
Average	378	377	378	399	378	444
Stdev	249	208	249	249	249	209
p(t-test)		0.99		0.61		0.25
Min	28.1	33.7	28.1	0.189	28.1	48.9
Max	1540	854	1540	1260	1540	813
n (Samp)	123	42	123	50	123	21
n (Patient)	78	42	78	50	78	21

	0hr prior to AKI stage			24hr prior to AKI stage			48hr prior to AKI stage		
	sCr or UO	sCr only	UO only	sCr or UO	sCr only	UO only	sCr or UO	sCr only	UO only
AUC	0.45	0.44	0.52	0.47	0.45	0.53	0.58	0.58	0.61
SE	0.048	0.076	0.052	0.049	0.081	0.049	0.066	0.096	0.070
p	0.31	0.43	0.72	0.54	0.54	0.56	0.21	0.42	0.11
nCohort 1	119	278	123	119	278	123	119	278	123
nCohort 2	52	16	42	49	14	50	24	10	21
Cutoff 1	238	194	238	250	220	250	301	277	300
Sens 1	71%	75%	71%	71%	71%	70%	71%	70%	71%
Spec 1	24%	21%	32%	27%	25%	35%	35%	37%	45%
Cutoff 2	218	192	220	202	150	218	259	247	259
Sens 2	81%	81%	81%	82%	86%	80%	83%	80%	81%
Spec 2	22%	21%	29%	19%	15%	29%	32%	29%	41%
Cutoff 3	135	117	135	122	145	122	229	242	211
Sens 3	90%	94%	90%	92%	93%	90%	92%	90%	90%
Spec 3	10%	11%	15%	8%	14%	12%	24%	28%	27%
Cutoff 4	539	497	475	539	497	475	539	497	475
Sens 4	21%	31%	24%	18%	21%	34%	38%	50%	43%
Spec 4	71%	70%	71%	71%	70%	71%	71%	70%	71%
Cutoff 5	618	599	544	618	599	544	618	599	544
Sens 5	13%	19%	21%	16%	14%	18%	21%	40%	33%
Spec 5	81%	80%	80%	81%	80%	80%	81%	80%	80%
Cutoff 6	741	721	673	741	721	673	741	721	673
Sens 6	10%	6%	14%	8%	14%	14%	8%	10%	14%
Spec 6	91%	90%	90%	91%	90%	90%	91%	90%	90%
OR Quart 2	1.3	0.75	2.5	2.9	0.66	1.1	1.2	4.2	1.4
p Value	0.63	0.71	0.081	0.035	0.65	0.80	0.76	0.21	0.69
95% CI of	0.49	0.16	0.89	1.1	0.11	0.42	0.31	0.46	0.28
OR Quart2	3.2	3.5	7.1	7.7	4.1	3.0	5.1	38	6.6
OR Quart 3	1.4	1.0	2.0	1.5	1.7	2.2	1.6	1.0	2.7
p Value	0.48	1.0	0.19	0.44	0.47	0.11	0.53	1.0	0.18
95% CI of	0.55	0.24	0.70	0.54	0.39	0.85	0.40	0.061	0.63
OR Quart3	3.6	4.2	5.8	4.2	7.5	5.5	6.0	16	11
OR Quart 4	1.5	1.3	1.3	1.9	1.4	1.2	2.6	4.2	2.7
p Value	0.43	0.72	0.62	0.21	0.70	0.67	0.15	0.21	0.18
95% CI of	0.57	0.33	0.44	0.69	0.29	0.47	0.71	0.46	0.63
OR Quart4	3.7	5.0	4.0	5.2	6.3	3.3	9.3	38	11

Thyroxine-binding globulin

sCr or UO	0hr prior to AKI stage		24hr prior to AKI stage		48hr prior to AKI stage	
	Cohort 1	Cohort 2	Cohort 1	Cohort 2	Cohort 1	Cohort 2
Median	38.2	37.2	38.2	33.1	38.2	32.2
Average	39.2	36.8	39.2	34.5	39.2	34.4
Stdev	11.0	10.3	11.0	9.68	11.0	9.33
p(t-test)		0.15		0.0040		0.034
Min	13.4	12.8	13.4	13.9	13.4	16.3
Max	75.8	56.7	75.8	56.1	75.8	51.1
n (Samp)	262	51	262	55	262	26
n (Patient)	110	51	110	55	110	26

sCr only	0hr prior to AKI stage		24hr prior to AKI stage		48hr prior to AKI stage	
	Cohort 1	Cohort 2	Cohort 1	Cohort 2	Cohort 1	Cohort 2
Median	36.0	33.2	36.0	33.2	36.0	33.2
Average	37.2	36.1	37.2	35.1	37.2	35.6
Stdev	11.3	10.9	11.3	9.71	11.3	7.59
p(t-test)		0.69		0.42		0.63
Min	12.8	23.2	12.8	22.7	12.8	26.8
Max	75.8	63.7	75.8	62.0	75.8	51.1
n (Samp)	466	18	466	20	466	13
n (Patient)	180	18	180	20	180	13

UO only	0hr prior to AKI stage		24hr prior to AKI stage		48hr prior to AKI stage	
	Cohort 1	Cohort 2	Cohort 1	Cohort 2	Cohort 1	Cohort 2
Median	36.8	34.2	36.8	33.2	36.8	32.1
Average	38.0	35.7	38.0	34.3	38.0	34.2
Stdev	10.4	10.8	10.4	9.95	10.4	10.2
p(t-test)		0.17		0.023		0.099
Min	13.4	12.8	13.4	13.9	13.4	16.3
Max	75.8	56.7	75.8	56.1	75.8	51.1
n (Samp)	221	50	221	52	221	23
n (Patient)	91	50	91	52	91	23

	0hr prior to AKI stage			24hr prior to AKI stage			48hr prior to AKI stage		
	sCr or UO	sCr only	UO only	sCr or UO	sCr only	UO only	sCr or UO	sCr only	UO only
AUC	0.44	0.45	0.44	0.38	0.43	0.40	0.37	0.46	0.40
SE	0.045	0.071	0.046	0.043	0.068	0.045	0.061	0.083	0.065
p	0.22	0.52	0.23	0.0041	0.30	0.030	0.037	0.61	0.14
nCohort 1	262	466	221	262	466	221	262	466	221
nCohort 2	51	18	50	55	20	52	26	13	23
Cutoff 1	29.1	28.0	29.1	28.7	28.5	27.9	28.1	29.8	28.0
Sens 1	71%	72%	70%	71%	70%	71%	73%	77%	74%
Spec 1	19%	22%	22%	18%	24%	16%	15%	28%	16%
Cutoff 2	26.5	26.7	26.5	26.5	28.3	25.0	27.8	29.4	27.4
Sens 2	80%	83%	80%	80%	80%	81%	81%	85%	87%
Spec 2	11%	18%	12%	11%	23%	10%	14%	27%	14%
Cutoff 3	24.2	24.4	23.7	22.5	25.7	21.4	26.5	27.8	17.9
Sens 3	90%	94%	90%	91%	90%	90%	92%	92%	91%
Spec 3	7%	12%	6%	5%	15%	4%	11%	21%	2%

	0hr prior to AKI stage			24hr prior to AKI stage			48hr prior to AKI stage		
	sCr or UO	sCr only	UO only	sCr or UO	sCr only	UO only	sCr or UO	sCr only	UO only
Cutoff 4	44.9	43.4	43.6	44.9	43.4	43.6	44.9	43.4	43.6
Sens 4	25%	22%	28%	18%	20%	19%	19%	15%	22%
Spec 4	70%	70%	71%	70%	70%	71%	70%	70%	71%
Cutoff 5	47.3	46.4	46.3	47.3	46.4	46.3	47.3	46.4	46.3
Sens 5	14%	17%	20%	11%	10%	15%	8%	15%	22%
Spec 5	80%	80%	80%	80%	80%	80%	80%	80%	80%
Cutoff 6	52.5	50.3	49.9	52.5	50.3	49.9	52.5	50.3	49.9
Sens 6	6%	11%	10%	4%	5%	6%	0%	8%	9%
Spec 6	90%	90%	90%	90%	90%	90%	90%	90%	90%
OR Quart 2	1.1	1.7	0.65	1.6	0.75	1.1	0.79	1.5	0.58
p Value	0.80	0.48	0.35	0.33	0.71	0.78	0.73	0.65	0.47
95% CI of	0.47	0.40	0.26	0.62	0.16	0.45	0.20	0.25	0.13
OR Quart2	2.6	7.3	1.6	4.2	3.4	2.9	3.1	9.2	2.5
OR Quart 3	0.73	1.0	0.91	1.9	1.5	1.3	1.4	3.1	1.5
p Value	0.50	1.0	0.82	0.16	0.52	0.62	0.55	0.17	0.54
95% CI of	0.29	0.20	0.38	0.76	0.42	0.51	0.44	0.61	0.43
OR Quart3	1.8	5.1	2.2	4.9	5.5	3.2	4.8	16	4.9
OR Quart 4	1.6	2.4	1.3	3.3	1.8	2.3	2.2	1.0	1.7
p Value	0.29	0.21	0.50	0.0089	0.35	0.058	0.18	0.99	0.38
95% CI of	0.69	0.61	0.58	1.3	0.52	0.97	0.70	0.14	0.52
OR Quart4	3.5	9.6	3.0	7.9	6.4	5.4	6.7	7.3	5.5

Pigment epithelium-derived factor

sCr or UO	0hr prior to AKI stage		24hr prior to AKI stage		48hr prior to AKI stage	
	Cohort 1	Cohort 2	Cohort 1	Cohort 2	Cohort 1	Cohort 2
Median	1630	1820	1630	1420	1630	1640
Average	1720	2180	1720	1690	1720	1580
Stdev	753	1290	753	987	753	695
p(t-test)		0.0042		0.78		0.36
Min	445	317	445	339	445	347
Max	4240	5620	4240	4750	4240	3400
n (Samp)	121	53	121	53	121	26
n (Patient)	87	53	87	53	87	26

sCr only	0hr prior to AKI stage		24hr prior to AKI stage		48hr prior to AKI stage	
	Cohort 1	Cohort 2	Cohort 1	Cohort 2	Cohort 1	Cohort 2
Median	1660	1950	1660	1670	1660	1960
Average	1920	2130	1920	1820	1920	2000
Stdev	1150	1270	1150	1050	1150	998
p(t-test)		0.47		0.77		0.82
Min	84.2	328	84.2	629	84.2	813
Max	7450	4300	7450	4910	7450	4360
n (Samp)	288	16	288	15	288	10
n (Patient)	161	16	161	15	161	10

UO only	0hr prior to AKI stage		24hr prior to AKI stage		48hr prior to AKI stage	
	Cohort 1	Cohort 2	Cohort 1	Cohort 2	Cohort 1	Cohort 2

UO only	0hr prior to AKI stage		24hr prior to AKI stage		48hr prior to AKI stage	
	Cohort 1	Cohort 2	Cohort 1	Cohort 2	Cohort 1	Cohort 2
Median	1560	1740	1560	1400	1560	1510
Average	1720	2200	1720	1690	1720	1480
Stdev	787	1320	787	1020	787	701
p(t-test)		0.0046		0.87		0.19
Min	328	317	328	339	328	347
Max	4510	5620	4510	4750	4510	3400
n (Samp)	125	43	125	54	125	23
n (Patient)	80	43	80	54	80	23

	0hr prior to AKI stage			24hr prior to AKI stage			48hr prior to AKI stage		
	sCr or UO	sCr only	UO only	sCr or UO	sCr only	UO only	sCr or UO	sCr only	UO only
AUC	0.58	0.55	0.59	0.44	0.49	0.45	0.47	0.57	0.43
SE	0.048	0.076	0.052	0.048	0.077	0.047	0.063	0.096	0.067
p	0.082	0.52	0.067	0.24	0.88	0.28	0.63	0.49	0.30
nCohort 1	121	288	125	121	288	125	121	288	125
nCohort 2	53	16	43	53	15	54	26	10	23
Cutoff 1	1310	1170	1340	1150	1280	1150	1190	1770	1040
Sens 1	72%	75%	72%	72%	73%	70%	73%	70%	74%
Spec 1	32%	26%	35%	22%	32%	22%	27%	58%	18%
Cutoff 2	1060	1080	1060	813	1220	812	1030	1450	760
Sens 2	81%	81%	81%	81%	80%	81%	81%	80%	83%
Spec 2	19%	22%	20%	8%	29%	7%	17%	41%	7%
Cutoff 3	974	529	999	733	760	677	591	852	529
Sens 3	91%	94%	91%	91%	93%	91%	92%	90%	91%
Spec 3	13%	4%	15%	7%	9%	6%	3%	10%	2%
Cutoff 4	1970	2080	1970	1970	2080	1970	1970	2080	1970
Sens 4	45%	44%	44%	25%	33%	28%	27%	30%	17%
Spec 4	70%	70%	70%	70%	70%	70%	70%	70%	70%
Cutoff 5	2210	2510	2160	2210	2510	2160	2210	2510	2160
Sens 5	38%	31%	40%	21%	13%	26%	12%	10%	9%
Spec 5	80%	80%	80%	80%	80%	80%	80%	80%	80%
Cutoff 6	2820	3520	2830	2820	3520	2830	2820	3520	2830
Sens 6	25%	31%	23%	11%	7%	13%	4%	10%	4%
Spec 6	90%	90%	90%	90%	90%	90%	90%	90%	90%
OR Quart 2	0.68	0.74	0.64	0.72	1.7	0.43	2.7	0.49	1.9
p Value	0.43	0.70	0.42	0.51	0.47	0.095	0.14	0.56	0.33
95% CI of	0.26	0.16	0.22	0.28	0.39	0.16	0.74	0.043	0.51
OR Quart2	1.8	3.4	1.9	1.9	7.4	1.2	9.5	5.5	7.2
OR Quart 3	0.70	1.0	0.87	1.1	1.4	0.90	1.6	2.1	1.3
p Value	0.47	1.0	0.79	0.82	0.70	0.82	0.50	0.41	0.72
95% CI of	0.27	0.24	0.31	0.45	0.29	0.37	0.41	0.37	0.32
OR Quart3	1.8	4.2	2.4	2.8	6.3	2.2	6.2	12	5.2
OR Quart 4	1.9	1.3	2.2	1.4	1.0	1.3	2.0	1.5	1.9
p Value	0.15	0.73	0.11	0.45	0.99	0.60	0.31	0.66	0.33
95% CI of	0.80	0.33	0.85	0.58	0.20	0.53	0.53	0.24	0.51
OR Quart4	4.6	4.9	5.6	3.5	5.2	3.0	7.5	9.2	7.2

Tumor necrosis factor receptor superfamily member 8

sCr or UO	0hr prior to AKI stage		24hr prior to AKI stage		48hr prior to AKI stage	
	Cohort 1	Cohort 2	Cohort 1	Cohort 2	Cohort 1	Cohort 2
Median	96.5	104	96.5	122	96.5	123
Average	184	201	184	187	184	122
Stdev	461	420	461	202	461	70.9
p(t-test)		0.83		0.97		0.57
Min	12.8	19.4	12.8	12.8	12.8	4.06
Max	3360	2810	3360	1040	3360	288
n (Samp)	94	45	94	42	94	18
n (Patient)	65	45	65	42	65	18

sCr only	0hr prior to AKI stage		24hr prior to AKI stage		48hr prior to AKI stage	
	Cohort 1	Cohort 2	Cohort 1	Cohort 2	Cohort 1	Cohort 2
Median	101	97.7	101	163	101	103
Average	199	192	199	343	199	115
Stdev	425	225	425	395	425	71.5
p(t-test)		0.95		0.17		0.55
Min	4.06	39.7	4.06	33.2	4.06	56.2
Max	3360	726	3360	1460	3360	288
n (Samp)	225	14	225	18	225	9
n (Patient)	132	14	132	18	132	9

UO only	0hr prior to AKI stage		24hr prior to AKI stage		48hr prior to AKI stage	
	Cohort 1	Cohort 2	Cohort 1	Cohort 2	Cohort 1	Cohort 2
Median	100	96.4	100	101	100	116
Average	211	184	211	129	211	110
Stdev	468	447	468	102	468	66.6
p(t-test)		0.76		0.27		0.41
Min	12.8	19.4	12.8	12.8	12.8	4.06
Max	3360	2810	3360	595	3360	208
n (Samp)	103	37	103	41	103	15
n (Patient)	64	37	64	41	64	15

	0hr prior to AKI stage			24hr prior to AKI stage			48hr prior to AKI stage		
	sCr or UO	sCr only	UO only	sCr or UO	sCr only	UO only	sCr or UO	sCr only	UO only
AUC	0.55	0.51	0.50	0.62	0.66	0.51	0.54	0.46	0.47
SE	0.053	0.080	0.056	0.054	0.072	0.054	0.076	0.10	0.081
p	0.32	0.94	0.93	0.031	0.025	0.85	0.56	0.67	0.74
nCohort 1	94	225	103	94	225	103	94	225	103
nCohort 2	45	14	37	42	18	41	18	9	15
Cutoff 1	76.5	76.5	75.6	96.4	104	83.2	84.9	65.4	56.2
Sens 1	71%	71%	70%	71%	72%	71%	72%	78%	73%
Spec 1	36%	33%	33%	50%	51%	40%	44%	23%	18%
Cutoff 2	74.6	62.3	73.4	83.2	82.7	68.4	56.2	56.6	54.3
Sens 2	80%	86%	81%	81%	83%	80%	83%	89%	80%
Spec 2	34%	20%	31%	41%	36%	28%	19%	16%	17%
Cutoff 3	62.3	53.7	62.3	68.4	50.8	47.2	34.2	54.3	36.7
Sens 3	91%	93%	92%	90%	94%	90%	94%	100%	93%
Spec 3	24%	13%	23%	31%	12%	15%	10%	14%	11%

	0hr prior to AKI stage			24hr prior to AKI stage			48hr prior to AKI stage		
	sCr or UO	sCr only	UO only	sCr or UO	sCr only	UO only	sCr or UO	sCr only	UO only
Cutoff 4	145	151	149	145	151	149	145	151	149
Sens 4	29%	21%	19%	33%	56%	20%	33%	11%	40%
Spec 4	70%	70%	71%	70%	70%	71%	70%	70%	71%
Cutoff 5	178	205	192	178	205	192	178	205	192
Sens 5	16%	21%	11%	24%	33%	15%	22%	11%	13%
Spec 5	81%	80%	81%	81%	80%	81%	81%	80%	81%
Cutoff 6	258	285	318	258	285	318	258	285	318
Sens 6	11%	21%	3%	17%	33%	5%	6%	11%	0%
Spec 6	90%	91%	90%	90%	91%	90%	90%	91%	90%
OR Quart 2	5.5	0.72	3.2	4.1	1.5	1.8	0.17	4.3	1.0
p Value	0.0040	0.68	0.039	0.028	0.66	0.30	0.12	0.20	0.96
95% CI of	1.7	0.15	1.1	1.2	0.24	0.61	0.019	0.47	0.23
OR Quart2	17	3.4	9.8	14	9.3	5.0	1.6	40	4.6
OR Quart 3	3.4	0.98	1.9	5.2	2.6	2.2	1.5	1.0	0.22
p Value	0.039	0.98	0.26	0.0091	0.27	0.13	0.52	1.0	0.19
95% CI of	1.1	0.23	0.62	1.5	0.48	0.79	0.42	0.061	0.024
OR Quart3	11	4.1	6.1	18	14	6.3	5.6	16	2.1
OR Quart 4	2.3	0.72	1.2	4.1	4.4	0.84	1.0	3.2	1.7
p Value	0.17	0.68	0.76	0.028	0.069	0.77	1.0	0.32	0.45
95% CI of	0.70	0.15	0.36	1.2	0.89	0.27	0.25	0.32	0.42
OR Quart4	7.7	3.4	4.0	14	22	2.6	3.9	31	6.8

Alpha-fetoprotein

sCr or UO	0hr prior to AKI stage		24hr prior to AKI stage		48hr prior to AKI stage	
	Cohort 1	Cohort 2	Cohort 1	Cohort 2	Cohort 1	Cohort 2
Median	0.324	0.333	0.324	0.394	0.324	0.477
Average	0.366	0.334	0.366	0.418	0.366	0.480
Stdev	0.364	0.323	0.364	0.325	0.364	0.292
p(t-test)		0.58		0.37		0.14
Min	0.00580	0.00580	0.00580	0.00580	0.00580	0.00580
Max	1.81	1.31	1.81	1.53	1.81	1.42
n (Samp)	121	53	121	53	121	26
n (Patient)	87	53	87	53	87	26

sCr only	0hr prior to AKI stage		24hr prior to AKI stage		48hr prior to AKI stage	
	Cohort 1	Cohort 2	Cohort 1	Cohort 2	Cohort 1	Cohort 2
Median	0.329	0.438	0.329	0.547	0.329	0.484
Average	0.355	0.401	0.355	0.502	0.355	0.488
Stdev	0.344	0.363	0.344	0.401	0.344	0.316
p(t-test)		0.61		0.11		0.23
Min	0.00580	0.00580	0.00580	0.00580	0.00580	0.00580
Max	1.81	1.11	1.81	1.40	1.81	0.979
n (Samp)	288	16	288	15	288	10
n (Patient)	161	16	161	15	161	10

UO only	0hr prior to AKI stage		24hr prior to AKI stage		48hr prior to AKI stage	
	Cohort 1	Cohort 2	Cohort 1	Cohort 2	Cohort 1	Cohort 2

UO only	0hr prior to AKI stage		24hr prior to AKI stage		48hr prior to AKI stage	
	Cohort 1	Cohort 2	Cohort 1	Cohort 2	Cohort 1	Cohort 2
Median	0.309	0.289	0.309	0.400	0.309	0.445
Average	0.341	0.311	0.341	0.444	0.341	0.437
Stdev	0.366	0.308	0.366	0.352	0.366	0.303
p(t-test)		0.63		0.082		0.24
Min	0.00580	0.00580	0.00580	0.00580	0.00580	0.00580
Max	1.81	1.31	1.81	1.53	1.81	1.42
n (Samp)	125	43	125	54	125	23
n (Patient)	80	43	80	54	80	23

	0hr prior to AKI stage			24hr prior to AKI stage			48hr prior to AKI stage		
	sCr or UO	sCr only	UO only	sCr or UO	sCr only	UO only	sCr or UO	sCr only	UO only
AUC	0.48	0.56	0.49	0.57	0.61	0.60	0.64	0.65	0.62
SE	0.048	0.076	0.051	0.048	0.079	0.047	0.063	0.096	0.067
p	0.70	0.47	0.81	0.16	0.18	0.028	0.029	0.12	0.073
nCohort 1	121	288	125	121	288	125	121	288	125
nCohort 2	53	16	43	53	15	54	26	10	23
Cutoff 1	0.00580	0.00580	0.00580	0.272	0.207	0.272	0.347	0.392	0.272
Sens 1	79%	88%	79%	72%	73%	72%	73%	70%	74%
Spec 1	16%	16%	19%	42%	39%	46%	55%	62%	46%
Cutoff 2	0	0.00580	0	0.00580	0	0.00580	0.272	0.387	0.173
Sens 2	100%	88%	100%	89%	100%	93%	81%	80%	83%
Spec 2	0%	16%	0%	16%	0%	19%	42%	61%	42%
Cutoff 3	0	0	0	0	0	0.00580	0.0850	0.00580	0.0687
Sens 3	100%	100%	100%	100%	100%	93%	92%	90%	91%
Spec 3	0%	0%	0%	0%	0%	19%	31%	16%	38%
Cutoff 4	0.446	0.485	0.446	0.446	0.485	0.446	0.446	0.485	0.446
Sens 4	32%	50%	28%	38%	60%	39%	50%	50%	48%
Spec 4	70%	70%	70%	70%	70%	70%	70%	70%	70%
Cutoff 5	0.607	0.585	0.588	0.607	0.585	0.588	0.607	0.585	0.588
Sens 5	17%	31%	14%	21%	40%	26%	27%	40%	22%
Spec 5	80%	80%	80%	80%	80%	80%	80%	80%	80%
Cutoff 6	0.836	0.767	0.836	0.836	0.767	0.836	0.836	0.767	0.836
Sens 6	8%	12%	7%	8%	20%	11%	8%	20%	4%
Spec 6	90%	90%	90%	90%	90%	90%	90%	90%	90%
OR Quart 2	1.3	2.1	1.5	1.8	0.24	1.6	6.8	0	8.4
p Value	0.59	0.41	0.45	0.24	0.20	0.34	0.084	na	0.052
95% CI of	0.52	0.37	0.54	0.67	0.026	0.60	0.77	na	0.98
OR Quart2	3.1	12	4.0	5.0	2.2	4.5	59	na	72
OR Quart 3	0.79	2.6	1.6	2.6	0.73	2.7	13	2.1	8.4
p Value	0.63	0.26	0.32	0.058	0.69	0.043	0.018	0.41	0.052
95% CI of	0.31	0.49	0.61	0.97	0.16	1.0	1.6	0.37	0.98
OR Quart3	2.0	14	4.4	6.9	3.4	7.2	110	12	72
OR Quart 4	1.2	2.6	1.0	2.5	1.8	2.7	11	2.0	9.9
p Value	0.76	0.26	1.0	0.068	0.36	0.043	0.026	0.42	0.035
95% CI of	0.46	0.49	0.35	0.94	0.50	1.0	1.3	0.36	1.2
OR Quart4	2.9	14	2.8	6.7	6.4	7.2	94	11	84

Apolipoprotein E

sCr or UO	0hr prior to AKI stage		24hr prior to AKI stage		48hr prior to AKI stage	
	Cohort 1	Cohort 2	Cohort 1	Cohort 2	Cohort 1	Cohort 2
Median	53900	51900	53900	41500	53900	28700
Average	66800	69000	66800	53100	66800	33700
Stdev	47000	50500	47000	43200	47000	20200
p(t-test)		0.76		0.051		4.4E-4
Min	8630	13000	8630	10300	8630	4980
Max	260000	244000	260000	232000	260000	73300
n (Samp)	145	64	145	62	145	27
n (Patient)	111	64	111	62	111	27

sCr only	0hr prior to AKI stage		24hr prior to AKI stage		48hr prior to AKI stage	
	Cohort 1	Cohort 2	Cohort 1	Cohort 2	Cohort 1	Cohort 2
Median	49300	50300	49300	51700	49300	49300
Average	61100	60300	61100	70300	61100	47800
Stdev	44800	37100	44800	61900	44800	22100
p(t-test)		0.94		0.38		0.29
Min	1940	20700	1940	13500	1940	4980
Max	260000	147000	260000	232000	260000	75700
n (Samp)	341	19	341	20	341	13
n (Patient)	193	19	193	20	193	13

UO only	0hr prior to AKI stage		24hr prior to AKI stage		48hr prior to AKI stage	
	Cohort 1	Cohort 2	Cohort 1	Cohort 2	Cohort 1	Cohort 2
Median	53200	49900	53200	41200	53200	26000
Average	64500	69900	64500	45600	64500	28600
Stdev	43200	52200	43200	26400	43200	15400
p(t-test)		0.46		0.0024		8.5E-5
Min	4980	13000	4980	10300	4980	5170
Max	218000	244000	218000	132000	218000	68300
n (Samp)	151	54	151	56	151	24
n (Patient)	103	54	103	56	103	24

	0hr prior to AKI stage			24hr prior to AKI stage			48hr prior to AKI stage		
	sCr or UO	sCr only	UO only	sCr or UO	sCr only	UO only	sCr or UO	sCr only	UO only
AUC	0.50	0.51	0.51	0.39	0.50	0.37	0.23	0.46	0.18
SE	0.043	0.068	0.046	0.044	0.067	0.045	0.056	0.083	0.055
p	0.99	0.91	0.81	0.0095	0.95	0.0039	2.0E-6	0.65	8.4E-9
nCohort 1	145	341	151	145	341	151	145	341	151
nCohort 2	64	19	54	62	20	56	27	13	24
Cutoff 1	39600	29600	39600	25800	33900	27000	23900	34000	19800
Sens 1	70%	74%	70%	71%	70%	71%	70%	77%	75%
Spec 1	31%	22%	33%	8%	29%	14%	7%	30%	9%
Cutoff 2	27200	25600	29100	19600	20200	23500	16400	28600	16500
Sens 2	81%	84%	81%	81%	80%	80%	81%	85%	83%
Spec 2	10%	16%	17%	6%	11%	10%	5%	20%	7%
Cutoff 3	20700	23900	20200	14300	19100	13800	8630	15100	13800
Sens 3	91%	95%	91%	90%	90%	91%	93%	92%	92%
Spec 3	6%	14%	9%	3%	10%	3%	1%	7%	3%

	0hr prior to AKI stage			24hr prior to AKI stage			48hr prior to AKI stage		
	sCr or UO	sCr only	UO only	sCr or UO	sCr only	UO only	sCr or UO	sCr only	UO only
Cutoff 4	76000	67600	76000	76000	67600	76000	76000	67600	76000
Sens 4	34%	32%	35%	19%	35%	14%	0%	23%	0%
Spec 4	70%	70%	70%	70%	70%	70%	70%	70%	70%
Cutoff 5	90100	86400	92000	90100	86400	92000	90100	86400	92000
Sens 5	27%	26%	26%	11%	30%	4%	0%	0%	0%
Spec 5	80%	80%	80%	80%	80%	80%	80%	80%	80%
Cutoff 6	131000	113000	120000	131000	113000	120000	131000	113000	120000
Sens 6	12%	11%	13%	6%	20%	2%	0%	0%	0%
Spec 6	90%	90%	90%	90%	90%	90%	90%	90%	90%
OR Quart 2	0.70	0.48	1.2	1.2	0.65	2.0	>7.0	>7.7	>2.1
p Value	0.40	0.31	0.66	0.65	0.52	0.15	<0.078	<0.059	<0.55
95% CI of	0.30	0.12	0.51	0.50	0.18	0.77	>0.80	>0.93	>0.18
OR Quart2	1.6	2.0	2.9	3.0	2.4	5.4	na	na	na
OR Quart 3	0.63	0.65	0.80	1.1	0.65	2.0	>5.7	>3.1	>6.9
p Value	0.29	0.52	0.64	0.82	0.52	0.15	<0.12	<0.33	<0.079
95% CI of	0.27	0.18	0.32	0.45	0.18	0.77	>0.63	>0.32	>0.80
OR Quart3	1.5	2.4	2.0	2.7	2.4	5.4	na	na	na
OR Quart 4	1.1	1.0	1.2	2.7	0.99	3.5	>25	>3.1	>26
p Value	0.89	1.0	0.70	0.020	0.98	0.0083	<0.0022	<0.33	<0.0021
95% CI of	0.47	0.31	0.50	1.2	0.31	1.4	>3.2	>0.32	>3.3
OR Quart4	2.4	3.2	2.8	6.4	3.2	9.1	na	na	na

Apolipoprotein(a)

sCr or UO	0hr prior to AKI stage		24hr prior to AKI stage		48hr prior to AKI stage	
	Cohort 1	Cohort 2	Cohort 1	Cohort 2	Cohort 1	Cohort 2
Median	47000	38500	47000	29800	47000	41500
Average	76700	78000	76700	72900	76700	82500
Stdev	99200	105000	99200	123000	99200	106000
p(t-test)		0.93		0.82		0.78
Min	7.99	1060	7.99	20.1	7.99	341
Max	631000	560000	631000	722000	631000	382000
n (Samp)	145	64	145	62	145	27
n (Patient)	111	64	111	62	111	27

sCr only	0hr prior to AKI stage		24hr prior to AKI stage		48hr prior to AKI stage	
	Cohort 1	Cohort 2	Cohort 1	Cohort 2	Cohort 1	Cohort 2
Median	41400	53200	41400	46900	41400	49600
Average	80100	84900	80100	109000	80100	94500
Stdev	102000	88500	102000	167000	102000	129000
p(t-test)		0.84		0.24		0.62
Min	7.99	2390	7.99	20.1	7.99	341
Max	631000	309000	631000	722000	631000	382000
n (Samp)	341	19	341	20	341	13
n (Patient)	193	19	193	20	193	13

UO only	0hr prior to AKI stage		24hr prior to AKI stage		48hr prior to AKI stage	
	Cohort 1	Cohort 2	Cohort 1	Cohort 2	Cohort 1	Cohort 2

UO only	0hr prior to AKI stage		24hr prior to AKI stage		48hr prior to AKI stage	
	Cohort 1	Cohort 2	Cohort 1	Cohort 2	Cohort 1	Cohort 2
Median	51100	29500	51100	22200	51100	29300
Average	75400	68600	75400	61700	75400	55600
Stdev	94800	104000	94800	92400	94800	68400
p(t-test)		0.66		0.35		0.33
Min	7.99	1060	7.99	977	7.99	1300
Max	631000	560000	631000	512000	631000	290000
n (Samp)	151	54	151	56	151	24
n (Patient)	103	54	103	56	103	24

	0hr prior to AKI stage			24hr prior to AKI stage			48hr prior to AKI stage		
	sCr or UO	sCr only	UO only	sCr or UO	sCr only	UO only	sCr or UO	sCr only	UO only
AUC	0.49	0.55	0.43	0.44	0.53	0.41	0.49	0.49	0.43
SE	0.044	0.070	0.046	0.044	0.068	0.046	0.061	0.082	0.065
p	0.75	0.48	0.12	0.20	0.63	0.052	0.88	0.89	0.27
nCohort 1	145	341	151	145	341	151	145	341	151
nCohort 2	64	19	54	62	20	56	27	13	24
Cutoff 1	14100	32400	11100	10500	25900	8730	16800	4700	15300
Sens 1	70%	74%	70%	71%	70%	71%	70%	77%	71%
Spec 1	29%	45%	19%	21%	40%	15%	32%	11%	28%
Cutoff 2	8730	15600	6840	5630	15300	5630	5630	4300	5630
Sens 2	81%	84%	81%	81%	80%	80%	81%	85%	83%
Spec 2	18%	31%	11%	12%	31%	9%	12%	9%	9%
Cutoff 3	4980	2640	4320	2640	4700	2640	1810	1680	3010
Sens 3	91%	95%	91%	90%	90%	91%	93%	92%	92%
Spec 3	8%	6%	5%	6%	11%	4%	6%	4%	5%
Cutoff 4	80900	89900	81800	80900	89900	81800	80900	89900	81800
Sens 4	27%	32%	22%	23%	30%	23%	33%	31%	25%
Spec 4	70%	70%	70%	70%	70%	70%	70%	70%	70%
Cutoff 5	122000	125000	112000	122000	125000	112000	122000	125000	112000
Sens 5	19%	21%	19%	16%	30%	18%	22%	23%	17%
Spec 5	80%	80%	80%	80%	80%	80%	80%	80%	80%
Cutoff 6	209000	214000	180000	209000	214000	180000	209000	214000	180000
Sens 6	11%	11%	11%	10%	15%	7%	11%	15%	4%
Spec 6	90%	90%	90%	90%	90%	90%	90%	90%	90%
OR Quart 2	0.85	1.7	0.91	0.90	1.3	0.55	0.58	0.75	0.46
p Value	0.71	0.47	0.85	0.82	0.73	0.23	0.37	0.71	0.30
95% CI of	0.36	0.40	0.35	0.38	0.33	0.20	0.17	0.16	0.11
OR Quart2	2.0	7.4	2.4	2.2	4.9	1.5	1.9	3.5	2.0
OR Quart 3	1.0	2.1	1.6	1.2	1.3	1.5	0.71	0.49	1.4
p Value	0.95	0.31	0.34	0.67	0.73	0.39	0.56	0.42	0.56
95% CI of	0.45	0.50	0.63	0.52	0.33	0.62	0.22	0.087	0.44
OR Quart3	2.4	8.6	3.8	2.8	4.9	3.4	2.3	2.7	4.5
OR Quart 4	1.2	1.7	2.0	1.6	1.5	1.6	1.0	1.0	1.2
p Value	0.63	0.47	0.11	0.26	0.53	0.26	1.0	0.99	0.73
95% CI of	0.54	0.40	0.84	0.70	0.41	0.70	0.34	0.24	0.38
OR Quart4	2.8	7.4	4.9	3.7	5.6	3.8	3.0	4.2	4.0

[0187] Fig. 6: Comparison of marker levels in EDTA samples collected from Cohort 1 (patients that did not progress beyond RIFLE stage 0 or R) and in EDTA samples collected from subjects at 0, 24 hours, and 48 hours prior to reaching stage I or F in Cohort 2.

Complement C4-B

sCr or UO	0hr prior to AKI stage		24hr prior to AKI stage		48hr prior to AKI stage	
	Cohort 1	Cohort 2	Cohort 1	Cohort 2	Cohort 1	Cohort 2
Median	70800	86100	70800	78800	70800	59900
Average	76600	85000	76600	83100	76600	71500
Stdev	39900	53500	39900	52600	39900	39100
p(t-test)		0.42		0.43		0.58
Min	305	7620	305	5510	305	10700
Max	223000	172000	223000	214000	223000	140000
n (Samp)	282	16	282	28	282	20
n (Patient)	160	16	160	28	160	20

sCr only	0hr prior to AKI stage		24hr prior to AKI stage		48hr prior to AKI stage	
	Cohort 1	Cohort 2	Cohort 1	Cohort 2	Cohort 1	Cohort 2
Median	nd	nd	nd	nd	72400	112000
Average	nd	nd	nd	nd	77600	104000
Stdev	nd	nd	nd	nd	41600	51900
p(t-test)	nd	nd	nd	nd		0.13
Min	nd	nd	nd	nd	305	15300
Max	nd	nd	nd	nd	223000	161000
n (Samp)	nd	nd	nd	nd	353	6
n (Patient)	nd	nd	nd	nd	193	6

UO only	0hr prior to AKI stage		24hr prior to AKI stage		48hr prior to AKI stage	
	Cohort 1	Cohort 2	Cohort 1	Cohort 2	Cohort 1	Cohort 2
Median	66200	84700	66200	67900	66200	59300
Average	73700	80900	73700	81800	73700	69000
Stdev	38600	57100	38600	54200	38600	35600
p(t-test)		0.53		0.33		0.62
Min	305	7620	305	5510	305	10700
Max	223000	172000	223000	214000	223000	126000
n (Samp)	258	13	258	26	258	17
n (Patient)	140	13	140	26	140	17

	0hr prior to AKI stage			24hr prior to AKI stage			48hr prior to AKI stage		
	sCr or UO	sCr only	UO only	sCr or UO	sCr only	UO only	sCr or UO	sCr only	UO only
AUC	0.54	nd	0.52	0.52	nd	0.52	0.47	0.68	0.47
SE	0.076	nd	0.083	0.058	nd	0.060	0.068	0.12	0.073
p	0.57	nd	0.83	0.74	nd	0.75	0.67	0.14	0.73
nCohort 1	282	nd	258	282	nd	258	282	353	258
nCohort 2	16	nd	13	28	nd	26	20	6	17
Cutoff 1	39400	nd	32200	46200	nd	45900	50900	81100	50900

	0hr prior to AKI stage			24hr prior to AKI stage			48hr prior to AKI stage		
	sCr or UO	sCr only	UO only	sCr or UO	sCr only	UO only	sCr or UO	sCr only	UO only
Sens 1	75%	nd	77%	71%	nd	73%	70%	83%	71%
Spec 1	19%	nd	13%	24%	nd	26%	30%	57%	33%
Cutoff 2	32200	nd	29600	34900	nd	34900	39400	81100	39400
Sens 2	81%	nd	85%	82%	nd	81%	80%	83%	82%
Spec 2	12%	nd	10%	15%	nd	16%	19%	57%	20%
Cutoff 3	7620	nd	7620	23300	nd	23300	21400	13500	21400
Sens 3	94%	nd	92%	93%	nd	92%	90%	100%	94%
Spec 3	2%	nd	3%	6%	nd	6%	5%	4%	5%
Cutoff 4	96100	nd	90900	96100	nd	90900	96100	100000	90900
Sens 4	38%	nd	38%	36%	nd	42%	35%	50%	29%
Spec 4	70%	nd	70%	70%	nd	70%	70%	70%	70%
Cutoff 5	111000	nd	108000	111000	nd	108000	111000	113000	108000
Sens 5	31%	nd	38%	32%	nd	35%	25%	50%	24%
Spec 5	80%	nd	80%	80%	nd	80%	80%	80%	80%
Cutoff 6	132000	nd	131000	132000	nd	131000	132000	132000	131000
Sens 6	25%	nd	23%	14%	nd	12%	5%	33%	0%
Spec 6	90%	nd	90%	90%	nd	90%	90%	90%	90%
OR Quart 2	0.19	nd	0.19	0.59	nd	0.84	0.80	0	0.74
p Value	0.13	nd	0.13	0.38	nd	0.77	0.75	na	0.70
95% CI of	0.021	nd	0.021	0.18	nd	0.27	0.21	na	0.16
OR Quart2	1.6	nd	1.6	1.9	nd	2.6	3.1	na	3.4
OR Quart 3	0.79	nd	0.38	0.73	nd	0.40	1.0	2.0	1.5
p Value	0.73	nd	0.25	0.58	nd	0.20	1.0	0.57	0.51
95% CI of	0.20	nd	0.070	0.24	nd	0.100	0.28	0.18	0.42
OR Quart3	3.1	nd	2.0	2.2	nd	1.6	3.6	22	5.7
OR Quart 4	1.2	nd	0.98	1.1	nd	1.5	1.2	3.0	1.0
p Value	0.77	nd	0.98	0.82	nd	0.44	0.74	0.34	0.98
95% CI of	0.35	nd	0.27	0.41	nd	0.54	0.36	0.31	0.24
OR Quart4	4.1	nd	3.6	3.1	nd	4.2	4.2	30	4.2

C-C motif chemokine 7

sCr or UO	0hr prior to AKI stage		24hr prior to AKI stage		48hr prior to AKI stage	
	Cohort 1	Cohort 2	Cohort 1	Cohort 2	Cohort 1	Cohort 2
Median	0.620	0.804	0.620	0.712	0.620	0.620
Average	7.83	22.1	7.83	11.9	7.83	10.9
Stdev	19.8	46.2	19.8	21.0	19.8	18.8
p(t-test)		0.015		0.31		0.54
Min	0.193	0.193	0.193	0.193	0.193	0.193
Max	166	181	166	79.4	166	60.8
n (Samp)	217	16	217	28	217	17
n (Patient)	133	16	133	28	133	17

UO only	0hr prior to AKI stage		24hr prior to AKI stage		48hr prior to AKI stage	
	Cohort 1	Cohort 2	Cohort 1	Cohort 2	Cohort 1	Cohort 2
Median	0.620	0.804	0.620	0.512	0.620	0.620
Average	8.13	24.1	8.13	10.6	8.13	10.8
Stdev	21.4	51.2	21.4	20.6	21.4	19.8

UO only	0hr prior to AKI stage		24hr prior to AKI stage		48hr prior to AKI stage	
	Cohort 1	Cohort 2	Cohort 1	Cohort 2	Cohort 1	Cohort 2
p(t-test)		0.022		0.56		0.65
Min	0.193	0.193	0.193	0.193	0.193	0.193
Max	166	181	166	79.4	166	60.8
n (Samp)	199	13	199	29	199	15
n (Patient)	118	13	118	29	118	15

	0hr prior to AKI stage			24hr prior to AKI stage			48hr prior to AKI stage		
	sCr or UO	sCr only	UO only	sCr or UO	sCr only	UO only	sCr or UO	sCr only	UO only
AUC	0.58	nd	0.56	0.52	nd	0.51	0.57	nd	0.55
SE	0.077	nd	0.085	0.059	nd	0.058	0.075	nd	0.079
p	0.30	nd	0.48	0.69	nd	0.93	0.37	nd	0.57
nCohort 1	217	nd	199	217	nd	199	217	nd	199
nCohort 2	16	nd	13	28	nd	29	17	nd	15
Cutoff 1	0.308	nd	0	0.193	nd	0.193	0.308	nd	0.308
Sens 1	75%	nd	100%	86%	nd	86%	88%	nd	87%
Spec 1	30%	nd	0%	18%	nd	20%	30%	nd	32%
Cutoff 2	0	nd	0	0.193	nd	0.193	0.308	nd	0.308
Sens 2	100%	nd	100%	86%	nd	86%	88%	nd	87%
Spec 2	0%	nd	0%	18%	nd	20%	30%	nd	32%
Cutoff 3	0	nd	0	0	nd	0	0.193	nd	0.193
Sens 3	100%	nd	100%	100%	nd	100%	94%	nd	93%
Spec 3	0%	nd	0%	0%	nd	0%	18%	nd	20%
Cutoff 4	2.71	nd	2.32	2.71	nd	2.32	2.71	nd	2.32
Sens 4	44%	nd	38%	32%	nd	34%	29%	nd	27%
Spec 4	71%	nd	71%	71%	nd	71%	71%	nd	71%
Cutoff 5	11.7	nd	9.52	11.7	nd	9.52	11.7	nd	9.52
Sens 5	38%	nd	31%	29%	nd	24%	29%	nd	27%
Spec 5	80%	nd	81%	80%	nd	81%	80%	nd	81%
Cutoff 6	19.2	nd	18.9	19.2	nd	18.9	19.2	nd	18.9
Sens 6	31%	nd	31%	25%	nd	21%	24%	nd	20%
Spec 6	90%	nd	90%	90%	nd	90%	90%	nd	90%
OR Quart 2	0.48	nd	0.24	0.72	nd	1.3	8.9	nd	3.2
p Value	0.41	nd	0.20	0.57	nd	0.59	0.042	nd	0.17
95% CI of	0.085	nd	0.025	0.23	nd	0.46	1.1	nd	0.61
OR Quart2	2.7	nd	2.2	2.2	nd	3.9	74	nd	17
OR Quart 3	1.0	nd	1.0	0.72	nd	0.69	3.1	nd	1.5
p Value	1.0	nd	1.0	0.57	nd	0.54	0.33	nd	0.65
95% CI of	0.24	nd	0.24	0.23	nd	0.20	0.31	nd	0.25
OR Quart3	4.2	nd	4.2	2.2	nd	2.3	31	nd	9.5
OR Quart 4	1.5	nd	1.0	0.98	nd	1.2	5.3	nd	2.0
p Value	0.53	nd	1.0	0.97	nd	0.78	0.13	nd	0.42
95% CI of	0.41	nd	0.24	0.34	nd	0.39	0.60	nd	0.36
OR Quart4	5.7	nd	4.2	2.8	nd	3.5	47	nd	12

Vascular endothelial growth factor receptor 3

sCr or UO	0hr prior to AKI stage		24hr prior to AKI stage		48hr prior to AKI stage	
	Cohort 1	Cohort 2	Cohort 1	Cohort 2	Cohort 1	Cohort 2

sCr or UO	0hr prior to AKI stage		24hr prior to AKI stage		48hr prior to AKI stage	
	Cohort 1	Cohort 2	Cohort 1	Cohort 2	Cohort 1	Cohort 2
Median	6100	5150	6100	5290	6100	5450
Average	7380	6360	7380	6050	7380	6270
Stdev	5900	3290	5900	3460	5900	3330
p(t-test)		0.49		0.24		0.44
Min	219	1190	219	1360	219	1500
Max	43200	12400	43200	16600	43200	12900
n (Samp)	217	16	217	28	217	17
n (Patient)	133	16	133	28	133	17

UO only	0hr prior to AKI stage		24hr prior to AKI stage		48hr prior to AKI stage	
	Cohort 1	Cohort 2	Cohort 1	Cohort 2	Cohort 1	Cohort 2
Median	6100	5110	6100	5810	6100	5450
Average	7350	6420	7350	6480	7350	6490
Stdev	5870	3590	5870	3710	5870	3400
p(t-test)		0.58		0.44		0.58
Min	219	1190	219	1360	219	1500
Max	43200	12400	43200	16600	43200	12900
n (Samp)	199	13	199	29	199	15
n (Patient)	118	13	118	29	118	15

	0hr prior to AKI stage			24hr prior to AKI stage			48hr prior to AKI stage		
	sCr or UO	sCr only	UO only	sCr or UO	sCr only	UO only	sCr or UO	sCr only	UO only
AUC	0.49	nd	0.49	0.45	nd	0.48	0.47	nd	0.49
SE	0.075	nd	0.083	0.059	nd	0.058	0.074	nd	0.078
p	0.90	nd	0.89	0.38	nd	0.71	0.70	nd	0.93
nCohort 1	217	nd	199	217	nd	199	217	nd	199
nCohort 2	16	nd	13	28	nd	29	17	nd	15
Cutoff 1	4400	nd	4400	3920	nd	3920	3700	nd	4610
Sens 1	75%	nd	77%	71%	nd	72%	71%	nd	73%
Spec 1	32%	nd	31%	28%	nd	28%	27%	nd	34%
Cutoff 2	4100	nd	4050	3400	nd	3400	3140	nd	3230
Sens 2	81%	nd	85%	82%	nd	83%	82%	nd	80%
Spec 2	29%	nd	29%	21%	nd	21%	17%	nd	18%
Cutoff 3	1630	nd	1630	1810	nd	1810	2780	nd	2780
Sens 3	94%	nd	92%	93%	nd	93%	94%	nd	93%
Spec 3	6%	nd	6%	6%	nd	7%	12%	nd	13%
Cutoff 4	8170	nd	8170	8170	nd	8170	8170	nd	8170
Sens 4	31%	nd	38%	21%	nd	24%	29%	nd	33%
Spec 4	70%	nd	70%	70%	nd	70%	70%	nd	70%
Cutoff 5	9670	nd	9630	9670	nd	9630	9670	nd	9630
Sens 5	25%	nd	31%	14%	nd	17%	18%	nd	27%
Spec 5	80%	nd	80%	80%	nd	80%	80%	nd	80%
Cutoff 6	12600	nd	12600	12600	nd	12600	12600	nd	12600
Sens 6	0%	nd	0%	4%	nd	7%	6%	nd	7%
Spec 6	90%	nd	90%	90%	nd	90%	90%	nd	90%
OR Quart 2	0.39	nd	0	0.83	nd	1.0	0.59	nd	0.38
p Value	0.27	nd	na	0.77	nd	1.0	0.48	nd	0.27

	0hr prior to AKI stage			24hr prior to AKI stage			48hr prior to AKI stage		
	sCr or UO	sCr only	UO only	sCr or UO	sCr only	UO only	sCr or UO	sCr only	UO only
95% CI of OR Quart2	0.072	nd	na	0.24	nd	0.33	0.13	nd	0.071
OR Quart3	2.1	nd	na	2.9	nd	3.1	2.6	nd	2.1
p Value	1.5	nd	1.2	1.8	nd	1.2	0.79	nd	0.78
95% CI of OR Quart3	0.52	nd	0.75	0.27	nd	0.78	0.73	nd	0.73
OR Quart4	0.44	nd	0.35	0.62	nd	0.39	0.20	nd	0.20
p Value	5.0	nd	4.3	5.4	nd	3.5	3.1	nd	3.1
95% CI of OR Quart4	0.39	nd	0.38	1.2	nd	1.0	1.0	nd	0.80
OR Quart4	0.27	nd	0.26	0.75	nd	1.0	0.98	nd	0.75
p Value	0.072	nd	0.070	0.38	nd	0.33	0.28	nd	0.20
95% CI of OR Quart4	2.1	nd	2.0	3.8	nd	3.1	3.7	nd	3.2

Interferon alpha-2

sCr or UO	0hr prior to AKI stage		24hr prior to AKI stage		48hr prior to AKI stage	
	Cohort 1	Cohort 2	Cohort 1	Cohort 2	Cohort 1	Cohort 2
Median	13.4	13.5	13.4	8.40	13.4	16.4
Average	17.6	19.9	17.6	14.8	17.6	16.6
Stdev	24.2	25.8	24.2	23.0	24.2	10.9
p(t-test)		0.72		0.56		0.86
Min	0.0320	0.0627	0.0320	0.0627	0.0320	0.0627
Max	223	95.9	223	121	223	35.3
n (Samp)	217	16	217	28	217	17
n (Patient)	133	16	133	28	133	17

UO only	0hr prior to AKI stage		24hr prior to AKI stage		48hr prior to AKI stage	
	Cohort 1	Cohort 2	Cohort 1	Cohort 2	Cohort 1	Cohort 2
Median	12.2	8.40	12.2	8.40	12.2	17.2
Average	16.8	19.1	16.8	16.5	16.8	17.7
Stdev	24.8	28.6	24.8	23.8	24.8	11.7
p(t-test)		0.75		0.95		0.89
Min	0.0320	0.0627	0.0320	0.0627	0.0320	0.0627
Max	223	95.9	223	121	223	35.3
n (Samp)	199	13	199	29	199	15
n (Patient)	118	13	118	29	118	15

	0hr prior to AKI stage			24hr prior to AKI stage			48hr prior to AKI stage		
	sCr or UO	sCr only	UO only	sCr or UO	sCr only	UO only	sCr or UO	sCr only	UO only
AUC	0.51	nd	0.49	0.46	nd	0.50	0.56	nd	0.60
SE	0.075	nd	0.083	0.059	nd	0.058	0.075	nd	0.080
p	0.89	nd	0.87	0.45	nd	0.97	0.45	nd	0.21
nCohort 1	217	nd	199	217	nd	199	217	nd	199
nCohort 2	16	nd	13	28	nd	29	17	nd	15
Cutoff 1	4.47	nd	0.0764	4.03	nd	4.03	9.68	nd	9.68
Sens 1	75%	nd	85%	71%	nd	72%	71%	nd	73%
Spec 1	34%	nd	18%	31%	nd	34%	45%	nd	48%
Cutoff 2	0.0627	nd	0.0764	0.0627	nd	0.0764	5.98	nd	8.88
Sens 2	88%	nd	85%	86%	nd	86%	82%	nd	80%
Spec 2	16%	nd	18%	16%	nd	18%	38%	nd	46%

	0hr prior to AKI stage			24hr prior to AKI stage			48hr prior to AKI stage		
	sCr or UO	sCr only	UO only	sCr or UO	sCr only	UO only	sCr or UO	sCr only	UO only
Cutoff 3	0.0324	nd	0.0324	0.0324	nd	0.0324	0.0627	nd	0.0764
Sens 3	100%	nd	100%	100%	nd	100%	94%	nd	93%
Spec 3	3%	nd	3%	3%	nd	3%	16%	nd	18%
Cutoff 4	23.2	nd	20.8	23.2	nd	20.8	23.2	nd	20.8
Sens 4	19%	nd	31%	14%	nd	28%	18%	nd	47%
Spec 4	71%	nd	71%	71%	nd	71%	71%	nd	71%
Cutoff 5	28.1	nd	27.4	28.1	nd	27.4	28.1	nd	27.4
Sens 5	19%	nd	15%	11%	nd	14%	18%	nd	27%
Spec 5	80%	nd	80%	80%	nd	80%	80%	nd	80%
Cutoff 6	38.0	nd	36.7	38.0	nd	36.7	38.0	nd	36.7
Sens 6	12%	nd	15%	4%	nd	7%	0%	nd	0%
Spec 6	90%	nd	90%	90%	nd	90%	90%	nd	90%
OR Quart 2	1.0	nd	1.5	1.9	nd	1.8	2.0	nd	1.5
p Value	1.0	nd	0.65	0.34	nd	0.29	0.42	nd	0.66
95% CI of	0.24	nd	0.25	0.52	nd	0.61	0.36	nd	0.24
OR Quart2	4.2	nd	9.5	6.8	nd	5.4	12	nd	9.4
OR Quart 3	1.3	nd	2.7	2.8	nd	1.4	4.5	nd	3.3
p Value	0.73	nd	0.26	0.093	nd	0.57	0.065	nd	0.16
95% CI of	0.32	nd	0.49	0.84	nd	0.45	0.91	nd	0.63
OR Quart3	5.0	nd	14	9.6	nd	4.3	22	nd	17
OR Quart 4	0.72	nd	1.5	1.9	nd	0.82	1.5	nd	2.0
p Value	0.68	nd	0.65	0.34	nd	0.75	0.66	nd	0.42
95% CI of	0.15	nd	0.25	0.52	nd	0.23	0.24	nd	0.36
OR Quart4	3.4	nd	9.5	6.8	nd	2.8	9.3	nd	12

Insulin-like growth factor-binding protein 4

sCr or UO	0hr prior to AKI stage		24hr prior to AKI stage		48hr prior to AKI stage	
	Cohort 1	Cohort 2	Cohort 1	Cohort 2	Cohort 1	Cohort 2
Median	2.93	20.4	2.93	8.48	2.93	2.93
Average	12.2	19.6	12.2	15.8	12.2	10.9
Stdev	19.3	15.9	19.3	17.1	19.3	11.5
p(t-test)		0.15		0.34		0.75
Min	0.0728	2.43	0.0728	0.572	0.0728	0.572
Max	158	47.3	158	57.3	158	33.5
n (Samp)	278	15	278	28	278	20
n (Patient)	160	15	160	28	160	20

sCr only	0hr prior to AKI stage		24hr prior to AKI stage		48hr prior to AKI stage	
	Cohort 1	Cohort 2	Cohort 1	Cohort 2	Cohort 1	Cohort 2
Median	nd	nd	nd	nd	2.93	13.3
Average	nd	nd	nd	nd	12.7	13.9
Stdev	nd	nd	nd	nd	18.5	13.3
p(t-test)	nd	nd	nd	nd		0.87
Min	nd	nd	nd	nd	0.0728	0.572
Max	nd	nd	nd	nd	158	26.9
n (Samp)	nd	nd	nd	nd	347	6
n (Patient)	nd	nd	nd	nd	193	6

UO only	0hr prior to AKI stage		24hr prior to AKI stage		48hr prior to AKI stage	
	Cohort 1	Cohort 2	Cohort 1	Cohort 2	Cohort 1	Cohort 2
Median	2.93	21.7	2.93	8.48	2.93	2.93
Average	12.2	20.2	12.2	15.2	12.2	9.66
Stdev	19.5	14.3	19.5	16.1	19.5	11.1
p(t-test)		0.16		0.45		0.60
Min	0.0728	2.43	0.0728	0.572	0.0728	0.572
Max	158	47.3	158	57.3	158	33.5
n (Samp)	254	12	254	26	254	17
n (Patient)	140	12	140	26	140	17

	0hr prior to AKI stage			24hr prior to AKI stage			48hr prior to AKI stage		
	sCr or UO	sCr only	UO only	sCr or UO	sCr only	UO only	sCr or UO	sCr only	UO only
AUC	0.68	nd	0.71	0.58	nd	0.57	0.54	0.54	0.51
SE	0.078	nd	0.086	0.059	nd	0.061	0.068	0.12	0.073
p	0.018	nd	0.015	0.19	nd	0.23	0.60	0.76	0.84
nCohort 1	278	nd	254	278	nd	254	278	347	254
nCohort 2	15	nd	12	28	nd	26	20	6	17
Cutoff 1	2.43	nd	10.7	0.971	nd	0.971	0.971	0.971	2.43
Sens 1	73%	nd	75%	79%	nd	77%	85%	83%	71%
Spec 1	41%	nd	61%	30%	nd	29%	30%	27%	39%
Cutoff 2	0.971	nd	0.971	0.572	nd	0.572	0.971	0.971	0.971
Sens 2	100%	nd	100%	89%	nd	88%	85%	83%	82%
Spec 2	30%	nd	29%	15%	nd	15%	30%	27%	29%
Cutoff 3	0.971	nd	0.971	0.0862	nd	0.0862	0.572	0.0862	0.0862
Sens 3	100%	nd	100%	100%	nd	100%	90%	100%	100%
Spec 3	30%	nd	29%	1%	nd	1%	15%	1%	1%
Cutoff 4	14.4	nd	14.4	14.4	nd	14.4	14.4	16.6	14.4
Sens 4	53%	nd	58%	46%	nd	46%	40%	50%	35%
Spec 4	71%	nd	71%	71%	nd	71%	71%	71%	71%
Cutoff 5	21.4	nd	20.4	21.4	nd	20.4	21.4	23.1	20.4
Sens 5	47%	nd	50%	32%	nd	38%	25%	50%	24%
Spec 5	81%	nd	80%	81%	nd	80%	81%	81%	80%
Cutoff 6	30.3	nd	28.1	30.3	nd	28.1	30.3	31.3	28.1
Sens 6	27%	nd	25%	18%	nd	23%	10%	0%	12%
Spec 6	90%	nd	91%	90%	nd	91%	90%	90%	91%
OR Quart 2	>5.4	nd	>3.1	1.2	nd	1.4	3.7	2.0	2.8
p Value	<0.13	nd	<0.33	0.77	nd	0.55	0.11	0.57	0.14
95% CI of	>0.61	nd	>0.31	0.35	nd	0.44	0.74	0.18	0.72
OR Quart2	na	nd	na	4.1	nd	4.8	18	23	11
OR Quart 3	>2.1	nd	>2.1	1.2	nd	0.79	2.6	0	0.65
p Value	<0.56	nd	<0.56	0.75	nd	0.73	0.26	na	0.64
95% CI of	>0.18	nd	>0.18	0.36	nd	0.20	0.49	na	0.10
OR Quart3	na	nd	na	4.2	nd	3.1	14	na	4.0
OR Quart 4	>8.8	nd	>7.7	2.4	nd	2.2	3.1	3.0	1.3
p Value	<0.042	nd	<0.060	0.13	nd	0.18	0.17	0.34	0.71
95% CI of	>1.1	nd	>0.92	0.78	nd	0.70	0.61	0.31	0.29
OR Quart4	na	nd	na	7.2	nd	6.7	16	30	6.2

Insulin-like growth factor-binding protein 5

sCr or UO	0hr prior to AKI stage		24hr prior to AKI stage		48hr prior to AKI stage	
	Cohort 1	Cohort 2	Cohort 1	Cohort 2	Cohort 1	Cohort 2
Median	14.4	0.488	14.4	0.488	14.4	10.7
Average	37.5	22.2	37.5	30.1	37.5	27.4
Stdev	52.0	40.5	52.0	49.6	52.0	39.9
p(t-test)		0.26		0.47		0.40
Min	0.204	0.222	0.204	0.204	0.204	0.222
Max	257	151	257	177	257	149
n (Samp)	278	15	278	28	278	20
n (Patient)	160	15	160	28	160	20

sCr only	0hr prior to AKI stage		24hr prior to AKI stage		48hr prior to AKI stage	
	Cohort 1	Cohort 2	Cohort 1	Cohort 2	Cohort 1	Cohort 2
Median	nd	nd	nd	nd	12.8	20.6
Average	nd	nd	nd	nd	34.3	50.2
Stdev	nd	nd	nd	nd	48.7	64.5
p(t-test)	nd	nd	nd	nd		0.43
Min	nd	nd	nd	nd	0.204	0.357
Max	nd	nd	nd	nd	257	149
n (Samp)	nd	nd	nd	nd	347	6
n (Patient)	nd	nd	nd	nd	193	6

UO only	0hr prior to AKI stage		24hr prior to AKI stage		48hr prior to AKI stage	
	Cohort 1	Cohort 2	Cohort 1	Cohort 2	Cohort 1	Cohort 2
Median	8.54	1.20	8.54	0.488	8.54	0.488
Average	32.1	15.1	32.1	24.5	32.1	14.6
Stdev	49.2	21.2	49.2	38.7	49.2	19.0
p(t-test)		0.24		0.44		0.15
Min	0.204	0.222	0.204	0.204	0.204	0.222
Max	257	66.0	257	126	257	51.0
n (Samp)	254	12	254	26	254	17
n (Patient)	140	12	140	26	140	17

	0hr prior to AKI stage			24hr prior to AKI stage			48hr prior to AKI stage		
	sCr or UO	sCr only	UO only	sCr or UO	sCr only	UO only	sCr or UO	sCr only	UO only
AUC	0.41	nd	0.44	0.43	nd	0.44	0.46	0.59	0.42
SE	0.079	nd	0.088	0.059	nd	0.061	0.068	0.12	0.075
p	0.27	nd	0.47	0.23	nd	0.35	0.51	0.46	0.29
nCohort 1	278	nd	254	278	nd	254	278	347	254
nCohort 2	15	nd	12	28	nd	26	20	6	17
Cutoff 1	0.316	nd	0.316	0.316	nd	0.222	0.316	0.357	0.222
Sens 1	80%	nd	83%	71%	nd	77%	75%	83%	82%
Spec 1	22%	nd	25%	22%	nd	18%	22%	28%	18%
Cutoff 2	0.316	nd	0.316	0.204	nd	0.204	0.222	0.357	0.222
Sens 2	80%	nd	83%	93%	nd	92%	85%	83%	82%
Spec 2	22%	nd	25%	5%	nd	6%	17%	28%	18%
Cutoff 3	0.204	nd	0.204	0.204	nd	0.204	0.204	0.316	0.204
Sens 3	100%	nd	100%	93%	nd	92%	100%	100%	100%

	0hr prior to AKI stage			24hr prior to AKI stage			48hr prior to AKI stage		
	sCr or UO	sCr only	UO only	sCr or UO	sCr only	UO only	sCr or UO	sCr only	UO only
Spec 3	5%	nd	6%	5%	nd	6%	5%	23%	6%
Cutoff 4	43.8	nd	35.0	43.8	nd	35.0	43.8	40.2	35.0
Sens 4	13%	nd	8%	25%	nd	31%	20%	33%	24%
Spec 4	71%	nd	70%	71%	nd	70%	71%	70%	70%
Cutoff 5	64.4	nd	55.8	64.4	nd	55.8	64.4	61.6	55.8
Sens 5	13%	nd	8%	18%	nd	19%	10%	33%	0%
Spec 5	80%	nd	80%	80%	nd	80%	80%	80%	80%
Cutoff 6	125	nd	105	125	nd	105	125	105	105
Sens 6	7%	nd	0%	11%	nd	8%	5%	33%	0%
Spec 6	90%	nd	91%	90%	nd	91%	90%	90%	91%
OR Quart 2	2.1	nd	4.3	0.83	nd	0.65	2.1	>3.1	3.2
p Value	0.40	nd	0.20	0.77	nd	0.51	0.30	<0.33	0.16
95% CI of	0.37	nd	0.46	0.24	nd	0.17	0.51	>0.32	0.62
OR Quart2	12	nd	39	2.9	nd	2.4	8.8	na	16
OR Quart 3	1.0	nd	5.3	1.0	nd	1.4	1.7	>1.0	1.5
p Value	0.99	nd	0.13	1.0	nd	0.57	0.47	<0.99	0.65
95% CI of	0.14	nd	0.60	0.31	nd	0.45	0.39	>0.062	0.25
OR Quart3	7.4	nd	47	3.2	nd	4.2	7.4	na	9.4
OR Quart 4	3.8	nd	2.1	2.0	nd	1.4	2.1	>2.0	3.2
p Value	0.10	nd	0.56	0.19	nd	0.57	0.30	<0.57	0.16
95% CI of	0.77	nd	0.18	0.70	nd	0.45	0.51	>0.18	0.63
OR Quart4	19	nd	23	5.7	nd	4.2	8.8	na	17

Immunoglobulin G4

sCr or UO	0hr prior to AKI stage		24hr prior to AKI stage		48hr prior to AKI stage	
	Cohort 1	Cohort 2	Cohort 1	Cohort 2	Cohort 1	Cohort 2
Median	414000	444000	414000	250000	414000	70300
Average	667000	519000	667000	415000	667000	205000
Stdev	807000	481000	807000	406000	807000	245000
p(t-test)		0.59		0.17		0.11
Min	2000	30100	2000	4650	2000	18500
Max	5190000	1210000	5190000	1350000	5190000	681000
n (Samp)	205	9	205	20	205	8
n (Patient)	127	9	127	20	127	8

UO only	0hr prior to AKI stage		24hr prior to AKI stage		48hr prior to AKI stage	
	Cohort 1	Cohort 2	Cohort 1	Cohort 2	Cohort 1	Cohort 2
Median	412000	444000	412000	250000	412000	90700
Average	642000	519000	642000	442000	642000	227000
Stdev	750000	481000	750000	418000	750000	255000
p(t-test)		0.63		0.27		0.15
Min	2000	30100	2000	4650	2000	18500
Max	5140000	1210000	5140000	1350000	5140000	681000
n (Samp)	191	9	191	18	191	7
n (Patient)	113	9	113	18	113	7

	0hr prior to AKI stage		24hr prior to AKI stage		48hr prior to AKI stage	

	sCr or UO	sCr only	UO only	sCr or UO	sCr only	UO only	sCr or UO	sCr only	UO only
AUC	0.46	nd	0.47	0.39	nd	0.42	0.24	nd	0.27
SE	0.10	nd	0.10	0.070	nd	0.073	0.10	nd	0.11
p	0.71	nd	0.73	0.12	nd	0.26	0.0093	nd	0.034
nCohort 1	205	nd	191	205	nd	191	205	nd	191
nCohort 2	9	nd	9	20	nd	18	8	nd	7
Cutoff 1	83300	nd	83300	206000	nd	206000	37500	nd	37500
Sens 1	78%	nd	78%	70%	nd	72%	75%	nd	71%
Spec 1	14%	nd	14%	25%	nd	27%	6%	nd	6%
Cutoff 2	51700	nd	51700	59500	nd	59500	33600	nd	33600
Sens 2	89%	nd	89%	80%	nd	83%	88%	nd	86%
Spec 2	7%	nd	7%	10%	nd	10%	5%	nd	5%
Cutoff 3	29400	nd	29400	52400	nd	8490	17900	nd	17900
Sens 3	100%	nd	100%	90%	nd	94%	100%	nd	100%
Spec 3	4%	nd	5%	7%	nd	2%	3%	nd	3%
Cutoff 4	731000	nd	731000	731000	nd	731000	731000	nd	731000
Sens 4	33%	nd	33%	15%	nd	17%	0%	nd	0%
Spec 4	70%	nd	70%	70%	nd	70%	70%	nd	70%
Cutoff 5	935000	nd	935000	935000	nd	935000	935000	nd	935000
Sens 5	33%	nd	33%	15%	nd	17%	0%	nd	0%
Spec 5	80%	nd	80%	80%	nd	80%	80%	nd	80%
Cutoff 6	1490000	nd	1380000	1490000	nd	1380000	1490000	nd	1380000
Sens 6	0%	nd	0%	0%	nd	0%	0%	nd	0%
Spec 6	90%	nd	90%	90%	nd	90%	90%	nd	90%
OR Quart 2	0.67	nd	0.65	1.4	nd	1.4	>2.1	nd	>2.1
p Value	0.66	nd	0.65	0.68	nd	0.68	<0.55	nd	<0.54
95% CI of	0.11	nd	0.10	0.30	nd	0.30	>0.19	nd	>0.19
OR Quart2	4.2	nd	4.1	6.5	nd	6.5	na	nd	na
OR Quart 3	0	nd	0	2.6	nd	2.2	>1.0	nd	>1.0
p Value	na	nd	na	0.19	nd	0.29	<0.98	nd	<0.99
95% CI of	na	nd	na	0.63	nd	0.51	>0.063	nd	>0.062
OR Quart3	na	nd	na	10	nd	9.2	na	nd	na
OR Quart 4	1.4	nd	1.4	2.2	nd	1.8	>5.6	nd	>4.4
p Value	0.68	nd	0.70	0.29	nd	0.45	<0.12	nd	<0.19
95% CI of	0.30	nd	0.29	0.51	nd	0.40	>0.63	nd	>0.48
OR Quart4	6.5	nd	6.4	9.1	nd	7.8	na	nd	na

Interleukin-21

sCr or UO	0hr prior to AKI stage		24hr prior to AKI stage		48hr prior to AKI stage	
	Cohort 1	Cohort 2	Cohort 1	Cohort 2	Cohort 1	Cohort 2
Median	0.430	0.784	0.430	0.630	0.430	1.63
Average	28.3	2.46	28.3	2.05	28.3	11.1
Stdev	369	3.78	369	3.54	369	31.5
p(t-test)		0.78		0.71		0.85
Min	0.0102	0.0102	0.0102	0.0102	0.0102	0.0102
Max	5430	12.6	5430	15.6	5430	132
n (Samp)	217	16	217	28	217	17
n (Patient)	133	16	133	28	133	17

UO only	0hr prior to AKI stage		24hr prior to AKI stage		48hr prior to AKI stage	
	Cohort 1	Cohort 2	Cohort 1	Cohort 2	Cohort 1	Cohort 2
Median	0.430	0.605	0.430	0.630	0.430	0.964
Average	30.7	1.70	30.7	1.61	30.7	11.4
Stdev	385	2.93	385	2.31	385	33.6
p(t-test)		0.79		0.68		0.85
Min	0.0102	0.0102	0.0102	0.0102	0.0102	0.0102
Max	5430	9.84	5430	8.04	5430	132
n (Samp)	199	13	199	29	199	15
n (Patient)	118	13	118	29	118	15

	0hr prior to AKI stage			24hr prior to AKI stage			48hr prior to AKI stage		
	sCr or UO	sCr only	UO only	sCr or UO	sCr only	UO only	sCr or UO	sCr only	UO only
AUC	0.53	nd	0.46	0.50	nd	0.50	0.62	nd	0.58
SE	0.076	nd	0.084	0.058	nd	0.058	0.075	nd	0.080
p	0.67	nd	0.67	0.97	nd	0.94	0.11	nd	0.33
nCohort 1	217	nd	199	217	nd	199	217	nd	199
nCohort 2	16	nd	13	28	nd	29	17	nd	15
Cutoff 1	0.0182	nd	0.0154	0.0257	nd	0.0257	0.783	nd	0.174
Sens 1	75%	nd	85%	71%	nd	72%	71%	nd	80%
Spec 1	26%	nd	18%	35%	nd	36%	55%	nd	40%
Cutoff 2	0.0154	nd	0.0154	0.0154	nd	0.0154	0.174	nd	0.174
Sens 2	88%	nd	85%	82%	nd	83%	82%	nd	80%
Spec 2	18%	nd	18%	18%	nd	18%	40%	nd	40%
Cutoff 3	0	nd	0	0.0102	nd	0.0102	0	nd	0
Sens 3	100%	nd	100%	93%	nd	93%	100%	nd	100%
Spec 3	0%	nd	0%	7%	nd	6%	0%	nd	0%
Cutoff 4	1.89	nd	1.89	1.89	nd	1.89	1.89	nd	1.89
Sens 4	38%	nd	23%	29%	nd	31%	29%	nd	27%
Spec 4	72%	nd	72%	72%	nd	72%	72%	nd	72%
Cutoff 5	2.75	nd	2.81	2.75	nd	2.81	2.75	nd	2.81
Sens 5	19%	nd	15%	21%	nd	17%	29%	nd	27%
Spec 5	80%	nd	80%	80%	nd	80%	80%	nd	80%
Cutoff 6	6.18	nd	7.58	6.18	nd	7.58	6.18	nd	7.58
Sens 6	12%	nd	8%	11%	nd	7%	29%	nd	27%
Spec 6	90%	nd	90%	90%	nd	90%	90%	nd	90%
OR Quart 2	0.48	nd	1.4	1.2	nd	0.69	0.32	nd	0.64
p Value	0.41	nd	0.70	0.77	nd	0.54	0.32	nd	0.63
95% CI of	0.085	nd	0.29	0.38	nd	0.20	0.032	nd	0.10
OR Quart2	2.7	nd	6.4	3.8	nd	2.3	3.1	nd	4.0
OR Quart 3	1.3	nd	0.65	1.4	nd	1.7	2.9	nd	2.1
p Value	0.73	nd	0.65	0.57	nd	0.31	0.13	nd	0.30
95% CI of	0.32	nd	0.10	0.45	nd	0.61	0.74	nd	0.50
OR Quart3	5.0	nd	4.1	4.3	nd	4.8	12	nd	9.0
OR Quart 4	1.2	nd	1.4	1.2	nd	0.84	1.7	nd	1.3
p Value	0.75	nd	0.70	0.79	nd	0.77	0.48	nd	0.72
95% CI of	0.32	nd	0.29	0.37	nd	0.26	0.39	nd	0.28
OR Quart4	4.9	nd	6.4	3.7	nd	2.7	7.5	nd	6.3

Interleukin-23

sCr or UO	0hr prior to AKI stage		24hr prior to AKI stage		48hr prior to AKI stage	
	Cohort 1	Cohort 2	Cohort 1	Cohort 2	Cohort 1	Cohort 2
Median	0.886	1.10	0.886	1.10	0.886	1.10
Average	1270	8060	1270	5040	1270	13400
Stdev	7660	25000	7660	19200	7660	33000
p(t-test)		0.0080		0.053		3.5E-5
Min	0.257	0.653	0.257	0.257	0.257	0.603
Max	100000	100000	100000	100000	100000	100000
n (Samp)	216	16	216	28	216	17
n (Patient)	132	16	132	28	132	17

UO only	0hr prior to AKI stage		24hr prior to AKI stage		48hr prior to AKI stage	
	Cohort 1	Cohort 2	Cohort 1	Cohort 2	Cohort 1	Cohort 2
Median	0.886	1.10	0.886	1.10	0.886	72.6
Average	1350	8370	1350	4290	1350	13800
Stdev	7990	27600	7990	18500	7990	35000
p(t-test)		0.017		0.14		1.2E-4
Min	0.257	0.653	0.257	0.257	0.257	0.603
Max	100000	100000	100000	100000	100000	100000
n (Samp)	198	13	198	29	198	15
n (Patient)	117	13	117	29	117	15

	0hr prior to AKI stage			24hr prior to AKI stage			48hr prior to AKI stage		
	sCr or UO	sCr only	UO only	sCr or UO	sCr only	UO only	sCr or UO	sCr only	UO only
AUC	0.63	nd	0.60	0.54	nd	0.52	0.62	nd	0.63
SE	0.077	nd	0.085	0.059	nd	0.058	0.075	nd	0.080
p	0.082	nd	0.24	0.51	nd	0.77	0.12	nd	0.097
nCohort 1	216	nd	198	216	nd	198	216	nd	198
nCohort 2	16	nd	13	28	nd	29	17	nd	15
Cutoff 1	0.770	nd	0.603	0.603	nd	0.603	0.770	nd	0.770
Sens 1	75%	nd	100%	75%	nd	72%	71%	nd	73%
Spec 1	41%	nd	23%	25%	nd	23%	41%	nd	41%
Cutoff 2	0.603	nd	0.603	0	nd	0	0.603	nd	0.603
Sens 2	100%	nd	100%	100%	nd	100%	88%	nd	93%
Spec 2	25%	nd	23%	0%	nd	0%	25%	nd	23%
Cutoff 3	0.603	nd	0.603	0	nd	0	0.257	nd	0.603
Sens 3	100%	nd	100%	100%	nd	100%	100%	nd	93%
Spec 3	25%	nd	23%	0%	nd	0%	15%	nd	23%
Cutoff 4	1.10	nd	1.10	1.10	nd	1.10	1.10	nd	1.10
Sens 4	38%	nd	31%	43%	nd	41%	47%	nd	53%
Spec 4	71%	nd	70%	71%	nd	70%	71%	nd	70%
Cutoff 5	179	nd	267	179	nd	267	179	nd	267
Sens 5	25%	nd	23%	32%	nd	24%	35%	nd	20%
Spec 5	80%	nd	80%	80%	nd	80%	80%	nd	80%
Cutoff 6	1040	nd	1040	1040	nd	1040	1040	nd	1040
Sens 6	25%	nd	23%	14%	nd	14%	24%	nd	20%
Spec 6	90%	nd	90%	90%	nd	90%	90%	nd	90%
OR Quart 2	>6.7	nd	>5.4	0.84	nd	0.71	1.5	nd	2.1
p Value	<0.083	nd	<0.13	0.77	nd	0.55	0.65	nd	0.41

	0hr prior to AKI stage			24hr prior to AKI stage			48hr prior to AKI stage		
	sCr or UO	sCr only	UO only	sCr or UO	sCr only	UO only	sCr or UO	sCr only	UO only
95% CI of OR Quart2	>0.78	nd	>0.61	0.27	nd	0.23	0.25	nd	0.36
	na	nd	na	2.7	nd	2.2	9.5	nd	12
OR Quart 3	>5.5	nd	>5.4	0.69	nd	0.58	2.6	nd	1.5
p Value	<0.13	nd	<0.13	0.54	nd	0.36	0.26	nd	0.65
95% CI of OR Quart3	>0.62	nd	>0.61	0.21	nd	0.18	0.49	nd	0.25
	na	nd	na	2.3	nd	1.9	14	nd	9.5
OR Quart 4	>5.5	nd	>3.1	1.5	nd	1.3	3.8	nd	3.2
p Value	<0.13	nd	<0.33	0.43	nd	0.64	0.11	nd	0.17
95% CI of OR Quart4	>0.62	nd	>0.31	0.54	nd	0.46	0.75	nd	0.61
	na	nd	na	4.3	nd	3.5	19	nd	17

Interleukin-28A

sCr or UO	0hr prior to AKI stage		24hr prior to AKI stage		48hr prior to AKI stage	
	Cohort 1	Cohort 2	Cohort 1	Cohort 2	Cohort 1	Cohort 2
Median	0.195	0.148	0.195	0.265	0.195	2.92
Average	31.1	18.2	31.1	12.7	31.1	26.0
Stdev	255	61.1	255	45.7	255	58.2
p(t-test)		0.84		0.70		0.93
Min	0.0727	0.0727	0.0727	0.0727	0.0727	0.0727
Max	3150	246	3150	243	3150	235
n (Samp)	216	16	216	28	216	17
n (Patient)	132	16	132	28	132	17

UO only	0hr prior to AKI stage		24hr prior to AKI stage		48hr prior to AKI stage	
	Cohort 1	Cohort 2	Cohort 1	Cohort 2	Cohort 1	Cohort 2
Median	0.195	0.148	0.195	0.265	0.195	0.195
Average	32.4	2.50	32.4	4.50	32.4	12.9
Stdev	266	5.90	266	8.06	266	23.4
p(t-test)		0.69		0.57		0.78
Min	0.0727	0.0727	0.0727	0.0727	0.0727	0.0727
Max	3150	20.8	3150	35.6	3150	71.6
n (Samp)	198	13	198	29	198	15
n (Patient)	117	13	117	29	117	15

	0hr prior to AKI stage			24hr prior to AKI stage			48hr prior to AKI stage		
	sCr or UO	sCr only	UO only	sCr or UO	sCr only	UO only	sCr or UO	sCr only	UO only
AUC	0.43	nd	0.35	0.54	nd	0.58	0.60	nd	0.57
SE	0.077	nd	0.085	0.059	nd	0.059	0.075	nd	0.080
p	0.34	nd	0.081	0.45	nd	0.17	0.16	nd	0.35
nCohort 1	216	nd	198	216	nd	198	216	nd	198
nCohort 2	16	nd	13	28	nd	29	17	nd	15
Cutoff 1	0	nd	0	0.158	nd	0.158	0.158	nd	0.158
Sens 1	100%	nd	100%	71%	nd	72%	76%	nd	73%
Spec 1	0%	nd	0%	38%	nd	41%	38%	nd	41%
Cutoff 2	0	nd	0	0.120	nd	0.120	0.120	nd	0.120
Sens 2	100%	nd	100%	86%	nd	86%	82%	nd	80%
Spec 2	0%	nd	0%	17%	nd	19%	17%	nd	19%

	0hr prior to AKI stage			24hr prior to AKI stage			48hr prior to AKI stage		
	sCr or UO	sCr only	UO only	sCr or UO	sCr only	UO only	sCr or UO	sCr only	UO only
Cutoff 3	0	nd	0	0	nd	0	0	nd	0
Sens 3	100%	nd	100%	100%	nd	100%	100%	nd	100%
Spec 3	0%	nd	0%	0%	nd	0%	0%	nd	0%
Cutoff 4	0.265	nd	0.265	0.265	nd	0.265	0.265	nd	0.265
Sens 4	38%	nd	23%	32%	nd	34%	53%	nd	40%
Spec 4	71%	nd	75%	71%	nd	75%	71%	nd	75%
Cutoff 5	10.2	nd	5.01	10.2	nd	5.01	10.2	nd	5.01
Sens 5	19%	nd	15%	21%	nd	31%	41%	nd	33%
Spec 5	80%	nd	80%	80%	nd	80%	80%	nd	80%
Cutoff 6	21.9	nd	20.8	21.9	nd	20.8	21.9	nd	20.8
Sens 6	6%	nd	0%	7%	nd	3%	24%	nd	20%
Spec 6	91%	nd	90%	91%	nd	90%	91%	nd	90%
OR Quart 2	0.48	nd	0	2.2	nd	1.8	0.74	nd	1.7
p Value	0.41	nd	na	0.23	nd	0.36	0.70	nd	0.47
95% CI of	0.085	nd	na	0.61	nd	0.50	0.16	nd	0.39
OR Quart2	2.7	nd	na	7.6	nd	6.6	3.4	nd	7.7
OR Quart 3	1.3	nd	1.7	1.8	nd	2.4	0.74	nd	0.32
p Value	0.73	nd	0.47	0.35	nd	0.16	0.70	nd	0.33
95% CI of	0.32	nd	0.39	0.51	nd	0.70	0.16	nd	0.032
OR Quart3	5.0	nd	7.7	6.7	nd	8.4	3.4	nd	3.2
OR Quart 4	1.3	nd	1.8	2.5	nd	2.4	1.8	nd	2.1
p Value	0.73	nd	0.45	0.15	nd	0.16	0.36	nd	0.32
95% CI of	0.32	nd	0.40	0.72	nd	0.70	0.50	nd	0.49
OR Quart4	5.0	nd	7.8	8.5	nd	8.4	6.6	nd	8.8

Interleukin-33

sCr or UO	0hr prior to AKI stage		24hr prior to AKI stage		48hr prior to AKI stage	
	Cohort 1	Cohort 2	Cohort 1	Cohort 2	Cohort 1	Cohort 2
Median	0.0981	0.0981	0.0981	0.0981	0.0981	2.20
Average	244	336	244	222	244	1080
Stdev	2720	1030	2720	849	2720	3330
p(t-test)		0.89		0.97		0.23
Min	0.0445	0.0445	0.0445	0.0445	0.0445	0.0445
Max	40000	4130	40000	4440	40000	13500
n (Samp)	217	16	217	28	217	17
n (Patient)	133	16	133	28	133	17

UO only	0hr prior to AKI stage		24hr prior to AKI stage		48hr prior to AKI stage	
	Cohort 1	Cohort 2	Cohort 1	Cohort 2	Cohort 1	Cohort 2
Median	0.0981	0.0981	0.0981	0.0981	0.0981	2.20
Average	264	351	264	196	264	1160
Stdev	2850	1140	2850	828	2850	3540
p(t-test)		0.91		0.90		0.25
Min	0.0445	0.0445	0.0445	0.0445	0.0445	0.0445
Max	40000	4130	40000	4440	40000	13500
n (Samp)	199	13	199	29	199	15
n (Patient)	118	13	118	29	118	15

	0hr prior to AKI stage			24hr prior to AKI stage			48hr prior to AKI stage		
	sCr or UO	sCr only	UO only	sCr or UO	sCr only	UO only	sCr or UO	sCr only	UO only
AUC	0.53	nd	0.52	0.51	nd	0.52	0.64	nd	0.66
SE	0.076	nd	0.084	0.058	nd	0.058	0.075	nd	0.079
p	0.72	nd	0.81	0.82	nd	0.79	0.053	nd	0.042
nCohort 1	217	nd	199	217	nd	199	217	nd	199
nCohort 2	16	nd	13	28	nd	29	17	nd	15
Cutoff 1	0.0494	nd	0.0494	0.0494	nd	0.0494	0.0996	nd	0.0996
Sens 1	88%	nd	92%	71%	nd	72%	71%	nd	73%
Spec 1	23%	nd	21%	23%	nd	21%	57%	nd	58%
Cutoff 2	0.0494	nd	0.0494	0.0445	nd	0.0445	0.0494	nd	0.0846
Sens 2	88%	nd	92%	93%	nd	93%	88%	nd	80%
Spec 2	23%	nd	21%	10%	nd	9%	23%	nd	39%
Cutoff 3	0	nd	0.0494	0.0445	nd	0.0445	0	nd	0.0494
Sens 3	100%	nd	92%	93%	nd	93%	100%	nd	93%
Spec 3	0%	nd	21%	10%	nd	9%	0%	nd	21%
Cutoff 4	0.821	nd	0.101	0.821	nd	0.101	0.821	nd	0.101
Sens 4	31%	nd	31%	39%	nd	41%	59%	nd	60%
Spec 4	71%	nd	70%	71%	nd	70%	71%	nd	70%
Cutoff 5	10.4	nd	13.1	10.4	nd	13.1	10.4	nd	13.1
Sens 5	25%	nd	23%	25%	nd	24%	35%	nd	33%
Spec 5	80%	nd	80%	80%	nd	80%	80%	nd	80%
Cutoff 6	58.1	nd	58.1	58.1	nd	58.1	58.1	nd	58.1
Sens 6	25%	nd	23%	14%	nd	14%	24%	nd	20%
Spec 6	90%	nd	90%	90%	nd	90%	90%	nd	90%
OR Quart 2	4.5	nd	7.9	0.86	nd	0.86	1.5	nd	0.48
p Value	0.065	nd	0.057	0.78	nd	0.78	0.66	nd	0.56
95% CI of	0.91	nd	0.94	0.29	nd	0.29	0.24	nd	0.042
OR Quart2	22	nd	67	2.5	nd	2.5	9.3	nd	5.5
OR Quart 3	0.49	nd	2.0	0.59	nd	0.72	2.6	nd	3.9
p Value	0.57	nd	0.57	0.38	nd	0.57	0.26	nd	0.10
95% CI of	0.043	nd	0.18	0.18	nd	0.23	0.49	nd	0.77
OR Quart3	5.6	nd	23	1.9	nd	2.2	14	nd	20
OR Quart 4	2.6	nd	3.1	0.98	nd	1.0	3.8	nd	2.6
p Value	0.27	nd	0.33	0.97	nd	1.0	0.11	nd	0.27
95% CI of	0.48	nd	0.31	0.34	nd	0.35	0.75	nd	0.48
OR Quart4	14	nd	31	2.8	nd	2.9	19	nd	14

Interleukin-4 receptor alpha chain

sCr or UO	0hr prior to AKI stage		24hr prior to AKI stage		48hr prior to AKI stage	
	Cohort 1	Cohort 2	Cohort 1	Cohort 2	Cohort 1	Cohort 2
Median	218	269	218	218	218	228
Average	288	396	288	297	288	332
Stdev	210	321	210	271	210	233
p(t-test)		0.057		0.83		0.40
Min	49.7	111	49.7	3.27	49.7	103
Max	1200	1090	1200	1210	1200	997
n (Samp)	217	16	217	28	217	17

sCr or UO	0hr prior to AKI stage		24hr prior to AKI stage		48hr prior to AKI stage	
	Cohort 1	Cohort 2	Cohort 1	Cohort 2	Cohort 1	Cohort 2
n (Patient)	133	16	133	28	133	17

UO only	0hr prior to AKI stage		24hr prior to AKI stage		48hr prior to AKI stage	
	Cohort 1	Cohort 2	Cohort 1	Cohort 2	Cohort 1	Cohort 2
Median	229	298	229	191	229	228
Average	297	442	297	286	297	341
Stdev	215	336	215	268	215	247
p(t-test)		0.024		0.82		0.45
Min	49.7	138	49.7	3.27	49.7	84.5
Max	1200	1090	1200	1210	1200	997
n (Samp)	199	13	199	29	199	15
n (Patient)	118	13	118	29	118	15

	0hr prior to AKI stage			24hr prior to AKI stage			48hr prior to AKI stage		
	sCr or UO	sCr only	UO only	sCr or UO	sCr only	UO only	sCr or UO	sCr only	UO only
AUC	0.59	nd	0.64	0.48	nd	0.44	0.56	nd	0.54
SE	0.077	nd	0.085	0.059	nd	0.059	0.075	nd	0.079
p	0.26	nd	0.11	0.72	nd	0.32	0.44	nd	0.58
nCohort 1	217	nd	199	217	nd	199	217	nd	199
nCohort 2	16	nd	13	28	nd	29	17	nd	15
Cutoff 1	195	nd	204	148	nd	142	178	nd	170
Sens 1	75%	nd	77%	71%	nd	72%	71%	nd	73%
Spec 1	43%	nd	42%	23%	nd	19%	35%	nd	30%
Cutoff 2	153	nd	195	104	nd	104	165	nd	165
Sens 2	81%	nd	85%	89%	nd	93%	82%	nd	80%
Spec 2	25%	nd	40%	6%	nd	6%	30%	nd	29%
Cutoff 3	111	nd	153	83.5	nd	104	121	nd	121
Sens 3	94%	nd	92%	93%	nd	93%	94%	nd	93%
Spec 3	6%	nd	24%	3%	nd	6%	9%	nd	8%
Cutoff 4	299	nd	317	299	nd	317	299	nd	317
Sens 4	44%	nd	46%	39%	nd	28%	47%	nd	47%
Spec 4	70%	nd	70%	70%	nd	70%	70%	nd	70%
Cutoff 5	380	nd	400	380	nd	400	380	nd	400
Sens 5	31%	nd	38%	18%	nd	17%	35%	nd	33%
Spec 5	80%	nd	80%	80%	nd	80%	80%	nd	80%
Cutoff 6	529	nd	560	529	nd	560	529	nd	560
Sens 6	25%	nd	23%	11%	nd	10%	18%	nd	20%
Spec 6	90%	nd	90%	90%	nd	90%	90%	nd	90%
OR Quart 2	1.4	nd	1.5	0.74	nd	0.54	1.7	nd	1.7
p Value	0.70	nd	0.65	0.59	nd	0.35	0.48	nd	0.48
95% CI of	0.29	nd	0.25	0.24	nd	0.15	0.39	nd	0.39
OR Quart2	6.4	nd	9.5	2.3	nd	2.0	7.5	nd	7.5
OR Quart 3	1.0	nd	1.5	0.60	nd	1.2	1.0	nd	0.32
p Value	1.0	nd	0.65	0.40	nd	0.78	1.0	nd	0.33
95% CI of	0.19	nd	0.25	0.19	nd	0.39	0.19	nd	0.032
OR Quart3	5.2	nd	9.5	2.0	nd	3.5	5.2	nd	3.2
OR Quart 4	2.1	nd	2.7	1.2	nd	1.5	2.1	nd	2.1

	0hr prior to AKI stage			24hr prior to AKI stage			48hr prior to AKI stage		
	sCr or UO	sCr only	UO only	sCr or UO	sCr only	UO only	sCr or UO	sCr only	UO only
p Value	0.32	nd	0.26	0.77	nd	0.43	0.32	nd	0.32
95% CI of	0.49	nd	0.49	0.42	nd	0.53	0.49	nd	0.49
OR Quart4	8.7	nd	14	3.3	nd	4.3	8.7	nd	8.8

Vascular endothelial growth factor receptor 2

sCr or UO	0hr prior to AKI stage		24hr prior to AKI stage		48hr prior to AKI stage	
	Cohort 1	Cohort 2	Cohort 1	Cohort 2	Cohort 1	Cohort 2
Median	7910	9090	7910	7270	7910	7250
Average	9670	9560	9670	8430	9670	17800
Stdev	11000	4770	11000	3820	11000	38600
p(t-test)	.	0.97		0.55		0.028
Min	3640	3140	3640	4110	3640	3340
Max	153000	18000	153000	19800	153000	166000
n (Samp)	217	16	217	28	217	17
n (Patient)	133	16	133	28	133	17

UO only	0hr prior to AKI stage		24hr prior to AKI stage		48hr prior to AKI stage	
	Cohort 1	Cohort 2	Cohort 1	Cohort 2	Cohort 1	Cohort 2
Median	7930	9140	7930	7590	7930	7250
Average	9820	9510	9820	8350	9820	19000
Stdev	11400	4780	11400	3590	11400	41100
p(t-test)		0.92		0.49		0.025
Min	3640	3140	3640	4110	3640	4480
Max	153000	18000	153000	19800	153000	166000
n (Samp)	199	13	199	29	199	15
n (Patient)	118	13	118	29	118	15

	0hr prior to AKI stage			24hr prior to AKI stage			48hr prior to AKI stage		
	sCr or UO	sCr only	UO only	sCr or UO	sCr only	UO only	sCr or UO	sCr only	UO only
AUC	0.53	nd	0.54	0.45	nd	0.45	0.45	nd	0.44
SE	0.076	nd	0.084	0.059	nd	0.059	0.075	nd	0.079
p	0.71	nd	0.67	0.38	nd	0.41	0.47	nd	0.46
nCohort 1	217	nd	199	217	nd	199	217	nd	199
nCohort 2	16	nd	13	28	nd	29	17	nd	15
Cutoff 1	5760	nd	5620	5720	nd	5720	6010	nd	6010
Sens 1	75%	nd	77%	71%	nd	72%	71%	nd	73%
Spec 1	15%	nd	14%	15%	nd	15%	18%	nd	18%
Cutoff 2	5620	nd	5310	5610	nd	5610	5140	nd	5880
Sens 2	81%	nd	85%	82%	nd	83%	82%	nd	80%
Spec 2	14%	nd	9%	14%	nd	14%	8%	nd	16%
Cutoff 3	4780	nd	4730	5140	nd	5140	4330	nd	5030
Sens 3	94%	nd	92%	93%	nd	93%	94%	nd	93%
Spec 3	6%	nd	5%	8%	nd	7%	4%	nd	6%
Cutoff 4	9260	nd	9260	9260	nd	9260	9260	nd	9260
Sens 4	44%	nd	46%	25%	nd	24%	29%	nd	27%
Spec 4	70%	nd	70%	70%	nd	70%	70%	nd	70%
Cutoff 5	10300	nd	10500	10300	nd	10500	10300	nd	10500

	0hr prior to AKI stage			24hr prior to AKI stage			48hr prior to AKI stage		
	sCr or UO	sCr only	UO only	sCr or UO	sCr only	UO only	sCr or UO	sCr only	UO only
Sens 5	25%	nd	23%	21%	nd	21%	29%	nd	27%
Spec 5	80%	nd	80%	80%	nd	80%	80%	nd	80%
Cutoff 6	14000	nd	14400	14000	nd	14400	14000	nd	14400
Sens 6	25%	nd	23%	14%	nd	7%	18%	nd	13%
Spec 6	90%	nd	90%	90%	nd	90%	90%	nd	90%
OR Quart 2	0.15	nd	0	1.2	nd	1.2	0.19	nd	0.24
p Value	0.086	nd	na	0.75	nd	0.77	0.13	nd	0.21
95% CI of	0.018	nd	na	0.38	nd	0.37	0.021	nd	0.026
OR Quart2	1.3	nd	na	3.8	nd	3.8	1.7	nd	2.2
OR Quart 3	0.64	nd	0.78	0.48	nd	0.82	0.79	nd	1.0
p Value	0.51	nd	0.73	0.32	nd	0.75	0.73	nd	1.0
95% CI of	0.17	nd	0.20	0.12	nd	0.23	0.20	nd	0.24
OR Quart3	2.4	nd	3.1	2.0	nd	2.8	3.1	nd	4.2
OR Quart 4	0.80	nd	0.78	2.3	nd	2.0	1.5	nd	1.6
p Value	0.73	nd	0.73	0.12	nd	0.19	0.52	nd	0.49
95% CI of	0.23	nd	0.20	0.80	nd	0.70	0.44	nd	0.42
OR Quart4	2.8	nd	3.1	6.5	nd	5.9	5.0	nd	6.0

Neural cell adhesion molecule 1

sCr or UO	0hr prior to AKI stage		24hr prior to AKI stage		48hr prior to AKI stage	
	Cohort 1	Cohort 2	Cohort 1	Cohort 2	Cohort 1	Cohort 2
Median	185000	178000	185000	185000	185000	165000
Average	192000	187000	192000	195000	192000	164000
Stdev	67100	63200	67100	86900	67100	55500
p(t-test)		0.77		0.84		0.067
Min	63300	93200	63300	81100	63300	49200
Max	520000	316000	520000	506000	520000	280000
n (Samp)	281	16	281	28	281	20
n (Patient)	159	16	159	28	159	20

sCr only	0hr prior to AKI stage		24hr prior to AKI stage		48hr prior to AKI stage	
	Cohort 1	Cohort 2	Cohort 1	Cohort 2	Cohort 1	Cohort 2
Median	nd	nd	nd	nd	181000	181000
Average	nd	nd	nd	nd	187000	203000
Stdev	nd	nd	nd	nd	65700	57300
p(t-test)	nd	nd	nd	nd		0.55
Min	nd	nd	nd	nd	49200	140000
Max	nd	nd	nd	nd	520000	280000
n (Samp)	nd	nd	nd	nd	352	6
n (Patient)	nd	nd	nd	nd	192	6

UO only	0hr prior to AKI stage		24hr prior to AKI stage		48hr prior to AKI stage	
	Cohort 1	Cohort 2	Cohort 1	Cohort 2	Cohort 1	Cohort 2
Median	184000	172000	184000	177000	184000	156000
Average	191000	168000	191000	173000	191000	155000
Stdev	69000	51800	69000	56900	69000	47600
p(t-test)		0.24		0.20		0.032

UO only	0hr prior to AKI stage		24hr prior to AKI stage		48hr prior to AKI stage	
	Cohort 1	Cohort 2	Cohort 1	Cohort 2	Cohort 1	Cohort 2
Min	63300	93200	63300	81100	63300	49200
Max	520000	282000	520000	331000	520000	230000
n (Samp)	257	13	257	26	257	17
n (Patient)	139	13	139	26	139	17

	0hr prior to AKI stage			24hr prior to AKI stage			48hr prior to AKI stage		
	sCr or UO	sCr only	UO only	sCr or UO	sCr only	UO only	sCr or UO	sCr only	UO only
AUC	0.48	nd	0.40	0.48	nd	0.42	0.37	0.58	0.35
SE	0.075	nd	0.085	0.058	nd	0.061	0.069	0.12	0.074
p	0.84	nd	0.24	0.73	nd	0.21	0.069	0.54	0.037
nCohort 1	281	nd	257	281	nd	257	281	352	257
nCohort 2	16	nd	13	28	nd	26	20	6	17
Cutoff 1	152000	nd	133000	158000	nd	130000	144000	166000	144000
Sens 1	75%	nd	77%	71%	nd	73%	70%	83%	71%
Spec 1	29%	nd	19%	31%	nd	18%	23%	40%	25%
Cutoff 2	133000	nd	121000	125000	nd	121000	121000	166000	107000
Sens 2	81%	nd	85%	82%	nd	81%	80%	83%	82%
Spec 2	18%	nd	13%	12%	nd	13%	11%	40%	8%
Cutoff 3	95600	nd	95600	105000	nd	105000	106000	140000	91800
Sens 3	94%	nd	92%	93%	nd	92%	90%	100%	94%
Spec 3	4%	nd	4%	6%	nd	7%	7%	23%	3%
Cutoff 4	214000	nd	215000	214000	nd	215000	214000	207000	215000
Sens 4	25%	nd	8%	29%	nd	19%	15%	33%	12%
Spec 4	70%	nd	70%	70%	nd	70%	70%	70%	70%
Cutoff 5	233000	nd	234000	233000	nd	234000	233000	228000	234000
Sens 5	19%	nd	8%	14%	nd	12%	10%	33%	0%
Spec 5	80%	nd	80%	80%	nd	80%	80%	80%	80%
Cutoff 6	266000	nd	266000	266000	nd	266000	266000	262000	266000
Sens 6	12%	nd	8%	11%	nd	4%	10%	33%	0%
Spec 6	90%	nd	90%	90%	nd	90%	90%	90%	90%
OR Quart 2	0.75	nd	3.1	1.0	nd	1.8	1.0	2.0	1.5
p Value	0.71	nd	0.33	0.98	nd	0.35	0.99	0.57	0.64
95% CI of	0.16	nd	0.32	0.34	nd	0.51	0.20	0.18	0.25
OR Quart2	3.5	nd	31	3.0	nd	6.6	5.2	22	9.6
OR Quart 3	1.3	nd	5.3	0.86	nd	1.5	2.5	1.0	3.8
p Value	0.72	nd	0.13	0.79	nd	0.51	0.20	1.0	0.11
95% CI of	0.33	nd	0.60	0.27	nd	0.42	0.62	0.062	0.76
OR Quart3	5.0	nd	47	2.7	nd	5.7	10	16	19
OR Quart 4	1.0	nd	4.3	1.2	nd	2.5	2.5	2.0	2.7
p Value	0.98	nd	0.20	0.77	nd	0.15	0.20	0.57	0.25
95% CI of	0.24	nd	0.46	0.40	nd	0.72	0.62	0.18	0.50
OR Quart4	4.2	nd	39	3.4	nd	8.4	10	22	14

Platelet-derived growth factor subunit B (dimer)

sCr or UO	0hr prior to AKI stage		24hr prior to AKI stage		48hr prior to AKI stage	
	Cohort 1	Cohort 2	Cohort 1	Cohort 2	Cohort 1	Cohort 2
Median	357	228	357	346	357	448

sCr or UO	0hr prior to AKI stage		24hr prior to AKI stage		48hr prior to AKI stage	
	Cohort 1	Cohort 2	Cohort 1	Cohort 2	Cohort 1	Cohort 2
Average	410	280	410	523	410	398
Stdev	246	155	246	668	246	234
p(t-test)		0.039		0.067		0.84
Min	28.1	33.7	28.1	74.0	28.1	45.0
Max	1540	601	1540	2720	1540	750
n (Samp)	274	16	274	27	274	19
n (Patient)	158	16	158	27	158	19

sCr only	0hr prior to AKI stage		24hr prior to AKI stage		48hr prior to AKI stage	
	Cohort 1	Cohort 2	Cohort 1	Cohort 2	Cohort 1	Cohort 2
Median	nd	nd	nd	nd	342	357
Average	nd	nd	nd	nd	391	385
Stdev	nd	nd	nd	nd	245	160
p(t-test)	nd	nd	nd	nd		0.95
Min	nd	nd	nd	nd	0.189	220
Max	nd	nd	nd	nd	1540	609
n (Samp)	nd	nd	nd	nd	341	6
n (Patient)	nd	nd	nd	nd	188	6

UO only	0hr prior to AKI stage		24hr prior to AKI stage		48hr prior to AKI stage	
	Cohort 1	Cohort 2	Cohort 1	Cohort 2	Cohort 1	Cohort 2
Median	334	224	334	346	334	352
Average	389	283	389	456	389	385
Stdev	238	171	238	532	238	247
p(t-test)		0.12		0.25		0.95
Min	28.1	33.7	28.1	74.0	28.1	45.0
Max	1540	601	1540	2720	1540	750
n (Samp)	250	13	250	25	250	16
n (Patient)	138	13	138	25	138	16

	0hr prior to AKI stage			24hr prior to AKI stage			48hr prior to AKI stage		
	sCr or UO	sCr only	UO only	sCr or UO	sCr only	UO only	sCr or UO	sCr only	UO only
AUC	0.34	nd	0.36	0.46	nd	0.47	0.50	0.52	0.49
SE	0.076	nd	0.085	0.059	nd	0.061	0.069	0.12	0.075
p	0.030	nd	0.11	0.50	nd	0.67	0.95	0.86	0.94
nCohort 1	274	nd	250	274	nd	250	274	341	250
nCohort 2	16	nd	13	27	nd	25	19	6	16
Cutoff 1	192	nd	171	220	nd	220	242	247	229
Sens 1	75%	nd	77%	70%	nd	72%	74%	83%	75%
Spec 1	19%	nd	18%	23%	nd	26%	26%	31%	27%
Cutoff 2	171	nd	165	155	nd	155	122	247	122
Sens 2	81%	nd	85%	81%	nd	80%	84%	83%	81%
Spec 2	16%	nd	18%	15%	nd	16%	10%	31%	11%
Cutoff 3	138	nd	138	88.8	nd	88.8	88.8	220	88.8
Sens 3	94%	nd	92%	93%	nd	92%	95%	100%	94%
Spec 3	12%	nd	13%	5%	nd	5%	5%	27%	5%
Cutoff 4	504	nd	478	504	nd	478	504	496	478

	0hr prior to AKI stage			24hr prior to AKI stage			48hr prior to AKI stage		
	sCr or UO	sCr only	UO only	sCr or UO	sCr only	UO only	sCr or UO	sCr only	UO only
Sens 4	12%	nd	23%	22%	nd	24%	42%	33%	44%
Spec 4	70%	nd	70%	70%	nd	70%	70%	70%	70%
Cutoff 5	613	nd	569	613	nd	569	613	583	569
Sens 5	0%	nd	8%	22%	nd	24%	16%	17%	25%
Spec 5	80%	nd	80%	80%	nd	80%	80%	80%	80%
Cutoff 6	728	nd	697	728	nd	697	728	704	697
Sens 6	0%	nd	0%	19%	nd	20%	11%	0%	19%
Spec 6	90%	nd	90%	90%	nd	90%	90%	90%	90%
OR Quart 2	4.2	nd	1.0	1.2	nd	1.2	1.0	>3.1	0.59
p Value	0.20	nd	1.0	0.75	nd	0.77	0.98	<0.34	0.48
95% CI of	0.46	nd	0.14	0.38	nd	0.38	0.28	>0.31	0.14
OR Quart2	39	nd	7.3	3.8	nd	3.7	3.7	na	2.6
OR Quart 3	3.1	nd	1.5	0.83	nd	0.82	0.80	>2.0	0.79
p Value	0.33	nd	0.65	0.77	nd	0.75	0.75	<0.57	0.73
95% CI of	0.31	nd	0.25	0.24	nd	0.24	0.21	>0.18	0.20
OR Quart3	30	nd	9.4	2.9	nd	2.8	3.1	na	3.1
OR Quart 4	9.0	nd	3.3	1.6	nd	1.2	1.0	>1.0	0.80
p Value	0.041	nd	0.16	0.40	nd	0.75	0.98	<1.0	0.75
95% CI of	1.1	nd	0.63	0.54	nd	0.38	0.28	>0.062	0.21
OR Quart4	74	nd	17	4.7	nd	3.8	3.7	na	3.1

Corticotropin

sCr or UO	0hr prior to AKI stage		24hr prior to AKI stage		48hr prior to AKI stage	
	Cohort 1	Cohort 2	Cohort 1	Cohort 2	Cohort 1	Cohort 2
Median	0.000668	0.00344	0.000668	0.00402	0.000668	0.00254
Average	0.00568	0.00650	0.00568	0.00599	0.00568	0.00960
Stdev	0.0263	0.00561	0.0263	0.00669	0.0263	0.0224
p(t-test)		0.93		0.96		0.56
Min	3.38E-6	6.17E-6	3.38E-6	3.38E-6	3.38E-6	3.38E-6
Max	0.292	0.0140	0.292	0.0251	0.292	0.0908
n (Samp)	197	7	197	20	197	16
n (Patient)	131	7	131	20	131	16

UO only	0hr prior to AKI stage		24hr prior to AKI stage		48hr prior to AKI stage	
	Cohort 1	Cohort 2	Cohort 1	Cohort 2	Cohort 1	Cohort 2
Median	nd	nd	0.000881	0.00389	0.000881	0.00297
Average	nd	nd	0.00636	0.00721	0.00636	0.0115
Stdev	nd	nd	0.0280	0.00813	0.0280	0.0246
p(t-test)	nd	nd		0.90		0.52
Min	nd	nd	3.38E-6	3.38E-6	3.38E-6	3.38E-6
Max	nd	nd	0.292	0.0251	0.292	0.0908
n (Samp)	nd	nd	173	18	173	13
n (Patient)	nd	nd	111	18	111	13

	0hr prior to AKI stage			24hr prior to AKI stage			48hr prior to AKI stage		
	sCr or UO	sCr only	UO only	sCr or UO	sCr only	UO only	sCr or UO	sCr only	UO only
AUC	0.74	nd	nd	0.67	nd	0.67	0.56	nd	0.63

	0hr prior to AKI stage			24hr prior to AKI stage			48hr prior to AKI stage		
	sCr or UO	sCr only	UO only	sCr or UO	sCr only	UO only	sCr or UO	sCr only	UO only
SE	0.11	nd	nd	0.069	nd	0.072	0.077	nd	0.086
p	0.026	nd	nd	0.016	nd	0.016	0.46	nd	0.12
nCohort 1	197	nd	nd	197	nd	173	197	nd	173
nCohort 2	7	nd	nd	20	nd	18	16	nd	13
Cutoff 1	0.00317	nd	nd	0.000466	nd	0.000293	4.31E-6	nd	0.00192
Sens 1	71%	nd	nd	70%	nd	72%	75%	nd	77%
Spec 1	76%	nd	nd	45%	nd	42%	16%	nd	64%
Cutoff 2	0.00183	nd	nd	0.000278	nd	0.000278	3.38E-6	nd	4.31E-6
Sens 2	86%	nd	nd	85%	nd	89%	88%	nd	85%
Spec 2	66%	nd	nd	41%	nd	39%	5%	nd	16%
Cutoff 3	4.31E-6	nd	nd	4.31E-6	nd	4.31E-6	0	nd	3.38E-6
Sens 3	100%	nd	nd	90%	nd	94%	100%	nd	92%
Spec 3	16%	nd	nd	16%	nd	16%	0%	nd	5%
Cutoff 4	0.00221	nd	nd	0.00221	nd	0.00297	0.00221	nd	0.00297
Sens 4	71%	nd	nd	60%	nd	61%	56%	nd	46%
Spec 4	70%	nd	nd	70%	nd	72%	70%	nd	72%
Cutoff 5	0.00423	nd	nd	0.00423	nd	0.00486	0.00423	nd	0.00486
Sens 5	43%	nd	nd	50%	nd	44%	31%	nd	31%
Spec 5	80%	nd	nd	80%	nd	80%	80%	nd	80%
Cutoff 6	0.00829	nd	nd	0.00829	nd	0.00914	0.00829	nd	0.00914
Sens 6	43%	nd	nd	35%	nd	33%	19%	nd	23%
Spec 6	90%	nd	nd	90%	nd	90%	90%	nd	90%
OR Quart 2	0	nd	nd	1.4	nd	2.0	0	nd	0
p Value	na	nd	nd	0.70	nd	0.42	na	nd	na
95% CI of	na	nd	nd	0.29	nd	0.36	na	nd	na
OR Quart2	na	nd	nd	6.4	nd	12	na	nd	na
OR Quart 3	2.0	nd	nd	0.65	nd	1.5	0.64	nd	1.7
p Value	0.57	nd	nd	0.65	nd	0.67	0.51	nd	0.46
95% CI of	0.18	nd	nd	0.10	nd	0.24	0.17	nd	0.39
OR Quart3	23	nd	nd	4.1	nd	9.4	2.4	nd	7.8
OR Quart 4	4.3	nd	nd	4.2	nd	5.2	0.98	nd	1.7
p Value	0.20	nd	nd	0.034	nd	0.042	0.97	nd	0.48
95% CI of	0.46	nd	nd	1.1	nd	1.1	0.29	nd	0.38
OR Quart4	39	nd	nd	16	nd	25	3.3	nd	7.6

Thyroxine-binding globulin

sCr or UO	0hr prior to AKI stage		24hr prior to AKI stage		48hr prior to AKI stage	
	Cohort 1	Cohort 2	Cohort 1	Cohort 2	Cohort 1	Cohort 2
Median	36.9	34.2	36.9	29.8	36.9	30.0
Average	37.8	35.8	37.8	33.3	37.8	35.1
Stdev	10.8	10.4	10.8	12.0	10.8	12.8
p(t-test)		0.36		0.026		0.31
Min	12.8	15.2	12.8	14.2	12.8	16.3
Max	75.8	57.7	75.8	63.7	75.8	62.0
n (Samp)	437	26	437	32	437	17
n (Patient)	174	26	174	32	174	17

sCr only	0hr prior to AKI stage		24hr prior to AKI stage		48hr prior to AKI stage	
	Cohort 1	Cohort 2	Cohort 1	Cohort 2	Cohort 1	Cohort 2
Median	36.2	28.7	36.2	30.3	36.2	33.2
Average	37.0	31.4	37.0	33.8	37.0	34.0
Stdev	11.1	12.8	11.1	14.8	11.1	14.2
p(t-test)		0.22		0.42		0.47
Min	12.8	18.0	12.8	15.9	12.8	15.2
Max	75.8	56.0	75.8	63.7	75.8	62.0
n (Samp)	535	6	535	8	535	7
n (Patient)	207	6	207	8	207	7

UO only	0hr prior to AKI stage		24hr prior to AKI stage		48hr prior to AKI stage	
	Cohort 1	Cohort 2	Cohort 1	Cohort 2	Cohort 1	Cohort 2
Median	35.6	32.5	35.6	28.5	35.6	30.0
Average	36.9	34.7	36.9	31.9	36.9	34.0
Stdev	10.6	9.63	10.6	10.5	10.6	12.5
p(t-test)		0.30		0.011		0.26
Min	12.8	15.2	12.8	14.2	12.8	16.3
Max	75.8	57.7	75.8	57.0	75.8	56.0
n (Samp)	363	26	363	31	363	17
n (Patient)	141	26	141	31	141	17

	0hr prior to AKI stage			24hr prior to AKI stage			48hr prior to AKI stage		
	sCr or UO	sCr only	UO only	sCr or UO	sCr only	UO only	sCr or UO	sCr only	UO only
AUC	0.44	0.32	0.43	0.36	0.39	0.34	0.42	0.40	0.42
SE	0.060	0.12	0.060	0.054	0.11	0.055	0.074	0.11	0.074
p	0.28	0.15	0.24	0.013	0.29	0.0049	0.31	0.36	0.26
nCohort 1	437	535	363	437	535	363	437	535	363
nCohort 2	26	6	26	32	8	31	17	7	17
Cutoff 1	28.4	26.8	28.4	25.7	28.4	26.4	28.2	29.8	27.4
Sens 1	73%	83%	73%	72%	75%	71%	71%	71%	71%
Spec 1	19%	18%	21%	12%	24%	15%	19%	28%	16%
Cutoff 2	27.6	26.8	27.6	23.9	22.2	24.7	23.8	26.9	22.2
Sens 2	85%	83%	81%	81%	88%	81%	82%	86%	82%
Spec 2	17%	18%	18%	8%	8%	11%	8%	18%	6%
Cutoff 3	26.5	17.9	26.5	20.5	15.8	20.5	19.6	15.0	19.6
Sens 3	92%	100%	92%	91%	100%	90%	94%	100%	94%
Spec 3	14%	4%	15%	5%	3%	6%	4%	1%	4%
Cutoff 4	43.6	42.9	42.2	43.6	42.9	42.2	43.6	42.9	42.2
Sens 4	19%	17%	23%	19%	25%	16%	29%	14%	35%
Spec 4	70%	71%	71%	70%	71%	71%	70%	71%	71%
Cutoff 5	46.7	46.3	46.0	46.7	46.3	46.0	46.7	46.3	46.0
Sens 5	15%	17%	15%	12%	12%	10%	18%	14%	18%
Spec 5	80%	80%	80%	80%	80%	80%	80%	80%	80%
Cutoff 6	50.4	50.1	49.7	50.4	50.1	49.7	50.4	50.1	49.7
Sens 6	12%	17%	8%	9%	12%	6%	12%	14%	18%
Spec 6	90%	90%	90%	90%	90%	90%	90%	90%	90%
OR Quart 2	0.79	0	1.3	1.0	0	1.5	0.75	1.0	0.39
p Value	0.73	na	0.72	0.99	na	0.51	0.71	1.00	0.26

	0hr prior to AKI stage			24hr prior to AKI stage			48hr prior to AKI stage		
	sCr or UO	sCr only	UO only	sCr or UO	sCr only	UO only	sCr or UO	sCr only	UO only
95% CI of	0.21	na	0.33	0.32	na	0.42	0.16	0.062	0.073
OR Quart2	3.0	na	4.9	3.2	na	5.7	3.4	16	2.0
OR Quart 3	1.6	2.0	2.1	0.66	1.0	1.3	1.0	3.0	0.39
p Value	0.40	0.57	0.24	0.53	1.0	0.73	1.0	0.34	0.26
95% CI of	0.52	0.18	0.61	0.18	0.14	0.33	0.24	0.31	0.073
OR Quart3	5.2	23	7.3	2.4	7.2	4.9	4.1	30	2.0
OR Quart 4	1.9	3.1	2.4	3.0	2.0	4.6	1.5	2.0	1.7
p Value	0.27	0.33	0.16	0.029	0.41	0.0081	0.51	0.57	0.39
95% CI of	0.61	0.32	0.71	1.1	0.37	1.5	0.42	0.18	0.52
OR Quart4	5.8	30	8.1	7.8	11	14	5.6	23	5.3

Tumor necrosis factor receptor superfamily member 8

sCr or UO	0hr prior to AKI stage		24hr prior to AKI stage		48hr prior to AKI stage	
	Cohort 1	Cohort 2	Cohort 1	Cohort 2	Cohort 1	Cohort 2
Median	101	105	101	98.7	101	69.9
Average	201	193	201	156	201	244
Stdev	415	178	415	144	415	637
p(t-test)		0.94		0.57		0.69
Min	12.8	53.7	12.8	12.8	12.8	4.06
Max	3360	611	3360	595	3360	2700
n (Samp)	217	16	217	28	217	17
n (Patient)	133	16	133	28	133	17

UO only	0hr prior to AKI stage		24hr prior to AKI stage		48hr prior to AKI stage	
	Cohort 1	Cohort 2	Cohort 1	Cohort 2	Cohort 1	Cohort 2
Median	101	105	101	104	101	67.7
Average	205	201	205	148	205	250
Stdev	431	189	431	137	431	680
p(t-test)		0.98		0.48		0.71
Min	12.8	53.7	12.8	12.8	12.8	4.06
Max	3360	611	3360	595	3360	2700
n (Samp)	199	13	199	29	199	15
n (Patient)	118	13	118	29	118	15

	0hr prior to AKI stage			24hr prior to AKI stage			48hr prior to AKI stage		
	sCr or UO	sCr only	UO only	sCr or UO	sCr only	UO only	sCr or UO	sCr only	UO only
AUC	0.57	nd	0.58	0.49	nd	0.49	0.38	nd	0.34
SE	0.077	nd	0.085	0.058	nd	0.058	0.075	nd	0.079
p	0.39	nd	0.32	0.85	nd	0.89	0.12	nd	0.042
nCohort 1	217	nd	199	217	nd	199	217	nd	199
nCohort 2	16	nd	13	28	nd	29	17	nd	15
Cutoff 1	75.4	nd	75.4	65.4	nd	68.4	47.2	nd	47.2
Sens 1	75%	nd	77%	71%	nd	72%	71%	nd	73%
Spec 1	29%	nd	30%	24%	nd	26%	13%	nd	13%
Cutoff 2	74.6	nd	74.6	54.3	nd	54.3	37.8	nd	37.8
Sens 2	81%	nd	85%	86%	nd	86%	82%	nd	80%
Spec 2	29%	nd	29%	15%	nd	15%	9%	nd	10%

	0hr prior to AKI stage			24hr prior to AKI stage			48hr prior to AKI stage		
	sCr or UO	sCr only	UO only	sCr or UO	sCr only	UO only	sCr or UO	sCr only	UO only
Cutoff 3	53.7	nd	64.9	36.7	nd	36.7	36.7	nd	36.7
Sens 3	94%	nd	92%	93%	nd	93%	94%	nd	93%
Spec 3	15%	nd	23%	8%	nd	9%	8%	nd	9%
Cutoff 4	148	nd	148	148	nd	148	148	nd	148
Sens 4	38%	nd	38%	29%	nd	24%	24%	nd	20%
Spec 4	70%	nd	70%	70%	nd	70%	70%	nd	70%
Cutoff 5	192	nd	192	192	nd	192	192	nd	192
Sens 5	31%	nd	31%	29%	nd	24%	12%	nd	7%
Spec 5	80%	nd	80%	80%	nd	80%	80%	nd	80%
Cutoff 6	285	nd	285	285	nd	285	285	nd	285
Sens 6	19%	nd	15%	18%	nd	14%	12%	nd	7%
Spec 6	90%	nd	90%	90%	nd	90%	90%	nd	90%
OR Quart 2	1.4	nd	1.5	0.74	nd	1.2	1.0	nd	0.67
p Value	0.70	nd	0.65	0.59	nd	0.78	0.98	nd	0.66
95% CI of	0.29	nd	0.25	0.24	nd	0.39	0.20	nd	0.11
OR Quart2	6.4	nd	9.5	2.3	nd	3.5	5.3	nd	4.2
OR Quart 3	1.4	nd	2.1	0.74	nd	0.84	1.4	nd	1.0
p Value	0.70	nd	0.41	0.59	nd	0.77	0.70	nd	1.0
95% CI of	0.29	nd	0.36	0.24	nd	0.26	0.29	nd	0.19
OR Quart3	6.4	nd	12	2.3	nd	2.7	6.3	nd	5.2
OR Quart 4	1.7	nd	2.1	1.0	nd	1.2	2.6	nd	2.6
p Value	0.48	nd	0.41	0.97	nd	0.78	0.19	nd	0.19
95% CI of	0.39	nd	0.36	0.36	nd	0.39	0.63	nd	0.63
OR Quart4	7.5	nd	12	2.9	nd	3.5	10	nd	11

Alpha-fetoprotein

sCr or UO	0hr prior to AKI stage		24hr prior to AKI stage		48hr prior to AKI stage	
	Cohort 1	Cohort 2	Cohort 1	Cohort 2	Cohort 1	Cohort 2
Median	0.321	0.00880	0.321	0.410	0.321	0.441
Average	0.350	0.327	0.350	0.470	0.350	0.497
Stdev	0.333	0.467	0.333	0.436	0.333	0.351
p(t-test)		0.79		0.078		0.058
Min	0.00580	0.00580	0.00580	0.00580	0.00580	0.00580
Max	1.81	1.63	1.81	1.53	1.81	1.19
n (Samp)	282	16	282	28	282	20
n (Patient)	160	16	160	28	160	20

sCr only	0hr prior to AKI stage		24hr prior to AKI stage		48hr prior to AKI stage	
	Cohort 1	Cohort 2	Cohort 1	Cohort 2	Cohort 1	Cohort 2
Median	nd	nd	nd	nd	0.327	0.484
Average	nd	nd	nd	nd	0.355	0.487
Stdev	nd	nd	nd	nd	0.348	0.303
p(t-test)	nd	nd	nd	nd		0.35
Min	nd	nd	nd	nd	0.00580	0.00580
Max	nd	nd	nd	nd	1.81	0.924
n (Samp)	nd	nd	nd	nd	353	6
n (Patient)	nd	nd	nd	nd	193	6

UO only	0hr prior to AKI stage		24hr prior to AKI stage		48hr prior to AKI stage	
	Cohort 1	Cohort 2	Cohort 1	Cohort 2	Cohort 1	Cohort 2
Median	0.321	0.00880	0.321	0.376	0.321	0.445
Average	0.342	0.279	0.342	0.438	0.342	0.527
Stdev	0.333	0.504	0.333	0.420	0.333	0.418
p(t-test)		0.52		0.18		0.030
Min	0.00580	0.00580	0.00580	0.00580	0.00580	0.00580
Max	1.81	1.63	1.81	1.53	1.81	1.31
n (Samp)	258	13	258	26	258	17
n (Patient)	140	13	140	26	140	17

	0hr prior to AKI stage			24hr prior to AKI stage			48hr prior to AKI stage		
	sCr or UO	sCr only	UO only	sCr or UO	sCr only	UO only	sCr or UO	sCr only	UO only
AUC	0.43	nd	0.38	0.58	nd	0.56	0.64	0.64	0.65
SE	0.076	nd	0.085	0.059	nd	0.061	0.069	0.12	0.074
p	0.38	nd	0.15	0.19	nd	0.31	0.035	0.26	0.050
nCohort 1	282	nd	258	282	nd	258	282	353	258
nCohort 2	16	nd	13	28	nd	26	20	6	17
Cutoff 1	0.00580	nd	0	0.0947	nd	0.00580	0.392	0.392	0.381
Sens 1	75%	nd	100%	71%	nd	85%	70%	83%	71%
Spec 1	16%	nd	0%	32%	nd	17%	62%	61%	59%
Cutoff 2	0	nd	0	0.00580	nd	0.00580	0.221	0.392	0.00580
Sens 2	100%	nd	100%	86%	nd	85%	80%	83%	94%
Spec 2	0%	nd	0%	16%	nd	17%	41%	61%	17%
Cutoff 3	0	nd	0	0	nd	0	0.00580	0	0.00580
Sens 3	100%	nd	100%	100%	nd	100%	95%	100%	94%
Spec 3	0%	nd	0%	0%	nd	0%	16%	0%	17%
Cutoff 4	0.496	nd	0.502	0.496	nd	0.502	0.496	0.509	0.502
Sens 4	31%	nd	23%	43%	nd	42%	45%	50%	47%
Spec 4	70%	nd	70%	70%	nd	70%	70%	70%	70%
Cutoff 5	0.581	nd	0.581	0.581	nd	0.581	0.581	0.607	0.581
Sens 5	25%	nd	23%	36%	nd	35%	35%	33%	41%
Spec 5	80%	nd	80%	80%	nd	80%	80%	80%	80%
Cutoff 6	0.767	nd	0.767	0.767	nd	0.767	0.767	0.803	0.767
Sens 6	12%	nd	15%	21%	nd	19%	20%	17%	24%
Spec 6	90%	nd	90%	90%	nd	90%	90%	90%	90%
OR Quart 2	0.75	nd	0.32	0.54	nd	1.8	4.1	0	4.1
p Value	0.71	nd	0.33	0.34	nd	0.35	0.21	na	0.21
95% CI of	0.16	nd	0.033	0.15	nd	0.51	0.45	na	0.45
OR Quart2	3.5	nd	3.2	1.9	nd	6.6	38	na	38
OR Quart 3	0.74	nd	1.7	0.85	nd	1.5	7.6	3.0	5.2
p Value	0.70	nd	0.47	0.77	nd	0.51	0.061	0.34	0.14
95% CI of	0.16	nd	0.39	0.27	nd	0.42	0.91	0.31	0.60
OR Quart3	3.4	nd	7.5	2.6	nd	5.7	64	30	46
OR Quart 4	1.6	nd	1.4	1.6	nd	2.4	8.7	2.0	7.6
p Value	0.50	nd	0.68	0.33	nd	0.16	0.044	0.57	0.062
95% CI of	0.42	nd	0.30	0.60	nd	0.71	1.1	0.18	0.90
OR Quart4	5.8	nd	6.4	4.5	nd	8.3	71	22	63

Apolipoprotein E

sCr or UO	0hr prior to AKI stage		24hr prior to AKI stage		48hr prior to AKI stage	
	Cohort 1	Cohort 2	Cohort 1	Cohort 2	Cohort 1	Cohort 2
Median	51700	43400	51700	47500	51700	32700
Average	63800	54300	63800	55300	63800	37200
Stdev	46700	35100	46700	43000	46700	23500
p(t-test)		0.30		0.31		0.014
Min	4980	14500	4980	10500	4980	1940
Max	260000	141000	260000	232000	260000	98400
n (Samp)	325	27	325	34	325	19
n (Patient)	192	27	192	34	192	19

sCr only	0hr prior to AKI stage		24hr prior to AKI stage		48hr prior to AKI stage	
	Cohort 1	Cohort 2	Cohort 1	Cohort 2	Cohort 1	Cohort 2
Median	nd	nd	51000	50300	nd	nd
Average	nd	nd	61200	86900	nd	nd
Stdev	nd	nd	44000	79800	nd	nd
p(t-test)	nd	nd		0.16	nd	nd
Min	nd	nd	1940	27200	nd	nd
Max	nd	nd	260000	232000	nd	nd
n (Samp)	nd	nd	417	6	nd	nd
n (Patient)	nd	nd	228	6	nd	nd

UO only	0hr prior to AKI stage		24hr prior to AKI stage		48hr prior to AKI stage	
	Cohort 1	Cohort 2	Cohort 1	Cohort 2	Cohort 1	Cohort 2
Median	51100	46800	51100	41600	51100	30200
Average	62700	55800	62700	46200	62700	34900
Stdev	45100	34800	45100	26700	45100	22900
p(t-test)		0.44		0.037		0.0100
Min	4980	14500	4980	10500	4980	1940
Max	244000	141000	244000	129000	244000	98400
n (Samp)	295	27	295	34	295	18
n (Patient)	167	27	167	34	167	18

	0hr prior to AKI stage			24hr prior to AKI stage			48hr prior to AKI stage		
	sCr or UO	sCr only	UO only	sCr or UO	sCr only	UO only	sCr or UO	sCr only	UO only
AUC	0.45	nd	0.47	0.44	0.57	0.40	0.32	nd	0.29
SE	0.059	nd	0.059	0.053	0.12	0.054	0.069	nd	0.070
p	0.37	nd	0.62	0.29	0.59	0.076	0.0077	nd	0.0033
nCohort 1	325	nd	295	325	417	295	325	nd	295
nCohort 2	27	nd	27	34	6	34	19	nd	18
Cutoff 1	29100	nd	30700	31300	33900	29100	25600	nd	25600
Sens 1	70%	nd	70%	71%	83%	71%	74%	nd	72%
Spec 1	22%	nd	25%	26%	29%	22%	17%	nd	17%
Cutoff 2	25700	nd	25600	24700	33900	20900	16700	nd	16700
Sens 2	81%	nd	81%	82%	83%	82%	84%	nd	83%
Spec 2	17%	nd	17%	16%	29%	14%	9%	nd	9%
Cutoff 3	20700	nd	20700	16700	27000	16700	4980	nd	4980
Sens 3	93%	nd	93%	91%	100%	91%	95%	nd	94%

	0hr prior to AKI stage			24hr prior to AKI stage			48hr prior to AKI stage		
	sCr or UO	sCr only	UO only	sCr or UO	sCr only	UO only	sCr or UO	sCr only	UO only
Spec 3	13%	nd	14%	9%	19%	9%	0%	nd	0%
Cutoff 4	75000	nd	75700	75000	68400	75700	75000	nd	75700
Sens 4	19%	nd	19%	18%	33%	12%	5%	nd	6%
Spec 4	70%	nd	70%	70%	70%	70%	70%	nd	70%
Cutoff 5	90400	nd	90900	90400	87000	90900	90400	nd	90900
Sens 5	11%	nd	11%	12%	33%	6%	5%	nd	6%
Spec 5	80%	nd	80%	80%	80%	80%	80%	nd	80%
Cutoff 6	124000	nd	121000	124000	120000	121000	124000	nd	121000
Sens 6	7%	nd	11%	9%	33%	3%	0%	nd	0%
Spec 6	90%	nd	90%	90%	90%	90%	90%	nd	90%
OR Quart 2	1.4	nd	1.7	1.9	2.0	4.1	3.1	nd	2.1
p Value	0.55	nd	0.38	0.27	0.57	0.035	0.34	nd	0.56
95% CI of	0.44	nd	0.53	0.61	0.18	1.1	0.31	nd	0.18
OR Quart2	4.7	nd	5.4	5.9	22	15	30	nd	23
OR Quart 3	1.2	nd	1.2	2.1	0.99	2.9	7.5	nd	6.5
p Value	0.76	nd	0.76	0.19	0.99	0.13	0.062	nd	0.087
95% CI of	0.36	nd	0.36	0.70	0.061	0.74	0.91	nd	0.76
OR Quart3	4.1	nd	4.2	6.5	16	11	63	nd	55
OR Quart 4	1.9	nd	1.7	2.2	2.0	4.6	8.7	nd	10
p Value	0.27	nd	0.38	0.18	0.57	0.022	0.043	nd	0.030
95% CI of	0.61	nd	0.53	0.70	0.18	1.2	1.1	nd	1.3
OR Quart4	5.9	nd	5.4	6.6	22	17	71	nd	82

Apolipoprotein(a)

sCr or UO	0hr prior to AKI stage		24hr prior to AKI stage		48hr prior to AKI stage	
	Cohort 1	Cohort 2	Cohort 1	Cohort 2	Cohort 1	Cohort 2
Median	52400	30100	52400	41200	52400	15800
Average	89500	61200	89500	73100	89500	42400
Stdev	110000	72000	110000	95100	110000	58500
p(t-test)		0.19		0.41		0.066
Min	7.99	380	7.99	1030	7.99	1300
Max	722000	234000	722000	423000	722000	187000
n (Samp)	325	27	325	34	325	19
n (Patient)	192	27	192	34	192	19

sCr only	0hr prior to AKI stage		24hr prior to AKI stage		48hr prior to AKI stage	
	Cohort 1	Cohort 2	Cohort 1	Cohort 2	Cohort 1	Cohort 2
Median	nd	nd	45000	30300	nd	nd
Average	nd	nd	84100	68400	nd	nd
Stdev	nd	nd	106000	83400	nd	nd
p(t-test)	nd	nd		0.72	nd	nd
Min	nd	nd	7.99	968	nd	nd
Max	nd	nd	722000	200000	nd	nd
n (Samp)	nd	nd	417	6	nd	nd
n (Patient)	nd	nd	228	6	nd	nd

UO only	0hr prior to AKI stage	24hr prior to AKI stage	48hr prior to AKI stage

	Cohort 1	Cohort 2	Cohort 1	Cohort 2	Cohort 1	Cohort 2
Median	47600	30100	47600	31200	47600	13500
Average	82800	61400	82800	68900	82800	41800
Stdev	102000	71900	102000	95000	102000	60300
p(t-test)		0.28		0.45		0.092
Min	7.99	380	7.99	1030	7.99	1300
Max	631000	234000	631000	423000	631000	187000
n (Samp)	295	27	295	34	295	18
n (Patient)	167	27	167	34	167	18

	0hr prior to AKI stage			24hr prior to AKI stage			48hr prior to AKI stage		
	sCr or UO	sCr only	UO only	sCr or UO	sCr only	UO only	sCr or UO	sCr only	UO only
AUC	0.41	nd	0.42	0.44	0.44	0.44	0.32	nd	0.32
SE	0.060	nd	0.060	0.053	0.12	0.054	0.069	nd	0.071
p	0.12	nd	0.20	0.29	0.60	0.23	0.0084	nd	0.010
nCohort 1	325	nd	295	325	417	295	325	nd	295
nCohort 2	27	nd	27	34	6	34	19	nd	18
Cutoff 1	9720	nd	9720	14100	4320	10500	3140	nd	3010
Sens 1	70%	nd	70%	71%	83%	71%	74%	nd	72%
Spec 1	16%	nd	17%	24%	9%	19%	5%	nd	6%
Cutoff 2	4320	nd	4320	6200	4320	6120	2260	nd	2260
Sens 2	81%	nd	81%	82%	83%	88%	84%	nd	83%
Spec 2	6%	nd	7%	10%	9%	11%	4%	nd	4%
Cutoff 3	2710	nd	3010	5110	887	5110	1680	nd	1680
Sens 3	93%	nd	93%	91%	100%	91%	95%	nd	94%
Spec 3	4%	nd	6%	7%	2%	7%	4%	nd	4%
Cutoff 4	99500	nd	92000	99500	95700	92000	99500	nd	92000
Sens 4	22%	nd	26%	26%	33%	26%	16%	nd	22%
Spec 4	70%	nd	70%	70%	70%	70%	70%	nd	70%
Cutoff 5	142000	nd	128000	142000	135000	128000	142000	nd	128000
Sens 5	15%	nd	15%	18%	33%	15%	16%	nd	17%
Spec 5	80%	nd	80%	80%	80%	80%	80%	nd	80%
Cutoff 6	235000	nd	219000	235000	225000	219000	235000	nd	219000
Sens 6	0%	nd	7%	6%	0%	6%	0%	nd	0%
Spec 6	90%	nd	90%	90%	90%	90%	90%	nd	90%
OR Quart 2	0.82	nd	0.83	0.42	0	0.74	0.66	nd	0.33
p Value	0.76	nd	0.77	0.16	na	0.59	0.65	nd	0.34
95% CI of	0.24	nd	0.24	0.12	na	0.25	0.11	nd	0.033
OR Quart2	2.8	nd	2.8	1.4	na	2.2	4.0	nd	3.2
OR Quart 3	1.0	nd	1.0	1.3	1.0	1.2	1.7	nd	1.7
p Value	1.0	nd	1.0	0.64	1.0	0.78	0.47	nd	0.46
95% CI of	0.31	nd	0.31	0.49	0.14	0.42	0.40	nd	0.40
OR Quart3	3.2	nd	3.2	3.2	7.2	3.2	7.4	nd	7.5
OR Quart 4	1.8	nd	1.8	1.1	1.0	1.5	3.2	nd	3.3
p Value	0.30	nd	0.29	0.79	0.99	0.45	0.087	nd	0.082
95% CI of	0.61	nd	0.62	0.44	0.14	0.55	0.84	nd	0.86
OR Quart4	5.0	nd	5.2	3.0	7.3	3.8	12	nd	13

[0188] Fig. 7: Comparison of marker levels in EDTA samples collected within 12 hours of reaching stage R from Cohort 1 (patients that reached, but did not progress beyond, RIFLE stage R) and from Cohort 2 (patients that reached RIFLE stage I or F).

C-C motif chemokine 7

	sCr or UO		sCr only		UO only	
	Cohort 1	Cohort 2	Cohort 1	Cohort 2	Cohort 1	Cohort 2
Median	0.620	0.512	nd	nd	0.620	0.512
Average	10.9	11.4	nd	nd	11.2	12.4
Stdev	28.1	22.4	nd	nd	30.3	24.3
p(t-test)		0.94	nd	nd		0.90
Min	0.193	0.193	nd	nd	0.193	0.193
Max	166	79.4	nd	nd	166	79.4
n (Samp)	41	19	nd	nd	31	15
n (Patient)	41	19	nd	nd	31	15

	At Enrollment		
	sCr or UO	sCr only	UO only
AUC	0.51	nd	0.49
SE	0.081	nd	0.092
p	0.95	nd	0.93
nCohort 1	41	nd	31
nCohort 2	19	nd	15
Cutoff 1	0.193	nd	0.193
Sens 1	95%	nd	93%
Spec 1	20%	nd	19%
Cutoff 2	0.193	nd	0.193
Sens 2	95%	nd	93%
Spec 2	20%	nd	19%
Cutoff 3	0.193	nd	0.193
Sens 3	95%	nd	93%
Spec 3	20%	nd	19%
Cutoff 4	9.43	nd	9.43
Sens 4	32%	nd	33%
Spec 4	71%	nd	71%
Cutoff 5	13.9	nd	13.9
Sens 5	21%	nd	20%
Spec 5	80%	nd	81%
Cutoff 6	19.6	nd	19.6
Sens 6	16%	nd	13%
Spec 6	90%	nd	90%
OR Quart 2	1.0	nd	0.75
p Value	1.0	nd	0.75
95% CI of	0.22	nd	0.13
OR Quart2	4.6	nd	4.5
OR Quart 3	0.73	nd	1.0
p Value	0.69	nd	1.0
95% CI of	0.15	nd	0.18
OR Quart3	3.5	nd	5.5

	At Enrollment		
	sCr or UO	sCr only	UO only
OR Quart 4	1.0	nd	1.1
p Value	1.0	nd	0.88
95% CI of	0.22	nd	0.21
OR Quart4	4.6	nd	6.4

Interleukin-33

	sCr or UO		sCr only		UO only	
	Cohort 1	Cohort 2	Cohort 1	Cohort 2	Cohort 1	Cohort 2
Median	0.0981	0.0981	nd	nd	0.0981	0.0543
Average	67.7	946	nd	nd	3.24	1200
Stdev	275	3200	nd	nd	8.39	3590
p(t-test)		0.084	nd	nd		0.067
Min	0.0445	0.0445	nd	nd	0.0445	0.0445
Max	1270	13500	nd	nd	42.0	13500
n (Samp)	41	19	nd	nd	31	15
n (Patient)	41	19	nd	nd	31	15

	At Enrollment		
	sCr or UO	sCr only	UO only
AUC	0.48	nd	0.48
SE	0.081	nd	0.092
p	0.82	nd	0.84
nCohort 1	41	nd	31
nCohort 2	19	nd	15
Cutoff 1	0.0445	nd	0.0445
Sens 1	84%	nd	87%
Spec 1	7%	nd	10%
Cutoff 2	0.0445	nd	0.0445
Sens 2	84%	nd	87%
Spec 2	7%	nd	10%
Cutoff 3	0	nd	0
Sens 3	100%	nd	100%
Spec 3	0%	nd	0%
Cutoff 4	0.101	nd	0.101
Sens 4	37%	nd	33%
Spec 4	76%	nd	81%
Cutoff 5	9.78	nd	0.101
Sens 5	21%	nd	33%
Spec 5	80%	nd	81%
Cutoff 6	17.9	nd	9.90
Sens 6	16%	nd	27%
Spec 6	90%	nd	90%
OR Quart 2	1.0	nd	0.14
p Value	1.0	nd	0.10
95% CI of	0.22	nd	0.013
OR Quart2	4.6	nd	1.5
OR Quart 3	0.31	nd	0.47

	At Enrollment		
	sCr or UO	sCr only	UO only
p Value	0.21	nd	0.39
95% CI of	0.049	nd	0.082
OR Quart3	1.9	nd	2.7
OR Quart 4	1.8	nd	1.7
p Value	0.46	nd	0.54
95% CI of	0.40	nd	0.32
OR Quart4	7.7	nd	8.8

Interleukin-4 receptor alpha chain

	sCr or UO		sCr only		UO only	
	Cohort 1	Cohort 2	Cohort 1	Cohort 2	Cohort 1	Cohort 2
Median	208	186	nd	nd	193	193
Average	301	235	nd	nd	289	254
Stdev	242	256	nd	nd	245	278
p(t-test)		0.34	nd	nd		0.67
Min	49.7	3.27	nd	nd	49.7	41.2
Max	1040	1210	nd	nd	1040	1210
n (Samp)	41	19	nd	nd	31	15
n (Patient)	41	19	nd	nd	31	15

	At Enrollment		
	sCr or UO	sCr only	UO only
AUC	0.39	nd	0.45
SE	0.081	nd	0.092
p	0.19	nd	0.59
nCohort 1	41	nd	31
nCohort 2	19	nd	15
Cutoff 1	104	nd	108
Sens 1	79%	nd	73%
Spec 1	7%	nd	6%
Cutoff 2	84.5	nd	104
Sens 2	84%	nd	87%
Spec 2	5%	nd	6%
Cutoff 3	3.27	nd	49.7
Sens 3	95%	nd	93%
Spec 3	0%	nd	3%
Cutoff 4	296	nd	234
Sens 4	21%	nd	33%
Spec 4	71%	nd	71%
Cutoff 5	431	nd	336
Sens 5	5%	nd	13%
Spec 5	80%	nd	81%
Cutoff 6	621	nd	621
Sens 6	5%	nd	7%
Spec 6	90%	nd	90%
OR Quart 2	2.0	nd	1.1
p Value	0.41	nd	0.88

	At Enrollment		
	sCr or UO	sCr only	UO only
95% CI of OR Quart2	0.38	nd	0.21
	11	nd	6.4
OR Quart 3	1.5	nd	0.40
p Value	0.67	nd	0.35
95% CI of OR Quart3	0.26	nd	0.058
	8.0	nd	2.8
OR Quart 4	3.5	nd	1.7
p Value	0.13	nd	0.55
95% CI of OR Quart4	0.69	nd	0.31
	18	nd	9.0

Lutropin subunit beta

	sCr or UO		sCr only		UO only	
	Cohort 1	Cohort 2	Cohort 1	Cohort 2	Cohort 1	Cohort 2
Median	3.69	1.32	nd	nd	nd	nd
Average	7.27	1.57	nd	nd	nd	nd
Stdev	10.3	1.24	nd	nd	nd	nd
p(t-test)		0.16	nd	nd	nd	nd
Min	0.0399	0.0768	nd	nd	nd	nd
Max	50.0	3.61	nd	nd	nd	nd
n (Samp)	30	7	nd	nd	nd	nd
n (Patient)	30	7	nd	nd	nd	nd

	At Enrollment		
	sCr or UO	sCr only	UO only
AUC	0.28	nd	nd
SE	0.12	nd	nd
p	0.057	nd	nd
nCohort 1	30	nd	nd
nCohort 2	7	nd	nd
Cutoff 1	0.565	nd	nd
Sens 1	71%	nd	nd
Spec 1	23%	nd	nd
Cutoff 2	0.429	nd	nd
Sens 2	86%	nd	nd
Spec 2	17%	nd	nd
Cutoff 3	0.0621	nd	nd
Sens 3	100%	nd	nd
Spec 3	7%	nd	nd
Cutoff 4	5.73	nd	nd
Sens 4	0%	nd	nd
Spec 4	70%	nd	nd
Cutoff 5	14.5	nd	nd
Sens 5	0%	nd	nd
Spec 5	80%	nd	nd
Cutoff 6	17.8	nd	nd

	At Enrollment		
	sCr or UO	sCr only	UO only
Sens 6	0%	nd	nd
Spec 6	90%	nd	nd
OR Quart 2	>1.2	nd	nd
p Value	<0.88	nd	nd
95% CI of	>0.067	nd	nd
OR Quart2	na	nd	nd
OR Quart 3	>8.0	nd	nd
p Value	<0.095	nd	nd
95% CI of	>0.70	nd	nd
OR Quart3	na	nd	nd
OR Quart 4	>2.9	nd	nd
p Value	<0.43	nd	nd
95% CI of	>0.21	nd	nd
OR Quart4	na	nd	nd

Platelet-derived growth factor subunit B (dimer)

	sCr or UO		sCr only		UO only	
	Cohort 1	Cohort 2	Cohort 1	Cohort 2	Cohort 1	Cohort 2
Median	347	370	nd	nd	356	390
Average	415	392	nd	nd	425	404
Stdev	228	193	nd	nd	228	215
p(t-test)		0.72	nd	nd		0.78
Min	65.1	152	nd	nd	65.1	152
Max	960	766	nd	nd	960	766
n (Samp)	57	15	nd	nd	43	12
n (Patient)	57	15	nd	nd	43	12

	At Enrollment		
	sCr or UO	sCr only	UO only
AUC	0.47	nd	0.46
SE	0.085	nd	0.096
p	0.77	nd	0.70
nCohort 1	57	nd	43
nCohort 2	15	nd	12
Cutoff 1	235	nd	220
Sens 1	73%	nd	75%
Spec 1	23%	nd	16%
Cutoff 2	220	nd	212
Sens 2	80%	nd	83%
Spec 2	19%	nd	16%
Cutoff 3	195	nd	192
Sens 3	93%	nd	92%
Spec 3	19%	nd	16%
Cutoff 4	515	nd	567
Sens 4	20%	nd	25%
Spec 4	70%	nd	72%
Cutoff 5	609	nd	629

	At Enrollment		
	sCr or UO	sCr only	UO only
Sens 5	20%	nd	17%
Spec 5	81%	nd	81%
Cutoff 6	782	nd	779
Sens 6	0%	nd	0%
Spec 6	91%	nd	91%
OR Quart 2	1.9	nd	1.0
p Value	0.43	nd	1.0
95% CI of	0.38	nd	0.16
OR Quart2	9.6	nd	6.1
OR Quart 3	0.62	nd	0.28
p Value	0.63	nd	0.30
95% CI of	0.091	nd	0.026
OR Quart3	4.3	nd	3.1
OR Quart 4	1.9	nd	2.3
p Value	0.43	nd	0.34
95% CI of	0.38	nd	0.42
OR Quart4	9.6	nd	13

Corticotropin

	sCr or UO		sCr only		UO only	
	Cohort 1	Cohort 2	Cohort 1	Cohort 2	Cohort 1	Cohort 2
Median	0.000624	0.00327	nd	nd	0.000539	0.00321
Average	0.00399	0.00614	nd	nd	0.00371	0.00648
Stdev	0.00894	0.00786	nd	nd	0.00924	0.00821
p(t-test)		0.44	nd	nd		0.42
Min	3.38E-6	4.31E-6	nd	nd	3.38E-6	0.000293
Max	0.0483	0.0251	nd	nd	0.0483	0.0251
n (Samp)	42	13	nd	nd	33	9
n (Patient)	42	13	nd	nd	33	9

	At Enrollment		
	sCr or UO	sCr only	UO only
AUC	0.66	nd	0.74
SE	0.091	nd	0.10
p	0.078	nd	0.021
nCohort 1	42	nd	33
nCohort 2	13	nd	9
Cutoff 1	0.000466	nd	0.00122
Sens 1	77%	nd	78%
Spec 1	45%	nd	61%
Cutoff 2	0.000261	nd	0.000293
Sens 2	85%	nd	89%
Spec 2	40%	nd	45%
Cutoff 3	4.31E-6	nd	0.000261
Sens 3	92%	nd	100%
Spec 3	24%	nd	42%
Cutoff 4	0.00201	nd	0.00183

	At Enrollment		
	sCr or UO	sCr only	UO only
Sens 4	62%	nd	67%
Spec 4	71%	nd	73%
Cutoff 5	0.00486	nd	0.00329
Sens 5	31%	nd	33%
Spec 5	81%	nd	82%
Cutoff 6	0.00761	nd	0.00658
Sens 6	31%	nd	33%
Spec 6	90%	nd	91%
OR Quart 2	0.92	nd	>2.2
p Value	0.94	nd	<0.54
95% CI of	0.11	nd	>0.17
OR Quart2	7.7	nd	na
OR Quart 3	2.2	nd	>4.3
p Value	0.42	nd	<0.25
95% CI of	0.33	nd	>0.37
OR Quart3	15	nd	na
OR Quart 4	3.1	nd	>5.7
p Value	0.24	nd	<0.15
95% CI of	0.47	nd	>0.52
OR Quart4	20	nd	na

Thyroxine-binding globulin

	sCr or UO		sCr only		UO only	
	Cohort 1	Cohort 2	Cohort 1	Cohort 2	Cohort 1	Cohort 2
Median	36.1	28.0	nd	nd	34.1	30.0
Average	36.5	30.9	nd	nd	36.1	31.3
Stdev	10.8	10.6	nd	nd	11.3	10.6
p(t-test)		0.044	nd	nd		0.14
Min	12.8	14.2	nd	nd	12.8	14.2
Max	56.7	48.3	nd	nd	56.7	46.0
n (Samp)	55	22	nd	nd	46	16
n (Patient)	55	22	nd	nd	46	16

	At Enrollment		
	sCr or UO	sCr only	UO only
AUC	0.35	nd	0.36
SE	0.072	nd	0.084
p	0.043	nd	0.10
nCohort 1	55	nd	46
nCohort 2	22	nd	16
Cutoff 1	24.7	nd	25.2
Sens 1	73%	nd	75%
Spec 1	15%	nd	20%
Cutoff 2	19.7	nd	22.8
Sens 2	82%	nd	81%
Spec 2	7%	nd	13%
Cutoff 3	15.8	nd	15.4

	At Enrollment		
	sCr or UO	sCr only	UO only
Sens 3	91%	nd	94%
Spec 3	5%	nd	7%
Cutoff 4	43.0	nd	42.3
Sens 4	18%	nd	25%
Spec 4	71%	nd	72%
Cutoff 5	46.9	nd	47.1
Sens 5	5%	nd	0%
Spec 5	80%	nd	80%
Cutoff 6	51.0	nd	51.0
Sens 6	0%	nd	0%
Spec 6	91%	nd	91%
OR Quart 2	1.1	nd	1.1
p Value	0.94	nd	0.93
95% CI of	0.23	nd	0.18
OR Quart2	5.0	nd	6.4
OR Quart 3	1.8	nd	2.0
p Value	0.41	nd	0.42
95% CI of	0.43	nd	0.38
OR Quart3	8.0	nd	10
OR Quart 4	2.9	nd	2.2
p Value	0.14	nd	0.36
95% CI of	0.70	nd	0.42
OR Quart4	12	nd	11

Alpha-fetoprotein

	sCr or UO		sCr only		UO only	
	Cohort 1	Cohort 2	Cohort 1	Cohort 2	Cohort 1	Cohort 2
Median	0.331	0.458	nd	nd	0.302	0.452
Average	0.318	0.516	nd	nd	0.298	0.452
Stdev	0.265	0.415	nd	nd	0.238	0.396
p(t-test)		0.023	nd	nd		0.095
Min	0.00580	0.00580	nd	nd	0.00580	0.00580
Max	1.11	1.31	nd	nd	0.997	1.31
n (Samp)	58	16	nd	nd	44	12
n (Patient)	58	16	nd	nd	44	12

	At Enrollment		
	sCr or UO	sCr only	UO only
AUC	0.65	nd	0.62
SE	0.082	nd	0.096
p	0.076	nd	0.20
nCohort 1	58	nd	44
nCohort 2	16	nd	12
Cutoff 1	0.225	nd	0.221
Sens 1	75%	nd	75%
Spec 1	40%	nd	39%
Cutoff 2	0.221	nd	0.00580

	At Enrollment		
	sCr or UO	sCr only	UO only
Sens 2	81%	nd	92%
Spec 2	38%	nd	14%
Cutoff 3	0.00580	nd	0.00580
Sens 3	94%	nd	92%
Spec 3	14%	nd	14%
Cutoff 4	0.446	nd	0.415
Sens 4	50%	nd	50%
Spec 4	71%	nd	70%
Cutoff 5	0.530	nd	0.513
Sens 5	44%	nd	50%
Spec 5	81%	nd	82%
Cutoff 6	0.598	nd	0.570
Sens 6	38%	nd	33%
Spec 6	91%	nd	91%
OR Quart 2	0.94	nd	0.61
p Value	0.94	nd	0.62
95% CI of	0.16	nd	0.085
OR Quart2	5.4	nd	4.4
OR Quart 3	1.0	nd	0.28
p Value	1.0	nd	0.30
95% CI of	0.17	nd	0.026
OR Quart3	5.8	nd	3.1
OR Quart 4	2.9	nd	2.8
p Value	0.18	nd	0.23
95% CI of	0.62	nd	0.52
OR Quart4	14	nd	14

Apolipoprotein E

	sCr or UO		sCr only		UO only	
	Cohort 1	Cohort 2	Cohort 1	Cohort 2	Cohort 1	Cohort 2
Median	59000	43100	nd	nd	59600	50600
Average	74200	47600	nd	nd	78300	50500
Stdev	52400	31200	nd	nd	54800	34500
p(t-test)		0.027	nd	nd		0.054
Min	12600	1940	nd	nd	13000	1940
Max	244000	120000	nd	nd	244000	120000
n (Samp)	68	22	nd	nd	53	17
n (Patient)	68	22	nd	nd	53	17

	At Enrollment		
	sCr or UO	sCr only	UO only
AUC	0.35	nd	0.36
SE	0.071	nd	0.081
p	0.029	nd	0.080
nCohort 1	68	nd	53
nCohort 2	22	nd	17
Cutoff 1	23900	nd	27300

	At Enrollment		
	sCr or UO	sCr only	UO only
Sens 1	73%	nd	71%
Spec 1	13%	nd	11%
Cutoff 2	17400	nd	14200
Sens 2	82%	nd	82%
Spec 2	6%	nd	4%
Cutoff 3	14100	nd	1940
Sens 3	91%	nd	94%
Spec 3	4%	nd	0%
Cutoff 4	85700	nd	91600
Sens 4	14%	nd	18%
Spec 4	71%	nd	72%
Cutoff 5	98600	nd	98600
Sens 5	9%	nd	12%
Spec 5	81%	nd	81%
Cutoff 6	164000	nd	164000
Sens 6	0%	nd	0%
Spec 6	91%	nd	91%
OR Quart 2	1.5	nd	1.1
p Value	0.64	nd	0.94
95% CI of	0.29	nd	0.18
OR Quart2	7.5	nd	6.2
OR Quart 3	3.6	nd	1.4
p Value	0.094	nd	0.67
95% CI of	0.80	nd	0.27
OR Quart3	16	nd	7.5
OR Quart 4	3.1	nd	3.5
p Value	0.14	nd	0.12
95% CI of	0.69	nd	0.73
OR Quart4	14	nd	17

[0189] Fig. 8: Comparison of the maximum marker levels in EDTA samples collected from Cohort 1 (patients that did not progress beyond RIFLE stage 0) and the maximum values in EDTA samples collected from subjects between enrollment and 0, 24 hours, and 48 hours prior to reaching stage F in Cohort 2.

Complement C4-B

sCr or UO	0hr prior to AKI stage		24hr prior to AKI stage		48hr prior to AKI stage	
	Cohort 1	Cohort 2	Cohort 1	Cohort 2	Cohort 1	Cohort 2
Median	65500	61600	65500	61600	nd	nd
Average	73300	68700	73300	68700	nd	nd
Stdev	40400	39200	40400	39200	nd	nd
p(t-test)		0.76		0.76	nd	nd
Min	641	13500	641	13500	nd	nd
Max	203000	125000	203000	125000	nd	nd
n (Samp)	87	8	87	8	nd	nd
n (Patient)	87	8	87	8	nd	nd

UO only	0hr prior to AKI stage		24hr prior to AKI stage		48hr prior to AKI stage	
	Cohort 1	Cohort 2	Cohort 1	Cohort 2	Cohort 1	Cohort 2
Median	65700	61600	65700	61600	nd	nd
Average	71600	68700	71600	68700	nd	nd
Stdev	35600	45800	35600	45800	nd	nd
p(t-test)		0.85		0.85	nd	nd
Min	641	13500	641	13500	nd	nd
Max	160000	125000	160000	125000	nd	nd
n (Samp)	80	6	80	6	nd	nd
n (Patient)	80	6	80	6	nd	nd

	0hr prior to AKI stage			24hr prior to AKI stage			48hr prior to AKI stage		
	sCr or UO	sCr only	UO only	sCr or UO	sCr only	UO only	sCr or UO	sCr only	UO only
AUC	0.48	nd	0.46	0.48	nd	0.46	nd	nd	nd
SE	0.11	nd	0.13	0.11	nd	0.13	nd	nd	nd
p	0.84	nd	0.76	0.84	nd	0.76	nd	nd	nd
nCohort 1	87	nd	80	87	nd	80	nd	nd	nd
nCohort 2	8	nd	6	8	nd	6	nd	nd	nd
Cutoff 1	57800	nd	29600	57800	nd	29600	nd	nd	nd
Sens 1	75%	nd	83%	75%	nd	83%	nd	nd	nd
Spec 1	41%	nd	10%	41%	nd	10%	nd	nd	nd
Cutoff 2	29600	nd	29600	29600	nd	29600	nd	nd	nd
Sens 2	88%	nd	83%	88%	nd	83%	nd	nd	nd
Spec 2	10%	nd	10%	10%	nd	10%	nd	nd	nd
Cutoff 3	5890	nd	5890	5890	nd	5890	nd	nd	nd
Sens 3	100%	nd	100%	100%	nd	100%	nd	nd	nd
Spec 3	2%	nd	2%	2%	nd	2%	nd	nd	nd
Cutoff 4	86300	nd	87900	86300	nd	87900	nd	nd	nd
Sens 4	25%	nd	33%	25%	nd	33%	nd	nd	nd
Spec 4	70%	nd	70%	70%	nd	70%	nd	nd	nd
Cutoff 5	104000	nd	100000	104000	nd	100000	nd	nd	nd
Sens 5	25%	nd	33%	25%	nd	33%	nd	nd	nd
Spec 5	80%	nd	80%	80%	nd	80%	nd	nd	nd
Cutoff 6	129000	nd	124000	129000	nd	124000	nd	nd	nd
Sens 6	0%	nd	17%	0%	nd	17%	nd	nd	nd
Spec 6	91%	nd	90%	91%	nd	90%	nd	nd	nd
OR Quart 2	0.48	nd	0	0.48	nd	0	nd	nd	nd
p Value	0.56	nd	na	0.56	nd	na	nd	nd	nd
95% CI of	0.040	nd	na	0.040	nd	na	nd	nd	nd
OR Quart2	5.7	nd	na	5.7	nd	na	nd	nd	nd
OR Quart 3	1.6	nd	1.0	1.6	nd	1.0	nd	nd	nd
p Value	0.64	nd	1.0	0.64	nd	1.0	nd	nd	nd
95% CI of	0.24	nd	0.13	0.24	nd	0.13	nd	nd	nd
OR Quart3	10	nd	7.8	10	nd	7.8	nd	nd	nd
OR Quart 4	1.0	nd	1.1	1.0	nd	1.1	nd	nd	nd
p Value	0.96	nd	0.96	0.96	nd	0.96	nd	nd	nd
95% CI of	0.13	nd	0.13	0.13	nd	0.13	nd	nd	nd
OR Quart4	8.1	nd	8.2	8.1	nd	8.2	nd	nd	nd

C-C motif chemokine 26

sCr or UO	0hr prior to AKI stage		24hr prior to AKI stage		48hr prior to AKI stage	
	Cohort 1	Cohort 2	Cohort 1	Cohort 2	Cohort 1	Cohort 2
Median	1.25	4.43	1.25	4.43	1.25	6.99
Average	18.1	7.55	18.1	7.36	18.1	6.64
Stdev	79.1	9.61	79.1	9.74	79.1	6.53
p(t-test)		0.65		0.64		0.71
Min	0.0121	0.0232	0.0121	0.0232	0.0121	0.652
Max	468	33.0	468	33.0	468	18.3
n (Samp)	64	12	64	12	64	7
n (Patient)	64	12	64	12	64	7

sCr only	0hr prior to AKI stage		24hr prior to AKI stage		48hr prior to AKI stage	
	Cohort 1	Cohort 2	Cohort 1	Cohort 2	Cohort 1	Cohort 2
Median	1.76	1.73	1.76	0.937	nd	nd
Average	11.9	2.36	11.9	1.99	nd	nd
Stdev	55.9	2.51	55.9	2.69	nd	nd
p(t-test)		0.68		0.67	nd	nd
Min	0.0121	0.0232	0.0121	0.0232	nd	nd
Max	468	6.99	468	6.99	nd	nd
n (Samp)	131	6	131	6	nd	nd
n (Patient)	131	6	131	6	nd	nd

UO only	0hr prior to AKI stage		24hr prior to AKI stage		48hr prior to AKI stage	
	Cohort 1	Cohort 2	Cohort 1	Cohort 2	Cohort 1	Cohort 2
Median	1.25	7.45	1.25	7.45	1.25	7.45
Average	18.5	10.5	18.5	10.5	18.5	7.54
Stdev	79.7	10.7	79.7	10.7	79.7	6.66
p(t-test)		0.78		0.78		0.74
Min	0.0121	0.652	0.0121	0.652	0.0121	0.652
Max	468	33.0	468	33.0	468	18.3
n (Samp)	63	8	63	8	63	6
n (Patient)	63	8	63	8	63	6

	0hr prior to AKI stage			24hr prior to AKI stage			48hr prior to AKI stage		
	sCr or UO	sCr only	UO only	sCr or UO	sCr only	UO only	sCr or UO	sCr only	UO only
AUC	0.63	0.46	0.73	0.59	0.38	0.73	0.65	nd	0.69
SE	0.093	0.12	0.11	0.093	0.13	0.11	0.12	nd	0.12
p	0.15	0.74	0.029	0.33	0.36	0.029	0.19	nd	0.12
nCohort 1	64	131	63	64	131	63	64	nd	63
nCohort 2	12	6	8	12	6	8	7	nd	6
Cutoff 1	0.949	0.355	5.00	0.0587	0.0325	5.00	0.949	nd	0.0587
Sens 1	75%	83%	75%	83%	83%	75%	71%	nd	100%
Spec 1	44%	33%	78%	31%	7%	78%	44%	nd	35%
Cutoff 2	0.0587	0.355	0.0587	0.0587	0.0325	0.0587	0.0587	nd	0.0587
Sens 2	92%	83%	100%	83%	83%	100%	100%	nd	100%
Spec 2	31%	33%	35%	31%	7%	35%	31%	nd	35%
Cutoff 3	0.0587	0.0121	0.0587	0.0232	0.0121	0.0587	0.0587	nd	0.0587
Sens 3	92%	100%	100%	92%	100%	100%	100%	nd	100%

	0hr prior to AKI stage			24hr prior to AKI stage			48hr prior to AKI stage		
	sCr or UO	sCr only	UO only	sCr or UO	sCr only	UO only	sCr or UO	sCr only	UO only
Spec 3	31%	2%	35%	8%	2%	35%	31%	nd	35%
Cutoff 4	3.61	5.00	3.57	3.61	5.00	3.57	3.61	nd	3.57
Sens 4	50%	17%	75%	50%	17%	75%	57%	nd	67%
Spec 4	70%	71%	71%	70%	71%	71%	70%	nd	71%
Cutoff 5	6.86	7.86	6.86	6.86	7.86	6.86	6.86	nd	6.86
Sens 5	42%	0%	62%	42%	0%	62%	57%	nd	67%
Spec 5	81%	80%	81%	81%	80%	81%	81%	nd	81%
Cutoff 6	14.2	14.2	14.2	14.2	14.2	14.2	14.2	nd	14.2
Sens 6	17%	0%	25%	17%	0%	25%	14%	nd	17%
Spec 6	91%	90%	90%	91%	90%	90%	91%	nd	90%
OR Quart 2	3.4	2.1	>2.1	1.6	1.0	>2.1	>3.4	nd	>2.3
p Value	0.31	0.55	<0.55	0.63	0.98	<0.55	<0.31	nd	<0.52
95% CI of	0.32	0.18	>0.18	0.23	0.062	>0.18	>0.32	nd	>0.19
OR Quart2	36	25	na	11	17	na	na	nd	na
OR Quart 3	3.4	2.1	>1.0	1.0	2.1	>1.0	>0	nd	>0
p Value	0.31	0.55	<1.0	1.0	0.55	<1.0	<na	nd	<na
95% CI of	0.32	0.18	>0.058	0.13	0.18	>0.058	>na	nd	>na
OR Quart3	36	25	na	7.9	25	na	na	nd	na
OR Quart 4	6.4	1.0	>6.5	3.0	2.1	>6.5	>4.9	nd	>4.9
p Value	0.11	0.98	<0.10	0.22	0.55	<0.10	<0.18	nd	<0.18
95% CI of	0.67	0.062	>0.68	0.51	0.18	>0.68	>0.49	nd	>0.49
OR Quart4	61	17	na	18	25	na	na	nd	na

C-C motif chemokine 7

sCr or UO	0hr prior to AKI stage		24hr prior to AKI stage		48hr prior to AKI stage	
	Cohort 1	Cohort 2	Cohort 1	Cohort 2	Cohort 1	Cohort 2
Median	0.804	5.45	0.804	5.45	0.804	10.4
Average	11.6	36.3	11.6	36.3	11.6	12.6
Stdev	26.0	65.4	26.0	65.4	26.0	13.3
p(t-test)		0.026		0.026		0.92
Min	0.193	0.308	0.193	0.308	0.193	0.308
Max	128	219	128	219	128	30.8
n (Samp)	65	12	65	12	65	7
n (Patient)	65	12	65	12	65	7

sCr only	0hr prior to AKI stage		24hr prior to AKI stage		48hr prior to AKI stage	
	Cohort 1	Cohort 2	Cohort 1	Cohort 2	Cohort 1	Cohort 2
Median	0.804	5.45	0.804	5.45	nd	nd
Average	13.2	22.1	13.2	22.1	nd	nd
Stdev	29.3	40.6	29.3	40.6	nd	nd
p(t-test)		0.48		0.48	nd	nd
Min	0.193	0.308	0.193	0.308	nd	nd
Max	181	104	181	104	nd	nd
n (Samp)	132	6	132	6	nd	nd
n (Patient)	132	6	132	6	nd	nd

UO only	0hr prior to AKI stage		24hr prior to AKI stage		48hr prior to AKI stage	

	Cohort 1	Cohort 2	Cohort 1	Cohort 2	Cohort 1	Cohort 2
Median	0.804	5.45	0.804	5.45	0.804	5.45
Average	10.4	39.2	10.4	39.2	10.4	11.9
Stdev	25.9	75.1	25.9	75.1	25.9	14.5
p(t-test)		0.028		0.028		0.89
Min	0.193	0.308	0.193	0.308	0.193	0.308
Max	128	219	128	219	128	30.8
n (Samp)	64	8	64	8	64	6
n (Patient)	64	8	64	8	64	6

	0hr prior to AKI stage			24hr prior to AKI stage			48hr prior to AKI stage		
	sCr or UO	sCr only	UO only	sCr or UO	sCr only	UO only	sCr or UO	sCr only	UO only
AUC	0.56	0.50	0.58	0.56	0.50	0.58	0.56	nd	0.55
SE	0.093	0.12	0.11	0.093	0.12	0.11	0.12	nd	0.13
p	0.52	1.00	0.47	0.52	1.00	0.47	0.59	nd	0.71
nCohort 1	65	132	64	65	132	64	65	nd	64
nCohort 2	12	6	8	12	6	8	7	nd	6
Cutoff 1	0.308	0.193	0.308	0.308	0.193	0.308	0.308	nd	0.193
Sens 1	75%	100%	75%	75%	100%	75%	71%	nd	100%
Spec 1	25%	3%	28%	25%	3%	28%	25%	nd	3%
Cutoff 2	0.193	0.193	0.193	0.193	0.193	0.193	0.193	nd	0.193
Sens 2	100%	100%	100%	100%	100%	100%	100%	nd	100%
Spec 2	3%	3%	3%	3%	3%	3%	3%	nd	3%
Cutoff 3	0.193	0.193	0.193	0.193	0.193	0.193	0.193	nd	0.193
Sens 3	100%	100%	100%	100%	100%	100%	100%	nd	100%
Spec 3	3%	3%	3%	3%	3%	3%	3%	nd	3%
Cutoff 4	8.40	8.42	4.51	8.40	8.42	4.51	8.40	nd	4.51
Sens 4	50%	50%	50%	50%	50%	50%	57%	nd	50%
Spec 4	71%	70%	70%	71%	70%	70%	71%	nd	70%
Cutoff 5	12.2	15.3	8.42	12.2	15.3	8.42	12.2	nd	8.42
Sens 5	42%	33%	50%	42%	33%	50%	43%	nd	50%
Spec 5	80%	80%	81%	80%	80%	81%	80%	nd	81%
Cutoff 6	32.2	33.2	18.9	32.2	33.2	18.9	32.2	nd	18.9
Sens 6	25%	17%	38%	25%	17%	38%	0%	nd	33%
Spec 6	91%	90%	91%	91%	90%	91%	91%	nd	91%
OR Quart 2	1.0	0.50	1.0	1.0	0.50	1.0	0.47	nd	0.44
p Value	1.0	0.58	1.0	1.0	0.58	1.0	0.55	nd	0.52
95% CI of	0.17	0.043	0.13	0.17	0.043	0.13	0.039	nd	0.036
OR Quart2	5.7	5.8	8.0	5.7	5.8	8.0	5.7	nd	5.4
OR Quart 3	0	0.49	0	0	0.49	0	0	nd	0
p Value	na	0.56	na	na	0.56	na	na	nd	na
95% CI of	na	0.042	na	na	0.042	na	na	nd	na
OR Quart3	na	5.6	na	na	5.6	na	na	nd	na
OR Quart 4	2.3	1.0	2.3	2.3	1.0	2.3	2.3	nd	1.5
p Value	0.30	0.98	0.38	0.30	0.98	0.38	0.38	nd	0.68
95% CI of	0.48	0.14	0.36	0.48	0.14	0.36	0.36	nd	0.22
OR Quart4	11	7.8	14	11	7.8	14	14	nd	10

Vascular endothelial growth factor receptor 3

sCr or UO	0hr prior to AKI stage		24hr prior to AKI stage		48hr prior to AKI stage	
	Cohort 1	Cohort 2	Cohort 1	Cohort 2	Cohort 1	Cohort 2
Median	5220	5750	5220	5190	5220	4620
Average	7140	7290	7140	7190	7140	6080
Stdev	5790	4660	5790	4690	5790	2970
p(t-test)		0.93		0.98		0.64
Min	565	1740	565	1740	565	3160
Max	29400	16600	29400	16600	29400	10400
n (Samp)	65	12	65	12	65	7
n (Patient)	65	12	65	12	65	7

sCr only	0hr prior to AKI stage		24hr prior to AKI stage		48hr prior to AKI stage	
	Cohort 1	Cohort 2	Cohort 1	Cohort 2	Cohort 1	Cohort 2
Median	6370	4450	6370	4280	nd	nd
Average	7630	5070	7630	4880	nd	nd
Stdev	5970	3070	5970	3030	nd	nd
p(t-test)		0.30		0.27	nd	nd
Min	565	1740	565	1740	nd	nd
Max	43200	10400	43200	10400	nd	nd
n (Samp)	132	6	132	6	nd	nd
n (Patient)	132	6	132	6	nd	nd

UO only	0hr prior to AKI stage		24hr prior to AKI stage		48hr prior to AKI stage	
	Cohort 1	Cohort 2	Cohort 1	Cohort 2	Cohort 1	Cohort 2
Median	5340	5790	5340	5790	5340	4410
Average	7390	7970	7390	7970	7390	5350
Stdev	6200	5200	6200	5200	6200	2480
p(t-test)		0.80		0.80		0.43
Min	565	3160	565	3160	565	3160
Max	32800	16600	32800	16600	32800	9630
n (Samp)	64	8	64	8	64	6
n (Patient)	64	8	64	8	64	6

	0hr prior to AKI stage			24hr prior to AKI stage			48hr prior to AKI stage		
	sCr or UO	sCr only	UO only	sCr or UO	sCr only	UO only	sCr or UO	sCr only	UO only
AUC	0.54	0.36	0.53	0.53	0.34	0.53	0.49	nd	0.40
SE	0.092	0.12	0.11	0.092	0.12	0.11	0.12	nd	0.13
p	0.70	0.25	0.79	0.78	0.19	0.79	0.90	nd	0.41
nCohort 1	65	132	64	65	132	64	65	nd	64
nCohort 2	12	6	8	12	6	8	7	nd	6
Cutoff 1	3920	3140	3920	3920	3140	3920	3920	nd	3400
Sens 1	75%	83%	75%	75%	83%	75%	71%	nd	83%
Spec 1	31%	16%	28%	31%	16%	28%	31%	nd	20%
Cutoff 2	3400	3140	3400	3400	3140	3400	3400	nd	3400
Sens 2	83%	83%	88%	83%	83%	88%	86%	nd	83%
Spec 2	23%	16%	20%	23%	16%	20%	23%	nd	20%
Cutoff 3	3140	1720	3140	3140	1720	3140	3140	nd	3140
Sens 3	92%	100%	100%	92%	100%	100%	100%	nd	100%
Spec 3	17%	5%	14%	17%	5%	14%	17%	nd	14%

	0hr prior to AKI stage			24hr prior to AKI stage			48hr prior to AKI stage		
	sCr or UO	sCr only	UO only	sCr or UO	sCr only	UO only	sCr or UO	sCr only	UO only
Cutoff 4	7590	8540	7610	7590	8540	7610	7590	nd	7610
Sens 4	33%	17%	38%	33%	17%	38%	29%	nd	17%
Spec 4	71%	70%	70%	71%	70%	70%	71%	nd	70%
Cutoff 5	9000	10300	9000	9000	10300	9000	9000	nd	9000
Sens 5	33%	17%	38%	33%	17%	38%	29%	nd	17%
Spec 5	80%	80%	81%	80%	80%	81%	80%	nd	81%
Cutoff 6	13800	13200	13800	13800	13200	13800	13800	nd	13800
Sens 6	17%	0%	25%	17%	0%	25%	0%	nd	0%
Spec 6	91%	90%	91%	91%	90%	91%	91%	nd	91%
OR Quart 2	0.63	0	1.0	1.0	0	1.0	0.47	nd	1.1
p Value	0.63	na	1.0	1.0	na	1.0	0.55	nd	0.97
95% CI of	0.092	na	0.13	0.17	na	0.13	0.039	nd	0.061
OR Quart2	4.3	na	8.0	5.7	na	8.0	5.7	nd	18
OR Quart 3	1.0	2.1	0.47	0.63	2.1	0.47	1.0	nd	2.1
p Value	1.0	0.56	0.55	0.63	0.56	0.55	1.0	nd	0.55
95% CI of	0.17	0.18	0.039	0.092	0.18	0.039	0.13	nd	0.18
OR Quart3	5.7	24	5.7	4.3	24	5.7	8.0	nd	26
OR Quart 4	1.3	3.3	1.6	1.3	3.3	1.6	1.0	nd	2.3
p Value	0.73	0.31	0.63	0.73	0.31	0.63	1.0	nd	0.52
95% CI of	0.26	0.32	0.23	0.26	0.32	0.23	0.13	nd	0.19
OR Quart4	6.9	33	11	6.9	33	11	8.0	nd	28

Interferon alpha-2

sCr or UO	0hr prior to AKI stage		24hr prior to AKI stage		48hr prior to AKI stage	
	Cohort 1	Cohort 2	Cohort 1	Cohort 2	Cohort 1	Cohort 2
Median	14.0	23.9	14.0	23.9	14.0	14.0
Average	22.3	34.7	22.3	34.4	22.3	16.8
Stdev	33.5	43.9	33.5	44.0	33.5	14.9
p(t-test)		0.26		0.28		0.67
Min	0.0320	0.209	0.0320	0.209	0.0320	0.209
Max	223	163	223	163	223	43.4
n (Samp)	65	12	65	12	65	7
n (Patient)	65	12	65	12	65	7

sCr only	0hr prior to AKI stage		24hr prior to AKI stage		48hr prior to AKI stage	
	Cohort 1	Cohort 2	Cohort 1	Cohort 2	Cohort 1	Cohort 2
Median	19.5	23.7	19.5	23.7	nd	nd
Average	23.8	20.4	23.8	19.7	nd	nd
Stdev	28.3	15.7	28.3	15.2	nd	nd
p(t-test)		0.78		0.73	nd	nd
Min	0.0320	0.209	0.0320	0.209	nd	nd
Max	223	39.2	223	39.2	nd	nd
n (Samp)	132	6	132	6	nd	nd
n (Patient)	132	6	132	6	nd	nd

UO only	0hr prior to AKI stage		24hr prior to AKI stage		48hr prior to AKI stage	
	Cohort 1	Cohort 2	Cohort 1	Cohort 2	Cohort 1	Cohort 2

UO only	0hr prior to AKI stage		24hr prior to AKI stage		48hr prior to AKI stage	
	Cohort 1	Cohort 2	Cohort 1	Cohort 2	Cohort 1	Cohort 2
Median	13.3	23.9	13.3	23.9	13.3	10.6
Average	21.0	39.9	21.0	39.9	21.0	15.9
Stdev	35.0	53.2	35.0	53.2	35.0	16.1
p(t-test)		0.18		0.18		0.73
Min	0.0320	0.209	0.0320	0.209	0.0320	0.209
Max	223	163	223	163	223	43.4
n (Samp)	64	8	64	8	64	6
n (Patient)	64	8	64	8	64	6

	0hr prior to AKI stage			24hr prior to AKI stage			48hr prior to AKI stage		
	sCr or UO	sCr only	UO only	sCr or UO	sCr only	UO only	sCr or UO	sCr only	UO only
AUC	0.61	0.52	0.63	0.61	0.50	0.63	0.48	nd	0.49
SE	0.093	0.12	0.11	0.093	0.12	0.11	0.12	nd	0.13
p	0.24	0.90	0.23	0.25	0.98	0.23	0.88	nd	0.91
nCohort 1	65	132	64	65	132	64	65	nd	64
nCohort 2	12	6	8	12	6	8	7	nd	6
Cutoff 1	6.46	2.04	6.46	6.46	2.04	6.46	6.46	nd	4.65
Sens 1	75%	83%	75%	75%	83%	75%	71%	nd	83%
Spec 1	28%	14%	31%	28%	14%	31%	28%	nd	25%
Cutoff 2	4.65	2.04	4.65	4.65	2.04	4.65	4.65	nd	4.65
Sens 2	83%	83%	88%	83%	83%	88%	86%	nd	83%
Spec 2	22%	14%	25%	22%	14%	25%	22%	nd	25%
Cutoff 3	2.04	0.0997	0.0997	2.04	0.0997	0.0997	0.0997	nd	0.0997
Sens 3	92%	100%	100%	92%	100%	100%	100%	nd	100%
Spec 3	15%	11%	9%	15%	11%	9%	8%	nd	9%
Cutoff 4	23.8	28.0	19.0	23.8	28.0	19.0	23.8	nd	19.0
Sens 4	50%	33%	62%	50%	33%	62%	29%	nd	33%
Spec 4	71%	70%	70%	71%	70%	70%	71%	nd	70%
Cutoff 5	29.2	32.9	26.8	29.2	32.9	26.8	29.2	nd	26.8
Sens 5	42%	17%	38%	33%	17%	38%	14%	nd	17%
Spec 5	80%	80%	81%	80%	80%	81%	80%	nd	81%
Cutoff 6	44.4	43.4	34.3	44.4	43.4	34.3	44.4	nd	34.3
Sens 6	17%	0%	38%	17%	0%	38%	0%	nd	17%
Spec 6	92%	90%	91%	92%	90%	91%	92%	nd	91%
OR Quart 2	0.30	0	0.47	0.30	0	0.47	3.4	nd	0.50
p Value	0.31	na	0.55	0.31	na	0.55	0.31	nd	0.59
95% CI of	0.028	na	0.039	0.028	na	0.039	0.32	nd	0.041
OR Quart2	3.1	na	5.7	3.1	na	5.7	36	nd	6.1
OR Quart 3	1.0	1.0	0.47	1.0	1.5	0.47	1.0	nd	1.0
p Value	1.0	1.0	0.55	1.0	0.64	0.55	1.0	nd	1.0
95% CI of	0.17	0.13	0.039	0.17	0.24	0.039	0.058	nd	0.13
OR Quart3	5.7	7.5	5.7	5.7	9.9	5.7	17	nd	8.0
OR Quart 4	1.8	0.97	2.3	1.8	0.47	2.3	2.1	nd	0.50
p Value	0.48	0.98	0.38	0.48	0.55	0.38	0.55	nd	0.59
95% CI of	0.36	0.13	0.36	0.36	0.041	0.36	0.18	nd	0.041
OR Quart4	8.8	7.3	14	8.8	5.4	14	26	nd	6.1

Insulin-like growth factor-binding protein 4

sCr or UO	0hr prior to AKI stage		24hr prior to AKI stage		48hr prior to AKI stage	
	Cohort 1	Cohort 2	Cohort 1	Cohort 2	Cohort 1	Cohort 2
Median	2.43	14.3	2.43	14.3	nd	nd
Average	12.0	16.2	12.0	16.2	nd	nd
Stdev	24.2	15.1	24.2	15.1	nd	nd
p(t-test)		0.63		0.63	nd	nd
Min	0.572	0.572	0.572	0.572	nd	nd
Max	158	33.4	158	33.4	nd	nd
n (Samp)	87	8	87	8	nd	nd
n (Patient)	87	8	87	8	nd	nd

UO only	0hr prior to AKI stage		24hr prior to AKI stage		48hr prior to AKI stage	
	Cohort 1	Cohort 2	Cohort 1	Cohort 2	Cohort 1	Cohort 2
Median	2.93	15.8	2.93	15.8	nd	nd
Average	13.3	16.8	13.3	16.8	nd	nd
Stdev	25.0	16.4	25.0	16.4	nd	nd
p(t-test)		0.74		0.74	nd	nd
Min	0.572	0.572	0.572	0.572	nd	nd
Max	158	33.4	158	33.4	nd	nd
n (Samp)	80	6	80	6	nd	nd
n (Patient)	80	6	80	6	nd	nd

	0hr prior to AKI stage			24hr prior to AKI stage			48hr prior to AKI stage		
	sCr or UO	sCr only	UO only	sCr or UO	sCr only	UO only	sCr or UO	sCr only	UO only
AUC	0.66	nd	0.61	0.66	nd	0.61	nd	nd	nd
SE	0.11	nd	0.13	0.11	nd	0.13	nd	nd	nd
p	0.14	nd	0.37	0.14	nd	0.37	nd	nd	nd
nCohort 1	87	nd	80	87	nd	80	nd	nd	nd
nCohort 2	8	nd	6	8	nd	6	nd	nd	nd
Cutoff 1	2.43	nd	0.971	2.43	nd	0.971	nd	nd	nd
Sens 1	75%	nd	83%	75%	nd	83%	nd	nd	nd
Spec 1	55%	nd	38%	55%	nd	38%	nd	nd	nd
Cutoff 2	0.971	nd	0.971	0.971	nd	0.971	nd	nd	nd
Sens 2	88%	nd	83%	88%	nd	83%	nd	nd	nd
Spec 2	43%	nd	38%	43%	nd	38%	nd	nd	nd
Cutoff 3	0	nd	0	0	nd	0	nd	nd	nd
Sens 3	100%	nd	100%	100%	nd	100%	nd	nd	nd
Spec 3	0%	nd	0%	0%	nd	0%	nd	nd	nd
Cutoff 4	6.75	nd	10.7	6.75	nd	10.7	nd	nd	nd
Sens 4	50%	nd	50%	50%	nd	50%	nd	nd	nd
Spec 4	70%	nd	70%	70%	nd	70%	nd	nd	nd
Cutoff 5	19.0	nd	21.4	19.0	nd	21.4	nd	nd	nd
Sens 5	50%	nd	50%	50%	nd	50%	nd	nd	nd
Spec 5	80%	nd	80%	80%	nd	80%	nd	nd	nd
Cutoff 6	31.3	nd	34.2	31.3	nd	34.2	nd	nd	nd
Sens 6	25%	nd	0%	25%	nd	0%	nd	nd	nd
Spec 6	91%	nd	90%	91%	nd	90%	nd	nd	nd
OR Quart 2	0	nd	2.0	0	nd	2.0	nd	nd	nd
p Value	na	nd	0.58	na	nd	0.58	nd	nd	nd

	0hr prior to AKI stage			24hr prior to AKI stage			48hr prior to AKI stage		
	sCr or UO	sCr only	UO only	sCr or UO	sCr only	UO only	sCr or UO	sCr only	UO only
95% CI of	na	nd	0.17	na	nd	0.17	nd	nd	nd
OR Quart2	na	nd	24	na	nd	24	nd	nd	nd
OR Quart 3	3.1	nd	0	3.1	nd	0	nd	nd	nd
p Value	0.34	nd	na	0.34	nd	na	nd	nd	nd
95% CI of	0.30	nd	na	0.30	nd	na	nd	nd	nd
OR Quart3	33	nd	na	33	nd	na	nd	nd	nd
OR Quart 4	4.4	nd	3.2	4.4	nd	3.2	nd	nd	nd
p Value	0.20	nd	0.34	0.20	nd	0.34	nd	nd	nd
95% CI of	0.45	nd	0.30	0.45	nd	0.30	nd	nd	nd
OR Quart4	43	nd	33	43	nd	33	nd	nd	nd

Insulin-like growth factor-binding protein 5

sCr or UO	0hr prior to AKI stage		24hr prior to AKI stage		48hr prior to AKI stage	
	Cohort 1	Cohort 2	Cohort 1	Cohort 2	Cohort 1	Cohort 2
Median	34.6	48.0	34.6	48.0	nd	nd
Average	47.2	43.5	47.2	43.5	nd	nd
Stdev	52.3	42.3	52.3	42.3	nd	nd
p(t-test)		0.85		0.85	nd	nd
Min	0.204	0.204	0.204	0.204	nd	nd
Max	257	117	257	117	nd	nd
n (Samp)	87	8	87	8	nd	nd
n (Patient)	87	8	87	8	nd	nd

UO only	0hr prior to AKI stage		24hr prior to AKI stage		48hr prior to AKI stage	
	Cohort 1	Cohort 2	Cohort 1	Cohort 2	Cohort 1	Cohort 2
Median	24.6	62.6	24.6	62.6	nd	nd
Average	41.6	52.3	41.6	52.3	nd	nd
Stdev	53.2	44.9	53.2	44.9	nd	nd
p(t-test)		0.63		0.63	nd	nd
Min	0.204	0.204	0.204	0.204	nd	nd
Max	257	117	257	117	nd	nd
n (Samp)	80	6	80	6	nd	nd
n (Patient)	80	6	80	6	nd	nd

	0hr prior to AKI stage			24hr prior to AKI stage			48hr prior to AKI stage		
	sCr or UO	sCr only	UO only	sCr or UO	sCr only	UO only	sCr or UO	sCr only	UO only
AUC	0.49	nd	0.59	0.49	nd	0.59	nd	nd	nd
SE	0.11	nd	0.13	0.11	nd	0.13	nd	nd	nd
p	0.92	nd	0.47	0.92	nd	0.47	nd	nd	nd
nCohort 1	87	nd	80	87	nd	80	nd	nd	nd
nCohort 2	8	nd	6	8	nd	6	nd	nd	nd
Cutoff 1	0.488	nd	0.488	0.488	nd	0.488	nd	nd	nd
Sens 1	75%	nd	83%	75%	nd	83%	nd	nd	nd
Spec 1	18%	nd	22%	18%	nd	22%	nd	nd	nd
Cutoff 2	0.204	nd	0.488	0.204	nd	0.488	nd	nd	nd
Sens 2	88%	nd	83%	88%	nd	83%	nd	nd	nd
Spec 2	6%	nd	22%	6%	nd	22%	nd	nd	nd

	0hr prior to AKI stage			24hr prior to AKI stage			48hr prior to AKI stage		
	sCr or UO	sCr only	UO only	sCr or UO	sCr only	UO only	sCr or UO	sCr only	UO only
Cutoff 3	0	nd	0	0	nd	0	nd	nd	nd
Sens 3	100%	nd	100%	100%	nd	100%	nd	nd	nd
Spec 3	0%	nd	0%	0%	nd	0%	nd	nd	nd
Cutoff 4	59.8	nd	47.6	59.8	nd	47.6	nd	nd	nd
Sens 4	50%	nd	67%	50%	nd	67%	nd	nd	nd
Spec 4	70%	nd	70%	70%	nd	70%	nd	nd	nd
Cutoff 5	76.0	nd	65.5	76.0	nd	65.5	nd	nd	nd
Sens 5	12%	nd	33%	12%	nd	33%	nd	nd	nd
Spec 5	80%	nd	80%	80%	nd	80%	nd	nd	nd
Cutoff 6	124	nd	97.6	124	nd	97.6	nd	nd	nd
Sens 6	0%	nd	17%	0%	nd	17%	nd	nd	nd
Spec 6	91%	nd	90%	91%	nd	90%	nd	nd	nd
OR Quart 2	1.0	nd	0.95	1.0	nd	0.95	nd	nd	nd
p Value	1.0	nd	0.97	1.0	nd	0.97	nd	nd	nd
95% CI of	0.13	nd	0.056	0.13	nd	0.056	nd	nd	nd
OR Quart2	7.7	nd	16	7.7	nd	16	nd	nd	nd
OR Quart 3	1.0	nd	0	1.0	nd	0	nd	nd	nd
p Value	1.0	nd	na	1.0	nd	na	nd	nd	nd
95% CI of	0.13	nd	na	0.13	nd	na	nd	nd	nd
OR Quart3	7.7	nd	na	7.7	nd	na	nd	nd	nd
OR Quart 4	1.0	nd	4.4	1.0	nd	4.4	nd	nd	nd
p Value	0.96	nd	0.20	0.96	nd	0.20	nd	nd	nd
95% CI of	0.13	nd	0.45	0.13	nd	0.45	nd	nd	nd
OR Quart4	8.1	nd	44	8.1	nd	44	nd	nd	nd

Interleukin-21

sCr or UO	0hr prior to AKI stage		24hr prior to AKI stage		48hr prior to AKI stage	
	Cohort 1	Cohort 2	Cohort 1	Cohort 2	Cohort 1	Cohort 2
Median	0.783	1.89	0.783	1.75	0.783	1.89
Average	88.7	4.14	88.7	3.98	88.7	2.64
Stdev	673	7.38	673	7.45	673	2.51
p(t-test)		0.67		0.67		0.74
Min	0.0102	0.0102	0.0102	0.0102	0.0102	0.829
Max	5430	26.6	5430	26.6	5430	8.25
n (Samp)	65	12	65	12	65	7
n (Patient)	65	12	65	12	65	7

sCr only	0hr prior to AKI stage		24hr prior to AKI stage		48hr prior to AKI stage	
	Cohort 1	Cohort 2	Cohort 1	Cohort 2	Cohort 1	Cohort 2
Median	0.783	2.01	0.783	1.80	nd	nd
Average	45.5	2.67	45.5	2.35	nd	nd
Stdev	473	2.84	473	3.02	nd	nd
p(t-test)		0.83		0.82	nd	nd
Min	0.0102	0.0102	0.0102	0.0102	nd	nd
Max	5430	8.25	5430	8.25	nd	nd
n (Samp)	132	6	132	6	nd	nd
n (Patient)	132	6	132	6	nd	nd

UO only	0hr prior to AKI stage		24hr prior to AKI stage		48hr prior to AKI stage	
	Cohort 1	Cohort 2	Cohort 1	Cohort 2	Cohort 1	Cohort 2
Median	1.02	1.89	1.02	1.89	1.02	1.89
Average	90.5	4.71	90.5	4.71	90.5	1.71
Stdev	678	8.88	678	8.88	678	0.455
p(t-test)		0.72		0.72		0.75
Min	0.0102	0.783	0.0102	0.783	0.0102	0.829
Max	5430	26.6	5430	26.6	5430	2.03
n (Samp)	64	8	64	8	64	6
n (Patient)	64	8	64	8	64	6

	0hr prior to AKI stage			24hr prior to AKI stage			48hr prior to AKI stage		
	sCr or UO	sCr only	UO only	sCr or UO	sCr only	UO only	sCr or UO	sCr only	UO only
AUC	0.69	0.66	0.66	0.65	0.59	0.66	0.74	nd	0.65
SE	0.090	0.12	0.11	0.092	0.12	0.11	0.11	nd	0.13
p	0.038	0.19	0.14	0.10	0.45	0.14	0.034	nd	0.23
nCohort 1	65	132	64	65	132	64	65	nd	64
nCohort 2	12	6	8	12	6	8	7	nd	6
Cutoff 1	1.53	1.53	1.53	0.783	0.0314	1.53	1.79	nd	1.53
Sens 1	75%	83%	75%	75%	83%	75%	71%	nd	83%
Spec 1	71%	67%	64%	51%	33%	64%	74%	nd	64%
Cutoff 2	0.783	1.53	0.783	0.605	0.0314	0.783	1.53	nd	1.53
Sens 2	83%	83%	88%	83%	83%	88%	86%	nd	83%
Spec 2	51%	67%	45%	49%	33%	45%	71%	nd	64%
Cutoff 3	0.605	0.0102	0.605	0.0314	0.0102	0.605	0.783	nd	0.783
Sens 3	92%	100%	100%	92%	100%	100%	100%	nd	100%
Spec 3	49%	8%	44%	34%	8%	44%	51%	nd	45%
Cutoff 4	1.53	1.79	1.89	1.53	1.79	1.89	1.53	nd	1.89
Sens 4	75%	67%	38%	67%	50%	38%	86%	nd	33%
Spec 4	71%	70%	70%	71%	70%	70%	71%	nd	70%
Cutoff 5	2.03	2.60	3.18	2.03	2.60	3.18	2.03	nd	3.18
Sens 5	25%	17%	12%	17%	17%	12%	14%	nd	0%
Spec 5	80%	81%	81%	80%	81%	81%	80%	nd	81%
Cutoff 6	10.6	5.72	11.4	10.6	5.72	11.4	10.6	nd	11.4
Sens 6	8%	17%	12%	8%	17%	12%	0%	nd	0%
Spec 6	91%	90%	91%	91%	90%	91%	91%	nd	91%
OR Quart 2	2.1	0	>2.2	3.4	0.97	>2.2	>1.1	nd	>1.0
p Value	0.55	na	<0.52	0.31	0.98	<0.52	<0.97	nd	<1.0
95% CI of	0.18	na	>0.19	0.32	0.058	>0.19	>0.061	nd	>0.058
OR Quart2	26	na	na	36	16	na	na	nd	na
OR Quart 3	4.8	2.1	>6.9	4.8	2.1	>6.9	>5.1	nd	>7.1
p Value	0.18	0.56	<0.094	0.18	0.56	<0.094	<0.16	nd	<0.091
95% CI of	0.48	0.18	>0.72	0.48	0.18	>0.72	>0.52	nd	>0.73
OR Quart3	48	24	na	48	24	na	na	nd	na
OR Quart 4	6.0	3.1	>1.1	4.5	2.0	>1.1	>2.2	nd	>0
p Value	0.12	0.34	<0.97	0.20	0.58	<0.97	<0.52	nd	<na
95% CI of	0.63	0.31	>0.061	0.45	0.17	>0.061	>0.19	nd	>na
OR Quart4	57	31	na	45	23	na	na	nd	na

Interleukin-23

sCr or UO	0hr prior to AKI stage		24hr prior to AKI stage		48hr prior to AKI stage	
	Cohort 1	Cohort 2	Cohort 1	Cohort 2	Cohort 1	Cohort 2
Median	0.995	256	0.995	216	0.995	22.3
Average	2550	9620	2550	9610	2550	1110
Stdev	13000	28600	13000	28600	13000	2390
p(t-test)		0.17		0.17		0.77
Min	0.257	0.257	0.257	0.257	0.257	0.257
Max	100000	100000	100000	100000	100000	6480
n (Samp)	64	12	64	12	64	7
n (Patient)	64	12	64	12	64	7

sCr only	0hr prior to AKI stage		24hr prior to AKI stage		48hr prior to AKI stage	
	Cohort 1	Cohort 2	Cohort 1	Cohort 2	Cohort 1	Cohort 2
Median	1.10	89.5	1.10	50.3	nd	nd
Average	3050	435	3050	421	nd	nd
Stdev	15200	637	15200	644	nd	nd
p(t-test)		0.68		0.67	nd	nd
Min	0.257	0.257	0.257	0.257	nd	nd
Max	100000	1520	100000	1520	nd	nd
n (Samp)	131	6	131	6	nd	nd
n (Patient)	131	6	131	6	nd	nd

UO only	0hr prior to AKI stage		24hr prior to AKI stage		48hr prior to AKI stage	
	Cohort 1	Cohort 2	Cohort 1	Cohort 2	Cohort 1	Cohort 2
Median	1.10	621	1.10	621	1.10	178
Average	3240	14200	3240	14200	3240	1290
Stdev	13600	34800	13600	34800	13600	2560
p(t-test)		0.091		0.091		0.73
Min	0.257	0.257	0.257	0.257	0.257	0.257
Max	100000	100000	100000	100000	100000	6480
n (Samp)	63	8	63	8	63	6
n (Patient)	63	8	63	8	63	6

	0hr prior to AKI stage			24hr prior to AKI stage			48hr prior to AKI stage		
	sCr or UO	sCr only	UO only	sCr or UO	sCr only	UO only	sCr or UO	sCr only	UO only
AUC	0.67	0.58	0.70	0.66	0.57	0.70	0.62	nd	0.61
SE	0.092	0.12	0.11	0.092	0.12	0.11	0.12	nd	0.13
p	0.070	0.54	0.072	0.072	0.58	0.072	0.32	nd	0.40
nCohort 1	64	131	63	64	131	63	64	nd	63
nCohort 2	12	6	8	12	6	8	7	nd	6
Cutoff 1	0.886	0.770	11.0	0.886	0.770	11.0	0.886	nd	0.603
Sens 1	75%	83%	75%	75%	83%	75%	71%	nd	83%
Spec 1	50%	32%	67%	50%	32%	67%	50%	nd	35%
Cutoff 2	0.770	0.770	0.603	0.770	0.770	0.603	0.770	nd	0.603
Sens 2	83%	83%	88%	83%	83%	88%	86%	nd	83%
Spec 2	36%	32%	35%	36%	32%	35%	36%	nd	35%
Cutoff 3	0	0	0	0	0	0	0	nd	0
Sens 3	100%	100%	100%	100%	100%	100%	100%	nd	100%

	0hr prior to AKI stage			24hr prior to AKI stage			48hr prior to AKI stage		
	sCr or UO	sCr only	UO only	sCr or UO	sCr only	UO only	sCr or UO	sCr only	UO only
Spec 3	0%	0%	0%	0%	0%	0%	0%	nd	0%
Cutoff 4	55.0	138	405	55.0	138	405	55.0	nd	405
Sens 4	58%	50%	50%	58%	33%	50%	43%	nd	33%
Spec 4	70%	70%	71%	70%	70%	71%	70%	nd	71%
Cutoff 5	861	637	861	861	637	861	861	nd	861
Sens 5	42%	33%	50%	42%	33%	50%	29%	nd	33%
Spec 5	81%	80%	81%	81%	80%	81%	81%	nd	81%
Cutoff 6	2000	1540	2000	2000	1540	2000	2000	nd	2000
Sens 6	25%	0%	38%	25%	0%	38%	14%	nd	17%
Spec 6	91%	90%	90%	91%	90%	90%	91%	nd	90%
OR Quart 2	0.47	1.0	>2.1	0.47	1.0	>2.1	0.94	nd	>2.3
p Value	0.55	1.0	<0.55	0.55	1.0	<0.55	0.97	nd	<0.52
95% CI of	0.039	0.060	>0.18	0.039	0.060	>0.18	0.054	nd	>0.19
OR Quart2	5.7	17	na	5.7	17	na	16	nd	na
OR Quart 3	2.3	2.1	>2.1	2.3	2.1	>2.1	3.2	nd	>2.3
p Value	0.38	0.56	<0.55	0.38	0.56	<0.55	0.34	nd	<0.52
95% CI of	0.36	0.18	>0.18	0.36	0.18	>0.18	0.30	nd	>0.19
OR Quart3	14	24	na	14	24	na	34	nd	na
OR Quart 4	3.0	2.0	>4.9	3.0	2.0	>4.9	2.0	nd	>2.1
p Value	0.22	0.58	<0.18	0.22	0.58	<0.18	0.59	nd	<0.55
95% CI of	0.51	0.17	>0.49	0.51	0.17	>0.49	0.16	nd	>0.18
OR Quart4	18	23	na	18	23	na	24	nd	na

Interleukin-28A

sCr or UO	0hr prior to AKI stage		24hr prior to AKI stage		48hr prior to AKI stage	
	Cohort 1	Cohort 2	Cohort 1	Cohort 2	Cohort 1	Cohort 2
Median	0.265	12.0	0.265	12.0	0.265	7.61
Average	87.3	181	87.3	181	87.3	14.1
Stdev	465	574	465	574	465	15.5
p(t-test)		0.54		0.54		0.68
Min	0.120	0.148	0.120	0.148	0.120	0.148
Max	3150	2000	3150	2000	3150	35.6
n (Samp)	64	12	64	12	64	7
n (Patient)	64	12	64	12	64	7

sCr only	0hr prior to AKI stage		24hr prior to AKI stage		48hr prior to AKI stage	
	Cohort 1	Cohort 2	Cohort 1	Cohort 2	Cohort 1	Cohort 2
Median	0.265	0.626	0.265	0.265	nd	nd
Average	47.7	10.8	47.7	10.7	nd	nd
Stdev	326	22.2	326	22.3	nd	nd
p(t-test)		0.78		0.78	nd	nd
Min	0.0727	0.148	0.0727	0.148	nd	nd
Max	3150	55.8	3150	55.8	nd	nd
n (Samp)	131	6	131	6	nd	nd
n (Patient)	131	6	131	6	nd	nd

UO only	0hr prior to AKI stage	24hr prior to AKI stage	48hr prior to AKI stage

	Cohort 1	Cohort 2	Cohort 1	Cohort 2	Cohort 1	Cohort 2
Median	0.265	21.0	0.265	21.0	0.265	16.6
Average	90.5	265	90.5	265	90.5	16.4
Stdev	468	703	468	703	468	15.6
p(t-test)		0.35		0.35		0.70
Min	0.120	0.265	0.120	0.265	0.120	0.265
Max	3150	2000	3150	2000	3150	35.6
n (Samp)	63	8	63	8	63	6
n (Patient)	63	8	63	8	63	6

	0hr prior to AKI stage			24hr prior to AKI stage			48hr prior to AKI stage		
	sCr or UO	sCr only	UO only	sCr or UO	sCr only	UO only	sCr or UO	sCr only	UO only
AUC	0.73	0.57	0.82	0.70	0.52	0.82	0.68	nd	0.78
SE	0.088	0.12	0.095	0.090	0.12	0.095	0.12	nd	0.11
p	0.0095	0.59	8.5E-4	0.025	0.86	8.5E-4	0.13	nd	0.015
nCohort 1	64	131	63	64	131	63	64	nd	63
nCohort 2	12	6	8	12	6	8	7	nd	6
Cutoff 1	0.195	0.195	3.03	0.195	0.168	3.03	0.195	nd	0.195
Sens 1	92%	83%	75%	83%	83%	75%	86%	nd	100%
Spec 1	41%	40%	78%	41%	31%	78%	41%	nd	43%
Cutoff 2	0.195	0.195	0.195	0.195	0.168	0.195	0.195	nd	0.195
Sens 2	92%	83%	100%	83%	83%	100%	86%	nd	100%
Spec 2	41%	40%	43%	41%	31%	43%	41%	nd	43%
Cutoff 3	0.195	0.120	0.195	0.168	0.120	0.195	0.120	nd	0.195
Sens 3	92%	100%	100%	92%	100%	100%	100%	nd	100%
Spec 3	41%	2%	43%	34%	2%	43%	2%	nd	43%
Cutoff 4	0.265	10.2	0.265	0.265	10.2	0.265	0.265	nd	0.265
Sens 4	67%	17%	75%	58%	17%	75%	57%	nd	67%
Spec 4	70%	71%	76%	70%	71%	76%	70%	nd	76%
Cutoff 5	12.3	14.3	10.8	12.3	14.3	10.8	12.3	nd	10.8
Sens 5	50%	17%	62%	50%	17%	62%	43%	nd	50%
Spec 5	81%	80%	81%	81%	80%	81%	81%	nd	81%
Cutoff 6	21.6	25.6	21.6	21.6	25.6	21.6	21.6	nd	21.6
Sens 6	42%	17%	50%	42%	17%	50%	43%	nd	50%
Spec 6	91%	91%	90%	91%	91%	90%	91%	nd	90%
OR Quart 2	3.4	0	>2.1	4.8	2.1	>2.1	2.0	nd	>2.3
p Value	0.31	na	<0.55	0.18	0.56	<0.55	0.59	nd	<0.52
95% CI of	0.32	na	>0.18	0.48	0.18	>0.18	0.16	nd	>0.19
OR Quart2	36	na	na	48	24	na	24	nd	na
OR Quart 3	2.1	4.4	>1.0	1.0	2.1	>1.0	0.94	nd	>0
p Value	0.55	0.20	<1.0	1.0	0.56	<1.0	0.97	nd	<na
95% CI of	0.18	0.47	>0.058	0.058	0.18	>0.058	0.054	nd	>na
OR Quart3	26	42	na	17	24	na	16	nd	na
OR Quart 4	8.3	0.97	>6.5	8.3	0.97	>6.5	3.2	nd	>4.9
p Value	0.063	0.98	<0.10	0.063	0.98	<0.10	0.34	nd	<0.18
95% CI of	0.89	0.058	>0.68	0.89	0.058	>0.68	0.30	nd	>0.49
OR Quart4	78	16	na	78	16	na	34	nd	na

Interleukin-33

sCr or UO	0hr prior to AKI stage		24hr prior to AKI stage		48hr prior to AKI stage	
	Cohort 1	Cohort 2	Cohort 1	Cohort 2	Cohort 1	Cohort 2
Median	0.101	15.5	0.101	15.5	0.101	9.09
Average	687	1070	687	1070	687	34.8
Stdev	4960	3520	4960	3520	4960	54.3
p(t-test)		0.80		0.80		0.73
Min	0.0445	0.0455	0.0445	0.0455	0.0445	0.0455
Max	40000	12300	40000	12300	40000	149
n (Samp)	65	12	65	12	65	7
n (Patient)	65	12	65	12	65	7

sCr only	0hr prior to AKI stage		24hr prior to AKI stage		48hr prior to AKI stage	
	Cohort 1	Cohort 2	Cohort 1	Cohort 2	Cohort 1	Cohort 2
Median	0.101	6.17	0.101	6.17	nd	nd
Average	489	24.6	489	24.6	nd	nd
Stdev	3680	44.2	3680	44.2	nd	nd
p(t-test)		0.76		0.76	nd	nd
Min	0.0445	0.0455	0.0445	0.0455	nd	nd
Max	40000	113	40000	113	nd	nd
n (Samp)	132	6	132	6	nd	nd
n (Patient)	132	6	132	6	nd	nd

UO only	0hr prior to AKI stage		24hr prior to AKI stage		48hr prior to AKI stage	
	Cohort 1	Cohort 2	Cohort 1	Cohort 2	Cohort 1	Cohort 2
Median	0.0981	39.7	0.0981	39.7	0.0981	12.6
Average	749	1600	749	1600	749	39.1
Stdev	5000	4310	5000	4310	5000	58.2
p(t-test)		0.65		0.65		0.73
Min	0.0445	0.0455	0.0445	0.0455	0.0445	0.0455
Max	40000	12300	40000	12300	40000	149
n (Samp)	64	8	64	8	64	6
n (Patient)	64	8	64	8	64	6

	0hr prior to AKI stage			24hr prior to AKI stage			48hr prior to AKI stage		
	sCr or UO	sCr only	UO only	sCr or UO	sCr only	UO only	sCr or UO	sCr only	UO only
AUC	0.70	0.62	0.75	0.70	0.62	0.75	0.70	nd	0.68
SE	0.090	0.12	0.10	0.090	0.12	0.10	0.12	nd	0.13
p	0.023	0.33	0.018	0.023	0.33	0.018	0.086	nd	0.15
nCohort 1	65	132	64	65	132	64	65	nd	64
nCohort 2	12	6	8	12	6	8	7	nd	6
Cutoff 1	2.20	0.0981	2.65	2.20	0.0981	2.65	2.65	nd	2.20
Sens 1	75%	83%	75%	75%	83%	75%	71%	nd	83%
Spec 1	68%	42%	67%	68%	42%	67%	68%	nd	67%
Cutoff 2	0.0981	0.0981	2.20	0.0981	0.0981	2.20	2.20	nd	2.20
Sens 2	83%	83%	88%	83%	83%	88%	86%	nd	83%
Spec 2	46%	42%	67%	46%	42%	67%	68%	nd	67%
Cutoff 3	0.0445	0.0445	0.0445	0.0445	0.0445	0.0445	0.0445	nd	0.0445
Sens 3	100%	100%	100%	100%	100%	100%	100%	nd	100%
Spec 3	11%	8%	8%	11%	8%	8%	11%	nd	8%

	0hr prior to AKI stage			24hr prior to AKI stage			48hr prior to AKI stage		
	sCr or UO	sCr only	UO only	sCr or UO	sCr only	UO only	sCr or UO	sCr only	UO only
Cutoff 4	4.56	7.37	4.56	4.56	7.37	4.56	4.56	nd	4.56
Sens 4	58%	50%	62%	58%	50%	62%	57%	nd	50%
Spec 4	71%	70%	70%	71%	70%	70%	71%	nd	70%
Cutoff 5	20.5	27.4	31.5	20.5	27.4	31.5	20.5	nd	31.5
Sens 5	50%	17%	50%	50%	17%	50%	43%	nd	33%
Spec 5	80%	80%	81%	80%	80%	81%	80%	nd	81%
Cutoff 6	89.5	89.5	99.5	89.5	89.5	99.5	89.5	nd	99.5
Sens 6	33%	17%	38%	33%	17%	38%	14%	nd	17%
Spec 6	91%	90%	91%	91%	90%	91%	91%	nd	91%
OR Quart 2	2.1	0	>1.1	2.1	0	>1.1	0	nd	>1.0
p Value	0.55	na	<0.97	0.55	na	<0.97	na	nd	<1.0
95% CI of	0.18	na	>0.061	0.18	na	>0.061	na	nd	>0.058
OR Quart2	26	na	na	26	na	na	na	nd	na
OR Quart 3	3.4	3.2	>3.6	3.4	3.2	>3.6	3.4	nd	>2.3
p Value	0.31	0.33	<0.29	0.31	0.33	<0.29	0.31	nd	<0.52
95% CI of	0.32	0.32	>0.34	0.32	0.32	>0.34	0.32	nd	>0.19
OR Quart3	36	32	na	36	32	na	36	nd	na
OR Quart 4	7.7	2.0	>5.1	7.7	2.0	>5.1	3.4	nd	>3.4
p Value	0.072	0.58	<0.16	0.072	0.58	<0.16	0.31	nd	<0.31
95% CI of	0.83	0.17	>0.52	0.83	0.17	>0.52	0.32	nd	>0.32
OR Quart4	72	23	na	72	23	na	36	nd	na

Vascular endothelial growth factor receptor 2

sCr or UO	0hr prior to AKI stage		24hr prior to AKI stage		48hr prior to AKI stage	
	Cohort 1	Cohort 2	Cohort 1	Cohort 2	Cohort 1	Cohort 2
Median	8020	7370	8020	7130	8020	7560
Average	11300	25200	11300	25100	11300	7430
Stdev	18600	60300	18600	60300	18600	1750
p(t-test)		0.13		0.13		0.59
Min	3720	5310	3720	5310	3720	5310
Max	153000	216000	153000	216000	153000	10600
n (Samp)	65	12	65	12	65	7
n (Patient)	65	12	65	12	65	7

sCr only	0hr prior to AKI stage		24hr prior to AKI stage		48hr prior to AKI stage	
	Cohort 1	Cohort 2	Cohort 1	Cohort 2	Cohort 1	Cohort 2
Median	8020	6320	8020	5950	nd	nd
Average	11200	7000	11200	6800	nd	nd
Stdev	19000	1860	19000	1900	nd	nd
p(t-test)		0.59		0.57	nd	nd
Min	3720	5750	3720	5750	nd	nd
Max	166000	10600	166000	10600	nd	nd
n (Samp)	132	6	132	6	nd	nd
n (Patient)	132	6	132	6	nd	nd

UO only	0hr prior to AKI stage		24hr prior to AKI stage		48hr prior to AKI stage	
	Cohort 1	Cohort 2	Cohort 1	Cohort 2	Cohort 1	Cohort 2

UO only	0hr prior to AKI stage		24hr prior to AKI stage		48hr prior to AKI stage	
	Cohort 1	Cohort 2	Cohort 1	Cohort 2	Cohort 1	Cohort 2
Median	8010	7860	8010	7860	8010	7130
Average	11900	34100	11900	34100	11900	6900
Stdev	19000	73700	19000	73700	19000	1150
p(t-test)		0.049		0.049		0.53
Min	3900	5310	3900	5310	3900	5310
Max	153000	216000	153000	216000	153000	8150
n (Samp)	64	8	64	8	64	6
n (Patient)	64	8	64	8	64	6

	0hr prior to AKI stage			24hr prior to AKI stage			48hr prior to AKI stage		
	sCr or UO	sCr only	UO only	sCr or UO	sCr only	UO only	sCr or UO	sCr only	UO only
AUC	0.46	0.31	0.52	0.44	0.28	0.52	0.39	nd	0.34
SE	0.093	0.12	0.11	0.093	0.12	0.11	0.12	nd	0.13
p	0.65	0.13	0.86	0.51	0.069	0.86	0.36	nd	0.21
nCohort 1	65	132	64	65	132	64	65	nd	64
nCohort 2	12	6	8	12	6	8	7	nd	6
Cutoff 1	5920	5830	6660	5920	5830	6660	6660	nd	5700
Sens 1	75%	83%	75%	75%	83%	75%	71%	nd	83%
Spec 1	12%	15%	33%	12%	15%	33%	31%	nd	12%
Cutoff 2	5750	5830	5700	5750	5830	5700	5310	nd	5700
Sens 2	83%	83%	88%	83%	83%	88%	86%	nd	83%
Spec 2	11%	15%	12%	11%	15%	12%	11%	nd	12%
Cutoff 3	5310	5720	5230	5310	5720	5230	5230	nd	5230
Sens 3	92%	100%	100%	92%	100%	100%	100%	nd	100%
Spec 3	11%	14%	9%	11%	14%	9%	11%	nd	9%
Cutoff 4	9430	9520	9430	9430	9520	9430	9430	nd	9430
Sens 4	33%	17%	38%	33%	17%	38%	14%	nd	0%
Spec 4	71%	70%	70%	71%	70%	70%	71%	nd	70%
Cutoff 5	10800	10800	11100	10800	10800	11100	10800	nd	11100
Sens 5	17%	0%	25%	17%	0%	25%	0%	nd	0%
Spec 5	80%	80%	81%	80%	80%	81%	80%	nd	81%
Cutoff 6	13800	14200	16000	13800	14200	16000	13800	nd	16000
Sens 6	8%	0%	12%	8%	0%	12%	0%	nd	0%
Spec 6	91%	90%	91%	91%	90%	91%	91%	nd	91%
OR Quart 2	0.67	0	1.0	0.67	0	1.0	1.0	nd	>1.1
p Value	0.68	na	1.0	0.68	na	1.0	1.0	nd	<0.94
95% CI of	0.099	na	0.13	0.099	na	0.13	0.058	nd	>0.065
OR Quart2	4.5	na	8.0	4.5	na	8.0	17	nd	na
OR Quart 3	1.1	2.1	1.0	0.67	1.0	1.0	3.4	nd	>3.6
p Value	0.95	0.56	1.0	0.68	1.0	1.0	0.31	nd	<0.29
95% CI of	0.19	0.18	0.13	0.099	0.060	0.13	0.32	nd	>0.34
OR Quart3	6.1	24	8.0	4.5	17	8.0	36	nd	na
OR Quart 4	1.5	3.3	1.0	2.0	4.5	1.0	2.1	nd	>2.4
p Value	0.62	0.31	1.0	0.39	0.19	1.0	0.55	nd	<0.49
95% CI of	0.29	0.32	0.13	0.41	0.48	0.13	0.18	nd	>0.20
OR Quart4	7.9	33	8.0	10.0	43	8.0	26	nd	na

Neural cell adhesion molecule 1

sCr or UO	0hr prior to AKI stage		24hr prior to AKI stage		48hr prior to AKI stage	
	Cohort 1	Cohort 2	Cohort 1	Cohort 2	Cohort 1	Cohort 2
Median	189000	172000	189000	172000	nd	nd
Average	192000	180000	192000	177000	nd	nd
Stdev	74500	49600	74500	44400	nd	nd
p(t-test)		0.65		0.56	nd	nd
Min	73000	111000	73000	111000	nd	nd
Max	520000	256000	520000	245000	nd	nd
n (Samp)	86	8	86	8	nd	nd
n (Patient)	86	8	86	8	nd	nd

UO only	0hr prior to AKI stage		24hr prior to AKI stage		48hr prior to AKI stage	
	Cohort 1	Cohort 2	Cohort 1	Cohort 2	Cohort 1	Cohort 2
Median	186000	162000	186000	162000	nd	nd
Average	193000	166000	193000	166000	nd	nd
Stdev	78400	45100	78400	45100	nd	nd
p(t-test)		0.41		0.41	nd	nd
Min	73000	111000	73000	111000	nd	nd
Max	520000	245000	520000	245000	nd	nd
n (Samp)	79	6	79	6	nd	nd
n (Patient)	79	6	79	6	nd	nd

	0hr prior to AKI stage			24hr prior to AKI stage			48hr prior to AKI stage		
	sCr or UO	sCr only	UO only	sCr or UO	sCr only	UO only	sCr or UO	sCr only	UO only
AUC	0.46	nd	0.39	0.45	nd	0.39	nd	nd	nd
SE	0.11	nd	0.13	0.11	nd	0.13	nd	nd	nd
p	0.72	nd	0.40	0.67	nd	0.40	nd	nd	nd
nCohort 1	86	nd	79	86	nd	79	nd	nd	nd
nCohort 2	8	nd	6	8	nd	6	nd	nd	nd
Cutoff 1	158000	nd	139000	158000	nd	139000	nd	nd	nd
Sens 1	75%	nd	83%	75%	nd	83%	nd	nd	nd
Spec 1	35%	nd	23%	35%	nd	23%	nd	nd	nd
Cutoff 2	139000	nd	139000	139000	nd	139000	nd	nd	nd
Sens 2	88%	nd	83%	88%	nd	83%	nd	nd	nd
Spec 2	22%	nd	23%	22%	nd	23%	nd	nd	nd
Cutoff 3	107000	nd	107000	107000	nd	107000	nd	nd	nd
Sens 3	100%	nd	100%	100%	nd	100%	nd	nd	nd
Spec 3	9%	nd	9%	9%	nd	9%	nd	nd	nd
Cutoff 4	217000	nd	217000	217000	nd	217000	nd	nd	nd
Sens 4	25%	nd	17%	25%	nd	17%	nd	nd	nd
Spec 4	71%	nd	71%	71%	nd	71%	nd	nd	nd
Cutoff 5	227000	nd	228000	227000	nd	228000	nd	nd	nd
Sens 5	25%	nd	17%	25%	nd	17%	nd	nd	nd
Spec 5	80%	nd	81%	80%	nd	81%	nd	nd	nd
Cutoff 6	272000	nd	262000	272000	nd	262000	nd	nd	nd
Sens 6	0%	nd	0%	0%	nd	0%	nd	nd	nd
Spec 6	91%	nd	91%	91%	nd	91%	nd	nd	nd
OR Quart 2	0.50	nd	0	0.50	nd	0	nd	nd	nd
p Value	0.58	nd	na	0.58	nd	na	nd	nd	nd

	0hr prior to AKI stage			24hr prior to AKI stage			48hr prior to AKI stage		
	sCr or UO	sCr only	UO only	sCr or UO	sCr only	UO only	sCr or UO	sCr only	UO only
95% CI of	0.042	nd	na	0.042	nd	na	nd	nd	nd
OR Quart2	5.9	nd	na	5.9	nd	na	nd	nd	nd
OR Quart 3	1.6	nd	3.5	1.6	nd	3.5	nd	nd	nd
p Value	0.64	nd	0.30	0.64	nd	0.30	nd	nd	nd
95% CI of	0.24	nd	0.33	0.24	nd	0.33	nd	nd	nd
OR Quart3	10	nd	37	10	nd	37	nd	nd	nd
OR Quart 4	1.0	nd	2.2	1.0	nd	2.2	nd	nd	nd
p Value	0.96	nd	0.53	0.96	nd	0.53	nd	nd	nd
95% CI of	0.13	nd	0.19	0.13	nd	0.19	nd	nd	nd
OR Quart4	8.1	nd	26	8.1	nd	26	nd	nd	nd

Platelet-derived growth factor subunit B (dimer)

sCr or UO	0hr prior to AKI stage		24hr prior to AKI stage		48hr prior to AKI stage	
	Cohort 1	Cohort 2	Cohort 1	Cohort 2	Cohort 1	Cohort 2
Median	468	535	468	535	nd	nd
Average	494	734	494	734	nd	nd
Stdev	267	833	267	833	nd	nd
p(t-test)		0.064		0.064	nd	nd
Min	113	91.9	113	91.9	nd	nd
Max	1540	2720	1540	2720	nd	nd
n (Samp)	85	8	85	8	nd	nd
n (Patient)	85	8	85	8	nd	nd

UO only	0hr prior to AKI stage		24hr prior to AKI stage		48hr prior to AKI stage	
	Cohort 1	Cohort 2	Cohort 1	Cohort 2	Cohort 1	Cohort 2
Median	438	535	438	535	nd	nd
Average	463	485	463	485	nd	nd
Stdev	254	247	254	247	nd	nd
p(t-test)		0.83		0.83	nd	nd
Min	113	91.9	113	91.9	nd	nd
Max	1540	721	1540	721	nd	nd
n (Samp)	78	6	78	6	nd	nd
n (Patient)	78	6	78	6	nd	nd

	0hr prior to AKI stage			24hr prior to AKI stage			48hr prior to AKI stage		
	sCr or UO	sCr only	UO only	sCr or UO	sCr only	UO only	sCr or UO	sCr only	UO only
AUC	0.55	nd	0.58	0.55	nd	0.58	nd	nd	nd
SE	0.11	nd	0.13	0.11	nd	0.13	nd	nd	nd
p	0.65	nd	0.52	0.65	nd	0.52	nd	nd	nd
nCohort 1	85	nd	78	85	nd	78	nd	nd	nd
nCohort 2	8	nd	6	8	nd	6	nd	nd	nd
Cutoff 1	326	nd	326	326	nd	326	nd	nd	nd
Sens 1	75%	nd	83%	75%	nd	83%	nd	nd	nd
Spec 1	34%	nd	41%	34%	nd	41%	nd	nd	nd
Cutoff 2	238	nd	326	238	nd	326	nd	nd	nd
Sens 2	88%	nd	83%	88%	nd	83%	nd	nd	nd
Spec 2	12%	nd	41%	12%	nd	41%	nd	nd	nd

	0hr prior to AKI stage			24hr prior to AKI stage			48hr prior to AKI stage		
	sCr or UO	sCr only	UO only	sCr or UO	sCr only	UO only	sCr or UO	sCr only	UO only
Cutoff 3	0	nd	0	0	nd	0	nd	nd	nd
Sens 3	100%	nd	100%	100%	nd	100%	nd	nd	nd
Spec 3	0%	nd	0%	0%	nd	0%	nd	nd	nd
Cutoff 4	595	nd	543	595	nd	543	nd	nd	nd
Sens 4	50%	nd	50%	50%	nd	50%	nd	nd	nd
Spec 4	71%	nd	71%	71%	nd	71%	nd	nd	nd
Cutoff 5	660	nd	618	660	nd	618	nd	nd	nd
Sens 5	38%	nd	50%	38%	nd	50%	nd	nd	nd
Spec 5	80%	nd	81%	80%	nd	81%	nd	nd	nd
Cutoff 6	763	nd	747	763	nd	747	nd	nd	nd
Sens 6	12%	nd	0%	12%	nd	0%	nd	nd	nd
Spec 6	91%	nd	91%	91%	nd	91%	nd	nd	nd
OR Quart 2	1.0	nd	2.1	1.0	nd	2.1	nd	nd	nd
p Value	1.0	nd	0.56	1.0	nd	0.56	nd	nd	nd
95% CI of	0.13	nd	0.18	0.13	nd	0.18	nd	nd	nd
OR Quart2	7.8	nd	25	7.8	nd	25	nd	nd	nd
OR Quart 3	0.48	nd	0	0.48	nd	0	nd	nd	nd
p Value	0.56	nd	na	0.56	nd	na	nd	nd	nd
95% CI of	0.040	nd	na	0.040	nd	na	nd	nd	nd
OR Quart3	5.7	nd	na	5.7	nd	na	nd	nd	nd
OR Quart 4	1.5	nd	3.3	1.5	nd	3.3	nd	nd	nd
p Value	0.67	nd	0.32	0.67	nd	0.32	nd	nd	nd
95% CI of	0.23	nd	0.32	0.23	nd	0.32	nd	nd	nd
OR Quart4	9.9	nd	35	9.9	nd	35	nd	nd	nd

Corticotropin

sCr or UO	0hr prior to AKI stage		24hr prior to AKI stage		48hr prior to AKI stage	
	Cohort 1	Cohort 2	Cohort 1	Cohort 2	Cohort 1	Cohort 2
Median	0.00105	0.00369	0.00105	0.00369	nd	nd
Average	0.00913	0.00636	0.00913	0.00636	nd	nd
Stdev	0.0411	0.00856	0.0411	0.00856	nd	nd
p(t-test)		0.86		0.86	nd	nd
Min	3.38E-6	3.38E-6	3.38E-6	3.38E-6	nd	nd
Max	0.292	0.0245	0.292	0.0245	nd	nd
n (Samp)	75	7	75	7	nd	nd
n (Patient)	75	7	75	7	nd	nd

UO only	0hr prior to AKI stage		24hr prior to AKI stage		48hr prior to AKI stage	
	Cohort 1	Cohort 2	Cohort 1	Cohort 2	Cohort 1	Cohort 2
Median	0.00140	0.00367	0.00140	0.00367	nd	nd
Average	0.0109	0.00681	0.0109	0.00681	nd	nd
Stdev	0.0444	0.00929	0.0444	0.00929	nd	nd
p(t-test)		0.82		0.82	nd	nd
Min	4.31E-6	3.38E-6	4.31E-6	3.38E-6	nd	nd
Max	0.292	0.0245	0.292	0.0245	nd	nd
n (Samp)	64	6	64	6	nd	nd
n (Patient)	64	6	64	6	nd	nd

	0hr prior to AKI stage			24hr prior to AKI stage			48hr prior to AKI stage		
	sCr or UO	sCr only	UO only	sCr or UO	sCr only	UO only	sCr or UO	sCr only	UO only
AUC	0.65	nd	0.59	0.65	nd	0.59	nd	nd	nd
SE	0.12	nd	0.13	0.12	nd	0.13	nd	nd	nd
p	0.21	nd	0.49	0.21	nd	0.49	nd	nd	nd
nCohort 1	75	nd	64	75	nd	64	nd	nd	nd
nCohort 2	7	nd	6	7	nd	6	nd	nd	nd
Cutoff 1	0.00170	nd	0.000278	0.00170	nd	0.000278	nd	nd	nd
Sens 1	71%	nd	83%	71%	nd	83%	nd	nd	nd
Spec 1	64%	nd	30%	64%	nd	30%	nd	nd	nd
Cutoff 2	0.000278	nd	0.000278	0.000278	nd	0.000278	nd	nd	nd
Sens 2	86%	nd	83%	86%	nd	83%	nd	nd	nd
Spec 2	36%	nd	30%	36%	nd	30%	nd	nd	nd
Cutoff 3	0	nd	0	0	nd	0	nd	nd	nd
Sens 3	100%	nd	100%	100%	nd	100%	nd	nd	nd
Spec 3	0%	nd	0%	0%	nd	0%	nd	nd	nd
Cutoff 4	0.00297	nd	0.00345	0.00297	nd	0.00345	nd	nd	nd
Sens 4	57%	nd	50%	57%	nd	50%	nd	nd	nd
Spec 4	71%	nd	70%	71%	nd	70%	nd	nd	nd
Cutoff 5	0.00423	nd	0.00550	0.00423	nd	0.00550	nd	nd	nd
Sens 5	43%	nd	33%	43%	nd	33%	nd	nd	nd
Spec 5	81%	nd	81%	81%	nd	81%	nd	nd	nd
Cutoff 6	0.00767	nd	0.00859	0.00767	nd	0.00859	nd	nd	nd
Sens 6	29%	nd	33%	29%	nd	33%	nd	nd	nd
Spec 6	91%	nd	91%	91%	nd	91%	nd	nd	nd
OR Quart 2	0.95	nd	0.94	0.95	nd	0.94	nd	nd	nd
p Value	0.97	nd	0.97	0.97	nd	0.97	nd	nd	nd
95% CI of	0.055	nd	0.054	0.055	nd	0.054	nd	nd	nd
OR Quart2	16	nd	16	16	nd	16	nd	nd	nd
OR Quart 3	2.1	nd	1.0	2.1	nd	1.0	nd	nd	nd
p Value	0.56	nd	1.0	0.56	nd	1.0	nd	nd	nd
95% CI of	0.18	nd	0.057	0.18	nd	0.057	nd	nd	nd
OR Quart3	25	nd	17	25	nd	17	nd	nd	nd
OR Quart 4	3.2	nd	3.2	3.2	nd	3.2	nd	nd	nd
p Value	0.34	nd	0.34	0.34	nd	0.34	nd	nd	nd
95% CI of	0.30	nd	0.30	0.30	nd	0.30	nd	nd	nd
OR Quart4	33	nd	34	33	nd	34	nd	nd	nd

Thyroxine-binding globulin

sCr or UO	0hr prior to AKI stage		24hr prior to AKI stage		48hr prior to AKI stage	
	Cohort 1	Cohort 2	Cohort 1	Cohort 2	Cohort 1	Cohort 2
Median	43.7	29.2	43.7	28.6	43.7	42.5
Average	42.7	35.2	42.7	34.5	42.7	42.1
Stdev	12.2	13.1	12.2	13.5	12.2	14.0
p(t-test)		0.029		0.017		0.89
Min	15.5	21.0	15.5	21.0	15.5	24.8
Max	75.8	63.7	75.8	63.7	75.8	62.0
n (Samp)	110	15	110	15	110	8

sCr or UO	0hr prior to AKI stage		24hr prior to AKI stage		48hr prior to AKI stage	
	Cohort 1	Cohort 2	Cohort 1	Cohort 2	Cohort 1	Cohort 2
n (Patient)	110	15	110	15	110	8

sCr only	0hr prior to AKI stage		24hr prior to AKI stage		48hr prior to AKI stage	
	Cohort 1	Cohort 2	Cohort 1	Cohort 2	Cohort 1	Cohort 2
Median	39.3	30.1	39.3	28.6	nd	nd
Average	41.1	40.0	41.1	38.9	nd	nd
Stdev	12.1	16.1	12.1	17.1	nd	nd
p(t-test)		0.82		0.65	nd	nd
Min	14.2	23.4	14.2	22.3	nd	nd
Max	75.8	63.7	75.8	63.7	nd	nd
n (Samp)	180	7	180	7	nd	nd
n (Patient)	180	7	180	7	nd	nd

UO only	0hr prior to AKI stage		24hr prior to AKI stage		48hr prior to AKI stage	
	Cohort 1	Cohort 2	Cohort 1	Cohort 2	Cohort 1	Cohort 2
Median	43.5	28.8	43.5	28.8	43.5	32.6
Average	41.9	33.2	41.9	33.0	41.9	37.5
Stdev	11.8	11.2	11.8	11.3	11.8	12.6
p(t-test)		0.030		0.026		0.39
Min	20.4	21.0	20.4	21.0	20.4	24.8
Max	75.8	56.1	75.8	56.1	75.8	56.1
n (Samp)	91	10	91	10	91	6
n (Patient)	91	10	91	10	91	6

	0hr prior to AKI stage			24hr prior to AKI stage			48hr prior to AKI stage		
	sCr or UO	sCr only	UO only	sCr or UO	sCr only	UO only	sCr or UO	sCr only	UO only
AUC	0.31	0.45	0.29	0.30	0.43	0.28	0.50	nd	0.41
SE	0.080	0.11	0.095	0.079	0.11	0.095	0.11	nd	0.13
p	0.018	0.66	0.024	0.011	0.54	0.021	1.00	nd	0.45
nCohort 1	110	180	91	110	180	91	110	nd	91
nCohort 2	15	7	10	15	7	10	8	nd	6
Cutoff 1	27.9	28.5	27.9	26.5	28.2	27.4	29.2	nd	29.1
Sens 1	73%	71%	70%	73%	71%	70%	75%	nd	83%
Spec 1	11%	14%	13%	8%	13%	11%	15%	nd	18%
Cutoff 2	27.4	28.2	27.4	23.7	23.3	26.8	29.1	nd	29.1
Sens 2	80%	86%	80%	80%	86%	80%	88%	nd	83%
Spec 2	9%	13%	11%	5%	7%	10%	15%	nd	18%
Cutoff 3	23.3	23.3	24.6	21.0	21.0	24.6	23.7	nd	24.6
Sens 3	93%	100%	90%	93%	100%	90%	100%	nd	100%
Spec 3	5%	7%	7%	2%	4%	7%	5%	nd	7%
Cutoff 4	48.0	47.1	47.2	48.0	47.1	47.2	48.0	nd	47.2
Sens 4	27%	43%	20%	27%	43%	20%	50%	nd	33%
Spec 4	70%	70%	70%	70%	70%	70%	70%	nd	70%
Cutoff 5	52.3	50.1	50.4	52.3	50.1	50.4	52.3	nd	50.4
Sens 5	13%	29%	10%	13%	29%	10%	25%	nd	17%
Spec 5	80%	80%	80%	80%	80%	80%	80%	nd	80%
Cutoff 6	57.6	56.1	55.2	57.6	56.1	55.2	57.6	nd	55.2

	0hr prior to AKI stage			24hr prior to AKI stage			48hr prior to AKI stage		
	sCr or UO	sCr only	UO only	sCr or UO	sCr only	UO only	sCr or UO	sCr only	UO only
Sens 6	7%	14%	10%	7%	14%	10%	12%	nd	17%
Spec 6	90%	90%	90%	90%	90%	90%	90%	nd	90%
OR Quart 2	0	0	0	0	0	0	0.32	nd	0
p Value	na	na	na	na	na	na	0.34	nd	na
95% CI of	na	na	na	na	na	na	0.031	nd	na
OR Quart2	na	na	na	na	na	na	3.3	nd	na
OR Quart 3	0.23	0	0.50	0.23	0	0.50	0.31	nd	0.50
p Value	0.21	na	0.58	0.21	na	0.58	0.32	nd	0.58
95% CI of	0.025	na	0.042	0.025	na	0.042	0.030	nd	0.042
OR Quart3	2.2	na	5.9	2.2	na	5.9	3.2	nd	5.9
OR Quart 4	3.3	1.4	4.7	3.3	1.4	4.7	1.0	nd	1.6
p Value	0.067	0.67	0.073	0.067	0.67	0.073	0.97	nd	0.61
95% CI of	0.92	0.29	0.86	0.92	0.29	0.86	0.19	nd	0.25
OR Quart4	12	6.6	25	12	6.6	25	5.6	nd	11

Pigment epithelium-derived factor

sCr or UO	0hr prior to AKI stage		24hr prior to AKI stage		48hr prior to AKI stage	
	Cohort 1	Cohort 2	Cohort 1	Cohort 2	Cohort 1	Cohort 2
Median	1670	1590	1670	1590	nd	nd
Average	1710	1630	1710	1590	nd	nd
Stdev	774	749	774	788	nd	nd
p(t-test)		0.78		0.67	nd	nd
Min	445	339	445	339	nd	nd
Max	4240	2850	4240	2850	nd	nd
n (Samp)	87	8	87	8	nd	nd
n (Patient)	87	8	87	8	nd	nd

UO only	0hr prior to AKI stage		24hr prior to AKI stage		48hr prior to AKI stage	
	Cohort 1	Cohort 2	Cohort 1	Cohort 2	Cohort 1	Cohort 2
Median	1620	1850	1620	1850	nd	nd
Average	1760	1720	1760	1720	nd	nd
Stdev	841	855	841	855	nd	nd
p(t-test)		0.93		0.93	nd	nd
Min	445	339	445	339	nd	nd
Max	4510	2850	4510	2850	nd	nd
n (Samp)	80	6	80	6	nd	nd
n (Patient)	80	6	80	6	nd	nd

	0hr prior to AKI stage			24hr prior to AKI stage			48hr prior to AKI stage		
	sCr or UO	sCr only	UO only	sCr or UO	sCr only	UO only	sCr or UO	sCr only	UO only
AUC	0.50	nd	0.53	0.48	nd	0.53	nd	nd	nd
SE	0.11	nd	0.12	0.11	nd	0.12	nd	nd	nd
p	0.99	nd	0.82	0.82	nd	0.82	nd	nd	nd
nCohort 1	87	nd	80	87	nd	80	nd	nd	nd
nCohort 2	8	nd	6	8	nd	6	nd	nd	nd
Cutoff 1	1280	nd	1280	1280	nd	1280	nd	nd	nd
Sens 1	75%	nd	83%	75%	nd	83%	nd	nd	nd

	0hr prior to AKI stage			24hr prior to AKI stage			48hr prior to AKI stage		
	sCr or UO	sCr only	UO only	sCr or UO	sCr only	UO only	sCr or UO	sCr only	UO only
Spec 1	37%	nd	34%	37%	nd	34%	nd	nd	nd
Cutoff 2	1170	nd	1280	756	nd	1280	nd	nd	nd
Sens 2	88%	nd	83%	88%	nd	83%	nd	nd	nd
Spec 2	30%	nd	34%	9%	nd	34%	nd	nd	nd
Cutoff 3	0	nd	0	0	nd	0	nd	nd	nd
Sens 3	100%	nd	100%	100%	nd	100%	nd	nd	nd
Spec 3	0%	nd	0%	0%	nd	0%	nd	nd	nd
Cutoff 4	2020	nd	2030	2020	nd	2030	nd	nd	nd
Sens 4	38%	nd	50%	38%	nd	50%	nd	nd	nd
Spec 4	70%	nd	70%	70%	nd	70%	nd	nd	nd
Cutoff 5	2350	nd	2350	2350	nd	2350	nd	nd	nd
Sens 5	12%	nd	17%	12%	nd	17%	nd	nd	nd
Spec 5	80%	nd	80%	80%	nd	80%	nd	nd	nd
Cutoff 6	2830	nd	2880	2830	nd	2880	nd	nd	nd
Sens 6	12%	nd	0%	12%	nd	0%	nd	nd	nd
Spec 6	91%	nd	91%	91%	nd	91%	nd	nd	nd
OR Quart 2	3.1	nd	0.95	3.3	nd	0.95	nd	nd	nd
p Value	0.34	nd	0.97	0.32	nd	0.97	nd	nd	nd
95% CI of	0.30	nd	0.056	0.32	nd	0.056	nd	nd	nd
OR Quart2	33	nd	16	34	nd	16	nd	nd	nd
OR Quart 3	3.1	nd	3.3	2.1	nd	3.3	nd	nd	nd
p Value	0.34	nd	0.32	0.56	nd	0.32	nd	nd	nd
95% CI of	0.30	nd	0.32	0.18	nd	0.32	nd	nd	nd
OR Quart3	33	nd	35	25	nd	35	nd	nd	nd
OR Quart 4	0.96	nd	0.95	2.2	nd	0.95	nd	nd	nd
p Value	0.98	nd	0.97	0.53	nd	0.97	nd	nd	nd
95% CI of	0.056	nd	0.056	0.18	nd	0.056	nd	nd	nd
OR Quart4	16	nd	16	26	nd	16	nd	nd	nd

Tumor necrosis factor receptor superfamily member 8

sCr or UO	0hr prior to AKI stage		24hr prior to AKI stage		48hr prior to AKI stage	
	Cohort 1	Cohort 2	Cohort 1	Cohort 2	Cohort 1	Cohort 2
Median	104	107	104	107	104	93.1
Average	226	271	226	268	226	166
Stdev	549	403	549	404	549	192
p(t-test)		0.78		0.80		0.78
Min	26.3	50.0	26.3	50.0	26.3	50.0
Max	3360	1460	3360	1460	3360	595
n (Samp)	65	12	65	12	65	7
n (Patient)	65	12	65	12	65	7

sCr only	0hr prior to AKI stage		24hr prior to AKI stage		48hr prior to AKI stage	
	Cohort 1	Cohort 2	Cohort 1	Cohort 2	Cohort 1	Cohort 2
Median	117	100	117	94.1	nd	nd
Average	236	107	236	101	nd	nd
Stdev	507	26.7	507	33.0	nd	nd
p(t-test)		0.54		0.52	nd	nd

sCr only	0hr prior to AKI stage		24hr prior to AKI stage		48hr prior to AKI stage	
	Cohort 1	Cohort 2	Cohort 1	Cohort 2	Cohort 1	Cohort 2
Min	26.3	82.5	26.3	60.0	nd	nd
Max	3360	152	3360	152	nd	nd
n (Samp)	132	6	132	6	nd	nd
n (Patient)	132	6	132	6	nd	nd

UO only	0hr prior to AKI stage		24hr prior to AKI stage		48hr prior to AKI stage	
	Cohort 1	Cohort 2	Cohort 1	Cohort 2	Cohort 1	Cohort 2
Median	115	107	115	107	115	98.7
Average	260	350	260	350	260	180
Stdev	575	483	575	483	575	206
p(t-test)		0.67		0.67		0.74
Min	30.2	50.0	30.2	50.0	30.2	50.0
Max	3360	1460	3360	1460	3360	595
n (Samp)	64	8	64	8	64	6
n (Patient)	64	8	64	8	64	6

	0hr prior to AKI stage			24hr prior to AKI stage			48hr prior to AKI stage		
	sCr or UO	sCr only	UO only	sCr or UO	sCr only	UO only	sCr or UO	sCr only	UO only
AUC	0.56	0.42	0.56	0.54	0.38	0.56	0.48	nd	0.46
SE	0.093	0.12	0.11	0.093	0.12	0.11	0.12	nd	0.13
p	0.49	0.54	0.62	0.66	0.34	0.62	0.86	nd	0.78
nCohort 1	65	132	64	65	132	64	65	nd	64
nCohort 2	12	6	8	12	6	8	7	nd	6
Cutoff 1	89.9	83.2	89.9	83.2	75.6	89.9	83.2	nd	83.2
Sens 1	75%	83%	75%	75%	83%	75%	71%	nd	83%
Spec 1	40%	28%	34%	34%	27%	34%	34%	nd	28%
Cutoff 2	83.2	83.2	83.2	75.6	75.6	83.2	75.6	nd	83.2
Sens 2	83%	83%	88%	83%	83%	88%	86%	nd	83%
Spec 2	34%	28%	28%	32%	27%	28%	32%	nd	28%
Cutoff 3	75.6	75.6	43.9	56.2	56.6	43.9	47.2	nd	43.9
Sens 3	92%	100%	100%	92%	100%	100%	100%	nd	100%
Spec 3	32%	27%	9%	14%	11%	9%	12%	nd	9%
Cutoff 4	165	167	167	165	167	167	165	nd	167
Sens 4	25%	0%	38%	25%	0%	38%	14%	nd	17%
Spec 4	71%	70%	70%	71%	70%	70%	71%	nd	70%
Cutoff 5	205	217	217	205	217	217	205	nd	217
Sens 5	25%	0%	38%	25%	0%	38%	14%	nd	17%
Spec 5	82%	80%	81%	82%	80%	81%	82%	nd	81%
Cutoff 6	292	310	323	292	310	323	292	nd	323
Sens 6	25%	0%	25%	25%	0%	25%	14%	nd	17%
Spec 6	91%	90%	91%	91%	90%	91%	91%	nd	91%
OR Quart 2	4.8	>2.2	4.9	1.6	>2.2	4.9	2.1	nd	1.1
p Value	0.18	<0.53	0.18	0.63	<0.53	0.18	0.55	nd	0.97
95% CI of	0.48	>0.19	0.49	0.23	>0.19	0.49	0.18	nd	0.061
OR Quart2	48	na	49	11	na	49	26	nd	18
OR Quart 3	4.8	>4.5	0	2.3	>3.3	0	3.4	nd	3.4
p Value	0.18	<0.19	na	0.38	<0.31	na	0.31	nd	0.31

	0hr prior to AKI stage			24hr prior to AKI stage			48hr prior to AKI stage		
	sCr or UO	sCr only	UO only	sCr or UO	sCr only	UO only	sCr or UO	sCr only	UO only
95% CI of	0.48	>0.48	na	0.36	>0.32	na	0.32	nd	0.32
OR Quart3	48	na	na	14	na	na	36	nd	36
OR Quart 4	3.2	>0	3.4	1.5	>1.1	3.4	1.0	nd	1.1
p Value	0.34	<na	0.31	0.68	<0.97	0.31	1.0	nd	0.97
95% CI of	0.30	>na	0.32	0.22	>0.064	0.32	0.058	nd	0.061
OR Quart4	34	na	36	10	na	36	17	nd	18

Alpha-fetoprotein

sCr or UO	0hr prior to AKI stage		24hr prior to AKI stage		48hr prior to AKI stage	
	Cohort 1	Cohort 2	Cohort 1	Cohort 2	Cohort 1	Cohort 2
Median	0.381	0.719	0.381	0.719	nd	nd
Average	0.450	0.803	0.450	0.803	nd	nd
Stdev	0.361	0.466	0.361	0.466	nd	nd
p(t-test)		0.011		0.011	nd	nd
Min	0.00580	0.00880	0.00580	0.00880	nd	nd
Max	1.81	1.53	1.81	1.53	nd	nd
n (Samp)	87	8	87	8	nd	nd
n (Patient)	87	8	87	8	nd	nd

UO only	0hr prior to AKI stage		24hr prior to AKI stage		48hr prior to AKI stage	
	Cohort 1	Cohort 2	Cohort 1	Cohort 2	Cohort 1	Cohort 2
Median	0.382	0.719	0.382	0.719	nd	nd
Average	0.449	0.851	0.449	0.851	nd	nd
Stdev	0.372	0.351	0.372	0.351	nd	nd
p(t-test)		0.012		0.012	nd	nd
Min	0.00580	0.583	0.00580	0.583	nd	nd
Max	1.81	1.53	1.81	1.53	nd	nd
n (Samp)	80	6	80	6	nd	nd
n (Patient)	80	6	80	6	nd	nd

	0hr prior to AKI stage			24hr prior to AKI stage			48hr prior to AKI stage		
	sCr or UO	sCr only	UO only	sCr or UO	sCr only	UO only	sCr or UO	sCr only	UO only
AUC	0.76	nd	0.82	0.76	nd	0.82	nd	nd	nd
SE	0.10	nd	0.11	0.10	nd	0.11	nd	nd	nd
p	0.011	nd	0.0024	0.011	nd	0.0024	nd	nd	nd
nCohort 1	87	nd	80	87	nd	80	nd	nd	nd
nCohort 2	8	nd	6	8	nd	6	nd	nd	nd
Cutoff 1	0.620	nd	0.620	0.620	nd	0.620	nd	nd	nd
Sens 1	75%	nd	83%	75%	nd	83%	nd	nd	nd
Spec 1	78%	nd	76%	78%	nd	76%	nd	nd	nd
Cutoff 2	0.558	nd	0.620	0.558	nd	0.620	nd	nd	nd
Sens 2	88%	nd	83%	88%	nd	83%	nd	nd	nd
Spec 2	74%	nd	76%	74%	nd	76%	nd	nd	nd
Cutoff 3	0.00580	nd	0.558	0.00580	nd	0.558	nd	nd	nd
Sens 3	100%	nd	100%	100%	nd	100%	nd	nd	nd
Spec 3	2%	nd	71%	2%	nd	71%	nd	nd	nd
Cutoff 4	0.541	nd	0.558	0.541	nd	0.558	nd	nd	nd

	0hr prior to AKI stage			24hr prior to AKI stage			48hr prior to AKI stage		
	sCr or UO	sCr only	UO only	sCr or UO	sCr only	UO only	sCr or UO	sCr only	UO only
Sens 4	88%	nd	100%	88%	nd	100%	nd	nd	nd
Spec 4	70%	nd	71%	70%	nd	71%	nd	nd	nd
Cutoff 5	0.705	nd	0.741	0.705	nd	0.741	nd	nd	nd
Sens 5	50%	nd	33%	50%	nd	33%	nd	nd	nd
Spec 5	80%	nd	80%	80%	nd	80%	nd	nd	nd
Cutoff 6	0.891	nd	0.891	0.891	nd	0.891	nd	nd	nd
Sens 6	38%	nd	33%	38%	nd	33%	nd	nd	nd
Spec 6	91%	nd	90%	91%	nd	90%	nd	nd	nd
OR Quart 2	0	nd	>0	0	nd	>0	nd	nd	nd
p Value	na	nd	<na	na	nd	<na	nd	nd	nd
95% CI of	na	nd	>na	na	nd	>na	nd	nd	nd
OR Quart2	na	nd	na	na	nd	na	nd	nd	nd
OR Quart 3	2.0	nd	>2.2	2.0	nd	>2.2	nd	nd	nd
p Value	0.58	nd	<0.53	0.58	nd	<0.53	nd	nd	nd
95% CI of	0.17	nd	>0.19	0.17	nd	>0.19	nd	nd	nd
OR Quart3	24	nd	na	24	nd	na	nd	nd	nd
OR Quart 4	5.8	nd	>4.7	5.8	nd	>4.7	nd	nd	nd
p Value	0.12	nd	<0.19	0.12	nd	<0.19	nd	nd	nd
95% CI of	0.62	nd	>0.48	0.62	nd	>0.48	nd	nd	nd
OR Quart4	54	nd	na	54	nd	na	nd	nd	nd

Apolipoprotein E

sCr or UO	0hr prior to AKI stage		24hr prior to AKI stage		48hr prior to AKI stage	
	Cohort 1	Cohort 2	Cohort 1	Cohort 2	Cohort 1	Cohort 2
Median	55900	45300	55900	44900	55900	42800
Average	67400	45200	67400	44600	67400	40300
Stdev	48000	9980	48000	11000	48000	10100
p(t-test)		0.11		0.12		0.14
Min	8630	29200	8630	25800	8630	22400
Max	260000	59600	260000	59600	260000	52300
n (Samp)	111	12	111	11	111	7
n (Patient)	111	12	111	11	111	7

sCr only	0hr prior to AKI stage		24hr prior to AKI stage		48hr prior to AKI stage	
	Cohort 1	Cohort 2	Cohort 1	Cohort 2	Cohort 1	Cohort 2
Median	56700	46700	nd	nd	nd	nd
Average	69900	47000	nd	nd	nd	nd
Stdev	49700	10900	nd	nd	nd	nd
p(t-test)		0.26	nd	nd	nd	nd
Min	8630	29200	nd	nd	nd	nd
Max	260000	59600	nd	nd	nd	nd
n (Samp)	193	6	nd	nd	nd	nd
n (Patient)	193	6	nd	nd	nd	nd

UO only	0hr prior to AKI stage		24hr prior to AKI stage		48hr prior to AKI stage	
	Cohort 1	Cohort 2	Cohort 1	Cohort 2	Cohort 1	Cohort 2
Median	56300	43900	56300	42800	56300	42800

UO only	0hr prior to AKI stage		24hr prior to AKI stage		48hr prior to AKI stage	
	Cohort 1	Cohort 2	Cohort 1	Cohort 2	Cohort 1	Cohort 2
Average	67500	43800	67500	41100	67500	39400
Stdev	43600	8230	43600	10200	43600	10700
p(t-test)		0.13		0.091		0.12
Min	8630	31000	8630	25800	8630	22400
Max	218000	54900	218000	54900	218000	52300
n (Samp)	103	8	103	8	103	6
n (Patient)	103	8	103	8	103	6

	0hr prior to AKI stage			24hr prior to AKI stage			48hr prior to AKI stage		
	sCr or UO	sCr only	UO only	sCr or UO	sCr only	UO only	sCr or UO	sCr only	UO only
AUC	0.38	0.38	0.34	0.36	nd	0.30	0.32	nd	0.28
SE	0.090	0.12	0.11	0.094	nd	0.11	0.11	nd	0.12
p	0.17	0.34	0.14	0.15	nd	0.066	0.11	nd	0.074
nCohort 1	111	193	103	111	nd	103	111	nd	103
nCohort 2	12	6	8	11	nd	8	7	nd	6
Cutoff 1	41000	41900	41000	41000	nd	33100	41000	nd	30600
Sens 1	75%	83%	75%	73%	nd	75%	71%	nd	83%
Spec 1	34%	32%	33%	34%	nd	22%	34%	nd	17%
Cutoff 2	33100	41900	33100	33100	nd	30600	30600	nd	30600
Sens 2	83%	83%	88%	82%	nd	88%	86%	nd	83%
Spec 2	23%	32%	22%	23%	nd	17%	19%	nd	17%
Cutoff 3	30600	28800	30600	30600	nd	25400	19800	nd	19800
Sens 3	92%	100%	100%	91%	nd	100%	100%	nd	100%
Spec 3	19%	17%	17%	19%	nd	11%	7%	nd	8%
Cutoff 4	76700	79500	79500	76700	nd	79500	76700	nd	79500
Sens 4	0%	0%	0%	0%	nd	0%	0%	nd	0%
Spec 4	71%	70%	72%	71%	nd	72%	71%	nd	72%
Cutoff 5	89800	93400	94900	89800	nd	94900	89800	nd	94900
Sens 5	0%	0%	0%	0%	nd	0%	0%	nd	0%
Spec 5	80%	80%	81%	80%	nd	81%	80%	nd	81%
Cutoff 6	131000	139000	120000	131000	nd	120000	131000	nd	120000
Sens 6	0%	0%	0%	0%	nd	0%	0%	nd	0%
Spec 6	90%	90%	90%	90%	nd	90%	90%	nd	90%
OR Quart 2	>3.3	>2.1	>1.0	>3.4	nd	>1.0	>0	nd	>0
p Value	<0.31	<0.55	<0.98	<0.30	nd	<0.98	<na	nd	<na
95% CI of	>0.33	>0.18	>0.062	>0.34	nd	>0.062	>na	nd	>na
OR Quart2	na	na	na	na	nd	na	na	nd	na
OR Quart 3	>7.4	>3.2	>6.1	>6.0	nd	>4.7	>6.0	nd	>4.9
p Value	<0.071	<0.32	<0.11	<0.11	nd	<0.18	<0.11	nd	<0.17
95% CI of	>0.84	>0.32	>0.66	>0.65	nd	>0.49	>0.66	nd	>0.51
OR Quart3	na	na	na	na	nd	na	na	nd	na
OR Quart 4	>3.4	>1.0	>2.2	>3.4	nd	>3.5	>2.2	nd	>2.2
p Value	<0.30	<0.98	<0.52	<0.30	nd	<0.29	<0.52	nd	<0.52
95% CI of	>0.34	>0.063	>0.19	>0.34	nd	>0.34	>0.19	nd	>0.19
OR Quart4	na	na	na	na	nd	na	na	nd	na

Apolipoprotein(a)

sCr or UO	0hr prior to AKI stage		24hr prior to AKI stage		48hr prior to AKI stage	
	Cohort 1	Cohort 2	Cohort 1	Cohort 2	Cohort 1	Cohort 2
Median	51300	43600	51300	44500	51300	94400
Average	81000	62200	81000	65900	81000	78300
Stdev	104000	61300	104000	62900	104000	47500
p(t-test)		0.54		0.64		0.95
Min	7.99	968	7.99	968	7.99	2260
Max	631000	200000	631000	200000	631000	125000
n (Samp)	111	12	111	11	111	7
n (Patient)	111	12	111	11	111	7

sCr only	0hr prior to AKI stage		24hr prior to AKI stage		48hr prior to AKI stage	
	Cohort 1	Cohort 2	Cohort 1	Cohort 2	Cohort 1	Cohort 2
Median	47400	43600	nd	nd	nd	nd
Average	84900	45900	nd	nd	nd	nd
Stdev	109000	33900	nd	nd	nd	nd
p(t-test)		0.38	nd	nd	nd	nd
Min	7.99	968	nd	nd	nd	nd
Max	631000	94400	nd	nd	nd	nd
n (Samp)	193	6	nd	nd	nd	nd
n (Patient)	193	6	nd	nd	nd	nd

UO only	0hr prior to AKI stage		24hr prior to AKI stage		48hr prior to AKI stage	
	Cohort 1	Cohort 2	Cohort 1	Cohort 2	Cohort 1	Cohort 2
Median	54000	68600	54000	68600	54000	104000
Average	81600	76000	81600	75900	81600	79300
Stdev	103000	69600	103000	69700	103000	52000
p(t-test)		0.88		0.88		0.96
Min	7.99	2260	7.99	2260	7.99	2260
Max	631000	200000	631000	200000	631000	125000
n (Samp)	103	8	103	8	103	6
n (Patient)	103	8	103	8	103	6

	0hr prior to AKI stage			24hr prior to AKI stage			48hr prior to AKI stage		
	sCr or UO	sCr only	UO only	sCr or UO	sCr only	UO only	sCr or UO	sCr only	UO only
AUC	0.47	0.45	0.52	0.49	nd	0.51	0.60	nd	0.59
SE	0.089	0.12	0.11	0.092	nd	0.11	0.12	nd	0.13
p	0.76	0.68	0.88	0.88	nd	0.89	0.38	nd	0.49
nCohort 1	111	193	103	111	nd	103	111	nd	103
nCohort 2	12	6	8	11	nd	8	7	nd	6
Cutoff 1	18200	18800	26200	25100	nd	25100	69900	nd	25100
Sens 1	75%	83%	75%	73%	nd	75%	71%	nd	83%
Spec 1	31%	33%	37%	37%	nd	36%	66%	nd	36%
Cutoff 2	2260	18800	2260	2260	nd	2260	25100	nd	25100
Sens 2	83%	83%	88%	82%	nd	88%	86%	nd	83%
Spec 2	7%	33%	5%	7%	nd	5%	37%	nd	36%
Cutoff 3	1680	814	1680	1680	nd	1680	1680	nd	1680
Sens 3	92%	100%	100%	91%	nd	100%	100%	nd	100%
Spec 3	7%	3%	5%	7%	nd	5%	7%	nd	5%

	0hr prior to AKI stage			24hr prior to AKI stage			48hr prior to AKI stage		
	sCr or UO	sCr only	UO only	sCr or UO	sCr only	UO only	sCr or UO	sCr only	UO only
Cutoff 4	80900	85400	85400	80900	nd	85400	80900	nd	85400
Sens 4	33%	17%	50%	36%	nd	50%	57%	nd	67%
Spec 4	70%	70%	71%	70%	nd	71%	70%	nd	71%
Cutoff 5	128000	129000	128000	128000	nd	128000	128000	nd	128000
Sens 5	8%	0%	12%	9%	nd	12%	0%	nd	0%
Spec 5	80%	80%	81%	80%	nd	81%	80%	nd	81%
Cutoff 6	210000	221000	198000	210000	nd	198000	210000	nd	198000
Sens 6	0%	0%	12%	0%	nd	12%	0%	nd	0%
Spec 6	90%	90%	90%	90%	nd	90%	90%	nd	90%
OR Quart 2	0.64	>2.1	0.96	0.67	nd	0.96	0.97	nd	1.0
p Value	0.64	<0.55	0.97	0.67	nd	0.97	0.98	nd	1.0
95% CI of	0.100	>0.18	0.13	0.10	nd	0.13	0.058	nd	0.059
OR Quart2	4.1	na	7.4	4.3	nd	7.4	16	nd	17
OR Quart 3	1.4	>3.2	0.46	1.0	nd	0.46	2.1	nd	1.0
p Value	0.69	<0.32	0.54	1.0	nd	0.54	0.56	nd	1.0
95% CI of	0.28	>0.32	0.039	0.19	nd	0.039	0.18	nd	0.059
OR Quart3	6.8	na	5.4	5.4	nd	5.4	24	nd	17
OR Quart 4	1.0	>1.0	1.5	1.0	nd	1.5	3.1	nd	3.1
p Value	0.97	<0.98	0.67	0.97	nd	0.67	0.34	nd	0.34
95% CI of	0.19	>0.063	0.23	0.19	nd	0.23	0.30	nd	0.30
OR Quart4	5.6	na	9.8	5.6	nd	9.8	32	nd	32

[0190] Fig. 9: Comparison of marker levels in urine samples collected from Cohort 1 (patients that did not progress beyond RIFLE stage 0, R, or I) and in urine samples collected from Cohort 2 (subjects who progress to RIFLE stage F) at 0, 24 hours, and 48 hours prior to the subject reaching RIFLE stage I.

C-C motif chemokine 7

sCr or UO	0hr prior to AKI stage		24hr prior to AKI stage		48hr prior to AKI stage	
	Cohort 1	Cohort 2	Cohort 1	Cohort 2	Cohort 1	Cohort 2
Median	0.584	1.22	0.584	0.618	0.584	0.623
Average	1.77	17.2	1.77	4.33	1.77	8.93
Stdev	8.21	24.8	8.21	11.0	8.21	14.1
p(t-test)		5.0E-16		0.17		0.0064
Min	0.146	0.188	0.146	0.319	0.146	0.319
Max	163	82.4	163	45.7	163	33.9
n (Samp)	1277	22	1277	20	1277	10
n (Patient)	452	22	452	20	452	10

sCr only	0hr prior to AKI stage		24hr prior to AKI stage		48hr prior to AKI stage	
	Cohort 1	Cohort 2	Cohort 1	Cohort 2	Cohort 1	Cohort 2
Median	0.584	1.22	nd	nd	nd	nd
Average	2.34	15.5	nd	nd	nd	nd
Stdev	12.1	24.5	nd	nd	nd	nd
p(t-test)		0.0024	nd	nd	nd	nd
Min	0.146	0.188	nd	nd	nd	nd

sCr only	0hr prior to AKI stage		24hr prior to AKI stage		48hr prior to AKI stage	
	Cohort 1	Cohort 2	Cohort 1	Cohort 2	Cohort 1	Cohort 2
Max	291	69.7	nd	nd	nd	nd
n (Samp)	1341	8	nd	nd	nd	nd
n (Patient)	467	8	nd	nd	nd	nd

UO only	0hr prior to AKI stage		24hr prior to AKI stage		48hr prior to AKI stage	
	Cohort 1	Cohort 2	Cohort 1	Cohort 2	Cohort 1	Cohort 2
Median	0.584	11.6	0.584	0.625	0.584	0.584
Average	1.81	30.2	1.81	11.2	1.81	5.17
Stdev	8.60	45.3	8.60	27.6	8.60	12.3
p(t-test)		1.1E-25		1.2E-5		0.30
Min	0.146	0.515	0.146	0.319	0.146	0.341
Max	163	166	163	114	163	33.0
n (Samp)	1124	14	1124	19	1124	7
n (Patient)	362	14	362	19	362	7

	0hr prior to AKI stage			24hr prior to AKI stage			48hr prior to AKI stage		
	sCr or UO	sCr only	UO only	sCr or UO	sCr only	UO only	sCr or UO	sCr only	UO only
AUC	0.75	0.70	0.78	0.54	nd	0.54	0.60	nd	0.53
SE	0.061	0.10	0.074	0.067	nd	0.068	0.095	nd	0.11
p	3.5E-5	0.054	1.6E-4	0.53	nd	0.58	0.28	nd	0.76
nCohort 1	1277	1341	1124	1277	nd	1124	1277	nd	1124
nCohort 2	22	8	14	20	nd	19	10	nd	7
Cutoff 1	0.584	0.582	0.612	0.336	nd	0.319	0.451	nd	0.451
Sens 1	77%	75%	86%	70%	nd	89%	70%	nd	71%
Spec 1	52%	48%	51%	34%	nd	25%	43%	nd	41%
Cutoff 2	0.582	0.386	0.612	0.319	nd	0.319	0.336	nd	0.336
Sens 2	86%	88%	86%	90%	nd	89%	90%	nd	100%
Spec 2	49%	38%	51%	26%	nd	25%	34%	nd	33%
Cutoff 3	0.512	0.146	0.582	0.319	nd	0.301	0.336	nd	0.336
Sens 3	91%	100%	93%	90%	nd	100%	90%	nd	100%
Spec 3	44%	4%	47%	26%	nd	17%	34%	nd	33%
Cutoff 4	1.04	1.04	1.04	1.04	nd	1.04	1.04	nd	1.04
Sens 4	59%	62%	57%	20%	nd	21%	30%	nd	14%
Spec 4	73%	72%	71%	73%	nd	71%	73%	nd	71%
Cutoff 5	1.12	1.12	1.12	1.12	nd	1.12	1.12	nd	1.12
Sens 5	59%	62%	57%	20%	nd	21%	30%	nd	14%
Spec 5	81%	81%	80%	81%	nd	80%	81%	nd	80%
Cutoff 6	1.59	1.59	1.59	1.59	nd	1.59	1.59	nd	1.59
Sens 6	41%	38%	50%	15%	nd	21%	30%	nd	14%
Spec 6	94%	93%	94%	94%	nd	94%	94%	nd	94%
OR Quart 2	4.0	2.0	>1.0	3.6	nd	1.2	3.0	nd	>4.0
p Value	0.21	0.57	<1.0	0.12	nd	0.74	0.34	nd	<0.21
95% CI of	0.45	0.18	>0.062	0.73	nd	0.33	0.31	nd	>0.45
OR Quart2	36	22	na	17	nd	4.7	29	nd	na
OR Quart 3	4.0	0	>5.1	3.6	nd	1.5	3.0	nd	>2.0
p Value	0.21	na	<0.14	0.12	nd	0.53	0.34	nd	<0.57
95% CI of	0.45	na	>0.59	0.73	nd	0.42	0.31	nd	>0.18

	0hr prior to AKI stage			24hr prior to AKI stage			48hr prior to AKI stage		
	sCr or UO	sCr only	UO only	sCr or UO	sCr only	UO only	sCr or UO	sCr only	UO only
OR Quart3	36	na	na	17	nd	5.4	29	nd	na
OR Quart 4	13	5.0	>8.2	2.0	nd	1.00	3.0	nd	>1.0
p Value	0.012	0.14	<0.048	0.42	nd	1.00	0.34	nd	<1.0
95% CI of	1.8	0.59	>1.0	0.36	nd	0.25	0.31	nd	>0.062
OR Quart4	100	43	na	11	nd	4.0	29	nd	na

Vascular endothelial growth factor receptor 3

sCr or UO	0hr prior to AKI stage		24hr prior to AKI stage		48hr prior to AKI stage	
	Cohort 1	Cohort 2	Cohort 1	Cohort 2	Cohort 1	Cohort 2
Median	317	401	317	318	317	247
Average	334	402	334	351	334	350
Stdev	240	181	240	211	240	334
p(t-test)		0.29		0.79		0.87
Min	1.37	81.1	1.37	1.37	1.37	3.04
Max	2750	711	2750	798	2750	913
n (Samp)	655	14	655	15	655	7
n (Patient)	299	14	299	15	299	7

UO only	0hr prior to AKI stage		24hr prior to AKI stage		48hr prior to AKI stage	
	Cohort 1	Cohort 2	Cohort 1	Cohort 2	Cohort 1	Cohort 2
Median	318	521	318	328	nd	nd
Average	341	475	341	359	nd	nd
Stdev	245	178	245	237	nd	nd
p(t-test)		0.10		0.81	nd	nd
Min	1.37	166	1.37	1.37	nd	nd
Max	2750	711	2750	798	nd	nd
n (Samp)	597	9	597	12	nd	nd
n (Patient)	262	9	262	12	nd	nd

	0hr prior to AKI stage			24hr prior to AKI stage			48hr prior to AKI stage		
	sCr or UO	sCr only	UO only	sCr or UO	sCr only	UO only	sCr or UO	sCr only	UO only
AUC	0.63	nd	0.73	0.55	nd	0.55	0.46	nd	nd
SE	0.081	nd	0.096	0.077	nd	0.086	0.11	nd	nd
p	0.11	nd	0.016	0.54	nd	0.58	0.73	nd	nd
nCohort 1	655	nd	597	655	nd	597	655	nd	nd
nCohort 2	14	nd	9	15	nd	12	7	nd	nd
Cutoff 1	315	nd	364	273	nd	273	163	nd	nd
Sens 1	71%	nd	78%	73%	nd	75%	71%	nd	nd
Spec 1	50%	nd	62%	43%	nd	41%	19%	nd	nd
Cutoff 2	247	nd	249	264	nd	171	74.3	nd	nd
Sens 2	86%	nd	89%	80%	nd	83%	86%	nd	nd
Spec 2	35%	nd	36%	40%	nd	20%	9%	nd	nd
Cutoff 3	164	nd	164	0	nd	0	2.36	nd	nd
Sens 3	93%	nd	100%	100%	nd	100%	100%	nd	nd
Spec 3	20%	nd	19%	0%	nd	0%	4%	nd	nd
Cutoff 4	414	nd	414	414	nd	414	414	nd	nd
Sens 4	36%	nd	67%	33%	nd	42%	29%	nd	nd

	0hr prior to AKI stage			24hr prior to AKI stage			48hr prior to AKI stage		
	sCr or UO	sCr only	UO only	sCr or UO	sCr only	UO only	sCr or UO	sCr only	UO only
Spec 4	72%	nd	72%	72%	nd	72%	72%	nd	nd
Cutoff 5	452	nd	455	452	nd	455	452	nd	nd
Sens 5	36%	nd	67%	33%	nd	42%	29%	nd	nd
Spec 5	80%	nd	80%	80%	nd	80%	80%	nd	nd
Cutoff 6	542	nd	542	542	nd	542	542	nd	nd
Sens 6	29%	nd	44%	13%	nd	17%	29%	nd	nd
Spec 6	90%	nd	90%	90%	nd	90%	90%	nd	nd
OR Quart 2	1.5	nd	0.99	1.3	nd	0.66	0.50	nd	nd
p Value	0.65	nd	1.00	0.71	nd	0.65	0.57	nd	nd
95% CI of	0.25	nd	0.062	0.29	nd	0.11	0.045	nd	nd
OR Quart2	9.2	nd	16	6.1	nd	4.0	5.6	nd	nd
OR Quart 3	2.0	nd	1.0	1.0	nd	0.66	0.50	nd	nd
p Value	0.42	nd	1.0	1.0	nd	0.65	0.57	nd	nd
95% CI of	0.37	nd	0.062	0.20	nd	0.11	0.045	nd	nd
OR Quart3	11	nd	16	5.0	nd	4.0	5.5	nd	nd
OR Quart 4	2.5	nd	6.2	1.7	nd	1.7	1.5	nd	nd
p Value	0.27	nd	0.094	0.48	nd	0.48	0.65	nd	nd
95% CI of	0.48	nd	0.73	0.39	nd	0.39	0.25	nd	nd
OR Quart4	13	nd	52	7.1	nd	7.1	9.2	nd	nd

Interferon alpha-2

sCr or UO	0hr prior to AKI stage		24hr prior to AKI stage		48hr prior to AKI stage	
	Cohort 1	Cohort 2	Cohort 1	Cohort 2	Cohort 1	Cohort 2
Median	0.0967	0.0970	0.0967	0.0974	0.0967	1.20
Average	7.83	6.68	7.83	2.57	7.83	8.13
Stdev	18.2	10.4	18.2	6.54	18.2	13.0
p(t-test)		0.77		0.20		0.96
Min	0.0238	0.0348	0.0238	0.0348	0.0238	0.0418
Max	126	31.4	126	24.7	126	34.2
n (Samp)	1277	22	1277	20	1277	10
n (Patient)	452	22	452	20	452	10

sCr only	0hr prior to AKI stage		24hr prior to AKI stage		48hr prior to AKI stage	
	Cohort 1	Cohort 2	Cohort 1	Cohort 2	Cohort 1	Cohort 2
Median	0.0967	1.14	nd	nd	nd	nd
Average	7.67	5.56	nd	nd	nd	nd
Stdev	17.9	8.77	nd	nd	nd	nd
p(t-test)		0.74	nd	nd	nd	nd
Min	0.0238	0.0656	nd	nd	nd	nd
Max	126	24.9	nd	nd	nd	nd
n (Samp)	1341	8	nd	nd	nd	nd
n (Patient)	467	8	nd	nd	nd	nd

UO only	0hr prior to AKI stage		24hr prior to AKI stage		48hr prior to AKI stage	
	Cohort 1	Cohort 2	Cohort 1	Cohort 2	Cohort 1	Cohort 2
Median	0.0967	0.0739	0.0967	0.0974	0.0967	2.39
Average	7.65	7.02	7.65	3.41	7.65	11.5

UO only	0hr prior to AKI stage		24hr prior to AKI stage		48hr prior to AKI stage	
	Cohort 1	Cohort 2	Cohort 1	Cohort 2	Cohort 1	Cohort 2
Stdev	17.8	11.6	17.8	7.11	17.8	14.5
p(t-test)		0.89		0.30		0.57
Min	0.0238	0.0348	0.0238	0.0348	0.0238	0.104
Max	126	31.4	126	24.7	126	34.2
n (Samp)	1124	14	1124	19	1124	7
n (Patient)	362	14	362	19	362	7

	0hr prior to AKI stage			24hr prior to AKI stage			48hr prior to AKI stage		
	sCr or UO	sCr only	UO only	sCr or UO	sCr only	UO only	sCr or UO	sCr only	UO only
AUC	0.56	0.58	0.49	0.50	nd	0.49	0.69	nd	0.76
SE	0.064	0.11	0.078	0.065	nd	0.067	0.094	nd	0.11
p	0.34	0.48	0.94	0.94	nd	0.89	0.045	nd	0.017
nCohort 1	1277	1341	1124	1277	nd	1124	1277	nd	1124
nCohort 2	22	8	14	20	nd	19	10	nd	7
Cutoff 1	0.0722	0.0672	0.0656	0.0802	nd	0.0722	0.114	nd	1.81
Sens 1	73%	75%	79%	70%	nd	74%	70%	nd	71%
Spec 1	37%	33%	29%	49%	nd	36%	65%	nd	75%
Cutoff 2	0.0656	0.0656	0.0435	0.0722	nd	0.0398	0.0974	nd	0.0974
Sens 2	91%	88%	86%	80%	nd	89%	90%	nd	100%
Spec 2	30%	30%	18%	37%	nd	14%	57%	nd	56%
Cutoff 3	0.0656	0.0606	0.0238	0.0398	nd	0.0369	0.0974	nd	0.0974
Sens 3	91%	100%	100%	90%	nd	95%	90%	nd	100%
Spec 3	30%	26%	3%	15%	nd	11%	57%	nd	56%
Cutoff 4	0.311	0.191	0.311	0.311	nd	0.311	0.311	nd	0.311
Sens 4	41%	50%	36%	15%	nd	21%	60%	nd	71%
Spec 4	74%	70%	74%	74%	nd	74%	74%	nd	74%
Cutoff 5	10.8	10.4	10.9	10.8	nd	10.9	10.8	nd	10.9
Sens 5	27%	25%	29%	10%	nd	16%	30%	nd	43%
Spec 5	80%	80%	80%	80%	nd	80%	80%	nd	80%
Cutoff 6	30.7	30.0	29.7	30.7	nd	29.7	30.7	nd	29.7
Sens 6	5%	0%	7%	0%	nd	0%	10%	nd	14%
Spec 6	90%	90%	90%	90%	nd	90%	90%	nd	90%
OR Quart 2	4.1	>4.0	0.50	0.75	nd	1.8	0	nd	>0
p Value	0.078	<0.21	0.42	0.70	nd	0.37	na	nd	<na
95% CI of	0.86	>0.45	0.091	0.17	nd	0.51	na	nd	>na
OR Quart2	19	na	2.7	3.4	nd	6.1	na	nd	na
OR Quart 3	1.5	>0	1.3	2.5	nd	1.0	5.0	nd	>3.0
p Value	0.66	<na	0.74	0.12	nd	1.0	0.14	nd	<0.34
95% CI of	0.25	>na	0.33	0.79	nd	0.25	0.59	nd	>0.31
OR Quart3	9.0	na	4.7	8.2	nd	4.0	43	nd	na
OR Quart 4	4.6	>4.0	0.75	0.75	nd	1.0	4.0	nd	>4.0
p Value	0.053	<0.21	0.71	0.70	nd	1.00	0.21	nd	<0.21
95% CI of	0.98	>0.45	0.17	0.17	nd	0.25	0.45	nd	>0.45
OR Quart4	21	na	3.4	3.4	nd	4.1	36	nd	na

Insulin-like growth factor-binding protein 4

sCr or UO	0hr prior to AKI stage	24hr prior to AKI stage	48hr prior to AKI stage

	Cohort 1	Cohort 2	Cohort 1	Cohort 2	Cohort 1	Cohort 2
Median	0.733	0.968	0.733	2.01	nd	nd
Average	1.72	1.38	1.72	4.03	nd	nd
Stdev	6.16	1.15	6.16	3.96	nd	nd
p(t-test)		0.88		0.22	nd	nd
Min	0.0319	0.0558	0.0319	0.0612	nd	nd
Max	85.6	2.84	85.6	11.4	nd	nd
n (Samp)	438	8	438	11	nd	nd
n (Patient)	226	8	226	11	nd	nd

UO only	0hr prior to AKI stage		24hr prior to AKI stage		48hr prior to AKI stage	
	Cohort 1	Cohort 2	Cohort 1	Cohort 2	Cohort 1	Cohort 2
Median	nd	nd	0.733	3.77	nd	nd
Average	nd	nd	1.77	4.23	nd	nd
Stdev	nd	nd	6.43	3.74	nd	nd
p(t-test)	nd	nd		0.28	nd	nd
Min	nd	nd	0.0319	0.870	nd	nd
Max	nd	nd	85.6	11.4	nd	nd
n (Samp)	nd	nd	399	8	nd	nd
n (Patient)	nd	nd	196	8	nd	nd

	0hr prior to AKI stage			24hr prior to AKI stage			48hr prior to AKI stage		
	sCr or UO	sCr only	UO only	sCr or UO	sCr only	UO only	sCr or UO	sCr only	UO only
AUC	0.64	nd	nd	0.75	nd	0.82	nd	nd	nd
SE	0.11	nd	nd	0.086	nd	0.092	nd	nd	nd
p	0.18	nd	nd	0.0036	nd	4.8E-4	nd	nd	nd
nCohort 1	438	nd	nd	438	nd	399	nd	nd	nd
nCohort 2	8	nd	nd	11	nd	8	nd	nd	nd
Cutoff 1	0.918	nd	nd	0.918	nd	0.870	nd	nd	nd
Sens 1	75%	nd	nd	73%	nd	88%	nd	nd	nd
Spec 1	57%	nd	nd	57%	nd	58%	nd	nd	nd
Cutoff 2	0.0585	nd	nd	0.845	nd	0.870	nd	nd	nd
Sens 2	88%	nd	nd	82%	nd	88%	nd	nd	nd
Spec 2	18%	nd	nd	56%	nd	58%	nd	nd	nd
Cutoff 3	0.0439	nd	nd	0.670	nd	0.845	nd	nd	nd
Sens 3	100%	nd	nd	91%	nd	100%	nd	nd	nd
Spec 3	12%	nd	nd	47%	nd	58%	nd	nd	nd
Cutoff 4	0.957	nd	nd	0.957	nd	0.957	nd	nd	nd
Sens 4	50%	nd	nd	55%	nd	62%	nd	nd	nd
Spec 4	75%	nd	nd	75%	nd	75%	nd	nd	nd
Cutoff 5	1.46	nd	nd	1.46	nd	1.46	nd	nd	nd
Sens 5	38%	nd	nd	55%	nd	62%	nd	nd	nd
Spec 5	80%	nd	nd	80%	nd	80%	nd	nd	nd
Cutoff 6	3.30	nd	nd	3.30	nd	3.30	nd	nd	nd
Sens 6	0%	nd	nd	45%	nd	50%	nd	nd	nd
Spec 6	90%	nd	nd	90%	nd	90%	nd	nd	nd
OR Quart 2	0	nd	nd	>1.0	nd	>0	nd	nd	nd
p Value	na	nd	nd	<0.99	nd	<na	nd	nd	nd
95% CI of	na	nd	nd	>0.062	nd	>na	nd	nd	nd

	0hr prior to AKI stage			24hr prior to AKI stage			48hr prior to AKI stage		
	sCr or UO	sCr only	UO only	sCr or UO	sCr only	UO only	sCr or UO	sCr only	UO only
OR Quart2	na	nd	nd	na	nd	na	nd	nd	nd
OR Quart 3	1.0	nd	nd	>4.1	nd	>3.1	nd	nd	nd
p Value	1.0	nd	nd	<0.21	nd	<0.34	nd	nd	nd
95% CI of	0.14	nd	nd	>0.46	nd	>0.31	nd	nd	nd
OR Quart3	7.2	nd	nd	na	nd	na	nd	nd	nd
OR Quart 4	2.0	nd	nd	>6.3	nd	>5.2	nd	nd	nd
p Value	0.42	nd	nd	<0.091	nd	<0.14	nd	nd	nd
95% CI of	0.36	nd	nd	>0.74	nd	>0.60	nd	nd	nd
OR Quart4	11	nd	nd	na	nd	na	nd	nd	nd

Insulin-like growth factor-binding protein 5

sCr or UO	0hr prior to AKI stage		24hr prior to AKI stage		48hr prior to AKI stage	
	Cohort 1	Cohort 2	Cohort 1	Cohort 2	Cohort 1	Cohort 2
Median	0.0682	0.811	0.0682	0.0682	nd	nd
Average	0.658	1.44	0.658	1.33	nd	nd
Stdev	1.43	1.85	1.43	1.59	nd	nd
p(t-test)		0.13		0.12	nd	nd
Min	0.0116	0.0210	0.0116	0.0210	nd	nd
Max	10.3	5.59	10.3	3.92	nd	nd
n (Samp)	439	8	439	11	nd	nd
n (Patient)	227	8	227	11	nd	nd

UO only	0hr prior to AKI stage		24hr prior to AKI stage		48hr prior to AKI stage	
	Cohort 1	Cohort 2	Cohort 1	Cohort 2	Cohort 1	Cohort 2
Median	nd	nd	0.0682	0.808	nd	nd
Average	nd	nd	0.652	1.45	nd	nd
Stdev	nd	nd	1.46	1.66	nd	nd
p(t-test)	nd	nd		0.13	nd	nd
Min	nd	nd	0.0116	0.0210	nd	nd
Max	nd	nd	10.3	3.92	nd	nd
n (Samp)	nd	nd	400	8	nd	nd
n (Patient)	nd	nd	197	8	nd	nd

	0hr prior to AKI stage			24hr prior to AKI stage			48hr prior to AKI stage		
	sCr or UO	sCr only	UO only	sCr or UO	sCr only	UO only	sCr or UO	sCr only	UO only
AUC	0.72	nd	nd	0.57	nd	0.57	nd	nd	nd
SE	0.10	nd	nd	0.091	nd	0.11	nd	nd	nd
p	0.038	nd	nd	0.43	nd	0.50	nd	nd	nd
nCohort 1	439	nd	nd	439	nd	400	nd	nd	nd
nCohort 2	8	nd	nd	11	nd	8	nd	nd	nd
Cutoff 1	0.369	nd	nd	0.0262	nd	0.0116	nd	nd	nd
Sens 1	75%	nd	nd	73%	nd	100%	nd	nd	nd
Spec 1	67%	nd	nd	23%	nd	14%	nd	nd	nd
Cutoff 2	0.0544	nd	nd	0.0116	nd	0.0116	nd	nd	nd
Sens 2	88%	nd	nd	100%	nd	100%	nd	nd	nd
Spec 2	46%	nd	nd	13%	nd	14%	nd	nd	nd
Cutoff 3	0.0116	nd	nd	0.0116	nd	0.0116	nd	nd	nd

	0hr prior to AKI stage			24hr prior to AKI stage			48hr prior to AKI stage		
	sCr or UO	sCr only	UO only	sCr or UO	sCr only	UO only	sCr or UO	sCr only	UO only
Sens 3	100%	nd	nd	100%	nd	100%	nd	nd	nd
Spec 3	13%	nd	nd	13%	nd	14%	nd	nd	nd
Cutoff 4	0.397	nd	nd	0.397	nd	0.397	nd	nd	nd
Sens 4	50%	nd	nd	45%	nd	50%	nd	nd	nd
Spec 4	77%	nd	nd	77%	nd	78%	nd	nd	nd
Cutoff 5	0.762	nd	nd	0.762	nd	0.558	nd	nd	nd
Sens 5	50%	nd	nd	45%	nd	50%	nd	nd	nd
Spec 5	80%	nd	nd	80%	nd	80%	nd	nd	nd
Cutoff 6	2.38	nd	nd	2.38	nd	2.38	nd	nd	nd
Sens 6	12%	nd	nd	36%	nd	38%	nd	nd	nd
Spec 6	90%	nd	nd	90%	nd	90%	nd	nd	nd
OR Quart 2	0	nd	nd	0.65	nd	0.33	nd	nd	nd
p Value	na	nd	nd	0.65	nd	0.34	nd	nd	nd
95% CI of	na	nd	nd	0.11	nd	0.033	nd	nd	nd
OR Quart2	na	nd	nd	4.0	nd	3.2	nd	nd	nd
OR Quart 3	3.0	nd	nd	0.33	nd	0	nd	nd	nd
p Value	0.34	nd	nd	0.34	nd	na	nd	nd	nd
95% CI of	0.31	nd	nd	0.034	nd	na	nd	nd	nd
OR Quart3	30	nd	nd	3.2	nd	na	nd	nd	nd
OR Quart 4	4.1	nd	nd	1.7	nd	1.3	nd	nd	nd
p Value	0.21	nd	nd	0.48	nd	0.70	nd	nd	nd
95% CI of	0.45	nd	nd	0.39	nd	0.29	nd	nd	nd
OR Quart4	37	nd	nd	7.2	nd	6.2	nd	nd	nd

Interleukin-33

sCr or UO	0hr prior to AKI stage		24hr prior to AKI stage		48hr prior to AKI stage	
	Cohort 1	Cohort 2	Cohort 1	Cohort 2	Cohort 1	Cohort 2
Median	40.9	22.9	40.9	35.9	40.9	21.0
Average	56.0	37.6	56.0	37.0	56.0	34.9
Stdev	60.8	43.3	60.8	24.9	60.8	42.2
p(t-test)		0.16		0.16		0.27
Min	0.0232	0.0523	0.0232	0.0232	0.0232	0.0688
Max	958	170	958	84.1	958	136
n (Samp)	1275	22	1275	20	1275	10
n (Patient)	452	22	452	20	452	10

sCr only	0hr prior to AKI stage		24hr prior to AKI stage		48hr prior to AKI stage	
	Cohort 1	Cohort 2	Cohort 1	Cohort 2	Cohort 1	Cohort 2
Median	40.2	28.8	nd	nd	nd	nd
Average	55.1	51.4	nd	nd	nd	nd
Stdev	59.8	57.8	nd	nd	nd	nd
p(t-test)		0.86	nd	nd	nd	nd
Min	0.0232	1.78	nd	nd	nd	nd
Max	958	170	nd	nd	nd	nd
n (Samp)	1339	8	nd	nd	nd	nd
n (Patient)	467	8	nd	nd	nd	nd

UO only	0hr prior to AKI stage		24hr prior to AKI stage		48hr prior to AKI stage	
	Cohort 1	Cohort 2	Cohort 1	Cohort 2	Cohort 1	Cohort 2
Median	41.0	19.8	41.0	27.1	41.0	41.9
Average	56.3	30.4	56.3	32.8	56.3	42.8
Stdev	62.1	31.4	62.1	27.2	62.1	49.0
p(t-test)		0.12		0.10		0.57
Min	0.0232	0.0436	0.0232	0.0232	0.0232	0.0688
Max	958	105	958	84.1	958	136
n (Samp)	1122	14	1122	19	1122	7
n (Patient)	362	14	362	19	362	7

	0hr prior to AKI stage			24hr prior to AKI stage			48hr prior to AKI stage		
	sCr or UO	sCr only	UO only	sCr or UO	sCr only	UO only	sCr or UO	sCr only	UO only
AUC	0.40	0.48	0.36	0.43	nd	0.39	0.39	nd	0.43
SE	0.064	0.10	0.080	0.067	nd	0.069	0.095	nd	0.11
p	0.13	0.84	0.080	0.33	nd	0.12	0.23	nd	0.52
nCohort 1	1275	1339	1122	1275	nd	1122	1275	nd	1122
nCohort 2	22	8	14	20	nd	19	10	nd	7
Cutoff 1	12.9	20.9	12.9	23.2	nd	14.3	7.14	nd	6.03
Sens 1	73%	75%	71%	70%	nd	74%	70%	nd	71%
Spec 1	25%	33%	25%	34%	nd	26%	19%	nd	17%
Cutoff 2	4.04	14.5	0.0558	14.9	nd	4.04	6.03	nd	0.0768
Sens 2	82%	88%	86%	80%	nd	84%	80%	nd	86%
Spec 2	16%	27%	5%	26%	nd	16%	18%	nd	10%
Cutoff 3	0.106	1.78	0.0518	7.14	nd	0.0360	0.0768	nd	0.0686
Sens 3	91%	100%	93%	90%	nd	95%	90%	nd	100%
Spec 3	12%	14%	3%	19%	nd	2%	10%	nd	6%
Cutoff 4	73.1	71.8	72.6	73.1	nd	72.6	73.1	nd	72.6
Sens 4	18%	25%	14%	5%	nd	5%	10%	nd	14%
Spec 4	70%	70%	70%	70%	nd	70%	70%	nd	70%
Cutoff 5	93.1	92.2	93.9	93.1	nd	93.9	93.1	nd	93.9
Sens 5	14%	25%	7%	0%	nd	0%	10%	nd	14%
Spec 5	80%	80%	80%	80%	nd	80%	80%	nd	80%
Cutoff 6	127	126	127	127	nd	127	127	nd	127
Sens 6	5%	12%	0%	0%	nd	0%	10%	nd	14%
Spec 6	90%	90%	90%	90%	nd	90%	90%	nd	90%
OR Quart 2	1.3	0	3.0	7.1	nd	6.1	3.0	nd	3.0
p Value	0.70	na	0.34	0.067	nd	0.094	0.34	nd	0.34
95% CI of	0.30	na	0.31	0.87	nd	0.73	0.31	nd	0.31
OR Quart2	6.0	na	29	58	nd	51	29	nd	29
OR Quart 3	3.1	2.5	5.1	9.2	nd	7.2	2.0	nd	0
p Value	0.095	0.27	0.14	0.036	nd	0.066	0.57	nd	na
95% CI of	0.82	0.49	0.59	1.2	nd	0.88	0.18	nd	na
OR Quart3	11	13	44	73	nd	59	22	nd	na
OR Quart 4	2.0	0.50	5.1	3.0	nd	5.1	4.1	nd	3.0
p Value	0.32	0.57	0.14	0.34	nd	0.14	0.21	nd	0.34
95% CI of	0.50	0.045	0.59	0.31	nd	0.59	0.45	nd	0.31
OR Quart4	8.2	5.5	44	29	nd	44	36	nd	29

Interleukin-4 receptor alpha chain

sCr or UO	0hr prior to AKI stage		24hr prior to AKI stage		48hr prior to AKI stage	
	Cohort 1	Cohort 2	Cohort 1	Cohort 2	Cohort 1	Cohort 2
Median	46.2	65.5	46.2	87.3	46.2	66.6
Average	56.4	62.9	56.4	81.4	56.4	75.3
Stdev	51.8	42.9	51.8	55.4	51.8	24.6
p(t-test)		0.63		0.066		0.33
Min	0.839	7.12	0.839	7.12	0.839	47.8
Max	299	156	299	230	299	119
n (Samp)	642	15	642	15	642	7
n (Patient)	293	15	293	15	293	7

UO only	0hr prior to AKI stage		24hr prior to AKI stage		48hr prior to AKI stage	
	Cohort 1	Cohort 2	Cohort 1	Cohort 2	Cohort 1	Cohort 2
Median	46.2	66.5	46.2	77.9	nd	nd
Average	56.9	73.2	56.9	85.4	nd	nd
Stdev	52.8	49.1	52.8	58.9	nd	nd
p(t-test)		0.36		0.065	nd	nd
Min	0.839	7.12	0.839	7.12	nd	nd
Max	299	156	299	230	nd	nd
n (Samp)	587	9	587	12	nd	nd
n (Patient)	258	9	258	12	nd	nd

	0hr prior to AKI stage			24hr prior to AKI stage			48hr prior to AKI stage		
	sCr or UO	sCr only	UO only	sCr or UO	sCr only	UO only	sCr or UO	sCr only	UO only
AUC	0.57	nd	0.61	0.66	nd	0.67	0.69	nd	nd
SE	0.078	nd	0.10	0.078	nd	0.087	0.11	nd	nd
p	0.37	nd	0.29	0.042	nd	0.057	0.089	nd	nd
nCohort 1	642	nd	587	642	nd	587	642	nd	nd
nCohort 2	15	nd	9	15	nd	12	7	nd	nd
Cutoff 1	50.2	nd	59.3	59.2	nd	59.2	60.1	nd	nd
Sens 1	73%	nd	78%	73%	nd	75%	71%	nd	nd
Spec 1	56%	nd	62%	61%	nd	61%	63%	nd	nd
Cutoff 2	11.8	nd	6.56	50.2	nd	50.2	59.3	nd	nd
Sens 2	80%	nd	100%	80%	nd	83%	86%	nd	nd
Spec 2	25%	nd	6%	56%	nd	56%	62%	nd	nd
Cutoff 3	6.56	nd	6.56	11.3	nd	11.3	46.5	nd	nd
Sens 3	100%	nd	100%	93%	nd	92%	100%	nd	nd
Spec 3	6%	nd	6%	20%	nd	19%	51%	nd	nd
Cutoff 4	75.2	nd	74.6	75.2	nd	74.6	75.2	nd	nd
Sens 4	27%	nd	33%	53%	nd	50%	43%	nd	nd
Spec 4	71%	nd	70%	71%	nd	70%	71%	nd	nd
Cutoff 5	94.3	nd	94.3	94.3	nd	94.3	94.3	nd	nd
Sens 5	20%	nd	33%	33%	nd	42%	29%	nd	nd
Spec 5	81%	nd	80%	81%	nd	80%	81%	nd	nd
Cutoff 6	122	nd	122	122	nd	122	122	nd	nd
Sens 6	13%	nd	11%	13%	nd	17%	0%	nd	nd
Spec 6	90%	nd	90%	90%	nd	90%	90%	nd	nd
OR Quart 2	0.33	nd	0	0.50	nd	0	>0	nd	nd
p Value	0.34	nd	na	0.57	nd	na	<na	nd	nd

	0hr prior to AKI stage			24hr prior to AKI stage			48hr prior to AKI stage		
	sCr or UO	sCr only	UO only	sCr or UO	sCr only	UO only	sCr or UO	sCr only	UO only
95% CI of	0.034	nd	na	0.045	nd	na	>na	nd	nd
OR Quart2	3.2	nd	na	5.5	nd	na	na	nd	nd
OR Quart 3	2.8	nd	2.0	2.0	nd	2.0	>5.2	nd	nd
p Value	0.14	nd	0.42	0.42	nd	0.42	<0.14	nd	nd
95% CI of	0.72	nd	0.37	0.37	nd	0.36	>0.60	nd	nd
OR Quart3	11	nd	11	11	nd	11	na	nd	nd
OR Quart 4	0.99	nd	1.5	4.1	nd	3.1	>2.0	nd	nd
p Value	0.99	nd	0.65	0.076	nd	0.17	<0.57	nd	nd
95% CI of	0.20	nd	0.25	0.86	nd	0.61	>0.18	nd	nd
OR Quart4	5.0	nd	9.2	20	nd	15	na	nd	nd

Vascular endothelial growth factor receptor 2

sCr or UO	0hr prior to AKI stage		24hr prior to AKI stage		48hr prior to AKI stage	
	Cohort 1	Cohort 2	Cohort 1	Cohort 2	Cohort 1	Cohort 2
Median	605	866	605	825	605	561
Average	804	1120	804	888	804	829
Stdev	870	1050	870	798	870	1040
p(t-test)		0.18		0.71		0.94
Min	0.218	106	0.218	27.3	0.218	1.48
Max	7140	4230	7140	2600	7140	2820
n (Samp)	644	14	644	15	644	6
n (Patient)	294	14	294	15	294	6

UO only	0hr prior to AKI stage		24hr prior to AKI stage		48hr prior to AKI stage	
	Cohort 1	Cohort 2	Cohort 1	Cohort 2	Cohort 1	Cohort 2
Median	626	1390	626	828	nd	nd
Average	824	1400	824	915	nd	nd
Stdev	875	1190	875	879	nd	nd
p(t-test)		0.051		0.72	nd	nd
Min	0.218	106	0.218	27.3	nd	nd
Max	7140	4230	7140	2600	nd	nd
n (Samp)	589	9	589	12	nd	nd
n (Patient)	259	9	259	12	nd	nd

	0hr prior to AKI stage			24hr prior to AKI stage			48hr prior to AKI stage		
	sCr or UO	sCr only	UO only	sCr or UO	sCr only	UO only	sCr or UO	sCr only	UO only
AUC	0.62	nd	0.69	0.55	nd	0.53	0.48	nd	nd
SE	0.081	nd	0.099	0.077	nd	0.086	0.12	nd	nd
p	0.15	nd	0.058	0.52	nd	0.73	0.86	nd	nd
nCohort 1	644	nd	589	644	nd	589	644	nd	nd
nCohort 2	14	nd	9	15	nd	12	6	nd	nd
Cutoff 1	626	nd	747	224	nd	182	65.6	nd	nd
Sens 1	71%	nd	78%	73%	nd	75%	83%	nd	nd
Spec 1	51%	nd	58%	26%	nd	21%	16%	nd	nd
Cutoff 2	152	nd	581	182	nd	140	65.6	nd	nd
Sens 2	86%	nd	89%	80%	nd	83%	83%	nd	nd
Spec 2	21%	nd	47%	23%	nd	18%	16%	nd	nd

	0hr prior to AKI stage			24hr prior to AKI stage			48hr prior to AKI stage		
	sCr or UO	sCr only	UO only	sCr or UO	sCr only	UO only	sCr or UO	sCr only	UO only
Cutoff 3	119	nd	106	119	nd	119	1.48	nd	nd
Sens 3	93%	nd	100%	93%	nd	92%	100%	nd	nd
Spec 3	19%	nd	16%	19%	nd	17%	8%	nd	nd
Cutoff 4	981	nd	1020	981	nd	1020	981	nd	nd
Sens 4	43%	nd	56%	40%	nd	42%	17%	nd	nd
Spec 4	70%	nd	70%	70%	nd	70%	70%	nd	nd
Cutoff 5	1330	nd	1340	1330	nd	1340	1330	nd	nd
Sens 5	36%	nd	56%	20%	nd	25%	17%	nd	nd
Spec 5	80%	nd	80%	80%	nd	80%	80%	nd	nd
Cutoff 6	1740	nd	1770	1740	nd	1770	1740	nd	nd
Sens 6	14%	nd	22%	13%	nd	17%	17%	nd	nd
Spec 6	90%	nd	90%	90%	nd	90%	90%	nd	nd
OR Quart 2	0.33	nd	0.99	0.49	nd	0	2.0	nd	nd
p Value	0.34	nd	1.00	0.42	nd	na	0.57	nd	nd
95% CI of	0.034	nd	0.062	0.089	nd	na	0.18	nd	nd
OR Quart2	3.2	nd	16	2.7	nd	na	23	nd	nd
OR Quart 3	1.7	nd	2.0	1.2	nd	0.79	1.0	nd	nd
p Value	0.48	nd	0.57	0.74	nd	0.74	1.0	nd	nd
95% CI of	0.40	nd	0.18	0.33	nd	0.21	0.062	nd	nd
OR Quart3	7.2	nd	22	4.7	nd	3.0	16	nd	nd
OR Quart 4	1.7	nd	5.1	0.99	nd	0.59	2.0	nd	nd
p Value	0.48	nd	0.14	0.99	nd	0.47	0.57	nd	nd
95% CI of	0.39	nd	0.59	0.24	nd	0.14	0.18	nd	nd
OR Quart4	7.1	nd	44	4.0	nd	2.5	23	nd	nd

Lutropin subunit beta

sCr or UO	0hr prior to AKI stage		24hr prior to AKI stage		48hr prior to AKI stage	
	Cohort 1	Cohort 2	Cohort 1	Cohort 2	Cohort 1	Cohort 2
Median	nd	nd	19.4	9.51	nd	nd
Average	nd	nd	56.4	42.0	nd	nd
Stdev	nd	nd	86.6	90.9	nd	nd
p(t-test)	nd	nd		0.57	nd	nd
Min	nd	nd	0.0297	0.341	nd	nd
Max	nd	nd	400	325	nd	nd
n (Samp)	nd	nd	353	12	nd	nd
n (Patient)	nd	nd	165	12	nd	nd

UO only	0hr prior to AKI stage		24hr prior to AKI stage		48hr prior to AKI stage	
	Cohort 1	Cohort 2	Cohort 1	Cohort 2	Cohort 1	Cohort 2
Median	nd	nd	21.0	4.44	nd	nd
Average	nd	nd	60.2	7.20	nd	nd
Stdev	nd	nd	90.0	8.59	nd	nd
p(t-test)	nd	nd		0.12	nd	nd
Min	nd	nd	0.0297	0.505	nd	nd
Max	nd	nd	400	24.5	nd	nd
n (Samp)	nd	nd	352	7	nd	nd

UO only	0hr prior to AKI stage		24hr prior to AKI stage		48hr prior to AKI stage	
	Cohort 1	Cohort 2	Cohort 1	Cohort 2	Cohort 1	Cohort 2
n (Patient)	nd	nd	156	7	nd	nd

	0hr prior to AKI stage			24hr prior to AKI stage			48hr prior to AKI stage		
	sCr or UO	sCr only	UO only	sCr or UO	sCr only	UO only	sCr or UO	sCr only	UO only
AUC	nd	nd	nd	0.41	nd	0.25	nd	nd	nd
SE	nd	nd	nd	0.088	nd	0.11	nd	nd	nd
p	nd	nd	nd	0.28	nd	0.018	nd	nd	nd
nCohort 1	nd	nd	nd	353	nd	352	nd	nd	nd
nCohort 2	nd	nd	nd	12	nd	7	nd	nd	nd
Cutoff 1	nd	nd	nd	1.09	nd	1.09	nd	nd	nd
Sens 1	nd	nd	nd	75%	nd	71%	nd	nd	nd
Spec 1	nd	nd	nd	12%	nd	11%	nd	nd	nd
Cutoff 2	nd	nd	nd	0.840	nd	0.840	nd	nd	nd
Sens 2	nd	nd	nd	83%	nd	86%	nd	nd	nd
Spec 2	nd	nd	nd	10%	nd	10%	nd	nd	nd
Cutoff 3	nd	nd	nd	0.463	nd	0.463	nd	nd	nd
Sens 3	nd	nd	nd	92%	nd	100%	nd	nd	nd
Spec 3	nd	nd	nd	9%	nd	9%	nd	nd	nd
Cutoff 4	nd	nd	nd	45.5	nd	49.1	nd	nd	nd
Sens 4	nd	nd	nd	17%	nd	0%	nd	nd	nd
Spec 4	nd	nd	nd	70%	nd	70%	nd	nd	nd
Cutoff 5	nd	nd	nd	84.1	nd	92.0	nd	nd	nd
Sens 5	nd	nd	nd	8%	nd	0%	nd	nd	nd
Spec 5	nd	nd	nd	80%	nd	80%	nd	nd	nd
Cutoff 6	nd	nd	nd	179	nd	207	nd	nd	nd
Sens 6	nd	nd	nd	8%	nd	0%	nd	nd	nd
Spec 6	nd	nd	nd	90%	nd	90%	nd	nd	nd
OR Quart 2	nd	nd	nd	1.5	nd	>1.0	nd	nd	nd
p Value	nd	nd	nd	0.64	nd	<0.99	nd	nd	nd
95% CI of	nd	nd	nd	0.25	nd	>0.062	nd	nd	nd
OR Quart2	nd	nd	nd	9.4	nd	na	nd	nd	nd
OR Quart 3	nd	nd	nd	1.0	nd	>2.0	nd	nd	nd
p Value	nd	nd	nd	0.99	nd	<0.56	nd	nd	nd
95% CI of	nd	nd	nd	0.14	nd	>0.18	nd	nd	nd
OR Quart3	nd	nd	nd	7.3	nd	na	nd	nd	nd
OR Quart 4	nd	nd	nd	2.6	nd	>4.2	nd	nd	nd
p Value	nd	nd	nd	0.26	nd	<0.20	nd	nd	nd
95% CI of	nd	nd	nd	0.49	nd	>0.46	nd	nd	nd
OR Quart4	nd	nd	nd	14	nd	na	nd	nd	nd

Neural cell adhesion molecule 1

sCr or UO	0hr prior to AKI stage		24hr prior to AKI stage		48hr prior to AKI stage	
	Cohort 1	Cohort 2	Cohort 1	Cohort 2	Cohort 1	Cohort 2
Median	2720	3990	2720	2660	2720	2100
Average	3320	4390	3320	6260	3320	2840
Stdev	2860	3520	2860	11900	2860	2900
p(t-test)		0.085		4.5E-5		0.60

sCr or UO	0hr prior to AKI stage		24hr prior to AKI stage		48hr prior to AKI stage	
	Cohort 1	Cohort 2	Cohort 1	Cohort 2	Cohort 1	Cohort 2
Min	0.234	142	0.234	375	0.234	138
Max	48400	15000	48400	55700	48400	9700
n (Samp)	1272	22	1272	20	1272	10
n (Patient)	450	22	450	20	450	10

sCr only	0hr prior to AKI stage		24hr prior to AKI stage		48hr prior to AKI stage	
	Cohort 1	Cohort 2	Cohort 1	Cohort 2	Cohort 1	Cohort 2
Median	2740	2260	nd	nd	nd	nd
Average	3430	2670	nd	nd	nd	nd
Stdev	3250	2170	nd	nd	nd	nd
p(t-test)		0.51	nd	nd	nd	nd
Min	0.234	142	nd	nd	nd	nd
Max	55700	6800	nd	nd	nd	nd
n (Samp)	1336	8	nd	nd	nd	nd
n (Patient)	465	8	nd	nd	nd	nd

UO only	0hr prior to AKI stage		24hr prior to AKI stage		48hr prior to AKI stage	
	Cohort 1	Cohort 2	Cohort 1	Cohort 2	Cohort 1	Cohort 2
Median	2820	4560	2820	4560	2820	3060
Average	3380	6830	3380	8190	3380	3540
Stdev	2830	6750	2830	12900	2830	3190
p(t-test)		1.1E-5		2.2E-10		0.88
Min	0.234	416	0.234	375	0.234	346
Max	48400	26600	48400	55700	48400	9700
n (Samp)	1118	14	1118	19	1118	7
n (Patient)	360	14	360	19	360	7

	0hr prior to AKI stage			24hr prior to AKI stage			48hr prior to AKI stage		
	sCr or UO	sCr only	UO only	sCr or UO	sCr only	UO only	sCr or UO	sCr only	UO only
AUC	0.59	0.42	0.71	0.55	nd	0.62	0.40	nd	0.48
SE	0.064	0.11	0.079	0.067	nd	0.069	0.095	nd	0.11
p	0.15	0.46	0.0090	0.44	nd	0.079	0.31	nd	0.86
nCohort 1	1272	1336	1118	1272	nd	1118	1272	nd	1118
nCohort 2	22	8	14	20	nd	19	10	nd	7
Cutoff 1	2200	1340	3860	2030	nd	2080	1180	nd	1650
Sens 1	73%	75%	71%	70%	nd	74%	70%	nd	71%
Spec 1	40%	19%	68%	35%	nd	34%	16%	nd	24%
Cutoff 2	1340	623	2310	1740	nd	1740	962	nd	1180
Sens 2	82%	88%	86%	80%	nd	84%	80%	nd	86%
Spec 2	20%	5%	40%	29%	nd	26%	11%	nd	14%
Cutoff 3	623	85.5	1490	1110	nd	1110	341	nd	337
Sens 3	91%	100%	93%	90%	nd	95%	90%	nd	100%
Spec 3	5%	0%	21%	15%	nd	14%	1%	nd	1%
Cutoff 4	3930	3980	3980	3930	nd	3980	3930	nd	3980
Sens 4	55%	12%	64%	45%	nd	58%	20%	nd	29%
Spec 4	70%	70%	70%	70%	nd	70%	70%	nd	70%
Cutoff 5	4840	4910	4890	4840	nd	4890	4840	nd	4890

	0hr prior to AKI stage			24hr prior to AKI stage			48hr prior to AKI stage		
	sCr or UO	sCr only	UO only	sCr or UO	sCr only	UO only	sCr or UO	sCr only	UO only
Sens 5	41%	12%	43%	35%	nd	42%	20%	nd	29%
Spec 5	80%	80%	80%	80%	nd	80%	80%	nd	80%
Cutoff 6	6370	6470	6410	6370	nd	6410	6370	nd	6410
Sens 6	23%	12%	36%	20%	nd	32%	10%	nd	14%
Spec 6	90%	90%	90%	90%	nd	90%	90%	nd	90%
OR Quart 2	0.33	2.0	0.50	1.5	nd	1.7	1.0	nd	1.0
p Value	0.17	0.57	0.57	0.53	nd	0.48	1.00	nd	1.00
95% CI of	0.066	0.18	0.045	0.42	nd	0.40	0.14	nd	0.14
OR Quart2	1.6	22	5.5	5.4	nd	7.1	7.2	nd	7.2
OR Quart 3	0.83	2.0	2.0	0.50	nd	0.33	1.0	nd	0
p Value	0.76	0.57	0.42	0.42	nd	0.34	1.0	nd	na
95% CI of	0.25	0.18	0.37	0.090	nd	0.034	0.14	nd	na
OR Quart3	2.7	22	11	2.7	nd	3.2	7.1	nd	na
OR Quart 4	1.5	3.0	3.6	2.0	nd	3.4	2.0	nd	1.5
p Value	0.44	0.34	0.12	0.25	nd	0.065	0.42	nd	0.65
95% CI of	0.53	0.31	0.73	0.60	nd	0.93	0.37	nd	0.25
OR Quart4	4.3	29	17	6.8	nd	13	11	nd	9.1

Platelet-derived growth factor subunit B (dimer)

sCr or UO	0hr prior to AKI stage		24hr prior to AKI stage		48hr prior to AKI stage	
	Cohort 1	Cohort 2	Cohort 1	Cohort 2	Cohort 1	Cohort 2
Median	1.19	3.23	1.19	1.55	1.19	2.47
Average	3.27	6.13	3.27	68.5	3.27	1.87
Stdev	12.5	8.36	12.5	249	12.5	1.44
p(t-test)		0.41		6.0E-14		0.77
Min	0.00246	1.15	0.00246	0.0144	0.00246	0.371
Max	270	30.4	270	935	270	3.71
n (Samp)	933	13	933	14	933	7
n (Patient)	344	13	344	14	344	7

sCr only	0hr prior to AKI stage		24hr prior to AKI stage		48hr prior to AKI stage	
	Cohort 1	Cohort 2	Cohort 1	Cohort 2	Cohort 1	Cohort 2
Median	1.23	2.28	nd	nd	nd	nd
Average	4.24	2.60	nd	nd	nd	nd
Stdev	32.3	1.38	nd	nd	nd	nd
p(t-test)		0.90	nd	nd	nd	nd
Min	0.00246	1.15	nd	nd	nd	nd
Max	935	4.52	nd	nd	nd	nd
n (Samp)	970	6	nd	nd	nd	nd
n (Patient)	354	6	nd	nd	nd	nd

UO only	0hr prior to AKI stage		24hr prior to AKI stage		48hr prior to AKI stage	
	Cohort 1	Cohort 2	Cohort 1	Cohort 2	Cohort 1	Cohort 2
Median	1.24	3.58	1.24	2.37	nd	nd
Average	3.30	10.3	3.30	72.4	nd	nd
Stdev	13.0	19.8	13.0	248	nd	nd
p(t-test)		0.13		1.2E-13	nd	nd

UO only	0hr prior to AKI stage		24hr prior to AKI stage		48hr prior to AKI stage	
	Cohort 1	Cohort 2	Cohort 1	Cohort 2	Cohort 1	Cohort 2
Min	0.00246	1.22	0.00246	0.0144	nd	nd
Max	270	59.1	270	935	nd	nd
n (Samp)	800	8	800	14	nd	nd
n (Patient)	263	8	263	14	nd	nd

	0hr prior to AKI stage			24hr prior to AKI stage			48hr prior to AKI stage		
	sCr or UO	sCr only	UO only	sCr or UO	sCr only	UO only	sCr or UO	sCr only	UO only
AUC	0.77	0.69	0.80	0.57	nd	0.62	0.56	nd	nd
SE	0.077	0.12	0.095	0.080	nd	0.081	0.11	nd	nd
p	4.6E-4	0.11	0.0018	0.40	nd	0.14	0.59	nd	nd
nCohort 1	933	970	800	933	nd	800	933	nd	nd
nCohort 2	13	6	8	14	nd	14	7	nd	nd
Cutoff 1	2.03	1.39	2.84	0.943	nd	0.938	0.393	nd	nd
Sens 1	77%	83%	75%	71%	nd	71%	71%	nd	nd
Spec 1	67%	54%	76%	44%	nd	43%	27%	nd	nd
Cutoff 2	1.39	1.39	2.03	0.162	nd	0.162	0.392	nd	nd
Sens 2	85%	83%	88%	86%	nd	86%	86%	nd	nd
Spec 2	55%	54%	66%	20%	nd	21%	27%	nd	nd
Cutoff 3	1.20	1.14	1.20	0.0140	nd	0.0140	0.365	nd	nd
Sens 3	92%	100%	100%	100%	nd	100%	100%	nd	nd
Spec 3	50%	48%	49%	11%	nd	12%	26%	nd	nd
Cutoff 4	2.18	2.23	2.22	2.18	nd	2.22	2.18	nd	nd
Sens 4	69%	50%	75%	43%	nd	50%	57%	nd	nd
Spec 4	70%	70%	70%	70%	nd	70%	70%	nd	nd
Cutoff 5	3.13	3.16	3.15	3.13	nd	3.15	3.13	nd	nd
Sens 5	54%	33%	62%	29%	nd	43%	14%	nd	nd
Spec 5	80%	80%	80%	80%	nd	80%	80%	nd	nd
Cutoff 6	5.13	5.13	5.05	5.13	nd	5.05	5.13	nd	nd
Sens 6	23%	0%	25%	14%	nd	29%	0%	nd	nd
Spec 6	90%	90%	90%	90%	nd	90%	90%	nd	nd
OR Quart 2	>2.0	>1.0	>1.0	1.00	nd	0.66	>3.0	nd	nd
p Value	<0.57	<1.00	<1.00	1.00	nd	0.65	<0.34	nd	nd
95% CI of	>0.18	>0.062	>0.062	0.20	nd	0.11	>0.31	nd	nd
OR Quart2	na	na	na	5.0	nd	4.0	na	nd	nd
OR Quart 3	>3.0	>3.0	>1.0	1.00	nd	0.66	>1.0	nd	nd
p Value	<0.34	<0.34	<1.00	1.00	nd	0.65	<1.00	nd	nd
95% CI of	>0.31	>0.31	>0.062	0.20	nd	0.11	>0.062	nd	nd
OR Quart3	na	na	na	5.0	nd	4.0	na	nd	nd
OR Quart 4	>8.2	>2.0	>6.2	1.7	nd	2.4	>3.0	nd	nd
p Value	<0.048	<0.57	<0.093	0.48	nd	0.22	<0.34	nd	nd
95% CI of	>1.0	>0.18	>0.74	0.40	nd	0.60	>0.31	nd	nd
OR Quart4	na	na	na	7.1	nd	9.3	na	nd	nd

Corticotropin

sCr or UO	0hr prior to AKI stage		24hr prior to AKI stage		48hr prior to AKI stage	
	Cohort 1	Cohort 2	Cohort 1	Cohort 2	Cohort 1	Cohort 2
Median	0.00162	0.00162	0.00162	0.00425	nd	nd

sCr or UO	0hr prior to AKI stage		24hr prior to AKI stage		48hr prior to AKI stage	
	Cohort 1	Cohort 2	Cohort 1	Cohort 2	Cohort 1	Cohort 2
Average	0.00219	0.00196	0.00219	0.00914	nd	nd
Stdev	0.00354	0.00112	0.00354	0.0119	nd	nd
p(t-test)		0.87		1.1E-7	nd	nd
Min	3.92E-6	0.00109	3.92E-6	0.000794	nd	nd
Max	0.0489	0.00427	0.0489	0.0377	nd	nd
n (Samp)	332	7	332	10	nd	nd
n (Patient)	193	7	193	10	nd	nd

UO only	0hr prior to AKI stage		24hr prior to AKI stage		48hr prior to AKI stage	
	Cohort 1	Cohort 2	Cohort 1	Cohort 2	Cohort 1	Cohort 2
Median	nd	nd	0.00163	0.00380	nd	nd
Average	nd	nd	0.00233	0.00797	nd	nd
Stdev	nd	nd	0.00396	0.0123	nd	nd
p(t-test)	nd	nd		3.4E-4	nd	nd
Min	nd	nd	0.000273	0.000794	nd	nd
Max	nd	nd	0.0489	0.0377	nd	nd
n (Samp)	nd	nd	290	8	nd	nd
n (Patient)	nd	nd	162	8	nd	nd

	0hr prior to AKI stage			24hr prior to AKI stage			48hr prior to AKI stage		
	sCr or UO	sCr only	UO only	sCr or UO	sCr only	UO only	sCr or UO	sCr only	UO only
AUC	0.50	nd	nd	0.78	nd	0.72	nd	nd	nd
SE	0.11	nd	nd	0.087	nd	0.10	nd	nd	nd
p	1.00	nd	nd	0.0013	nd	0.032	nd	nd	nd
nCohort 1	332	nd	nd	332	nd	290	nd	nd	nd
nCohort 2	7	nd	nd	10	nd	8	nd	nd	nd
Cutoff 1	0.00134	nd	nd	0.00375	nd	0.00229	nd	nd	nd
Sens 1	71%	nd	nd	70%	nd	75%	nd	nd	nd
Spec 1	32%	nd	nd	92%	nd	72%	nd	nd	nd
Cutoff 2	0.00106	nd	nd	0.00229	nd	0.00106	nd	nd	nd
Sens 2	100%	nd	nd	80%	nd	88%	nd	nd	nd
Spec 2	19%	nd	nd	73%	nd	20%	nd	nd	nd
Cutoff 3	0.00106	nd	nd	0.00106	nd	0.000687	nd	nd	nd
Sens 3	100%	nd	nd	90%	nd	100%	nd	nd	nd
Spec 3	19%	nd	nd	19%	nd	9%	nd	nd	nd
Cutoff 4	0.00212	nd	nd	0.00212	nd	0.00218	nd	nd	nd
Sens 4	29%	nd	nd	80%	nd	75%	nd	nd	nd
Spec 4	70%	nd	nd	70%	nd	70%	nd	nd	nd
Cutoff 5	0.00274	nd	nd	0.00274	nd	0.00275	nd	nd	nd
Sens 5	14%	nd	nd	70%	nd	62%	nd	nd	nd
Spec 5	80%	nd	nd	80%	nd	80%	nd	nd	nd
Cutoff 6	0.00352	nd	nd	0.00352	nd	0.00362	nd	nd	nd
Sens 6	14%	nd	nd	70%	nd	62%	nd	nd	nd
Spec 6	90%	nd	nd	90%	nd	90%	nd	nd	nd
OR Quart 2	0.49	nd	nd	0	nd	0	nd	nd	nd
p Value	0.57	nd	nd	na	nd	na	nd	nd	nd
95% CI of	0.044	nd	nd	na	nd	na	nd	nd	nd

	0hr prior to AKI stage			24hr prior to AKI stage			48hr prior to AKI stage		
	sCr or UO	sCr only	UO only	sCr or UO	sCr only	UO only	sCr or UO	sCr only	UO only
OR Quart2	5.6	nd	nd	na	nd	na	nd	nd	nd
OR Quart 3	1.0	nd	nd	0.49	nd	0.49	nd	nd	nd
p Value	1.0	nd	nd	0.57	nd	0.57	nd	nd	nd
95% CI of	0.14	nd	nd	0.044	nd	0.044	nd	nd	nd
OR Quart3	7.3	nd	nd	5.6	nd	5.6	nd	nd	nd
OR Quart 4	1.0	nd	nd	3.7	nd	2.6	nd	nd	nd
p Value	0.99	nd	nd	0.11	nd	0.27	nd	nd	nd
95% CI of	0.14	nd	nd	0.74	nd	0.48	nd	nd	nd
OR Quart4	7.4	nd	nd	18	nd	14	nd	nd	nd

Pigment epithelium-derived factor

sCr or UO	0hr prior to AKI stage		24hr prior to AKI stage		48hr prior to AKI stage	
	Cohort 1	Cohort 2	Cohort 1	Cohort 2	Cohort 1	Cohort 2
Median	3.21	8.76	3.21	11.6	3.21	4.86
Average	20.2	39.5	20.2	41.2	20.2	21.3
Stdev	47.4	63.3	47.4	54.0	47.4	36.7
p(t-test)		0.060		0.050		0.94
Min	0.000401	0.0312	0.000401	0.117	0.000401	0.00102
Max	400	204	400	168	400	115
n (Samp)	1273	22	1273	20	1273	10
n (Patient)	451	22	451	20	451	10

sCr only	0hr prior to AKI stage		24hr prior to AKI stage		48hr prior to AKI stage	
	Cohort 1	Cohort 2	Cohort 1	Cohort 2	Cohort 1	Cohort 2
Median	3.33	12.0	nd	nd	nd	nd
Average	20.9	37.0	nd	nd	nd	nd
Stdev	47.9	57.0	nd	nd	nd	nd
p(t-test)		0.34	nd	nd	nd	nd
Min	0.000401	0.0312	nd	nd	nd	nd
Max	400	168	nd	nd	nd	nd
n (Samp)	1337	8	nd	nd	nd	nd
n (Patient)	466	8	nd	nd	nd	nd

UO only	0hr prior to AKI stage		24hr prior to AKI stage		48hr prior to AKI stage	
	Cohort 1	Cohort 2	Cohort 1	Cohort 2	Cohort 1	Cohort 2
Median	3.46	19.8	3.46	14.9	3.46	2.22
Average	22.0	53.2	22.0	55.6	22.0	26.7
Stdev	50.6	75.1	50.6	71.6	50.6	43.3
p(t-test)		0.023		0.0045		0.81
Min	0.000401	0.106	0.000401	0.190	0.000401	0.644
Max	400	204	400	250	400	115
n (Samp)	1119	14	1119	19	1119	7
n (Patient)	361	14	361	19	361	7

	0hr prior to AKI stage			24hr prior to AKI stage			48hr prior to AKI stage		
	sCr or UO	sCr only	UO only	sCr or UO	sCr only	UO only	sCr or UO	sCr only	UO only

	0hr prior to AKI stage			24hr prior to AKI stage			48hr prior to AKI stage		
	sCr or UO	sCr only	UO only	sCr or UO	sCr only	UO only	sCr or UO	sCr only	UO only
AUC	0.62	0.64	0.66	0.64	nd	0.68	0.52	nd	0.53
SE	0.064	0.11	0.080	0.067	nd	0.069	0.093	nd	0.11
p	0.069	0.19	0.048	0.033	nd	0.0099	0.81	nd	0.81
nCohort 1	1273	1337	1119	1273	nd	1119	1273	nd	1119
nCohort 2	22	8	14	20	nd	19	10	nd	7
Cutoff 1	2.66	4.16	3.30	2.20	nd	2.20	1.56	nd	1.56
Sens 1	73%	75%	71%	70%	nd	74%	70%	nd	71%
Spec 1	46%	55%	49%	43%	nd	41%	36%	nd	34%
Cutoff 2	2.01	2.29	2.01	1.99	nd	1.99	0.682	nd	0.682
Sens 2	82%	88%	86%	80%	nd	84%	80%	nd	86%
Spec 2	41%	43%	39%	41%	nd	39%	21%	nd	19%
Cutoff 3	0.351	0.0292	0.511	1.24	nd	1.24	0.643	nd	0.640
Sens 3	91%	100%	93%	90%	nd	95%	90%	nd	100%
Spec 3	12%	1%	14%	31%	nd	29%	20%	nd	19%
Cutoff 4	10.1	10.5	11.0	10.1	nd	11.0	10.1	nd	11.0
Sens 4	50%	50%	57%	50%	nd	53%	40%	nd	43%
Spec 4	70%	70%	70%	70%	nd	70%	70%	nd	70%
Cutoff 5	21.8	23.1	23.9	21.8	nd	23.9	21.8	nd	23.9
Sens 5	41%	38%	43%	40%	nd	47%	20%	nd	29%
Spec 5	80%	80%	80%	80%	nd	80%	80%	nd	80%
Cutoff 6	52.9	58.1	60.9	52.9	nd	60.9	52.9	nd	60.9
Sens 6	23%	25%	29%	30%	nd	32%	20%	nd	14%
Spec 6	90%	90%	90%	90%	nd	90%	90%	nd	90%
OR Quart 2	0.75	1.0	1.5	2.5	nd	5.1	0.66	nd	1.00
p Value	0.70	1.0	0.66	0.27	nd	0.14	0.65	nd	1.00
95% CI of	0.17	0.062	0.25	0.49	nd	0.59	0.11	nd	0.14
OR Quart2	3.4	16	9.1	13	nd	44	4.0	nd	7.1
OR Quart 3	1.2	2.0	0.50	2.0	nd	4.0	0.66	nd	0.50
p Value	0.74	0.57	0.57	0.42	nd	0.21	0.65	nd	0.57
95% CI of	0.33	0.18	0.045	0.37	nd	0.45	0.11	nd	0.045
OR Quart3	4.7	22	5.5	11	nd	36	4.0	nd	5.5
OR Quart 4	2.5	4.0	4.1	4.6	nd	9.2	1.00	nd	1.00
p Value	0.12	0.21	0.077	0.053	nd	0.036	1.00	nd	1.00
95% CI of	0.79	0.45	0.86	0.98	nd	1.2	0.20	nd	0.14
OR Quart4	8.2	36	19	21	nd	73	5.0	nd	7.1

Tumor necrosis factor receptor superfamily member 8

sCr or UO	0hr prior to AKI stage		24hr prior to AKI stage		48hr prior to AKI stage	
	Cohort 1	Cohort 2	Cohort 1	Cohort 2	Cohort 1	Cohort 2
Median	19.5	38.9	19.5	19.6	19.5	13.2
Average	29.9	57.9	29.9	29.5	29.9	23.3
Stdev	44.8	86.8	44.8	30.1	44.8	23.1
p(t-test)		0.020		0.97		0.70
Min	0.0493	0.121	0.0493	0.0561	0.0493	0.196
Max	554	353	554	102	554	50.0
n (Samp)	658	15	658	16	658	7
n (Patient)	300	15	300	16	300	7

UO only	0hr prior to AKI stage		24hr prior to AKI stage		48hr prior to AKI stage	
	Cohort 1	Cohort 2	Cohort 1	Cohort 2	Cohort 1	Cohort 2
Median	19.5	38.9	19.5	19.8	nd	nd
Average	29.9	44.8	29.9	31.2	nd	nd
Stdev	46.4	32.5	46.4	33.2	nd	nd
p(t-test)		0.34		0.92	nd	nd
Min	0.0493	6.52	0.0493	0.0561	nd	nd
Max	554	117	554	102	nd	nd
n (Samp)	600	9	600	13	nd	nd
n (Patient)	263	9	263	13	nd	nd

	0hr prior to AKI stage			24hr prior to AKI stage			48hr prior to AKI stage		
	sCr or UO	sCr only	UO only	sCr or UO	sCr only	UO only	sCr or UO	sCr only	UO only
AUC	0.65	nd	0.72	0.51	nd	0.51	0.48	nd	nd
SE	0.078	nd	0.098	0.074	nd	0.082	0.11	nd	nd
p	0.053	nd	0.027	0.84	nd	0.86	0.85	nd	nd
nCohort 1	658	nd	600	658	nd	600	658	nd	nd
nCohort 2	15	nd	9	16	nd	13	7	nd	nd
Cutoff 1	25.6	nd	30.2	5.76	nd	4.22	6.53	nd	nd
Sens 1	73%	nd	78%	75%	nd	77%	71%	nd	nd
Spec 1	60%	nd	68%	23%	nd	17%	25%	nd	nd
Cutoff 2	15.4	nd	15.4	4.22	nd	3.98	0.196	nd	nd
Sens 2	80%	nd	89%	81%	nd	85%	86%	nd	nd
Spec 2	44%	nd	45%	16%	nd	16%	8%	nd	nd
Cutoff 3	1.18	nd	5.76	1.80	nd	1.80	0.121	nd	nd
Sens 3	93%	nd	100%	94%	nd	92%	100%	nd	nd
Spec 3	12%	nd	25%	15%	nd	16%	6%	nd	nd
Cutoff 4	32.7	nd	31.4	32.7	nd	31.4	32.7	nd	nd
Sens 4	60%	nd	67%	38%	nd	46%	43%	nd	nd
Spec 4	70%	nd	70%	70%	nd	70%	70%	nd	nd
Cutoff 5	41.7	nd	41.1	41.7	nd	41.1	41.7	nd	nd
Sens 5	40%	nd	33%	19%	nd	23%	43%	nd	nd
Spec 5	80%	nd	80%	80%	nd	80%	80%	nd	nd
Cutoff 6	62.5	nd	62.5	62.5	nd	62.5	62.5	nd	nd
Sens 6	20%	nd	22%	12%	nd	15%	0%	nd	nd
Spec 6	90%	nd	90%	90%	nd	90%	90%	nd	nd
OR Quart 2	0.33	nd	>2.0	0.39	nd	0.49	0	nd	nd
p Value	0.34	nd	<0.57	0.27	nd	0.42	na	nd	nd
95% CI of	0.034	nd	>0.18	0.075	nd	0.089	na	nd	nd
OR Quart2	3.2	nd	na	2.0	nd	2.7	na	nd	nd
OR Quart 3	1.0	nd	>2.0	0.80	nd	0.49	0.67	nd	nd
p Value	1.0	nd	<0.57	0.74	nd	0.42	0.66	nd	nd
95% CI of	0.20	nd	>0.18	0.21	nd	0.089	0.11	nd	nd
OR Quart3	5.0	nd	na	3.0	nd	2.7	4.0	nd	nd
OR Quart 4	2.7	nd	>5.1	0.99	nd	1.2	0.67	nd	nd
p Value	0.14	nd	<0.14	0.99	nd	0.74	0.66	nd	nd
95% CI of	0.71	nd	>0.59	0.28	nd	0.33	0.11	nd	nd
OR Quart4	10	nd	na	3.5	nd	4.7	4.0	nd	nd

Alpha-fetoprotein

sCr or UO	0hr prior to AKI stage		24hr prior to AKI stage		48hr prior to AKI stage	
	Cohort 1	Cohort 2	Cohort 1	Cohort 2	Cohort 1	Cohort 2
Median	0.00505	0.00508	0.00505	0.0385	0.00505	0.00446
Average	0.0526	0.0780	0.0526	0.263	0.0526	0.0371
Stdev	0.146	0.123	0.146	0.722	0.146	0.0669
p(t-test)		0.59		1.4E-5		0.77
Min	0.000463	0.000463	0.000463	0.000463	0.000463	0.000463
Max	1.74	0.296	1.74	2.85	1.74	0.185
n (Samp)	558	10	558	15	558	8
n (Patient)	262	10	262	15	262	8

sCr only	0hr prior to AKI stage		24hr prior to AKI stage		48hr prior to AKI stage	
	Cohort 1	Cohort 2	Cohort 1	Cohort 2	Cohort 1	Cohort 2
Median	nd	nd	nd	nd	0.00505	0.00286
Average	nd	nd	nd	nd	0.0577	0.0473
Stdev	nd	nd	nd	nd	0.187	0.0760
p(t-test)	nd	nd	nd	nd		0.89
Min	nd	nd	nd	nd	0.000463	0.000463
Max	nd	nd	nd	nd	2.85	0.185
n (Samp)	nd	nd	nd	nd	575	6
n (Patient)	nd	nd	nd	nd	269	6

UO only	0hr prior to AKI stage		24hr prior to AKI stage		48hr prior to AKI stage	
	Cohort 1	Cohort 2	Cohort 1	Cohort 2	Cohort 1	Cohort 2
Median	nd	nd	0.00505	0.0604	nd	nd
Average	nd	nd	0.0546	0.339	nd	nd
Stdev	nd	nd	0.151	0.885	nd	nd
p(t-test)	nd	nd		3.0E-6	nd	nd
Min	nd	nd	0.000463	0.000463	nd	nd
Max	nd	nd	1.74	2.85	nd	nd
n (Samp)	nd	nd	533	10	nd	nd
n (Patient)	nd	nd	235	10	nd	nd

	0hr prior to AKI stage			24hr prior to AKI stage			48hr prior to AKI stage		
	sCr or UO	sCr only	UO only	sCr or UO	sCr only	UO only	sCr or UO	sCr only	UO only
AUC	0.50	nd	nd	0.60	nd	0.58	0.46	0.40	nd
SE	0.092	nd	nd	0.078	nd	0.095	0.10	0.12	nd
p	0.97	nd	nd	0.22	nd	0.39	0.74	0.40	nd
nCohort 1	558	nd	nd	558	nd	533	558	575	nd
nCohort 2	10	nd	nd	15	nd	10	8	6	nd
Cutoff 1	0.00132	nd	nd	0.00296	nd	0.00296	0.00132	0.00132	nd
Sens 1	90%	nd	nd	73%	nd	70%	88%	83%	nd
Spec 1	15%	nd	nd	22%	nd	23%	15%	14%	nd
Cutoff 2	0.00132	nd	nd	0.00132	nd	0.00132	0.00132	0.00132	nd
Sens 2	90%	nd	nd	80%	nd	80%	88%	83%	nd
Spec 2	15%	nd	nd	15%	nd	17%	15%	14%	nd
Cutoff 3	0.00132	nd	nd	0	nd	0	0	0	nd
Sens 3	90%	nd	nd	100%	nd	100%	100%	100%	nd
Spec 3	15%	nd	nd	0%	nd	0%	0%	0%	nd

	0hr prior to AKI stage			24hr prior to AKI stage			48hr prior to AKI stage		
	sCr or UO	sCr only	UO only	sCr or UO	sCr only	UO only	sCr or UO	sCr only	UO only
Cutoff 4	0.00660	nd	nd	0.00660	nd	0.00660	0.00660	0.00660	nd
Sens 4	30%	nd	nd	60%	nd	60%	25%	33%	nd
Spec 4	72%	nd	nd	72%	nd	73%	72%	72%	nd
Cutoff 5	0.0499	nd	nd	0.0499	nd	0.0499	0.0499	0.0499	nd
Sens 5	30%	nd	nd	47%	nd	50%	25%	33%	nd
Spec 5	80%	nd	nd	80%	nd	80%	80%	80%	nd
Cutoff 6	0.141	nd	nd	0.141	nd	0.154	0.141	0.141	nd
Sens 6	30%	nd	nd	27%	nd	20%	12%	17%	nd
Spec 6	90%	nd	nd	90%	nd	90%	90%	90%	nd
OR Quart 2	0.66	nd	nd	0.49	nd	0.33	1.0	0	nd
p Value	0.65	nd	nd	0.42	nd	0.33	0.99	na	nd
95% CI of	0.11	nd	nd	0.089	nd	0.033	0.14	na	nd
OR Quart2	4.0	nd	nd	2.7	nd	3.2	7.3	na	nd
OR Quart 3	0.33	nd	nd	0.24	nd	0.33	0.50	0	nd
p Value	0.34	nd	nd	0.21	nd	0.33	0.57	na	nd
95% CI of	0.034	nd	nd	0.027	nd	0.033	0.045	na	nd
OR Quart3	3.2	nd	nd	2.2	nd	3.2	5.5	na	nd
OR Quart 4	1.3	nd	nd	2.0	nd	1.7	1.5	2.0	nd
p Value	0.70	nd	nd	0.25	nd	0.48	0.65	0.41	nd
95% CI of	0.30	nd	nd	0.60	nd	0.39	0.25	0.37	nd
OR Quart4	6.1	nd	nd	6.9	nd	7.2	9.2	11	nd

Apolipoprotein E

sCr or UO	0hr prior to AKI stage		24hr prior to AKI stage		48hr prior to AKI stage	
	Cohort 1	Cohort 2	Cohort 1	Cohort 2	Cohort 1	Cohort 2
Median	2.46	1.66	2.46	1.59	2.46	1.96
Average	18.0	33.9	18.0	99.3	18.0	3.18
Stdev	114	122	114	435	114	3.65
p(t-test)		0.50		0.0018		0.64
Min	0.000147	0.00122	0.000147	0.000147	0.000147	0.00328
Max	2160	594	2160	2140	2160	12.3
n (Samp)	1388	24	1388	24	1388	13
n (Patient)	484	24	484	24	484	13

sCr only	0hr prior to AKI stage		24hr prior to AKI stage		48hr prior to AKI stage	
	Cohort 1	Cohort 2	Cohort 1	Cohort 2	Cohort 1	Cohort 2
Median	2.41	0.351	2.41	0.985	2.41	0.907
Average	19.4	75.3	19.4	3.39	19.4	1.85
Stdev	125	210	125	5.64	125	2.68
p(t-test)		0.21		0.75		0.71
Min	0.000147	0.0847	0.000147	0.000147	0.000147	0.0263
Max	2160	594	2160	14.6	2160	7.68
n (Samp)	1455	8	1455	6	1455	7
n (Patient)	500	8	500	6	500	7

UO only	0hr prior to AKI stage		24hr prior to AKI stage		48hr prior to AKI stage	
	Cohort 1	Cohort 2	Cohort 1	Cohort 2	Cohort 1	Cohort 2

UO only	0hr prior to AKI stage		24hr prior to AKI stage		48hr prior to AKI stage	
	Cohort 1	Cohort 2	Cohort 1	Cohort 2	Cohort 1	Cohort 2
Median	2.40	1.08	2.40	3.49	2.40	3.25
Average	17.1	17.0	17.1	116	17.1	4.27
Stdev	105	37.4	105	464	105	4.05
p(t-test)		1.00		1.7E-4		0.75
Min	0.000147	0.00122	0.000147	0.00247	0.000147	0.211
Max	2140	135	2140	2140	2140	12.3
n (Samp)	1246	15	1246	21	1246	7
n (Patient)	397	15	397	21	397	7

	0hr prior to AKI stage			24hr prior to AKI stage			48hr prior to AKI stage		
	sCr or UO	sCr only	UO only	sCr or UO	sCr only	UO only	sCr or UO	sCr only	UO only
AUC	0.44	0.35	0.41	0.46	0.36	0.52	0.42	0.32	0.52
SE	0.061	0.11	0.078	0.061	0.12	0.064	0.083	0.11	0.11
p	0.32	0.16	0.24	0.48	0.26	0.73	0.32	0.12	0.84
nCohort 1	1388	1455	1246	1388	1455	1246	1388	1455	1246
nCohort 2	24	8	15	24	6	21	13	7	7
Cutoff 1	0.404	0.201	0.172	0.309	0.260	0.422	0.207	0.624	2.00
Sens 1	71%	75%	73%	71%	83%	71%	77%	71%	71%
Spec 1	18%	12%	11%	15%	13%	18%	13%	24%	45%
Cutoff 2	0.172	0.130	0.130	0.0258	0.260	0.130	0.0537	0.0258	1.36
Sens 2	83%	88%	80%	83%	83%	81%	85%	100%	86%
Spec 2	11%	10%	10%	7%	13%	10%	8%	7%	38%
Cutoff 3	0.00154	0.0782	0.00129	0.00238	0	0.0258	0.0258	0.0258	0.207
Sens 3	92%	100%	93%	92%	100%	90%	92%	100%	100%
Spec 3	3%	9%	2%	4%	0%	7%	7%	7%	12%
Cutoff 4	6.82	6.82	6.52	6.82	6.82	6.52	6.82	6.82	6.52
Sens 4	25%	12%	33%	33%	17%	43%	15%	14%	14%
Spec 4	70%	70%	70%	70%	70%	70%	70%	70%	70%
Cutoff 5	11.8	12.1	11.3	11.8	12.1	11.3	11.8	12.1	11.3
Sens 5	17%	12%	20%	29%	17%	38%	8%	0%	14%
Spec 5	80%	80%	80%	80%	80%	80%	80%	80%	80%
Cutoff 6	25.4	26.2	24.2	25.4	26.2	24.2	25.4	26.2	24.2
Sens 6	12%	12%	20%	17%	0%	24%	0%	0%	0%
Spec 6	90%	90%	90%	90%	90%	90%	90%	90%	90%
OR Quart 2	1.2	2.0	0.25	0.57	1.0	0.11	4.0	>1.0	2.0
p Value	0.76	0.57	0.21	0.37	1.00	0.035	0.21	<1.00	0.57
95% CI of	0.36	0.18	0.028	0.16	0.062	0.014	0.45	>0.063	0.18
OR Quart2	4.0	22	2.2	2.0	16	0.86	36	na	22
OR Quart 3	0.80	0	0.75	0.28	1.0	0.33	4.0	>3.0	3.0
p Value	0.74	na	0.71	0.12	1.00	0.095	0.21	<0.34	0.34
95% CI of	0.21	na	0.17	0.058	0.062	0.087	0.45	>0.31	0.31
OR Quart3	3.0	na	3.4	1.4	16	1.2	36	na	29
OR Quart 4	1.8	5.1	1.8	1.6	3.0	0.88	4.0	>3.0	1.00
p Value	0.29	0.14	0.36	0.34	0.34	0.80	0.21	<0.34	1.00
95% CI of	0.60	0.59	0.51	0.61	0.31	0.34	0.45	>0.31	0.062
OR Quart4	5.5	44	6.1	4.1	29	2.3	36	na	16

[0191] Fig. 10: Comparison of marker levels in EDTA samples collected from Cohort 1 (patients that did not progress beyond RIFLE stage 0, R, or I) and in EDTA samples collected from Cohort 2 (subjects who progress to RIFLE stage F) at 0, 24 hours, and 48 hours prior to the subject reaching RIFLE stage I.

C-C motif chemokine 7

sCr or UO	0hr prior to AKI stage		24hr prior to AKI stage		48hr prior to AKI stage	
	Cohort 1	Cohort 2	Cohort 1	Cohort 2	Cohort 1	Cohort 2
Median	nd	nd	0.758	0.410	nd	nd
Average	nd	nd	8.98	14.0	nd	nd
Stdev	nd	nd	22.1	22.1	nd	nd
p(t-test)	nd	nd		0.59	nd	nd
Min	nd	nd	0.193	0.193	nd	nd
Max	nd	nd	181	51.7	nd	nd
n (Samp)	nd	nd	298	6	nd	nd
n (Patient)	nd	nd	167	6	nd	nd

	0hr prior to AKI stage			24hr prior to AKI stage			48hr prior to AKI stage		
	sCr or UO	sCr only	UO only	sCr or UO	sCr only	UO only	sCr or UO	sCr only	UO only
AUC	nd	nd	nd	0.47	nd	nd	nd	nd	nd
SE	nd	nd	nd	0.12	nd	nd	nd	nd	nd
p	nd	nd	nd	0.78	nd	nd	nd	nd	nd
nCohort 1	nd	nd	nd	298	nd	nd	nd	nd	nd
nCohort 2	nd	nd	nd	6	nd	nd	nd	nd	nd
Cutoff 1	nd	nd	nd	0.193	nd	nd	nd	nd	nd
Sens 1	nd	nd	nd	83%	nd	nd	nd	nd	nd
Spec 1	nd	nd	nd	17%	nd	nd	nd	nd	nd
Cutoff 2	nd	nd	nd	0.193	nd	nd	nd	nd	nd
Sens 2	nd	nd	nd	83%	nd	nd	nd	nd	nd
Spec 2	nd	nd	nd	17%	nd	nd	nd	nd	nd
Cutoff 3	nd	nd	nd	0	nd	nd	nd	nd	nd
Sens 3	nd	nd	nd	100%	nd	nd	nd	nd	nd
Spec 3	nd	nd	nd	0%	nd	nd	nd	nd	nd
Cutoff 4	nd	nd	nd	2.71	nd	nd	nd	nd	nd
Sens 4	nd	nd	nd	33%	nd	nd	nd	nd	nd
Spec 4	nd	nd	nd	70%	nd	nd	nd	nd	nd
Cutoff 5	nd	nd	nd	13.1	nd	nd	nd	nd	nd
Sens 5	nd	nd	nd	33%	nd	nd	nd	nd	nd
Spec 5	nd	nd	nd	80%	nd	nd	nd	nd	nd
Cutoff 6	nd	nd	nd	26.6	nd	nd	nd	nd	nd
Sens 6	nd	nd	nd	33%	nd	nd	nd	nd	nd
Spec 6	nd	nd	nd	90%	nd	nd	nd	nd	nd
OR Quart 2	nd	nd	nd	0	nd	nd	nd	nd	nd
p Value	nd	nd	nd	na	nd	nd	nd	nd	nd
95% CI of	nd	nd	nd	na	nd	nd	nd	nd	nd
OR Quart2	nd	nd	nd	na	nd	nd	nd	nd	nd
OR Quart 3	nd	nd	nd	0.49	nd	nd	nd	nd	nd
p Value	nd	nd	nd	0.57	nd	nd	nd	nd	nd

	0hr prior to AKI stage			24hr prior to AKI stage			48hr prior to AKI stage		
	sCr or UO	sCr only	UO only	sCr or UO	sCr only	UO only	sCr or UO	sCr only	UO only
95% CI of	nd	nd	nd	0.044	nd	nd	nd	nd	nd
OR Quart3	nd	nd	nd	5.6	nd	nd	nd	nd	nd
OR Quart 4	nd	nd	nd	1.5	nd	nd	nd	nd	nd
p Value	nd	nd	nd	0.65	nd	nd	nd	nd	nd
95% CI of	nd	nd	nd	0.25	nd	nd	nd	nd	nd
OR Quart4	nd	nd	nd	9.4	nd	nd	nd	nd	nd

Vascular endothelial growth factor receptor 3

sCr or UO	0hr prior to AKI stage		24hr prior to AKI stage		48hr prior to AKI stage	
	Cohort 1	Cohort 2	Cohort 1	Cohort 2	Cohort 1	Cohort 2
Median	nd	nd	6150	5990	nd	nd
Average	nd	nd	7130	7240	nd	nd
Stdev	nd	nd	5340	4850	nd	nd
p(t-test)	nd	nd		0.96	nd	nd
Min	nd	nd	219	3540	nd	nd
Max	nd	nd	43200	16600	nd	nd
n (Samp)	nd	nd	298	6	nd	nd
n (Patient)	nd	nd	167	6	nd	nd

	0hr prior to AKI stage			24hr prior to AKI stage			48hr prior to AKI stage		
	sCr or UO	sCr only	UO only	sCr or UO	sCr only	UO only	sCr or UO	sCr only	UO only
AUC	nd	nd	nd	0.50	nd	nd	nd	nd	nd
SE	nd	nd	nd	0.12	nd	nd	nd	nd	nd
p	nd	nd	nd	0.98	nd	nd	nd	nd	nd
nCohort 1	nd	nd	nd	298	nd	nd	nd	nd	nd
nCohort 2	nd	nd	nd	6	nd	nd	nd	nd	nd
Cutoff 1	nd	nd	nd	3920	nd	nd	nd	nd	nd
Sens 1	nd	nd	nd	83%	nd	nd	nd	nd	nd
Spec 1	nd	nd	nd	28%	nd	nd	nd	nd	nd
Cutoff 2	nd	nd	nd	3920	nd	nd	nd	nd	nd
Sens 2	nd	nd	nd	83%	nd	nd	nd	nd	nd
Spec 2	nd	nd	nd	28%	nd	nd	nd	nd	nd
Cutoff 3	nd	nd	nd	3530	nd	nd	nd	nd	nd
Sens 3	nd	nd	nd	100%	nd	nd	nd	nd	nd
Spec 3	nd	nd	nd	22%	nd	nd	nd	nd	nd
Cutoff 4	nd	nd	nd	8160	nd	nd	nd	nd	nd
Sens 4	nd	nd	nd	17%	nd	nd	nd	nd	nd
Spec 4	nd	nd	nd	70%	nd	nd	nd	nd	nd
Cutoff 5	nd	nd	nd	9630	nd	nd	nd	nd	nd
Sens 5	nd	nd	nd	17%	nd	nd	nd	nd	nd
Spec 5	nd	nd	nd	80%	nd	nd	nd	nd	nd
Cutoff 6	nd	nd	nd	12100	nd	nd	nd	nd	nd
Sens 6	nd	nd	nd	17%	nd	nd	nd	nd	nd
Spec 6	nd	nd	nd	90%	nd	nd	nd	nd	nd
OR Quart 2	nd	nd	nd	2.0	nd	nd	nd	nd	nd
p Value	nd	nd	nd	0.57	nd	nd	nd	nd	nd
95% CI of	nd	nd	nd	0.18	nd	nd	nd	nd	nd

	0hr prior to AKI stage			24hr prior to AKI stage			48hr prior to AKI stage		
	sCr or UO	sCr only	UO only	sCr or UO	sCr only	UO only	sCr or UO	sCr only	UO only
OR Quart2	nd	nd	nd	23	nd	nd	nd	nd	nd
OR Quart 3	nd	nd	nd	2.0	nd	nd	nd	nd	nd
p Value	nd	nd	nd	0.57	nd	nd	nd	nd	nd
95% CI of	nd	nd	nd	0.18	nd	nd	nd	nd	nd
OR Quart3	nd	nd	nd	23	nd	nd	nd	nd	nd
OR Quart 4	nd	nd	nd	1.0	nd	nd	nd	nd	nd
p Value	nd	nd	nd	1.0	nd	nd	nd	nd	nd
95% CI of	nd	nd	nd	0.061	nd	nd	nd	nd	nd
OR Quart4	nd	nd	nd	16	nd	nd	nd	nd	nd

Interferon alpha-2

sCr or UO	0hr prior to AKI stage		24hr prior to AKI stage		48hr prior to AKI stage	
	Cohort 1	Cohort 2	Cohort 1	Cohort 2	Cohort 1	Cohort 2
Median	nd	nd	12.3	6.12	nd	nd
Average	nd	nd	17.0	10.5	nd	nd
Stdev	nd	nd	23.1	12.0	nd	nd
p(t-test)	nd	nd		0.50	nd	nd
Min	nd	nd	0.0320	0.0627	nd	nd
Max	nd	nd	223	28.5	nd	nd
n (Samp)	nd	nd	298	6	nd	nd
n (Patient)	nd	nd	167	6	nd	nd

	0hr prior to AKI stage			24hr prior to AKI stage			48hr prior to AKI stage		
	sCr or UO	sCr only	UO only	sCr or UO	sCr only	UO only	sCr or UO	sCr only	UO only
AUC	nd	nd	nd	0.44	nd	nd	nd	nd	nd
SE	nd	nd	nd	0.12	nd	nd	nd	nd	nd
p	nd	nd	nd	0.61	nd	nd	nd	nd	nd
nCohort 1	nd	nd	nd	298	nd	nd	nd	nd	nd
nCohort 2	nd	nd	nd	6	nd	nd	nd	nd	nd
Cutoff 1	nd	nd	nd	0.0997	nd	nd	nd	nd	nd
Sens 1	nd	nd	nd	83%	nd	nd	nd	nd	nd
Spec 1	nd	nd	nd	25%	nd	nd	nd	nd	nd
Cutoff 2	nd	nd	nd	0.0997	nd	nd	nd	nd	nd
Sens 2	nd	nd	nd	83%	nd	nd	nd	nd	nd
Spec 2	nd	nd	nd	25%	nd	nd	nd	nd	nd
Cutoff 3	nd	nd	nd	0.0324	nd	nd	nd	nd	nd
Sens 3	nd	nd	nd	100%	nd	nd	nd	nd	nd
Spec 3	nd	nd	nd	2%	nd	nd	nd	nd	nd
Cutoff 4	nd	nd	nd	21.2	nd	nd	nd	nd	nd
Sens 4	nd	nd	nd	33%	nd	nd	nd	nd	nd
Spec 4	nd	nd	nd	70%	nd	nd	nd	nd	nd
Cutoff 5	nd	nd	nd	27.4	nd	nd	nd	nd	nd
Sens 5	nd	nd	nd	17%	nd	nd	nd	nd	nd
Spec 5	nd	nd	nd	80%	nd	nd	nd	nd	nd
Cutoff 6	nd	nd	nd	36.4	nd	nd	nd	nd	nd
Sens 6	nd	nd	nd	0%	nd	nd	nd	nd	nd
Spec 6	nd	nd	nd	90%	nd	nd	nd	nd	nd

	0hr prior to AKI stage			24hr prior to AKI stage			48hr prior to AKI stage		
	sCr or UO	sCr only	UO only	sCr or UO	sCr only	UO only	sCr or UO	sCr only	UO only
OR Quart 2	nd	nd	nd	1.0	nd	nd	nd	nd	nd
p Value	nd	nd	nd	1.0	nd	nd	nd	nd	nd
95% CI of	nd	nd	nd	0.061	nd	nd	nd	nd	nd
OR Quart2	nd	nd	nd	16	nd	nd	nd	nd	nd
OR Quart 3	nd	nd	nd	3.1	nd	nd	nd	nd	nd
p Value	nd	nd	nd	0.33	nd	nd	nd	nd	nd
95% CI of	nd	nd	nd	0.31	nd	nd	nd	nd	nd
OR Quart3	nd	nd	nd	30	nd	nd	nd	nd	nd
OR Quart 4	nd	nd	nd	1.0	nd	nd	nd	nd	nd
p Value	nd	nd	nd	1.0	nd	nd	nd	nd	nd
95% CI of	nd	nd	nd	0.061	nd	nd	nd	nd	nd
OR Quart4	nd	nd	nd	16	nd	nd	nd	nd	nd

Insulin-like growth factor-binding protein 4

sCr or UO	0hr prior to AKI stage		24hr prior to AKI stage		48hr prior to AKI stage	
	Cohort 1	Cohort 2	Cohort 1	Cohort 2	Cohort 1	Cohort 2
Median	nd	nd	2.93	4.81	nd	nd
Average	nd	nd	12.8	12.6	nd	nd
Stdev	nd	nd	18.4	14.7	nd	nd
p(t-test)	nd	nd		0.98	nd	nd
Min	nd	nd	0.0728	0.572	nd	nd
Max	nd	nd	158	33.4	nd	nd
n (Samp)	nd	nd	361	6	nd	nd
n (Patient)	nd	nd	197	6	nd	nd

	0hr prior to AKI stage			24hr prior to AKI stage			48hr prior to AKI stage		
	sCr or UO	sCr only	UO only	sCr or UO	sCr only	UO only	sCr or UO	sCr only	UO only
AUC	nd	nd	nd	0.55	nd	nd	nd	nd	nd
SE	nd	nd	nd	0.12	nd	nd	nd	nd	nd
p	nd	nd	nd	0.66	nd	nd	nd	nd	nd
nCohort 1	nd	nd	nd	361	nd	nd	nd	nd	nd
nCohort 2	nd	nd	nd	6	nd	nd	nd	nd	nd
Cutoff 1	nd	nd	nd	2.43	nd	nd	nd	nd	nd
Sens 1	nd	nd	nd	83%	nd	nd	nd	nd	nd
Spec 1	nd	nd	nd	38%	nd	nd	nd	nd	nd
Cutoff 2	nd	nd	nd	2.43	nd	nd	nd	nd	nd
Sens 2	nd	nd	nd	83%	nd	nd	nd	nd	nd
Spec 2	nd	nd	nd	38%	nd	nd	nd	nd	nd
Cutoff 3	nd	nd	nd	0.0862	nd	nd	nd	nd	nd
Sens 3	nd	nd	nd	100%	nd	nd	nd	nd	nd
Spec 3	nd	nd	nd	1%	nd	nd	nd	nd	nd
Cutoff 4	nd	nd	nd	17.1	nd	nd	nd	nd	nd
Sens 4	nd	nd	nd	33%	nd	nd	nd	nd	nd
Spec 4	nd	nd	nd	70%	nd	nd	nd	nd	nd
Cutoff 5	nd	nd	nd	23.5	nd	nd	nd	nd	nd
Sens 5	nd	nd	nd	33%	nd	nd	nd	nd	nd
Spec 5	nd	nd	nd	80%	nd	nd	nd	nd	nd

	0hr prior to AKI stage			24hr prior to AKI stage			48hr prior to AKI stage		
	sCr or UO	sCr only	UO only	sCr or UO	sCr only	UO only	sCr or UO	sCr only	UO only
Cutoff 6	nd	nd	nd	30.5	nd	nd	nd	nd	nd
Sens 6	nd	nd	nd	17%	nd	nd	nd	nd	nd
Spec 6	nd	nd	nd	90%	nd	nd	nd	nd	nd
OR Quart 2	nd	nd	nd	2.0	nd	nd	nd	nd	nd
p Value	nd	nd	nd	0.57	nd	nd	nd	nd	nd
95% CI of	nd	nd	nd	0.18	nd	nd	nd	nd	nd
OR Quart2	nd	nd	nd	22	nd	nd	nd	nd	nd
OR Quart 3	nd	nd	nd	0.99	nd	nd	nd	nd	nd
p Value	nd	nd	nd	0.99	nd	nd	nd	nd	nd
95% CI of	nd	nd	nd	0.061	nd	nd	nd	nd	nd
OR Quart3	nd	nd	nd	16	nd	nd	nd	nd	nd
OR Quart 4	nd	nd	nd	2.0	nd	nd	nd	nd	nd
p Value	nd	nd	nd	0.57	nd	nd	nd	nd	nd
95% CI of	nd	nd	nd	0.18	nd	nd	nd	nd	nd
OR Quart4	nd	nd	nd	22	nd	nd	nd	nd	nd

Insulin-like growth factor-binding protein 5

sCr or UO	0hr prior to AKI stage		24hr prior to AKI stage		48hr prior to AKI stage	
	Cohort 1	Cohort 2	Cohort 1	Cohort 2	Cohort 1	Cohort 2
Median	nd	nd	11.5	0.763	nd	nd
Average	nd	nd	34.9	22.5	nd	nd
Stdev	nd	nd	49.9	34.1	nd	nd
p(t-test)	nd	nd		0.54	nd	nd
Min	nd	nd	0.204	0.204	nd	nd
Max	nd	nd	257	69.8	nd	nd
n (Samp)	nd	nd	361	6	nd	nd
n (Patient)	nd	nd	197	6	nd	nd

	0hr prior to AKI stage			24hr prior to AKI stage			48hr prior to AKI stage		
	sCr or UO	sCr only	UO only	sCr or UO	sCr only	UO only	sCr or UO	sCr only	UO only
AUC	nd	nd	nd	0.44	nd	nd	nd	nd	nd
SE	nd	nd	nd	0.12	nd	nd	nd	nd	nd
p	nd	nd	nd	0.61	nd	nd	nd	nd	nd
nCohort 1	nd	nd	nd	361	nd	nd	nd	nd	nd
nCohort 2	nd	nd	nd	6	nd	nd	nd	nd	nd
Cutoff 1	nd	nd	nd	0.222	nd	nd	nd	nd	nd
Sens 1	nd	nd	nd	83%	nd	nd	nd	nd	nd
Spec 1	nd	nd	nd	18%	nd	nd	nd	nd	nd
Cutoff 2	nd	nd	nd	0.222	nd	nd	nd	nd	nd
Sens 2	nd	nd	nd	83%	nd	nd	nd	nd	nd
Spec 2	nd	nd	nd	18%	nd	nd	nd	nd	nd
Cutoff 3	nd	nd	nd	0	nd	nd	nd	nd	nd
Sens 3	nd	nd	nd	100%	nd	nd	nd	nd	nd
Spec 3	nd	nd	nd	0%	nd	nd	nd	nd	nd
Cutoff 4	nd	nd	nd	40.2	nd	nd	nd	nd	nd
Sens 4	nd	nd	nd	33%	nd	nd	nd	nd	nd
Spec 4	nd	nd	nd	70%	nd	nd	nd	nd	nd

	0hr prior to AKI stage			24hr prior to AKI stage			48hr prior to AKI stage		
	sCr or UO	sCr only	UO only	sCr or UO	sCr only	UO only	sCr or UO	sCr only	UO only
Cutoff 5	nd	nd	nd	62.1	nd	nd	nd	nd	nd
Sens 5	nd	nd	nd	33%	nd	nd	nd	nd	nd
Spec 5	nd	nd	nd	80%	nd	nd	nd	nd	nd
Cutoff 6	nd	nd	nd	119	nd	nd	nd	nd	nd
Sens 6	nd	nd	nd	0%	nd	nd	nd	nd	nd
Spec 6	nd	nd	nd	90%	nd	nd	nd	nd	nd
OR Quart 2	nd	nd	nd	0	nd	nd	nd	nd	nd
p Value	nd	nd	nd	na	nd	nd	nd	nd	nd
95% CI of	nd	nd	nd	na	nd	nd	nd	nd	nd
OR Quart2	nd	nd	nd	na	nd	nd	nd	nd	nd
OR Quart 3	nd	nd	nd	1.0	nd	nd	nd	nd	nd
p Value	nd	nd	nd	1.0	nd	nd	nd	nd	nd
95% CI of	nd	nd	nd	0.14	nd	nd	nd	nd	nd
OR Quart3	nd	nd	nd	7.3	nd	nd	nd	nd	nd
OR Quart 4	nd	nd	nd	1.0	nd	nd	nd	nd	nd
p Value	nd	nd	nd	0.99	nd	nd	nd	nd	nd
95% CI of	nd	nd	nd	0.14	nd	nd	nd	nd	nd
OR Quart4	nd	nd	nd	7.3	nd	nd	nd	nd	nd

Interleukin-33

sCr or UO	0hr prior to AKI stage		24hr prior to AKI stage		48hr prior to AKI stage	
	Cohort 1	Cohort 2	Cohort 1	Cohort 2	Cohort 1	Cohort 2
Median	nd	nd	0.0981	5.87	nd	nd
Average	nd	nd	278	36.4	nd	nd
Stdev	nd	nd	2480	73.0	nd	nd
p(t-test)	nd	nd		0.81	nd	nd
Min	nd	nd	0.0445	0.0455	nd	nd
Max	nd	nd	40000	184	nd	nd
n (Samp)	nd	nd	298	6	nd	nd
n (Patient)	nd	nd	167	6	nd	nd

	0hr prior to AKI stage			24hr prior to AKI stage			48hr prior to AKI stage		
	sCr or UO	sCr only	UO only	sCr or UO	sCr only	UO only	sCr or UO	sCr only	UO only
AUC	nd	nd	nd	0.67	nd	nd	nd	nd	nd
SE	nd	nd	nd	0.12	nd	nd	nd	nd	nd
p	nd	nd	nd	0.16	nd	nd	nd	nd	nd
nCohort 1	nd	nd	nd	298	nd	nd	nd	nd	nd
nCohort 2	nd	nd	nd	6	nd	nd	nd	nd	nd
Cutoff 1	nd	nd	nd	0.0996	nd	nd	nd	nd	nd
Sens 1	nd	nd	nd	83%	nd	nd	nd	nd	nd
Spec 1	nd	nd	nd	56%	nd	nd	nd	nd	nd
Cutoff 2	nd	nd	nd	0.0996	nd	nd	nd	nd	nd
Sens 2	nd	nd	nd	83%	nd	nd	nd	nd	nd
Spec 2	nd	nd	nd	56%	nd	nd	nd	nd	nd
Cutoff 3	nd	nd	nd	0.0445	nd	nd	nd	nd	nd
Sens 3	nd	nd	nd	100%	nd	nd	nd	nd	nd
Spec 3	nd	nd	nd	10%	nd	nd	nd	nd	nd

	0hr prior to AKI stage			24hr prior to AKI stage			48hr prior to AKI stage		
	sCr or UO	sCr only	UO only	sCr or UO	sCr only	UO only	sCr or UO	sCr only	UO only
Cutoff 4	nd	nd	nd	1.13	nd	nd	nd	nd	nd
Sens 4	nd	nd	nd	67%	nd	nd	nd	nd	nd
Spec 4	nd	nd	nd	70%	nd	nd	nd	nd	nd
Cutoff 5	nd	nd	nd	13.1	nd	nd	nd	nd	nd
Sens 5	nd	nd	nd	33%	nd	nd	nd	nd	nd
Spec 5	nd	nd	nd	80%	nd	nd	nd	nd	nd
Cutoff 6	nd	nd	nd	76.8	nd	nd	nd	nd	nd
Sens 6	nd	nd	nd	17%	nd	nd	nd	nd	nd
Spec 6	nd	nd	nd	90%	nd	nd	nd	nd	nd
OR Quart 2	nd	nd	nd	0	nd	nd	nd	nd	nd
p Value	nd	nd	nd	na	nd	nd	nd	nd	nd
95% CI of	nd	nd	nd	na	nd	nd	nd	nd	nd
OR Quart2	nd	nd	nd	na	nd	nd	nd	nd	nd
OR Quart 3	nd	nd	nd	2.0	nd	nd	nd	nd	nd
p Value	nd	nd	nd	0.57	nd	nd	nd	nd	nd
95% CI of	nd	nd	nd	0.18	nd	nd	nd	nd	nd
OR Quart3	nd	nd	nd	23	nd	nd	nd	nd	nd
OR Quart 4	nd	nd	nd	3.1	nd	nd	nd	nd	nd
p Value	nd	nd	nd	0.33	nd	nd	nd	nd	nd
95% CI of	nd	nd	nd	0.31	nd	nd	nd	nd	nd
OR Quart4	nd	nd	nd	30	nd	nd	nd	nd	nd

Interleukin-4 receptor alpha chain

sCr or UO	0hr prior to AKI stage		24hr prior to AKI stage		48hr prior to AKI stage	
	Cohort 1	Cohort 2	Cohort 1	Cohort 2	Cohort 1	Cohort 2
Median	nd	nd	219	275	nd	nd
Average	nd	nd	294	314	nd	nd
Stdev	nd	nd	230	226	nd	nd
p(t-test)	nd	nd		0.83	nd	nd
Min	nd	nd	3.27	84.5	nd	nd
Max	nd	nd	1210	646	nd	nd
n (Samp)	nd	nd	298	6	nd	nd
n (Patient)	nd	nd	167	6	nd	nd

	0hr prior to AKI stage			24hr prior to AKI stage			48hr prior to AKI stage		
	sCr or UO	sCr only	UO only	sCr or UO	sCr only	UO only	sCr or UO	sCr only	UO only
AUC	nd	nd	nd	0.52	nd	nd	nd	nd	nd
SE	nd	nd	nd	0.12	nd	nd	nd	nd	nd
p	nd	nd	nd	0.86	nd	nd	nd	nd	nd
nCohort 1	nd	nd	nd	298	nd	nd	nd	nd	nd
nCohort 2	nd	nd	nd	6	nd	nd	nd	nd	nd
Cutoff 1	nd	nd	nd	104	nd	nd	nd	nd	nd
Sens 1	nd	nd	nd	83%	nd	nd	nd	nd	nd
Spec 1	nd	nd	nd	7%	nd	nd	nd	nd	nd
Cutoff 2	nd	nd	nd	104	nd	nd	nd	nd	nd
Sens 2	nd	nd	nd	83%	nd	nd	nd	nd	nd
Spec 2	nd	nd	nd	7%	nd	nd	nd	nd	nd

	0hr prior to AKI stage			24hr prior to AKI stage			48hr prior to AKI stage		
	sCr or UO	sCr only	UO only	sCr or UO	sCr only	UO only	sCr or UO	sCr only	UO only
Cutoff 3	nd	nd	nd	83.5	nd	nd	nd	nd	nd
Sens 3	nd	nd	nd	100%	nd	nd	nd	nd	nd
Spec 3	nd	nd	nd	4%	nd	nd	nd	nd	nd
Cutoff 4	nd	nd	nd	304	nd	nd	nd	nd	nd
Sens 4	nd	nd	nd	50%	nd	nd	nd	nd	nd
Spec 4	nd	nd	nd	70%	nd	nd	nd	nd	nd
Cutoff 5	nd	nd	nd	376	nd	nd	nd	nd	nd
Sens 5	nd	nd	nd	33%	nd	nd	nd	nd	nd
Spec 5	nd	nd	nd	80%	nd	nd	nd	nd	nd
Cutoff 6	nd	nd	nd	554	nd	nd	nd	nd	nd
Sens 6	nd	nd	nd	17%	nd	nd	nd	nd	nd
Spec 6	nd	nd	nd	90%	nd	nd	nd	nd	nd
OR Quart 2	nd	nd	nd	0.49	nd	nd	nd	nd	nd
p Value	nd	nd	nd	0.57	nd	nd	nd	nd	nd
95% CI of	nd	nd	nd	0.044	nd	nd	nd	nd	nd
OR Quart2	nd	nd	nd	5.6	nd	nd	nd	nd	nd
OR Quart 3	nd	nd	nd	0	nd	nd	nd	nd	nd
p Value	nd	nd	nd	na	nd	nd	nd	nd	nd
95% CI of	nd	nd	nd	na	nd	nd	nd	nd	nd
OR Quart3	nd	nd	nd	na	nd	nd	nd	nd	nd
OR Quart 4	nd	nd	nd	1.5	nd	nd	nd	nd	nd
p Value	nd	nd	nd	0.65	nd	nd	nd	nd	nd
95% CI of	nd	nd	nd	0.25	nd	nd	nd	nd	nd
OR Quart4	nd	nd	nd	9.4	nd	nd	nd	nd	nd

Vascular endothelial growth factor receptor 2

sCr or UO	0hr prior to AKI stage		24hr prior to AKI stage		48hr prior to AKI stage	
	Cohort 1	Cohort 2	Cohort 1	Cohort 2	Cohort 1	Cohort 2
Median	nd	nd	7870	7420	nd	nd
Average	nd	nd	9920	7340	nd	nd
Stdev	nd	nd	13200	1600	nd	nd
p(t-test)	nd	nd		0.63	nd	nd
Min	nd	nd	3020	5310	nd	nd
Max	nd	nd	166000	9440	nd	nd
n (Samp)	nd	nd	298	6	nd	nd
n (Patient)	nd	nd	167	6	nd	nd

	0hr prior to AKI stage			24hr prior to AKI stage			48hr prior to AKI stage		
	sCr or UO	sCr only	UO only	sCr or UO	sCr only	UO only	sCr or UO	sCr only	UO only
AUC	nd	nd	nd	0.42	nd	nd	nd	nd	nd
SE	nd	nd	nd	0.12	nd	nd	nd	nd	nd
p	nd	nd	nd	0.54	nd	nd	nd	nd	nd
nCohort 1	nd	nd	nd	298	nd	nd	nd	nd	nd
nCohort 2	nd	nd	nd	6	nd	nd	nd	nd	nd
Cutoff 1	nd	nd	nd	5920	nd	nd	nd	nd	nd
Sens 1	nd	nd	nd	83%	nd	nd	nd	nd	nd
Spec 1	nd	nd	nd	20%	nd	nd	nd	nd	nd

	0hr prior to AKI stage			24hr prior to AKI stage			48hr prior to AKI stage		
	sCr or UO	sCr only	UO only	sCr or UO	sCr only	UO only	sCr or UO	sCr only	UO only
Cutoff 2	nd	nd	nd	5920	nd	nd	nd	nd	nd
Sens 2	nd	nd	nd	83%	nd	nd	nd	nd	nd
Spec 2	nd	nd	nd	20%	nd	nd	nd	nd	nd
Cutoff 3	nd	nd	nd	5300	nd	nd	nd	nd	nd
Sens 3	nd	nd	nd	100%	nd	nd	nd	nd	nd
Spec 3	nd	nd	nd	11%	nd	nd	nd	nd	nd
Cutoff 4	nd	nd	nd	9430	nd	nd	nd	nd	nd
Sens 4	nd	nd	nd	17%	nd	nd	nd	nd	nd
Spec 4	nd	nd	nd	70%	nd	nd	nd	nd	nd
Cutoff 5	nd	nd	nd	10600	nd	nd	nd	nd	nd
Sens 5	nd	nd	nd	0%	nd	nd	nd	nd	nd
Spec 5	nd	nd	nd	80%	nd	nd	nd	nd	nd
Cutoff 6	nd	nd	nd	14300	nd	nd	nd	nd	nd
Sens 6	nd	nd	nd	0%	nd	nd	nd	nd	nd
Spec 6	nd	nd	nd	90%	nd	nd	nd	nd	nd
OR Quart 2	nd	nd	nd	>3.1	nd	nd	nd	nd	nd
p Value	nd	nd	nd	<0.33	nd	nd	nd	nd	nd
95% CI of	nd	nd	nd	>0.32	nd	nd	nd	nd	nd
OR Quart2	nd	nd	nd	na	nd	nd	nd	nd	nd
OR Quart 3	nd	nd	nd	>1.0	nd	nd	nd	nd	nd
p Value	nd	nd	nd	<0.99	nd	nd	nd	nd	nd
95% CI of	nd	nd	nd	>0.062	nd	nd	nd	nd	nd
OR Quart3	nd	nd	nd	na	nd	nd	nd	nd	nd
OR Quart 4	nd	nd	nd	>2.1	nd	nd	nd	nd	nd
p Value	nd	nd	nd	<0.56	nd	nd	nd	nd	nd
95% CI of	nd	nd	nd	>0.18	nd	nd	nd	nd	nd
OR Quart4	nd	nd	nd	na	nd	nd	nd	nd	nd

Neural cell adhesion molecule 1

sCr or UO	0hr prior to AKI stage		24hr prior to AKI stage		48hr prior to AKI stage	
	Cohort 1	Cohort 2	Cohort 1	Cohort 2	Cohort 1	Cohort 2
Median	nd	nd	182000	166000	nd	nd
Average	nd	nd	189000	177000	nd	nd
Stdev	nd	nd	70000	50000	nd	nd
p(t-test)	nd	nd		0.68	nd	nd
Min	nd	nd	49200	125000	nd	nd
Max	nd	nd	520000	245000	nd	nd
n (Samp)	nd	nd	366	6	nd	nd
n (Patient)	nd	nd	196	6	nd	nd

	0hr prior to AKI stage			24hr prior to AKI stage			48hr prior to AKI stage		
	sCr or UO	sCr only	UO only	sCr or UO	sCr only	UO only	sCr or UO	sCr only	UO only
AUC	nd	nd	nd	0.46	nd	nd	nd	nd	nd
SE	nd	nd	nd	0.12	nd	nd	nd	nd	nd
p	nd	nd	nd	0.75	nd	nd	nd	nd	nd
nCohort 1	nd	nd	nd	366	nd	nd	nd	nd	nd
nCohort 2	nd	nd	nd	6	nd	nd	nd	nd	nd

	0hr prior to AKI stage			24hr prior to AKI stage			48hr prior to AKI stage		
	sCr or UO	sCr only	UO only	sCr or UO	sCr only	UO only	sCr or UO	sCr only	UO only
Cutoff 1	nd	nd	nd	131000	nd	nd	nd	nd	nd
Sens 1	nd	nd	nd	83%	nd	nd	nd	nd	nd
Spec 1	nd	nd	nd	19%	nd	nd	nd	nd	nd
Cutoff 2	nd	nd	nd	131000	nd	nd	nd	nd	nd
Sens 2	nd	nd	nd	83%	nd	nd	nd	nd	nd
Spec 2	nd	nd	nd	19%	nd	nd	nd	nd	nd
Cutoff 3	nd	nd	nd	125000	nd	nd	nd	nd	nd
Sens 3	nd	nd	nd	100%	nd	nd	nd	nd	nd
Spec 3	nd	nd	nd	15%	nd	nd	nd	nd	nd
Cutoff 4	nd	nd	nd	209000	nd	nd	nd	nd	nd
Sens 4	nd	nd	nd	33%	nd	nd	nd	nd	nd
Spec 4	nd	nd	nd	70%	nd	nd	nd	nd	nd
Cutoff 5	nd	nd	nd	230000	nd	nd	nd	nd	nd
Sens 5	nd	nd	nd	33%	nd	nd	nd	nd	nd
Spec 5	nd	nd	nd	80%	nd	nd	nd	nd	nd
Cutoff 6	nd	nd	nd	268000	nd	nd	nd	nd	nd
Sens 6	nd	nd	nd	0%	nd	nd	nd	nd	nd
Spec 6	nd	nd	nd	90%	nd	nd	nd	nd	nd
OR Quart 2	nd	nd	nd	0	nd	nd	nd	nd	nd
p Value	nd	nd	nd	na	nd	nd	nd	nd	nd
95% CI of	nd	nd	nd	na	nd	nd	nd	nd	nd
OR Quart2	nd	nd	nd	na	nd	nd	nd	nd	nd
OR Quart 3	nd	nd	nd	1.0	nd	nd	nd	nd	nd
p Value	nd	nd	nd	1.0	nd	nd	nd	nd	nd
95% CI of	nd	nd	nd	0.14	nd	nd	nd	nd	nd
OR Quart3	nd	nd	nd	7.3	nd	nd	nd	nd	nd
OR Quart 4	nd	nd	nd	1.0	nd	nd	nd	nd	nd
p Value	nd	nd	nd	1.0	nd	nd	nd	nd	nd
95% CI of	nd	nd	nd	0.14	nd	nd	nd	nd	nd
OR Quart4	nd	nd	nd	7.3	nd	nd	nd	nd	nd

Platelet-derived growth factor subunit B (dimer)

sCr or UO	0hr prior to AKI stage		24hr prior to AKI stage		48hr prior to AKI stage	
	Cohort 1	Cohort 2	Cohort 1	Cohort 2	Cohort 1	Cohort 2
Median	nd	nd	337	403	nd	nd
Average	nd	nd	394	748	nd	nd
Stdev	nd	nd	270	983	nd	nd
p(t-test)	nd	nd		0.0034	nd	nd
Min	nd	nd	0.189	91.9	nd	nd
Max	nd	nd	2690	2720	nd	nd
n (Samp)	nd	nd	355	6	nd	nd
n (Patient)	nd	nd	192	6	nd	nd

	0hr prior to AKI stage			24hr prior to AKI stage			48hr prior to AKI stage		
	sCr or UO	sCr only	UO only	sCr or UO	sCr only	UO only	sCr or UO	sCr only	UO only
AUC	nd	nd	nd	0.57	nd	nd	nd	nd	nd
SE	nd	nd	nd	0.12	nd	nd	nd	nd	nd

	0hr prior to AKI stage			24hr prior to AKI stage			48hr prior to AKI stage		
	sCr or UO	sCr only	UO only	sCr or UO	sCr only	UO only	sCr or UO	sCr only	UO only
p	nd	nd	nd	0.59	nd	nd	nd	nd	nd
nCohort 1	nd	nd	nd	355	nd	nd	nd	nd	nd
nCohort 2	nd	nd	nd	6	nd	nd	nd	nd	nd
Cutoff 1	nd	nd	nd	242	nd	nd	nd	nd	nd
Sens 1	nd	nd	nd	83%	nd	nd	nd	nd	nd
Spec 1	nd	nd	nd	31%	nd	nd	nd	nd	nd
Cutoff 2	nd	nd	nd	242	nd	nd	nd	nd	nd
Sens 2	nd	nd	nd	83%	nd	nd	nd	nd	nd
Spec 2	nd	nd	nd	31%	nd	nd	nd	nd	nd
Cutoff 3	nd	nd	nd	91.4	nd	nd	nd	nd	nd
Sens 3	nd	nd	nd	100%	nd	nd	nd	nd	nd
Spec 3	nd	nd	nd	7%	nd	nd	nd	nd	nd
Cutoff 4	nd	nd	nd	495	nd	nd	nd	nd	nd
Sens 4	nd	nd	nd	33%	nd	nd	nd	nd	nd
Spec 4	nd	nd	nd	70%	nd	nd	nd	nd	nd
Cutoff 5	nd	nd	nd	581	nd	nd	nd	nd	nd
Sens 5	nd	nd	nd	33%	nd	nd	nd	nd	nd
Spec 5	nd	nd	nd	80%	nd	nd	nd	nd	nd
Cutoff 6	nd	nd	nd	699	nd	nd	nd	nd	nd
Sens 6	nd	nd	nd	17%	nd	nd	nd	nd	nd
Spec 6	nd	nd	nd	90%	nd	nd	nd	nd	nd
OR Quart 2	nd	nd	nd	1.0	nd	nd	nd	nd	nd
p Value	nd	nd	nd	1.0	nd	nd	nd	nd	nd
95% CI of	nd	nd	nd	0.062	nd	nd	nd	nd	nd
OR Quart2	nd	nd	nd	16	nd	nd	nd	nd	nd
OR Quart 3	nd	nd	nd	2.0	nd	nd	nd	nd	nd
p Value	nd	nd	nd	0.57	nd	nd	nd	nd	nd
95% CI of	nd	nd	nd	0.18	nd	nd	nd	nd	nd
OR Quart3	nd	nd	nd	23	nd	nd	nd	nd	nd
OR Quart 4	nd	nd	nd	2.0	nd	nd	nd	nd	nd
p Value	nd	nd	nd	0.57	nd	nd	nd	nd	nd
95% CI of	nd	nd	nd	0.18	nd	nd	nd	nd	nd
OR Quart4	nd	nd	nd	22	nd	nd	nd	nd	nd

Pigment epithelium-derived factor

sCr or UO	0hr prior to AKI stage		24hr prior to AKI stage		48hr prior to AKI stage	
	Cohort 1	Cohort 2	Cohort 1	Cohort 2	Cohort 1	Cohort 2
Median	nd	nd	1670	1350	nd	nd
Average	nd	nd	1920	1180	nd	nd
Stdev	nd	nd	1130	498	nd	nd
p(t-test)	nd	nd		0.11	nd	nd
Min	nd	nd	84.2	339	nd	nd
Max	nd	nd	7450	1650	nd	nd
n (Samp)	nd	nd	367	6	nd	nd
n (Patient)	nd	nd	197	6	nd	nd

	0hr prior to AKI stage		24hr prior to AKI stage		48hr prior to AKI stage	

	sCr or UO	sCr only	UO only	sCr or UO	sCr only	UO only	sCr or UO	sCr only	UO only
AUC	nd	nd	nd	0.29	nd	nd	nd	nd	nd
SE	nd	nd	nd	0.12	nd	nd	nd	nd	nd
p	nd	nd	nd	0.086	nd	nd	nd	nd	nd
nCohort 1	nd	nd	nd	367	nd	nd	nd	nd	nd
nCohort 2	nd	nd	nd	6	nd	nd	nd	nd	nd
Cutoff 1	nd	nd	nd	823	nd	nd	nd	nd	nd
Sens 1	nd	nd	nd	83%	nd	nd	nd	nd	nd
Spec 1	nd	nd	nd	10%	nd	nd	nd	nd	nd
Cutoff 2	nd	nd	nd	823	nd	nd	nd	nd	nd
Sens 2	nd	nd	nd	83%	nd	nd	nd	nd	nd
Spec 2	nd	nd	nd	10%	nd	nd	nd	nd	nd
Cutoff 3	nd	nd	nd	328	nd	nd	nd	nd	nd
Sens 3	nd	nd	nd	100%	nd	nd	nd	nd	nd
Spec 3	nd	nd	nd	1%	nd	nd	nd	nd	nd
Cutoff 4	nd	nd	nd	2120	nd	nd	nd	nd	nd
Sens 4	nd	nd	nd	0%	nd	nd	nd	nd	nd
Spec 4	nd	nd	nd	70%	nd	nd	nd	nd	nd
Cutoff 5	nd	nd	nd	2510	nd	nd	nd	nd	nd
Sens 5	nd	nd	nd	0%	nd	nd	nd	nd	nd
Spec 5	nd	nd	nd	80%	nd	nd	nd	nd	nd
Cutoff 6	nd	nd	nd	3550	nd	nd	nd	nd	nd
Sens 6	nd	nd	nd	0%	nd	nd	nd	nd	nd
Spec 6	nd	nd	nd	90%	nd	nd	nd	nd	nd
OR Quart 2	nd	nd	nd	>0	nd	nd	nd	nd	nd
p Value	nd	nd	nd	<na	nd	nd	nd	nd	nd
95% CI of	nd	nd	nd	>na	nd	nd	nd	nd	nd
OR Quart2	nd	nd	nd	na	nd	nd	nd	nd	nd
OR Quart 3	nd	nd	nd	>4.2	nd	nd	nd	nd	nd
p Value	nd	nd	nd	<0.20	nd	nd	nd	nd	nd
95% CI of	nd	nd	nd	>0.46	nd	nd	nd	nd	nd
OR Quart3	nd	nd	nd	na	nd	nd	nd	nd	nd
OR Quart 4	nd	nd	nd	>2.1	nd	nd	nd	nd	nd
p Value	nd	nd	nd	<0.56	nd	nd	nd	nd	nd
95% CI of	nd	nd	nd	>0.18	nd	nd	nd	nd	nd
OR Quart4	nd	nd	nd	na	nd	nd	nd	nd	nd

Tumor necrosis factor receptor superfamily member 8

sCr or UO	0hr prior to AKI stage		24hr prior to AKI stage		48hr prior to AKI stage	
	Cohort 1	Cohort 2	Cohort 1	Cohort 2	Cohort 1	Cohort 2
Median	nd	nd	102	71.9	nd	nd
Average	nd	nd	195	189	nd	nd
Stdev	nd	nd	388	223	nd	nd
p(t-test)	nd	nd		0.97	nd	nd
Min	nd	nd	4.06	30.8	nd	nd
Max	nd	nd	3360	595	nd	nd
n (Samp)	nd	nd	298	6	nd	nd
n (Patient)	nd	nd	167	6	nd	nd

	0hr prior to AKI stage			24hr prior to AKI stage			48hr prior to AKI stage		
	sCr or UO	sCr only	UO only	sCr or UO	sCr only	UO only	sCr or UO	sCr only	UO only
AUC	nd	nd	nd	0.43	nd	nd	nd	nd	nd
SE	nd	nd	nd	0.12	nd	nd	nd	nd	nd
p	nd	nd	nd	0.58	nd	nd	nd	nd	nd
nCohort 1	nd	nd	nd	298	nd	nd	nd	nd	nd
nCohort 2	nd	nd	nd	6	nd	nd	nd	nd	nd
Cutoff 1	nd	nd	nd	54.3	nd	nd	nd	nd	nd
Sens 1	nd	nd	nd	83%	nd	nd	nd	nd	nd
Spec 1	nd	nd	nd	14%	nd	nd	nd	nd	nd
Cutoff 2	nd	nd	nd	54.3	nd	nd	nd	nd	nd
Sens 2	nd	nd	nd	83%	nd	nd	nd	nd	nd
Spec 2	nd	nd	nd	14%	nd	nd	nd	nd	nd
Cutoff 3	nd	nd	nd	30.2	nd	nd	nd	nd	nd
Sens 3	nd	nd	nd	100%	nd	nd	nd	nd	nd
Spec 3	nd	nd	nd	4%	nd	nd	nd	nd	nd
Cutoff 4	nd	nd	nd	149	nd	nd	nd	nd	nd
Sens 4	nd	nd	nd	33%	nd	nd	nd	nd	nd
Spec 4	nd	nd	nd	70%	nd	nd	nd	nd	nd
Cutoff 5	nd	nd	nd	205	nd	nd	nd	nd	nd
Sens 5	nd	nd	nd	33%	nd	nd	nd	nd	nd
Spec 5	nd	nd	nd	81%	nd	nd	nd	nd	nd
Cutoff 6	nd	nd	nd	305	nd	nd	nd	nd	nd
Sens 6	nd	nd	nd	33%	nd	nd	nd	nd	nd
Spec 6	nd	nd	nd	90%	nd	nd	nd	nd	nd
OR Quart 2	nd	nd	nd	0	nd	nd	nd	nd	nd
p Value	nd	nd	nd	na	nd	nd	nd	nd	nd
95% CI of	nd	nd	nd	na	nd	nd	nd	nd	nd
OR Quart2	nd	nd	nd	na	nd	nd	nd	nd	nd
OR Quart 3	nd	nd	nd	0.49	nd	nd	nd	nd	nd
p Value	nd	nd	nd	0.57	nd	nd	nd	nd	nd
95% CI of	nd	nd	nd	0.044	nd	nd	nd	nd	nd
OR Quart3	nd	nd	nd	5.6	nd	nd	nd	nd	nd
OR Quart 4	nd	nd	nd	1.5	nd	nd	nd	nd	nd
p Value	nd	nd	nd	0.65	nd	nd	nd	nd	nd
95% CI of	nd	nd	nd	0.25	nd	nd	nd	nd	nd
OR Quart4	nd	nd	nd	9.4	nd	nd	nd	nd	nd

Alpha-fetoprotein

sCr or UO	0hr prior to AKI stage		24hr prior to AKI stage		48hr prior to AKI stage	
	Cohort 1	Cohort 2	Cohort 1	Cohort 2	Cohort 1	Cohort 2
Median	nd	nd	0.328	0.608	nd	nd
Average	nd	nd	0.351	0.738	nd	nd
Stdev	nd	nd	0.339	0.576	nd	nd
p(t-test)	nd	nd		0.0065	nd	nd
Min	nd	nd	0.00580	0.00580	nd	nd
Max	nd	nd	1.81	1.53	nd	nd
n (Samp)	nd	nd	367	6	nd	nd
n (Patient)	nd	nd	197	6	nd	nd

	0hr prior to AKI stage			24hr prior to AKI stage			48hr prior to AKI stage		
	sCr or UO	sCr only	UO only	sCr or UO	sCr only	UO only	sCr or UO	sCr only	UO only
AUC	nd	nd	nd	0.71	nd	nd	nd	nd	nd
SE	nd	nd	nd	0.12	nd	nd	nd	nd	nd
p	nd	nd	nd	0.087	nd	nd	nd	nd	nd
nCohort 1	nd	nd	nd	367	nd	nd	nd	nd	nd
nCohort 2	nd	nd	nd	6	nd	nd	nd	nd	nd
Cutoff 1	nd	nd	nd	0.369	nd	nd	nd	nd	nd
Sens 1	nd	nd	nd	83%	nd	nd	nd	nd	nd
Spec 1	nd	nd	nd	57%	nd	nd	nd	nd	nd
Cutoff 2	nd	nd	nd	0.369	nd	nd	nd	nd	nd
Sens 2	nd	nd	nd	83%	nd	nd	nd	nd	nd
Spec 2	nd	nd	nd	57%	nd	nd	nd	nd	nd
Cutoff 3	nd	nd	nd	0	nd	nd	nd	nd	nd
Sens 3	nd	nd	nd	100%	nd	nd	nd	nd	nd
Spec 3	nd	nd	nd	0%	nd	nd	nd	nd	nd
Cutoff 4	nd	nd	nd	0.509	nd	nd	nd	nd	nd
Sens 4	nd	nd	nd	67%	nd	nd	nd	nd	nd
Spec 4	nd	nd	nd	70%	nd	nd	nd	nd	nd
Cutoff 5	nd	nd	nd	0.598	nd	nd	nd	nd	nd
Sens 5	nd	nd	nd	50%	nd	nd	nd	nd	nd
Spec 5	nd	nd	nd	80%	nd	nd	nd	nd	nd
Cutoff 6	nd	nd	nd	0.784	nd	nd	nd	nd	nd
Sens 6	nd	nd	nd	33%	nd	nd	nd	nd	nd
Spec 6	nd	nd	nd	90%	nd	nd	nd	nd	nd
OR Quart 2	nd	nd	nd	0	nd	nd	nd	nd	nd
p Value	nd	nd	nd	na	nd	nd	nd	nd	nd
95% CI of	nd	nd	nd	na	nd	nd	nd	nd	nd
OR Quart2	nd	nd	nd	na	nd	nd	nd	nd	nd
OR Quart 3	nd	nd	nd	1.0	nd	nd	nd	nd	nd
p Value	nd	nd	nd	1.0	nd	nd	nd	nd	nd
95% CI of	nd	nd	nd	0.062	nd	nd	nd	nd	nd
OR Quart3	nd	nd	nd	16	nd	nd	nd	nd	nd
OR Quart 4	nd	nd	nd	4.1	nd	nd	nd	nd	nd
p Value	nd	nd	nd	0.21	nd	nd	nd	nd	nd
95% CI of	nd	nd	nd	0.45	nd	nd	nd	nd	nd
OR Quart4	nd	nd	nd	37	nd	nd	nd	nd	nd

Apolipoprotein E

sCr or UO	0hr prior to AKI stage		24hr prior to AKI stage		48hr prior to AKI stage	
	Cohort 1	Cohort 2	Cohort 1	Cohort 2	Cohort 1	Cohort 2
Median	51000	28200	51000	42800	nd	nd
Average	61600	35600	61600	39400	nd	nd
Stdev	44300	15000	44300	11700	nd	nd
p(t-test)		0.098		0.19	nd	nd
Min	1940	22400	1940	25800	nd	nd
Max	260000	59600	260000	54900	nd	nd
n (Samp)	434	8	434	7	nd	nd
n (Patient)	233	8	233	7	nd	nd

UO only	0hr prior to AKI stage		24hr prior to AKI stage		48hr prior to AKI stage	
	Cohort 1	Cohort 2	Cohort 1	Cohort 2	Cohort 1	Cohort 2
Median	nd	nd	48700	37100	nd	nd
Average	nd	nd	59500	38400	nd	nd
Stdev	nd	nd	42000	12400	nd	nd
p(t-test)	nd	nd		0.22	nd	nd
Min	nd	nd	1940	25800	nd	nd
Max	nd	nd	244000	54900	nd	nd
n (Samp)	nd	nd	400	6	nd	nd
n (Patient)	nd	nd	205	6	nd	nd

	0hr prior to AKI stage			24hr prior to AKI stage			48hr prior to AKI stage		
	sCr or UO	sCr only	UO only	sCr or UO	sCr only	UO only	sCr or UO	sCr only	UO only
AUC	0.30	nd	nd	0.36	nd	0.36	nd	nd	nd
SE	0.10	nd	nd	0.11	nd	0.12	nd	nd	nd
p	0.058	nd	nd	0.21	nd	0.25	nd	nd	nd
nCohort 1	434	nd	nd	434	nd	400	nd	nd	nd
nCohort 2	8	nd	nd	7	nd	6	nd	nd	nd
Cutoff 1	25600	nd	nd	31300	nd	25800	nd	nd	nd
Sens 1	75%	nd	nd	71%	nd	83%	nd	nd	nd
Spec 1	17%	nd	nd	26%	nd	19%	nd	nd	nd
Cutoff 2	23900	nd	nd	25800	nd	25800	nd	nd	nd
Sens 2	88%	nd	nd	86%	nd	83%	nd	nd	nd
Spec 2	15%	nd	nd	18%	nd	19%	nd	nd	nd
Cutoff 3	20900	nd	nd	25800	nd	25800	nd	nd	nd
Sens 3	100%	nd	nd	100%	nd	100%	nd	nd	nd
Spec 3	13%	nd	nd	18%	nd	19%	nd	nd	nd
Cutoff 4	69500	nd	nd	69500	nd	67600	nd	nd	nd
Sens 4	0%	nd	nd	0%	nd	0%	nd	nd	nd
Spec 4	70%	nd	nd	70%	nd	70%	nd	nd	nd
Cutoff 5	87400	nd	nd	87400	nd	86400	nd	nd	nd
Sens 5	0%	nd	nd	0%	nd	0%	nd	nd	nd
Spec 5	80%	nd	nd	80%	nd	80%	nd	nd	nd
Cutoff 6	120000	nd	nd	120000	nd	110000	nd	nd	nd
Sens 6	0%	nd	nd	0%	nd	0%	nd	nd	nd
Spec 6	90%	nd	nd	90%	nd	90%	nd	nd	nd
OR Quart 2	>2.1	nd	nd	>1.0	nd	>2.1	nd	nd	nd
p Value	<0.56	nd	nd	<0.99	nd	<0.56	nd	nd	nd
95% CI of	>0.18	nd	nd	>0.063	nd	>0.18	nd	nd	nd
OR Quart2	na	nd	nd	na	nd	na	nd	nd	nd
OR Quart 3	>1.0	nd	nd	>4.2	nd	>2.0	nd	nd	nd
p Value	<0.99	nd	nd	<0.20	nd	<0.56	nd	nd	nd
95% CI of	>0.062	nd	nd	>0.46	nd	>0.18	nd	nd	nd
OR Quart3	na	nd	nd	na	nd	na	nd	nd	nd
OR Quart 4	>5.3	nd	nd	>2.1	nd	>2.1	nd	nd	nd
p Value	<0.13	nd	nd	<0.56	nd	<0.56	nd	nd	nd
95% CI of	>0.61	nd	nd	>0.18	nd	>0.18	nd	nd	nd
OR Quart4	na	nd	nd	na	nd	na	nd	nd	nd

[0192] Fig. 11: Comparison of marker levels in enroll urine samples collected from Cohort 1 (patients that did not progress beyond RIFLE stage 0 or R within 48hrs) and in enroll urine samples collected from Cohort 2 (subjects reaching RIFLE stage I or F within 48hrs). Enroll samples from patients already at RIFLE stage I or F were included in Cohort 2.

Complement C4-B

	sCr or UO		sCr only		UO only	
	Cohort 1	Cohort 2	Cohort 1	Cohort 2	Cohort 1	Cohort 2
Median	16.6	33.8	18.1	31.8	18.9	43.7
Average	59.8	80.1	63.5	70.6	59.4	84.2
Stdev	150	154	154	83.8	152	163
p(t-test)		0.25		0.84		0.21
Min	0.00329	0.00263	0.00263	0.448	0.00329	0.00263
Max	1950	1150	1950	245	1950	1150
n (Samp)	383	92	451	20	296	79
n (Patient)	383	92	451	20	296	79

	At Enrollment		
	sCr or UO	sCr only	UO only
AUC	0.59	0.57	0.60
SE	0.034	0.068	0.037
p	0.0090	0.33	0.0092
nCohort 1	383	451	296
nCohort 2	92	20	79
Cutoff 1	8.26	9.33	8.97
Sens 1	71%	70%	71%
Spec 1	38%	41%	38%
Cutoff 2	4.30	4.27	5.44
Sens 2	80%	80%	81%
Spec 2	25%	24%	28%
Cutoff 3	1.74	1.07	1.77
Sens 3	90%	90%	91%
Spec 3	15%	9%	14%
Cutoff 4	36.7	44.0	38.7
Sens 4	49%	50%	51%
Spec 4	70%	70%	70%
Cutoff 5	62.0	65.8	62.0
Sens 5	34%	40%	34%
Spec 5	80%	80%	80%
Cutoff 6	147	150	129
Sens 6	15%	20%	18%
Spec 6	90%	90%	90%
OR Quart 2	0.93	0.58	1.1
p Value	0.84	0.47	0.72
95% CI of	0.46	0.14	0.54
OR Quart2	1.9	2.5	2.5
OR Quart 3	1.1	0.58	1.1

	At Enrollment		
	sCr or UO	sCr only	UO only
p Value	0.75	0.47	0.72
95% CI of	0.57	0.14	0.54
OR Quart3	2.2	2.5	2.5
OR Quart 4	2.1	1.8	2.4
p Value	0.023	0.28	0.013
95% CI of	1.1	0.60	1.2
OR Quart4	3.9	5.7	4.9

C-C motif chemokine 26

	sCr or UO		sCr only		UO only	
	Cohort 1	Cohort 2	Cohort 1	Cohort 2	Cohort 1	Cohort 2
Median	0.0311	0.0405	0.0320	0.0436	0.0311	0.0402
Average	0.0737	0.647	0.162	0.728	0.0500	0.737
Stdev	0.497	4.50	2.04	2.03	0.177	4.85
p(t-test)		0.015		0.23		0.015
Min	0.00872	0.00872	0.00872	0.00872	0.00872	0.00872
Max	9.14	42.3	42.3	7.53	2.75	42.3
n (Samp)	383	92	451	20	297	79
n (Patient)	383	92	451	20	297	79

	At Enrollment		
	sCr or UO	sCr only	UO only
AUC	0.60	0.66	0.57
SE	0.034	0.068	0.037
p	0.0030	0.020	0.056
nCohort 1	383	451	297
nCohort 2	92	20	79
Cutoff 1	0.0297	0.0311	0.0291
Sens 1	71%	70%	76%
Spec 1	49%	49%	45%
Cutoff 2	0.0236	0.0262	0.0232
Sens 2	80%	80%	82%
Spec 2	45%	44%	35%
Cutoff 3	0.0195	0.0232	0.0195
Sens 3	95%	90%	94%
Spec 3	18%	35%	18%
Cutoff 4	0.0443	0.0443	0.0443
Sens 4	28%	40%	25%
Spec 4	75%	75%	72%
Cutoff 5	0.0486	0.0486	0.0504
Sens 5	24%	40%	20%
Spec 5	80%	80%	86%
Cutoff 6	0.0525	0.0525	0.0525
Sens 6	21%	30%	19%
Spec 6	91%	90%	90%
OR Quart 2	2.3	2.0	2.6
p Value	0.031	0.42	0.017

	At Enrollment		
	sCr or UO	sCr only	UO only
95% CI of OR Quart2	1.1 5.0	0.36 11	1.2 5.7
OR Quart 3	3.9	3.1	3.0
p Value	3.0E-4	0.17	0.0047
95% CI of OR Quart3	1.9 8.1	0.61 16	1.4 6.6
OR Quart 4	2.5	4.2	1.7
p Value	0.021	0.074	0.22
95% CI of OR Quart4	1.1 5.3	0.87 20	0.73 3.8

C-C motif chemokine 7

	sCr or UO		sCr only		UO only	
	Cohort 1	Cohort 2	Cohort 1	Cohort 2	Cohort 1	Cohort 2
Median	0.515	0.812	0.515	1.29	0.584	0.625
Average	2.03	14.0	2.82	39.3	2.36	14.4
Stdev	8.31	60.4	15.9	110	9.29	64.5
p(t-test)		2.0E-4		6.4E-9		0.0020
Min	0.146	0.146	0.146	0.188	0.146	0.146
Max	125	488	291	488	125	488
n (Samp)	385	92	453	20	298	79
n (Patient)	385	92	453	20	298	79

	At Enrollment		
	sCr or UO	sCr only	UO only
AUC	0.62	0.76	0.56
SE	0.034	0.064	0.037
p	6.5E-4	5.6E-5	0.11
nCohort 1	385	453	298
nCohort 2	92	20	79
Cutoff 1	0.386	0.812	0.336
Sens 1	71%	70%	73%
Spec 1	47%	65%	33%
Cutoff 2	0.320	0.584	0.319
Sens 2	83%	80%	84%
Spec 2	34%	54%	26%
Cutoff 3	0.264	0.386	0.264
Sens 3	92%	90%	91%
Spec 3	15%	45%	13%
Cutoff 4	0.816	0.816	1.04
Sens 4	45%	60%	38%
Spec 4	73%	70%	76%
Cutoff 5	1.07	1.11	1.15
Sens 5	40%	60%	24%
Spec 5	80%	80%	82%
Cutoff 6	1.59	1.59	1.59
Sens 6	20%	40%	19%

	At Enrollment		
	sCr or UO	sCr only	UO only
Spec 6	93%	92%	92%
OR Quart 2	2.1	3.1	2.0
p Value	0.052	0.34	0.072
95% CI of	0.99	0.31	0.94
OR Quart2	4.3	30	4.1
OR Quart 3	1.5	4.1	1.0
p Value	0.34	0.21	1.0
95% CI of	0.68	0.45	0.45
OR Quart3	3.1	37	2.2
OR Quart 4	3.6	13	2.3
p Value	2.7E-4	0.014	0.026
95% CI of	1.8	1.7	1.1
OR Quart4	7.3	100	4.7

Vascular endothelial growth factor receptor 3

	sCr or UO		sCr only		UO only	
	Cohort 1	Cohort 2	Cohort 1	Cohort 2	Cohort 1	Cohort 2
Median	308	354	315	403	308	348
Average	297	431	322	403	295	437
Stdev	170	381	241	87.3	168	412
p(t-test)		2.1E-4		0.32		5.1E-4
Min	1.37	1.37	1.37	308	1.37	1.37
Max	942	2750	2750	601	942	2750
n (Samp)	196	53	238	9	171	45
n (Patient)	196	53	238	9	171	45

	At Enrollment		
	sCr or UO	sCr only	UO only
AUC	0.63	0.68	0.63
SE	0.045	0.10	0.049
p	0.0029	0.081	0.010
nCohort 1	196	238	171
nCohort 2	53	9	45
Cutoff 1	282	332	273
Sens 1	72%	78%	71%
Spec 1	48%	55%	46%
Cutoff 2	229	315	219
Sens 2	81%	89%	82%
Spec 2	37%	52%	34%
Cutoff 3	163	295	66.4
Sens 3	91%	100%	96%
Spec 3	22%	47%	11%
Cutoff 4	397	414	381
Sens 4	49%	33%	47%
Spec 4	72%	73%	70%
Cutoff 5	440	445	425
Sens 5	36%	11%	40%

	At Enrollment		
	sCr or UO	sCr only	UO only
Spec 5	81%	81%	81%
Cutoff 6	496	537	486
Sens 6	28%	11%	33%
Spec 6	90%	90%	90%
OR Quart 2	1.6	>1.0	1.3
p Value	0.33	<1.0	0.61
95% CI of	0.61	>0.061	0.47
OR Quart2	4.3	na	3.6
OR Quart 3	1.6	>6.5	1.0
p Value	0.33	<0.087	1.0
95% CI of	0.61	>0.76	0.35
OR Quart3	4.3	na	2.9
OR Quart 4	3.4	>2.0	3.1
p Value	0.0087	<0.57	0.017
95% CI of	1.4	>0.18	1.2
OR Quart4	8.4	na	8.0

Insulin-like growth factor-binding protein 5

	sCr or UO		sCr only		UO only	
	Cohort 1	Cohort 2	Cohort 1	Cohort 2	Cohort 1	Cohort 2
Median	0.0682	0.0682	nd	nd	0.0682	0.0682
Average	0.801	0.752	nd	nd	0.788	0.760
Stdev	1.63	1.13	nd	nd	1.66	1.16
p(t-test)		0.87	nd	nd		0.93
Min	0.0116	0.0116	nd	nd	0.0116	0.0116
Max	10.3	3.92	nd	nd	10.3	3.92
n (Samp)	138	32	nd	nd	119	30
n (Patient)	138	32	nd	nd	119	30

	At Enrollment		
	sCr or UO	sCr only	UO only
AUC	0.49	nd	0.49
SE	0.057	nd	0.059
p	0.86	nd	0.86
nCohort 1	138	nd	119
nCohort 2	32	nd	30
Cutoff 1	0.0116	nd	0.0116
Sens 1	88%	nd	87%
Spec 1	8%	nd	9%
Cutoff 2	0.0116	nd	0.0116
Sens 2	88%	nd	87%
Spec 2	8%	nd	9%
Cutoff 3	0	nd	0
Sens 3	100%	nd	100%
Spec 3	0%	nd	0%
Cutoff 4	0.397	nd	0.397
Sens 4	34%	nd	33%

	At Enrollment		
	sCr or UO	sCr only	UO only
Spec 4	73%	nd	75%
Cutoff 5	1.43	nd	1.40
Sens 5	19%	nd	23%
Spec 5	81%	nd	81%
Cutoff 6	3.00	nd	3.00
Sens 6	6%	nd	7%
Spec 6	91%	nd	92%
OR Quart 2	0.31	nd	0.54
p Value	0.061	nd	0.29
95% CI of	0.089	nd	0.17
OR Quart2	1.1	nd	1.7
OR Quart 3	0.57	nd	0.34
p Value	0.29	nd	0.094
95% CI of	0.20	nd	0.096
OR Quart3	1.6	nd	1.2
OR Quart 4	0.91	nd	1.0
p Value	0.85	nd	0.94
95% CI of	0.34	nd	0.37
OR Quart4	2.4	nd	2.9

Immunoglobulin G4

	sCr or UO		sCr only		UO only	
	Cohort 1	Cohort 2	Cohort 1	Cohort 2	Cohort 1	Cohort 2
Median	180	384	203	460	203	405
Average	452	829	508	894	476	853
Stdev	664	921	717	977	671	928
p(t-test)		8.8E-6		0.021		6.1E-5
Min	0.00862	0.00996	0.00862	4.20	0.410	0.00996
Max	2400	2400	2400	2400	2400	2400
n (Samp)	379	92	447	20	292	79
n (Patient)	379	92	447	20	292	79

	At Enrollment		
	sCr or UO	sCr only	UO only
AUC	0.62	0.60	0.62
SE	0.034	0.068	0.037
p	4.7E-4	0.15	0.0011
nCohort 1	379	447	292
nCohort 2	92	20	79
Cutoff 1	132	241	134
Sens 1	71%	70%	71%
Spec 1	42%	54%	40%
Cutoff 2	76.0	32.8	95.9
Sens 2	80%	80%	81%
Spec 2	29%	15%	33%
Cutoff 3	21.3	20.5	41.4
Sens 3	90%	90%	91%

	At Enrollment		
	sCr or UO	sCr only	UO only
Spec 3	13%	12%	18%
Cutoff 4	383	431	402
Sens 4	50%	50%	51%
Spec 4	70%	70%	70%
Cutoff 5	597	676	663
Sens 5	38%	40%	35%
Spec 5	80%	80%	80%
Cutoff 6	1470	2150	1510
Sens 6	26%	25%	25%
Spec 6	90%	90%	90%
OR Quart 2	0.99	0	1.2
p Value	0.98	na	0.70
95% CI of	0.47	na	0.52
OR Quart2	2.1	na	2.6
OR Quart 3	1.5	0.82	1.9
p Value	0.23	0.75	0.10
95% CI of	0.76	0.24	0.88
OR Quart3	3.1	2.8	4.0
OR Quart 4	2.9	1.5	2.8
p Value	0.0015	0.44	0.0067
95% CI of	1.5	0.53	1.3
OR Quart4	5.6	4.4	5.7

Interleukin-21

	sCr or UO		sCr only		UO only	
	Cohort 1	Cohort 2	Cohort 1	Cohort 2	Cohort 1	Cohort 2
Median	8.33	5.94	7.99	5.73	7.44	5.97
Average	11.0	8.67	10.7	7.27	10.1	8.75
Stdev	10.9	8.64	10.7	6.70	10.1	8.81
p(t-test)		0.055		0.16		0.28
Min	0.0122	0.00404	0.00404	0.0219	0.0122	0.00404
Max	67.7	42.1	67.7	22.6	66.5	42.1
n (Samp)	383	92	451	20	297	79
n (Patient)	383	92	451	20	297	79

	At Enrollment		
	sCr or UO	sCr only	UO only
AUC	0.43	0.42	0.46
SE	0.034	0.068	0.037
p	0.051	0.22	0.24
nCohort 1	383	451	297
nCohort 2	92	20	79
Cutoff 1	2.65	2.61	3.08
Sens 1	71%	70%	71%
Spec 1	26%	26%	29%
Cutoff 2	0.596	1.78	0.586
Sens 2	80%	80%	81%

	At Enrollment		
	sCr or UO	sCr only	UO only
Spec 2	9%	20%	10%
Cutoff 3	0.0247	0.0528	0.0247
Sens 3	92%	90%	92%
Spec 3	3%	5%	3%
Cutoff 4	14.5	13.9	12.8
Sens 4	23%	20%	24%
Spec 4	70%	70%	70%
Cutoff 5	18.0	17.5	16.9
Sens 5	13%	10%	15%
Spec 5	80%	80%	80%
Cutoff 6	24.7	24.2	22.6
Sens 6	5%	0%	6%
Spec 6	90%	90%	90%
OR Quart 2	1.1	0.74	1.0
p Value	0.86	0.70	1.0
95% CI of	0.53	0.16	0.48
OR Quart2	2.2	3.4	2.1
OR Quart 3	1.8	1.8	1.6
p Value	0.076	0.36	0.22
95% CI of	0.94	0.51	0.77
OR Quart3	3.5	6.3	3.1
OR Quart 4	1.6	1.5	1.3
p Value	0.17	0.51	0.47
95% CI of	0.82	0.42	0.64
OR Quart4	3.1	5.6	2.7

Interleukin-23

	sCr or UO		sCr only		UO only	
	Cohort 1	Cohort 2	Cohort 1	Cohort 2	Cohort 1	Cohort 2
Median	302	96.7	268	3.63	302	102
Average	492	329	466	280	487	327
Stdev	691	526	671	497	700	520
p(t-test)		0.035		0.22		0.059
Min	0.491	0.491	0.491	0.552	0.491	0.491
Max	8520	3250	8520	1820	8520	3250
n (Samp)	383	92	451	20	297	79
n (Patient)	383	92	451	20	297	79

	At Enrollment		
	sCr or UO	sCr only	UO only
AUC	0.40	0.35	0.41
SE	0.034	0.068	0.037
p	0.0044	0.028	0.011
nCohort 1	383	451	297
nCohort 2	92	20	79
Cutoff 1	1.09	0.747	1.30
Sens 1	71%	70%	71%

	At Enrollment		
	sCr or UO	sCr only	UO only
Spec 1	20%	12%	23%
Cutoff 2	0.844	0.708	1.01
Sens 2	80%	80%	81%
Spec 2	14%	10%	17%
Cutoff 3	0.708	0.552	0.708
Sens 3	90%	95%	94%
Spec 3	10%	1%	9%
Cutoff 4	603	553	608
Sens 4	21%	20%	20%
Spec 4	70%	70%	70%
Cutoff 5	844	794	813
Sens 5	12%	10%	13%
Spec 5	80%	80%	80%
Cutoff 6	1350	1180	1200
Sens 6	5%	10%	5%
Spec 6	90%	90%	90%
OR Quart 2	1.0	1.0	1.2
p Value	1.0	1.0	0.68
95% CI of	0.47	0.20	0.53
OR Quart2	2.1	5.1	2.6
OR Quart 3	2.3	1.3	2.3
p Value	0.016	0.70	0.032
95% CI of	1.2	0.29	1.1
OR Quart3	4.4	6.1	4.7
OR Quart 4	2.1	3.6	2.4
p Value	0.031	0.058	0.021
95% CI of	1.1	0.96	1.1
OR Quart4	4.1	13	5.0

Interleukin-28A

	sCr or UO		sCr only		UO only	
	Cohort 1	Cohort 2	Cohort 1	Cohort 2	Cohort 1	Cohort 2
Median	17.6	13.7	17.6	3.22	20.5	12.2
Average	32.5	29.4	32.3	20.4	32.6	29.5
Stdev	39.0	38.5	39.2	28.4	38.8	39.7
p(t-test)		0.49		0.18		0.54
Min	0.0254	0.0254	0.0254	0.0495	0.0254	0.0254
Max	197	164	197	91.1	197	164
n (Samp)	383	92	451	20	297	79
n (Patient)	383	92	451	20	297	79

	At Enrollment		
	sCr or UO	sCr only	UO only
AUC	0.47	0.38	0.47
SE	0.034	0.068	0.037
p	0.43	0.076	0.38
nCohort 1	383	451	297

DEMANDE OU BREVET VOLUMINEUX

LA PRÉSENTE PARTIE DE CETTE DEMANDE OU CE BREVET COMPREND PLUS D'UN TOME.

CECI EST LE TOME 1 DE 2
CONTENANT LES PAGES 1 À 337

NOTE : Pour les tomes additionels, veuillez contacter le Bureau canadien des brevets

JUMBO APPLICATIONS/PATENTS

THIS SECTION OF THE APPLICATION/PATENT CONTAINS MORE THAN ONE VOLUME

THIS IS VOLUME 1 OF 2
CONTAINING PAGES 1 TO 337

NOTE: For additional volumes, please contact the Canadian Patent Office

NOM DU FICHER / FILE NAME :

NOTE POUR LE TOME / VOLUME NOTE:

We claim:

1. A method for evaluating renal status in a subject, comprising:
performing one or more assays configured to detect one or more biomarkers selected from the group consisting of Tumor necrosis factor receptor superfamily member 8, Alpha-Fetoprotein, Thyroxine-binding globulin, Prostate-specific antigen (free form), Apolipoprotein A, Apolipoprotein E, Thyrotropin subunit beta, Platelet-derived growth factor B/B dimer, C-C motif chemokine 7, C-C motif chemokine 26, Complement C4-B, Corticotropin, Interferon alpha-2, Interleukin-4 receptor alpha chain, Insulin-like growth factor-binding protein 4, Insulin-like growth factor-binding protein 5, Interleukin 21, Interleukin 23 alpha subunit, Interleukin-28A, Interleukin-33, Lutropin subunit beta, Matrix Metalloproteinase-1, Neural cell adhesion molecule 1, Pigment epithelium-derived factor, Vascular endothelial growth factor receptor 2, Vascular endothelial growth factor receptor 3, and IgG4 on a body fluid sample obtained from the subject to provide an assay result; and
correlating the assay result(s) to the renal status of the subject.
2. A method according to claim 1, wherein said correlation step comprises correlating the assay result(s) to one or more of risk stratification, diagnosis, staging, prognosis, classifying and monitoring of the renal status of the subject.
3. A method according to claim 1, wherein said correlating step comprises assigning a likelihood of one or more future changes in renal status to the subject based on the assay result(s).
4. A method according to claim 3, wherein said one or more future changes in renal status comprise one or more of a future injury to renal function, future reduced renal function, future improvement in renal function, and future acute renal failure (ARF).
5. A method according to one of claims 1-4, wherein said assay results comprise at least 2, 3, 4, or 5 of:
a measured concentration of Tumor necrosis factor receptor superfamily member 8,
a measured concentration of Alpha-Fetoprotein,
a measured concentration of Thyroxine-binding globulin,
a measured concentration of Prostate-specific antigen (free form),

a measured concentration of Apolipoprotein A,
a measured concentration of Apolipoprotein E,
a measured concentration of Thyrotropin subunit beta,
a measured concentration of Platelet-derived growth factor B/B dimer,
a measured concentration of C-C motif chemokine 7,
a measured concentration of C-C motif chemokine 26,
a measured concentration of Complement C4-B,
a measured concentration of Corticotropin,
a measured concentration of Interferon alpha-2,
a measured concentration of Interleukin-4 receptor alpha chain,
a measured concentration of Insulin-like growth factor-binding protein 4,
a measured concentration of Insulin-like growth factor-binding protein 5,
a measured concentration of Interleukin 21,
a measured concentration of Interleukin 23 alpha subunit,
a measured concentration of Interleukin-28A,
a measured concentration of Interleukin-33,
a measured concentration of Lutropin subunit beta,
a measured concentration of Matrix Metalloproteinase-1,
a measured concentration of Neural cell adhesion molecule 1,
a measured concentration of Pigment epithelium-derived factor,
a measured concentration of Vascular endothelial growth factor receptor 2,
a measured concentration of Vascular endothelial growth factor receptor 3, and
a measured concentration of IgG4.

6. A method according to one of claims 1-5, wherein a plurality of assay results are combined using a function that converts the plurality of assay results into a single composite result.

7. A method according to claim 3, wherein said one or more future changes in renal status comprise a clinical outcome related to a renal injury suffered by the subject.
8. A method according to claim 3, wherein the likelihood of one or more future changes in renal status is that an event of interest is more or less likely to occur within 30 days of the time at which the body fluid sample is obtained from the subject.
9. A method according to claim 8, wherein the likelihood of one or more future changes in renal status is that an event of interest is more or less likely to occur within a period selected from the group consisting of 21 days, 14 days, 7 days, 5 days, 96 hours, 72 hours, 48 hours, 36 hours, 24 hours, and 12 hours.
10. A method according to one of claims 1-5, wherein the subject is selected for evaluation of renal status based on the pre-existence in the subject of one or more known risk factors for prerenal, intrinsic renal, or postrenal ARF.
11. A method according to one of claims 1-5, wherein the subject is selected for evaluation of renal status based on an existing diagnosis of one or more of congestive heart failure, preeclampsia, eclampsia, diabetes mellitus, hypertension, coronary artery disease, proteinuria, renal insufficiency, glomerular filtration below the normal range, cirrhosis, serum creatinine above the normal range, sepsis, injury to renal function, reduced renal function, or ARF, or based on undergoing or having undergone major vascular surgery, coronary artery bypass, or other cardiac surgery, or based on exposure to NSAIDs, cyclosporines, tacrolimus, aminoglycosides, foscarnet, ethylene glycol, hemoglobin, myoglobin, ifosfamide, heavy metals, methotrexate, radiopaque contrast agents, or streptozotocin.
12. A method according to one of claims 1-5, wherein said correlating step comprises assigning a diagnosis of the occurrence or nonoccurrence of one or more of an injury to renal function, reduced renal function, or ARF to the subject based on the assay result(s).
13. A method according to one of claims 1-5, wherein said correlating step comprises assessing whether or not renal function is improving or worsening in a subject who has suffered from an injury to renal function, reduced renal function, or ARF based on the assay result(s).
14. A method according to one of claims 1-5, wherein said method is a method of diagnosing the occurrence or nonoccurrence of an injury to renal function in said subject.

15. A method according to one of claims 1-5, wherein said method is a method of diagnosing the occurrence or nonoccurrence of reduced renal function in said subject.
16. A method according to one of claims 1-5, wherein said method is a method of diagnosing the occurrence or nonoccurrence of acute renal failure in said subject.
17. A method according to one of claims 1-5, wherein said method is a method of diagnosing the occurrence or nonoccurrence of a need for renal replacement therapy in said subject.
18. A method according to one of claims 1-5, wherein said method is a method of diagnosing the occurrence or nonoccurrence of a need for renal transplantation in said subject.
19. A method according to one of claims 1-5, wherein said method is a method of assigning a risk of the future occurrence or nonoccurrence of an injury to renal function in said subject.
20. A method according to one of claims 1-5, wherein said method is a method of assigning a risk of the future occurrence or nonoccurrence of reduced renal function in said subject.
21. A method according to one of claims 1-5, wherein said method is a method of assigning a risk of the future occurrence or nonoccurrence of acute renal failure in said subject.
22. A method according to one of claims 1-5, wherein said method is a method of assigning a risk of the future occurrence or nonoccurrence of a need for renal replacement therapy in said subject.
23. A method according to one of claims 1-5, wherein said method is a method of assigning a risk of the future occurrence or nonoccurrence of a need for renal transplantation in said subject.
24. A method according to one of claims 1-5, wherein said one or more future changes in renal status comprise one or more of a future injury to renal function, future reduced renal function, future improvement in renal function, and future acute renal failure (ARF) within 72 hours of the time at which the body fluid sample is obtained.
25. A method according to one of claims 1-5, wherein said one or more future changes in renal status comprise one or more of a future injury to renal function, future

reduced renal function, future improvement in renal function, and future acute renal failure (ARF) within 48 hours of the time at which the body fluid sample is obtained.

26. A method according to one of claims 1-5, wherein said one or more future changes in renal status comprise one or more of a future injury to renal function, future reduced renal function, future improvement in renal function, and future acute renal failure (ARF) within 24 hours of the time at which the body fluid sample is obtained.

27. A method according to one of claims 1-5, wherein the subject is in RIFLE stage 0 or R.

28. A method according to claim 27, wherein the subject is in RIFLE stage 0, and said correlating step comprises assigning a likelihood that the subject will reach RIFLE stage R, I or F within 72 hours.

29. A method according to claim 28, wherein the subject is in RIFLE stage 0, and said correlating step comprises assigning a likelihood that the subject will reach RIFLE stage I or F within 72 hours.

30. A method according to claim 28, wherein the subject is in RIFLE stage 0, and said correlating step comprises assigning a likelihood that the subject will reach RIFLE stage F within 72 hours.

31. A method according to claim 27, wherein the subject is in RIFLE stage 0 or R, and said correlating step comprises assigning a likelihood that the subject will reach RIFLE stage I or F within 72 hours.

32. A method according to claim 31, wherein the subject is in RIFLE stage 0 or R, and said correlating step comprises assigning a likelihood that the subject will reach RIFLE stage F within 72 hours.

33. A method according to claim 27, wherein the subject is in RIFLE stage R, and said correlating step comprises assigning a likelihood that the subject will reach RIFLE stage I or F within 72 hours.

34. A method according to claim 33, wherein the subject is in RIFLE stage R, and said correlating step comprises assigning a likelihood that the subject will reach RIFLE stage F within 72 hours.

35. A method according to one of claims 1-5, wherein the subject is in RIFLE stage 0, R, or I, and said correlating step comprises assigning a likelihood that the subject will reach RIFLE stage F within 72 hours.
36. A method according to claim 35, wherein the subject is in RIFLE stage I, and said correlating step comprises assigning a likelihood that the subject will reach RIFLE stage F within 72 hours.
37. A method according to claim 28, wherein said correlating step comprises assigning a likelihood that the subject will reach RIFLE stage R, I or F within 48 hours.
38. A method according to claim 29, wherein said correlating step comprises assigning a likelihood that the subject will reach RIFLE stage I or F within 48 hours.
39. A method according to claim 30, wherein said correlating step comprises assigning a likelihood that the subject will reach RIFLE stage F within 48 hours.
40. A method according to claim 31, wherein said correlating step comprises assigning a likelihood that the subject will reach RIFLE stage I or F within 48 hours.
41. A method according to claim 32, wherein said correlating step comprises assigning a likelihood that the subject will reach RIFLE stage F within 48 hours.
42. A method according to claim 33, wherein said correlating step comprises assigning a likelihood that the subject will reach RIFLE stage I or F within 48 hours.
43. A method according to claim 34, wherein said correlating step comprises assigning a likelihood that the subject will reach RIFLE stage F within 48 hours.
44. A method according to claim 35, wherein said correlating step comprises assigning a likelihood that the subject will reach RIFLE stage F within 48 hours.
45. A method according to claim 36, wherein said correlating step comprises assigning a likelihood that the subject will reach RIFLE stage F within 48 hours.
46. A method according to claim 28, wherein said correlating step comprises assigning a likelihood that the subject will reach RIFLE stage R, I or F within 24 hours.
47. A method according to claim 29, wherein said correlating step comprises assigning a likelihood that the subject will reach RIFLE stage I or F within 24 hours.
48. A method according to claim 30, wherein said correlating step comprises assigning a likelihood that the subject will reach RIFLE stage F within 24 hours.

49. A method according to claim 31, wherein said correlating step comprises assigning a likelihood that the subject will reach RIFLE stage I or F within 24 hours.
50. A method according to claim 32, wherein said correlating step comprises assigning a likelihood that the subject will reach RIFLE stage F within 24 hours.
51. A method according to claim 33, wherein said correlating step comprises assigning a likelihood that the subject will reach RIFLE stage I or F within 24 hours.
52. A method according to claim 34, wherein said correlating step comprises assigning a likelihood that the subject will reach RIFLE stage F within 24 hours.
53. A method according to claim 35, wherein said correlating step comprises assigning a likelihood that the subject will reach RIFLE stage F within 24 hours.
54. A method according to claim 36, wherein said correlating step comprises assigning a likelihood that the subject will reach RIFLE stage F within 24 hours.
55. A method according to one of claims 1-5, wherein the subject is not in acute renal failure.
56. A method according to one of claims 1-5, wherein the subject has not experienced a 1.5-fold or greater increase in serum creatinine over a baseline value determined prior to the time at which the body fluid sample is obtained.
57. A method according to one of claims 1-5, wherein the subject has a urine output of at least 0.5 ml/kg/hr over the 6 hours preceding the time at which the body fluid sample is obtained.
58. A method according to one of claims 1-5, wherein the subject has not experienced an increase of 0.3 mg/dL or greater in serum creatinine over a baseline value determined prior to the time at which the body fluid sample is obtained.
59. A method according to one of claims 1-5, wherein the subject (i) has not experienced a 1.5-fold or greater increase in serum creatinine over a baseline value determined prior to the time at which the body fluid sample is obtained, (ii) has a urine output of at least 0.5 ml/kg/hr over the 6 hours preceding the time at which the body fluid sample is obtained, and (iii) has not experienced an increase of 0.3 mg/dL or greater in serum creatinine over a baseline value determined prior to the time at which the body fluid sample is obtained.

60. A method according to one of claims 1-5, wherein the subject has not experienced a 1.5-fold or greater increase in serum creatinine over a baseline value determined prior to the time at which the body fluid sample is obtained.

61. A method according to one of claims 1-5, wherein the subject has a urine output of at least 0.5 ml/kg/hr over the 6 hours preceding the time at which the body fluid sample is obtained.

62. A method according to one of claims 1-5, wherein the subject (i) has not experienced a 1.5-fold or greater increase in serum creatinine over a baseline value determined prior to the time at which the body fluid sample is obtained, (ii) has a urine output of at least 0.5 ml/kg/hr over the 12 hours preceding the time at which the body fluid sample is obtained, and (iii) has not experienced an increase of 0.3 mg/dL or greater in serum creatinine over a baseline value determined prior to the time at which the body fluid sample is obtained.

63. A method according to one of claims 1-5, wherein said correlating step comprises assigning one or more of: a likelihood that within 72 hours the subject will (i) experience a 1.5-fold or greater increase in serum creatinine (ii) have a urine output of less than 0.5 ml/kg/hr over a 6 hour period, or (iii) experience an increase of 0.3 mg/dL or greater in serum creatinine.

64. A method according to claim 63, wherein said correlating step comprises assigning one or more of: a likelihood that within 48 hours the subject will (i) experience a 1.5-fold or greater increase in serum creatinine (ii) have a urine output of less than 0.5 ml/kg/hr over a 6 hour period, or (iii) experience an increase of 0.3 mg/dL or greater in serum creatinine.

65. A method according to claim 63, wherein said correlating step comprises assigning one or more of: a likelihood that within 24 hours the subject will (i) experience a 1.5-fold or greater increase in serum creatinine (ii) have a urine output of less than 0.5 ml/kg/hr over a 6 hour period, or (iii) experience an increase of 0.3 mg/dL or greater in serum creatinine.

66. A method according to claim 63, wherein said correlating step comprises assigning a likelihood that within 72 hours the subject will experience a 1.5-fold or greater increase in serum creatinine.

67. A method according to claim 63, wherein said correlating step comprises assigning a likelihood that within 72 hours the subject will have a urine output of less than 0.5 ml/kg/hr over a 6 hour period.

68. A method according to claim 63, wherein said correlating step comprises assigning a likelihood that within 72 hours the subject will experience an increase of 0.3 mg/dL or greater in serum creatinine.

69. A method according to claim 63, wherein said correlating step comprises assigning a likelihood that within 48 hours the subject will experience a 1.5-fold or greater increase in serum creatinine.

70. A method according to claim 63, wherein said correlating step comprises assigning a likelihood that within 48 hours the subject will have a urine output of less than 0.5 ml/kg/hr over a 6 hour period.

71. A method according to claim 63, wherein said correlating step comprises assigning a likelihood that within 48 hours the subject will experience an increase of 0.3 mg/dL or greater in serum creatinine.

72. A method according to claim 63, wherein said correlating step comprises assigning a likelihood that within 24 hours the subject will experience a 1.5-fold or greater increase in serum creatinine.

73. A method according to claim 63, wherein said correlating step comprises assigning a likelihood that within 24 hours the subject will have a urine output of less than 0.5 ml/kg/hr over a 6 hour period.

74. A method according to claim 63, wherein said correlating step comprises assigning a likelihood that within 24 hours the subject will experience an increase of 0.3 mg/dL or greater in serum creatinine.

75. A method according to one of claims 1-5, wherein the subject has not experienced a 2-fold or greater increase in serum creatinine over a baseline value determined prior to the time at which the body fluid sample is obtained.

76. A method according to one of claims 1-5, wherein the subject has a urine output of at least 0.5 ml/kg/hr over the 12 hours preceding the time at which the body fluid sample is obtained.

77. A method according to one of claims 1-5, wherein the subject (i) has not experienced a 2-fold or greater increase in serum creatinine over a baseline value determined prior to the time at which the body fluid sample is obtained, (ii) has a urine output of at least 0.5 ml/kg/hr over the 2 hours preceding the time at which the body fluid sample is obtained, and (iii) has not experienced an increase of 0.3 mg/dL or greater in serum creatinine over a baseline value determined prior to the time at which the body fluid sample is obtained.

78. A method according to one of claims 1-5, wherein the subject has not experienced a 3-fold or greater increase in serum creatinine over a baseline value determined prior to the time at which the body fluid sample is obtained.

79. A method according to one of claims 1-5, wherein the subject has a urine output of at least 0.3 ml/kg/hr over the 24 hours preceding the time at which the body fluid sample is obtained, or anuria over the 12 hours preceding the time at which the body fluid sample is obtained.

80. A method according to one of claims 1-5, wherein the subject (i) has not experienced a 3-fold or greater increase in serum creatinine over a baseline value determined prior to the time at which the body fluid sample is obtained, (ii) has a urine output of at least 0.3 ml/kg/hr over the 24 hours preceding the time at which the body fluid sample is obtained, or anuria over the 12 hours preceding the time at which the body fluid sample is obtained, and (iii) has not experienced an increase of 0.3 mg/dL or greater in serum creatinine over a baseline value determined prior to the time at which the body fluid sample is obtained.

81. A method according to one of claims 1-5, wherein said correlating step comprises assigning one or more of: a likelihood that within 72 hours the subject will (i) experience a 2-fold or greater increase in serum creatinine (ii) have a urine output of less than 0.5 ml/kg/hr over a 12 hour period, or (iii) experience an increase of 0.3 mg/dL or greater in serum creatinine.

82. A method according to claim 81, wherein said correlating step comprises assigning one or more of: a likelihood that within 48 hours the subject will (i) experience a 2-fold or greater increase in serum creatinine (ii) have a urine output of less than 0.5 ml/kg/hr over a 6 hour period, or (iii) experience an increase of 0.3 mg/dL or greater in serum creatinine.

83. A method according to claim 81, wherein said correlating step comprises assigning one or more of: a likelihood that within 24 hours the subject will (i) experience a 2-fold or greater increase in serum creatinine, or (ii) have a urine output of less than 0.5 ml/kg/hr over a 6 hour period.

84. A method according to claim 81, wherein said correlating step comprises assigning a likelihood that within 72 hours the subject will experience a 2-fold or greater increase in serum creatinine.

85. A method according to claim 81, wherein said correlating step comprises assigning a likelihood that within 72 hours the subject will have a urine output of less than 0.5 ml/kg/hr over a 6 hour period.

86. A method according to claim 81, wherein said correlating step comprises assigning a likelihood that within 48 hours the subject will experience a 2-fold or greater increase in serum creatinine.

87. A method according to claim 81, wherein said correlating step comprises assigning a likelihood that within 48 hours the subject will have a urine output of less than 0.5 ml/kg/hr over a 6 hour period.

88. A method according to claim 81, wherein said correlating step comprises assigning a likelihood that within 24 hours the subject will experience a 2-fold or greater increase in serum creatinine.

89. A method according to claim 81, wherein said correlating step comprises assigning a likelihood that within 24 hours the subject will have a urine output of less than 0.5 ml/kg/hr over a 6 hour period.

90. A method according to one of claims 1-5, wherein said correlating step comprises assigning one or more of: a likelihood that within 72 hours the subject will (i) experience a 3-fold or greater increase in serum creatinine, or (ii) have a urine output of less than 0.3 ml/kg/hr over a 24 hour period or anuria over a 12 hour period.

91. A method according to claim 90, wherein said correlating step comprises assigning one or more of: a likelihood that within 48 hours the subject will (i) experience a 3-fold or greater increase in serum creatinine, or (ii) have a urine output of less than 0.3 ml/kg/hr over a 24 hour period or anuria over a 12 hour period.

92. A method according to claim 90, wherein said correlating step comprises assigning one or more of: a likelihood that within 24 hours the subject will (i) experience a 3-fold or greater increase in serum creatinine, or (ii) have a urine output of less than 0.3 ml/kg/hr over a 24 hour period or anuria over a 12 hour period.

93. A method according to claim 90, wherein said correlating step comprises assigning a likelihood that within 72 hours the subject will experience a 3-fold or greater increase in serum creatinine.

94. A method according to claim 90, wherein said correlating step comprises assigning a likelihood that within 72 hours the subject will have a urine output of less than 0.3 ml/kg/hr over a 24 hour period or anuria over a 12 hour period.

95. A method according to claim 90, wherein said correlating step comprises assigning a likelihood that within 48 hours the subject will experience a 3-fold or greater increase in serum creatinine.

96. A method according to claim 90, wherein said correlating step comprises assigning a likelihood that within 48 hours the subject will have a urine output of less than 0.3 ml/kg/hr over a 24 hour period or anuria over a 12 hour period.

97. A method according to claim 90, wherein said correlating step comprises assigning a likelihood that within 24 hours the subject will experience a 3-fold or greater increase in serum creatinine.

98. A method according to claim 90, wherein said correlating step comprises assigning a likelihood that within 24 hours the subject will have a urine output of less than 0.3 ml/kg/hr over a 24 hour period or anuria over a 12 hour period.

99. A method according to one of claims 1-98, wherein the body fluid sample is a urine sample.

100. A method according to one of claims 1-99, wherein said method comprises performing assays that detect one, two or three, or more of Tumor necrosis factor receptor superfamily member 8, Alpha-Fetoprotein, Thyroxine-binding globulin, Prostate-specific antigen (free form), Apolipoprotein A, Apolipoprotein E, Thyrotropin subunit beta, Platelet-derived growth factor B/B dimer, C-C motif chemokine 7, C-C motif chemokine 26, Complement C4-B, Corticotropin, Interferon alpha-2, Interleukin-4 receptor alpha chain, Insulin-like growth factor-binding protein 4, Insulin-like growth factor-binding

protein 5, Interleukin 21, Interleukin 23 alpha subunit, Interleukin-28A, Interleukin-33, Lutropin subunit beta, Matrix Metalloproteinase-1, Neural cell adhesion molecule 1, Pigment epithelium-derived factor, Vascular endothelial growth factor receptor 2, Vascular endothelial growth factor receptor 3, and IgG4.

101. Measurement of one or more biomarkers selected from the group consisting of Tumor necrosis factor receptor superfamily member 8, Alpha-Fetoprotein, Thyroxine-binding globulin, Prostate-specific antigen (free form), Apolipoprotein A, Apolipoprotein E, Thyrotropin subunit beta, Platelet-derived growth factor B/B dimer, C-C motif chemokine 7, C-C motif chemokine 26, Complement C4-B, Corticotropin, Interferon alpha-2, Interleukin-4 receptor alpha chain, Insulin-like growth factor-binding protein 4, Insulin-like growth factor-binding protein 5, Interleukin 21, Interleukin 23 alpha subunit, Interleukin-28A, Interleukin-33, Lutropin subunit beta, Matrix Metalloproteinase-1, Neural cell adhesion molecule 1, Pigment epithelium-derived factor, Vascular endothelial growth factor receptor 2, Vascular endothelial growth factor receptor 3, and IgG4 for the evaluation of renal injury.

102. Measurement of one or more biomarkers selected from the group consisting of Tumor necrosis factor receptor superfamily member 8, Alpha-Fetoprotein, Thyroxine-binding globulin, Prostate-specific antigen (free form), Apolipoprotein A, Apolipoprotein E, Thyrotropin subunit beta, Platelet-derived growth factor B/B dimer, C-C motif chemokine 7, C-C motif chemokine 26, Complement C4-B, Corticotropin, Interferon alpha-2, Interleukin-4 receptor alpha chain, Insulin-like growth factor-binding protein 4, Insulin-like growth factor-binding protein 5, Interleukin 21, Interleukin 23 alpha subunit, Interleukin-28A, Interleukin-33, Lutropin subunit beta, Matrix Metalloproteinase-1, Neural cell adhesion molecule 1, Pigment epithelium-derived factor, Vascular endothelial growth factor receptor 2, Vascular endothelial growth factor receptor 3, and IgG4 for the evaluation of acute renal injury.

103. A kit, comprising:

reagents for performing one or more assays configured to detect one or more kidney injury markers selected from the group consisting of Tumor necrosis factor receptor superfamily member 8, Alpha-Fetoprotein, Thyroxine-binding globulin, Prostate-specific antigen (free form), Apolipoprotein A, Apolipoprotein E, Thyrotropin subunit beta, Platelet-derived growth factor B/B dimer, C-C motif chemokine 7, C-C motif chemokine

26, Complement C4-B, Corticotropin, Interferon alpha-2, Interleukin-4 receptor alpha chain, Insulin-like growth factor-binding protein 4, Insulin-like growth factor-binding protein 5, Interleukin 21, Interleukin 23 alpha subunit, Interleukin-28A, Interleukin-33, Lutropin subunit beta, Matrix Metalloproteinase-1, Neural cell adhesion molecule 1, Pigment epithelium-derived factor, Vascular endothelial growth factor receptor 2, Vascular endothelial growth factor receptor 3, and IgG4.

104. A kit according to claim 103, wherein said reagents comprise one or more binding reagents, each of which specifically binds one of said of kidney injury markers.

105. A kit according to claim 104, wherein a plurality of binding reagents are contained in a single assay device.

106. A kit according to claim 103, wherein at least one of said assays is configured as a sandwich binding assay.

107. A kit according to claim 103, wherein at least one of said assays is configured as a competitive binding assay.

108. A kit according to one of claims 103-107, wherein said one or more assays comprise assays that detect one, two or three, or more of Tumor necrosis factor receptor superfamily member 8, Alpha-Fetoprotein, Thyroxine-binding globulin, Prostate-specific antigen (free form), Apolipoprotein A, Apolipoprotein E, Thyrotropin subunit beta, Platelet-derived growth factor B/B dimer, C-C motif chemokine 7, C-C motif chemokine 26, Complement C4-B, Corticotropin, Interferon alpha-2, Interleukin-4 receptor alpha chain, Insulin-like growth factor-binding protein 4, Insulin-like growth factor-binding protein 5, Interleukin 21, Interleukin 23 alpha subunit, Interleukin-28A, Interleukin-33, Lutropin subunit beta, Matrix Metalloproteinase-1, Neural cell adhesion molecule 1, Pigment epithelium-derived factor, Vascular endothelial growth factor receptor 2, Vascular endothelial growth factor receptor 3, and IgG4.